<SEC-DOCUMENT>0000950170-23-010632.txt : 20230329
<SEC-HEADER>0000950170-23-010632.hdr.sgml : 20230329
<ACCEPTANCE-DATETIME>20230329163302
ACCESSION NUMBER:		0000950170-23-010632
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230329
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39273
		FILM NUMBER:		23775668

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lyra-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-28T19:03:40.1401+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:lyra="http://lyratherapeutics.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_4471ca7f-4d79-47e2-9c65-d4f601168d4c" name="us-gaap:PreferredStockValue" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric id="F_c6a416ad-dce4-436c-b762-84f45186a40a" name="dei:DocumentFiscalPeriodFocus" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140">FY</ix:nonNumeric><ix:nonNumeric id="F_2b89e99d-b7ce-4efb-88f7-90ebab7441a0" name="dei:EntityCentralIndexKey" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140">0001327273</ix:nonNumeric><ix:nonNumeric id="F_d727f80b-943d-4713-9f66-c687759b7604" name="dei:CurrentFiscalYearEndDate" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140">--12-31</ix:nonNumeric><ix:nonFraction id="F_b556901c-3c67-411f-ae41-cb8f4493d60e" name="us-gaap:PreferredStockValue" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1998289b-eb61-4a17-beb7-899c1a25802a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_4cef5287-028b-4d16-aa13-f50aae7b67ec" name="us-gaap:LeaseExpirationDate1" contextRef="C_f6258f7a-902f-4145-8c22-422abafbe4f4">2024-06-30</ix:nonNumeric><ix:nonNumeric id="F_4c389388-d196-4c1e-93e8-ff25ff427d32" name="dei:AmendmentFlag" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140">false</ix:nonNumeric><ix:nonNumeric id="F_9e6d9c4d-d173-4c37-9051-37c0e1abf253" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonFraction id="F_43989a1a-5a9f-4a95-98ff-670e92082ebc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55">http://fasb.org/us-gaap/2022#Liabilities</ix:nonNumeric><ix:nonNumeric id="F_e9f4b3d3-691b-4381-9a0b-ee7b93945cac" name="lyra:LeaseInitiationDate" contextRef="C_f6258f7a-902f-4145-8c22-422abafbe4f4">2020-04-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lyra-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_50d08448-36cd-45bf-bf96-7b413773153a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76c90dc7-305d-40d5-b5dc-e2b7e2b5fdde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9a9b4ce-3240-47fa-87b6-f4310526dffe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19f3c088-c2ce-4eed-bded-16d5bf3a940e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_274faa51-b01e-4850-a412-77a812b2749d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffdb9268-e81e-4854-abb7-7dc620a278a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd72f40f-15bc-4abd-9ca3-7c1f5c45455d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3cac587-28df-4995-8b75-2a1e2e20870c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d44362fb-4fc5-4481-be17-c8446450f94c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1150276-615f-4f08-88b8-81bc087d354d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b11a23eb-8f92-4a47-afbb-ff79b85ab2b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc16a771-bf4e-44a5-b112-8ea51be13588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:MarketBasedConditionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab6efa41-abc1-41e2-a447-bc1e9acb264e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bef293d-84d2-4550-baa7-b971b193887a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c64f210-b096-4f52-af04-9a9929413c0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86d35cfd-3d7d-4cd3-aad0-bbb425c6ea04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65a305a6-5b98-4d3a-a30d-a699dba9390c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30fc43ea-2218-4e8e-9220-f7894e107d70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_501a2778-23f4-4564-91d7-2770cfe05137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32a3b395-08bb-4bd8-8e69-bf7a8289138b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72a3022b-e3e8-4f67-b88c-e60be2a42056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2e5de28-b6f2-4a80-a975-f131ab84261b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db2e146e-6da1-4245-84c4-73c704b05e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b81447d-9f3f-4a61-a5b3-d086c511a31c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e88491c6-140e-4267-b33d-457c84a7b90d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_947e7a14-7124-4460-8622-c6ac515eacd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24c6e4df-a738-4298-9c1a-6fa22126a4d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e404146f-8c43-4dcb-b085-fef72fda8da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76580e45-0c6f-4827-9602-bda9e3bdb18d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56c02857-b6c9-47ae-b10d-01237cf26d18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_162858c9-f666-4eb7-be16-4f285ac5ff81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b069fcd9-9753-4c58-ba29-e3011d30aa97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4b292d3-94d2-4fbb-87a6-ac9741243b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f2c78a8-2fcc-49a1-9802-0c096355e6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87f11c83-03d7-43d6-be6a-f07729b1a6be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:PerformanceBasedCriteriaRelatedToScientificMilestonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85081da2-be87-496a-85a8-2491428bc94f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6c540e-0dee-49f8-b317-487ce471c7fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5ad16fc-e41d-4d55-b3e3-5c4dc3774b7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9dcd205a-e6a8-477e-b3ae-d74f48fdecea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2042739f-ff2e-4355-bf6e-f55d146a1334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c7ec31f-db19-4dca-ad79-3648a2ac432f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed0926d1-d179-4325-b910-278483ee97af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6a86586-b423-4033-bd3a-ef5d462ae4d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97589ddb-9445-4ee0-bf35-ac2868ceabab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aacb10f4-b39c-44f8-9057-452a5c746b5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ae07729-2d6f-4f3d-99ca-a96fa38b8e31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e0d2435-49ae-4291-85fd-1d7c3f1ac975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4825109d-f60c-4752-b276-40c0b1627135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:OpenSalesAgreement2021ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27b196b3-9d37-40ba-88f6-5c5770d52577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23a96427-b264-4ccf-a621-6b9aa5d2b550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d87b7e0-a503-4674-86f1-acabd1e0af4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e5eaed3-f8d9-42a7-a095-56cf4842b09e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fba1a08-71d7-45ba-a07a-724089146c63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d2f621d-ce9f-493a-be01-01b725615ebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bd706c2-ee7f-484b-8abe-a01b92725182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de44d7f7-7bdf-4087-aa60-6edb982677c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fb4fa36-a2d1-4278-8d67-32d8fe50d72f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc9a827e-3051-4dad-ab8e-60d812a8a89d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36e6caae-c368-4a2e-a60b-afef8e9340a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0e81f8d-8072-4ce7-bb01-1bc6a7641b89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86cdf56f-cd6f-4aa3-8f8d-0db4f6e082d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df183939-be99-4d3c-9b1f-74b82cfaddf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b59d6e76-1457-4f77-983e-3ed77e38bb34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca643c6d-178f-4cdd-919d-765a5892183d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a870f0e-a464-4613-8b30-3072bec4780a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f340881c-2e0f-4b0b-8367-5d095a57a0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb3a8b23-6728-4d59-a97d-1ecc7e3adfb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c20b9c24-a16c-4bcb-912d-93a745a09007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98c9dcf4-d3b8-48d5-812c-7b771021577f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49be5531-186a-4558-b31a-130bbf009546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:OpenSalesAgreement2021ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f95fb07-e221-4065-a799-bb4bc71b7c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbac6298-1ee5-459c-a52f-a26dcfb2675c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7887ec17-ea58-4a4a-bcdd-f4316823027d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fad3289e-7f1e-4eac-8c33-f77ea1386219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5d83e3e-bc90-46f1-8c80-aac50e8a3314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:PerformanceBasedCriteriaRelatedToScientificMilestonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ce20db0-1512-4e67-bb88-1bf3499c3582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4efe985e-4d85-45ef-b622-70a88c48d6e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58783042-c5b7-49c6-8ed2-272d1bada5b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cda70942-437f-46cb-bfca-673305f8f4dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_661e6304-38fc-4780-9c4b-9199c12da66d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1144d35-ca6f-497e-a18a-73cf52e16156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3aa72f08-9dea-4749-a7ce-7cde7d1d2163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6da6f05-7316-4bfb-b017-2251df6ace0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1a83be4-a034-4dba-99d0-ff646e8a3287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64558a68-90ad-4900-b292-8c860e88674b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_317254de-de84-4738-817e-1c29f2dbec3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab8a831d-cce2-4c50-b8fb-f3c8eb1c821a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de48ac60-b50a-4c29-8f31-b67fc2eace77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c41e863-c7f2-463b-9e14-58690fc53cbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3cb6888-3032-461e-8265-3245f2051004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfa4b7bb-7c8f-4561-8f51-cc77823b6c84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58907f21-5a15-4e54-ab25-e6d84a3c9652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a7c6366-9118-4794-b989-2d8394630634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d75bf0-5f97-4279-84fa-a52de2aac093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11390654-f6a8-4a62-8bd2-4e84437ccd94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f909c39-112d-4ab7-82d9-d31b6680680d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9fe63fe-accc-4fe2-9acf-9c7f5eb6a624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a4eab87-52a4-4143-a37b-fabafd2119ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12eb5289-6285-4814-bd77-f25959811158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lyra:CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6447ee5-c057-4921-8817-cccd0a901dc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e636ef1-70ab-4e6d-bbb9-b62e055ce520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50d4ea11-cb80-4911-8caa-b2ac6d60f202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2247c2b1-0ab0-4254-9c47-7754e5b3eb9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb418092-ad75-441f-aea1-c853723d2837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_946ce1f5-0df2-4562-bf11-7d539009d00f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a03fff14-a210-4e02-928c-f0e2c6e0d975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77e94b31-e6d8-437a-8894-b8188333e621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a18f3701-43ff-4fd7-a44f-d3b3dc016a73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42595f81-0b68-440f-b7f6-c0b65eb4d4fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_435574cf-1a94-488f-97a2-8dce8c5c419d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7939e4b4-a73f-4851-9eb8-a2e8bee1ad5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03cb3063-9002-40eb-a812-0f647395fbc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_259fea07-483e-459f-85c3-cc48ff87d140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86716da2-023d-4ddf-84dd-2aa61048c050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3558ff97-70d1-4ac8-90d8-25851e56f82f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:CommercialRevenueBasedMilestoneAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8445ea3c-4a1b-4d11-bc4a-34295fa25cb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6258f7a-902f-4145-8c22-422abafbe4f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e56cf9c7-99bc-4107-a492-f1caeb308084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc9e381c-707b-4016-a540-87b86a5d1ac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83e9be91-41f7-4203-b44e-71feb55201e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42784fde-fb41-49b8-91a2-89eeebce4be2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">lyra:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bce75e89-097d-40fe-96e7-7fef938bd51e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>lyra:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>lyra:Vote</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_42eb2d3f-d752-46f7-9771-2fc3935845e8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">o</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_69772ec5-cd14-43db-b7ff-5dfda3078b0c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_819663a6-f16a-4516-b226-0d7698671862" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a89c2812-129b-4778-8aff-3ae461fc2b56" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_3a89b6fb-cbd3-4314-97cd-4fdfed40f622" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4f328c9f-7ed0-4e49-841e-c7d1f6ee560d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dcfdb3a7-e0a4-414e-a6f8-9a902338be1d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.083%;"></td>
    <td style="width:49.917%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf452bda-3609-4013-b2da-e37541d15c1f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f54ad1b-612a-4acc-b58c-f3011c2d1e57" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84-1700838</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_714514c2-9bc3-4bd0-92cb-67e70d860da2" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">480 Arsenal Way</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99341db8-661d-4888-831a-98528b124ff0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38606be7-c1c0-4cfe-9128-2b37b911dab9" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f792c4d-ab01-4741-8599-2ebcd1dcde30" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7bbee9ad-a488-46c8-af60-9579f600a4e2" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3651ce8f-7aff-4112-a004-8c93bba672d0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">393-4600</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:38.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e832919-bfd5-4bbb-9394-a61a35c598bd" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4d5bc11-7c5e-43e7-8400-00633ecd07a8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a1044586-1a2c-4afe-a406-ad6739b4d8e1" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to section 12(g) of the Act: None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7417bd2d-e6df-42e2-b8dc-2577eff99246" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c801700d-59ec-4404-8405-e5491793a8b7" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_12c591ba-5c1d-4b41-ba0f-8b0843e006b1" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ca94111-c36f-47fd-975b-68e371344f46" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.685%;"></td>
    <td style="width:1.148%;"></td>
    <td style="width:2.287%;"></td>
    <td style="width:45.787%;"></td>
    <td style="width:23.676%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:2.278%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b13891f-d435-447e-b08d-4bc4de4aa432" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_f3426001-6fe4-4987-9ea4-549edf6dd019" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_5ac8998e-24ef-492c-8803-81c4da268a4e" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_0177a0a5-40e9-4eea-94ea-df58a4c65bfe" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_61be0e36-e015-462a-9771-80600095c64d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_685f5f0b-dd74-42c8-b87b-94523b4f39a6" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of outstanding shares of common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Global Market on June 30, 2022, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, was $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cb3d9a0-d34a-4eaf-aceb-c47f851a56c8" contextRef="C_58907f21-5a15-4e54-ab25-e6d84a3c9652" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,992,856</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For purposes of this disclosure, shares of common stock held by officers and directors of the registrant and by persons who hold more than 10% of the registrant&#x2019;s outstanding common shares have been excluded because such persons may be deemed to be affiliates.  This determination of affiliate status is not necessarily conclusive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of the registrant&#x2019;s Common Stock, $0.001 par value per share, outstanding as of March 1, 2023 was </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7196d3a4-a0c3-4979-a03b-ada7e8d99901" contextRef="C_5d87b7e0-a503-4674-86f1-acabd1e0af4d" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,829,774</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_52261440-d400-4a41-970e-9e60dd5e449f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.102%;"></td>
    <td style="width:82.0%;"></td>
    <td style="width:7.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_consolidated_financial_d"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements, including but not limited to statements regarding:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to develop and commercialize our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of our ongoing or planned clinical trials for LYR-210, LYR-220, and any future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approvals for LYR-210, LYR-220, and any future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical utility of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our commercialization, marketing, and manufacturing capabilities and strategy; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations about the willingness of healthcare professionals to use LYR-210, LYR-220, and any future product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the development and commercialization of LYR-210 pursuant to the terms of the LianBio License Agreement (as defined below);</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our intellectual property position; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitive position and developments and projections relating to our competitors or our industry; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to identify, recruit, and retain key personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of laws and regulations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks associated with the COVID-19 pandemic (&#34;COVID-19&#34;) and related macroeconomic factors, which may adversely impact our business and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates and statements regarding our future revenue, future results of operations, and financial position; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sufficiency of our cash and cash equivalents to fund out operations;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our remediation of a material weakness;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our business strategy; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our research and development costs; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the plans and objectives of management for future operations.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;would&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future viability;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we currently intend to manufacture clinical materials in-house, but we may rely on third parties for the manufacture of materials for our research programs, pre-clinical studies and clinical trials and we do not have long-term contracts with any of these parties. Any inability to scale up our internal capabilities, or our reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We may never achieve profitability;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our business is highly dependent on the success of our most advanced product candidate, LYR-210, which will require significant additional clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we identified a material weakness in our internal control over financial reporting that resulted in a restatement of our unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2022 and as of and for the three and six months ended June 30, 2022. This material weakness, if not remediated, could adversely affect our business, our stock price and our ability to report our results of operations and financial condition accurately and in a timely manner;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our obligations under our license and other strategic agreements may divert management time and attention, causing delays or disruptions to our business;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have entered into a collaboration, and may enter into collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we rely on third parties to conduct our pre-clinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to good clinical practices &#34;GCPs&#34; and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other significant personnel, or experience increases in our compensation costs, our business may materially suffer; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the global pandemic caused by COVID-19 has disrupted and may continue to adversely impact our business and operations, including our clinical trials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unless the context requires otherwise, we use the terms &#x201c;Lyra,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and similar designations in this Annual Report on Form 10-K to refer to Lyra Therapeutics, Inc. and its wholly-owned subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The drug embedded within LYR-210 and LYR-220 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery. A pivotal Phase 3 program of LYR-210, called the ENLIGHTEN program, consists of two pivotal trials and is currently ongoing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-220</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing our second pipeline product candidate, LYR-220, for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. LYR-220 is also designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. A Phase 2 clinical trial of LYR-220, called BEACON, is currently ongoing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Technology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The technology is comprised of three interrelated components:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a biocompatible mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an engineered elastomeric matrix, a polymeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with &#x201c;shape memory&#x201d; that dynamically adapt to nasal anatomy; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a versatile polymer-drug complex, which can be customized for the treatment of various chronic diseases treatable with ENT delivery to achieve the desired drug dose and drug elution rate. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                         </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our mission is to transform the ENT treatment paradigm by utilizing our proprietary technology to develop safe and effective therapies for the treatment of CRS. We intend to achieve this through the following strategies:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Complete the development and secure FDA approval of LYR-210 for the treatment of CRS.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We believe LYR-210, if approved, is well positioned in the CRS treatment paradigm. LYR-210, which is being studied in the ongoing Phase 3 ENLIGHTEN clinical program, utilizes MF, the active ingredient in various FDA-approved drugs. We intend to seek marketing approval for LYR-210 through a 505(b)(2) New Drug Application &#34;NDA&#34; submitted to the FDA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance our second product candidate, LYR-220, through clinical development to provide a comprehensive solution for CRS patients who have failed medical management and surgery. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed a larger version of LYR-210 designed for use in the enlarged nasal cavity of CRS patients who have had sinus surgery. We believe LYR-220, if successfully developed and approved, is well positioned to provide a preferred alternative to revision surgery and post-surgical medical management. LYR-220 is being studied in the ongoing Phase 2 BEACON clinical trial. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Build a commercialization infrastructure in the U.S. market for LYR-210 and LYR-220. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If either of our product candidates are approved, we plan to launch an efficient, go-to-market commercialization model focused on targeted outreach to our key physician, payor, and patient audiences. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chronic Rhinosinusitis: A Disease with High Unmet Medical Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRS is an inflammatory disease of the paranasal sinuses causing the soft, moist layer of mucus-producing tissue, or mucosa, that lines the sinuses to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies, or environmental factors, as well as structural issues such as blockages of an ostium.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRS has been described in the literature as an &#x201c;unrecognized epidemic&#x201d; due to its high prevalence, its substantial impact on patient quality of life, and the significant limitations of currently available treatment options. We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or approximately 30 million people, making it the fifth most common condition in people under the age of 65 and more prevalent than diabetes or heart disease. Of this population, we estimate that approximately 14 million people are affected by CRS. We estimate that approximately 8 million people are treated for CRS by physicians annually, of whom approximately 4 million fail medical management every year.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRS is grouped into two phenotypes for regulatory purposes: CRS without nasal polyps and CRS with nasal polyps. The non-polyp form of CRS represents approximately 70%-to-90% of CRS patients. Currently there are no approved treatments for CRS patients without polyps.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current Treatments and Their Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The goals of therapy for CRS are to reduce mucosal swelling resulting from underlying inflammation, promote sinus drainage, and eradicate infections that may be present. The treatment of CRS is progressive in nature and typically begins with medical management, primarily with topical intranasal steroids and oral steroids. Topical intranasal steroids typically do not reach the epicenter of the disease deep in the sinuses, have fast clearance and poor compliance. The systemic complications of oral steroids limit their use. If this treatment is unsuccessful, an ENT physician may perform sinus surgery. Sinus surgery is costly, does not address the underlying inflammation, and is invasive with significant post-operative pain.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, there are no FDA-approved drug therapies for CRS for non-polyp patients, although some drugs approved for nasal polyps are used off-label in this population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Solution for CRS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is an anti-inflammatory implantable drug matrix that is designed to consistently and locally elute MF to the inflamed mucosal tissue for up to six months in surgically na&#xef;ve CRS patients who fail medical management. MF, the active ingredient in various FDA-approved drugs, has a well-established efficacy and safety profile, which we believe will support the development process for LYR-210. LYR-210 is designed to enable sustained drug delivery at difficult-to-access nasal inflammation sites without the need for patient compliance, while avoiding the systemic side effects associated with oral steroids. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure by an ENT physician under endoscopic visualization via a single-use applicator. We are developing our second pipeline product candidate, LYR-220, for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. LYR-220 is also designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. LYR-220 is designed as a potential preferred alternative to revision sinus surgery and post-surgical medical management.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the key potential benefits of our current investigational product portfolio, LYR-210 and LYR-220, include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We believe LYR-210 and LYR-220 have the potential to significantly improve symptoms by maintaining a steady, high dose of MF at the site of inflammation for up to six months with a single administration. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient Compliance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Because drug delivery for LYR-210 and LYR-220 is designed to be sustained for up to six months with a single administration, the efficacy of LYR-210 and LYR-220 will not depend on patient compliance within the treatment period, unlike other CRS treatment options that require repeated daily administrations, such as topical intranasal steroids and oral steroids. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient Experience</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: LYR-210 and LYR-220 are designed to be administered via a simple, brief, non-invasive in-office procedure every six months, which is intended to enhance convenience for patients, unlike the repeated daily medical management and/or time-consuming and painful surgery required by certain other CRS treatment options. Moreover, we believe patients may also benefit from the biocompatible, flexible structure of LYR-210 and LYR-220 that is designed to maximize comfort over the therapy period. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Physician Experience</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: LYR-210 and LYR-220 are designed to enable physicians to perform the placement of LYR-210 and LYR-220 in-office in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for physicians to schedule separate surgical time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Localized Delivery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: LYR-210 and LYR-220 are designed to benefit from our technology, which is intended to provide localized delivery to avoid systemic side effects that are common with certain other CRS treatment options, such as oral steroids. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient Applicability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: LYR-210 and LYR-220 are designed to treat the entire spectrum of CRS patients who have failed medical management, including pre- and post-surgical patients and patients with and without nasal polyps. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacoeconomic Impact</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: LYR-210 and LYR-220 are designed as an alternative to surgery (initial or revision), and as such have the potential to provide significant savings to the healthcare industry by reducing the number and frequency of expensive surgical and biologic treatment options. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe LYR-210 and LYR-220, if approved, would be the only products able to deliver up to six months of continuous topical treatment in a single administration to treat the broad spectrum of CRS patients who fail medical management, including pre- and post-surgery patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Clinical Pipeline</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The current status of our clinical product candidates is summarized below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img222343278_0.jpg" alt="img222343278_0.jpg" style="width:502px;height:357px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 for the Treatment of CRS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe LYR-210, if successfully developed and approved, has the potential to become a preferred alternative to surgery for the treatment of CRS. It is the only product candidate that we are aware of that is designed to provide up to six months of local delivery of anti-inflammatory medication with a single administration. The brief, non-invasive, in-office procedure allows for its implantation without the need for surgery. Further, we believe our studies have shown that LYR-210 has the potential to be an effective treatment for both patients with and without polyps. We believe LYR-210 has the potential to be a safe, effective, and broadly applicable CRS treatment, designed to enhance patient comfort and physician experience and eliminate patient compliance issues associated with other CRS treatments, such as intranasal steroid sprays, while achieving reduced costs compared to other CRS treatments, such as sinus surgery.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img222343278_1.jpg" alt="img222343278_1.jpg" style="width:422px;height:320px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 3. Illustration of Placement of LYR-210 in Middle Meatus.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is an investigational local drug delivery system designed to fit within, and conform to, the confined space of a surgically na&#xef;ve patient&#x2019;s middle meatus, an air-containing space that plays a fundamental role in drainage of the paranasal sinuses (see Figure 3, above). LYR-210 consists of MF, the active ingredient in various FDA-approved drugs, embedded in biocompatible polymers to aid in the controlled and sustained delivery of MF to the sinonasal mucosal tissue from a single drug administration. LYR-210 has a tubular braid configuration with a uniform diamond pattern throughout and is 13 mm in diameter and 10 mm in length in the unconstrained state. It has elastic properties to promote patient comfort and is designed to be self-retaining against the mucosal tissue to allow effective drug transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is intended to be administered bilaterally into the non-operated middle meatus by an ENT physician under endoscopic visualization via a provided, single use applicator. It is designed for office-based administration performed with topical anesthesia. Once administered, LYR-210 is designed to gradually release MF to the inflamed mucosal tissue for up to six months from a single administration. LYR-210 can be removed at six months or earlier at the physician&#x2019;s discretion using standard instruments and, if needed, replaced with a new LYR-210. LYR-210 is made with bioresorbable polymers that, if left in place, would gradually dissolve over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Our Clinical Development for LYR-210</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below summarizes our completed and ongoing clinical trials for LYR-210 for CRS in patients who have failed medical management and have not undergone endoscopic sinus surgery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:15.456%;"></td>
    <td style="width:14.444%;"></td>
    <td style="width:17.52%;"></td>
    <td style="width:28.859%;"></td>
    <td style="width:23.72%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Status</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Design</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Objectives</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Results</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completed</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Prospective, multi-center, non-randomized, single-arm, open-label clinical trial</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 25-week trial, including 24 week treatment period, plus one week post-removal</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Bilateral 2,500 &#xb5;g dose</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 20 patients</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 5 study sites</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Study objective: Evaluate the safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Primary endpoint: Product-related serious adverse events from baseline to 4 weeks post-procedure</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Additional data collected: Morning serum cortisol, change in intraocular pressure, plasma pharmacokinetics, quality of life by SNOT-22 (secondary endpoint), endoscopy and MRI</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Primary safety endpoint achieved / 2,500 &#xb5;g was well tolerated during entire duration of treatment</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Significant improvement from baseline in SNOT-22 scores was observed from week 1 through week 25</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Average change in baseline SNOT-22 score at week 1 was -13.0 points (P= 0.008 to pre-treatment)</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Symptom relief, as measured by SNOT-22 score, was observed through the entire duration of study, achieving an average change from baseline of -20.5 points at week 24 (p &lt; 0.0001 to pre-treatment), which was the end of the treatment period, and -20.0 (p &lt; 0.0001) at week 25, which was the end of the study</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(LANTERN)</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completed</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, dose-ranging, parallel-group clinical trial</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 24-week treatment period, plus 24 week safety follow up post-removal</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Bilateral 2,500 &#xb5;g or 7,500 &#xb5;g dose</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 99 evaluable patients with the option to increase to up to 150 patients. Enrollment discontinued at 67 patients due to COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Up to 50 study sites globally</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 4 cardinal symptoms (4CSS) at week 4</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Secondary objectives: Symptom improvement at week 24, sinus imaging to assess reduction in inflammation, SNOT-22, time to treatment failure, reduction in inflammation, frequency of exacerbations, pharmacokinetics/pharmacodynamics</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; At the 7,500 &#xb5;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012) and week 24 (-1.64) (p=0.016).</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; At the 7,500 &#xb5;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001) and week 24 (-19.0) (p=0.001).</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#xb5;g dose (-0.36) (p=0.306) or 2,500 &#xb5;g dose (0.04)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:15.456%;"></td>
    <td style="width:14.444%;"></td>
    <td style="width:17.52%;"></td>
    <td style="width:28.859%;"></td>
    <td style="width:23.72%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Status</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Design</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Objectives</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trial Results</span></p><p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(p=0.525). We believe this was due primarily to the discontinuation of enrollment related to COVID-19.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PK Characterization Study</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completed</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 24 patients in the United States with bilateral 2,500 &#xb5;g or 7,500 &#xb5;g dose</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Pharmacokinetic timepoints through 56 days, safety, SNOT-22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; LYR-210 delivered a constant daily dose of MF over 56 days without a drug burst</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Steady state plasma concentrations were 41.2 pg/mL and 12.2 pg/mL in the 7,500 &#xb5;g and 2,500 &#xb5;g dose groups respectively</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Clinically relevant improvement from baseline in SNOT-22 observed within 2 weeks</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; LYR-210 safe and well tolerated with no serious adverse events</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ENLIGHTEN I)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiated February 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, parallel-group clinical trial</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 52-week trial duration: 24-week treatment period, followed by a safety extension period involving crossover treatment for control patients and 1:1 re-randomization to control or repeat treatment for LYR-210 patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Approximately 180 adult CRS patients who have failed prior medical management and 2:1 randomization (bilateral LYR-210 7,500 &#xb5;g): sham procedure</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Up to 60 sites worldwide</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 3 cardinal symptoms at week 24</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Secondary objectives: Change from baseline in individual cardinal symptoms at week 24, CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Recruiting</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ENLIGHTEN II)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiated September 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Randomized, blinded, sham-controlled, parallel-group clinical trial</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; 24-week treatment period</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Approximately 180 adult CRS patients who have failed prior medical management 2:1 randomization (bilateral LYR-210 (7,500 &#xb5;g)): sham procedure</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Up to 60 sites worldwide</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Primary endpoint: Change from baseline in composite score of 7-day average of 3 cardinal symptoms at week 24</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Secondary objectives: Change from baseline in individual cardinal symptoms at week 24, CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; Enrollment paused; expected to resume in the second quarter of 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The LYR-210 Phase 3 program consists of two pivotal trials &#x2013; ENLIGHTEN I and ENLIGHTEN II. ENLIGHTEN I is a 52-week, multi-center, randomized, blinded, sham-controlled trial designed to evaluate the efficacy and safety of LYR-210 in approximately 180 surgically na&#xef;ve CRS who have failed prior medical management. The trial consists of three stages &#x2013; a 2- to 4-week screening and run-in stage, a 24-week treatment stage followed by a 28-week safety extension stage. In the treatment stage, patients are randomized 2:1 to receive LYR-210 (7,500 &#xb5;g) or sham-procedure.  At the end of the treatment stage, patients in the control group receive crossover LYR-210 treatment while patients in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 group are re-randomized 1:1 to either receive a crossover sham-procedure or a repeat treatment with LYR-210 (7,500 &#xb5;g). The ENLIGHTEN I trial was initiated in February 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ENLIGHTEN II is a 24-week, multi-center, randomized, blinded, sham-controlled trial designed to evaluate the efficacy and safety of LYR-210 in approximately 180 surgically na&#xef;ve CRS patients who have failed prior medical management. The trial consists of two stages &#x2013; a 2- to 4-week screening and run-in stage and a 24-week treatment stage. Patients are randomized 2:1 to receive LYR-210 (7,500 &#xb5;g) or sham-procedure.  ENLIGHTEN II was initiated in September 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary endpoint of both ENLIGHTEN I and ENLIGHTEN II is change from baseline (CFBL) at week 24 in the composite score of 3 cardinal symptoms (3CS) score. The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. Secondary endpoints include CFBL in individual cardinal symptoms at week 24, CFBL in CT sinus opacification score at week 24, CFBL in SNOT-22 at week 24, rescue treatment use through week 24.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 8, 2022, we announced a pause in enrollment of ENLIGHTEN II to align with internal manufacturing timelines for clinical trial supply. We will focus our resources on the timely completion of ENLIGHTEN I during this period.  Moving forward, we intend to utilize our internal manufacturing capabilities in order to supply the entire ENLIGHTEN clinical program and mitigate any further risk to overall program timelines.  We believe that focusing on our internal manufacturing capabilities reduces risk associated with technology transfer to third parties. We expect to resume enrollment in ENLIGHTEN II in the second quarter of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Phase 2 LANTERN clinical trial for LYR-210 was initiated in May 2019. The clinical trial was designed as a multi-center, randomized, controlled, patient blinded trial. The study was designed to enroll 99 evaluable patients with the option to expand to up to 150 patients at up to 30 sites in the United States, Australia, Austria, Czech Republic, New Zealand, and Poland. Due to COVID-19, we discontinued enrollment at 67 patients and did not open any sites in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img222343278_2.jpg" alt="img222343278_2.jpg" style="width:406px;height:220px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 4. Design of Phase 2 LANTERN Clinical Trial for LYR-210.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial consisted of three arms with a 1:1:1 randomization: (1) an experimental arm with bilateral placement of 2,500 &#xb5;g of LYR-210, with 23 patients; (2) an experimental arm with bilateral placement of 7,500 &#xb5;g of LYR-210, with 21 patients; and (3) a control arm with a bilateral sham procedure only, with 23 patients (see Figure 4, above). In addition, subjects were supplied with saline for daily nasal irrigation treatment during the course of the treatment period and were permitted to use rescue medication if deemed medically necessary by their physician.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary endpoint of the trial was a change from baseline in the 7-day average scores of the 4CSS at week 4. Because the FDA prefers a composite score of the cardinal symptoms of CRS for patients with CRS, we utilized the 4CSS for the trial. The 4CSS is comprised of four domains that are scored 0-3 with a total score of 12. The four domains are: (1) nasal obstruction and congestion; (2) facial pain and pressure; (3) nasal discharge; and (4) olfactory loss (loss of sense of smell).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key secondary endpoints for the trial were the change from baseline in 7-day average 4CSS at week 24, time to treatment failure, and percentage of subjects with at least 1-point decrease in the bilateral Zinreich score (a measure of inflammation) in at least one pair of the anterior ethmoid, maxillary, posterior ethmoid, frontal, or sphenoid sinuses at Week 24.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we reported positive topline results from our Phase 2 LANTERN clinical trial. In our readout of top-line results, we reported that, at the 7,500 &#xb5;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012), and week 24 (-1.64) (p=0.016) (see Figure 5, below). However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#xb5;g dose (-0.36) (p=0.306) or 2,500 &#xb5;g dose (0.04) (p=0.525). We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order to achieve statistical significance for the primary endpoint.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><img src="img222343278_3.jpg" alt="img222343278_3.jpg" style="width:605px;height:308px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 5. Total Symptom Improvement by 4CSS for Phase 2 LANTERN Clinical Trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the 7,500 &#xb5;g dose of LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001), and week 24 (-19.0) (p=0.001) (see Figure 6, below). In particular, the improvement of the 7,500 &#xb5;g dose of LYR-210 at week 24 over the control group (-19.0) was over two times the minimal clinically important difference of -8.9.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img222343278_4.jpg" alt="img222343278_4.jpg" style="width:595px;height:307px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 6. Total Symptom Improvement by SNOT-22 for Phase 2 LANTERN Clinical Trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 was observed to be safe and well-tolerated at all doses in the trial. There was one serious adverse event, which was deemed to be unrelated to LYR-210. No treatment-related serious adverse events were reported. Treatment-related adverse events included epistaxis, rhinitis, rhinorrhea, and headache. All treatment-related adverse events were generally mild to moderate in nature, other than one incident of increased viscosity of upper respiratory secretion in the 2,500 &#xb5;g dose treatment arm, and in line with the known safety profile of MF.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />                  After 24 weeks, LYR-210 drug matrices were removed, and patients then underwent a 24-week post-treatment follow-up. The main objective of the post-treatment period was to assess long-term safety post-removal. LYR-210 continued to show strong safety through 24 weeks post-treatment with no increased incidence of treatment-related AEs. Approximately 50% of patients experienced a durable response post-removal of LYR-210 (7,500&#x3bc;g), with no worsening of 4CS scores from the Week 24 baseline, compared to approximately 90% of control patients who either experienced a worsening of 4CS scores from the Week 24 baseline or required a rescue treatment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because of developments relating to the COVID-19 pandemic, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States as planned. The LANTERN Phase 2 manuscript won the Clinical Science Maurice Cottle Award at the 67th Annual Meeting of the American Rhinologic Society (ARS) held in October 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmacokinetic characterization study</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PK study was a 56-day open label, multi-center, U.S. study of the PK and safety of LYR-210 in adult subjects with chronic rhinosinusitis. The primary objective of the study was to establish the PK profile of LYR-210 (see Figure 7, below). The study enrolled 24 patients, half of whom received LYR-210 2,500 &#xb5;g and the other half received LYR-210 7,500 &#xb5;g. The study indicated that both doses were safe and well tolerated, with the mean maximum plasma concentration, or Cmax, observed with the 7,500 &#xb5;g dose well below the Cmax established for FDA-approved formulations of mometasone furoate, or MF. MF blood plasma levels observed during the PK study support LYR-210&#x2019;s ability to deliver consistent and steady dosing over the entire treatment period. The PK study was selected as the top clinical abstract at the 67th ARS held in October 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><img src="img222343278_5.jpg" alt="img222343278_5.jpg" style="width:534px;height:236px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 7. Plasma MF Concentration for Pharmacokinetic Characterization Study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Phase 1 clinical trial for LYR-210 was a prospective, multi-center, non-randomized, single-arm, open-label clinical trial with adult surgically na&#xef;ve CRS patients who have failed medical management. The objective of the trial was to evaluate safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210 with an additional measurement taken one week post-removal. The trial was conducted across five sites in New Zealand and Australia. Forty LYR-210 matrices were placed bilaterally in 20 patients with and without nasal polyps. Each matrix contained 2,500 &#xb5;g of MF. LYR-210 met its primary safety endpoint, and significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale was observed through 25 weeks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1 trial achieved its primary safety endpoint at week 4. LYR-210 at 2,500 &#xb5;g was well tolerated by patients during the entire duration of treatment and also gave insight into the successful office-based placement of the matrix and clinical outcomes in non-polyp and polyp patients. There were no reports of unexpected adverse events, or AEs, or local nasal AEs, including epistaxis, nasal burning, nasal dryness, nasal irritation, and nasal septal perforation during the 24-week MF local dosing treatment duration. Additionally, no change in morning serum cortisol levels or intraocular pressures were noted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most common reported AEs were nasopharyngitis, upper respiratory tract infection, sinusitis, nasal odor, procedural headache, nasal discomfort, and facial pain. There was one serious adverse event, an acute myocardial infarction, which was deemed to be unrelated to LYR-210.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant reduction in SNOT-22 scores was observed at week 1 and this reduction persisted through week 25, the end of the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar efficacy was observed in both polyp and non-polyp patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-220 for the Treatment of CRS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing our second pipeline product candidate, LYR-220, for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. LYR-220 is a new investigative therapy for CRS patients with and without nasal polyps that have failed medical management and have had a prior endoscopic sinus surgery. In the treatment paradigm, LYR-220, if approved, is positioned for use in patients post-surgical intervention who continue to have recurrent CRS symptoms or relapse, as a potential preferred alternative to revision surgery. LYR-220 is also</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. We estimate that 40% of patients that present to an ENT physician with CRS have had a prior surgery. These patients represent the addressable market for LYR-220.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No product is currently approved by the FDA to treat post-surgery CRS patients that do not have polyps, representing the vast majority of such CRS patients. A three-month steroid-eluting sinus implant was approved by the FDA to treat CRS in adults with nasal polyps and three subcutaneously-administered monoclonal antibodies (mAbs) were recently approved as add-on maintenance therapy for uncontrolled disease in adults with nasal polyps. We believe LYR-220 is meaningfully differentiated from currently approved products because, if successfully developed and approved, it would be the only product able to deliver up to six months of topical treatment in a single administration to treat both polyp and non-polyp post-surgery CRS patients who fail medical management. Further, with respect to the mAbs, LYR-220 is differentiated because it would provide localized delivery so as to avoid systemic side effects with the added benefit of being a significantly more economical treatment alternative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, we initiated the Phase 2 BEACON clinical trial for LYR-220 which is a controlled, randomized, parallel-group study to evaluate safety, tolerability, pharmacokinetics, and efficacy comparing two designs of LYR-220 to control over a 24-week period in approximately 40 symptomatic adult CRS subjects who have had a prior bilateral sinus surgery. The trial consists of two parts &#x2013; Part 1 is designed to assess the feasibility of placement and procedural refinements in up to 10 patients who will receive one of two designs of LYR-220; in Part 2, approximately 40 patients will be randomized 1:1 to receive either one of two designs of LYR-220 or sham procedure. The primary endpoint of the trial is incidence of product-related unexpected serious adverse events. Other safety endpoints include incidence of serious and non-serious adverse events, new or worsening of abnormal clinically significant findings in lab values, ophthalmology exams, and nasal endoscopies. Efficacy endpoints include change from baseline in 3CS, SNOT-22 and other CRS symptoms, CFBL in ethmoid opacification by CT, and use of rescue treatments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we announced positive initial data from the Part 1, non-randomized portion of the BEACON trial, demonstrating the feasibility and tolerability of LYR-220 placement bilaterally in this patient population. All six patients were treated for at least six weeks and no serious or unexpected product related adverse events have been reported. Enrollment is complete in the Part 2, randomized stage of the BEACON trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Technology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. Our technology platform, developed over the past decade, was first patented in 2009 by members of our team who have extensive experience in drug formulation and delivery, materials science, and biotechnology. This expertise has allowed us to significantly improve upon polymer drug delivery technology and add shape-memory properties to bioresorbable polymeric implants, one of our key innovations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img222343278_6.jpg" alt="img222343278_6.jpg" style="width:624px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 1. Lyra&#x2019;s Proprietary Drug-Eluting Matrix.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug-eluting bioresorbable technology is comprised of three polymeric components, which are designed to work together to enable highly efficient, localized drug delivery (see Figure 1, above). This proprietary technology is designed to enable sustained delivery of medications for many months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches. The components of our technology include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biocompatible Mesh Scaffold</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;our biocompatible mesh scaffold is designed to maximize surface area for drug release while maintaining underlying tissue function. The mesh scaffold is comprised of bioresorbable polymers and is pliable to maximize patient comfort. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Engineered Elastomeric Matrix</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014; our engineered elastomeric matrix, which means a polymeric matrix composed of polymers having elastic characteristics, has advanced physical properties resulting in implants with &#x201c;shape memory&#x201d; that dynamically adapt to nasal anatomy and ensure persistent positioning in the target location. The matrix works in conjunction with the underlying mesh to exert outward retention force, keeping it in place as tissue remodels. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Versatile Polymer-Drug Complex</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014; our versatile polymer-drug complex can be customized for the treatment of various chronic diseases treatable with ENT delivery to achieve the desired drug dose and drug elution rate.    </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three integrated components are fundamental to the successful function and versatility of the technology. For application to a targeted tissue, the implant is compressed into a narrow applicator, which allows non-invasive placement deep within cavities of the ear, nose, and throat. The shape-memory properties ensure the implant self-expands as it is administered through the applicator to comfortably fit within and adapt to the target anatomy. The implant is designed to be oversized for the target anatomy and therefore will push outwards to stay fixed at the target location. Over time, as inflammation recedes due to the local drug therapy, the shape-memory properties are intended to allow the implant to actively adapt to the anatomy and continue to stay in place to elute drug locally for a prolonged period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beyond CRS, we believe our technology has potential applications in other disease areas, which we are exploring to further broaden its therapeutic potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property and Barriers to Entry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own all the material intellectual property rights related to our technology and product candidate portfolio. As of December 31, 2022, our product candidate portfolio is protected by issued and pending patents in the U.S. and major foreign countries with claims directed to devices, systems, and method of use, which, exclusive of possible patent term adjustments or extensions or other forms of exclusivity through 2036.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely upon know-how, continuing technological innovation, and technical barriers to entry, including manufacturing and drug delivery complexities, to develop and maintain our competitive intellectual property position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management Team</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management team has extensive drug development, manufacturing, and commercialization experience across a broad spectrum of disease areas, for both drug and drug-device combination products, with a successful track record in large pharmaceutical, medical device, and biotech companies. Additionally, our management team has been involved in the development of successfully approved and commercialized products including Avonex, Copaxone, Eylea, Rezurock, Taxus (drug-eluting stent), Velcade, and XenMatrix.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Approval Commercialization Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If LYR-210 and LYR-220 are successfully developed and approved, we intend to engage in targeted outreach to our key physician, payor, and patient audiences. ENT physicians are the primary treaters of CRS patients who have failed medical management and thus represent our target physician base. Given the requirement for endoscopic placement of our products, we plan to build a targeted in-house sales force that will target ENT physicians who perform 80% of the CRS procedural volume. Given that LYR-210 and LYR-220 can be administered in a brief, simple, in-office procedure requiring no additional equipment, we anticipate that our sales representatives&#x2019; time will primarily be directed at educating the ENT physicians around product attributes and patient selection. We plan to supplement our direct physician outreach with appropriate medical education and marketing efforts to further penetrate our physician base and drive adoption of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring physician and patient market access to our products will be critical to our success, and we plan to execute a holistic reimbursement strategy, consisting of a reimbursement support hub and field-based reimbursement experts, that will integrate payor coverage and physician practice management initiatives. We believe that the primary decision makers from a payor perspective are private payors, which represent approximately 80% of the payor mix for our products. We intend to deploy a market access team to educate payors on the clinical and pharmacoeconomic attributes of our products and to seek to secure favorable coverage policies and to maximize the covered lives that have reimbursement for our products. To maximize access to LYR-210 and LYR-220, we plan to develop a reimbursement support model which aims to reduce physician financial risk associated with physician-administered products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to our initial ENT physician and payor efforts, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician visits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 26, 2022, we entered into an amended License and Collaboration Agreement, or the LianBio License Agreement with LianBio Inflammatory Limited, or LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. Under the terms of the LianBio License Agreement, we received an upfront payment of $12.0 million and are eligible to receive up to $135.0 million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, we will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and we will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to our LYR-220 product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical, and, to a lesser degree, medical device companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel, in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 and LYR-220 are positioned following the failure of medical management and therefore are not anticipated to compete directly with branded, generic, or over-the-counter inhaled corticosteroids. LYR-210 is positioned for use in surgically na&#xef;ve CRS patients where the primary competitive treatment is surgical procedures, including endoscopic sinus surgery with and without balloon sinus dilation (BSD) and BSD as a standalone procedure. In this space, LYR-210 would be the only product we are aware of that may deliver six months of local treatment with a single administration as an alternative to surgical interventions. LYR-220 is positioned for use in patients who have had a prior endoscopic sinus surgery, but require ongoing medical management. Currently there are no competitive treatments for post-surgical patients without polyps, which represent the large majority of patients. For patients with polyps, LYR-220 would compete against steroid-releasing sinus implants and mAbs. We believe LYR-220 has competitive advantages over these interventions, including a longer elution profile than the existing sinus implant and no systemic exposure relative to mAbs. Key competitive factors affecting the commercial success of both LYR-210 and LYR-220 and any other product candidates we may develop are likely to be efficacy, safety, and tolerability profile, reliability, convenience of administration, price, and reimbursement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sanofi/Regeneron and Optinose are currently seeking to expand the indication of their existing products to include CRS patients without nasal polyps. If these indications are approved by the FDA, they could represent competition for non-polyp patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing and Supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently manufacture our drug delivery products at our facility in Watertown, Massachusetts with components supplied by external suppliers. This facility enables us to produce clinical trial material for all studies. We perform inspections of these components before use in our manufacturing operations. Using these components, we manufacture, assemble, inspect, and package our implants, and send them to a third-party sterilization vendor. After sterilization, we inspect the product and test via third-party laboratories to determine compliance with our specifications. Upon release of the lot to inventory, the product is labeled and distributed via a third-party vendor to clinical sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The API and a number of the components used in our implants are currently supplied to us from single source suppliers. We source our supplies from manufacturers with a track record of compliance with current good manufacturing practices, or cGMP. We rely on single source suppliers for some of our polymer materials, some extrusions, and molded components, and for finished goods testing, labeling, and distribution. Our ability to supply our products and to develop our product candidates depends, in part, on our ability to obtain successfully the API and polymer materials used in these products in accordance with regulatory requirements and in sufficient quantities. We plan to enter into manufacturing, supply, and quality agreements with our single source suppliers. We generally acquire our single source components pursuant to purchase orders placed in the ordinary course of business. We currently maintain sufficient supplies of the API and components from our single source suppliers to support our ongoing development activities. In the future, we intend to maintain sufficient supplies such that our ability to supply the clinic or commercial market will not be compromised and so as to allow for sufficient time necessary to obtain another source of API or components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently improving our manufacturing capabilities and increasing capacity to support larger scale clinical studies and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We actively seek to protect the intellectual property and proprietary technology platform that we believe is important to our business, which includes seeking and maintaining patents covering our technology platform and products, and any other inventions that are commercially or strategically important to the development of our business. We also rely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon trademarks to build and maintain the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business. For more information, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents and Patent Applications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we own 24 issued U.S. patents, 16 foreign issued patents, 4 PCT pending applications, 7 U.S. pending applications, and 24 foreign pending applications, out of which 17 issued U.S. patents, 16 foreign issued patents, 7 U.S. pending applications, and 24 foreign pending applications are directed to our technology, LYR-210, and LYR-220.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All technology to our business has been developed in-house and is protected with patents and patent applications in three major lineages, along with the beginning of a fourth, more recent lineage of patent applications. The first lineage dates from 2009 and provides protection potentially until 2030, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This first lineage includes issued patents in the U.S., Europe, Japan, Canada, and Great Britain that are not limited to any particular drug, site of delivery, or patient condition, but specify features of the implant, delivery system, method, and polymers. The second lineage dates from 2015 and provides protection potentially until 2036, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This second lineage includes issued patents with ENT-specific method claims directed to the specific drug, site of delivery (i.e., middle meatus), and patient condition, with allowed and issued cases in the U.S., China, and Japan along with numerous pending applications in the U.S., Europe, Japan, Canada, China, and Great Britain. The third lineage dates from 2017 with the prospect of patent protection potentially until 2038, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This third lineage attempts to capture the products drug release features and patient results from the recent clinical trial. It includes allowed cases in Australia and Great Britain, along with pending applications in the U.S., Canada, Australia, Europe, Korea, Singapore, China, and Japan. The fourth lineage dates from 2021 and provides protection potentially until 2042, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. The fourth lineage is directed to a higher drug load (7500 ug).  The lineage stems from a patent application filed under the Patent Cooperation Treaty that will enter the National Phase in September of 2023.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks and Trade Secrets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely upon trade secrets, know-how, and continuing technological innovation, and may pursue licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements, invention assignment agreements, and non-solicitation and non-compete agreements with suppliers, employees, consultants, and others who may have access to proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state, and local levels, and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of pharmaceutical products such as those we are developing. We will be required to navigate the various preclinical, clinical, and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The processes for obtaining regulatory approvals in the United States and other countries, as appropriate, along with subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations, require the expenditure of substantial time and resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, we are subject to extensive regulation by the FDA, which regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations, and other federal, state, and local regulatory authorities. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#x2019;s Good Laboratory Practice regulations; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#x2019;s identity, strength, quality, and purity; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility at which the drug is produced and selected clinical sites to assess compliance with current Good Manufacturing Practice, or cGMP, regulations; GCPs; and the integrity of the clinical data;</span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payment of user fees; and </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing our product candidates using an innovative drug delivery technology comprised of a mesh scaffold, an elastomeric matrix, and a polymer-drug complex delivered through a narrow applicator. In the United States, products composed of components that would normally be regulated by different centers at the FDA are known as combination products. Typically, the FDA&#x2019;s Office of Combination Products assigns a combination product to a specific Agency Center as the lead reviewer. The FDA determines which Center will lead a product&#x2019;s review based upon the product&#x2019;s primary mode of action. Depending on the type of combination product, its approval, clearance, or licensure may usually be obtained through the submission of a single marketing application. We anticipate that LYR-210 and LYR-220 will be regulated as drugs, and for each product candidate, the FDA will permit a single regulatory submission seeking approval. However, the FDA sometimes will require separate marketing applications for individual constituent parts of the combination product which may require additional time, effort, and information. Even when a single marketing application is required for a combination product, such as an NDA for a combination pharmaceutical and device product, both the FDA&#x2019;s Center for Drug Evaluation and Research and the FDA&#x2019;s Center for Devices and Radiological Health may participate in the review. An applicant will also need to discuss with the Agency how to apply certain premarket requirements and post-marketing regulatory requirements, including conduct of clinical trials, adverse event reporting, and cGMPs, to their combination product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective, and a clinical trial proposed in the IND may begin 30 days after the FDA receives the IND, unless before</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three or four sequential phases, which may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 4: In some cases, the FDA may conditionally approve an NDA for a product candidate on the sponsor&#x2019;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post-approval trials are typically referred to as Phase 4 clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketing Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of 10 months to review and act on a standard NDA and 6 months to review and act on a priority NDA, measured from the &#x201c;filing&#x201d; date for an NDA for a new molecular entity, or NME, or from the receipt date for an NDA for a non-NME product. Measuring from the &#x201c;filing&#x201d; date typically adds approximately two months to the timeline for review and decision because the FDA has sixty days from receipt to make a &#x201c;filing&#x201d; decision, as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#x2019;s continued safety, quality, and purity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole basis for marketing approval if (1) the foreign data are applicable to the U.S. population and U.S. medical practice, (2) the studies were performed by clinical investigators with recognized competence, and (3) the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The testing and approval process for an NDA requires substantial time, effort, and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit, or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met to secure final approval of the NDA and may require additional clinical testing, preclinical testing, manufacturing, or formulation modifications or other changes in order for the FDA to reconsider the application. Even with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Hatch-Waxman Amendments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current regulatory strategy is to pursue development of LYR-210 as a Section 505(b)(2) NDA. As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments. A Section 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness, or both for an approved drug product. As such, under Section 505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant. Therefore, if we can satisfy the conditions required for a Section 505(b)(2) NDA submission, it may eliminate the need for us to conduct some of the preclinical studies or clinical trials for the new product candidate that might otherwise have been required, although the review time is not shortened. The FDA may then approve the new product candidate for the new indication sought by the 505(b)(2) applicant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orange Book Listing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#x2019;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Any applicant who files an Abbreviated New Drug Application, or ANDA, seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed in the Orange Book for the referenced drug, to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the date on which such patent expires, or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. The fourth certification described above is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA refers. The applicant may also elect to submit a &#x201c;section viii&#x201d; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. This section viii statement does not require notice to the patent holder or NDA owner. There might also be no relevant patent certification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant. Even if the 45 days expire, a patent infringement lawsuit can be brought and could delay market entry, but it would not extend the FDA-related 30-month stay of approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired. Specifically, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon NDA approval of an NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#x201c;active moiety&#x201d; is defined as the molecule or ion responsible for the drug substance&#x2019;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#x2019;s findings regarding that drug, except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. This exclusivity period may be extended by an additional six months if certain requirements are met to qualify the product for pediatric exclusivity, including the receipt of a written request from the FDA that the NDA holder conduct certain pediatric studies, the submission of study reports from such studies to the FDA after receipt of the written request, and satisfaction of the conditions specified in the written request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Review and Approval Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the &#x201c;filing&#x201d; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, a sponsor can request designation of a product candidate as a &#x201c;breakthrough therapy.&#x201d; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA and other government authorities, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes, or other labeling claims, are subject to prior FDA review and approval. There also are continuing annual program fee requirements for any marketed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state authorities, and are subject to periodic unannounced inspections by the FDA and these state authorities for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters, or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:10.13%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.708690330477356%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA and other authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare and Data Privacy and Security Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business. Such laws include, without limitation, U.S. federal anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, data privacy and security, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers, and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health-related and other personal information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act, or HIPAA, thus complicating compliance efforts. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligation, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#x2019;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged and examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#x2019; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal, or replace the ACA will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020, through December 31, 2021, absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 58 full-time employees. None of our employees is represented by a labor union or covered by a collective bargaining agreement. Employee turnover has not had a material impact on our operations. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated under the laws of the state of Delaware in November 2005 under the name WMR Biomedical, Inc. In July 2018, we changed our name to Lyra Therapeutics, Inc. Our principal executive offices are located at 480 Arsenal Way, Watertown, MA 02472 and our telephone number is (617) 393-4600. Our website address is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.lyratx.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The information contained in, or accessible through, our website does not constitute a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Internet address is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.lyratx.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are filed with the U.S. Securities and Exchange Commission, or the SEC, and are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. Our filings with the SEC may be accessed through the SEC&#x2019;s website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">http://www.sec.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information contained in this Annual Report on Form 10-K before making an investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. See &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company established in November 2005. Our operations to date have been limited to financing and staffing our Company, developing our technology, and identifying and developing our product candidates. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We have not yet demonstrated an ability to obtain marketing approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for, and commercializing CRS treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant operating losses in each year since our inception, including operating losses of approximately $55.3 million and $43.5 million for the fiscal years ended December 31, 2022 and December 31, 2021, respectively. In addition, we have not commercialized any products and have never generated any revenue from product sales. We have devoted almost all of our financial resources to research and development, including our pre-clinical development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we expect to continue to incur significant additional operating losses for the foreseeable future as we seek to advance product candidates through pre-clinical and clinical development, expand our research and development activities, develop new product candidates, complete pre-clinical studies and clinical trials, seek regulatory approval, and, if we receive FDA approval, commercialize our products. In order to obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as non-clinical or pre-clinical studies, as well as human tests, which are referred to as clinical trials. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with ENT disease treatment product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue the two pivotal Phase 3 ENLIGHTEN clinical trials of our most advanced product candidate, LYR-210; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete the Phase 2 BEACON clinical trial of LYR-220; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish manufacturing and supply chain capacity sufficient to provide clinical and commercial quantities of any product candidates for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional staff, including clinical, scientific, technical, manufacturing, regulatory, operational, financial, commercial, and support personnel, to execute our business plan; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add clinical, scientific operational, financial, and management information systems and personnel to support our product development and potential future commercialization efforts, and as to enable us to operate as a public reporting company; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utilize external vendors for support with respect to research, development, commercialization, regulatory, pharmacovigilance, and other functions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license other commercial products, product candidates, and technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand internationally; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">make royalty, milestone, or other payments under any future in-license agreements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operate as a public company. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our ability to successfully develop, commercialize, and license our products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our product candidates will require additional pre-clinical and/or clinical development, potential regulatory approval in multiple jurisdictions, the securing of manufacturing supply, capacity, and expertise, the use of external vendors, the building of a manufacturing and commercial organization, substantial investment, and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing manufacturing, sales, and market acceptance of our products and marketing infrastructure to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need significant additional funding in order to complete development of, manufacture, and obtain regulatory approval for our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to need additional capital, which we may raise through equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements or other sources. Additional sources of financing might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned clinical trials or obtain approval of any of our product candidates from the FDA, or any foreign regulatory authorities, and could be forced to discontinue product development. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial funds to further develop, manufacture, obtain approval for, and commercialize our product candidates, including LYR-210, for which we have initiated two pivotal Phase 3 clinical trials. We will also require substantial funds to further develop, obtain approval for, and commercialize our other product candidate, LYR-220, which is currently being studied in a Phase 2 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into mid-2024. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of LYR-210 and LYR-220 is highly uncertain, we are unable to estimate the actual funds we will require for development, approval, and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope and results of our pre-clinical studies and clinical trials, including any unforeseen costs we may incur as a result of pre-clinical study or clinical trial delays due to COVID-19 or other causes; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for LYR-210 and LYR-220; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of changes in the regulatory environment and enforcement rules; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing in changes in pharmaceutical pricing and reimbursement infrastructure; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other patent-related costs, including any litigation costs and the results of such litigation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we in-license or acquire other products and technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of establishing sales, marketing, manufacturing, and distribution capabilities for our product candidates in regions where we choose to commercialize our products; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, progress, timing, and results of our commercialization of LYR-210 and LYR-220, if approved for commercial sale. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending on our business performance, the economic climate, and market conditions, we may be unable to raise additional funds through any sources. Market volatility resulting from COVID-19 or other causes could also adversely impact our ability to access capital as and when needed. If we are unable to obtain adequate funding on a timely basis, we may be required to curtail or discontinue one or more of our development programs for LYR-210 or LYR-220, or to reduce our operations. If we raise additional funds by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preference over those of our existing common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our operations and our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, redeeming our stock, making certain investments, and engaging in certain merger, consolidation, or asset sale transactions, among other restrictions. If we raise additional funds through additional collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We identified a material weakness in our internal control over financial reporting that resulted in a restatement of our unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2022 and as of and for the three and six months ended June 30, 2022. This material weakness, if not remediated, could adversely affect our business, our stock price and our ability to report our results of operations and financial condition accurately and in a timely manner.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any changes and material weaknesses identified through such evaluation in those internal controls.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or combination of deficiencies, in internal controls that is less severe than a material weakness, yet important enough to merit attention by those charged with governance. When evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the &#x201c;Sarbanes-Oxley Act&#x201d;).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As described in Part I, Item 4 &#x201c;Controls and Procedures&#x201d;, we identified a material weakness in our internal control over financial reporting related to the accounting and reporting for the LianBio License Agreement entered into with LianBio, which resulted in a restatement of our financial statements for the three months ended March 31, 2022 and the three and six months ended June 30, 2022. Accordingly, our management concluded that our internal control over financial reporting was not effective as of December 31, 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To respond to this material weakness, we have devoted, and plan to continue to devote, significant effort and resources to the remediation and improvement of our internal control over financial reporting. The elements of our remediation plan can only be accomplished over time, and we can provide no assurance that these initiatives will ultimately have the intended effects. For a discussion of management&#x2019;s consideration of the material weakness identified with respect to our accounting and reporting for the LianBio transaction, see Part II, Item 9A, &#x201c;Controls and Procedures.&#x201d;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure to remediate our existing or any future material weaknesses or otherwise maintain effective internal control over financial reporting could adversely impact our ability to report our financial position and results of operations on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations and may lose confidence in our financial reporting and our business, reputation, results of operations, liquidity, financial condition, stock price and our ability to access the capital markets could be adversely affected. In addition,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to maintain or regain compliance with applicable securities laws, stock market listing requirements and covenants regarding the timely filing of periodic reports. We may be subject to regulatory investigations and penalties by the SEC, Nasdaq or other regulatory authorities, and we may face claims invoking the federal and state securities laws. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We can provide no assurance that the measures we have taken and plan to take in the future will remediate the material weakness identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or circumvention of these controls. In addition, even if we are successful in strengthening our internal controls and procedures, in the future these internal controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have no approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have no approved product on the market and have generated no product revenues. Unless we receive approval from the FDA or other regulatory authorities for our product candidates, we will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and licensing fees and grants, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates are in various stages of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a biotechnology company focused on the development and commercialization of novel integrated drug and drug delivery solutions for the localized treatment of patients with ENT diseases. Our product candidates are in clinical development, and favorable results in early-stage clinical trials may not be predictive of success in later clinical trials and may not lead to commercially viable products for any of several reasons. For example, our product candidates may fail to be safe and effective in current or future clinical trials or pre-clinical studies, or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. Our product candidates will require significant additional development, clinical trials, regulatory authorizations, and additional investment by us before they can be commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of our most advanced product candidate, LYR-210, which will require significant additional clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for, and successfully commercialize our most advanced product candidate, LYR-210. We currently have no products that are approved for commercial sale and have not completed the development of any product candidates, and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to LYR-210, which will require additional clinical development and potential additional pre-clinical development, management of clinical and medical affairs and manufacturing activities, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, the building of a commercial organization, substantial investment, and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that LYR-210 will be successful in ongoing or future clinical trials, receive regulatory approval, or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market LYR-210 from the FDA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. Nor can we be certain that, if and when approved, the safety and efficacy profile of LYR-210 or our other product candidates will be consistent with the profiles observed in clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We advanced LYR-210 through our Phase 2 randomized, controlled, patient blinded LANTERN clinical trial, evaluating the safety and efficacy in surgically na&#xef;ve CRS patients who have failed previous medical management. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, and Poland. In December 2019, the FDA authorized our investigational new drug application, and, prior to the COVID-19 pandemic, we planned to enroll patients in the United States. However, in light of developments relating to the COVID-19 pandemic, as described below, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 7, 2020, we reported top-line results from our Phase 2 LANTERN clinical trial, including that LYR-210 failed to meet the primary endpoint of the trial. We believe this was primarily due to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67) patients in our Phase 2 LANTERN clinical trial, a greater magnitude of change in composite score of the seven-day average of four cardinal symptoms from baseline at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order for the trial to achieve statistical significance for the primary endpoint. There can be no assurance that we will achieve the primary endpoint or any other endpoints in the ENLIGHTEN Phase 3 clinical trials we conduct for LYR-210.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, while we leveraged remote electronic data collection to enable us to complete the clinical assessments and generate sufficient information in our Phase 2 LANTERN clinical trial to commence designing our Phase 3 clinical trial, there can be no assurance that COVID-19 or other delays or disruptions will not hinder our electronic data collection or our ability to collect data or measurements requiring sinus imaging to assess reduction in inflammation and phlebotomy to assess pharmacokinetics/pharmacodynamics. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to COVID-19, and as a result, we initiated a separate characterization study in September 2020, as a follow-on to our Phase 2 LANTERN clinical trial, in order to collect such data. The characterization study was a 56-day open label, multi-center, U.S. study of the PK and safety of LYR-210 in adult subjects with chronic rhinosinusitis. The primary objective of the study was to establish the PK profile of LYR-210. The study enrolled 24 patients, half of whom received LYR-210 2,500 &#xb5;g and the other half received LYR-210 7,500 &#xb5;g. The study indicated that both doses were safe and well tolerated, with the mean maximum plasma concentration, or Cmax, observed with the 7,500 &#xb5;g dose well below the Cmax established for FDA-approved formulations of mometasone furoate, or MF. MF blood plasma levels observed during the PK study support LYR-210&#x2019;s ability to deliver consistent and steady dosing over the entire treatment period. There can be no assurance that any future trial we may conduct will not be affected or further affected by COVID-19 or other delays and disruptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the required regulatory approvals for LYR-210 are not obtained or are significantly delayed, including as a result of COVID-19, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is our most advanced product candidate, and if we experience regulatory or developmental issues with respect to LYR-210, our development plans and business could be significantly harmed. Moreover, if we experience similar regulatory or developmental issues with our other pipeline product candidates, our development plans and business could be significantly harmed. Further, our competitors may be developing products with similar mechanisms of action and may experience problems with their products that could identify problems that would potentially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Managing our obligations under our license and other strategic agreements may divert management time and attention, causing delays or disruptions to our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and as amended on September 26, 2022, we have entered into the LianBio License Agreement. The LianBio License Agreement grants an exclusive license to develop and commercialize the Company&#x2019;s product candidate LYR-210, an anti-inflammatory, intra-nasal drug matrix designed to treat chronic rhinosinusitis Disease in Greater China (mainland China, Hong Kong, Macau, and Taiwan), Singapore, South Korea, and Thailand, or the Territory. Furthermore, under the LianBio License Agreement, LianBio has the first right to obtain a license to develop and commercialize Lyra&#x2019;s product candidate LYR-220, an anti-inflammatory, intra-nasal, drug matrix in development for the treatment of chronic rhinosinusitis patients who have undergone a prior sinus surgery but continue to have persistent disease in the Territory. We also may in the future enter into license and strategic agreements, which, subject us to various obligations, including diligence obligations, reporting and notification obligations, payment obligations for achievement of certain milestone as well as other material obligations. We may need to devote substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert management&#x2019;s time and attention away from our research and development programs or other day-to-day activities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our license and strategic agreements are also complex and certain provisions in those agreements may be susceptible to multiple interpretations. In the event of any disagreement about the interpretation of these provisions, our management may need to devote a disproportionate amount of its attention to resolving these disagreements. Such disruptions may cause delays in our research and development programs and other business objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our license and strategic agreements, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to the LianBio License Agreement, we made certain covenants to not commercialize a competing product anywhere in the Territory, nor collaborate with, enable, or otherwise authorize, license, or grant any right to any third party to commercialize a competing product anywhere in the Territory, subject to certain carve-outs. We also made certain covenants to grant an exclusive option to LianBio for the development and commercialization of our product candidate, LYR-220, in the Territory. These provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other product candidates and may materially harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market and sell our products in jurisdictions outside of the United States, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Additionally, we may be dependent on third-party collaborators to develop and commercialize our product candidates in certain international jurisdictions, such as in the case of our exclusive license agreement with LianBio for the development and commercialization of LYR-210 in the Territory. In the agreement with LianBio, while we have agreed that we must use commercially reasonable efforts to complete a global Phase III clinical trial for LR-210 and seek regulatory approval for the same in the United States, LianBio must also use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize LYR-210 in the Territory.  We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We and our third-party collaborators may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have entered into a collaboration, and may enter into collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug development programs and the potential commercialization of our drug candidates will require substantial additional cash to fund expenses. For some of our drug candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those drug candidates in selected geographic territories or for selected patient populations. For example, in May 2021, we entered into the LianBio License Agreement to develop and commercialize LYR-210 in the Territory. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration or successfully maintain a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed or existing collaboration and the proposed or existing collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate. The terms of any existing or additional collaborations or other arrangements that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify and successfully commercialize additional product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates we develop may nevertheless be covered by third parties&#x2019; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities, or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product candidates may not be effective in treating their targeted diseases or symptoms; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. If we are unable to identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated the pivotal Phase 3 clinical trials for our most advanced product candidate, LYR-210. Additionally, our other product candidate, LYR-220, commenced its Phase 2 BEACON clinical trial in November 2021. It is impossible to predict when or if either of our product candidates will prove effective and safe in humans or if we will receive regulatory approval for any of our product candidates, and the risk of failure through the development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical development is a long, expensive, and uncertain process that is subject to significant delays. Due to known or unknown circumstances beyond our control, it may take us several years to complete our testing, and failure can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. We cannot assure you that any clinical trial that we are conducting, or may conduct in the future, will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays associated with products for which we are directly conducting pre-clinical studies or clinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of pre-clinical studies or clinical trials may be delayed by, or terminated because of, many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our pre-clinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to obtain regulatory approval to commence a trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to reach, or delays in reaching, an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">slower than expected rates of recruitment of patients or failure to recruit a sufficient number of patients; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">modification of pre-clinical studies or clinical trial protocols; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements for pre-clinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of unusual placebo effects; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the lack of effectiveness during pre-clinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the emergence of unforeseen safety issues or undesirable side effects; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to obtain institutional review board, or the IRB, approval at each site; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays, suspension, or termination of clinical trials by the IRB responsible for overseeing the trial at a particular trial site; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of patients in completing a trial or returning for post-treatment follow-up; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites deviating from trial protocol, dropping out of a trial, or failing to comply with regulatory requirements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to address patient safety concerns that arise during the course of a trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to manufacture sufficient quantities of product candidate for use in clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">government, IRB, or other regulatory delays or &#x201c;clinical holds&#x201d; requiring suspension or termination of the trials; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from COVID-19. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators, IRBs, or independent ethics committees, or IECs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may experience delays in reaching or fail to reach agreement on acceptable pre-clinical study or clinical trial contracts or pre-clinical study or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of pre-clinical studies or clinical trials of our product candidates may be greater than we anticipate and we may not have funds to cover the costs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct pre-clinical studies or clinical trials of our product candidates, or commercialize our products, may be insufficient or inadequate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any current or future collaborators that conduct pre-clinical studies or clinical trials may face any of the above issues, and may conduct pre-clinical studies or clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to extend the duration of current pre-clinical studies or clinical trials or to conduct additional pre-clinical studies or clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete pre-clinical studies or clinical trials of our product candidates or other testing, if the results of these trials, studies, or tests are not positive or are only modestly positive, if there are safety concerns, or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur unplanned costs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could encounter delays if a clinical trial is materially modified, suspended, or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial, or by the FDA or other regulatory authorities. Such authorities may impose a material modification, suspension, or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects for our product candidates, or other products or product candidates in the same drug class, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials and while we would have agreements governing their committed activities, we would have limited influence over their actual performance, as described in &#x201c;&#x2014;Risks Related to Our Dependence on Third Parties.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our most advanced product candidate, LYR-210, is in clinical development and will require the completion of clinical testing before we are prepared to submit an NDA for regulatory approval. We cannot predict if or when we might complete the development of LYR-210 and submit an NDA or whether any such NDA will be approved by the FDA. We may also seek feedback from the FDA or other regulatory authorities on our clinical development programs, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. If the results of ongoing and future clinical trials for LYR-210 are positive, we plan to submit an NDA in the United States. However, no assurance can be given that we will be successful in the near term, obtain regulatory approval, or have any commercial sales of LYR-210.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities. For example, our Phase 2 LANTERN clinical study for LYR-210 did not meet its primary endpoint and the FDA may not find such result to be sufficient to advance to a Phase 3 pivotal study. Pre-clinical and clinical data can be interpreted in different ways by different reviewers and regulators, which could delay, limit, or prevent regulatory approval. Drug-related adverse events during a pre-clinical study or clinical trial could cause us to repeat a trial or study, perform an additional trial or study, expand the size and/or duration of a trial or study, terminate a trial or study, or even cancel a pre-clinical or clinical program. The failure of pre-clinical studies or clinical trials to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of our NDAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our future and ongoing pre-clinical studies and clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of LYR-210, LYR-220, and/or any future product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays in the commencement or completion of, or have to extend or expand, our pre-clinical studies or clinical trials, or if we terminate a pre-clinical study or clinical trial prior to completion, the commercial prospects of LYR-210, LYR-220, or any future product candidate could be harmed, and our ability to generate revenues from LYR-210, LYR-220, or any future product candidate may be delayed. In addition, any delays in our pre-clinical studies or clinical trials could increase our costs, slow down the development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of pre-clinical studies or clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our pre-clinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates and the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both of our current product candidates are in clinical development. Notwithstanding the data obtained to date with respect to LYR-210 and LYR-220 in CRS, LYR-210 and LYR-220 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from our product sales. In addition, if we encounter safety or efficacy problems, developmental delays or regulatory issues, delays caused by COVID-19, or other problems, our developmental plans and business could be significantly harmed. For example, our Phase 2 LANTERN clinical trial for LYR-210 failed to meet its primary endpoint which may delay our overall commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the development of LYR-210, LYR-220, or any other future product candidate is unsuccessful, our ability to generate revenues will be adversely affected. Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new products and product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in product development, pre-clinical, or clinical testing or manufacturing; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unplanned expenditures in product development, pre-clinical, or clinical testing or manufacturing; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to receive regulatory approvals; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to secure rights from third parties for new technology; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to achieve market acceptance; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">emergence of superior or equivalent products. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, product candidates in later stages of clinical trials may fail to show the desired safety profiles and efficacy results despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we have not conducted, nor do we believe we are required to conduct, any head-to-head trials comparing LYR-210 to other approved or experimental treatments for CRS. Any such head-to-head trial, if conducted, may show that LYR-210 is not more effective than any of such other drugs. Material adverse differences in the relative efficacy of LYR-210 could significantly harm the adoption of LYR-210 and our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of these risks, our research and development efforts may not result in any commercially viable products. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Success in pre-clinical or earlier clinical trials may not be indicative of results in future clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Pre-clinical studies and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, study pharmacokinetics and pharmacodynamics, and understand the side effects of product candidates at various doses and schedules. Success in pre-clinical studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials. For example, our Phase 2 LANTERN clinical trial for LYR-210 failed to meet its primary endpoint and we may be required to conduct additional trials to evaluate the efficacy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of this product candidate beyond those trials we currently anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical studies and earlier-stage clinical trials. Data obtained from pre-clinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates may likely take significantly longer, cost significantly more, and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to seek FDA approval for our current product candidates, LYR-210 and LYR-220, and we may seek FDA approval for future product candidates, through the Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#x2019;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as we anticipate, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and complications and risks associated with the development of our product candidates, would likely substantially increase. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in competitive products reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization, or that a competitor would not obtain approval first along with subsequent market exclusivity from the FDA, thereby delaying potential approval of our product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have conducted, are conducting, and, in the future, may conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have conducted and are conducting clinical trials for LYR-210 outside the United States, specifically in Australia, Austria, Czech Republic, New Zealand, and Poland, and we may in the future choose to conduct other clinical trials outside the United States for LYR-210, LYR-220, or any of our other future product candidates. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an IEC and receipt of informed consent from subjects. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign exchange fluctuations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing, customs, shipment, and storage requirements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cultural differences in medical practice and clinical research; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publish interim or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between interim or preliminary data and final data could significantly harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LYR-210 and LYR-220 are drug-device combinations, which may result in additional regulatory and other risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 and LYR-220 are drug-device combination products. We may experience delays in obtaining regulatory approval of these product candidates given the increased complexity of the review process when approval of a drug and a delivery device is sought under a single marketing application. Both LYR-210 and LYR-220 will be regulated as drug-device combination products, which require coordination within the FDA and similar foreign regulatory agencies for review of the product candidates&#x2019; device and drug components. The determination whether a combination product requires a single marketing application or two separate marketing applications for each component is made by the FDA on a case-by-case basis. Although we believe a single marketing application for the approval of a combination product would be successful, there can be no assurance that the FDA will not determine that separate marketing applications are necessary. This determination could significantly increase the resources and time required to bring a particular combination product to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process, as well as coordination between two different centers within FDA responsible for review of the different components of the combination product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 8, 2022, we announced a pause in enrollment of ENLIGHTEN II to align with internal manufacturing timelines for clinical trial supply. We will focus our resources on the timely completion of ENLIGHTEN I during this period. Moving forward, we intend to utilize our internal manufacturing capabilities in order to supply the entire ENLIGHTEN clinical program and mitigate any further risk to overall program timelines.  We believe that focusing on our internal manufacturing capabilities reduces risk associated with technology transfer to third parties. We expect to resume enrollment in ENLIGHTEN II in the second quarter of 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to successfully develop or supply the device component, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of the device component of LYR-210 or LYR-220, as appropriate, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in these product candidates reaching the market. Further, failure to successfully develop or supply the device, or to gain or maintain its approval, could adversely affect sales of LYR-210 and LYR-220.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to obtain the necessary U.S. regulatory approvals to commercialize any product candidate, we will not be able to generate revenue in the U.S. market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that we will receive the approvals necessary to commercialize our product candidates, or any product candidate we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the United States and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. Satisfaction of the FDA&#x2019;s regulatory requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, and testing. We cannot predict whether our research and clinical efforts will result in drugs that the FDA will determine are safe for humans and effective for their intended uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional pre-clinical and clinical testing, perform post-marketing studies, address manufacturing concerns, or otherwise limit or impose conditions on any approval we obtain. The approval process may also be delayed by changes in government regulation, the impact of COVID-19, future legislation or administrative action, or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose costly procedures on us; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive approval of an NDA or comparable foreign regulatory filing for our product candidates, the FDA or the applicable foreign regulatory body may approve our product candidates for a more limited indication than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a commercially available product, and therefore without any source of revenues, until another product candidate can be developed or obtained and ultimately approved. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will be able to obtain FDA approval to commercialize such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend, either on our own or through collaborations or partnerships, to market our products in international markets. In order to market any products in the European Union and many other foreign jurisdictions, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional pre-clinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, costly, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot predict when or if, and in which territories, we, or any of our potential future collaborators, will obtain marketing approval to commercialize a product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that neither LYR-210, LYR-220, nor any future product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses in patients. Results from non-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the non-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy and costly approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of clinical trials. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development activities and receipt of regulatory approvals could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to the COVID-19 pandemic, and, as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the perceived risks and benefits of the product candidate in the trial; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of alternative therapies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of ongoing COVID-19. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays, or both, which could have a harmful effect on our ability to develop LYR-210, LYR-220, and/or any other future product candidates, or could render further development impossible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause serious adverse events or undesirable side effects including injury and death or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval. If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any potential future collaborators, to market the drug could be compromised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive pre-clinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Serious adverse events, or SAEs, or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our clinical trials or pre-clinical studies could reveal a high and unacceptable severity and prevalence of side effects, toxicities, or unexpected characteristics, including death. For example, in our Phase 1 clinical trial for our most advanced product candidate, LYR-210, there was one SAE in the active group (acute myocardial infarction), which was considered not related to LYR-210. For more information, see &#x201c;Business&#x2014;LYR-210 for the Treatment of CRS&#x2014;Overview of Our Clinical Development for LYR-210&#34; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, subjects treated with LYR-210 have experienced adverse events, including epistaxis, rhinitis, rhinorrhea, facial pain, nasopharyngitis, sinusitis, upper respiratory tract infection, procedural headache, nasal discomfort, and nasal odor, among others. In our Phase 2 LANTERN clinical trial, treatment-related adverse events were reported in 16 patients, and all treatment-related adverse events except one (increased viscosity of upper respiratory secretion) were mild or moderate in nature. In addition, there was one patient in the LYR-210 (2,500 &#xb5;g) group who had a serious adverse event of acarodermatitis in our Phase 2 LANTERN clinical trial, which was deemed to be not related to treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, or DSMB, could materially modify, suspend, or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease pre-clinical studies or clinical trials, require us to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated, or deny approval of our product candidates for any or all targeted indications. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We currently train and expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#x201c;black box&#x201d; warning or contraindication; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require long-term patient registries for the product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product could become less competitive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or at all. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As product candidates proceed through pre-clinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results or in the process of conducting technology transfer with contract manufacturers. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, and property, auto, workers&#x2019; compensation, umbrella, and directors&#x2019; and officers&#x2019; insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for LYR-210 and/or LYR-220, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating as a public company has made it more difficult and more expensive for us to obtain director and officer liability insurance, and in the future we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retain qualified people to serve on our board of directors, our board committees, or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization, could include intentional, reckless, or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, the European Medicines Agency, or the EMA, and other similar regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, fraud and abuse, and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of pre-clinical studies or clinical trials, creation of fraudulent data in pre-clinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of system failures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our computer systems, as well as those of our CROs and other contractors, vendors, suppliers, and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war (including the war between Russia and Ukraine), and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs and our business. For example, the loss of pre-clinical studies or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential, or proprietary information, we could incur liability and the further development of LYR-210, LYR-220, or any other product candidate could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we directly or indirectly collect and store sensitive data, including intellectual property, confidential information, pre-clinical and clinical trial data, proprietary business information, personal data, and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The secure processing, maintenance, and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure has been and, from time to time, may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance, or other disruptions. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with COVID-19. Although, to our knowledge, we have not experienced any material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, or significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials, which could adversely affect our business reputation and delay our clinical development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will be subject to extensive and costly government regulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates employing our technology will be subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments, and their respective equivalents outside of the United States. The FDA regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory review and approval process, which includes pre-clinical testing and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct pre-clinical studies and clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#x2019;s safety and efficacy, potency, and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we, our collaborators, consultants, contract manufacturers, CROs, or other vendors fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and could adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the EU, and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our products in development, restrict or regulate post-approval activities involving any product candidates for which we obtain marketing approval, impact pricing and reimbursement, and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#x201c;transfers of value&#x201d; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the constitutionality of the ACA, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal, or replace the ACA will impact the law and may impact our business or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. While any proposed measures will require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA&#x2019;s regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, the EMA, and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. In addition, the sponsor of an approved NDA is subject to periodic inspections and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and other information such as the failure of a product to meet the specifications in the NDA. NDA sponsors must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. The FDA may require changes in the labeling of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">already approved drug products and require that sponsors conduct post-marketing studies. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a medication guide, physician communication plans, or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk mitigation tools. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. In addition, advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDA&#x2019;s restrictions relating to the promotion of prescription products may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The distribution of product samples to physicians must comply with the requirements of the FDCA. NDA sponsors must obtain FDA approval for product, manufacturing, and labeling changes, depending on the nature of the change. Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, consent decrees of permanent injunction, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on manufacturing such products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall of products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention; or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our Company and our operating results will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of LYR-210, LYR-220, and/or any other future product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects, and ability to achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, approved, or commercialized in a timely manner, or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the government agency&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safe to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would be appropriate. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such obligations include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection, and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our partners may be subject to diverse laws and regulations relating to data privacy and security, including, in the United States, HIPAA and, in the EU and the European Economic Area, or EEA, the General Data Protection Regulation, or the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. For example, on June 28, 2018, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Complying with these numerous, complex, and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss, or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by us or another third-party, could adversely affect our business, financial condition, and results of operations, including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services, and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, the GDPR went into effect on May 25, 2018. The GDPR requires us, among other things, to make detailed disclosures to data subjects, to disclose the legal basis on which we can process personal data, to obtain valid consent for processing, to appoint data protection officers when sensitive personal data, such as health data, is processed on a large scale, and provides robust rights for data subjects, introduces mandatory data breach notification, imposes additional obligations on us when contracting with service providers, and requires us to adopt appropriate privacy governance including policies, procedures, training, and data audit. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#x201c;adequate&#x201d; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. If we do not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of &#x20ac;20 million or up to 4% of our total global annual revenue in the event of a significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations, and financial condition. Additionally, following the United Kingdom&#x2019;s withdrawal from the EEA and the EU, and the expiry of the transition period, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that our third-party service providers with access to our or our customers&#x2019;, suppliers&#x2019;, trial patients&#x2019;, and employees&#x2019; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations, and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#x2019;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#x2019;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the GDPR and legislation of the EU and EEA member states implementing it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals&#x2019; health information. The GDPR provides that EU and EEA member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase. Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">individuals&#x2019; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or third-party contract manufacturing organizations or CMOs, CROs, or other contractors or consultants fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#x2019; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing, and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to environmental, health, and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, including our development, testing, and manufacturing activities, are subject to numerous environmental, health, and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures, and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health, and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our policies and other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image, and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry has been characterized by extensive research and development efforts, rapid developments in technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies either marketing or developing therapeutics to treat CRS. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may provide them with competitive advantages. Our potential products may not compete successfully. If these competitors access the marketplace before we do with better or less expensive therapeutics, our product candidates, if approved for commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products, or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability, availability, timing, scope of regulatory approval, acceptance, and price, among other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining regulatory approvals, and manufacturing and selling commercial quantities of potential products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are intended to compete directly or indirectly with existing products and treatments. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians, or patients. Hospitals, physicians, or patients may conclude that our potential products are less safe or effective or otherwise less attractive than these existing drugs. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would materially adversely affect our ability to become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant competition exists in the treatment of polyps. We will need to compete with all currently available or future therapies within the indications where our development is focused. LYR-210, if approved and commercialized, will face significant competition. The main classes of marketed products that are available for the treatment of polyps include nasal saline irrigation, intranasal corticosteroidal sprays and antibiotics, as well as surgical intervention. In addition, three companies are currently marketing, and several companies are also currently developing, biologic monoclonal antibodies, or mAbs, for the treatment of nasal polyps. If these biologic mAbs are successfully developed and approved for marketing, they could represent competition for LYR-220 for the segment of patients that have polyps. There are two companies pursuing the treatment of non-polyp patients.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of companies developing or marketing therapies for the treatment and management of CRS that may compete with our current product candidates, including many major pharmaceutical and biotechnology companies. These companies include, among others: Hoffman-La Roche, GlaxoSmithKline, AnaptysBio, Regeneron, Optinose, and Medtronic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most of our competitors, including many of those listed above, have substantially greater capital resources, robust product candidate pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. As a result, our competitors may achieve product commercialization or patent protection earlier than we can. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers, and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Similarly, our product candidates are physician-administered treatments and as such, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. To the extent separate coverage and reimbursement should become available for LYR-210, we anticipate that it will be sold to physicians on a &#x201c;buy and bill&#x201d; basis. Buy and bill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the status of reimbursement codes for any of our product candidates, if approved, could also affect reimbursement. J-Codes and Q-Codes are reimbursement codes maintained by the Centers for Medicare and Medicaid Services, or CMS, that are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We currently do not have a specific J-Code or Q-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code or Q-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code or Q-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. We cannot be sure that coverage and reimbursement in the United States, the EU, or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our clinical studies were designed to demonstrate the safety and efficacy of LYR-210 based on FDA requirements and may not be seen as compelling to physicians or patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends on the medical community&#x2019;s acceptance of LYR-210, if approved, as a treatment for CRS patients. LYR-210 was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, which achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we also observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in SNOT-22 scores was observed at week 1, and this reduction persisted through week 25, which was the end of the trial. In our Phase 2 LANTERN clinical trial, we reported positive top-line results but failed to achieve the primary endpoint. Although not statistically significant at week 4 (the primary endpoint), at the 7,500 &#xb5;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. Furthermore, at the 7,500 &#xb5;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm at weeks 8, 16, 20, and 24. Even if the results of these clinical trials suggest a favorable safety and efficacy profile, the study designs and results, and the designs and results of future clinical trials we conduct, may not be viewed as compelling to our physician customers or patients. If physicians do not find our data compelling, even if LYR-210 receives marketing approval they may choose not to use our products or limit their use. We cannot assure you that any data that we or others generate, including from any pivotal Phase 3 clinical study we may pursue for LYR-210, will be consistent with that observed in the Phase 1 clinical trial of LYR-210 and Phase 2 LANTERN clinical trial, nor that results will be maintained beyond the time points studied. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be clinically meaningful and may not demonstrate that LYR-210 is an attractive procedure when compared against data from alternative treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If either LYR-210 or LYR-220 receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of LYR-210 or LYR-220, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our technology; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the perception by members of the healthcare community, including physicians, or patients that the process of administering LYR-210 or LYR-220 is not unduly cumbersome; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectiveness of sales and marketing efforts; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA, the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#x2019;s approved labeling; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any restrictions on the use of our product together with other medications. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, healthcare payors, and patients, we may not generate sufficient revenue from these products, and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. In addition, our ability to successfully commercialize our product candidates will depend on our ability to manufacture our products through third-party manufacturers, differentiate our products from competing products, and defend the intellectual property of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect sales of LYR-210, if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If physicians or patients are not willing to change current practices and adopt our office-based administration procedure for LYR-210 and LYR-220, our products may fail to gain market acceptance, and our business will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure by an ENT physician under endoscopic visualization via a single-use applicator. While we believe ENT physicians will be able to administer our product candidates, if successfully developed and approved, in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for ENT physicians to schedule separate surgical time, ENT physicians may not adopt our in-office procedure for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of significant experience with the placement procedure via a single-use applicator; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of availability of adequate insurance coverage or reimbursement for the placement procedure; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of the placement procedure and/or our products in general over existing alternatives; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a perception that patients may be unable to tolerate the placement procedure in the physician office setting; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liability risks generally associated with the use of new products and procedures. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If ENT physicians do not adopt the placement procedure for any reason, including those listed above, our ability to grow our business would be impaired, even if LYR-210 and LYR-220 receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe recommendations and support of our products by notable ENT physicians could influence market acceptance and adoption. If we do not receive support from influential ENT physicians, our ability to achieve broad market acceptance for our products may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if patient receptivity toward treatment in an ENT physician office setting becomes less favorable in the future, this shift could negatively impact market acceptance of our products. Any negative change due to patient receptivity could also be compounded by patients reporting to physicians or other patients through word-of-mouth or social media.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, while it is currently more cost-effective to the healthcare system for providers to perform the placement procedure in an ENT physician&#x2019;s office than endoscopic sinus surgery in an operating room, healthcare economics are subject to change. If the use of our products were to cease being more cost-effective than endoscopic sinus surgery due to changes in reimbursement economics, our products may fail to gain market acceptance, our future growth would be limited, and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing, and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing LYR-210 or LYR-220, if approved, and we may not be able to generate any revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any infrastructure for the sales, marketing, or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to build our own focused sales, distribution, and marketing infrastructure to market LYR-210 and LYR-220 in the United States, if approved. There are significant expenses and risks involved with establishing our own sales, marketing, and distribution capabilities, including our ability to hire, retain, and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities could delay any product launch, which would adversely impact the commercialization of LYR-210. Additionally, if the commercial launch of LYR-210 or LYR-220 for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to develop or obtain sufficient operational functions to support our commercial activities; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of LYR-210, LYR-220, or any future product candidates in markets outside of the United States. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#x2019;s strategic interest in the product, and such collaborator&#x2019;s ability to successfully market and sell the product. We intend to selectively pursue collaborative arrangements regarding the sale and marketing of LYR-210, if approved, for certain markets outside of the United States; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LYR-210 or LYR-220, we may be forced to delay the potential commercialization of LYR-210 or LYR-220 or reduce the scope of our sales or marketing activities for LYR-210 or LYR-220. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LYR-210 or LYR-220 or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LYR-210 or LYR-220 and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing, and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our customers&#x2019; ability to obtain reimbursement for our product candidates in foreign markets; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to directly control commercial activities if we are relying on third parties; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting, and legal requirements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">import or export licensing requirements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">longer accounts receivable collection times; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">longer lead times for shipping; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">language barriers for technical training and the need for language translations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the existence of additional potentially relevant third-party intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency exchange rate fluctuations; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions, and changes in tariffs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The sizes of the patient populations that our product candidates are intended to treat have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population than we anticipate, our revenue and ability to achieve profitability may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The precise incidence and prevalence of the conditions we aim to address with our programs is unknown and cannot be precisely determined. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases, and the incidence or prevalence of these diseases is subject to change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indications and conditions of use for which the product candidates are approved and may be marketed, acceptance by the medical community, and patient access, drug pricing, and reimbursement. The sizes of the patient populations that our product candidates are intended to treat in the United States and other major markets and elsewhere may turn out to be smaller than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, we may never achieve profitability despite obtaining such significant market share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we cannot compete for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates receive FDA approval, they will compete with a number of existing and future drugs and therapies developed, manufactured, and marketed by other companies. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. Many of these competitors may have compounds already approved or in development in the therapeutic categories that we are targeting with our current and future product candidates. In addition, many of these competitors, either alone or together with their collaborative partners, may operate larger research and development programs or have substantially greater financial resources than we do, as well as greater experience in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undertaking pre-clinical testing and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining NDA approval by the FDA and comparable foreign regulatory approvals of product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching, marketing, and selling products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If either LYR-210 or LYR-220 is approved for commercialization, we intend to selectively partner with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced protection for intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign reimbursement, pricing, and insurance regimes; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and similar anti-bribery and anticorruption laws in other jurisdictions; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor, and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be very challenging.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain legal and political risks are also inherent in foreign operations. For example, it may be more difficult for us to enforce our agreements or collect receivables through foreign legal systems. There is a risk that foreign governments may nationalize private enterprises in certain countries where we may operate. In certain countries or regions, terrorist activities and the response to such activities may threaten our operations more than in the United States. Social and cultural norms in certain countries may not support compliance with our corporate policies including those that require compliance with substantive laws and regulations. Also, changes in general economic and political conditions in countries where we may operate are a risk to our financial performance and future growth. Additionally, the need to identify financially and commercially strong partners for commercialization outside the United States who will comply with the high manufacturing and legal and regulatory compliance standards we require is a risk to our financial performance. As we operate our business globally, our success will depend, in part, on our ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to our international operations will not have an adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of our product candidates, including LYR-210 and LYR-220, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. For example, complications arising from the placement procedure for LYR-210 or LYR-220, or from the degradation or dislodgment of the LYR-210 or LYR-220 polymeric matrix within the sinuses after placement, or from foreign growth occurring in the sinus after placement, could give rise to product liability claims against us. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impairment of our business reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of participants from our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant costs to defend the related litigation and related litigation; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">distraction of management&#x2019;s attention from our primary business; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to patients or other claimants; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to commercialize LYR-210 or LYR-220 or any other product candidate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for LYR-210 or LYR-220 or any other product candidate, if approved for commercial sale; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently intend to manufacture clinical materials in-house, but we may rely on third parties for the manufacture of materials for our research programs, pre-clinical studies, and clinical trials and we do not have long-term contracts with any of these parties. Any inability to scale up our internal capabilities, or our reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have relied on third parties for the manufacture of our product candidates and related raw materials for future pre-clinical and clinical development, and may rely on third parties for commercial manufacture if any of our product candidates receive marketing approval. We purchase certain required materials for pre-clinical and clinical drug supply on a purchase order basis. In addition, we have engaged a third-party contract manufacturer to complete the manufacturing for the anticipated LYR-210 Phase 3 clinical trials. Certain of these manufacturers are critical to our production and the loss of these manufacturers to one of our competitors or otherwise, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent, or impair our ability to timely conduct pre-clinical studies or clinical trials, and would materially and adversely affect our development and commercialization efforts.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Some of our contract manufacturers may not have produced a commercially-approved product and therefore may not have obtained the requisite FDA approvals to do so. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to manufacture our product according to our specifications; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to manufacture our product according to our schedule or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. The extent to which COVID-19 impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects and may cause delays. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on third parties to conduct our pre-clinical studies and clinical trials, including our planned and ongoing clinical trials for LYR-210, and we expect to rely on third parties to conduct future clinical trials and pre-clinical studies for our product candidates, including LYR-220. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs, and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no guarantee that any such CROs, investigators, or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols, or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with these third-parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators, and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. COVID-19 and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our pre-clinical studies and clinical trials. Though we carefully manage our relationships with our CROs, investigators, and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may collaborate with third parties for the development and commercialization of LYR-210, LYR-220, and any of our future product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize LYR-210, LYR-220, or our future product candidates successfully, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional collaborative relationships for the development and commercialization of LYR-210, LYR-220, or any future product candidates. Failure to obtain a collaborative relationship for LYR-210, LYR-220, or any future product candidates may significantly impair the potential for these product candidates. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control, or other reasons; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may not devote sufficient capital or resources towards our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution, or sale of a product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaboration partner may terminate a strategic alliance; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a dispute may arise between us and a partner concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones, royalty payments, or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a partner may use our products or technology in such a way as to invite litigation from a third party. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital. Moreover, any collaborative partners we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate or terminate their relationships with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we seek, but are not able to establish, collaborations, we may have to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party vendors, such as CROs, scientists, and collaborators to provide us with significant data and other information related to our projects, pre-clinical studies, or clinical trials and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not have multiple sources of supply for some of the components used in LYR-210 or LYR-220, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of LYR-210 or LYR-220. If we obtain regulatory approval for LYR-210 or LYR-220, we would need to expand the supply of their components in order to commercialize them.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have multiple sources of supply for the components used in the manufacturing of LYR-210 or LYR-220. We also do not have long-term supply agreements with any of our component suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Manufacturing suppliers are subject to cGMP quality and regulatory requirements covering manufacturing, testing, quality control, and record keeping relating to our product candidates and are subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing suppliers are also subject to local, state, and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. Additionally, certain of our suppliers are critical to our production and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of any marketing approval, regulatory authorities conduct inspections that must be successful prior to the approval of the product. Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of LYR-210 or LYR-220 or, if we obtain regulatory approval for LYR-210 or LYR-220, to commercialize them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships, or other arrangements to develop new products and to pursue new markets. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenues and could be terminated prior to developing any products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may not be in a position to exercise sole decision making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any current or future collaborators devote to our or their future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain, and enforce such licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. If our licensors do not adequately protect such licensed intellectual property, competitors may be able to use such intellectual property and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our products and product candidates, and delay or render impossible our achievement of profitability. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect our intellectual property and prevent others from duplicating LYR-210, LYR-220, and any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal, factual, and scientific questions and can be uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity, enforceability, or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create new products or methods that achieve similar results without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the patent applications we hold with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before enactment of the Leahy-Smith Act on March 16, 2013, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for the patent covering a product, we may be open to competition from generic competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our product candidate, if approved, or practicing our own patented technology. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Once disclosed, we are likely to lose trade secret protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Further, although we require that all of our employees, consultants, collaborators, advisors, and any third parties who have access to our proprietary know-how, information, or technology enter into confidentiality agreements, we cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently discover our trade secrets or develop substantially equivalent information and techniques. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. Misappropriation or unauthorized disclosure of our trade secrets or other confidential proprietary information could impair our competitive position and may have a material adverse effect on our business. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret or other confidential proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement, or allegations of infringement, of the patents and other proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, and inter partes review proceedings before the United States Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies, products, compositions, and their uses do not or will not infringe third party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent, and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates, or the method of use for any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, which may not be available or may not be available on commercially reasonable terms, or until such patents expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties, which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our patents, trademarks, copyrights, or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product. To counter infringement or unauthorized use, we may be required to file infringement claims on a country-by-country basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid, is unenforceable and/or is not infringed, or may construe the patent&#x2019;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or held unenforceable, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent patent reform legislation has increased the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, and may diminish the value of patents in general.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biotechnology companies, our commercial success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity and is therefore costly, time consuming, and inherently uncertain. Recent wide-ranging patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. Under The Leahy-Smith Act, the United States transitioned from a &#x201c;first-to-invent&#x201d; to a &#x201c;first-to-file&#x201d; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, and it expanded the scope of procedures that a third party may use to challenge a U.S. patent, including post grant review and inter partes review procedures. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, recent court rulings in cases such as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Association for Molecular Pathology v. Myriad Genetics, Inc., BRCA1-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &amp;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> BRCA2-Based Hereditary Cancer Test Patent Litigation,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Promega Corp. v. Life Technologies Corp.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#x2019;s former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO, European, and other patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. A defendant could also challenge our ownership of patents assigned to us. We cannot be certain that a third party would not challenge our rights to these patents and patent applications. Any legal proceeding or enforcement action can also be expensive and time-consuming.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the United States and, if available, in other countries. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise, or failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and pre-clinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting, and defending our intellectual property in all countries throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Therefore, we may choose not to pursue or maintain protection for certain intellectual property in certain jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitors from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#x201c;work&#x201d; the invention in that country, or the third party has patented improvements) or limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we seek to protect the trademarks we use in the United States and in other countries, we may be unsuccessful in obtaining registrations and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands, and trademarks unless we enter into appropriate royalty, license, or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks, and domain names, then we may not be able to compete effectively, resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted, or declared generic, or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. If we are unable to establish name</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others, including inventors or developers of our patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we might not have been the first to conceive and reduce to practice the inventions covered by our patents or patent applications; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we might not have been the first to file patent applications covering certain of our patents or patent applications; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our issued patents may not provide us with any commercially viable products or competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Supreme Court of the United States, other U.S. federal courts, Congress, the USPTO, or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our collaboration partners&#x2019; patents; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ownership, validity, or enforceability of our patents or patent applications may be challenged by third parties; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs, and sales, marketing, and distribution over the next few years. As of December 31, 2022, we had 58 full-time employees. To manage our growth activities, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. As we expand our organization, we may have difficulty identifying, hiring, and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate, and integrate additional employees, consultants, and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the biotechnology and pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other significant personnel, or experience increases in our compensation costs, our business may materially suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our management and directors, including our chief executive officer, Maria Palasis, Ph.D., among others. Due to the specialized knowledge each of our officers and key employees possesses with respect to our product candidates and our operations, the loss of service of any of our officers or directors could delay or prevent the successful enrollment and completion of our clinical trials. We do not carry key person life insurance on our officers or directors. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our future success and growth will depend in part on the continued service of our directors, employees, and management personnel and our ability to identify, hire, and retain additional personnel. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, we may enter into transactions to acquire other businesses, products, or technologies or enter into strategic partnerships, including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner. Acquisitions or partnerships may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing, or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#x2019;s current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. The Company maintains the majority of its cash and cash equivalents in accounts with major U.S. institutions, and our deposits at certain of these institutions exceed insured limits.  Market conditions can impact the viability of these institutions.  In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all.  Any inability to access or delay in accessing these funds could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The global pandemic caused by COVID-19 has disrupted and may continue to adversely impact our business and operations, including our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 global pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In light of developments relating to the COVID-19 pandemic and the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#x2019;s updated industry guidance for conducting clinical trials issued on March 18, 2020, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and we did not open any sites in the United States. Ultimately, LYR-210 did not achieve the primary endpoint in our Phase 2 LANTERN clinical trial, we believe due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline was required in order to achieve statistical significance for the primary endpoint at week 4.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data, and as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. We are also experiencing delays enrolling patients in our Phase 2 BEACON clinical trial at our sites in Australia as a result of restrictions imposed in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, certain third parties, including manufacturers, medical institutions, clinical investigators, CROs, and consultants with whom we conduct business are similarly adjusting their operations and assessing their capacity in light of COVID-19. If these third parties continue to experience shutdowns or business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, as a result of COVID-19, there could be delays in the manufacturing supply chain for mometasone furoate, which could delay or otherwise impact the manufacturing of LYR-210. It is also likely that the disproportionate impact of COVID-19 on hospitals and clinical sites will have an impact on recruitment and retention for our planned clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent COVID-19 adversely affects our business, financial condition, and results of operations, it may also have the effect of heightening many of the other risks described in this &#x201c;Risk Factors&#x201d; section.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation against us could be costly and time-consuming to defend and could result in additional liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients, or vendors of our customers, or stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management&#x2019;s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby adversely impacting our results of operations and resulting in a reduction in the trading price of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price may be volatile. The stock market in general and the market for smaller biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the purchase price. The market price for our common stock may be influenced by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or expected changes in our growth rate relative to our competitors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of clinical trials of our product candidates or those of our competitors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments related to our existing or any future collaborations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#x2019; products and product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development of new product candidates that may address our markets and make our product candidates less attractive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in physician, hospital, or healthcare provider practices that may make our product candidates less useful; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements by us, our partners, or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our efforts to discover, develop, acquire, or in-license additional product candidates or products; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or expected changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">short selling activities;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, industry, and market conditions; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the other factors described in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the trading prices for common stock of other biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. The extent to which COVID-19 may impact our business, pre-clinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the number of shares of common stock outstanding as of March 1, 2023, our current executive officers, directors, and stockholders who own more than 10% of our outstanding common stock and their respective affiliates will, in the aggregate, hold shares representing approximately 58.8% of our outstanding voting stock. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management, and approval of any merger, consolidation, or sale of all or substantially all of our assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of approximately 5.4 million shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 or until the rights terminate pursuant to the terms of the ninth amended and restated investor rights agreement between us and such holders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act, and may remain an emerging growth company until December 31, 2025. However, if certain events occur prior to such date, including if we become a &#x201c;large accelerated filer,&#x201d; our annual gross revenues exceed $1.235 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to such date. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure in this Annual Report on Form 10-K; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property, or our stock performance, or if our target pre-clinical studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a &#x201c;smaller reporting company&#x201d; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are considered a &#x201c;smaller reporting company.&#x201d; We are therefore entitled to rely on certain reduced disclosure requirements, and have provided only two years of audited financial statements in this Annual Report on Form 10-K. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend, or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholder&#x2019;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have incurred significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We may discover significant deficiencies or additional material weaknesses, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. The identification of one or more material weaknesses, including the one described in this Annual Report on Form 10-K, could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our common shares for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had net operating loss carryforwards, or NOLs, of $112.1 million for federal income tax purposes and $25.5 million for state income tax purposes, which may be available to offset our future taxable income, if any, and begin to expire at various dates through 2037. As of December 31, 2022, we also had federal and state research and development credit carryforwards of $1.8 million, which begin to expire at various dates through 2037. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, or IRC, as amended, or the Code, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset future taxable income. The Company has performed an IRC 382 study during the year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The impact of the Tax Cuts and Jobs Act on our financial results is not entirely clear and could differ materially from the financial statements provided herein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act, or TCJA, that significantly reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense; limitation of the deduction for NOLs and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits. The financial statements contained herein reflect the effects of the TCJA based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of the TCJA, and, as a result, we made certain judgments and assumptions in the interpretation thereof. The U.S. Treasury Department and the Internal Revenue Service may issue further guidance on how the provisions of the TCJA will be applied or otherwise administered that differs from our current interpretation. In addition, the TCJA could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation on us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unstable global political or economic conditions may have serious adverse consequences on our business, financial condition and share price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If the equity and credit markets continue to deteriorate, or the United States enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, the war between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business, results of operations and price of our common stock may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been increasing public focus by investors, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, we may experience increased costs in order to execute upon our sustainability goals and measure achievement of those goals, which could have an adverse impact on our business and financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We occupy office and laboratory space in Watertown, Massachusetts under a lease agreement, as amended, that terminates on April 30, 2024. We do not own any real property. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, we executed a new lease for laboratory and office space. This lease will commence when we obtain possession of the underlying asset, which is expected to occur in the fourth quarter of 2023, following completion of construction to prepare the premises for our intended use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2023, we filed a complaint in the Court of Chancery of the State of Delaware against a former contract manufacturer alleging breach of contract.  We alleged in our complaint that our former contract manufacturer breached our Master Clinical Supply Agreement (&#x201c;MCSA&#x201d;) by misrepresenting their ability to produce LYR-210 in accordance with our specifications and with a robust quality system in place, and failed to return certain customer materials and equipment as required under the MCSA. Our complaint seeks monetary damages and the return of equipment and materials that we own. On March 28, 2023, the contract manufacturer filed a motion to remove the case from the Chancery Court to the United States District Court for the District of Delaware.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed on The Nasdaq Global Market under the symbol &#x201c;LYRA.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 1, 2023, there were approximately 70 holders of record of our common stock. However, because many of our outstanding shares are held in accounts with brokers and other institutions, we believe we have more beneficial owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects, and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have not declared or paid any cash dividends on our capital stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities; Purchases of Equity Securities by the Issuer or Affiliated Purchaser</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the quarter ended December 31, 2022, we did not repurchase any of our equity securities or issue any securities that were not registered under the Securities Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from Initial Public Offering of Common Stock</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 5, 2020, we completed the sale of 4,025,000 shares of our common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $16.00 per share. The offer and sale of the shares in our initial public offering, or IPO, was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-236962), which was declared effective by the SEC on April 30, 2020 (the &#x201c;Registration Statement&#x201d;).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus for our IPO dated April 30, 2020 and filed pursuant to Rule 424(b)(4) under the Securities Act on May 1, 2020. We invested the funds received in cash equivalents and other short-term investments in accordance with our investment policy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_consolidated_financial_d"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report on Form 10-K. In addition, even if our results of operations, financial condition, and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report on Form 10-K, they may not be predictive of results or developments in future periods.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Annual Report on Form 10-K, including those risks identified under Part I, Item 1A. Risk Factors.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-210 is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery. A pivotal Phase 3 program of LYR-210, called the ENLIGHTEN program, consists of two pivotal trials and is currently ongoing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYR-220</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing our second pipeline product candidate, LYR-220, for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. LYR-220 is also designed to utilize MF, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. A Phase 2 clinical trial of LYR-220, called BEACON, is currently ongoing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Technology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The technology is comprised of three interrelated components:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a biocompatible mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an engineered elastomeric matrix, a polymeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with &#x201c;shape memory&#x201d; that dynamically adapt to nasal anatomy; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a versatile polymer-drug complex, which can be customized for the treatment of various chronic diseases treatable with ENT delivery to achieve the desired drug dose and drug elution rate. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated as a Delaware corporation on November 21, 2005, and our headquarters is located in Watertown, Massachusetts. Our operations to date have been limited to organizing and staffing our Company, business planning, raising capital, developing our technology, building our intellectual property portfolio and conducting research and development activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 5, 2020, we completed our IPO in which we issued and sold 4,025,000 shares of our common stock (including shares issued upon the underwriters&#x2019; exercise in full of their option to purchase additional shares of our common stock) at a public offering price of $16.00 per share, par value $0.001, for aggregate gross proceeds of $64.4 million. We received approximately $57.3 million in net proceeds after deducting underwriting discounts and commissions and offering expenses paid by us. The shares began trading on The Nasdaq Global Market on May 1, 2020. Upon completion of our IPO, all of our outstanding shares of convertible preferred stock converted into 8,335,248 shares of our common stock, par value $0.001.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From inception through December 31, 2022, we have raised an aggregate of $350.4 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $96.3 million were net proceeds from our April 2022 Financing (as defined below); $57.3 million were net proceeds from our initial public offering, $16.8 million were gross proceeds from government contracts and $17.0 million were gross proceeds from our license and collaboration agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net operating losses in every year since inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our net losses were $55.3 million and $43.5 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $248.7 million. We anticipate that our expenses will increase significantly as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conduct additional clinical trials of our most advanced product candidate, LYR-210, including two ongoing pivotal Phase 3 clinical trials of LYR-210; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conduct a Phase 2 clinical trial of LYR-220; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if any; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional staff, including clinical, scientific, technical, regulatory, operational, financial, commercial and support personnel, to execute our business plan; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add clinical, scientific, operational, financial and management information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. Additionally, we may engage third party contract manufacturers to manufacture out products in the future. We do not yet have a sales organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including strategic collaborations and licensing arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash and cash equivalents totaling $32.6 million and short-term investments of $65.3 million. We believe that our existing cash, cash equivalents, and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into mid-2024. We have based these estimates on assumptions that may prove to be imprecise or incorrect, and we may use our available capital resources sooner than we currently expect. See &#x201c;&#x2014;Liquidity and Capital Resources.&#x201d; Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates and technology, and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Operations Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. To date, we have recognized $1.6 million of collaboration revenue from our LianBio License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, or additional collaboration agreements, we may generate revenue in the future from product sales, payments from additional collaboration or license agreements that we may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our revenue for the next several years will be derived primarily from our collaboration agreement with LianBio as well as any additional collaborations that we may enter into in the future. We cannot provide assurance as to the timing of future milestone or royalty payments or that we will receive any of these payments at all.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 26, 2022, we entered into an amended LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. Under the terms of the LianBio License Agreement, we received an upfront payment of $12.0 million and are eligible to receive up to $135.0 million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, we will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and we will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to our LYR-220 product candidate.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, we identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial. We determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, we determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (2) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, we determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations. The potential milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we determined that LianBio&#x2019;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#x2019;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will recognize the revenue associated with the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure combined performance obligation as the clinical supply of LYR-210 is delivered. We recognize revenue associated with the development activities related to the global Phase 3 clinical trial performance obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on our consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of regulatory approval of our most advanced product candidate, LYR-210, for the treatment of CRS, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with CROs, investigative sites, and consultants; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs of manufacturing our product candidates for use in our clinical trials, including fees paid to CMOs as well as other manufacturers that provide components of our product candidates for use in our potential future clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consulting and professional fees related to research and development activities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to compliance with clinical regulatory requirements; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment costs related to long-lived assets.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as clinical site activations, patient enrollment, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and may be reflected in our consolidated financial statements as prepaid or accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of costs such as employee compensation, consulting fees, fees paid to CMOs and CRO expenses in connection with our preclinical and clinical development activities. We typically use our employee and infrastructure resources across our development programs and we do not allocate personnel costs and other internal costs to specific product candidates or development programs with the exception of the costs to manufacture our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we initiate additional</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials, including two clinical trials for LYR-210 and one clinical trial for LYR-220, scale our manufacturing processes, and continue to discover and develop additional product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of LYR-210, LYR-220, and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we may obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs, and timing of preclinical studies, clinical trials, and development of our product candidates will depend on a variety of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful completion of clinical trials with safety, tolerability, and efficacy profiles for LYR-210, LYR-220, and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval of an IND for LYR-220 and any potential future product candidate to commence planned or future clinical trials in the United States or foreign countries; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant and changing government regulation and regulatory guidance; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timing and receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making arrangements with CMOs for third-party clinical and commercial manufacturing to obtain sufficient supply of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competition with other therapies; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from COVID-19. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development, manufacture, or commercialization enabling activities of any of our product candidates would significantly change the costs, timing, and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we may be required to expend significant additional financial resources and time on the completion of clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services, and insurance costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys, and accountants, among other expenses. Additionally, we will continue to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists of interest income earned on our cash and cash equivalents and short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods and estimates used to assess our ability to continue as a going concern. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern Evaluation and Presentation</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, we believe that our current cash, cash equivalents, and short-term investments will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into mid-2024. Significant assumptions exist surrounding the use of our capital resources which could give rise to the use of available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of LYR-210 and LYR-220 is highly uncertain, we are unable to estimate the actual funds we will require for development, approval, and any approved marketing and commercialization activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner, and the availability of the associated expertise in the general marketplace. We also consider the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, we consider applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. We validate the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assessed our revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative arrangement revenue</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into the LianBio License Agreement with LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. See Note 9 to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion of the arrangement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the accounting for this arrangement, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. For example, a proportion of the stand-alone selling price is related to research and clinical trial work and development performed whereby revenue is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized as the underlying services are performed using a cost-to-cost model. We measure the extent of progress towards completion based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which we have not yet been invoiced:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with preclinical development activities; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors in connection with the testing of preclinical and clinical trial materials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CROs in connection with preclinical and clinical studies; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigative sites in connection with clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We contract with CROs to conduct clinical and other research and development services on our behalf. We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We apply the fair value recognition provisions of ASC 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation&#x2014;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 718, for stock-based awards granted to employees and directors for their services on the board of directors. Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to ASC 718, we measure stock-based awards granted to employees and members of the board of directors at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for stock-based awards to non-employees in accordance with ASU No. 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASU No. 2018-07, which simplifies the accounting for stock-based payments granted to non-employees for goods and services. Under ASU No. 2018-07, most of the guidance on such payments to non-employees would be aligned with the requirements for stock-based payments granted to employees. Prior to January 1, 2019, we accounted for stock-based payments to non-employees in accordance with ASC 505-50, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity-Based Payments to Non-Employees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or ASC 505-50. Pursuant to ASC 505-50, we measured stock-based awards granted to non-employees at fair value as the awards vested and recognized the resulting value as expense during the period the related services were rendered, which was typically the vesting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield. We utilize historical volatility to approximate expected volatility. Prior to our IPO in 2020, we have historically been a private company and lack company-specific historical and implied volatility data. Therefore, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, we utilize the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and has no current plans to pay any cash dividends on its common stock. Our policy is to recognize forfeitures as they occur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.539%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.788%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.927%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.927%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">285</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,078</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,797</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,694</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,103</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,556</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,206</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,350</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on impairment of long-lived assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,669</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,900</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,769</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(56,306</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,615</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,691</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,041</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,041</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss before taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(55,265</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,513</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(11,752</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(55,278</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,513</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(11,765</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in collaboration revenue was a result of revenue recognized under the LianBio License Agreement.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expense increased by $9.1 million to $38.8 million for the year ended December 31, 2022 from $29.7 million for the year ended December 31, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in research and development expenses for the year ended December 31, 2022 was primarily attributable to an increase in clinical spend of $9.0 million as we progress along our clinical trials; an increase in employee related costs of $3.5 million as we increased research and development headcount, including an increase of $0.3 million of stock-based compensation; and a $0.4 million cost increase due to depreciation and shared allocation and support costs within research and development. These expenses were partially offset by a $2.5 million decrease in product development and manufacturing costs; and $1.1 million decrease in professional and consulting fees as many of these costs were absorbed by the increase in headcount.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expense increased by $3.4 million to $17.6 million for the year ended December 31, 2022 from $14.2 million for the year ended December 31, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in general and administrative expenses for the year ended December 31, 2022 was primarily attributable to an increase in employee related fees of $3.7 million of which $2.3 million was attributed to stock-based compensation.  These were partially offset by $0.7 million decrease in costs primarily public related which was driven by savings on D&amp;O insurance.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Loss on Impairment of Long-Lived Assets</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized $1.3 million related to loss on long-lived research and development assets. In October of 2022, we terminated an agreement with a contract manufacturer. We have funded certain leasehold improvements at the CMO&#x2019;s facility that we do not anticipate receiving the benefit of in the future and have accordingly impaired the respective assets.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income increased $0.9 million to $1.0 million for the year ended December 31, 2022 from $0.1 million for the year ended December 31, 2021. The increase in interest income was attributable to improved cash management and investment strategy as there was a higher cash balance allowing for investment opportunities in the advantageous rate environment for the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations from inception through December 31, 2022 primarily with gross proceeds of $162.1 million from sales of our redeemable convertible preferred stock, net proceeds of $96.3 million from our April 2022 Financing, net proceeds of $57.3 million from our IPO, $16.8 million from government contracts and proceeds of $17.0 million from our license and collaboration agreement. The following table provides information regarding our total cash, cash equivalents, and short-term investments at December 31, 2022 and 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.258%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.696%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.052999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,550</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,344</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have an effective shelf registration statement on Form S-3 (No. 333-256020) filed with the SEC on May 11, 2021, or the Form S-3, under which we may offer from time to time in one or more offerings any combination of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">common and preferred stock, debt securities, warrants and units of up to $250.0 million in the aggregate. As of December 31, 2022, we have not sold any securities under the Form S-3.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 11, 2021, we entered into an Open Market Sales Agreement, or 2021 ATM Agreement, or Sales Agreement, with Jefferies LLC, or Jefferies, to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million, through an at-the-market equity offering program under which Jefferies will act as our sales agent. As of December 31, 2022, we had received no proceeds from the sale of shares of common stock pursuant to the 2021 ATM Agreement. As of March 27, 2023 we terminated the 2021 ATM agreement with Jefferies.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million (&#x201c;April 2022 Financing&#x201d;). The Company received approximately $96.3 million in net proceeds after deducting estimated offering costs of $4.2 million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of 18,815,159 shares of common stock at $4.22 per share for gross proceeds to the Company of $79.4 million and (ii) certain investors purchased pre-funded warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price of $0.001 per share for gross proceeds of $21.1 million to the Company.  The warrants are exercisable on and after April 13, 2022 and expire on April 12, 2027.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides information regarding our cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.175%;"></td>
    <td style="width:1.436%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.888%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.436%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.065%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,385</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(25,820</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(65,006</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,385</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,257</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">359</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,134</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(28,846</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Net cash used in operating activities was $43.4 million for the year ended December 31, 2022, primarily resulting from our net loss of $55.3 million, partially offset by non-cash adjustments of $7.3 million and cash provided by changes in our operating assets and liabilities of $4.6 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses.  Our net non-cash charges during the year ended December 31, 2022 primarily consisted of $5.4 million of share-based compensation expense, $1.3 million of non-cash loss on impairment of long-lived assets and $1.1 million of depreciation expense, which were partially offset by $0.5 million of net amortization of premiums on short-term investments. Net cash provided by changes in our operating assets and liabilities during the year ended December 31, 2022 consisted primarily of an increase of $3.6 million of deferred revenue, $2.4 million, net increase in accrued expenses and accounts payable due to the timing of payments, partially offset by an increased in prepaid expenses and other assets of $1.3 million, also due to the timing of payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $25.8 million for the year ended December 31, 2021, primarily resulting from our net loss of $43.5 million, partially offset by non-cash charges of $3.7 million and cash provided by changes in our operating assets and liabilities of $14.0 million. Our net loss was primarily attributed to research and development activities, and our general and administrative expenses.  Our net non-cash charges during the year ended December 31, 2021 primarily consisted of $2.7 million of stock-based compensation expense and $1.0 million of depreciation expense. Net cash provided by changes in our operating assets and liabilities during the year ended December 31, 2021 consisted primarily of a $11.7 million increase in deferred revenue due to payments received under our License and Collaboration agreement, and a $3.6 million increase in accounts payable and accrued expenses, partially offset by a $1.3 million increase in prepaid expenses and other current assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $65.0 million for the year ended December 31, 2022 compared to $3.4 million for the year ended December 31, 2021. The increase in cash used in investing activities of $61.6 million was attributable to purchases of short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $96.3 million for the year ended December 31, 2022 compared to $0.4 million for the year ended December 31, 2021. The increase in cash provided by financing activities of $95.9 million was primarily attributable to the gross proceeds of $100.5 million resulting in net proceeds of $96.3 million from our April 2022 financing. See Note 7 to the consolidated financial statements included in this Annual Report on Form 10-K for a further discussion of the April 2022 Financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, begin the manufacturing scale up process for, initiate later stage clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our existing cash, cash equivalents, and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into mid-2024. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of conducting future clinical trials of LYR-210 and LYR-220; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of manufacturing additional material for one or more pivotal Phase 3 clinical trials of LYR-210 and a Phase 2 clinical trial of LYR-220 as well as potential future clinical studies we might conduct for our other product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of scaling up our manufacturing process and supply chain capacity to provide sufficient quantities of LYR-210 and LYR-220 for the potential commercialization of LYR-210 and LYR-220 if our clinical development program is successful and we obtain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, and clinical trials for other potential product candidates we may develop, if any; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, obtaining, maintaining, and enforcing our intellectual property rights, and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our business operations, our research and development activities, and our manufacturing scale up; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of potential business interruptions resulting from COVID-19. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. All of these factors could impact our liquidity and future funding requirements, including but not limited to our ability to raise additional capital when needed on acceptable terms, if at all. The duration of this economic slowdown is uncertain and the impact on our business is difficult to predict. See &#x201c;Risk Factors&#x2014; Unstable global political or economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. We have access to additional funds to be earned in connection with our LianBio License Agreement, if development activities are successful under that agreement. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, that could adversely impact our ability to conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The JOBS Act permits an &#x201c;emerging growth company&#x201d; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, or December 31, 2025, (b) in which we have total annual gross revenues of $1.235 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by non-affiliates exceeds $700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements required to be filed pursuant to this Item 8 are appended to this report and are incorporated herein by reference.  An index to those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">untants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitations on Effectiveness of Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of December 31, 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As further described below, our management is in the process of developing and implementing plans to remediate the material weakness identified, but it has not been remediated as of the date of filing of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Material Weakness in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the preparation of our unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022, management identified a material weakness in our internal control over financial reporting related to the allocation of the transaction price related to the LianBio License Agreement, which was entered into on May 31, 2021, and amended on September 26, 2022, and the associated allocation of previously identified constrained amounts of the transaction price to the two performance obligations identified in the LianBio License Agreement. This material weakness resulted in a restatement of our previously issued financial statements as of and for the three months ended March 31, 2022 and our previously issued financial statements as of and for the three and six months ended June 30, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Remediation Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to evaluate the material weakness and are continuing to develop and implement a plan of remediation to strengthen the effectiveness of the design and operation of our internal control environment. Our remediation plan includes the following actions:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enhance our review procedures with respect to accounting for any new and complex transactions, such as the LianBio License Agreement, as well as the periodic evaluation of ongoing activities associated with any collaboration and license agreements and the related accounting and disclosure;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implement additional review procedures with respect to accounting under ASC 808 and ASC 606 to ensure our accounting will continue to be in accordance with that guidance on an ongoing basis; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implement additional identification, accounting, and review controls with respect to complex and nonrecurring transactions, as well as augment existing staff with outside technical accounting resources, as appropriate, and strengthen the review process.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The actions that we are taking are subject to ongoing senior management review as well as Audit Committee oversight. We are committed to maintaining a strong internal control environment and believe that these remediation efforts will represent significant improvements to the internal controls around complex nonrecurring transactions. We have started to implement these steps; however, some of these steps will take time to be fully integrated and assessed as being designed and operating effectively. Until the remediation steps set forth above are fully implemented and tested, the material weakness described above will continue to exist.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the identified material weakness, management believes that the consolidated financial statements included in this Annual Report on Form 10-K present fairly, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented in accordance with U.S. GAAP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company&#x2019;s internal control over financial reporting based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.  Based on this assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting was not effective as a result of the material weakness described above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Attestation Report of the Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as described above, there was no change in our internal control over financial reporting identified in management&#x2019;s evaluation pursuant to Rules 13a-15(f) or 15d-15(f) of the Exchange Act during the quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information about our Directors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information concerning our board of directors as of December 31, 2022.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.734%;"></td>
    <td style="width:2.123%;"></td>
    <td style="width:8.522%;"></td>
    <td style="width:2.123%;"></td>
    <td style="width:40.298%;"></td>
    <td style="width:2.123%;"></td>
    <td style="width:19.077%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Age</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Current Position Since</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2015</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2018</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward Anderson</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2019</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 2019</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2019</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James R. Tobin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are brief biographies describing the backgrounds of our directors.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Harlan W. Waksal, M.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our Executive Chair since February 2022 and was elected to our board of directors in February 2022. Prior to his role with us as Executive Chair, Dr. Waksal served as President and Chief Executive Officer of Kadmon Holdings, Inc., or Kadmon, a biopharmaceutical company, from August 2014 and a director since 2013 until its acquisition by Sanofi in November 2021. Prior to joining Kadmon as an employee, Dr. Waksal served as President and Sole Proprietor of Waksal Consulting LLC from 2003 to 2014. From 2011 to 2014, Dr. Waksal served as Executive Vice President, Business and Scientific Affairs at Acasti Pharma, Inc., a publicly traded biopharmaceutical company, and as a consultant to Neptune Technologies &amp; Bioresources, Inc., a publicly traded life sciences company and the parent company of Acasti. Dr. Waksal co&#x2011;founded ImClone Systems (&#x201c;ImClone&#x201d;) in 1987, a publicly traded biopharmaceutical company acquired by Eli Lilly and Company in 2008. Dr. Waksal served in senior roles at ImClone, including: President (1987 to 1994); Executive Vice President and Chief Operating Officer (1994 to 2002); and President, Chief Executive Officer and Chief Operating Officer (2002 to 2003). Dr. Waksal also served as a Director of ImClone from 1987 to 2005. Dr. Waksal served on the boards of Oberlin College and Sevion Therapeutics through March 2016 and the boards of Acasti and Neptune through February 2016 and July 2015, respectively. Dr. Waksal's additional roles include serving as a Member of the Board of Directors at Neptune Technologies &amp; Bioresources, Observer of the Board of Directors at NeuroBiopharm, Chairman of the American Committee for the Weizmann Institute of Science and Member of the Technology Advisory Board at the New Jersey Edison Innovation Fund. Dr. Waksal received his B.A. from Oberlin College and his M.D. from Tufts University School of Medicine. He completed his training in internal medicine at New England Medical Center and in pathology at Kings County Hospital Center in Brooklyn. We believe Dr. Waksal&#x2019;s extensive management experience in the life science industry and drug development experience provides him with the qualifications and skills to serve on our board of directors.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="palasis_bio"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maria Palasis, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our President and Chief Executive Officer and a member of our board of directors since January 2015. Prior to her role with us as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine. We believe that Dr. Palasis&#x2019; experience in the industry and knowledge of our Company qualifies her to serve on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.2%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Michael Altman</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since June 2018. Since 2007, Mr. Altman has been employed on the investment team at Perceptive Advisors, a life sciences focused investment firm, where he currently serves as Managing Director and focuses on medical devices, diagnostics, digital health and specialty pharmaceutical investments. Since October 2018, Mr. Altman has also served as Chief Financial Officer and member of the board of directors of ARYA Sciences Acquisition Corp., a special purpose acquisition company. From October 2005 to October 2007, Mr. Altman served as a healthcare trader and analyst at First New York Securities. Since June 2021, Mr. Altman has served on the board of directors of Nautilus Biotechnologies, Inc., a biotechnology company. Mr. Altman has also served on the board of directors of Vitruvius Therapeutics, Inc., a pharmaceutical company, since January 2018, and Vensun Pharmaceuticals, Inc., a pharmaceutical company, from November 2016 to January 2019. Mr. Altman holds a B.S. in Business Administration from the University of Vermont. We believe that Mr. Altman&#x2019;s broad operational and transactional experience qualifies him to serve on our board of directors.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Edward Anderson</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since February 2019. Mr. Anderson founded two venture capital firms, North Bridge Venture Partners in May 1993, where he currently serves as a Managing Partner focusing on early-stage high-tech companies, and North Bridge Growth Equity in February 2007. Mr. Anderson currently serves as a member of the board of directors of Couchbase, Inc., a public software company, since  2020 and MarkForged, an IT company, since 2015. Mr. Anderson holds an M.A. from Columbia Business School and a B.F.A. from University of Denver, where he has served on the board of trustees since 2011 and currently serves as chair on its Investment Committee. We believe that Mr. Anderson&#x2019;s extensive experience in venture capital investments qualifies him to serve on our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C. Ann Merrifield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., since November 2014, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, Spaulding Rehabilitation Network (the post-acute care services division of Mass General Brigham), the Huntington Theatre Company and the YMCA of Greater Boston. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. We believe that Ms. Merrifield&#x2019;s extensive industry experience qualifies her to serve on our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Konstantin Poukalov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since January 2020. Since March 2019, Mr. Poukalov has served as Managing Director at Perceptive Advisors, a life sciences focused investment firm. Since October 2019, Mr. Poukalov has served on the board of directors of LianBio, a biotechnology company. From July 2012 to October 2018, Mr. Poukalov served in roles of increasing responsibility at Kadmon Holdings, Inc., a biopharmaceutical company, most recently serving as Executive Vice President and Chief Financial Officer from July 2014 to October 2018. Mr. Poukalov holds a B.S. in Electrical Engineering from Stony Brook University. We believe that Mr. Poukalov&#x2019;s extensive financial and industry experience qualify him to serve on our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">W. Bradford Smith</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since November 2019. Mr. Smith has served as the Chief Financial Officer, Chief Business Officer and Treasurer since March 2022 and Chief Financial Officer and Treasurer from April 2017 to March 2022 of Homology Medicines, Inc., a genetic medicines company, since April 2017 and as Secretary since July 2017. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company. Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Since May 2021, Mr. Smith has served on the board of directors of eGenesis, a private gene editing company. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire. We believe that Mr. Smith&#x2019;s extensive financial and industry experience qualify him to serve on our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since October 2020.  Dr. Snyderman has also served on the boards of directors of Axonics Modulation Technologies, Inc., a medical device company, since April 2019 and Alkermes plc, a biopharmaceutical company, since May 2016. From 2006 to 2018, Dr. Snyderman served as an advisory board member to GE's Healthymagination, General Electric Company&#x2019;s healthcare initiative.  From 2003 to 2008, Dr. Snyderman also served as a vice president for corporate communications at Johnson &amp; Johnson. Dr. Snyderman is a board-certified head and neck surgeon and has had academic appointments at the University of Pennsylvania and the University of California-San Francisco. From 2016 to 2018, she served as a professor at the Center for Innovation for Global Health at Stanford University. Dr. Snyderman is an Emmy award winning medical correspondent, having worked at ABC News from 1987 to 2003 and later as chief medical editor at NBC News from 2004 to 2015. Dr. Snyderman holds a B.A. in Microbiology from Indiana University and a M.D. from the University of Nebraska and has completed residencies in Pediatrics and Otolaryngology Head and Neck Surgery at the University of Pittsburgh. We believe that Dr. Snyderman's extensive experience as a veteran healthcare journalist, a practicing physician, and an executive at a pharmaceutical company, as well as her roles in academia and as advisor to policy organizations, qualify her to serve on our board of directors.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">James R. Tobin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as a member of our board of directors since March 2022. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997, its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as Chairman of the Board at TransMedics, Inc. and as a director of Globus Medical Inc., each of which are public companies, and as a director at lmpulse Dynamics N.V. and Xenter, Inc., both private companies. Mr. Tobin has also served on the boards of Oxford Immunotec, Inc., from 2014 to 2021, Corindus Vascular Robotics, from 2018 to 2019, Curis, Inc., from 1995 to 2015, Medical Simulation Corp, from 2012 to 2018, CardioDX, Inc., from 2014 to 2017, Chiasma, Inc., from 2015 to 2016, and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an M.B.A. from Harvard Business School. Mr. Tobin also served as a Lieutenant in the U.S. Navy. We believe Mr. Tobin is qualified to serve on our board of directors because of his decades of experience as President and Chief Executive Officer or Chief Operating Officer of three large biotechnology and medical device companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information about our Executive Officers</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information concerning our executive officers as of March 1, 2023.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.127%;"></td>
    <td style="width:2.103%;"></td>
    <td style="width:8.403%;"></td>
    <td style="width:2.103%;"></td>
    <td style="width:42.004%;"></td>
    <td style="width:2.103%;"></td>
    <td style="width:19.157%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Age</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Current Position Since</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2015</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer, Treasurer and Secretary</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Medical Officer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert Richard, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Vice President of Technical Operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John E. Bishop, Ph.D</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Technology Officer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corinne Noyes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Vice President of Commercial Strategy and Market Development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 2018</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are brief biographies describing the backgrounds of our executive officers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biography for Dr. Waksal appears above.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biography for Dr. Palasis appears above.</span></p>
  <p style="text-indent:9.2%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Jason Cavalier</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our Chief Financial Officer, Treasurer, and Secretary since September 2021. Prior to joining our Company, Mr. Cavalier served as a Managing Director and the Head of Life Sciences Mergers and Acquisitions at Cantor Fitzgerald &amp; Co., where he led transactions across the medical technology, diagnostics and biopharma sectors, from 2017 to 2021.  Prior to that, Mr. Cavalier served as a Director, Mergers and Acquisitions, at RBC Capital Markets LLC from 2009 to 2017, where he primarily focused on advising senior management and boards of directors on a range of strategic advisory assignments including mergers, acquisitions, divestitures and leveraged buyouts.  Mr. Cavalier has also held positions of increasing responsibility within the investment banking divisions of Barclays Capital Inc., Bear Stearns &amp; Co. Inc., and Lehman Brothers Inc. Mr. Cavalier received a B.S. in Applied Economics and Business Management from Cornell University and an M.B.A. from Columbia University Business School.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.2%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Richard Nieman, M.D. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has served as our Chief Medical Officer since July 2022. Dr Nieman, a pulmonologist by training, has had prior leadership roles as SVP &amp; Worldwide Medical Head of Immunology at Bristol Myers Squibb (BMS) from March to November 2020, Head of R&amp;D China at BMS, Global Medical Officer &amp; Head of Medical at Teva from January 2013 to March 2018, and Head of Asia-Pacific Medical at Bayer from January 2009 to December 2012. At Teva, he led the company's medical and heath economic and outcome research (HEOR) function of 550 professionals and was a member of the Specialty Executive Team. He has been involved in bringing numerous important medicines to the market in the U.S. and Europe, including Cinquair in asthma, Copaxone 40 mg 3x/week in multiple sclerosis, Austedo in movement disorders, Ajovy in migraine and Xarelto in thrombosis and stroke prevention. Richard is a Fellow of the UK Royal College of Physicians, a Visiting Senior Lecturer at the School of Cancer and Pharmaceutical Sciences, Kings College, London, and was a Visiting Professor at Fudan University School of Public Health in Shanghai, China. He has published extensively and trained and practiced medicine in the UK.</span></p>
  <p style="text-indent:9.2%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Robert Richard, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our Senior Vice President of Technical Operations since June 2020.  Prior to joining our Company, from February 2019 to May 2020 Dr. Richard served as Vice President of Research and Development at Anika Therapeutics, Inc., a therapeutics company. Prior to that, he held research and development leadership positions at Hyalex Orthopaedics, Inc., a medical device company, from November 2017 to February 2019, C.R. Bard, Inc., a medical device company, from June 2008 to November 2017, Boston Scientific Corporation, a global medical device company, from September 2000 to June 2008, and Johnson &amp; Johnson, a global medical device, pharmaceutical and consumer product company, from September 1991 to August 2000.  Dr. Richard holds a B.S. in chemistry and a B.S. in biology from University of Massachusetts at Dartmouth and a Ph.D. in polymer chemistry and plastics engineering from the University of Massachusetts at Lowell.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Corinne Noyes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our Senior Vice President of Commercial Strategy and Market Development since September 2018. Prior to joining our Company, from January 2018 to August 2018, Ms. Noyes served as an independent contractor to our Company, providing biopharmaceutical consulting services. Before that, from January 2005 to August 2018, Ms. Noyes worked as a strategic advisor and independent biopharmaceutical consultant providing commercial leadership to emerging life sciences companies, including, among others, AMAG Pharmaceuticals, Inc., Avila Therapeutics, Inc. (Celgene Corporation), Adnexus Therapeutics Inc. (Bristol-Myers Squibb Company), Constellation Pharmaceuticals, Inc. and Editas Medicine, Inc. Before that, from 1997 to 2004, Ms. Noyes held various commercial leadership positions at Biogen Inc., a biotechnology company. Prior to joining Biogen Inc., from 1992 to 1996, Ms. Noyes worked as a health care strategy consultant at Deloitte &amp; Touche LLP. Ms. Noyes holds a B.A. in Humanities and a B.B.A. in Business from St. Mary&#x2019;s College of Notre Dame and an M.B.A. in finance from University of Chicago Graduate School of Business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">John E. Bishop, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has served as our Chief Technology Officer since February 2023. Dr. Bishop previously served as the Senior Vice President, Chief Technology Officer at Forma Therapeutics Holdings, Inc. (Forma) from June 2021 to February 2023. Prior to joining Forma, he served as Senior Vice President of Pharmaceutical Sciences at Epizyme, Inc. (&#x201c;Epizyme&#x201d;) from May 2017 to May 2021. Prior to Epizyme, Dr. Bishop was Executive Vice President of Pharmaceutical Sciences at Genocea Biosciences Inc. from May 2016 to May 2017. Prior to that, he held positions of increasing responsibility at Momenta Pharmaceuticals, Inc., including Senior Vice President, Pharmaceutical Sciences from December 2006 to May 2016 and Vice President, Pharmaceutical Sciences and Manufacturing from November 2004 to December 2006. Dr. Bishop received his B.S. magna cum laude in Chemistry and German from Tufts University, his Ph.D. in Organic Chemistry from University of California, Berkeley and his M.B.A. from Northeastern University.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Family Relationships</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are no family relationships among any of our executive officers or directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board has adopted a written code of business conduct (the &#x201c;Code of Business Conduct and Ethics&#x201d;) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. A copy of the Code of Business Conduct and Ethics is available on our website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.lyratx.com </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the &#x201c;Governance&#x201d; section of the &#x201c;Investors &amp; News&#x201d; page. In addition, we intend to post on our website all disclosures that are required by law or The Nasdaq Stock Market LLC concerning any amendments to, or waivers from, any provision of our Code of Business Conduct and Ethics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit Committee and Audit Committee Financial Expert</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a separately-designated standing audit committee (&#x201c;Audit Committee&#x201d;) that consists of Edward Anderson, James R. Tobin and W. Bradford Smith. Mr. Smith serves as the Chair of the Audit Committee. Our board of directors has determined that all members of the audit committee (Edward Anderson, James R. Tobin and W. Bradford Smith) are independent directors under the Nasdaq rules and the additional independence standards applicable to audit committee members established pursuant to Rule 10A-3 under the Exchange Act. Our board of directors has also determined that each of Edward Anderson, James R. Tobin and W. Bradford Smith meets the &#x201c;financial literacy&#x201d; requirement for audit committee members under the Nasdaq Stock Market rules and W. Bradford Smith is an &#x201c;audit committee financial expert&#x201d; within the meaning of the SEC rules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#x201c;2022 Summary Compensation Table&#x201d; below. In 2022, our &#x201c;named executive officers&#x201d; and their positions were as follows:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D., President and Chief Executive Officer; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D., Executive Chair and Chairperson of the Board; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D., Chief Medical Officer.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dr. Waksal commenced employment with us effective February 16, 2022 and Dr. Nieman commenced employment with us effective July 11, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Summary Compensation Table</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth information concerning the compensation of our named executive officers for the years shown.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.664%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:6.717%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.799%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.416%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.951%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.021999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.283%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.45%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name and Principal Position</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Salary<br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option<br />Awards</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Equity<br />Incentive Plan<br />Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Other<br />Compensation<br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total <br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D. <br />&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">583,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">870,601</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,150</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,735,751</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">552,115</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">906,410</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">287,374</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,700</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,754,599</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W.Waksal, M.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Executive Chairman</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,385</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,839,974</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,016</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3,4)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,027,375</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(7)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Chief Medical Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">205,625</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,024,301</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,541</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3,5)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,399,467</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts represent the full grant date fair value of stock options granted during 2022 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all option awards made to named executive officers in Note 8 to the consolidated financial statements included in this Annual Report on Form 10-K. </span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts represent performance-based annual cash bonuses determined by our board of directors for the named executive officers for fiscal year 2022. </span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts represent company 401(k) matching contributions.</span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount represents travel expenses and related tax gross-ups.</span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amount represents use of a corporate apartment, travel expenses, and related tax gross-ups.</span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(6)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dr. Waksal commenced employment with us effective February 16, 2022.</span></div></div>
  <div style="margin-left:2.5%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.273846153846153%;">(7)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dr. Nieman commenced employment with us effective July 11, 2022. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Narrative to Summary Compensation Table</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Salaries</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The named executive officers receive a base salary to provide a fixed component of compensation reflecting the executive&#x2019;s skill set, experience, role and responsibilities.  For 2022, the base salaries for Dr. Palasis, Dr. Waksal and Dr. Nieman were $583,000, $200,000 and $455,000, respectively. Dr. Waksal and Dr. Nieman's salaries shown in the 2022 Summary Compensation Table above reflect a partial year of employment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Bonuses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For 2022, we offered Dr. Palasis and Dr. Nieman the opportunity to earn annual cash bonuses to compensate them for attaining short-term company goals as approved by our board of directors. Consistent with his employment agreement, Dr. Waksal is not eligible for an annual bonus unless our board of directors otherwise determines. For 2022, bonuses were based entirely on attaining clinical, regulatory, research and development, strategic and financial goals. The 2022 target bonuses for each of Dr. Palasis and Dr. Nieman were 55% and 40%, respectively, of his or her annual base salary earned for the year based on each individual's commencement date. Each individual's respective target bonuses was set by the board of directors. The actual annual cash bonuses awarded to Dr. Palasis and Dr. Nieman for 2022 performance are set forth above in the 2022 Summary Compensation Table in the column titled &#x201c;Non-Equity Incentive Plan Compensation.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. Our stock options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant. With respect to grants made in connection with the commencement of employment, our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in equal monthly installments over the following three years, subject to the holder&#x2019;s continued service with us. From time to time, our board of directors may also construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Historically, our stock options have been intended to qualify as &#x201c;incentive stock options&#x201d; to the extent permitted under the Internal Revenue Code.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the stock options granted to our named executive officers in 2022.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.786%;"></td>
    <td style="width:4.52%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:26.694%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Named Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Stock Options Granted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302,400</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,473,002</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">230,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our annual performance review in February 2022, Dr. Palasis was granted an option to purchase 127,400 shares of our common stock that vests in 48 equal monthly installments following the vesting commencement date, subject to her continued service with us on each applicable vesting date. In addition, in connection with the amendment of her employment agreement in February 2022, Dr. Palasis was granted a performance-based option to purchase up to 175,000 shares of our common stock that vests based on the achievement of three specified market capitalization targets.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The option awards to Dr. Waksal were made in connection with the commencement of his employment with us and a subsequent equity financing, as described below.  The options vest based on the achievement of three specified market capitalization targets. The option award to Dr. Nieman was made in connection with the commencement of his employment with us and is subject to our standard time-based vesting schedule for grants made in connection with the commencement of employment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Elements of Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Retirement Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terms as other full-time employees. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. For 2022, we made matching contributions of 50% of the first 6% of eligible compensation contributed under our 401(k) plan.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Benefits and Perquisites</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our full-time employees, including our named executive officers, are eligible to participate in our employee benefit plans and programs, including medical, dental, and vision benefits, health spending accounts, and short- and long-term disability, accidental death and dismemberment, and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding Equity Awards at 2022 Fiscal Year-End</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2022.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.052%;"></td>
    <td style="width:0.874%;"></td>
    <td style="width:14.945%;"></td>
    <td style="width:0.955%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.842%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.246%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.213000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.045%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.164%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.291%;"></td>
    <td style="width:10.923%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting<br />Commencement<br />Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Exercisable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Unexercisable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity<br />Incentive Plan<br />Awards:<br />Number of<br />Securities<br />Underlying<br />Unexercised<br />Unearned<br />Options (#)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option<br />Exercise<br />Price<br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option <br />Expiration <br />Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/26/2013</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,358</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.73</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/26/2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/1/2015</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,287</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.76</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/23/2025</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/13/2017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,429</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,429</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.73</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/13/2027</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/6/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,802</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,653</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.76</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/6/2029</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4/30/2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">217,535</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,768</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4/29/2030</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/8/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.63</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/7/2031</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/12/2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,541</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">`</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,859</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.78</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/11/2032</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/16/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.21</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/15/2032</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/16/2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.21</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/15/2032</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/16/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">953,002</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.09</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/15/2032</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/11/2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">230,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/10/2032</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vest and become exercisable in equal monthly installments over four years following the vesting commencement date, subject to the named executive officer&#x2019;s continued service with us on each applicable vesting date. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vest and become exercisable at the end of any given three-month period occurring prior to six years from the vesting commencement date in which we recognize revenue from the commercial sale of an FDA-approved product each month and in amounts, with respect to the second and third months of such period that increase from the revenue recognized from such product sales in the immediately preceding month, subject to Dr. Palasis&#x2019; continued employment with us on each applicable vesting date. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vest and become exercisable as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in 36 equal monthly installments over the following three years, subject to the named executive officer&#x2019;s continued service with us on each applicable vesting date.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vest and become exercisable as to one-third of the shares underlying the option, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to the named executive officer&#x2019;s continued service on each applicable vesting date.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into a new employment agreement with Dr. Palasis in connection with our initial public offering that superseded her prior employment arrangement with us, which was amended effective February 16, 2022, and we entered into employment agreements with Dr. Waksal and Dr. Nieman in connection with their commencement of employment with us. The employment agreements provide for the annual base salaries, as applicable, and annual target bonus opportunities described above under the headings &#x201c;2022 Salaries&#x201d; and &#x201c;2022 Bonuses.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dr. Waksal is also entitled to reimbursement of reasonable travel and other business expenses incurred in the performance of his duties to the Company in accordance with the Company's expense reimbursement policy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until June 30, 2025, and thereafter subject to the discretion of the board of directors, Dr. Nieman is also entitled to (i) reimbursement of reasonable travel expenses from his home to our offices in Massachusetts, and (ii) use of a corporate apartment while working in Massachusetts</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or reimbursement for reasonable hotel costs while working in Massachusetts; provided, that for each calendar month during which he is entitled to such commuting and housing benefits, the sum of the amount of any such expenses eligible for reimbursement and the cost to the Company of providing a corporate apartment shall not exceed $6,250. Dr. Nieman is also eligible for reimbursement for income and employment taxes incurred by him as a result of the above commuting payments and benefits.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to his employment agreement, Dr. Waksal was entitled to an initial option award in connection with the commencement of his employment, containing the performance-vesting terms described above, and was also promised an anti-dilutive option in an amount equal to the difference between the shares subject to the initial option and four percent of our &#x201c;capitalization&#x201d; (as defined in the his employment agreement) immediately following our first bona fide equity financing following February 16, 2022. The anti-dilutive option was granted on June 16, 2022 and is subject to the same vesting terms as the initial option.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, Dr. Palasis and Dr. Waksal are each entitled to receive a cash bonus upon a change in control transaction in which our market capitalization equals or exceeds $750,000,000 (each, a &#x201c;Transaction Bonus&#x201d;), in an amount equal to 1.0% of our market capitalization at the time of the change in control transaction, subject to the named executive officer&#x2019;s continued service through the completion of the change in control transaction and execution of a release of claims.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the employment agreements, if we terminate the employment of Dr. Palasis, Dr. Waksal or Dr. Nieman without &#x201c;cause&#x201d; or the executive resigns for &#x201c;good reason&#x201d; (each as defined below), subject to the executive&#x2019;s timely execution of a release of claims and continued compliance with a separate restrictive covenant agreement (described below), the executive is entitled to receive (i) base salary continuation for a period of 12 months for Dr. Palasis and Dr. Waksal, and 9 months for Dr. Nieman; (ii) in the case of Dr. Palasis and Dr. Nieman payment of any annual bonus for the prior year earned but unpaid as of the date of termination (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 12 months for Dr. Palasis and Dr. Waksal, and 9 months for Dr. Nieman, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#x2019;s termination date, and (iv) in the case of Dr. Palasis and Dr.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waksal, any vested and exercisable options will remain outstanding and exercisable for 15 months or 12 months, respectively, following termination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we terminate Dr. Palasis, Dr. Waksal, or Dr. Nieman without &#x201c;cause&#x201d; or the executive resigns for &#x201c;good reason,&#x201d; in either case, on or within three months prior to or 12 months following a change in control, then, in lieu of the severance benefits described above, subject to the executive&#x2019;s timely execution of a release of claims, the executive is entitled to receive (i) an amount equal in cash equal to 1.5 times for Dr. Palasis and Dr. Waksal, one times for Dr. Nieman  the sum of the named executive officer&#x2019;s annual base salary plus target annual bonus for the year of termination, (ii) in the case of Dr. Palasis and Dr. Nieman, payment of any annual bonus for the prior year earned but unpaid as of the date of termination, (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 18 months for Dr. Palasis and Dr. Waksal and 12 months for Dr. Nieman, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#x2019;s termination date, (iv) accelerated vesting of all unvested equity or equity-based awards held by the named executive officer that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement, (v) in the case of Dr. Palasis and Dr. Waksal, any vested and exercisable options will remain outstanding and exercisable for 15 months or 12 months, respectively, following termination, and (vi) in the case of Dr. Palasis and Dr. Waksal, payment of the Transaction Bonus, provided that the conditions for payment are otherwise satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of our named executive officers has agreed to refrain from competing with us while employed and following his or her termination of employment for any reason for a period of one year and to refrain from soliciting our employees or customers while employed and following his or her termination of employment for any reason for a period of two years in the case of Dr. Palasis and one year in the case of Dr. Waksal and Dr. Nieman.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of the employment agreements, &#x201c;cause&#x201d; generally means the named executive officer&#x2019;s refusal to substantially perform the duties associated with his or her position with our Company or to carry out the reasonable and lawful instructions of our board of directors concerning duties or actions consistent with his or her position, his or her breach of a material provision of the employment agreement which remains uncured (to the extent capable of cure) for a period of 30 days following written notice from our Company, his or her conviction, plea of no contest or nolo contendere or imposition of unadjudicated probation for any felony or crime involving moral turpitude, his or her unlawful use (including being under the influence) or possession of illegal drugs on our premises or while performing his or her duties and responsibilities under the employment agreement, or his or her commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of the employment agreements, &#x201c;good reason&#x201d; generally means, subject to certain cure rights, the named executive officer&#x2019;s termination of employment due to a reduction in salary or target bonus (other than a reduction of 20% or less of the named executive officer&#x2019;s base salary implemented as part of an across the board, proportionate reduction of base salaries for other members of our management team), a material decrease in authority or areas of responsibility, our Company&#x2019;s breach of any one or more of the material provisions of the employment agreement, or a relocation by our Company of the named executive officer&#x2019;s primary office to a location more than 50 miles from the named executive officer&#x2019;s primary office on the date of the agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Director Compensation Table</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.156%;"></td>
    <td style="width:2.978%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.168%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.968%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.380999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.968%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.380999999999998%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fees Earned or Paid in Cash<br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Awards<br />($)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:normal;font-size:5.36pt;font-family:&quot;Calibri&quot;, sans-serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,064</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,972</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward Anderson</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,500</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,408</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,542</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,450</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Tobin</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,886</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,933</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,818</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,908</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nancy Snyderman, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2022 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information regarding the assumptions used to calculate the value of all stock awards and option awards made to our directors in Note 8 to the consolidated financial statements included in this Annual Report on Form 10-K.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of December 31, 2022 by each non-employee director. None of our non-employee directors held unvested stock awards as of December 31, 2022.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.061%;"></td>
    <td style="width:6.044%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:25.895999999999997%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding at Fiscal Year End</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,788</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward Anderson</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,789</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Tobin</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,500</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nancy Snyderman, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Employee Director Compensation Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our initial public offering, we adopted, and our stockholders approved, a compensation program for our non-employee directors under which each non-employee director receives the following amounts for their services on our board of directors:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the director&#x2019;s initial election or appointment to our board of directors, an option to purchase 14,500 shares of our common stock; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the director has served on our board of directors for at least six months as of the date of an annual meeting of stockholders and will continue to serve as a director immediately following such meeting, an option to purchase 7,250 shares of our common stock on the date of the annual meeting; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An annual director fee of $40,000; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the director serves as lead independent director or chair or on a committee of our board of directors, an additional annual fee as follows: </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the board or lead independent director: $25,000; </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the audit committee: $20,000; </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit committee member other than the chair, $7,500; </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the compensation committee, $15,000; </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation committee member other than the chair, $5,000; </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the nominating and corporate governance committee, $8,000; and </span></div></div>
  <div style="margin-left:12.435%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8805458802032775%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nominating and corporate governance committee member other than the chair, $4,000. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, upon the recommendation of the Compensation Committee following a competitive market review by Pay Governance, the Compensation Committee&#x2019;s independent compensation consultant, the Board approved the following changes to our non-employee director compensation program, effective January 1, 2023:</span></p>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to the option award granted upon the director&#x2019;s initial election or appointment to our board of directors, increased the shares of our common stock subject to the option from 14,500 to 40,000 shares; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to the annual option award granted to continuing directors on the date of the annual meeting, increased the shares of our common stock subject to the option from 7,250 to 20,000 shares; </span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The additional annual fee paid to a director who serves as chair or lead independent director was increased from $25,000 to $30,000; and</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The additional annual fee paid to members of the compensation committee (other than the chair) was increased from $5,000 to $5,250.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director is not serving on our board of directors and no fee was payable in respect of any period prior to the effective date of the registration statement relating to our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted to our non-employee directors under the program have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. The stock options granted upon a director&#x2019;s initial election or appointment vest in 36 substantially equal monthly installments following the date of grant. The stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Compensation Plan Information (As of December 31, 2022)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.59%;"></td>
    <td style="width:1.312%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.397%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.056%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.216999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.397%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan category:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Securities to<br />be Issued Upon<br />Exercise<br />of Outstanding<br />Options,<br />Warrants, and<br />Rights</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise Price of<br />Outstanding<br />Options,<br />Warrants, and<br />Rights</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Securities<br />Available for<br />Future<br />Issuance Under<br />Equity<br />Compensation<br />Plans<br />(excludes<br />securities<br />Reflected in<br />first column) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(5)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation plans approved by<br />&#160;&#160;&#160;security holders</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,498,331</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.55</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,599,265</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation plans not approved by<br />&#160;&#160;&#160;security holders</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,813,002</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.03</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.07</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,199,265</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of the Lyra Therapeutics, Inc. 2020 Stock Incentive Plan, as amended (the &#x201c;2020 Plan&#x201d;), 2016 Equity Incentive Plan, as amended (&#x201c;2016 Plan&#x201d;), 2005 Equity Incentive Plan, as amended (&#x201c;2005 Plan&#x201d;), and 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;).</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of the Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan (the &#x201c;Inducement Award Plan&#x201d;), which was adopted without stockholder approval in reliance on the exception for &#x201c;inducement awards&#x201d; provided by Nasdaq Rule 5635(c)(4).  The material terms of the Inducement Award Plan are described in Note 8 to the consolidated financial statements in this Annual Report on Form 10-K.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes 124,440 shares of common stock issuable upon exercise of stock options under the 2005 Plan, 547,868 shares of common stock issuable upon exercise of stock options under the 2016 Plan, and 1,826,023 shares of common stock issuable upon exercise of stock options under the 2020 Plan.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the weighted-average exercise price of outstanding options under the 2005 Plan was $22.57, the weighted-average exercise price of outstanding options under the 2016 Plan was $2.90, and the weighted-average exercise price of outstanding options under the 2020 Plan was $9.29. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes 1,319,569 shares available for future issuance under the 2020 Plan and 279,696 shares available for issuance under the 2020 ESPP. We no longer make any grants under the 2016 Plan or the 2005 Plan, and we have </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not yet commenced offering periods under the 2020 ESPP. The 2020 Plan provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the board of directors, provided that no more than 8,800,000 shares of our common stock may be issued pursuant to the exercise of incentive stock options. On January 1, 2022, the shares available for grant under the 2020 Plan was automatically increased by 520,287 and on January 1, 2023, the shares available for grant under the 2020 Plan was automatically increased by 1,273,106. In addition, any shares that were subject to awards outstanding under the 2005 Plan and the 2016 Plan as of the effective date of the 2020 Plan which are forfeited, expire, lapse for any reason or are settled for cash without the issuance of shares will be added to the number of shares available for issuance under the 2020 Plan. The 2020 ESPP provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 0.5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the board of directors, provided that no more than 987,500 shares of our common stock may be issued under the 2020 ESPP. On January 1, 2022, the shares available for grant under the 2020 ESPP was automatically increased by 65,035 and no increase was made on January 1, 2023.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth information with respect to the beneficial ownership of our common stock by (i) each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock and (ii) each of our named executive officers, each of our directors and all of our current executive officers and directors as a group as of March 1, 2023, unless otherwise indicated.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on 31,829,774 shares of common stock outstanding as of March 1, 2023. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options held by such person that are currently exercisable or will become exercisable within 60 days of March 1, 2023 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.613%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.923000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.346%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.117999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Beneficial Owner</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares of Common Stock Beneficially Owned</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percentage</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5% or Greater Stockholders</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities Affiliated with Perceptive Advisors, LLC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,146,731</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.73</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities Affiliated with North Bridge Venture Partners</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,083,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.82</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities Affiliated with Venrock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,433,268</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nantahala Capital Partners and affiliates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,220,830</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.98</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pura Vida and affiliates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(5)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,157,298</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.78</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Named Executive Officers and Directors</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(6)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">683,039</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harlan W. Waksal, M.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(7)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249,466</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Nieman, M.D. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(8)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,471</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Altman (Perceptive) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,750</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward T. Anderson (Northbridge) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,223,233</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. Ann Merrifield </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(9)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,866</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Konstantin Poukalov (Perceptive) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,750</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W. Bradford Smith </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(10)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,539</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nancy L. Snyderman, M.D. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(11)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,358</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James R. Tobin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(12)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,236</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All current executive officers and directors as a group (14 Persons)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(13)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,475,297</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.15</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Less than 1% ownership as of March 1, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless noted otherwise, the address of all listed stockholders is 480 Arsenal Way, Watertown, MA 02472.  Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">________</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pursuant to a Schedule 13D/A filed with the SEC on April 14, 2022, Perceptive Life Sciences Master Fund, Ltd. (&#x201c;Perceptive Life&#x201d;) reported shared voting power and shared dispositive power over 7,858,285 shares of common stock; Perceptive LS (A), LLC (&#x201c;Perceptive LS&#x201d;) reported shared voting power and shared dispositive power over 1,288,446 shares of common stock; Joseph Edelman reported shared voting power and shared dispositive power over 9,146,731 shares of common stock; and Perceptive Advisors LLC reported shared voting power and shared dispositive power over 9,146,731 shares of common stock. Perceptive Advisors LLC serves as the investment advisor to Perceptive Life. Perceptive LS GP, LLC is the manager of Perceptive LS. Joseph Edelman is the managing member of Perceptive Advisors LLC and the sole member of Perceptive LS GP, LLC. Michael Altman and Konstantin Poukalov, two of our directors, are Managing Directors at Perceptive Advisors LLC. Messrs. Altman and Poukalov each have sole voting power and sole dispositive power over 21,750 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023. The address of the aforementioned individuals and entities is c/o Perceptive Advisors, LLC, 51 Astor Place, 10th Floor, New York, New York 10003.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Schedule 13D/A filed with the SEC on April 22, 2022, North Bridge Venture Partners V-A, L.P. (&#x201c;NBVP V-A&#x201d;) reported shared voting power and shared dispositive power over 91,855,443 shares of common stock; North Bridge Venture Partners V-B, L.P. (&#x201c;NBVP V-B&#x201d;) reported shared voting power and shared dispositive power over 909,424 shares of common stock;  and North Bridge Venture Partners VI, L.P. (&#x201c;NBVP VI&#x201d;) reported shared voting power and shared dispositive power over 1,318,133 shares of common stock. North Bridge Venture Management V, L.P. (&#x201c;NBVM V&#x201d;), is the sole General Partner of NBVP V-A and NBVP V-B and may be deemed to have voting and dispositive power with respect to the shares held by those entities. NBVM GP, LLC, the General Partner of NBVM V, may be deemed to have voting and dispositive power over the shares held of record by NBVP VA and NBVP V-B. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#x2019;Amore. North Bridge Venture Management VI, L.P. (&#x201c;NBVM VI&#x201d;), is the sole General Partner of NBVP VI. NBVM GP, LLC, the General Partner of NBVM VI, and may be deemed to have voting and dispositive power over the shares held of record by NBVP VI. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#x2019;Amore. Mr. Anderson, a member of our board of directors and a manager of NBVM GP, LLC, disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein. Mr. Anderson has sole voting power and sole dispositive power over 21,750 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023. The address of all entities affiliated with North Bridge Venture Partners is 60 William Street, Suite 350, Wellesley, MA 02481. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.272399060692894%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Schedule 13G/A filed with the SEC on February 14, 2023, (i) Venrock Healthcare Capital Partners II, L.P. reported shared voting power and shared dispositive power over 148,699 shares and 403,714 shares issuable upon the exercise of immediately exercisable warrants (&#x201c;Warrants&#x201d;); (ii) VHCP Co-Investment Holdings II, LLC reported shared voting and shared dispositive power over 60,256 shares and 163,593 shares issuable upon the exercise of Warrants; (iii) Venrock Healthcare Capital Partners III, L.P reported shared voting and shared dispositive power over 321,426 shares and 872,664 shares issuable upon the exercise of Warrants; (iv) VHCP Co-Investment Holdings III, LLC reported shared voting power and shared dispositive power over 32,161 shares and 87,317 shares issuable upon the exercise of Warrants; and (v) Venrock Healthcare Capital Partners EG, L.P. reported shared voting power and shared dispositive power over 361,628 shares and 981,810 shares issuable upon the exercise of Warrants. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Company may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.999% of the number of shares of common stock outstanding immediately after giving effect to the exercise. Accordingly, notwithstanding the number of shares of common stock listed above as being beneficially owned by the entities affiliated with Venrock, the entities affiliated with Venrock disclaim beneficial ownership of the shares of common stock issuable upon exercise of the Warrants to the extent the number of shares of common stock beneficially owned by each entity affiliated with Venrock and any other person or entities with which such entity&#x2019;s beneficial ownership would be aggregated for purposes of Section 13(d) of the Exchange Act would exceed 9.999% of the total number of shares of common stock outstanding. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Mr. Nimish Shah and Mr. Bong Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC. The address of the aforementioned individuals and entities is 7 Bryant Park 23rd Floor, New York, NY 10018. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Schedule 13G filed with the SEC on February 14, 2023, Nantahala Capital Management, LLC (&#34;Nantahala&#34;) may be deemed to be the beneficial owner of 2,220,830 shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Wilmot B. Harkey and Daniel Mack may be deemed to be a beneficial owner of those shares.  The address of Nantahala and its affiliates is 130 Main Street, 2nd Floor, New Canaan, CT  06840.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Schedule 13G/A filed with the SEC on February 14, 2023, Pura Vida Investments, LLC (&#34;PVI&#34;) and Efrem Kamen reported shared voting power and shared dispositive power over 2,157,298 shares.  The shares reported are owned by Pura Vida Master Fund, Ltd. (the &#34;Pura Vida Master Fund&#34;), Pura Vida X Fund LP (the &#34;Pura Vida X Fund&#34;) and certain separately managed accounts (the &#34;Managed Accounts,&#34; collectively the &#34;Client Accounts&#34;). PVI serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. Efrem Kamen serves as the managing member of PVI.  By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the shares owned directly by the Pura Vida Master Fund and the Managed Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Persons pecuniary interest therein. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(6)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of options to purchase 683,039 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(7)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of 236,966 shares of common stock and 12,500 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(8)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of options to purchase 3,471 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(9)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of 11,328 shares of common stock and 20,538 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(10)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of options to purchase 20,539 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(11)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of 1,025 shares of common stock and 19,333 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(12)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of options to purchase 5,326 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.310674790776583%;">(13)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consists of 4,450,802 shares of common stock and 1,024,495 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2023.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policies and Procedures for Approval of Related Person Transactions</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests (or the perception thereof) and has adopted a written related person transactions policy to comply with Section 404 of the Exchange Act. Under the policy, our finance team is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. In addition, any potential related person transaction that is proposed to be entered into by the Company must be reported to the Company&#x2019;s Chief Financial Officer, by both the related person and the person at the Company responsible for such potential related person transaction.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our finance team determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Financial Officer is required to present to the Audit Committee all relevant facts and circumstances relating to the related person transaction. Our Audit Committee must review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm's length dealings with an unrelated third party and the extent of the related person's interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics, and either approve or disapprove the related person transaction. If advance Audit Committee approval of a related person transaction requiring the Audit Committee's approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the Audit Committee subject to ratification of the transaction by the Audit Committee at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then upon such recognition the transaction will be presented to the Audit Committee for ratification at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management will update the Audit Committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LianBio License Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both us and LianBio.  Additionally, Konstantin Poukalov and Michael Altman are each a Managing Director at Perceptive Advisors, LLC and Mr. Poukalov is also the Executive Chairman of LianBio&#x2019;s board of directors.  See &#x201c;Management&#x2019;s Discussion and Analysis&#x2014;Financial Operations Overview&#x201d; for a description of the LianBio License Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investor Rights Agreement</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, we entered into a Ninth Amended and Restated Investor Rights Agreement with the holders of our then-outstanding preferred stock, including Perceptive Advisers, LLC and, North Bridge Venture Partners, which are 5% or greater holders of our common stock and entities with which certain of our directors are related. The agreement provides for certain rights relating to the registration of such holders&#x2019; common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification Agreements</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#x2019;s services as a director or executive officer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Independence of the Board of Directors</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors has determined that each of Michael Altman, Edward Anderson, C. Ann Merrifield, Konstantin Poukalov, W. Bradford Smith, Nancy Snyderman, M.D., FACS and James R. Tobin qualify as &#x201c;independent&#x201d; in accordance with the listing requirements of Nasdaq.  The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#x2019;s business and personal activities and relationships as they may relate to us and our management, including that Mr. Altman, Mr. Anderson and Mr. Poukalov are affiliated with certain of our significant stockholders. Harlan W. Waksal, M.D. and Maria Palasis, Ph.D. are not independent. There are no family relationships among any of our directors or executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tant Fees and Services.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the fees of BDO USA, LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.7%;"></td>
    <td style="width:1.61%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.040000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.61%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.040000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fee Category</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396,977</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">297,607</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit-Related Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,775</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,900</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Other Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Fees</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409,752</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">308,507</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">________</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:3.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For 2022, audit fees consist of fees for the audit of our financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements. For 2021, audit fees also included fees for services incurred in connection with our Registration Statement on Form S-3.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:3.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For 2022 and 2021, audit-related fees consist of fees reasonably related to the performance of the audit and the review of our financial statements and which are not reported under &#x201c;Audit Fees.&#x201d;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:3.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For 2022 and 2021, tax fees consisted of fees for tax-related services, including tax compliance and tax advice.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:3.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other fees consist of fees for all other services that are not reported above.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Audit Committee has adopted a policy (the &#x201c;Pre-Approval Policy&#x201d;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage BDO USA, LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the Audit Committee (&#x201c;specific pre-approval&#x201d;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#x201c;general pre-approval&#x201d;). Unless a type of service to be provided by BDO USA, LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC's rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company's business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company's ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. The Audit Committee periodically reviews and generally pre-approves any services (and related fee levels or budgeted amounts) that may be provided by BDO USA, LLP without first obtaining specific pre-approvals from the Audit Committee or the Chair of the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits and Finan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Documents filed as part of this report:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are included on pages F-1 through F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto and are filed as part of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.996%;"></td>
    <td style="width:7.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(BDO USA, LLP, Boston, Massachusetts, PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_67eabbc7-1ff5-43c2-8e27-61cb811c07dc" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">243</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the financial statements or the notes thereto.</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Exhibits.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.762%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:44.782%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:8.115%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.317%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:10.377%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with SEC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520133819/d925971dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 5, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520133819/d925971dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 5, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ninth Amended and Restated Investor Rights Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen Stock Certificate evidencing the shares of Common Stock of the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312520120337/d805799dex43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Warrants to Purchase Common Stock, dated various dates, issued by the Registrant to various investors, together with a schedule of warrants and warrantholders</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex42.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Purchase Warrant, together with a schedule of Warrants, each dated April 12, 2022, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex4_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2005 Equity Incentive Plan, as amended, and form of agreements thereunder</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2016 Equity Incentive Plan, as amended, and form of agreements thereunder</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Incentive Award Plan and form of agreements thereunder</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.762%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:44.782%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:8.115%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.317%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:10.377%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with SEC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Inducement Award Plan and form of agreements thereunder</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. 2022 Inducement Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Harlan Waksal, M.D. on February 16, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Maria Palasis, Ph.D. on February 16, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex101_67.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Lyra Therapeutics, Inc. 2022 Inducement Award Plan</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex102_68.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to Lyra Therapeutics, Inc. 2022 Inducement Award Plan</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017022023266/lyra-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3 to Lyra Therapeutics, Inc. 2022 Inducement Award Plan</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 8, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.6#*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex10_46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan as Amended and Restated, Effective December 12, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Employee Director Compensation Program</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement for directors and officers of the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement between the Registrant and ARE-480 Arsenal St, LLC, dated August 14, 2007, as amended</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and Maria Palasis, Ph.D., dated as of April 27, 2020</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 27, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459021042711/lyra-ex101_31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Collaboration Agreement dated May 31, 2021, by and between the Registrant and LianBio Inflammatory Limited and LianBio.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017022023266/lyra-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to License and Collaboration Agreement, dated September 26, 2022, between Registrant and LianBio Inflammatory Limited and LianBio</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 8, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459021055778/lyra-ex102_83.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and Jason Cavalier dated as of September 13, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 9, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-ex1014_177.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and Corinne Noyes dated as of April 27, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-ex1016_179.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and Robert Richard dated as of June 20, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15#*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex10_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and John Bishop dated as of February 2, 2023</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to the Employment Agreement between the Registrant and Maria Palasis, Ph.D. dated as of February 16, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.762%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:44.782%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:8.115%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.317%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:10.377%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with SEC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the Registrant and Harlan Waksal, M.D. dated as of February 16, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 18, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex103_69.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between the Registrant and Richard Nieman, M.D. dated as of June 30, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000119312522104425/d323142dex102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights Agreement, dated as of April 7, 2022, by and among Lyra Therapeutics, Inc. and the Investors named therein</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 13, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000095017022025323/lyra-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sixth Amendment to Lease, dated November 14, 2022, by and between Lyra Therapeutics, Inc. and ARE-480 Arsenal Street, LLC</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 16, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex42_66.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement, dated May 31, 2022, between the Registrant, as the tenant, and BXP Waltham Woods LLC, as the landlord</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1327273/000156459022028609/lyra-ex43_65.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease Agreement, dated July 20, 2022, between Registrant, as the tenant, and BXP Waltham Woods LLC, as the landlord</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 9, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39273</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex10_24.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Lease Agreement (Notice and Acknowledgement thereof), dated March 3, 2023, between Registrant, as the tenant, and BXP Waltham woods LLC, as the landlord</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiaries of the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-236962</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of BDO USA, LLP Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="lyra-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; this instance document appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.762%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:44.782%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:8.115%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.317%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:10.377%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with SEC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC File</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:8.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:8.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.25pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Indicates management contract or compensatory plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Certain portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.119%;"></td>
    <td style="width:4.98%;"></td>
    <td style="width:3.264%;"></td>
    <td style="width:46.637%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.998%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:30.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:33.998%;"></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jason Cavalier</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer (principal financial officer and principal accounting officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Harlan Waksal, M.D.</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Harlan Waksal, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Chair and Chairperson of the Board</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Altman</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Altman</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Edward T. Anderson</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward T. Anderson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ C. Ann Merrifield</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. Ann Merrifield</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Konstantin Poukalov</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Konstantin Poukalov</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ W. Bradford Smith</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">W. Bradford Smith</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Nancy Snyderman, M.D., FACS</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nancy Snyderman, M.D., FACS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ James R. Tobin</span></p><p style="border-top:0.25pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James R. Tobin</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:12.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:12.75pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.677%;"></td>
    <td style="width:1.379%;"></td>
    <td style="width:6.944%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGIST</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board of Directors and Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown, MA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. and subsidiary (the &#x201c;Company&#x201d;)  as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-1.695%;padding-left:1.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b8dd620c-f11d-4ae6-989d-68e3fc44ab36" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BDO USA, LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2013.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a0249a7b-0f76-45c8-b113-7d15bfdf6cf8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED BA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LANCE SHEETS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.771%;"></td>
    <td style="width:1.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.964%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.042%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbf9ddd7-4eb1-42c8-b939-51769252bc3d" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f2f5012-038b-42eb-a9ac-7c08e306f08f" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5454f506-e961-46c8-b129-b5794ff20827" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0db2b67-b511-4265-af46-9edac2721a68" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_832afe09-dab5-4275-bfd8-8cfe2a1bd9fc" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e95bd202-b09f-4247-927c-d6caa08ab10a" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_957c004c-653b-4eec-a867-1565c136782c" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19a16a68-46b7-408b-a9fe-3fdea3e03c40" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,243</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d7e9662-859c-47f6-961b-121aa93c81e7" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_101c8694-0fed-4a79-9792-d46f70ecd6c8" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2eef7639-5e70-4aeb-be97-06cb86593036" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_908acbf5-0176-4cf1-a390-2e5e362372df" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_593baab8-bc70-45c9-b82d-dd4e5e9bee08" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cd11d5b-8f52-4b01-8625-2c7cc84a5975" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d08c94e-ce3d-4ecf-93f6-bb1131a42e0b" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">762</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2df1f897-2ad9-4631-b476-85e8d1af1fe3" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8ec7402-1c80-4abe-a67a-c43c68ebef2c" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c0dac01-1201-41d2-9665-9e7373d50587" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2d9ac42-6961-4b1d-b2d4-8cf8f7dead3e" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aabc040-fe2e-4b52-a114-56251109f3c3" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,030</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d06731a-74e0-4562-83d1-b939e9c8b288" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="lyra:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f21f01e-658d-46c6-a0cc-d0adde2c0b48" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e21e2f9-8b73-49bb-8ce2-373ca92a3b71" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,074</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98ff23fa-97ab-459e-b659-6ec6b0ad6c99" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d11aec35-8765-4833-a271-a1e7cc0fb5b6" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78f4567a-d5f7-493b-9d11-67434edcfac2" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76000ccf-2c69-47b7-8c72-d3222d953e63" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53ee9229-7e99-4b42-bd4f-ec3f7e334219" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">667</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_208e673e-ba2e-400d-bafb-4c6aba1080d4" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92ee6b96-2c17-4b50-8508-7961d276e055" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f372d27-165e-4bb0-9e79-a9d8b7230aa7" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0b6afe9-9000-4d0e-9f9f-6226ef0f74ec" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d82198b-31f9-4f43-adf8-a6daea0959a5" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,551</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1998289b-eb61-4a17-beb7-899c1a25802a;"><span style="-sec-ix-hidden:F_43989a1a-5a9f-4a95-98ff-670e92082ebc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 11)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56c11b76-8e55-40de-846b-84e969120be5" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_497a63cf-44f8-4747-965b-6c5b772062ff" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9503e305-afac-44f9-8fd5-263c499447ab" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e905d707-7798-4196-a5e9-afe45ed10b2d" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at<br />&#160;&#160;&#160;December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d25a8ec-6590-4f04-9671-5b92ad37ddac" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bb53aa57-4af8-464c-8475-b2d2cc6a6d56" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4bc50c54-3770-47aa-a79b-1a1c61f9aef5" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f9c948ed-3f1c-4020-96a3-875099fdb3b8" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, <br />&#160;&#160;&#160;2022 and 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b556901c-3c67-411f-ae41-cb8f4493d60e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4471ca7f-4d79-47e2-9c65-d4f601168d4c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_523c8137-d11e-4037-85c7-5c9cc314c34e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_307ea8e7-65f8-4553-85ed-28fca5b5d077" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfe09542-db9a-418e-aa6d-7681e5cf89ce" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_416ceaa0-6ac1-4bac-822d-905dc483bb60" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at<br />&#160;&#160;&#160;December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca8c5cc-2734-489f-8082-739542d5dd17" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ed9532d1-0d36-4d24-ad9e-ee5885d5083e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,827,659</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07cf091d-c464-4af9-893b-0c4b08afe4e4" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b89fcd69-4c91-49e7-a202-c735a1805cb2" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,007,178</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and <br />&#160;&#160;&#160;outstanding at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8036db4b-0957-4463-8618-13953a4bc625" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08a13179-3310-43af-b737-a44ec9fc4541" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55b31397-2382-4a2e-a246-d7b82bc52e5c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba2ef8a1-1c13-4a6d-be2f-b5ef042d624f" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive income, net of tax</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c82e64e5-5c9f-4786-87d7-10a1735b47dd" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c33dd1c5-e9bd-4291-ac54-73a93b239134" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">248,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_998ffc5e-4d93-4f3a-a9a8-a437fa06bef7" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">193,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc7a5e6c-60ce-443f-895b-893645d90d2a" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7d6e964-8a41-4bff-8dd4-e370ae4fadb2" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stock and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff8195fd-861d-46a7-9e2c-247d31e77ea0" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a4a7e43-bf7a-4ade-b872-e7a2bada3602" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPER</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATIONS AND COMPREHENSIVE LOSS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.807%;"></td>
    <td style="width:1.711%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.816%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.711%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.955%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b71d78f-f435-4da2-bc83-354811321252" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8aef143-4b18-4e82-9b1a-dd2886f2c608" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8a08acc-5530-45b5-a82f-3798cd98cea8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9016e91-941b-44be-8c1a-6c4723420531" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea0d2ee5-efec-401a-a2aa-814695bb3925" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05393532-9b7a-4352-b470-eed4ff0a4294" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on impairment of long-lived assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_231d5903-65a3-4dde-b811-950f9be0c055" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b825ac3-bc87-4ef7-9df2-4ef6e089032a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbd1c424-4997-43a6-bf2d-64a589447723" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81766c15-5832-4d64-affe-e350533cc868" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47a99f22-67df-4419-a481-21b082cdcc93" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf7fdcdb-1e4d-4f47-8ada-474291293fa3" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57f5e10d-c67e-403a-846b-26cfe68497bf" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18e4f912-5292-4427-b576-9031bde58d31" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f654e29-4c42-4c4b-80d7-4e2884f80c16" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28d4b030-daab-43d4-ab28-f4d2ff35b630" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd7e0caf-401f-40c2-874b-58930ef8ca19" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64b170e6-94c7-4af9-96ea-bdccf6a246d4" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87728ba0-0a0b-40ed-992f-348178e995cd" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_003e2956-48c6-499c-8c48-6a57871d9a66" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized holding gain on short-term investments, net of tax</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b25a4e98-afc3-419c-951c-9a296c1d622f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bf76f13-21a4-43b6-bcd4-7f413a1076d5" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c8ddd77-176b-4af2-baaf-2136b9f986c1" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_429929bc-b567-4529-8acf-5d8cadee1595" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_0f3ef7a8-a9f3-47cc-9e4e-17036359ad4a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.83</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e28bf11-a2a7-4755-a874-ab3b8711d0bb" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_fc86e4a6-6afc-4c08-a595-5d3bb0bcfd19" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.35</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2014b6b-bd98-4598-9777-ec5eafed80fb" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_a303d1d5-e1ae-4640-a782-099afb4edbb2" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,235,689</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a207650a-ca2d-417e-b2fd-2c689dd8b12e" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_6d8ab473-1bf0-491c-8541-e452edbc18f1" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">12,986,101</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_redeemable_conve"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.994%;"></td>
    <td style="width:0.654%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.308%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.370000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.370000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.739%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.370000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.388%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.111%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.388%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income, net of tax</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8735df60-8c3f-4677-96f8-188cb4777544" contextRef="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,932,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e16e9d6-8dfb-4195-a53b-bd075a1be84e" contextRef="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6180182-c206-4e3c-ac4f-49db85d43b0f" contextRef="C_274faa51-b01e-4850-a412-77a812b2749d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9a3562a-0128-4e92-ad86-0d2b0fa2dd1d" contextRef="C_a03fff14-a210-4e02-928c-f0e2c6e0d975" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">149,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97ec9195-39c9-4ace-b8dc-96dd4427a459" contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,492</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_976fa9ba-b303-4ca2-8f82-d4ae6724f0a5" contextRef="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58" name="lyra:VestingOfRestrictedCommonStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71e6a9da-5f2e-4ab8-b9fd-fdda10acfd91" contextRef="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">72,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_545df319-8bd9-49f9-b4eb-4e25faea536c" contextRef="C_fc9e381c-707b-4016-a540-87b86a5d1ac7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe50aaa3-139b-488c-a5ef-6a85186d7af0" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49d5b2d4-87f1-4114-8bf4-474c9fad7d29" contextRef="C_fc9e381c-707b-4016-a540-87b86a5d1ac7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ece631d-0de7-44ca-a0f7-bf0588be1405" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f307009e-a9fd-4567-bef6-42779a8453ab" contextRef="C_2ce20db0-1512-4e67-bb88-1bf3499c3582" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d464c4c-fbb0-4780-b590-66d3f86c341f" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e83419c2-2fb2-407c-9ca1-840db4383e2b" contextRef="C_03cb3063-9002-40eb-a812-0f647395fbc2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,007,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06960887-79e9-4555-adcc-cddffabf63b8" contextRef="C_03cb3063-9002-40eb-a812-0f647395fbc2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e3c4ada-79fb-4901-b86c-8b7bc4568bda" contextRef="C_2247c2b1-0ab0-4254-9c47-7754e5b3eb9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fea8ebea-dba5-4b92-b093-53c52ad401c0" contextRef="C_e88491c6-140e-4267-b33d-457c84a7b90d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">193,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5f61826-0026-4e04-9808-b3942c5941fd" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b915a62d-7d0d-4107-b5c1-0f4d5b62a16e" contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37fad1d7-4d27-481a-b882-4d8d92ea0de7" contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4b28cdc-354e-459a-8221-1243f1b552a2" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock and pre-funded<br />&#160;&#160;warrants, net of issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7966abc8-7276-4a03-b71d-428d8b98fe48" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1114bd6d-d5c5-4c07-b27d-9910e7f3ca2e" contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba" name="lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,815,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b167f8a3-4476-49f5-8659-a75671b349b1" contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33b6924e-752a-4f4e-a66f-07a667984196" contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7b415f7-9877-4080-b090-e13c88312597" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,251</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon RSU<br />&#160;&#160;vesting</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e5221e3-ae43-4f8b-bf98-2bfdf11b1eb4" contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba" name="lyra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c33ed15c-35d7-4488-b99f-b5d8b60e181b" contextRef="C_8e5eaed3-f8d9-42a7-a095-56cf4842b09e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0099413-a1f7-41c5-a474-4d5d768625af" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f98f8af-6aac-4194-a3ca-5c8a349d9446" contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20617700-02f0-4885-a6bd-41f911f1a741" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0d264bb-54a2-447c-bb4c-8b114748e239" contextRef="C_3c64f210-b096-4f52-af04-9a9929413c0d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_101ad789-4e9d-4689-b994-2dc5a72e94ac" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc800b42-9bea-4116-abb6-df9a87566c63" contextRef="C_4a4eab87-52a4-4143-a37b-fabafd2119ff" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,827,659</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6275c13b-4694-42d3-acb4-ca8d9d25d324" contextRef="C_4a4eab87-52a4-4143-a37b-fabafd2119ff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efa330e6-32d1-4e49-a8ac-7adb1d22d36b" contextRef="C_e404146f-8c43-4dcb-b085-fef72fda8da0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6de6b466-5ba1-4a1d-9179-a7aa0215da51" contextRef="C_58783042-c5b7-49c6-8ed2-272d1bada5b9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34437001-332f-4d94-9b99-a95604cec7de" contextRef="C_77e94b31-e6d8-437a-8894-b8188333e621" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">248,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12c1ff27-5713-4d18-a34d-858fa28a88d1" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ENTS OF CASH FLOWS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.792%;"></td>
    <td style="width:1.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.062%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a07d0ce-5ff0-408c-87d6-f39ebb32a6ef" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b0d4dc2-9fc5-4ea6-b561-2f75ff19695c" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_815c6548-e52b-4cda-b1eb-9258fc317808" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d526f37c-cefe-4eb4-8856-fe484ba3322c" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aabd2cac-d74a-47d2-8023-4e557ef45c77" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bd55b9b-7907-4a9f-9a0d-01fdd919de8e" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on impairment of long-lived assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_025a33dc-44b1-4f58-a172-b5995d419e97" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net amortization of premium on short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_180785c2-5adc-4b55-9ae6-017c92f14e73" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">492</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41ccbd46-430b-4c75-935d-b976ae3c1683" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3">764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4e2003e-381b-4785-8c84-71cfbdf0c970" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3">847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ed746fa-508e-419f-ba04-8bae15e5db9d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a589a543-52c5-41ce-93df-a23b94594cfe" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d13f00ff-4c82-4e0a-b680-4d6e2ca8c0f1" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3">574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8680fb81-10be-43b8-b936-7e8c79dc868a" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3">500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_560ba08f-a1c5-4794-a7a2-2cf69d7a97a8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06182f69-dfe4-4206-9605-307929fcb870" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51ea17dd-35e3-49ea-aa66-e00a920847c7" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d1b7328-9f96-457f-b4ad-2c512f4564fb" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e21a1c25-2c14-4944-9b63-3f9c1eacb8b9" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3da70b8a-c855-4a25-8fe3-240c8e48875b" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-">986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f22c2d7f-00ef-43b6-b029-a7f081994286" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,637</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8a9e183-3feb-4fdb-ab1d-211d42f8bd35" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_556b521c-91a8-4bb2-aec9-e9d139f9db1e" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bda3ebb-f869-4619-a6f9-aab5a2fb9851" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25,820</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffe72e54-28b9-4905-9b52-86edf06d1f63" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1267322e-4500-4984-ac3e-79e26c5e7f24" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77263bfa-6f0f-4b35-b04c-3d9adc79ff4e" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f3aea8-b6c0-4cbb-af16-63bb6bfbc91f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52e487f5-5bb2-4f81-a355-b173d30329a7" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of common stock and pre-funded warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85cebbfd-f588-4b5b-a02d-f2eb4aec8c85" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of deferred offering expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15ad0634-68a6-47a6-bbd2-e94db3a0bfb8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a28a90ae-7709-4438-9358-f3741468a0fd" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3">245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_059ab689-d980-48c5-9db5-636e0411bc7c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48d217f7-0475-4415-9a1d-991f071e33d0" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a98579bc-6a0e-42fd-9278-8451f5f7b2c0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,257</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fb065f3-41a7-4f49-bd29-dc7143f6b1ab" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3">359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e531f7e4-140e-4120-90ae-82ef6454e85d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88efb6b2-3f6f-448d-9c36-f41479d53371" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26397c30-1172-409f-8e52-c92a1064c7fb" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,076</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d68d94c1-832c-4062-89f0-df0c2fe6491e" contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a15a82af-6cda-4891-a473-9224e5faf253" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b586964-7c65-47bd-befe-55fabf9b6f9d" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,076</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of non-cash financing and investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases included in accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e4f725c-0721-40af-8e06-dd4b72b897db" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74069c22-e164-4a0d-9aca-01f864af36d5" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d35af7ff-4a58-40a1-a0f2-eed56e966990" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modification of lease agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3cdaac3-b9b5-4f55-840e-c4e9fe941be0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:ModificationOfLeaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs included in accounts payable and accrued expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd73154f-1100-4b18-abae-1f1254de0b2d" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:DeferredOfferingCostsIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2d9d156-63b1-4735-9ca1-d82dce239357" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#x2019;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#x2019;s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ea3e886-34a6-4b0b-9bad-c059e1b54ca8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2005</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From inception through December 31, 2022, the Company has raised an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3196a298-a471-41d7-aaa7-341d3b3f4dae" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:CashProvidedByFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">350.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to fund its operations primarily from the equity financings, government grants and its License and Collaboration Agreement with LianBio discussed in Note 9. The Company has incurred recurring net losses since inception and had net losse</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_647d9b4d-85ba-4e94-9f41-3fa09638c9f9" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">55.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dda34f0-6e35-4e8f-9a31-16c9b66c85b1" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">43.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. In addition, the Company has an accumulated deficit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51122c2f-18f0-41c5-b485-728f58471fe8" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">248.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f73130-78ef-45f9-98df-77fbc32e4a6e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52bb9701-0f74-4b1a-9a07-7d4480e2d33c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of short-term investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that its cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund the Company&#x2019;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.  The inability to obtain funding as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1405b2d3-e495-4311-988c-ccf78086fe35" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_dbf1e56c-8849-40dd-bf29-f9a61304222a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fd987f6-5659-4753-b9f3-c06e6d28d517" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce6cfcfb-8039-4223-8b64-b5f718e07a45" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_919e3837-131d-4d7f-93b3-3f07b2e09a71" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s chief executive officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34699c96-0366-4d96-b00e-ec5fba8678bc" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the year ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other comprehensive income consisted of unrealized gains and losses, net of taxes from its short-term investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company did not have any element of other comprehensive income or loss during the year ended December 31, 2021, its comprehensive loss is equal to its net loss for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_74021805-11f2-4677-a511-dd99b6854f00" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f533e5f0-80b5-411e-a22c-2ebc01cc2f64" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:RestrictedCashPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had restricted cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_690c74e4-0f42-4782-bb99-76e747d5a31d" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a85f34af-0ecc-4abd-880f-882e0aca1b8b" contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. These balances were held unsecured as of December 31, 2022  at the Company&#x2019;s financial institution to secure the Company&#x2019;s letters of credit for its facility leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55e2bdd8-bd5c-4abd-9268-c924a23d6665" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true" continuedAt="F_55e2bdd8-bd5c-4abd-9268-c924a23d6665_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_55e2bdd8-bd5c-4abd-9268-c924a23d6665_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.258%;"></td>
          <td style="width:1.496%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.696%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.496%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.052999999999999%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e890c82a-26b4-4d89-a758-b45b260a0725" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,550</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_321d90c3-ef2d-439e-a1c0-837fccd4aa67" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,747</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8db8048-8fe9-44e5-8c10-d2b20586c1c7" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,392</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f4ddfdd-796b-4ac1-ba49-cca269f2ca11" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6b7f0f0-1287-490c-8d6d-002d0a53e26b" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,942</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58a9bc1a-6079-40af-afd8-b8f3b523fc96" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,076</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed72b269-357d-4c0a-9c30-c796fca3b60a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#x2019; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#x2019;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#x201c;other than temporary&#x201d;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24c5d288-4474-440a-afba-6df80801ffcc" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:OtherAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets.  The Company had other assets of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7bc996-81e2-4238-91c8-fe3cb015451a" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OtherAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4476dab2-7746-456e-a29b-d2f269d3d5d6" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OtherAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Other assets are primarily comprised of long-term deposits for our clinical trial agreements as well as prepaid rent related to our new facility lease in Waltham which will be reclassified to a right of use asset upon possession of the space.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f977a81c-09e6-4fb9-aec2-1d09423cb445" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_633b5cc1-d209-47b7-9884-53fea70f14b9" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:SignificantSuppliersPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1b5ea22f-d914-4e2e-b8be-8eade05efdac" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de50a710-10d0-499c-8f4f-d4fee24b7992" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf_1" continuedAt="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.998%;"></td>
          <td style="width:1.002%;"></td>
          <td style="width:50.0%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_914cee37-44c6-4df0-9da0-485c022f148b" contextRef="C_e9a9b4ce-3240-47fa-87b6-f4310526dffe" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb809780-9457-4c9b-8ec7-e909b94d0fde" contextRef="C_86d35cfd-3d7d-4cd3-aad0-bbb425c6ea04" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_400398aa-01f6-4d14-9c63-9801586ea7b4" contextRef="C_e56cf9c7-99bc-4107-a492-f1caeb308084" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_86fa0743-b7fc-40ce-9b89-ac1580345a74" contextRef="C_76580e45-0c6f-4827-9602-bda9e3bdb18d" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99649401-9240-48e3-82a1-4e7f41121518" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recorded impairment losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8468e7ad-405c-411b-8a03-fa77f03094eb" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4bdd380-030a-4055-8e09-6dff92855df5" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the contract manufacturing organizations or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMO&#x2019;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b3d4ae6b-5ce7-4009-a3d8-cae7a6de001a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc0b125b-32c4-44bb-a04a-556e1a7fd734" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3092d553-adb8-49cc-8cdf-9b5ce385bbe7" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right-of-use asse</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9e6d9c4d-d173-4c37-9051-37c0e1abf253;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease liability</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f4463cb-0ae3-4685-be7d-c0d99dd0f6aa" contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance leases</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1375f98a-0a6d-423f-8def-64de768f4f0b" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 9 for further discussion of the arrangement.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_966f3438-6a62-4c2d-b3a4-0e9e2c432e88" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bcc1b215-1058-43e4-87c2-8ad58f8cbc56" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:PatentsCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b0311a5-e367-4fd1-b27b-a3bbd92d7acd" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation&#x2014;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#x2019;s common stock, the expected volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#x2019;s stock options, and the Company&#x2019;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#x2019;s policy is to recognize forfeitures as they occur.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 740&#x201d;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d24b4213-7be8-4477-8a63-fa9f60fc5e3a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3524f9ba-9ee4-4b01-bbd7-863272cc65fd" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:70.807%;"></td>
          <td style="width:1.711%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:10.816%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.711%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:10.955%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a4cf050-709a-41ae-a0bd-20db13646a98" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b99001cc-b7b6-4984-800d-a2dd23fe98b4" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a408a8f6-76a3-43cd-80e7-0ddae780b11d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,278</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03809afc-60e5-4fde-a94e-09a38a466948" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,513</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares&#x2014;basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f867e38f-412d-497a-8968-b1fa094e7b8a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_a1e84d9e-b54e-4602-a8ff-562fb6248fef" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,235,689</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c58fe6be-3541-43e1-af52-5d30514cfb80" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_be059c39-685f-4f70-81a6-b1ec6118bae2" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">12,986,101</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#x2014;basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86f4b495-62f8-49ab-9c81-9d3508dbefc6" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_e1d51fca-7bb2-409d-a703-84c57092c2fd" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.83</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7db2bef-2e3b-48be-808b-dd0e73334cd8" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_fab01a58-ba9f-47cc-bca2-14baaa3aaee0" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.35</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02544c71-2af1-4353-97d3-bc8b53959047" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.68%;"></td>
          <td style="width:1.163%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.812%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.173%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.172999999999998%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d321c9e-f482-4ed3-9640-5b8610926737" contextRef="C_bc9a827e-3051-4dad-ab8e-60d812a8a89d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,311,333</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5ab85e1-da55-4f0a-b053-bc850d9e830f" contextRef="C_76c90dc7-305d-40d5-b5dc-e2b7e2b5fdde" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,662,861</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a607f41a-2acb-4034-9275-efc2492f8145" contextRef="C_0f2c78a8-2fcc-49a1-9802-0c096355e6c8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,212</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dbaa253-2961-44e7-881c-e343e1226c6b" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,339,545</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0edccff9-029c-468c-a65b-b48d35d490bf" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,662,861</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_745a770b-a22c-40c6-981f-7709eecbe370" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#x2019;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU 2016-13 are effective for interim and annual fiscal periods beginning after December 15, 2022. The Company is continuing to evaluate the impact of ASU 2016-13 but does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0008b5bb-bf90-486b-8ba8-5d57cb039e24" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_9a0c4acb-6a7b-4dc3-a32e-fcee713cbeba" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.878%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.834%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.024000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.834%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1c7e9fb-2469-4da3-afcd-e7e142069dbe" contextRef="C_50d4ea11-cb80-4911-8caa-b2ac6d60f202" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_603b61e5-cf5e-4499-b818-56cc4d9936d0" contextRef="C_a6447ee5-c057-4921-8817-cccd0a901dc8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_422e5b10-b032-44e1-a860-59e6ae7aef6a" contextRef="C_fbac6298-1ee5-459c-a52f-a26dcfb2675c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a289cc4-2682-47f1-a2ad-4bdbbb3f6abb" contextRef="C_b59d6e76-1457-4f77-983e-3ed77e38bb34" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7e9f22c-28c6-41c1-9152-630000519e17" contextRef="C_b0e81f8d-8072-4ce7-bb01-1bc6a7641b89" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94ad8f81-af38-49bb-8607-fa774cfe03df" contextRef="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3caacd7-b416-4473-816f-90edbbe2384d" contextRef="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c1fadbe-80c8-41d2-8658-c76dc81014c8" contextRef="C_4efe985e-4d85-45ef-b622-70a88c48d6e6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_088eaf1d-aeb3-4fcb-971f-fc24b64ebf89" contextRef="C_e6da6f05-7316-4bfb-b017-2251df6ace0f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,966</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2ffa226-3bae-4c0c-8163-3eb5bb6e0533" contextRef="C_8445ea3c-4a1b-4d11-bc4a-34295fa25cb6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,966</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4ebbea5-b93c-447c-a0ec-0545764f856d" contextRef="C_fad3289e-7f1e-4eac-8c33-f77ea1386219" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c3f4c2a-89bf-4923-83d1-091e35398f44" contextRef="C_3c41e863-c7f2-463b-9e14-58690fc53cbf" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5341e72-7b8e-4024-ada9-e3d71f669a9b" contextRef="C_fd72f40f-15bc-4abd-9ca3-7c1f5c45455d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dabaadb1-ce87-4a1f-9dd0-eac5e358e28b" contextRef="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba05cfb-e3ac-4b1c-a135-c9f0a91c0dfd" contextRef="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec708a41-b5d3-4996-aff2-3a5a13e57135" contextRef="C_f9fe63fe-accc-4fe2-9acf-9c7f5eb6a624" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company&#x2019;s cash equivalents were invested in money market funds which were valued based on Level 1 inputs, and highly liquid corporate debt securities which were valued based on level 2 inputs. As of December 31, 2022, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 1 inputs and Corporate Bonds and U.S. Government Agency Securities which were valued based on Level 2 inputs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities have contractual maturities of less than one year. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_124d8b41-ff59-4182-a81d-1d58c7b53f07" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8cb1600e-a35e-41d7-8ca7-0009b096e7ac" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a72f5726-d2f9-4e4f-b70a-f0a58f9a071e" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_15394ce2-ec5d-403c-ba80-e82583cc33b0" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have financial assets and liabilities measured at fair value at December 31, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac07da5f-5c01-4e1f-a163-c8ad08428a37" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Short-term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_cd768355-98e4-48c3-8b63-ac9a94f9501c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.581%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.466000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.769%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.607%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.698%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c893667-cddc-48da-ac4d-e3537aa480ec" contextRef="C_cda70942-437f-46cb-bfca-673305f8f4dd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,966</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cd0eaaa-a6b5-4640-98cc-8349eb817548" contextRef="C_cda70942-437f-46cb-bfca-673305f8f4dd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,966</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fef6e11-0e38-4838-a6fa-8f2361e5ea53" contextRef="C_12eb5289-6285-4814-bd77-f25959811158" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca862eda-611c-4d8c-8593-24c7653dbcfb" contextRef="C_12eb5289-6285-4814-bd77-f25959811158" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03f5f2c3-66e8-442f-a4e7-d49c6cf91f1e" contextRef="C_12eb5289-6285-4814-bd77-f25959811158" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0b177c5-50eb-4ad6-9e92-5c0f1fdde7b4" contextRef="C_12eb5289-6285-4814-bd77-f25959811158" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdbc8da4-ac80-456b-a1a5-221a1489ae94" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_137267e2-1d84-4159-90fa-54ccf8d45b17" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_725ee1a5-6333-40c3-bea1-924b463b9bfd" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0a981cf-9180-4a98-b309-f0d0ccf036be" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2881671-f9c5-4dc1-8d86-0ffd96d2dbcc" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> debt securities that were in an unrealized loss position as of December 31, 2022. The aggregated fair value of debt securities in an unrealized loss position was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4612bbbe-da27-43ab-8458-714c3fc0fd00" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2c68c44-f512-4cb6-b848-8353b5fe38ee" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold debt securities in a continuous unrealized loss position for more than 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have the intent to sell the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment, and changes in value subsequent to the end of the period. The unrealized losses at December 31, 2022 are attributable to changes in interest rates, and we do not believe any unrealized losses represent other-than-temporary impairments.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f9c8a70-4247-46e9-bd4f-8aa28ef1c433" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:ShortTermInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> short-term investments.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c28b43f-5ebb-4f47-aaaf-9570257ad7ca" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf_2"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.792%;"></td>
        <td style="width:1.612%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.612%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.062%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f7eeab6-cca9-42d2-acf3-3e205d014f88" contextRef="C_64558a68-90ad-4900-b292-8c860e88674b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3b06aad-c8a7-44e8-ac58-d9c810bf1da9" contextRef="C_8f95fb07-e221-4065-a799-bb4bc71b7c44" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,293</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_971094ff-3cba-4d37-b8af-96ddcad3a54e" contextRef="C_7939e4b4-a73f-4851-9eb8-a2e8bee1ad5e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">675</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27f218b6-45f6-45bb-8671-5a8540c44a94" contextRef="C_e4b292d3-94d2-4fbb-87a6-ac9741243b27" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">675</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea353858-0abe-4768-b739-e84ee43bc262" contextRef="C_9dcd205a-e6a8-477e-b3ae-d74f48fdecea" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c6446f8-82c1-4bcd-801b-994fa8fe4f0e" contextRef="C_6f909c39-112d-4ab7-82d9-d31b6680680d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">301</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58c397fa-0e57-45b6-bef5-dd8365e69f50" contextRef="C_bb3a8b23-6728-4d59-a97d-1ecc7e3adfb8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">397</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f270764-6007-4d70-b574-d99e6df14d6d" contextRef="C_6e636ef1-70ab-4e6d-bbb9-b62e055ce520" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75657e37-b736-4c10-bb3b-828a7e3b5bfc" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,417</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60c54599-0ea8-4404-bb66-36f5f329fe2c" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,382</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d90e6742-91bf-4201-8e3d-87f206857d66" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eb3b7da-fe56-4fb6-95e1-87ff7b23d252" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,879</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b679eed-fe25-4dd7-bf61-88c5073443b0" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,243</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0fc6013-31bd-4f72-b52b-6e5cda4a4429" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,503</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f442798-e4a9-4506-97ed-1d027885caa0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9f77330-4a5f-46c8-b25f-396e774f1adf" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of depreciation expense for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionall</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">y, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2494ef1d-b648-4c8a-b808-4d284da7bd40" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to loss on impairment of long-lived research and development assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the CMO&#x2019;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2e53c52-5446-41b0-82ba-27a69453ace6" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a44f05a-a6a2-4866-a1c9-740ce7289659" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.941%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.735000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.092%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e5e55b6-95f4-4116-aa6e-1818a081fa3a" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e875c7fd-4489-4db4-b198-c4c577823dfb" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,429</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b383fc9-f622-4cdb-9c85-6d3e9bbca57f" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4347b46-34c2-4bce-85bc-bb63fb9cae42" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,196</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd263a19-088b-487e-974c-a109f9b4d9da" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:LeaseRelatedCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,961</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6ea7621-3b48-45b8-88bb-797811921d30" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">659</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccfd4855-73ae-4834-9078-a5f95ba32e72" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8862ad99-d856-494d-af70-1096e1a9c1f9" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9d98e14-0a74-4f94-a239-1ddf731b67ca" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="lyra:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,258</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span><span><ix:nonNumeric id="F_9f2c6838-c4af-4415-9c8e-ebdfffdb1cba" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_9f2c6838-c4af-4415-9c8e-ebdfffdb1cba_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Preferred and Common Stock </span></ix:nonNumeric></span><span style=""></span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_9f2c6838-c4af-4415-9c8e-ebdfffdb1cba_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34a46877-ffeb-4429-a352-063fb234911a" contextRef="C_a1144d35-ca6f-497e-a18a-73cf52e16156" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of undesignated preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_997712ad-b3a4-4e8e-92d4-5f51406b87f0" contextRef="C_a1144d35-ca6f-497e-a18a-73cf52e16156" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28599318-bb3d-440c-a8ff-c51682ad9599" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7fc1aa63-156c-4ae4-84f5-11bb4737baa6" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_313dafb8-de9a-4346-8e51-8bfadaaef7b5" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8133c045-fcf3-49e9-be8e-afa86a016470" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued or outstanding as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8a39eb2-442d-4520-b186-03b085b2b7db" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c48ce84-8f64-463a-a484-d06c265640f5" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:CommonStockVotingRightsNumberOfVotes" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share held.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently has an effective shelf registration statement on Form S-3 (No. 333-256020) filed with the SEC on May 11, 2021 (&#x201c;Form S-3&#x201d;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3849bef6-5e26-4de7-bced-e77b2dcca37a" contextRef="C_85081da2-be87-496a-85a8-2491428bc94f" name="lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="U_USD" scale="6" decimals="-5">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has not sold any securities under the Form S-3.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 11, 2021, the Company entered into an Open Market Sales Agreement (&#x201c;2021 ATM Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) to sell shares of its common stock, from time to time, with aggregate gross sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b16097a-e905-40bd-9068-bc846ebf87e1" contextRef="C_49be5531-186a-4558-b31a-130bbf009546" name="lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-2">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, through an at-the-market equity offering program under which Jefferies will act as the Company&#x2019;s sales agent. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f86b4c-67da-4094-b844-b7679335262f" contextRef="C_4825109d-f60c-4752-b276-40c0b1627135" name="lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> proceeds </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from the sale of shares of common stock pursuant to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATM Agreement. The offering of the Company's shares of common stock pursuant to the 2021 ATM Agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the 2021 ATM Agreement and (ii) the termination of the 2021 ATM Agreement as permitted therein. As of March 27, 2023, the Company terminated the 2021 ATM Agreement with Jefferies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">April 2022 Financing</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d09480f0-0dc8-465f-97e0-f9d557e603ce" contextRef="C_4a7c6366-9118-4794-b989-2d8394630634" name="lyra:GrossProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (&#x201c;April 2022 Financing&#x201d;). The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f55fce90-2556-4c3c-9919-0c6a9b3330a5" contextRef="C_4a7c6366-9118-4794-b989-2d8394630634" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">96.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting estimated offering costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecd0c70f-16a2-4e94-b41c-0a666e510036" contextRef="C_4a7c6366-9118-4794-b989-2d8394630634" name="lyra:EstimatedOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aafe8eb9-815e-4962-b33b-b483519adb6a" contextRef="C_df183939-be99-4d3c-9b1f-74b82cfaddf9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,815,159</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad470a76-1791-4cb1-829e-c12ec347593e" contextRef="C_8ae07729-2d6f-4f3d-99ca-a96fa38b8e31" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds to the Company of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ec391c5-e3f8-4f8d-8f81-d5a0677bafc8" contextRef="C_df183939-be99-4d3c-9b1f-74b82cfaddf9" name="lyra:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and (ii) certain investors purchased pre-funded warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d37ca1b-aec2-4e39-a07f-c57fbe8f4589" contextRef="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, with the exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46da6ec9-3af6-496d-9b72-afc0d31a804e" contextRef="C_2042739f-ff2e-4355-bf6e-f55d146a1334" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4de73b2-8ac2-4d6d-a8d8-9cd4dd420a9f" contextRef="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company.  The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he sale proportionately to the common stock and pre-funded warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55b2621f-742a-46b9-a4ae-8f726077f02f" contextRef="C_bce75e89-097d-40fe-96e7-7fef938bd51e" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8df9cdab-b9a5-45a7-8699-cd5b9bb1bf9b" contextRef="C_bce75e89-097d-40fe-96e7-7fef938bd51e" name="lyra:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants have been exercised as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b101314b-be7b-4781-baaf-8d8f56a8acf6" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.468%;"></td>
        <td style="width:1.474%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.059%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cbd9025-c756-45ac-afa1-36795fed1572" contextRef="C_f1a83be4-a034-4dba-99d0-ff646e8a3287" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1da78dc-9043-41fe-8d4d-533adf741f58" contextRef="C_42784fde-fb41-49b8-91a2-89eeebce4be2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,259,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aada101c-8085-4667-9bd1-65cfacb0bac7" contextRef="C_b11a23eb-8f92-4a47-afbb-ff79b85ab2b6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">279,696</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6c86d20-bb0d-4fb3-a584-2eb72e55a064" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,538,810</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8af8505-d788-4028-9c77-cd7f0920efa0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;). The Company previously granted equity-based awards under its 2005 Equity Inventive Plan (&#34;2005 Plan&#34;) and 2016 Equity Incentive Plan (&#34;2016 Plan&#34;).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial number of shares of the Company&#x2019;s common stock that may be issued under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93d77de7-f8cd-4637-a621-befb11f8cf99" contextRef="C_162858c9-f666-4eb7-be16-4f285ac5ff81" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares plus the number of shares of the Company&#x2019;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80593f4c-0dcf-4209-b5e8-d8a040608427" contextRef="C_501a2778-23f4-4564-91d7-2770cfe05137" name="lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#x2019;s Board of Directors. However, no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f63a72e-90a3-4f6a-a359-b02d44050601" contextRef="C_501a2778-23f4-4564-91d7-2770cfe05137" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,800,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3393918f-6df1-482b-b346-fad2c31efa4b" contextRef="C_bb418092-ad75-441f-aea1-c853723d2837" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">520,287</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cfc8a9e-020f-4d6b-9014-93d03b004643" contextRef="C_11390654-f6a8-4a62-8bd2-4e84437ccd94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,319,569</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the 2020 Plan. On January 1, 2023, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38e92862-c66b-477f-88ec-61a6df6a5bac" contextRef="C_19f3c088-c2ce-4eed-bded-16d5bf3a940e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,273,106</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2022 Employment Inducement Award Plan (&#x201c;Inducement Award Plan,&#x201d; and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#x201c;Plans&#x201d;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#x201c;Rule 5635(c)(4)&#x201d;), and allows for the granting of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deae37d6-c84e-4242-822a-6236193258e0" contextRef="C_8e0d2435-49ae-4291-85fd-1d7c3f1ac975" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,413,002</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock.  The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#x2019;s entering into employment with the Company or its subsidiary. During 2022, the Company granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b821c890-ef01-46ac-be0b-0fdc4044a7e2" contextRef="C_72a3022b-e3e8-4f67-b88c-e60be2a42056" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,813,002</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to certain executives. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf87339a-30a1-4b16-b404-17d3e0f0b6e2" contextRef="C_9bef293d-84d2-4550-baa7-b971b193887a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remaining available for issuance as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#x2019;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_89d53693-d3d9-4511-bf0b-c57a2ac83f62" contextRef="C_21d75bf0-5f97-4279-84fa-a52de2aac093" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79bef21b-44f4-41ba-82d5-592e944818d8" contextRef="C_6fb4fa36-a2d1-4278-8d67-32d8fe50d72f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fbe437f2-86eb-430a-9aa4-371350cd2f11" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.017%;"></td>
        <td style="width:1.677%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.625%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.677%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.002%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ed4b296-c0b1-4110-ac4c-808652854cbe" contextRef="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac3526be-3197-4f9c-9010-d261da3adcea" contextRef="C_ed0926d1-d179-4325-b910-278483ee97af" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3">508</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8511ef2c-e9bd-4cec-be0f-e97c1d5ba1ba" contextRef="C_32a3b395-08bb-4bd8-8e69-bf7a8289138b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49c7e813-f75e-4e76-9211-2bb5728278e1" contextRef="C_317254de-de84-4738-817e-1c29f2dbec3e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,262</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6914e544-14d7-46b1-937d-070ad0eb30b7" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e24084a2-e4e0-4452-83a2-504b4526741c" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0beb6d8b-968c-4cdc-b68b-9673063d7012" contextRef="C_b5d83e3e-bc90-46f1-8c80-aac50e8a3314" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_842746e5-bd2e-46cc-8f43-a4f32cc04884" contextRef="C_87f11c83-03d7-43d6-be6a-f07729b1a6be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,429</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock that vest based on the achievement of performance-based criteria related to scientific milestones, for which the Company has not recorded any stock-based compensation associated with the achievement of the milestone as it was not deemed probable as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdb65154-273a-4810-aab3-ed55637e7014" contextRef="C_3558ff97-70d1-4ac8-90d8-25851e56f82f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">36,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized stock-based compensation related to a stock option award related to the achievement of a commercial revenue-based milestone.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7807c3e-be34-4250-b051-58db477cd964" contextRef="C_fc16a771-bf4e-44a5-b112-8ea51be13588" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,648,002</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of  common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efe890b5-7498-48aa-8fda-6c7580e28094" contextRef="C_fc16a771-bf4e-44a5-b112-8ea51be13588" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9df89c10-6b59-4dd1-bf8c-5301fa17f6cb" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#x2019;s unrecognized stock-based compensation as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.073%;"></td>
        <td style="width:0.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.74%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.104%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.714%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Expense<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period of Recognition<br />(years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3d21c02-fd04-4831-99bf-c6a93076537b" contextRef="C_3aa72f08-9dea-4749-a7ce-7cde7d1d2163" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_726cafc8-2134-4fd3-a8cc-99e47ddccba9" contextRef="C_f340881c-2e0f-4b0b-8367-5d095a57a0be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b74cd44-67a1-42bc-a438-e865df1bb68a" contextRef="C_27b196b3-9d37-40ba-88f6-5c5770d52577" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,247</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b82cbc3a-c102-42a8-9af8-1eb1372ee3e2" contextRef="C_661e6304-38fc-4780-9c4b-9199c12da66d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69536114-b860-4376-95ca-78461195a6d6" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_ab9d51cd-49bf-46c9-adf4-4c979e943bba" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_ab9d51cd-49bf-46c9-adf4-4c979e943bba_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to executive officers, with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_ab9d51cd-49bf-46c9-adf4-4c979e943bba_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.704%;"></td>
        <td style="width:1.258%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.432%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.258%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.349%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9395252c-d935-48d4-9447-6669e995fc4c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">2.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b40ae8d2-2cd2-413b-8a85-a085e68b6fee" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14a2a470-32c2-498a-9def-d74ade372222" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_989176bc-005e-4e05-82b8-ec08357270f7" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60105ab8-d115-43fb-b774-ca89f5f3e922" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">81.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e70dcac-6c92-49bc-a287-f1600e90d0c1" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3">85.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c4bf5e7-4827-4d5b-85b6-5af85f23269e" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the stock option activity under the Plans for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.749%;"></td>
        <td style="width:0.978%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.552%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.198%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.38%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.978%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.344%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.198%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.625%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Life<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be89f7a1-b0d9-4d8c-97d2-6d71ef6781a8" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,662,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abef45d5-850d-4bec-aeb8-e4e5475f0b7d" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c1013ed-921d-46d4-b15e-a7affbd84a62" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4be1cc0e-5c1e-4821-998c-f4562d1da8f3" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7322382-18f5-470f-bde8-2d30c8cadfaa" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,828,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6491068d-1739-40ba-932b-f4d02c14c7f8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad5767a8-1fcf-48cf-bf9f-ced1ea4d2373" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,718</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e0afd73-2caa-4a51-98c1-17affbe5ef1b" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15892346-88c2-4537-b753-f635f441235c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">177,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8088575-af6f-45fc-9c44-e22b5c81bdd0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ada0a72c-78af-4aa4-80a3-4a79e3e30a42" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,311,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06b964ed-a19c-452f-b55b-600c961fe137" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2bf10bd1-0c23-47c6-85b2-dd7c14eadaec" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56788694-8fb8-477d-98f9-87f80c2a4a1c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3">378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e90531d-e6e3-4e42-97eb-94de73cfbacc" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,350,357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29320b11-050a-4f4a-909d-bf0260e3ecb9" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f93e0fd3-339c-4f29-88fb-32146343098f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b549fcad-63c5-4546-a3e2-9cbcccda566c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3">328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90b2814c-c03b-493d-9b5c-8484fda6b91b" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,311,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6e777d1-a460-4d42-85b7-dd85eae39c71" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ae518bd8-d16c-430e-a7d8-c4bf8cd2e521" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24cfb960-4f7b-44b5-a899-e941ad72c51c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3">378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35b03c91-f5da-430f-8ed1-fe4e6cfae3e8" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0de3ad60-93d0-4db5-bf34-0b1a8d6cf02b" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f14cf241-fe59-459e-b33d-8bf58e10febe" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da4a8b80-93ab-4576-8360-76869d8a8182" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94e7d70f-7000-4b1a-8046-5d1bd8c28e46" contextRef="C_a18f3701-43ff-4fd7-a44f-d3b3dc016a73" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for issuance under the 2020 ESPP.  In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6059a37f-382a-426d-967e-bafe268883a6" contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" unitRef="U_pure" scale="-2" decimals="3">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#x2019;s Board of Directors, provided that no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0326e15-c5e7-415c-882a-7ac3f82e91da" contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">987,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock may be issued under the 2020 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb75451e-f8eb-43a5-abe0-1c24ca3066f4" contextRef="C_2fba1a08-71d7-45ba-a07a-724089146c63" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">65,035</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_951c95dd-e71f-427c-ace6-82fa7869fcf0" contextRef="C_c3cb6888-3032-461e-8265-3245f2051004" name="lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> increase to the shares available for grant under the 2020 ESPP plan as of January 1, 2023. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48b58e88-ead4-47af-a8a3-f0aee582892b" contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d" name="lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5da2d7d4-f006-4525-b505-68136c143485" contextRef="C_bfa4b7bb-7c8f-4561-8f51-cc77823b6c84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the 2020 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_55489dfb-7ecf-4a1b-a886-06736ed23046" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Collaboration Agreement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and as amended on September 26, 2022, we entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the LianBio License Agreement, the Company received an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf28718b-ef44-4a34-9db8-eba67e409212" contextRef="C_ab8a831d-cce2-4c50-b8fb-f3c8eb1c821a" name="lyra:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eca4f5f-591c-493d-881a-523da05f440a" contextRef="C_de48ac60-b50a-4c29-8f31-b67fc2eace77" name="lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">135.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#x2019;s LYR-220 product candidate.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 808&#x201d;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#x201c;Combined Performance Obligation&#x201d;), and (2) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial (&#x201c;Development Activities Performance Obligation&#x201d;).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a596a35b-8920-476b-a6e0-8ea5a806fefb" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DeferredRevenueDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aaeef4b-bf2b-4ae4-8979-ad6970bc5ea9" contextRef="C_aacb10f4-b39c-44f8-9057-452a5c746b5e" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1379db8-e17d-42cd-b4aa-023939ec6ee3" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5e0368f-28bf-4bcc-b4f2-78fc92157ec4" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Development Activities Performance Obligation. In February 2022, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a5592aa-ec90-44cd-bd40-b219fef49b8c" contextRef="C_f1150276-615f-4f08-88b8-81bc087d354d" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32dfcefe-5fa5-4ec2-a2b0-36da5428d67b" contextRef="C_946ce1f5-0df2-4562-bf11-7d539009d00f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which was allocated to the two performance obligations as follows: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5658cac-b20f-402b-87c0-a2951c5eda4b" contextRef="C_f1150276-615f-4f08-88b8-81bc087d354d" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d395ff49-aaf7-4d49-91e0-b63ee35101c7" contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as all milestone amounts were fully constrained based on the probability of achievement. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022.  There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#x2019;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the Company determined that LianBio&#x2019;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#x2019;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#x2019;s consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company achieved a development milestone of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8323657c-404a-4079-9073-b148a437fab0" contextRef="C_946ce1f5-0df2-4562-bf11-7d539009d00f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for dosing the first patient in the US, and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5787fd81-0918-4553-8a30-2867578414b5" contextRef="C_ab6efa41-abc1-41e2-a447-bc1e9acb264e" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7015d04-fe8c-4db9-ba9c-32d840b60b3f" contextRef="C_c20b9c24-a16c-4bcb-912d-93a745a09007" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with the original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f95d0ffa-de66-4b30-a6e5-cd393abe8d64" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock" escape="true" continuedAt="F_f95d0ffa-de66-4b30-a6e5-cd393abe8d64_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_f95d0ffa-de66-4b30-a6e5-cd393abe8d64_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.062%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.040000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.277%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.838%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.277%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.252%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d93e3685-0702-4217-b8db-4a04bb0e18ae" contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_729cb96e-9119-4311-ad97-f3d1e179cc7b" contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_325c79a8-1ad3-4d18-8624-9c4b04d8b455" contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0" name="lyra:CombinedPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,862</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab5a9d5a-76e3-466b-b47c-f62e6cb2c7af" contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bc6c91c-2605-4b34-81ba-e23e8552669b" contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a97e229-63e6-408f-bf9e-22ab4faeff13" contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0" name="lyra:DevelopmentActivitiesPerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5b88baa-5f41-465a-b1b8-f0bb1068bf97" contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31ca3cbf-77fd-458d-b4f9-e266ba3bd371" contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2659dc58-8d9a-4166-a06a-081ef2f77364" contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0" name="lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_12ac0a6a-0c81-4160-82ac-f59f0852c3d5" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.906%;"></td>
        <td style="width:1.245%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.001000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.286%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.051%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.286%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.224%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_675e717c-f505-42fa-930b-749ae7ebeb33" contextRef="C_97589ddb-9445-4ee0-bf35-ac2868ceabab" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdc9e7a3-55e9-4e8a-9356-9c4c6d773f0b" contextRef="C_50d08448-36cd-45bf-bf96-7b413773153a" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc68529a-8542-4eb6-a238-fcf035b27a31" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e71b43a-e7f2-4b30-b150-7ad1d6489e84" contextRef="C_b069fcd9-9753-4c58-ba29-e3011d30aa97" name="lyra:DevelopmentMilestoneAchieved" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fce7f5f9-c3c8-41ed-95d9-d812d835acdb" contextRef="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1" name="lyra:DevelopmentMilestoneAchieved" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3271dea2-b2e8-45db-98c2-6623554a9a9c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:DevelopmentMilestoneAchieved" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2ada0ba-4bdc-47d1-a551-6b939ddd7ee8" contextRef="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a806abf-db51-47eb-9db3-2d36478d7d62" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8f50307-8840-4a08-b212-84e5645ae633" contextRef="C_86716da2-023d-4ddf-84dd-2aa61048c050" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e5fc6a4-8475-446c-bbe6-1652294ece2f" contextRef="C_ff6c540e-0dee-49f8-b317-487ce471c7fa" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30f50f96-a716-4c0a-845b-aca338b2672e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company achieved a milestone, which resulted in the receipt of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a5883e-f093-4381-b101-e0322ebab91c" contextRef="C_36e6caae-c368-4a2e-a60b-afef8e9340a0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8404e20c-14ae-4936-a122-44edcaa99513" contextRef="C_6a870f0e-a464-4613-8b30-3072bec4780a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestones achieved during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.  No royalty revenue has been earned as of December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#x2019;s directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBio&#x2019;s board of directors.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_517fdb70-f4e9-4ea3-9614-a7cadbed73af" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Income Taxes</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2022 and 2021, the Company recorded net losses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9def8d5-a8aa-4574-95b7-9d0b0743e877" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">55.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d65232bc-4f5b-4e8f-8a90-b5ba3f8b52cc" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">43.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3df4c7b2-497e-4aba-ba9f-0fbce1cf3a7d" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b54de03a-d7e8-4375-9513-f7977be1b755" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record an income tax benefit for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5dac073-8bee-423e-b2c3-7e76e6917ee0" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.729%;"></td>
        <td style="width:1.157%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.484%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.157%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.474%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4012a728-10b2-48ae-9dbc-f022acfd9dc2" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88ab53bf-c372-4435-9cfb-3fb7fed2d7c4" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c4eae92-c36f-45f6-8e9e-06ccfe0a8445" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a73b5f4a-26a2-4c7a-ad74-e9c1d347f44e" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1929f2b9-9e63-4d9d-a4eb-55feb4c799d5" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8a39fbe-9edb-4742-8bdf-b35b8cf04bb9" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc52ed8b-bc5a-4f8f-bfa8-1766a5ad2b1b" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a9ca961-3ad3-4c8c-8281-684f688b51fc" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f2bff90-1369-4ee1-8c9d-32754eb4a092" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">25.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8912773-4ebc-4bf3-8e2b-b0a4f792c806" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">30.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e753da02-164b-4346-8afb-b21249618379" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">54.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fd9fb87-d9c1-4285-8933-c8a3667d9d19" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ac13422-48a3-4380-a7f0-9e6df2c9417f" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.89%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.652%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.299%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe259915-acb5-425d-8e07-9b056ddefde1" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ec04390-da10-461b-be42-7542e99e1a5c" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c84ce59c-e39b-4d29-abef-1baf84225eb8" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,751</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61d2e678-2d72-4cbc-96ce-362af8d6ca75" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_837d259d-5233-47b8-97d7-89ebe6ed2b13" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d4cd829-7ef3-4a19-b6db-762470380fad" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3">848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08d2f647-6fd4-4580-8001-2c0bbf2f1d17" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ebce29e-3fbc-4f00-aaa7-7d9a443a35b6" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="lyra:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3">382</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80b777e4-9b44-4588-92cd-353eb599433d" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,076</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5e5833e-fbcd-43ec-a9f6-b6d9a2bf3131" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02997564-c67c-445a-8085-234e7f0ae4a3" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc680766-1afe-440e-8f8b-4ecaddfeece7" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1561a08-0464-4991-8d55-ecab7e42e12e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,096</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bde8846d-e74d-4565-b51c-7f94e1313cf8" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cfd3707-88b3-445f-a848-0b1712994346" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,512</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32c3c829-f5b0-411c-85d5-247d8a0d5fb7" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,697</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7178220-59ed-420d-aee6-985adf4cf42f" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3">584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ca95e21-858d-47db-91ee-88d1f4f98def" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">356</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c5da884-a42f-4f5e-a2d2-53f5002fb7ca" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcfc616a-b05d-42b0-b645-675d1cbd6ed4" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">356</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_094b7f3b-f2f2-4ffc-8832-f236afa1a818" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3">584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7b50f57-43f6-4196-9bfb-bd439b11da43" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3">356</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Internal Revenue Code, or IRC, 382 study performed during the current year the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98c6d185-b53e-4bbb-a592-4fe4d26790d8" contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b61b161c-a820-4dc8-ad85-a3b72c269c31" contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had U.S. federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e712a750-bf15-452a-940d-d3ed7009b2d4" contextRef="C_e3cac587-28df-4995-8b75-2a1e2e20870c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">23.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be able to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46b860fe-da09-4619-8f17-d3713b1f53d9" contextRef="C_5d2f621d-ce9f-493a-be01-01b725615ebe" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44370b90-698a-447c-8cb1-41fd5f9c6d7e" contextRef="C_4b81447d-9f3f-4a61-a5b3-d086c511a31c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">88.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss carryforwards that may be carried forward indefinitely.  As a result of the IRC 382 study performed during the current year, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dffd4521-c1d2-4c24-ba90-17f6f9584ee3" contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b3283bc-9152-4d10-bda6-e7245df14019" contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e04378-2eb5-460a-8eb6-b3857c8fbda2" contextRef="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">25.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be available to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52d746ff-b843-4faa-bf83-156ae49aba77" contextRef="C_23a96427-b264-4ccf-a621-6b9aa5d2b550" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4adf1e7-ef45-449a-936f-68c7780b55cc" contextRef="C_e3cac587-28df-4995-8b75-2a1e2e20870c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f052d95-250d-4e53-b2e2-8f1c9112db91" contextRef="C_ca643c6d-178f-4cdd-919d-765a5892183d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042. As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e5fa227-eeb1-463b-be96-b363704c6aa1" contextRef="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b47fcc4-1549-40ed-a210-f1aa733c5882" contextRef="C_98c9dcf4-d3b8-48d5-812c-7b771021577f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f1cff78-cbc9-4f5f-9de5-9990ebcbe541" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company has performed an IRC 382 study during the year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. Based on these ownership changes and the calculated IRC 382 annual limitations, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33275a63-992f-4771-b20f-806e3f26dcff" contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55935067-c679-482a-8db3-34320bc29689" contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. For state purposes, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7f1bf3b-694c-4ece-b57f-da2e51016ad5" contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_513f3673-af55-4260-ae4c-06936b0b5158" contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. The remainder of the attributes have an annual limitation that will impact how the attributes may be utilized in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets at December 31, 2022 and 2021 because the Company&#x2019;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caa5148a-43f4-41e3-a2dc-29858a468f8c" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de81d4c8-a3b5-4e75-bf6a-e3a0472967f5" contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, has been established at December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance decreased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f02466ad-3fa0-43dc-8344-5ad78c963d2a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2022 due to the write-off of net operating losses and research and development credits as a result of the IRC 382 study compared to the increase of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38fb7b88-fe7b-4758-b161-5493703f12a1" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, during the year ended December 31, 2021 due primarily to the generation of net operating losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2022 and 2021. The Company&#x2019;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#x2019;s statement of operations and comprehensive loss. In many cases, the Company&#x2019;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2019. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0332a0df-1d72-4d57-9c82-4c3672275c84" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown Lease</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#x201c;2017 Amendment&#x201d;) to extend the lease term through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0cdc65f8-e9bf-4ed2-806d-16269cc522fc" contextRef="C_24c6e4df-a738-4298-9c1a-6fa22126a4d0" name="lyra:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In November 2022, the Company amended the lease to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5a66391-124d-4684-9818-bb7758b6bc77" contextRef="C_ffdb9268-e81e-4854-abb7-7dc620a278a7" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend the lease term</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_068d9282-f45f-4f59-9cf3-4b0146fc1573" contextRef="C_db2e146e-6da1-4245-84c4-73c704b05e73" name="lyra:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease includes certain rent escalations. The lease modification was assessed as of December 31, 2022 and changes to the right of use asset and liability was reflected within the consolidated balance sheet.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains a letter of credit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e5ea69-757d-47c2-a0f3-993b4fc770fa" contextRef="C_42595f81-0b68-440f-b7f6-c0b65eb4d4fa" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million securing its obligations under the operating lease which is unsecured by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbfe2295-d4c8-4cbb-882b-c4c7de10486b" contextRef="C_c6a86586-b423-4033-bd3a-ef5d462ae4d3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waltham Lease</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, the Company executed a new lease for laboratory and office space. This lease will be recorded on the Company's balance sheet when the Company obtains possession of the underlying asset, which is expected to occur in the fourth quarter of 2023, following completion of construction to prepare the premises for the Company&#x2019;s intended use. Annual base rent will start at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c56d9a22-91f4-457d-bcb3-ff6a8ea680a7" contextRef="C_86cdf56f-cd6f-4aa3-8f8d-0db4f6e082d6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increasing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fa09fe1-b15c-4fa4-b523-a4e06521700e" contextRef="C_947e7a14-7124-4460-8622-c6ac515eacd4" name="lyra:PercentageOfAnnualRentIncrement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year through the original non-cancelable term of the lease, which is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0988300-8a6e-4003-bd1c-4909ebddefe0" contextRef="C_947e7a14-7124-4460-8622-c6ac515eacd4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years and two months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the lease commencement date. The Company has the option to extend the lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad58d419-7e76-4888-aca1-a7948634c222" contextRef="C_83e9be91-41f7-4203-b44e-71feb55201e8" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one additional 5-year term</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the lease was not recorded on the consolidated balance sheet as the facility is under construction. When payments are made by the Company relating to landlord-owned leasehold improvements, they will be recorded to prepaid rent as a component of other non-current assets. Upon control of the space, The Company will reclassify the prepayment to the right-of-use asset, thereby increasing its initial value, but the prepayment will not be included in the measurement of the lease liability. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5fafbc6-75d0-4536-b7f4-2dd7c6fdd603" contextRef="C_c2e5de28-b6f2-4a80-a975-f131ab84261b" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of prepaid rent was recorded in other assets with a corresponding liability recorded in accrued expenses. The lease will be recorded as a component of the Company&#x2019;s right-of-use asset and operating lease liabilities when the Company takes possession of the space.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company provided a letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cfd9860-9845-485f-9c82-c260a46d0500" contextRef="C_7887ec17-ea58-4a4a-bcdd-f4316823027d" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a security for the lease, which expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_efff79a9-1012-47dd-8314-ae160d97a632" contextRef="C_3c7ec31f-db19-4dca-ad79-3648a2ac432f" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at which point the letter will automatically renew each calendar year up to but not beyond </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5228340c-a787-435f-9be4-f6bcd4afea6f" contextRef="C_b5ad16fc-e41d-4d55-b3e3-5c4dc3774b7c" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 31, 2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The unsecured letter of credit is classified as restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the leases discussed above, the Company is party to an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e9f4b3d3-691b-4381-9a0b-ee7b93945cac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2020</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease for office equipment that expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4cef5287-028b-4d16-aa13-f50aae7b67ec;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2024</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The equipment lease is accounted for as an operating lease.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Embedded Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company entered into a clinical supply agreement with a CMO for clinical production of the Company&#x2019;s product candidates at an existing facility and a facility under construction. The Company concluded that this clinical supply agreement contains embedded operating leases as the clean rooms in the existing facility and the new facility are designated for the Company&#x2019;s exclusive use during the term of the agreement and the clinical supply agreement contains fixed commitments and variable costs related to production and material costs in excess of the fixed commitment specified in the agreement. The Company determined that it did not control the new facility during construction and, thus, the lease did not fall in the scope of &#x201c;build-to-suit&#x201d; accounting. The term of the clinical supply agreement is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e860c316-2d47-4d89-a140-649df74ded24" contextRef="C_56c02857-b6c9-47ae-b10d-01237cf26d18" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and will automatically renew for additional successive terms of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e605793b-82a6-470a-b56b-47d0799d0f7d" contextRef="C_56c02857-b6c9-47ae-b10d-01237cf26d18" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless either party gives notice of nonrenewal.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease period for the existing facility is less than 12 months and the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or right-of-use asset but instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate, as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with the clinical supply agreement. In October 2022, the Company terminated the agreement with the contract manufacturing organization.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6bb4be9a-4187-443d-b81b-db6600169f28" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost recorded in the Company&#x2019;s consolidated financial statements were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.964%;"></td>
        <td style="width:1.714%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.625%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.714%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.982%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56f22476-3d45-4cec-a237-6b86e720998d" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9141cbe6-6918-4949-a128-017ba334d2b5" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,056</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f74d2f3-3f1d-4858-bb74-e398df18c42a" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,931</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c897777e-5bab-4762-a64a-3c00f01583bf" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,542</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1007527d-ace8-4518-8dcd-4b7c4caac465" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6754eb62-7a2f-4b9f-8b4b-65b2d9c953b7" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building and variable lease costs associated with the Company&#x2019;s CMO embedded lease arrangement. During the year ended December 31, 2022, the Company recorded as research and development expense approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa53dcc6-87b5-42f4-8774-c06eaaed272e" contextRef="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of operating lease costs related to the CMO embedded lease.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55f6a69a-1d20-4f82-9aa0-47c8bf55c63c" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#x2019;s operating leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.947%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.432%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c89e364a-ee95-456a-acb2-9ea4deb94019" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4faf32cd-5e44-4fd8-ab54-0f457879917a" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3">8.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_137eafd8-4771-4421-b9a7-35e6c5c171ab" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of the Company&#x2019;s operating lease liabilities in accordance with ASC 842 as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.127%;"></td>
        <td style="width:2.019%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.854%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_870e6649-5890-4397-a459-baa418ccef29" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf51181-74a5-4e50-a37f-b7f053fcc36e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3">694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2637abe8-0ea0-4be2-8209-6ec835888fad" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Effects of discounting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b315e13-63dd-4dfb-ae54-84c6d33ff519" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cac06fbd-d264-4bf2-8f14-1ffda3d0213f" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3b5c899-737a-4f50-9ccc-fcf75841e28e" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,549</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_702f92e4-da81-4af1-b882-8d4a3d558719" contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3">667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total rent expense under the Company's leases amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6259786e-c870-4957-a394-6ed0b7136379" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_1354873c-98bc-4dc1-8c3e-5dd5cec5d9fd" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#x2014; Continued</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a98e217-558c-45ba-9455-27084dcec79e" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="final_fpage"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Retirement Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company made a discretionary match that matches 50%, up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d0f3019-6652-42aa-a079-85e33e088e16" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="lyra:DefinedContributionPlanMaximumContributionEmployeePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4a244ede-2168-4b70-abc1-35a289e5b961" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="lyra:DefinedContributionPlanMaximumContributionEmployeePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% employee contribution, and therefore a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_848e1add-2f4a-4c20-997e-ef44b5b5b293" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1c0406ff-d1aa-4589-9e3d-38db507619e5" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of employees&#x2019; salary. Matching contributions are fully vested at the time of contribution. The Company matched $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a48ade9a-2ab6-494c-9bdb-4d3ac5f7c712" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebc46beb-6b8b-427f-ab7d-2464c84ae5e2" contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of employee 401(k) contributions for the years ended December 31, 2022 and 2021, respectively, which is included in the statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a874f365-7ee1-4a06-8d7d-b7101d3d8e52" contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2023, the Company filed a complaint in the Court of Chancery of the State of Delaware against a former contract manufacturer alleging breach of contract.  The Company alleged in its complaint that its former contract manufacturer breached the Master Clinical Supply Agreement (&#x201c;MCSA&#x201d;) by misrepresenting their ability to produce LYR-210 in accordance with the specifications and with a robust quality system in place, and failed to return certain customer materials and equipment as required under the MCSA. The Company's complaint seeks monetary damages and the return of equipment and materials that the Company owns. On March 28, 2023, the contract manufacturer filed a motion to remove the case from the Chancery Court to the United States District Court for the District of Delaware.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 27, 2023, the Company notified Jefferies LLC (&#x201c;Jefferies&#x201d;) of the termination of the Open Market Sales Agreement, dated May 11, 2021, between the Company and Jefferies.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>lyra-ex4_5.htm
<DESCRIPTION>EX-4.5
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). References herein to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and the &#x201c;Company&#x201d; refer to Lyra Therapeutics, Inc. and not to any of its subsidiaries.</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following description of our  securities and certain provisions of our amended and restated certificate of incorporation (our &#x201c;certificate of incorporation&#x201d;), and amended and restated bylaws (our &#x201c;bylaws&#x201d;) are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and amended and restated bylaws, each of which has been publicly filed with the SEC and applicable provisions of the General Corporation Law of the State of Delaware (the &#x201c;DGCL&#x201d;). Our authorized capital stock consists of:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200,000,000 shares of common stock, par value $0.001 per share; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000 shares of preferred stock, par value $0.001 per share.</font></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Market under the symbol &#x201c;LYRA.&#x201d;</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our certificate of incorporation and bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our certificate of incorporation. See below under &#x201c;&#x2014;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#x2014;Amendment of Charter Provisions.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rights Upon Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, or the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common stock. We do not intend to pay cash dividends for the foreseeable future. We currently expect to retain all future earnings, if any, for use in the development, operation and expansion of our business. Any determination to pay cash dividends in the future will depend upon, among other things, our results of operations, plans for expansion, tax considerations, available net profits and reserves, limitations under law, financial condition, capital requirements and other factors that our board of directors considers to be relevant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of our certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.  There are no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, options to purchase an aggregate of 124,440 shares of our common stock were outstanding under our 2005 Equity Incentive Plan, or our 2005 Plan (all of which were vested and exercisable as of such date), options to purchase 547,868 shares of common stock were outstanding under our 2016 Equity Incentive Plan, or our 2016 Plan (of which 502,715 shares were vested and exercisable as of such date), options to purchase 1,826,023 shares of common stock were outstanding under our 2020 Incentive Award Plan, or our 2020 Plan (of which 723,202 shares were vested and exercisable as of such date), restricted stock units covering 28,212 shares of common stock were outstanding under our 2020 Plan and options to purchase 1,813,002 shares of common stock were outstanding under our 2022 Employment Inducement Plan (none of which were vested or exercisable as of such date).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into a securities purchase agreement with certain purchasers named therein, pursuant to which the Company agreed to sell securities to such purchasers in a private placement. In the private placement, the purchasers had the option to purchase either shares of our common stock or, in lieu thereof, pre-funded warrants to purchase shares of our common stock, each with an exercise price of $0.001 per share. Accordingly, the Company issued pre-funded warrants to purchase 5,000,000 shares of our common stock upon the closing of the private placement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, warrants to purchase an aggregate of 5,000,000 shares of our common stock were outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The warrants are exercisable until 5:00 p.m., New York time, on April 12, 2027. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including in the event of a stock dividend, a forward or reverse split of our shares of common stock, and certain other events. However, the warrants will not be adjusted for issuances of common stock at prices below their respective exercise prices.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued the warrants in certificated form. A holder of a warrant certificate may exercise such warrant upon surrender of the applicable warrant certificate on or prior to the applicable expiration date at our principal office, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price for the number of warrants being exercised.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&#x2019;s affiliates, and any persons acting as a group together with such holder or any of such holder&#x2019;s affiliates) would beneficially own a number of shares of our common stock in excess of 9.999% of the shares of our common stock then outstanding after giving effect to such exercise (the &#x201c;Beneficial Ownership Limitation&#x201d;); provided, however, that upon notice to us, the holder may increase or decrease the Beneficial Ownership Limitation, provided that in no event shall the Beneficial Ownership Limitation exceed 19.99% and any increase in the Beneficial Ownership Limitation will not be effective until 61 days following notice of such increase from the holder to us.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the warrants must pay the exercise price in cash upon exercise of the warrants, unless such holders are utilizing the cashless exercise provision of the warrants. The warrants may be exercised (in the sole discretion of the holder), in whole or in part, at such time by means of a &#x201c;cashless exercise&#x201d; in which the holder of such warrants shall be entitled to receive that number of warrant shares determined according to the following formula:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[(A-B)*(X)]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(A)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A = the VWAP (as defined below) on the trading day immediately preceding the date of such election;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B = the exercise price then in effect; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X = the number of shares of our common stock for which the warrant is being exercised (which shall include both the number of shares of our common stock issued to the holder thereof and the number of shares of our common stock subject to the portion of the warrant being cancelled in payment of the exercise price).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used above, the &#x201c;VWAP&#x201d; means, for any date, the price determined by the first of the following clauses that applies: (i) if our common stock is then listed on The Nasdaq Global Select Market, The Nasdaq Global Market, The Nasdaq Capital Market or the New York Stock Exchange (such market, the &#x201c;Trading Market&#x201d;), the daily volume-weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market as reported by Bloomberg Financial L.P. (based on a &#x201c;Trading Day&#x201d; from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (ii) the volume-weighted average price of our common stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (iii) if our common stock is not then listed on a Trading Market or quoted on the OTC Bulletin Board and if prices for our common stock are then reported in the &#x201c;Pink Sheets&#x201d; published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recent bid price per share of our common stock so reported; or (iv) in all other cases, the fair market value of a share of our common stock as determined by a good faith determination of our Board of Directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not intend to apply for listing of the warrants on any securities exchange or other trading system.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain holders of shares of our common stock are entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to our ninth amended and restated investors&#x2019; rights agreement, or the investor rights agreement, until the rights otherwise terminate pursuant to the terms of the investor rights agreement. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Form S-1 Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If at any time the holders of at least 30% of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities then outstanding having an anticipated aggregate offering price that would exceed $5,000,000, we may be required to register their shares. We are obligated to effect at most (i) three registrations initiated by Perceptive Life Sciences Master Fund Ltd and Perceptive LS (A), LLC, collectively referred to as Perceptive, and (ii) three registrations covering registrable securities held by investors other than Perceptive, in each case in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Piggyback Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If at any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities then outstanding will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Form S-3 Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form S-3, the holders of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities having an anticipated aggregate offering price to the public in the offering of at least $2,000,000, we will be required to effect such registration; provided, however, that we will not be required to effect such a registration if, within any twelve month period, we have already effected two registrations on Form S-3 for the holders of registrable securities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses and Indemnification</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination of Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registration rights terminate upon the earlier of the date on which no stockholder holds any registrable securities, the closing of a company sale, as defined in the investor rights agreement, at such time as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of a stockholder&#x2019;s shares without limitation during a three-month period without registration, at such time a stockholder is not an affiliate (as defined under the Securities Act) of the Company, or May 5, 2028.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some provisions of Delaware law, our certificate of incorporation and our bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Undesignated Preferred Stock.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholder Meetings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Elimination of Stockholder Action by Written Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Staggered Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Removal of Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholders Not Entitled to Cumulative Voting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware Anti-Takeover Statute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Choice of Forum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or stockholders to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; or (4) any action asserting a claim governed by the internal affairs doctrine. Under our certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could rule that either or both of the choice of forum provisions contained in our certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment of Charter Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>lyra-ex10_46.htm
<DESCRIPTION>EX-10.4.6
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.4.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="border-top:0.5pt solid;padding-top:6.0pt;border-right:0.5pt solid;text-indent:0.0%;border-left:0.5pt solid;padding-left:1.107%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;padding-right:1.107%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.<br>2022 EMPLOYMENT INDUCEMENT AWARD PLAN</font></p>
  <p style="border-right:0.5pt solid;text-indent:0.0%;border-left:0.5pt solid;padding-left:1.107%;padding-bottom:6.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;border-bottom:0.5pt solid;padding-right:1.107%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> AS AMENDED AND RESTATED EFFECTIVE DECEMBER 12, 2022</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE I.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Purpose</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Plan&#x2019;s purpose is to enhance the Company&#x2019;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities.  Capitalized terms used in the Plan are defined in Article XI.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE II.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Eligibility</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eligible Individuals are eligible to be granted Awards under the Plan, subject to the limitations described herein.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE III.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Administration and Delegation</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Administration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Plan is administered by the Administrator.  The Administrator has authority to determine which Eligible Individuals receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan.  The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable.  The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards.  The Administrator may adopt procedures from time to time that are intended to ensure that an individual is an Eligible Individual prior to the granting of any Awards to such individual (including without limitation a requirement that each such individual certify to the Company prior to the receipt of an Award that he or she is not currently employed by the Company or a Subsidiary and, if previously so employed, has had a bona fide period of interruption of employment, and that the grant of Awards is an inducement material to his or her agreement to enter into employment with the Company or a Subsidiary).  The Administrator&#x2019;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appointment of Committees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees.  The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE IV.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Stock Available for Awards</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to adjustment under Article VIII and the terms of this Article IV, Awards may be made under the Plan covering up to the Overall Share Limit.  Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share Recycling</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If all or any part of an Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in a manner that results in the Company acquiring Shares covered by the Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award, the unused Shares covered by the Award will again be available for Award grants under the Plan.  Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) will again be available for Award grants under the Plan.  The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not count against the Overall Share Limit.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE V.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Stock Options and Stock Appreciation Rights</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may grant Non-Qualified Options or Stock Appreciation Rights to Eligible Individuals subject to the conditions and limitations in the Plan.  The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right.  A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator will establish each Option&#x2019;s and Stock Appreciation Right&#x2019;s exercise price and specify the exercise price in the Award Agreement.  The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Duration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#x201c;lock-up&#x201d; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right.  Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines.  In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#x2019;s transferees to exercise any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#x2019;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#x2019;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#x2019;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such Termination of Service).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section 5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section 9.5 for any applicable taxes.  Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment Upon Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to Section 10.9, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </font></div></div>
  <div style="margin-left:5.87%;text-indent:7.932%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:7.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#x2019;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#x2019;s exercise valued at their Fair Market Value on the exercise date;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE VI.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Restricted Stock; Restricted Stock Units</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Eligible Individual, subject to the Company&#x2019;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award and subject to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions and limitations in the Plan.  In addition, subject to the conditions and limitations in the Plan, the Administrator may grant to Eligible Individuals Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement.  The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement.  In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Certificates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Settlement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#x2019;s election, in a manner intended to comply with Section 409A.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholder Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Equivalents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents.  Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE VII.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Other Stock or Cash Based Awards </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled.  Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines.  Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE VIII.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Adjustments for Changes in Common Stock <br>and Certain Other Events</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Restructuring</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#x2019;s exercise price or grant price (if applicable), granting new Awards to Participants (subject to Section 10.4), and making a cash payment to Participants.  The adjustments provided under this Section 8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#x2019;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#x2019;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article IV hereof on the maximum number and kind of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to replace such Award with other rights or property selected by the Administrator; and/or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Administrative Stand Still</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except as expressly provided in the Plan or the Administrator&#x2019;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation.  Except as expressly provided with respect to an Equity Restructuring under Section 8.1 above or the Administrator&#x2019;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#x2019;s grant or exercise price.  The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#x2019;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares.  The Administrator may treat Participants and Awards (or portions thereof) differently under this Article VIII.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE IX.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>General Provisions Applicable to Awards </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except as the Administrator may determine or provide in an Award Agreement or otherwise, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#x2019;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant.  References to a Participant, to the extent relevant in the context, will include references to a Participant&#x2019;s authorized transferee that the Administrator specifically approves.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Documentation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discretion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award.  The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination of Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#x2019;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#x2019;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#x2019;s Awards by the date of the event creating the tax liability.  The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant.  Subject to Section 10.9 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares retained from the Award creating the tax obligation, valued at their Fair Market Value, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding, provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator.  If any tax withholding obligation will be satisfied under clause (ii) of the immediately preceding sentence by the Company&#x2019;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#x2019;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#x2019;s acceptance of an Award under the Plan will constitute the Participant&#x2019;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment of Award; Repricing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type or changing the exercise or settlement date.  The Participant&#x2019;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#x2019;s rights under the Award, or (ii) the change is permitted under Article VIII or pursuant to Section 10.7.  Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditions on Delivery of Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all Award </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions have been met or removed to the Company&#x2019;s satisfaction, (ii) as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws.  The Company&#x2019;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acceleration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Action Required Upon Grant of Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Promptly following the grant of an Award, the Company shall, in accordance with NASDAQ Rule 5635(c), (a) issue a press release disclosing the material terms of the Award, including the recipient(s) of the Award and the number of Shares involved and (b) provide written notice to the NASDAQ of the grant.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE X.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Miscellaneous </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Right to Employment or Other Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company.  The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Rights as Stockholder; Certificates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares.  Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).  The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date and Term of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Unless earlier terminated by the Board, the Plan will become effective on the date it is approved by the Board and will remain in effect until the tenth anniversary of such date, but Awards previously granted may extend beyond that date in accordance with the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholder Approval Not Required</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  It is expressly intended that approval of the Company&#x2019;s stockholders not be required as a condition of the effectiveness of the Plan, and the Plan&#x2019;s provisions shall be interpreted in a manner consistent with such intent for all purposes.  Specifically, NASDAQ Rule 5635(c) generally requires stockholder approval for equity compensation plans adopted by companies whose securities are listed on the NASDAQ Stock Market that provide for the delivery of equity securities to any employees, directors or other service providers of such companies as compensation for services.  NASDAQ Rule 5635(c)(4) provides an exemption in certain circumstances for employment inducement awards.  Notwithstanding anything to the contrary herein, in accordance with NASDAQ Rule 5635(c)(4), Awards may only be granted as material inducements to Eligible Individuals being hired or rehired as Employees, as applicable, and must be approved by (a) the Board, acting through a majority of the Company&#x2019;s Independent Directors or (b) the independent Compensation Committee of the Board.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, pursuant to NASDAQ Rule 5635(c)(4), the issuance of Awards and the Shares issuable upon exercise or vesting of such Awards pursuant to the Plan is not subject to the approval of the Company&#x2019;s stockholders.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#x2019;s consent.  No Awards may be granted under the Plan during any suspension period or after Plan termination.  Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination.  The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions for Foreign Participants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company intends that all Awards be structured to comply with, or be exempt from, Section 409A, such that no adverse tax consequences, interest, or penalties under Section 409A apply.  Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#x2019;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A) exempt this Plan or any Award from Section 409A, or (B) comply with Section 409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#x2019;s grant date.  The Company makes no representations or warranties as to an Award&#x2019;s tax treatment under Section 409A or otherwise.  The Company will have no obligation under this Section 10.7 or otherwise to avoid the taxes, penalties or interest under Section 409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#x201c;nonqualified deferred compensation&#x201d; subject to taxes, penalties or interest under Section 409A.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If an Award constitutes &#x201c;nonqualified deferred compensation&#x201d; under Section 409A, any payment or settlement of such Award upon a termination of a Participant&#x2019;s Service Provider relationship will, to the extent necessary to avoid taxes under Section 409A, be made only upon the Participant&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A), whether such &#x201c;separation from service&#x201d; occurs upon or after the termination of the Participant&#x2019;s Service Provider relationship.  For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms means a &#x201c;separation from service.&#x201d;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments to Specified Employees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#x201c;nonqualified deferred compensation&#x201d; required to be made under an Award to a &#x201c;specified employee&#x201d; (as defined under Section 409A and as the Administrator determines) due to his or her &#x201c;separation from service&#x201d; will, to the extent necessary to avoid taxes under Section 409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#x201c;separation from service&#x201d; (or, if earlier, until the specified employee&#x2019;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following such six-month period or as soon as administratively practicable thereafter (without interest).  Any payments of &#x201c;nonqualified deferred compensation&#x201d; under such Award payable more than six months following the Participant&#x2019;s &#x201c;separation from service&#x201d; will be paid at the time or times the payments are otherwise scheduled to be made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Limitations on Liability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary.  The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#x2019;s administration or interpretation, against any cost or expense (including attorneys&#x2019; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#x2019;s approval) arising from any act or omission concerning this Plan unless arising from such person&#x2019;s own fraud or bad faith.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lock-Up Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data Privacy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#x2019;s participation in the Plan.  The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#x2019;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#x2019;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management.  These recipients may be located in the Participant&#x2019;s country, or elsewhere, and the Participant&#x2019;s country may have different data privacy laws and protections than the recipients&#x2019; country.  By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#x2019;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares.  The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#x2019;s participation in the Plan.  A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section 10.10 in writing, without cost, by contacting the local human resources representative.  The Company may cancel Participant&#x2019;s ability to participate in the Plan and, in the Administrator&#x2019;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section 10.10.  For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#x2019;s choice-of-law principles requiring the application of a jurisdiction&#x2019;s laws other than the State of Delaware.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Claw-back Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back policy, including any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as set forth in such claw-back policy or the Award Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.15</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Titles and Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#x2019;s text, rather than such titles or headings, will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.16</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conformity to Securities Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws.  Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws.  To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.17</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Relationship to Other Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.18</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Broker-Assisted Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section 9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c) the applicable Participant will be responsible for all broker&#x2019;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#x2019;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#x2019;s obligation.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">ARTICLE XI.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Definitions </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used in the Plan, the following words and phrases will have the following meanings:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Administrator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Board or a Committee to the extent that the Board&#x2019;s powers or authority under the Plan have been delegated to such Committee.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Applicable Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means (i) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#x201c;cause&#x201d; is defined (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Relevant Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), &#x201c;Cause&#x201d; as defined in the Relevant Agreement, and (ii) if no Relevant Agreement exists, (A) the Administrator&#x2019;s determination that the Participant failed to substantially perform the Participant&#x2019;s duties (other than a failure resulting from the Participant&#x2019;s Disability); (B) the Administrator&#x2019;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#x2019;s immediate supervisor; (C) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#x2019;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude; (D) the Participant&#x2019;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#x2019;s duties and responsibilities for the Company or any of its Subsidiaries; or (E) the Participant&#x2019;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means and includes each of the following:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any &#x201c;person&#x201d; or related &#x201c;group&#x201d; of &#x201c;persons&#x201d; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#x201c;person&#x201d; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#x2019;s securities outstanding immediately after such acquisition; or</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">during any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#x2019;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:</font></div></div>
  <div style="margin-left:12.537%;text-indent:8.537%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:7.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which results in the Company&#x2019;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#x2019;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Successor Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#x2019;s outstanding voting securities immediately after the transaction, and</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#x201c;change in control event&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit.  To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3; however, a Committee member&#x2019;s failure to qualify as a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Lyra Therapeutics, Inc., a Delaware corporation, or any successor.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Consultant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (i) renders bona fide services to the Company; (ii) renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#x2019;s securities; and (iii) is a natural person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Designated Beneficiary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#x2019;s rights if the Participant dies or becomes incapacitated.  Without a Participant&#x2019;s effective designation, &#x201c;Designated Beneficiary&#x201d; will mean the Participant&#x2019;s estate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a Board member.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.15</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a permanent and total disability under Section 22(e)(3) of the Code, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.16</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Equivalents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.17</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eligible Individual</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any individual who was not previously an Employee or Director hired as a new Employee or rehired as an Employee following a bona fide period of interruption of employment if such person is granted an Award as a material inducement to his or her entering into employment with the Company or a Subsidiary (within the meaning of the NASDAQ Rule 5635(c)(4)).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.18</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any employee of the Company or its Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.19</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Restructuring</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.20</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.21</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Market Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, as of any date, the value of Common Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (ii) if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliable; or (iii) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.22</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Incentive Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an Option intended to qualify as an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.23</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Independent Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a Director who qualifies as &#x201c;independent&#x201d; within the meaning of NASDAQ Rule 5635(c)(4), or any successor rule, as such rule may be amended from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.24</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NASDAQ Rule 5635(c)(4)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means NASDAQ Rule 5635(c)(4), or any successor rule, and all guidance and other interpretative authority thereunder, as such rule, guidance and other authority may be amended from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.25</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Qualified Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an Option not intended to qualify as an Incentive Stock Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.26</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an option to purchase Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.27</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Stock or Cash Based Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.28</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overall Share Limit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means 2,413,002 Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.29</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an Eligible Individual who has been granted an Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.30</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance Criteria</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#x2019; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#x2019;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies.  The Committee may provide for exclusion of the impact of an event or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence which the Committee determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans or debt securities, (j) unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities to Common Stock, (m) any business interruption event, (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.31</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means this 2022 Employment Inducement Award Plan, as it may be amended and/or restated from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.32</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Shares awarded to a Participant under Article VI subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.33</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Unit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.34</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rule 16b-3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.35</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.36</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.37</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Service Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an Employee, Consultant or Director.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.38</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means shares of Common Stock.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.39</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Appreciation Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a stock appreciation right granted under Article V.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.40</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsidiary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.41</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination of Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the date the Participant ceases to be a Service Provider.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* * * * *</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\129439106.3||</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>lyra-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Employment Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), dated as of February 2, 2023, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John Bishop (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (collectively referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or individually referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A.	It is the desire of the Company to assure itself of the services of Executive commencing on or about February 27, 2023 (the actual date Executive commences employment, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and thereafter by entering into this Agreement.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B.	Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows:</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Effective upon the Start Date, the Company shall employ Executive, and Executive shall be employed by the Company, for the period and in the positions set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and subject to the other terms and conditions herein provided.  </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At-Will Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and Executive acknowledge that Executive&#x2019;s employment is and shall continue to be &#x201c;at-will,&#x201d; as defined under applicable law, and that Executive&#x2019;s employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).  This &#x201c;at-will&#x201d; nature of Executive&#x2019;s employment shall remain unchanged during Executive&#x2019;s tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company.  If Executive&#x2019;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law.  The term of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall commence on the Start Date and end on the date this Agreement is terminated under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Positions and Duties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, Executive shall serve as Chief Technology Officer, with such responsibilities, duties and authority normally associated with such position and as may from time to time be assigned to Executive by the Chief Executive Officer of the Company.  Executive shall devote substantially all of Executive&#x2019;s working time and efforts to the business and affairs of the Company (which shall include service to its affiliates, if applicable) and shall not engage in outside business activities (including serving on outside boards or committees) without the consent of the Board of Directors of the Company or an authorized committee of the thereof (in either case, the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), provided that Executive shall be permitted to (i) manage Executive&#x2019;s personal, financial and legal affairs, (ii) participate in trade associations, and (iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, in each case, subject to compliance with this Agreement and provided that such activities do not materially interfere with Executive&#x2019;s performance of Executive&#x2019;s duties and responsibilities hereunder.  Executive agrees to observe and comply with the rules and policies of the Company as adopted by the Company from time to time, in each case, as amended from time to time, and as delivered or made available to Executive (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and, each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation and Related Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, Executive shall receive a base salary at a rate of $455,000 per annum, which shall be paid in accordance with the customary payroll practices of the Company and shall be pro-rated for partial years of employment.  Such annual base salary shall be reviewed (and may be adjusted) from time to time by the Board (such annual base salary, as it may be in effect from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;" id="ole_link1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Cash Bonus</font><font id="ole_link2"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Opportunity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, Executive will be eligible to participate in an annual incentive program established by the Board.  Executive&#x2019;s annual incentive compensation under such incentive program (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall be targeted at forty (40%) of Executive&#x2019;s Annual Base Salary (such target, as may be increased by the Board from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Annual Bonus payable under the incentive program shall be based on the achievement of performance goals to be determined by the Board.  Executive&#x2019;s Annual Bonus, if earned (as determined by the Board in its discretion), for the 2023 fiscal year will be pro-rated for Executive&#x2019;s partial year of employment based on the number of days that Executive is employed by the Company during the 2023 fiscal year. The payment of any Annual Bonus pursuant to the incentive program shall be subject to Executive&#x2019;s continued employment with the Company through the date of payment, except as otherwise provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.   In addition, we will provide you with a $68,000 signing bonus for repayment of a bonus to your previous employer.  This signing bonus will be paid after your first 30 days of employment and with the proper documentation showing the funds are owed to your previous employer. If you voluntarily leave employment with the Company within one year of hire, this signing bonus must be repaid to the Company on a pro-rated basis.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to the approval of the Board, Executive will be granted an option to purchase 220,000 shares of the common stock of the Company at an exercise price equal to the closing price per share of the Company&#x2019;s common stock on the date of grant or the last trading day preceding the date of grant if the date of grant is not a trading day (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Subject to Executive&#x2019;s continued service to the Company through each applicable vesting date, twenty-five percent (25%) of the shares subject to the Option will vest on the first (1st) anniversary of the Start Date, and the remaining shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter, such that the Option will be fully vested on the fourth anniversary of the Start Date.  The Option will be subject to the terms of the Company&#x2019;s 2022 Employment Inducement Award Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and a stock option agreement (on the Company&#x2019;s form of stock option agreement under the Plan) to be entered into between Executive and the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, Executive shall be eligible to participate in employee benefit plans, programs and arrangements of the Company (including medical, dental and 401(k) plans), subject to the terms and eligibility requirements thereof and as such plans, programs and arrangements may be amended from time to time.  In no event shall Executive be eligible to participate in any severance plan or program of the Company, except as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of this Agreement.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vacation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, Executive shall be entitled to paid personal leave in accordance with the Company&#x2019;s Policies.  Any vacation shall be taken at the reasonable and mutual convenience of the Company and Executive. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Term, the Company shall reimburse Executive for all reasonable travel and other business expenses incurred by Executive in the performance of Executive&#x2019;s duties to the Company in accordance with the Company&#x2019;s expense reimbursement Policy. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Key Person Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  At any time during the Term, the Company shall have the right (but not the obligation) to insure the life of Executive for the Company&#x2019;s sole benefit.  The Company shall have the right to determine the amount of insurance and the type of policy.  Executive shall reasonably cooperate with the Company in obtaining such insurance by submitting to physical examinations, by supplying all information reasonably required by any insurance carrier and by executing all necessary documents reasonably required by any insurance carrier, provided that any information provided to an insurance company or broker shall not be provided to the Company without the prior written authorization of Executive.  Executive shall incur no financial obligation by executing any required document and shall have no interest in any such policy.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both Executive&#x2019;s employment hereunder and the Term may be terminated by the Company or Executive, as applicable, without any breach of this Agreement under the following circumstances:</font></p>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Circumstances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Executive&#x2019;s employment hereunder shall terminate upon Executive&#x2019;s death.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If Executive has incurred a Disability, as defined below, the Company may terminate Executive&#x2019;s employment, provided that such termination would not violate any federal or state disability, paid family leave or other similar applicable law.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company may terminate Executive&#x2019;s employment for Cause, as defined below.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination without Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company may terminate Executive&#x2019;s employment without Cause.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Resignation from the Company with Good Reason.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive may resign Executive&#x2019;s employment with the Company with Good Reason, as defined below.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Resignation from the Company without Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Executive may resign Executive&#x2019;s employment with the Company for any reason other than Good Reason or for no reason.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any termination of Executive&#x2019;s employment by the Company or by Executive under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (other than termination pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(i))</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be communicated by a written notice to the other Party hereto (i) indicating the specific termination provision in this Agreement relied upon, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#x2019;s employment under the provision so indicated, if applicable, and (iii) specifying a Date of Termination (as defined below) which, if submitted by Executive, shall be at least thirty (30) days following the date of such notice (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of the Company&#x2019;s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination will still be considered a resignation by Executive.  A Notice of Termination submitted by the Company may provide for a Date of Termination on the date Executive receives the Notice of Termination, or any date thereafter elected by the Company.  The failure by either Party to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party&#x2019;s rights hereunder.    </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Obligations upon Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon termination of Executive&#x2019;s employment pursuant to any of the circumstances listed in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Executive (or Executive&#x2019;s estate) shall be entitled to receive the sum of:  (i) the portion of Executive&#x2019;s Annual Base Salary earned through the Date of Termination, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2(f)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; and (iii) any amount accrued and arising from Executive&#x2019;s participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Arrangements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Except as otherwise expressly required by law (e.g., the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)) or as specifically provided herein, all of Executive&#x2019;s rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive&#x2019;s employment hereunder. In the event that Executive&#x2019;s employment is terminated by the Company for any reason, Executive&#x2019;s sole and exclusive remedy shall be to receive the payments and benefits described in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as applicable.  </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deemed Resignation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Upon termination of Executive&#x2019;s employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination for Cause, or Termination Upon Death, Disability or Resignation from the Company Without Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If Executive&#x2019;s employment shall terminate as a result of Executive&#x2019;s death pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as a result of Disability pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for Cause pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or for Executive&#x2019;s resignation from </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company without Good Reason pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(iv)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, then Executive shall not be entitled to any severance payments or benefits, except as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination without Cause, or Resignation from the Company with Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If Executive&#x2019;s employment terminates without Cause pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(iv)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(v)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to Executive&#x2019;s resignation with Good Reason, then, subject to Executive signing on or before the twenty-first (21st) day following Executive&#x2019;s Separation from Service (as defined below) or in the event that such Separation from Service is &#x201c;in connection with an exit incentive or other employment termination program&#x201d; (as such phrase is defined in the Age Discrimination in Employment Act of 1967, as amended) on or before the forty-fifth (45th) day following Executive's Separation from Service, and not revoking, a release of claims substantially in the form attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;),  and Executive&#x2019;s continued compliance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Executive shall receive, in addition to payments and benefits set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the following:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an amount in cash equal to 0.75 times the Annual Base Salary, payable in the form of salary continuation in regular installments over the nine (9)-month period following the date of Executive&#x2019;s Separation from Service (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in accordance with the Company&#x2019;s normal payroll practices;  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent unpaid as of the Date of Termination, an amount of cash equal to any Annual Bonus earned by Executive for the Company&#x2019;s fiscal year prior to the fiscal year in which the Date of Termination occurs, as determined by the Board in its discretion based upon actual performance achieved, which Annual Bonus, if any, shall be paid to Executive in the fiscal year in which the Date of Termination occurs when bonuses for such prior fiscal year are paid in the ordinary course to actively employed senior executives of the Company; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if Executive timely elects to receive continued medical, dental or vision coverage under one or more of the Company&#x2019;s group medical, dental or vision plans pursuant to COBRA, then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for Executive and Executive&#x2019;s covered dependents under such plans, less the amount Executive would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the Date of Termination, during the period commencing on Executive&#x2019;s Separation from Service and ending upon the earliest of (X) the last day of the Severance Period, (Y) the date that Executive and/or Executive&#x2019;s covered dependents become no longer eligible for COBRA or (Z) the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a subsequent employer (and Executive agrees to promptly notify the Company of such eligibility).  Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act) or incurring an excise tax or that the foregoing benefit may be discriminatory under Section 105(h) of the Code, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#x2019;s and Executive&#x2019;s covered dependents&#x2019; group health coverage in effect on the Date of Termination (which amount shall be based on the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and Executive&#x2019;s covered dependents based on the cost sharing levels in effect on the Date of Termination, which payments shall be made regardless of whether Executive elects COBRA continuation coverage and shall commence in the month following the month in which </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Date of Termination occurs and shall end on the earliest of (X) the last day of the Severance Period, (Y) the date that Executive and/or Executive&#x2019;s covered dependents become no longer eligible for COBRA or (Z) the date Executive becomes eligible to receive healthcare coverage from a subsequent employer (and Executive agrees to promptly notify the Company of such eligibility).</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In lieu of the payments and benefits set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in the event Executive&#x2019;s employment terminates without Cause pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(iv)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or due to Executive&#x2019;s resignation with Good Reason pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(v)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in either case, within three (3) months prior or twelve (12) months following the date of a Change in Control, subject to Executive signing on or before the twenty-first (21st) day following Executive&#x2019;s Separation from Service or in the event that such Separation from Service is &#x201c;in connection with an exit incentive or other employment termination program&#x201d; (as such phrase is defined in the Age Discrimination in Employment Act of 1967, as amended) on or before the forty-fifth (45th) day following Executive&#x2019;s Separation from Service, and not revoking, the Release, Executive shall receive, in addition to the payments and benefits set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the following:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an amount in cash equal to 1.0 times the sum of (A) the Annual Base Salary plus (B) the Target Annual Bonus, payable in equal installments over the twelve (12)-month period following the date of Executive&#x2019;s Separation from Service (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CIC Severance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in accordance with the Company&#x2019;s normal payroll practices;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the payment set forth in Section 4(b)(ii);</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the benefits set forth in Section 4(b)(iii), provided that the &#x201c;Severance Period&#x201d; will mean the CIC Severance Period; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all unvested equity or equity-based awards held by Executive under any Company equity compensation plans that vest solely based on the passage of time shall immediately become one hundred percent (100%) vested (for the avoidance of doubt, with any such awards that vest in whole or in part based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement).</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Notwithstanding anything to the contrary in this Agreement, the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 through 9 will survive the termination of Executive&#x2019;s employment and the termination of the Term.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictive Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a condition to the effectiveness of this Agreement and Executive&#x2019;s employment by the Company, Executive will execute and deliver to the Company contemporaneously herewith the Employee Proprietary Information and Inventions Assignment Agreement attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictive Covenant Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Executive agrees to abide by the terms of the Restrictive Covenant Agreement, which are hereby incorporated by reference into this Agreement.  Executive acknowledges that the provisions of the Restrictive Covenant Agreement will survive the termination of Executive&#x2019;s employment and the termination of the Term for the periods set forth in the Restrictive Covenant Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assignment and Successors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable.  None of Executive&#x2019;s rights or obligations may be assigned or transferred by Executive, other than Executive&#x2019;s rights to payments hereunder, which may be transferred only by will or operation of law.  Notwithstanding the foregoing, Executive shall be entitled, to the extent permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation hereunder following Executive&#x2019;s death by giving written notice thereof to the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company shall have &#x201c;Cause&#x201d; to terminate Executive&#x2019;s employment hereunder upon:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board&#x2019;s reasonable, good faith determination that Executive has refused to (A) substantially perform the duties associated with Executive&#x2019;s position with the Company or (B) carry out the reasonable and lawful instructions of the Board concerning duties or actions consistent with Executive&#x2019;s position with the Company; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive&#x2019;s breach of a material provision of this Agreement that, to the extent capable of cure, has remained uncured for a period of thirty (30) days following written notice from the Company;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive&#x2019;s conviction, plea of no contest, plea of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or imposition of unadjudicated probation for any felony or crime involving moral turpitude; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive&#x2019;s unlawful use (including being under the influence) or possession of illegal drugs on the Company&#x2019;s (or any of its affiliate&#x2019;s) premises or while performing Executive&#x2019;s duties and responsibilities under this Agreement; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive&#x2019;s commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against the Company or any of its affiliates. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  &#x201c;Change in Control&#x201d; shall have the meaning set forth in the Plan. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  &#x201c;Code&#x201d; shall mean the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  &#x201c;Date of Termination&#x201d; shall mean (i) if Executive&#x2019;s employment is terminated by Executive&#x2019;s death, the date of Executive&#x2019;s death; or (ii) if Executive&#x2019;s employment is terminated pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(a)(ii) &#x2013; (vi)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> either the date indicated in the Notice of Termination or the date specified by the Company pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, whichever is earlier.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  &#x201c;Disability&#x201d; shall mean, at any time the Company or any of its affiliates sponsors a long-term disability plan for the Company&#x2019;s employees, &#x201c;disability&#x201d; as defined in such long-term disability plan for the purpose of determining a participant&#x2019;s eligibility for benefits, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if the long-term disability plan contains multiple definitions of disability, &#x201c;Disability&#x201d; shall refer to that definition of disability which, if Executive qualified for such disability benefits, would provide coverage for the longest period of time.  The determination of whether Executive has a Disability shall be made by the person or persons required to make disability determinations under the long-term disability plan.  At any time the Company does not sponsor a long-term disability plan for its employees, &#x201c;Disability&#x201d; shall mean Executive&#x2019;s inability to perform, with or without reasonable accommodation, the essential functions of Executive&#x2019;s positions hereunder for a total of three (3) months during any six (6)-month period as a result of incapacity due to mental or physical illness as determined by a physician selected by the Company or its insurers and acceptable to Executive or Executive&#x2019;s legal representative, with such agreement as to acceptability not to be unreasonably withheld or delayed.  Any refusal by Executive to submit to a medical examination for the purpose of determining Disability shall be deemed to constitute conclusive evidence of Executive&#x2019;s Disability. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For the sole purpose of determining Executive&#x2019;s right to severance payments and benefits as described above, Executive&#x2019;s resignation will be with &#x201c;Good Reason&#x201d; if Executive resigns within ninety (90) days after any of the following events, unless Executive consents in writing to the applicable event:  (i) a reduction in Executive&#x2019;s Annual Base Salary or Target Annual Bonus, other than a reduction of twenty percent (20%) or less of Executive&#x2019;s Annual Base Salary implemented as part of an across the board, proportionate reduction of base salaries for other members of the Company&#x2019;s management team, (ii) a material decrease in Executive&#x2019;s authority or areas of responsibility as are commensurate with Executive&#x2019;s title or position with the Company, (iii) the relocation of Executive&#x2019;s primary office to a location more than fifty (50) miles from Executive&#x2019;s primary office as of the date of this Agreement or (iv) the Company&#x2019;s breach of a material provision of this Agreement.  Notwithstanding the foregoing, no Good Reason will have occurred unless and until Executive has:  (a) provided the Company, within sixty (60) days of Executive&#x2019;s knowledge of the occurrence of the facts and circumstances underlying the Good Reason event, written notice stating with specificity the applicable facts and circumstances underlying such finding of Good Reason; (b) provided the Company with an opportunity to cure the same within thirty (30) days after the receipt of such notice; and (c) the Company shall have failed to so cure within such period. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parachute Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hereof, being hereinafter referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), then the Total Payments shall be reduced (in the order provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Total Payments shall be reduced in the following order:  (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All determinations regarding the application of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Independent Advisors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the &#x201c;base amount&#x201d; (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation.  The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the excess amount shall be returned promptly by Executive to the Company. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the Commonwealth of Massachusetts without reference to the principles of conflicts of law of the Commonwealth of Massachusetts or any other jurisdiction that would result in the application of the laws of a jurisdiction other than the Commonwealth of Massachusetts, and where applicable, the laws of the United States.  </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Validity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to the Company, to the Chief Executive Officer of the Company at the Company&#x2019;s headquarters,</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to Executive, to the last address that the Company has in its personnel records for Executive, or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At any other address as any Party shall have specified by notice in writing to the other Party.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.  Signatures delivered by facsimile or PDF shall be deemed effective for all purposes.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The terms of this Agreement, and the Restrictive Covenant Agreement incorporated herein by reference as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including any prior employment offer letter or employment agreement between Executive and the Company.  The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative or other legal proceeding to vary the terms of this Agreement. </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendments; Waivers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company.  By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure.  No failure to exercise and no delay in exercising any right, remedy or power hereunder will preclude any other or further exercise of any other right, remedy or power provided herein or by law or in equity.  </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall be deemed drafted equally by both the Parties. Its language shall be construed as a whole and according to its fair meaning.  Any presumption or principle that the language is to be construed against any Party shall not apply.  The headings in this Agreement are only for convenience and are not intended to affect construction or interpretation.  Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary.  Also, unless the context clearly indicates to the contrary, (i) the plural includes the singular and the singular includes the plural; (ii) &#x201c;and&#x201d; and &#x201c;or&#x201d; are each used both conjunctively and disjunctively; (iii) &#x201c;any,&#x201d; &#x201c;all,&#x201d; &#x201c;each,&#x201d; or &#x201c;every&#x201d; means &#x201c;any and all&#x201d; and &#x201c;each and every&#x201d;; (iv) &#x201c;includes&#x201d; and &#x201c;including&#x201d; are each &#x201c;without limitation&#x201d;; (v) &#x201c;herein,&#x201d; &#x201c;hereof,&#x201d; &#x201c;hereunder&#x201d; and other similar compounds of the word &#x201c;here&#x201d; refer to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (vi) all pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the entities or persons referred to may require.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any controversy, claim or dispute arising out of or relating to this Agreement, shall be settled solely and exclusively by a binding arbitration process administered by JAMS/Endispute in Boston, Massachusetts.  Such arbitration shall be conducted in accordance with the then-existing JAMS/Endispute Rules of Practice and Procedure, with the following exceptions if in conflict:  (i) one arbitrator who is a retired judge shall be chosen by JAMS/Endispute; (ii) each Party to the arbitration will pay one-half of the expenses and fees of the arbitrator, together with other expenses of the arbitration incurred or approved by the arbitrator; and (iii) arbitration may proceed in the absence of any Party if written notice (pursuant to the JAMS/Endispute rules and regulations) of the proceedings has been given to such Party.  Each Party shall bear its own attorney&#x2019;s fees and expenses; provided that the arbitrator may assess the prevailing Party&#x2019;s fees and costs against the non-prevailing Party as part of the arbitrator&#x2019;s award.  The Parties agree to abide by all decisions and awards rendered in such proceedings.  Such decisions and awards rendered by the arbitrator shall be final and conclusive.  All such controversies, claims or disputes shall be settled in this manner in lieu of any action at law or equity; provided, however, that nothing in this subsection shall be construed as precluding the bringing of an action for injunctive relief or specific performance as provided in this Agreement or the Restrictive Covenant Agreement.  This dispute resolution process and any arbitration hereunder shall be confidential and neither any Party nor the neutral arbitrator shall disclose the existence, contents or results of such process without the prior written consent of all Parties, except where necessary or compelled in a court to enforce this arbitration provision or an award from such arbitration or otherwise in a legal proceeding.  If JAMS/Endispute no longer exists or is otherwise unavailable, the Parties agree that the American Arbitration Association (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall administer the arbitration in accordance with its then-existing rules as modified by this subsection.  In such event, all references herein to JAMS/Endispute shall mean AAA.  Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by court action instead of arbitration.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement.  Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.</font></div></div>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the advice of counsel if any questions as to the amount or requirement of withholding shall arise.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.796%;text-indent:7.474%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.474215246636771%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Separation from Service.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this Agreement that is designated under this Agreement as payable upon Executive&#x2019;s termination of employment shall be payable only upon Executive&#x2019;s &#x201c;separation from service&#x201d; with the Company within the meaning of Section 409A (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and, except as provided below, any such compensation or benefits described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not be paid, or, in the case of installments, shall not commence payment, until the sixtieth (60th) day following Executive&#x2019;s Separation from Service (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Payment Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#x2019;s Separation from Service but for the preceding sentence shall be paid to Executive on the First Payment Date and the remaining payments shall be made as provided in this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Specified Employee.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the Company at the time of Executive&#x2019;s Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service with the Company or (ii) the date of Executive&#x2019;s death.  Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as otherwise provided herein.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expense Reimbursements.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that any reimbursements under this Agreement are subject to Section 409A, any such reimbursements payable to Executive shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred.  Executive will submit Executive&#x2019;s reimbursement request promptly following the date the expense is incurred, and the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, other than medical expenses referred to in Section 105(b) of the Code.  Executive&#x2019;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Installments.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Executive&#x2019;s right to receive any installment payments under this Agreement, including without limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted under Section 409A.  Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest pursuant to Section 409A.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Acknowledgement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#x2019;s own judgment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Signature Page Follows</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first written above.			</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">				</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</font></p>
  <p style="text-indent:33.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:33.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: _/s/Maria Palasis________________</font></p>
  <p style="text-indent:36.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:  Maria Palasis, Ph.D.</font></p>
  <p style="text-indent:36.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:    Chief Executive Officer</font></p>
  <p style="margin-left:6.667%;text-indent:35.714%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:35.714%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">				EXECUTIVE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:35.714%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:33.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">___/s/ John Bishop____________</font></p>
  <p style="text-indent:33.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John Bishop, Ph.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">[Signature Page to Employment Agreement]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separation Agreement and Release</font></p>
  <p style="text-indent:1.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	This Separation Agreement and Release (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made by and between John Bishop (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Lyra Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) (collectively referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or individually referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Capitalized terms used but not defined in this Release shall have the meanings set forth in the Employment Agreement (as defined below).</font></p>
  <p style="text-indent:1.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	WHEREAS, the Parties have previously entered into that certain Employment Agreement, dated as of [_____], 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and that certain Employee Proprietary Information and Inventions Assignment Agreement, dated as of [________], 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictive Covenant Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:1.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	WHEREAS, in connection with Executive&#x2019;s termination of employment with the Company or a subsidiary or affiliate of the Company effective [________, 20__], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions and demands that Executive may have against the Company and any of the Releasees (as defined below), including, but not limited to, any and all claims arising out of or in any way related to Executive&#x2019;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any rights or remedies in connection with Executive&#x2019;s ownership of vested equity securities of the Company, vested benefits or Executive&#x2019;s right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Retained Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:1.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	NOW, THEREFORE, in consideration of the severance payments and benefits described in Section 4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#x2019;s execution and non-revocation of this Release, and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severance Payments and Benefits; Salary and Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company agrees to provide Executive with the severance payments and benefits described in Section [4(b)][4(c)] of the Employment Agreement, payable at the times set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive all other payments or benefits described in Section 3(c) of the Employment Agreement, subject to and in accordance with the terms thereof. The severance payments and benefits described in Section [4(b)][4(c)] of the Employment Agreement shall be provided in lieu of any Garden Leave payment (as such term is used in the Restrictive Covenants Agreement) and Executive will not be eligible to receive any Garden Leave payment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release of Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Executive agrees that, other than with respect to the Retained Claims, the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries and affiliates and any of its or their current and former officers, directors, equityholders, managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, subsidiaries, predecessor and successor corporations and assigns (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Releasees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Executive, on Executive&#x2019;s own behalf and on behalf of any of Executive&#x2019;s affiliated companies or entities and any of their respective heirs, family members, executors, agents and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute or pursue, any claim, complaint, charge, duty, obligation or cause of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	A-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts or damages that have occurred up until and including the date Executive signs this Release, including, without limitation:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(a)	any and all claims relating to or arising from Executive&#x2019;s employment or service relationship with the Company or any of its direct or indirect subsidiaries or affiliates and the termination of that relationship;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(b)	any and all claims relating to, or arising from, Executive&#x2019;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state law and securities fraud under any state or federal law;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(c)	any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(d)	any and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the Massachusetts Fair Employment Practices Act, M.G.L. c. 151B, &#167; 1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">et seq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.; the Massachusetts Civil Rights Act, M.G.L. c. 12, &#167;&#167; IIH and 111; the Massachusetts Equal Rights Act, M.G.L. c. 93, &#167; 102 and M.G.L. c. 214, &#167; IC; the Massachusetts Labor and Industries Act, M.G.L. c. 149, &#167; 1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">et seq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.; the Massachusetts Privacy Act, M.G.L. c. 214, &#167; 1B; and the Massachusetts Maternity Leave Act, M.G.L. c. 49, &#167; 105D;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(e)	any and all claims for violation of the federal or any state constitution;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(f) 	any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(g)	any claim for any loss, cost, damage or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by Executive as a result of this Release;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(h)	any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has provided service to the Company or any of its affiliates (including without limitation the Massachusetts Payment of Wages Law); and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		(i)	any and all claims for attorneys&#x2019; fees and costs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	A-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released.  This Release does not release claims that cannot be released as a matter of law, including, but not limited to, Executive&#x2019;s right to report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, Executive&#x2019;s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company for discrimination (with the understanding that Executive&#x2019;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#x2019;s group benefit plans pursuant to the terms and conditions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, claims to any benefit entitlements vested as the date of separation of Executive&#x2019;s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#x2019;s right under applicable law and any Retained Claims.  This Release further does not release claims for breach of Section 3(c) or Section 4 of the Employment Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acknowledgment of Waiver of Claims under ADEA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Executive understands and acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADEA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and that this waiver and release is knowing and voluntary.  Executive understands and agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Release.  Executive understands and acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Executive was already entitled.  Executive further understands and acknowledges that Executive has been advised by this writing that:  (a) Executive should consult with an attorney prior to executing this Release; (b) Executive has twenty-one (21) days within which to consider this Release, and the Parties agree that such time period to review this Release shall not be extended upon any material or immaterial changes to this Release; (c) Executive has seven (7) business days following Executive&#x2019;s execution of this Release to revoke this Release pursuant to written notice to the General Counsel of the Company; (d) this Release shall not be effective until after the revocation period has expired; and (e) nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law.  In the event Executive signs this Release and returns it to the Company in less than the twenty-one (21) day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictive Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Executive acknowledges that Executive remains bound by the Restrictive Covenants Agreement, which is incorporated by reference herein as if re-executed along with this Release.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	A-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">arbitrator to be illegal, unenforceable or void, this Release shall continue in full force and effect without said provision or portion of provision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Oral Modification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Release may only be amended in a writing signed by Executive and a duly authorized officer of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law; Dispute Resolution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Release shall be subject to the provisions of Sections 9(a), 9(c) and 9(h) of the Employment Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	8.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.   Executive understands that this Release shall become effective, irrevocable, and binding upon Executive on the day following the seventh (7th) business day from the date upon which Executive signs this Release, so long as Executive has not revoked it within the time period and in the manner specified in Section 3 above.  Executive further understands that Executive will not be given any severance benefits under the Agreement unless this Release becomes effective pursuant to its terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	9.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voluntary Execution of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Executive understands and agrees that Executive executed this Release voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#x2019;s claims against the Company and any of the other Releasees.  Executive acknowledges that:  (a) Executive has read this Release; (b) Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Release; (c) Executive has been represented in the preparation, negotiation and execution of this Release by legal counsel of Executive&#x2019;s own choice or has elected not to retain legal counsel; (d) Executive understands the terms and consequences of this Release and of the releases it contains; and (e) Executive is fully aware of the legal and binding effect of this Release.	</font></p>
  <p style="text-indent:1.947%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXECUTIVE</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">					</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>John Bishop, Ph.D.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:  Maria Palasis, Ph.D.<br>Title:    Chief Executive Officer</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	A-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictive Covenant Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[attached]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	B-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|US-DOCS\134600386.3||</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>lyra-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:16.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:14.0%;"></td>
   </tr>
   <tr style="height:31.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:31.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(8,66,154,1);white-space:pre-wrap;font-weight:bold;font-size:31.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bxP</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prudential Center </font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">800 </font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boylston Street</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, MA 02199-8103</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">www.</font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bostonproperties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">com</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties, Inc.</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(NYSE:BXP)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.24</font><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2023</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:8.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:18.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VIA EMAIL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:47.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:20.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">480 Arsenal Way</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown, MA 02472</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: lpham@lyratx.com</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RE:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880 Winter Street, Waltham, MA 02451</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To Whom It May Concern:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Los Angeles</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">New </font><font style="background-color:rgba(0,0,0,0);color:rgba(59,59,59,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">York</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">San Francisco</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to that certain Lease dated May 31, 2022 (as amended to date, the &#34;Lease&#34;) between BXP Waltham Woods LLC as landlord (&#34;Landlord&#34;), and Lyra Therapeutics, Inc. as tenant (&#34;Tenant&#34;) for certain premises (&#34;Premises&#34;) located within the building located at 880 Winter Street, Waltham, MA (the &#34;Property&#34;). All capitalized terms used in this letter (the &#34;Notice&#34;) and not otherwise defined herein shall have the meanings ascribed to them in the Lease. Reference is also made to that certain letter dated as of the date hereof (the &#34;GC Work Letter&#34;), an unexecuted copy of which, excluding the exhibits of such letter, is attached hereto as Exhibit A.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Washington. DC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:5.8pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:5.8pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Per Exhibit B-1 of the Lease, Landlord is currently performing Landlord's Work. Tenant is currently contemplating making changes to the Final Plans with respect to the square footage of lab space within the Premises (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(59,59,59,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Contemplated </font><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change&#34;).</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By countersigning and returning this Notice and the GC Work Letter, Tenant hereby acknowledges that, if Landlord provides Landlord's Change Order Response to the Contemplated Change and Tenant approves such Change Proposal to Landlord, </font><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the extent the Contemplated Change requires, or Tenant desires, any governmental or regulatory validation or approvals, including FDA validation, of any or all of the Premises before Tenant utilizes such portion of the Premises for its intended purpose (the &#34;Validations&#34;), without limiting the Landlord's obligations under the Lease with regard to the conduct and completion of the Landlord's Work, the Landlord's Work shall not include any component of the process required for the Validations and failure to obtain the Validations, if required or desired, shall be considered a Tenant Delay to the extent such failure prohibits the Premises from being treated as having been substantially completed; (ii) Landlord's approval of the Contemplated Change shall not create any responsibility or liability on the part of Landlord for the Contemplate Change's completeness, sufficiency, design or compliance with Legal Requirements or the requirements for the Validations; (iii) upon the occurrence of a Service Interruption, the condition will be deemed completely corrected on the date that Landlord resolves the interruption or curtailment, suspension or stoppage of the subject Essential Service and bring such Essential Service back into compliance with the Base Building Specifications as set forth on the Exhibit C of the Lease, it being understood that in no instance (a) shall revalidation of the Validations be required for a Service Interruption to be deemed completely corrected by Landlord, or (b) shall the lack of revalidation of the Validations be a cause for the Tenant to deem any portion of the Premises as untenantable; (iv) Landlord makes no representation or warranty regarding the </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sufficiency </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the base building </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">systems with respect </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to any requirements for </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Validations and Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have no </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligation to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">modify any base building systems to assist Tenant's efforts or </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligations </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to obtain or maintain the Validations, and, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">except </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as explicitly set forth in this Notice, Landlord shall not have any ongoing </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obligations </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to assist Tenant in maintaining its Validations; and (v) in no event shall Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ever </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be liable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for any indirect or consequential damages or loss of profits or loss </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of production </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">like </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">connection </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease or the Validations.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.996%;"></td>
    <td style="width:30.0%;"></td>
    <td style="width:57.004%;"></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img110160433_0.jpg" alt="img110160433_0.jpg" style="width:83px;height:53px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</font></p><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything to the contrary herein or in the Lease, Landlord hereby agrees that (i) Landlord understands and acknowledges that Tenant's use of the Premises for the manufacture of pharmaceutical </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">drug </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(alone or in combination </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with device products) shall, subject to Legal Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deemed </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">part </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Permitted </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uses under the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">; provided however</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Landlord makes </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no representations </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or warranties </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant regarding </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or not such manufacturing activities are permitted under the </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">current </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zoning regulations and/or zoning restrictions </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">covering the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property; and (b) any and all such manufacturing activities must be </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undertaken </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terms and conditions of the Lease; (ii) Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) authorize each vendor hired by Landlord for pest control services (&#34;Pest Services&#34;) at the Property (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Control Provider&#34;) to provide Tenant with records related to such Pest Services as reasonably requested by Tenant; </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided, however, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">while Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">use commercially reasonable efforts to assist Tenant's efforts to obtain </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">records from the Pest Control Provider, Landlord shall have no liability to Tenant or any other person for the Pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Control Provider's failure to properly maintain or timely provide such </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">records </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant, and (b) to the extent Tenant is unable to obtain records from any given Pest Control Provider (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Unobtained </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Records</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), use commercially reasonable efforts to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">promptly respond </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant's </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">request for copies of any Unobtained </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Records; </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provid</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e</font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">d</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ho</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">we</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ver, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">without limiting Landlord's obligation to use commercially reasonable efforts to promptly respond to </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tenant requests, Landlord shall have no liability to Tenant or any other person for Landlord's failure to properly maintain or timely provide such records </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant; (iii) Tenant shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the right, at </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its sole cost and expense, to contract with the Pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Control Provider to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">control services (&#34;Additional Pest Services&#34;) supplementing </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pest Services provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">by the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Control </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided however, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that (a) such Additional </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pest </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services shall be subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord's prior </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval (which approval shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unreasonably </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with, held conditioned or </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delayed), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) sucb Additional Pest Services </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall only be in locations to which Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">otherwise </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">access to pursuant to the Lease (for </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">example, within the Premises or the common </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities to which Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">non-exclusive rights </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under Section 2.2 of the Lease); (iv) Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">use </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercially </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">efforts to promptly </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">respond </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant's </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">request for </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">information </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to operation, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">main</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t</font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enance, and calibration of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">base </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">building HVAC </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">system; </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">however, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">without limiting </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord's obligation </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to use commercially reasonable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">efforts </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to promptly respond to </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">request</font><font style="background-color:rgba(0,0,0,0);color:rgba(80,80,80,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have no liability to Tenant or any other person for Landlord's failure </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to properly maintain or timely provide such information </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to Tenant; and (v) consistent with Section 4.2 of the Lease, except in case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">emergency </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">repairs, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord shall give Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice of (a) any contemplated </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of any service or </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utility </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">system serving the Premises </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and/or </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) any contemplated material changes to the services or </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utility </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">systems </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">serving </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Premises </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and/or </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(105,105,105,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with regard to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">both the matters set forth in subsection </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(v)(a) or (v)(b), Landlord will use commercially </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonable efforts to avoid unnecessary inconvenience to Tenant by reason thereof.</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.996%;"></td>
    <td style="width:30.0%;"></td>
    <td style="width:57.004%;"></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img110160433_0.jpg" alt="img110160433_0.jpg" style="width:83px;height:53px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</font></p><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms and conditions of this Notice are of no force or effect unless and until Tenant countersigns and returns this letter and the GC Work Letter to Landlord.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If you have any questions or concerns, please do not hesitate to contact Phil Cregg at (781) 759-9486.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:36.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.735%;"></td>
    <td style="width:85.725%;"></td>
    <td style="width:0.54%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BXP WALTHAM WOODS LLC, </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware limited liability company</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BOSTON PROPERTIES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;LIMITED PARTNERSHIP,	</font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware	limited partnership, its manager</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;BOSTON PROPERTIES, INC., </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Randall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Randall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SVP - Construction</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:13.333%;border-spacing:0;table-layout:fixed;width:30.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.025%;"></td>
    <td style="width:4.012%;"></td>
    <td style="width:72.963%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreed to and accepted this</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6th day of March 2023</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;CFO</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:16.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:14.0%;"></td>
   </tr>
   <tr style="height:31.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:31.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(8,66,154,1);white-space:pre-wrap;font-weight:bold;font-size:31.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bxP</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prudential Center </font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">800 </font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boylston Street</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, MA 02199-8103</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">www.</font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bostonproperties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">com</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties, Inc.</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(NYSE:BXP)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(56,56,56,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[attached]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:16.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:14.0%;"></td>
   </tr>
   <tr style="height:31.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:31.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(8,66,154,1);white-space:pre-wrap;font-weight:bold;font-size:31.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bxP</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prudential Center </font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">800 </font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boylston Street</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, MA 02199-8103</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">www.</font><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">bostonproperties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(79,80,84,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">com</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston Properties, Inc.</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(63,63,68,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(NYSE:BXP)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:63.6%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.747%;text-indent:0.0%;font-size:10.0pt;margin-top:8.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:18.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VIA EMAIL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc.</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">480 Arsenal Way</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown, MA 02472</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: Ipham@lyratx.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:23.413%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RE: 880 Winter Street, Waltham, MA 02451</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.707%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To Whom It May Concern:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.747%;text-indent:0.248%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.287%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to that certain Lease dated </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 (as amended to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">date, </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease&#34; ) </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">between BXP Waltham Woods LLC as landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#34;Landlord&#34;), and Lyra Therapeutics, </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inc. </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#34;Tenant&#34;) for certain </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">premises located </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880 </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Winter Street, Waltham, MA (&#34;Premises&#34;). All capitalized terms used in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">letter </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the &#34;Notice&#34;) and </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">otherwise defined </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">herein </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meanings </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ascribed to them in the Lease. </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is also made to that certain letter dated as of the date hereof (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(87,87,87,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Validation </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter&#34;), an unexecuted </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">copy of which, excluding the exhibits </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">letter, is attached </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hereto </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.693%;text-indent:0.114%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.287%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Per Exhibit B-1 of the Lease, Landlord is currently performing Landlord's Work. Tenant is currently </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contemplating </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Final Plans with </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">respect </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the square footage of </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lab </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">space within the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Premises </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contemplated </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change&#34;).</font></p>
  <p style="margin-left:16.693%;text-indent:0.114%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.287%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.693%;text-indent:0.114%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.287%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord continues </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performing </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord's </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prior </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) Landlord providing Landlord's Change Order </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Response </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the Contemplated Change and (ii) Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approving or withdrawing such Change Proposal, such continued performance will likely result in higher Change Order Costs and an increased length in Tenant Delay for the Contemplated Change.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.8%;text-indent:0.191%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countersigning and </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">returning </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Notice and the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Validation Letter to Landlord, Tenant hereby (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorizes and directs Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stop </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performing Landlord's Work on the date that is five (5) business days </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after the </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">date </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tenant countersigns </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and returns this Notice to Landlord (such </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stoppage </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the performance of Landlord's Work is hereinafter defined as the </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;Cessation </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord's </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work&#34;) until the earliest of </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the date Tenant approves or withdraws the Change Proposal contemplated herein, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the date </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receives written notice from Tenant to Landlord authorizing and directing Landlord </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">resume Landlord's Work, and (c) May 15, </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(it being understood and agreed that Landlord shall resume Landlord's Work upon the earliest of such dates to occur); (ii) acknowledges that any delay in completion of Landlord's Work resulting from </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Cessation </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Landlord's Work shall be a Tenant Delay; (iii) acknowledges that, during </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Cessation </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Landlord's Work, the personnel of the Contractor and its </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subcontractors </font><font style="background-color:rgba(0,0,0,0);color:rgba(68,68,68,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall stay </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mobilized such that they are </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">still </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assigned to perform the Tenant Improvement Work and Tenant shall reimburse Landlord for the </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incurred by Landlord as a result of such mobilization during the Cessation of Landlord's Work pursuant to the change order attached hereto as Exhibit B (which </font><font style="background-color:rgba(0,0,0,0);color:rgba(52,52,52,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be prorated to reflect the actual duration of the Cessation of Landlord's Work), and (iv) acknowledges that it shall reimburse Landlord for the</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.996%;"></td>
    <td style="width:30.0%;"></td>
    <td style="width:57.004%;"></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img110160433_0.jpg" alt="img110160433_0.jpg" style="width:83px;height:53px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</font></p><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.04%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:13.35pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">out-of-pocket costs incurred by Landlord as a result of Landlord preparing Landlord's Change Order Response to the Contemplated Change, including the costs associated with developing the plans and specifications identifying the Contemplated Change. Unless and until Tenant countersigns and returns this letter and the Validation Letter to Landlord, the terms hereof shall not go into effect and Landlord shall continue performing Landlord's Work pursuant to the Lease.</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If you have any questions or concerns, please do not hesitate to contact Phil Cregg at (781) 759- 9486.</font></p>
  <p style="margin-left:56.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:56.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.326%;"></td>
    <td style="width:88.547%;"></td>
    <td style="width:0.127%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BXP WALTHAM WOODS LLC, </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware limited liability company</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BOSTON PROPERTIES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIMITED PARTNERSHIP, </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware	limited partnership, its manager</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;BOSTON PROPERTIES, INC., </font><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font><font style="color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jonathan Randall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jonathan Randall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SVP - Construction</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:16.667%;border-spacing:0;table-layout:fixed;width:32.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.75%;"></td>
    <td style="width:3.125%;"></td>
    <td style="width:78.125%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreed to and accepted this</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6th	day of March 2023</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LYRA THERAPEUTICS, INC.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;CFO</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>lyra-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (333-237973), Form S-8 (333-263402), Form S-3 (333-264864), and Form S-3 (333-256020) of Lyra Therapeutics, Inc. of our report dated March 29, 2023 relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ BDO USA, LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>lyra-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Maria Palasis, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.075%;"></td>
    <td style="width:4.925%;"></td>
    <td style="width:3.462%;"></td>
    <td style="width:46.538%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>8
<FILENAME>lyra-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Jason Cavalier, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.989%;"></td>
    <td style="width:4.925%;"></td>
    <td style="width:3.462%;"></td>
    <td style="width:46.624%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>lyra-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:44.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maria Palasis, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>lyra-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:44.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jason Cavalier</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img110160433_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img110160433_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" &8# 2(  A$! Q$!_\0
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img222343278_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N Q # 2(  A$! Q$!_\0
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MIRG\*N9-%6[W2[_32HOK.>W+?=\U",T7FEW^GQPR7EI+ DPS&SK@./;\Q1=
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M-Q (] /3TI-.^B+HSC&C%5)-7D]8NW;\"?XB76G?\)5I1<1R/"!]K"<_+N!
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MM[U)XJ_LS2[K0=3GLH+/4OM*27$,)!P@^\3CK@XP:?,^8B6%I.@I)6T6KO\
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MD_Z ]Q_X[_C2YEW*>'J\J7*_N,*BMW_A"_$G_0'N/_'?\:/^$+\2?] >X_\
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M?^._XT?\(7XD_P"@/<?^._XT<R[A]6K?R/[F85%;O_"%^)/^@/<?^._XT?\
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MS,*BMW_A"_$G_0'N/_'?\:/^$+\2?] >X_\ '?\ &CF7</JU;^1_<S"J^?\
MD7Q_U]_^R5>_X0OQ)_T![C_QW_&KG_"(^(/[%$/]DS^9]IW[>.FW&>M)R7<N
M&&K:^X]NS.6HK=_X0OQ)_P! >X_\=_QH_P"$+\2?] >X_P#'?\:?,NY'U:M_
M(_N9A45N_P#"%^)/^@/<?^._XT?\(7XD_P"@/<?^._XT<R[A]6K?R/[F85%;
MO_"%^)/^@/<?^._XT?\ "%^)/^@/<?\ CO\ C1S+N'U:M_(_N9A45N_\(7XD
M_P"@/<?^._XT?\(7XD_Z ]Q_X[_C1S+N'U:M_(_N9A45N_\ "%^)/^@/<?\
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MR>*&-\L[8P!@^]3*2L]3;#X>LJT&XO=='W/5:***Y#[0**** "BBB@ HHHH
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M&L?XC_8=OA_^TK<W%E_:0\V(1&4L/+?C: 2>W2BP7TN=JDL<APDB,?0'-.#
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MC)8)+(26,@+$EAZ<BNRI"0.I ^M%Q<J.4L]'UB;5=!O[V*VMWLK2>WF6*4N
M6V!"N5&?NY/I[UBW?@[6M2O81>66C1W$4ZR'6[8M'<, V?\ 5A0-Q'&2Q%>C
M447#E04444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"E116?K6N:?X>T_[?J<Y@MMX3>$+?,>G &: -"BHK
M6XBO;6&YMVWPS('C;&,J>1P:R],\5Z+J^JW&F6=V6O;?/FPO$R,,'!^\!G%
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M9@93=@ )UZ8)XZTZ;XEZ'',RHEY+"K;3<1Q93^>?TKE?#D<TOA/Q@D 8R%N
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M01@BJ.EZ-I^BQ21:?;+ DC;F ).3^-7F8(I9C@ 9)K/TO7=,UH2_V==I/Y1
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ME?U//O%,9\5^.;30$=A;VL9>9E_A)&3_ .RC\:N?#:_DBAOM NN)[&4E5/\
M=)P1^!_G6%X:\*ZCXC%WK<NIW.G33S,/W:D,PZGN.,_RI\FE7?@CQGIUXUS/
M?07.5FF*'."<'/)Z<'\*T=K<MSRX2J1J+%..C>K\GHM/(V_^$NURY\2ZEHNG
MV%O-+"Q$3,2JH >6<YY_"KGA7Q3J&I:M?:/J]K%%>VH+9AZ$ X(ZGU%9_A:)
MU^)/B)VC8*0=K%2 ?F'0TS2$N$^)VOR1Q-N-NWEEE(4M\F.:EI:HZ*=2JG&;
MDW>35O+4L7>O^,76\N[?2K6TLK;) O,AW YR.1VK-\0^(;[Q!\.UO8;>..)I
M/+O/FY7!&-OL36+:36]_%?)KUOJE]KI9A#;X;8#CC@<#!S[<5>TVVGF^$FI0
M)%(9H[C<R;3G *GI]*JR1S>VJ55**D[.+^]?+3T.@T'7+O0_ JW^K01"WBB1
M;01-\TJD<9]#50^+/%T6FKK<ND6O]F'#; Q\P(>_7^E55)\5_#<:;I\4QN]/
M6+<C+C>1GA?7BFS>,Q=>$O[$CTR[.J-"+8Q^5\HXQGU_#%*VNQI[9J,5SM+E
MT\WVVZ=C;U_QNUEX>TW5]-CCDCNY-K+*#E1CD<'KD8JEJ7C/Q!HMQ:76I:5;
MII]UGRXD?,H'H3G&>1QBL?Q'HMSI7@30[*6-GG6X+R*H+;2V3C\,UK_$J*22
MVT,)&[XFYVJ3CA:$HZ(=2MB+3DY-.*B[>;W)9?%^OZ7J]@FL:=;16=\P$:QL
M2Z D#DYQD9':M.U\2WJ^.KC0+Z.%8F0O;2*""PQD9Y],_B*R_B+'(^I>'=D;
ML%N#G:I..4IWQ$MY;";3/$=JH,UG*$?W4\C/MG(_&DDG;S-95*M)S?,VH-/Y
M-:FG9>)+S4?'%WI%O%#]@M$S+(0=V['3.<=3^AKJ:XSX<6#QZ-/JDX_TC49F
ME)/7;DX_7)KLZB5D[([L(YRI<\^NOHNGX!1114G2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"E67K_A^Q\2:<+'4/-\D2+*/*?:P8=.:U*K7NH66F6_VB_NX;6'(7S)G"
MKD]LF@&<O_PK;1\_\?\ K/\ X'O6IJ_A+3=8GM[F1KFWO;=/+CN[64QR[?0G
MN/K6U%+'/"DT,BR12*&1T.0P/0@U ^IV$>H)I[WMNMZZ[DMS(/,8>H7KV-.[
M%9&7IW@_2M-M;Z*,3S37R%+FZGE+RR*1C&X]!]*OVFD6MEH<>CPA_LB0^0H+
M9;;C'7UJ_12N%D<9XCT_3]$\*Z?I4FC3:CHD3B.8HQ:6V7M(,<D@YZ5RZ:9I
M&M>(=&B\.Q:E=^1=+<7>H7OFD11+T0&3U/85ZWG'2CMCMZ4[B<;@3DDUSVH^
M#=/O]6DU..YO[&[F4).]G.8_. Z;A_6NAHI#:N8&E^#=&T:_>\LH9%EE@,$P
M>0N)03DE\]6/K5$_#G1/]2)M073R^\Z>+IOLY.<XV^GMFNL5E=0RL&4]"#D&
MEIW861BZ[X5TWQ!;6L-R)H#:'-O):R&)XN,84CH,5)!X=L8-1N;]3,UQ<VJ6
MDK.^<HHP/Q]ZUJ*5PLBAI>CVFCZ-%I5H'%K$A1=[9;!SGG\:QM1TR#P[X'ET
M^PTEM5M(N'LW?+/&S98CU(SD"NHHIW"QXSJFG^'M7TZ/2_#5MJU[J$[HD:W?
MG&.R3(+'Y^%XXKV.*,10QQ Y"*%S]!BGYZ^_7WHH;N)*P4444B@HHHH QO$P
MW:=; =3?6X_\?%8,WQG\+P7$L+Q:EOB=D;$ QD'!_B]JZ#Q'_P >%K_U_P!O
M_P"ABOF34O\ D+7W_7S+_P"AFM(I-',Y-596[+]3WC_A=GA7_GCJ?_@./_BJ
M/^%V>%?^>.I_^ X_^*KY^HI\B*]I(^@?^%V>%?\ GCJ?_@./_BJ/^%V>%?\
MGCJ?_@./_BJ^?J*.1![21] _\+L\*_\ /'4__ <?_%4?\+L\*_\ /'4__ <?
M_%5\_44<B#VDCZ!_X79X5_YXZG_X#C_XJC_A=GA7_GCJ?_@./_BJ^?J*.1![
M21] _P#"[/"O_/'4_P#P''_Q5'_"[/"O_/'4_P#P''_Q5?/U%'(@]I(^@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M23VH L16=K )!#;0QB7F0)&!O^N.M1P:;86RNMO8VL2R##B.%5W#WP.:M44
M0R6EM-;BWEMH9(!TB>,%1^!XHMK2VLXO*M;>&"/KLB0(/R%344 5[FPL[W;]
MKM+>XV_=\V)7Q],BI&@A>$0M#&T0QB,H"HQTXZ5)10 R2*.:,QRQHZ'JKJ"#
M^%*\:21F-T5HV&"C#((],4ZB@"O:V-G9!A:6EO;AOO>3$J9^N!5BBB@ HHHH
M R/$?_'A:_\ 7_;_ /H8KYDU+_D+7W_7S+_Z&:^F_$?_ !X6O_7_ &__ *&*
M^9-2_P"0M??]?,O_ *&:UAL<DOXLO1?J5J***H HHHH **** "BBB@ HHHH
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MQ_X#+_C1_P *'M?^A@N/_ 9?\:.9![.1XK17M7_"A[7_ *&"X_\  9?\:/\
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M@RW_ .OVW_\ 0Q73US'B?_D&6_\ U^V__H8KIZ?0QC_%EZ+]0HHHI&P4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!2HINYO^>?_CPHW-_SS_\ 'A0 ZBF[F_YY_P#CPHW-_P \_P#QX4 .
MHINYO^>?_CPHW-_SS_\ 'A0 ZBF[F_YY_P#CPHW-_P \_P#QX4 .HINYO^>?
M_CPHW-_SS_\ 'A0 ZBF[F_YY_P#CPHW-_P \_P#QX4 .HINYO^>?_CPHW-_S
MS_\ 'A0 ZBF[F_YY_P#CPHW-_P \_P#QX4 .HINYO^>?_CPHW-_SS_\ 'A0
MZBF[F_YY_P#CPHW-_P \_P#QX4 .HINYO^>?_CPHW-_SS_\ 'A0!C^)_^09;
M_P#7[;_^ABNGKF/$GS:= '^0?;(#GKD[QQQ71[Y/^>)_[Z%/H8Q_BR]%^I)1
M4>^3_GB?^^A1OD_YXG_OH4C8DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_S
MQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\
MWT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-
M\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/
M$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\
M?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H
MDHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/
M?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_S
MQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\
MWT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-
M\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/
M$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\
M?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H
MDHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/
M?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_S
MQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\
MWT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*-\G_/$_\ ?0H DHJ/?)_SQ/\ WT*
M[D\Q$#UW"@"M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 8OB?\ Y!EO_P!?MO\ ^ABNGKF/$_\ R#+?_K]M_P#T,5T]/H8Q
M_BR]%^H4444C8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOH^JM83R>7%?B$&)CG&< [@N1U(Q18+HZ>BBBD,**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *5%%(S*HRS!1[G% "T444 %%%% !1110 4444 %%%% !112;E+%=PW#
MJ,\T +1110 4444 %%%% !1110!B^)_^09;_ /7[;_\ H8KIZYCQ/_R#+?\
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MC_W6_P#0Q7H5>>^%3_Q<WQ'_ +K?^AK7?7$\=K;2W$K!8XD+L3V &343W.O
M.U)M]W^9Y]XY,OB'Q-IWAFV?;@&65NH4D'&?H!G\:N?#74G?3;K1KCBXL)2
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MIZEI5AK%K]EU&TBNH-P?RY!D9'0U<K-US7M/\.:?]NU.5HK?>(]RH6.3TX%
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M?TJ7&Q49IZ'>4445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#7_;_^ABOF34O^0M??]?,O_H9KZ;\1_P#'A:_]?]O_ .ABOF34O^0M??\
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M *%Z]_)?\:/^%?\ B[_H7KW\E_QHN@LSG**Z/_A7_B[_ *%Z]_)?\:/^%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"E1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8OB?_D&6_\ U^V__H8KIZYCQ/\ \@RW_P"O
MVW_]#%=/3Z&,?XLO1?J%%%%(V"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *5%8Y7Q/DX_LC&>,^92;?%'
M_4'_ /(G^%5RLY?K<.S-FBL;;XH_Z@__ )$_PHV^*/\ J#_^1/\ "CE8?6X=
MF;-%8VWQ1_U!_P#R)_A1M\4?]0?_ ,B?X4<K#ZW#LS9HK&V^*/\ J#_^1/\
M"C;XH_Z@_P#Y$_PHY6'UN'9FS16-M\4?]0?_ ,B?X4;?%'_4'_\ (G^%'*P^
MMP[,V:*QMOBC_J#_ /D3_"C;XH_Z@_\ Y$_PHY6'UN'9FS16-M\4?]0?_P B
M?X4;?%'_ %!__(G^%'*P^MP[,V:*QMOBC_J#_P#D3_"C;XH_Z@__ )$_PHY6
M'UN'9FS16-M\4?\ 4'_\B?X4;?%'_4'_ /(G^%'*P^MP[,V:*QMOBC_J#_\
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IH:*Y[S?%7IH_YRU+:R>(S=1BZ&E^06&_RS)NQ[9XS1RL:Q4&[69__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img222343278_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" += \<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *;DTZB@!C?>K\[?V^O&!U/QOING0N"B
M0LK#KSN%?H5>7"6MO)*QP%&2:_)KX^:Y)XK^,5\B_/Y5V47G/&17EXZ=H*/<
M]#"1O*Y[%\ -).G^!X)'XD9VKU#>R]ZP_"&FKI/A^T@']P-^@K<KSH+EC9G?
M)ML-QQG-+N/K2451(NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^
MM)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M&X^M)10 NX^M%"]
M:* /KVBBBOHSP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFGK0!Q?Q@UC^P
MOAUKMZ&VF&W+ _B*_+#PBI\6_%:25P7\Z1I/R(K]"_VP/$@T7X5:E;[MINX6
M05\'_LXZ4UUXL%ZW/EAES7AXV7--0/9P2Y8.3/J2VC\N"-.RJ!^0J?[J\4+2
MU@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% "KUHH7K10!]>T445]&>$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*3)I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.ZJ&N?'GP[H.OQZ1<R,MXS!0N#U-7_"?A33]6\"^'3) H=;:%MX'.0!7RO\
M'.1+']HC2&";D6Y'RXZX4U4(1G*PG*45<^IKSXQ:19R0B02@2$*&VG'/ KNX
M91-#'(OW74,/Q&17CW@6XL/B?I]U#):+$+.=5!V@'(YKV&WC$4*1#[J@ ?@,
M5G)):&D6WJ34445F4%%%% !1110 J]:*%ZT4 ?7M%%%?1GA!1110 44E .:
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MC!QQ]*]"K_"1\I@';&U#';32O:FMI9ZXKK?[-]J:VF\]*\_0^N4CD9-,XZ5
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M*G ;CCWKKG2E-IPZGSG#^(<.;#U.C,3[W%.2W8]>.];^E^$=0U:15MK21RW
M(!KU;PG^S/X@U[RWFC\N,GG<,5VT<O;^,^QE52V/%+>R:1L("WT%=+H7@?5-
M:F"6UI(YZ?=KZ_\ !'[*>EZ:L<E^"\G=:]ET/X?Z/H$(6WL8@5'WBG->S3HT
MJ*V,'4E)Z'Q;X6_9F\0:M*GVFW:&)OXB*]N\*_LJZ7I\:/>2"5LY*D5]"!8[
M=<*H4#T%4KB\$>>:W]H]HHP:=]6>>V?P5\-Z;-)*+6/:5VJ/0^M27?@O2H8"
MD:*KCA7 ^Z*Z.^U'<2 :S))=V23Q6L92:NS*2BCDK[PS+;J)K63-ST+8Y(K.
M:.72;:7[:A=YSGFNYZ'-03017"KYR!\>HK93Z,QL<8NJ>=I B8^6BR;AFMK1
M[\S/9/;+G:<R/ZT:QX9M[Z4&/,:8P57I5319'TR>>U( BC&%/K5.S6@MF=7=
M:D7)W''XUG27BMT-4;J[5CPU9,^I>6>#2C =W<U)KT+G%9&H:C',ACD4/&>"
MI[UG76I\'#5C7%\7Z-6WLE+1["<F<%\6OAC9:Q:R7VE1K'.HR8U'6OFN[LY+
M6X>)P0ZG::^R=YD5@>01TKYG^*UC%I_B218A@-\YQ7R^9X:%-*43T\-4;T>I
MQ+4L2[GP?_UT*"R]*OZ+ILFH:A%"G)+9KYE:NQT5IJG3<WLCUWX0:*;73Y+U
MDP91M%?I+^Q1X,?3=!O=2GCP9W5XV(ZC%?#'@_16BM[6PBC+-GHH[U]O?#CX
MR/X+\)V&FIIDXDAC"N=G4UZ#NH6/SS U%B,=*O+9'UENHW"OG7_AI*X_Z!\_
M_?!I/^&DI_\ H&W'_?LUQ\I]S];@?1.?I0K5\[_\-(3?] ZX_P"^#3O^&DIL
M?\@ZX_[X-'+YA]<@?0Y8=ZPO&'BBS\(Z)<ZA>2+''$I;YCU]J\/N/VFWLX7D
MFL9DC49+,AKYH_:'_:6N?B59KIFG3&"V#D, <$_6L*EX+0UABH-ZW."_: ^,
M6H?%GQE/#!*[6,4A2)5.01FO2/@A\-5\.Z>M[>1#[3(/XAV(S7C7P]T$:9J<
M6H7D#3*#D<9!KWG3_B0ZJBK92>6N,87MGI7@NA.4W-GK+,*44HQN>O:'H[7D
MBNP_=BNLEF@TNU:1F$<,:\YXKQO_ (7<NGP _8I$B3J=E><?$K]H"7Q%8M96
M,GE*>&['WK*5&<F>KAL73DTK$OQR^,DNN7DNE:5-BU4X=T/WAZ5XU;P&1\MR
M>I/K5="DCL[,6+'DDU=BND7'%9_5I=3[/#YKA:$;),T[6V"]JU+6V'<5C0ZD
MBCN?PJY#KBK_  M[4OJTNAT_V[1V.@M;?YNE:4-O@_=KFX?$ 7G8WY5:A\4;
M>?*;\J7U:9#SVCV.KM[<#H*TK>TW**Y"'Q=C_EBWY5=3QQM_Y8M^5'U69G_;
M=%]SM+>W^[Q5Y54'(KS]_B$4Z0N/PJ/_ (66%ZQM^51]5D92SRBGU/1.,=:R
MM>A$EBU<?_PLI?\ GFWY57N_B()[<KL;\J:PDV*.?48N]CD=<W:3K"7D7#1G
M->R>&=8CUC28I4?>V &^N*\-US5TU!B&^7-;?@/Q<VAQFTR9"[;@OI3^IS-Y
M9]AY+0]N;@<FA1WS7"-XZDW8\A_RH_X3UQP8F_[YH^J2V.?^W,.>CKJ<>GVL
MDTC[0@SS7G6LZ]?>,-0>*%VBLT.,^HK"USQQ+JC)9193)R^?2NS\%Z0LT*(J
MX"]_[U=T*:P\;R6I\SB,0\VK<M-^ZMQ-+\)JB@1QY)ZDULCPSY:\I^E=S9:4
MD,:C:,XHNK4[>!7'.I*1]%A<+1HI)1/.IO#R!ONC\JQ]4\*1W )*9QTKT2>V
M^?D55DM R\BL54G%IH]&IA:%:+4EN>.LUYX5O REFM2>?:N\T+6X]2A5@W![
M9JQK?A^.]A=&C'/->>Z/)+X?UJ2RD)\L?,I/UZ5UR2KPOU1\Y3E4RK$*%[P>
MQZPK!NE+5+3[CSHE;-6AS7DZIGW4'S1NA]%%%,H*:RAEY&:=10!F7>FQS _+
M7/ZAH6<_NZ[+;VJ-HED'S"E8M2:/,KS0@5(,>?PK$O/#:]?+Q7K=QIJ2+P*S
M+C0]_P##1J;1J=V>13^&VC/R@C\:IMH=PARK,*]9GT/_ &:H2Z&%/W/THN:*
M4>IYH=+NQ_RU;\Z;_9-RW61OS->BMH>3]VE&@'THNR^:)YZNAR,W))'UJ:/P
M^.FW/UKOAH84]*?'HO\ LT7#F2V.%301Q\E6X]$V]%_2NWCT8_W*L+HI'\-&
MHO:'%Q:/\W*_I5Q-'P.$KK$T8]A5J/1SW%*VIBZRON<G'I?^S5J/2_\ 9KJ8
M]'QSBK$>E@=A02ZZ.9CTWVJY'II 7BNA73E6IEM5XP!09^U6YC0Z>?2M"VL0
MO45?$:AN!3U&VCED2ZB?49%$(Z9J'_'K+_NG^56,XJIJ# 6<IS_"?Y5K2^-'
M#BI+V4M>AQ'A_P#X_)Z[BU7=",BN%\/M_IDV/6N^LF_=9KHQ'QV/,R9_N65[
M[3TO+>6(KPXQ7G7@\'3O$5]IK\"20E1["O4NIKRWQ8QT#QI9W2C 96+'ZFN0
M^FAK='=-I_<"H'T_':M+3;Y+ZU213G(JTT.[K2C<QDVE8\P\:V?EM!Q_&HK8
MTFQW1CCM2?$",+);X'_+1?Z5O:/"K*.*]"L_W43Y? M_7JA4;3SZ5&UCM[5T
MQMP1TIC6J'/RUY^I]7=G+-9X[56FM-O\-=5)9YZ"J<UF/2B[*4K:G*RVGR]*
MJ36?M737%KCH*I36N.<5:\RU)[G-7%J.F*SYK/T%=3-9]R*HR6IR>*9:EW.6
MFL\$G%4I+4KSBNHDM>N1FJ$UMP1B@T1S$ML4VE<A@>O2NC\)?$K6?!US$T$[
MM"A^://455GM-JXQ6;/:]>*6JU1E4IQJJS1]B_#7XR:;XUMXX9'6*[VC*,>M
M=CK&CQWT)DC7]YU)%? VFZI=^'[Y+JSD:.1&!^4]?:OK+X+_ !AA\76:V5ZX
M6]08.>,UK";/DL?EW(G)(UYH7@DV.N,&C=75:]I N(_.C'S#G'K7*,I4D$8(
M]:[83YD?'U*;INPJTM(M+6AD%%%% !1110 J]:*%ZT4 ?7M%%%?1GA"4UURN
M*=33F@+7T/A_]L?X6MI]^/$%G%BV("R8'5B>:^6O#?PVTCQ9XF0WRJ,L.O<U
M^K'Q%\&VOC;PS<:==1APRDKQ_%CBOS7\>>$[[X8^,IK=U:,POE&]>>U>QA*J
MO9GYSF-"67XI8BGL]SV+PO\ "/0_#\<?V6SC! !SMS^-=O!I<=O&JK&%QZ"N
M=^%OC"V\3:0BLX^TQ@*P)Y/%=K,P4G'05Z_M&]F?682K'$4E.+W*GV<(N<U4
MNIA%R:==WFWH:PM0U$MD5I&[W.EOEV)[N\+5@75VS,1S74?#N.'7/%5I97"A
MHI'VG-9'Q&MXM+\13V\*A(T8CCV-:PDE+EZF,KM<QS<C,S9P=OK4;$]5!(]*
M]&^%^GZ=XFMKVPN$1;K9^Z8]2U<_>Z2?#=W?K=1#,,A55;O]*T51<W*2T[7.
M;9CM! XJ"63RU^9:]7T30;6Z^&ZZPMLLERTKJ%QG@=*R/''A2SM_!-CJ@_<7
M<L>]HNE$:R<N43@^AYG<7G85D7]P=K,%^K8J03*D\;3AA$K98^U>H?8/#WB3
MX:ZM?0 13V,&]3C!8UU2GR6OU,DK[GB,U[)VS^%95Y>,VX#)/>O6_A=X1TOQ
M)X;U*\E^>>$-M4^RYK*^&O@.'5-%\2:O=IO%G$SQ*>A(;%4ZT8_(:BV>2/<N
MSX/RTJ9;KWKT[XM?#V'P[H?AW5[9=HU"U\Z11T!KPOQAXVM?#%J3O#3'[JYH
M^M04.9C5.3=C3\0^);;P]9O+*XWXX7-?,?BK7&UW5I;AN06(7Z9XJUXH\7W?
MB2\+R2$1D\+FN>Q^\X&:^0Q^,==VCL>K1I*FB6/.WI7JOPL\*EY/[0F0Y7@
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MLXZYXOGA<VK6]FQ'S[<<41I1CK(^9Q&<5L5+V>&B>1^"_A]+)(EII=JTTAP
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M.6KN.VCTI:**9F%%%% !1110 4444 %%%% #&4,.:HW%N?2M&HI!NH*1SMQ
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M7H5QIGH*S+C2SC[M(WC4TU/.[C22R\K65<:0RME,J?:O29M,^7&*S;C10V[
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M/845-RK'WS1117TQX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)/KZBBBOI#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3+5NX\7(.(TYK-F\574GW#MK14V>!4S&<NITD.BZ;9<0VL,?T JQYL$&,,H
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MA';+#@*N![4*_4+HJ:7I*6"9_B/4UH[0HI:*H!%I:** "BBB@ HHHH ****
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MY04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9(]<4M(II:[#YX**** "BBB@!5ZT4+UHH ^O:***^C/""BBB@ HHHH ****
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M0]*56^SAG')+5U%OH>FV(VB"(#M\HJN5GFSS2$79(^3K3PGXBU)@J02(6_O
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MM)0 M)D5'),J=365=>)+2UW9E7<.U &QDTJMN%<D_CJU4\<TZ/QU:2-@D**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M R:GD\.6$BX,"_E0!Y1:>*;VP8!9"?7-=EH7CR.Z98[CY6/>K&K> K:Y5C$
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MT8KSGX=V'G7KRLO"X(.*]0H **** $H!I:;MH Y_QK&)-%D!]17F7AW]WK4
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MP<&.91A3STKSJN'E0=UL=U*LJRL]SZK1@^"#D&G^6,8KC/AAXNB\5>'+>7S
M]PB 2?6NUI1>@/X@HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%  >:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ P*
MO:+?&TOE'16/-4:;RK CL<U$DVBX2<7<UOBEX5C\6>$YT" R(-X;V S7RKX=
MNFM;QXG)5D<K@\=Z^S-+F74=+,74,FQORKY3^*7A_P#X13Q]<K&NV!R-N.F3
MUKADK'W.4U^9<C.TTV?SH%.<\5=S7/\ AFZ\ZW"CKBMVL#WVK:#Z***" HHH
MH **** ,7Q)'OLW^E>?> 7\GQ7>)_><5Z/K@W6AS7F?A-C'X\D7^]+BB)O'X
M3UUE^0BL/4UZUOMTK%U->IH[&"O<X_4E.#7)ZH-K&NQU3JU<EJ@Y-58[('6?
ML[R>7\1K5?[Q/'X5]4>,%_T-3_M5\F? *;R_B?I_ID_RKZT\6?-8*3S\U;T?
MB/CLZ^(Y&BBBN\^,"BBB@!5ZT4+UHH ^H_$FGR:A8&*-BK8QQ7D6I:5-IMPZ
MS*1SUKW7:/K63K&@6^K0%94Y['%?1GA'BRMZ4Y36UKWA:?1Y#M4R1'H:Q/YT
M .%%%% !1110 444&@ [T44BJ\G !/X4 >I^ X8DT>-E(,G?%=7D#BO&/#?B
M*71)@,DQ$\KGM7IVD^(;74XD*R -_=[T ;-+4?F+V-*9 * 'U#/*(HRS' 7J
M:ANM0AM(\RR*@]6KS[Q9XU-QYEM:G"="PH S/&>O'4KXHK?(IV\?6MGX=Z.?
M,>YD7"D?+7*:/H\NL7RJ <$Y)KV'2M/33;-(57 44 7P:=3<&G4 %%%% !11
M10 4444 ,8<4^BB@ I *6B@"/:#7@?[6WPN@\<?#VYN1$#<62M.&"Y)..E>^
MUC^*K%-4\/7]JXRDD3*?QK"I%3BT:TY.,DS\N/V>==ET?Q-)I$WRF5^5)Z8%
M?4:MNKY+U"/_ (1?X]:C%%\JPW11>WI7U98R>9:P/_>53^E?.QT=CW)K9EFB
MBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH WO"MUMD,)/'6O-_
MVE/#IGL;#4(AATE)D(],5VFCS?9[^-L\=*N_%;2_[2\%ZD2-QCA+#ZXKCJ))
MGOY;6Y)QU/GOP3=;E4YX(KM>&P17FO@F8QRA#]X'!%>D1L, 5R,^]Z7):***
M1F%%%% !28I:* *&KKNMC7E>CM]G^(D8_O2UZSJ1W6[<5Y!GR?'UJW3,AHB;
MPU5CVC=N7-9&I#*UJ1MNC4^HK+U+[N*.IDMSD]44Y:N2U7[QKL=2[UQ^K]ZK
M4ZHZFU\!QN^*6FX'=J^O?%:YT]./XJ^1O@)_R5+3O^!5]=^*/^0>O^]6U'<^
M.SKXSBZ*&SFBO0/B^H4444#%7K10O6B@#ZY9PBMGH*J1:A%)(RAN0<8JOKD[
M6]K\IZYKE8[AUD+@\YKZ,\([:XM8KV$JZAE(KS[Q-X):$O/:+\G=:[;2;M[F
MWRW6IY6W0N<=NE 'AYC9'VMD'IBEJ[K$ADU*9L ?-T ]ZI4 %%%% !112-0
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MHHHK0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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E]ZM:6Z/C<Y^,XQNOXT4/]X45Z'4^,ZA1113&*O6BA>M% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img222343278_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'X Z(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** /R
MI_X*9RLOQNC /'V*+^5?'?G/ZU]@_P#!3;_DN$?_ %Y1?R%?'5>A#X4?G6/_
M -YEZDGG/ZT><_K4=%6>>:&CS-_:]CS_ ,MT_G7[G? DY^&>D?\ 7)?_ $$5
M^%NC_P#(6LO^NZ?SK]T/@3_R3/2/^N*_^@BN:KL?3Y+\<CT "G445RGUP444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE !7F'[19Q\*]5/^P?
MY5Z?7F'[1G_)*]6_W#_*JC\2,*_\.7H?AYJ$S?VC=\_\MG_]"-5_M#"I=0_Y
M"-W_ -=G_P#0C5>O0/S.6Y)YS^M'G/ZU'13$?:?_  3/D+?%J;)_Y=7K]2Z_
M+'_@F7_R5F;_ *]GK]3JX:GQ'W>4_P"[+U"BBBLCV0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK\L_^"90_P"+LS?]>LE?J;7#4^(^\RG_ '9>H4445D>R%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 44AH'K0 M%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0US'Q"UN;P]X=FO81EX@6_+
MFNGKAOC'_P B+?\ ;]VW\J ,CX-?&:Q^).F!7E6+48_]9&>,\]J]0K\O?"?B
M_4/!FM)?V,S1RQONX/7FOO#X+_&:P^(^DQ1O*L>I( &B9N6P.30!ZEFEHHH
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MXC:3G^UK'_KLG\Z_;KX'_P#).=*_ZY+_ .@BE5V.O)?BD=[1117,?6!1110
M4444 %%%% !1110 44RX9EMY"IPVTD?6O(/ 7CSQ!K?Q4US0+RXC>TLH4E4*
MF#SGBG;J*]M#V*BN6^(LVN6OARXFT&1(KU!D;TW<=ZX;X>_%JZ\3> [JYNKF
M.'6T>2%(V&"6!P./J*+!?6S/8J*\4\;^,O&'A#X5S:]-<PB]CC#,OE]"2*RV
M^+GB'PSJ6A-JL\=];ZC#&WD0IA@7QS]*?*^@N9'O]%,B?SH5?&-RAL?A7DWQ
M&OO'L+27VA7UO9V-NV)(9XMS2#U!SZ5(V['KE%>8P_$/4-7^$E]XBM5^SWEO
M$^1(N?F7@G\Z=H'Q.DM?A)8^*-7(DD>!6D*_+\QIV871Z917B<_Q4UCPS:Z9
MJFK2I-8ZE>);0Q(N&&XX!)_&O7-8URWT/1YM1NG"6\2AF8G 'XT6!-,T**X)
M=>US6O#\UWIQ$;R2;82ZY&TCAOI7'^"?&_B[2?'5WH?BBXBU!,*(GMH]H0GU
MHL+F/;:*\+U7X@Z]XD\:2:;H/B33=*%K,8I+2Z3=))@\E?:N@UGX@:I?^,[C
MPIHTJ1:E96R3S2NN58$#H*.5AS(]4HKQ&Z^.S0Z/JEB#NUZP<128Z,V>PK;\
M-_$34(_&D.AZM(K^;:"X611@<]!]:.5AS(]3HJK>:I:V+1K<7"0M)]P.<;JC
M_MNP^TBW^U1^=MW[-W.WU^E(HO45BS>--#M_+\W4[=/,)5<M]X^E8UUXV&D^
M*+/3[IUDM[U#)%.O"@>]%@NCLZ*17#*&4Y##(-+0 4444 %%%% !1110 444
M4 %>:_M$?\DMU3_</\J]*KS7]HC_ ));JG^X?Y54=S*M_"9^*%__ ,A"[_Z[
M/_Z$:@J>_P#^0A=_]=G_ /0C4%=I^:2^)A1113)/L;_@FU_R5:3_ *]WK].J
M_,7_ ()M?\E6D_Z]WK].JY*FY]SE7^[H5?O"ML?=6L1?O"ML?=6L&>VAU%)2
M9PN:0QU%0&^@4X,J@TGVZW_Y[+^= %BBJ_VZW_Y[+^='VZW_ .>R_G0!8HJO
M]NM_^>R_G1]NM_\ GLOYT 6**K_;K?\ Y[+^='VZW_Y[+^= %BBJ_P!NM_\
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M/U>&^L9FC>-@2,\&OO'X,_&>P^(VD1))*L>I( '1CRQ]0* /4Z*** "BBB@
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M-O56>S\S=&IYP.P]JT=/\"Z1I<A>&V13_NCBE=!9Z'C_ ,4/"GAG6(7U'PU
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M_P"A@O/S'^%<C10!UW_"W?&/_0P7GYC_  H_X6[XQ_Z&"\_,?X5R-% '7?\
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MI=I]*-I]* $HI=I]*-I]* $HI=I]*-I]* $HI=I]*-I]* $Z4"EVGTI"#Z4
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MM#JHZY_R![S_ *Y-_*KU4=<_Y ]Y_P!<F_E2&?FM\3_^1XU7_KI7+5U/Q/\
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M'8V0V.1TZU\._%JXCNOB%J\L5VM]&TG$Z<*WTK[8TJ".\\'1ZG#\/?#K6L<
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M6ZI_N'^54EJC&L_W4O0_$_4/^0C=?]=G/_CQJ72;I;/4()G7<%8?+^-17_\
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MGUMC-_LYO6C^SF]:TJ* L9O]G-ZT?V<WK6E10%C-_LYO6C^SF]:TJ* L9O\
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MAQ?RKY"V^]=\/A1^=X[_ 'F7J>X? 7P$/&5E-]NUO^R-)23,K,N1@=?TK?\
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M*** "BBB@ HIOG)NQO7/ID9IU !1110 4444 %%'UI%97Y5@1TX.: %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O-/VB#_P 6NU3_ '#_ "->
MEUYI^T/_ ,DOU3_</\JI;HQK_P *1^*6H?\ (0NO^NS_ /H1KV;X':#JWBSP
MAKVC:%=;=5N'7RK6,?O),=<5XQJ/_'_=?]=G_P#0C6AX8\7:MX-U2._TB]FL
MKF,Y5XFP179NM#\[A)1G=['NGAG]G7XK:#K(U"_T_4=/LH6\R:XN#E-H/)/-
M>0?%29;GQYJKI<+<KOQYL8P#78^)OVI/'WBC1O[.N-:NDA9=KD2D[AW!KR62
M1I69W8L['DGJ32BGNRZU2#5J=_F?87_!-K_DJ[_]>[U^G=?F+_P3:_Y*M)_U
M[O7Z=5SU-SZ[*O\ =T*OWA6V/NK6(OWA6V/NK6#/;0ZJ.N?\@>\_ZY-_*KU4
M=<_Y ]Y_UR;^5(9^:WQ/_P"1XU7_ *Z5RU=3\3_^1XU7_KI7+4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444F>U "U-I]A<:I=I;6D3
M33.<*B]33M/T^?5+J.VMHS)+(V%"@]:^R?V>_P!GV+PY:PZQK,0DO7 =489V
MGVH =^SU^S[#X=M8M8U>(/>,-RJPY (KZ*10BA5 4#H!1&HC4*HVJ. *=S0
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M9'^W7#;6!'!D.#1:R'=\Q[*3BBD/K2U!H%%%% !1110 4444 %%%% !1110
M4444 %%%% !7FO[1'_)+=4_W#_*O2J\U_:(_Y);JG^X?Y54=S*M_"9^*%_\
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M%%% !1110!\&?'K]JOXI_!/7C;7>B6;VF!MF2,LN>_.*\C_X>9^-?^@;8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+MDCV* \F,EFQR<UVF.,UQSGS.Q]U@<##"QN_B'48H%+61ZPF!2T44 %%%%
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M^&B-%_NS?]^Z/^&B-%_NS?\ ?NC^VL!_S\0>UAW/7OPH_"O(?^&B-%_NS?\
M?NC_ (:(T7^[-_W[H_MK ?\ /Q![6'<]>_"C\*\A_P"&B-%_NS?]^Z/^&B-%
M_NS?]^Z/[:P'_/Q![6'<]>_"C\*\A_X:(T7^[-_W[H_X:(T7^[-_W[H_MK ?
M\_$'M8=SU[\*/PKR'_AHC1?[LW_?NC_AHC1?[LW_ '[H_MK ?\_$'M8=SU[\
M*/PKR'_AHC1?[LW_ '[H_P"&B-%_NS?]^Z/[:P'_ #\0>UAW/7^?2CGTKR#_
M (:)T7^[+_WQ1_PT1HO]V7_OBG_;6!_Y^(/:P[GK_/I1SZ5Y!_PT3HO]V;_O
MV:/^&B-%_NS?]^Z/[:P/_/Q![6'<]?\ PH_"O(/^&B-%_NS?]^Z/^&B-%_NS
M?]^S2_MK _\ /Q![6'<]?S1FO(/^&B-%_NR_]\4?\-$:+_=F_P"_=/\ MK _
M\_$'M8=SU_-&:\@_X:(T7^[-_P!^Z/\ AHC1?[LW_?NE_;6!_P"?B#VL.YZ_
MFC->0?\ #1&B_P!V;_OBC_AHC1?[LW_?LT?VU@?^?B#VL.YZ_P T<UY!_P -
M$Z+_ '9O^_='_#1&B_W9?^^*/[:P/_/Q![2'<]?S1FO(/^&B=%_NR_\ ?%+_
M ,-$:+_=F_[X-']M8'_GX@]K#N>N\FC->?>&?C-HGB2\6VC9XYFX&]<"O0%8
M,H(Z>M>EA\51Q4>:C*Z+C)2V8^BBBNLH**** "BBB@ HHHH **** "BBB@#Y
M^_:(NI/.AC+80-G&?:O %\3:6UT]N+R,S1G#)W'M7O?[0_-W%]1_*OA3X@^9
MX!^*6FZ@VY].O [3\=">!7X]F5%8K,*D&]>AYDX\TVCW&S\1:;J"R-;7<<JQ
MYW;3TQZ_2KEK=0WD0E@D$D;=&'2OF?P3KEYX6^(EWH]ZC?9;Z,RQ'K]\Y'\Z
M[SQ)\1[CP=-!HVGVZ3W$9VE7X_*O*K9=*,^2&MS*5-IV1[#5,ZS9+>&U-RGV
M@=8^]>27GQHO&UZSTFWM4,LD/FR9R"#W%<CK7CR33_&CZC<;HVRO[L9Q^-*G
MEE63M+L"IOJ?2N*K7.H6UBT8GF6(R':N[N?:LSP[K$FJ:&FH2!0KIYB[3GC%
M>#^.O'PUCQIHK13S1QB]5#%@A>#@US8?!SK3<'T%&#;/I2BF)()4#+T/-.6N
M!Z.QF+1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LDBQ(6=MJCO67'XJTB
M6%Y$OXFC3.X@],>M:=Q&)H9$/.Y2/TKYH\R7PEXWU[PS=;GBO+1_LSX)_>-T
M_G7IX/"QQ5[NS1I&/,?1<.O:?<6GVJ*Z1[?_ )Z \5=CD6:-70AE89##H17S
MM\&]:NY)M0\(Z@K>9:D*SGGWZUT5W\8+NVOA:6%LDR6\GDN&R#M'4UK4RZ<9
MN$!NF[V1[1[U4M=8LKRX>&"X225#AE&<@^E>3VWQDO=4\52V%K:HUK#MW-SN
M&1W%<;H?CYM!\7ZA(S$R2W+;5;[HR<=:<,MJM2OO8:IOJ?2<DJQ*6=@JKU)K
M/L?$NEZE</;VM['/,APR*>0?2G0JVHZ21.PC\U.64Y !%>-:7H<>E_$D:G97
MK&QLV<7,8(^=L<<=ZYJ&'C4YN9V:(C&Y[;/J-M;2B.254D;HIJ=I!'&68X7U
MKYPO/'!U;XJ0,UQ,L>Y4$./EZ]:].^+'B*;2[&TL869&O!CS%ZC%:U,#.$H0
M;^)%.#5D=?<^*-*LY1'/?11.>@8U-9:Y8:E))';722O&,L%/2OGOXO336.H:
M(8/GD\B,LI/WC77Z[>SZ+\*]7URWB%MJ<EMDI'U&!Q6\LOBH0:EK+0?L]M=S
MT]_%&DQLZM?1!D.T^QJ6ZU_3K%0T]W'$/5CV]:\?\$V<6J?"DZA<ONO)H1,\
MC?>#8S69\+[JX\2?"35[_4MT\\:S!'DZC!.,4/+XQN[[.P>S/:H?%NC74@6+
M4(G9N@%:D5PDR[HV#+ZBO%?@7I<.K:+>37 WRQCY6(Y'%;_PSU^==>O-%E=I
ME0M(';J!GI7/7PB@YJ#^$F4;/1GI]%(*6O+,PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "F3W$=M"TDCA$49+>E/JMJ5H+
MZPGMFX$B%:J.^H%)?%6CR6[3K?Q&%/O.#P*G37+"2U6=;I&@8@+)G@DU\UVO
MVK3-<\6>$Y=V^X8)8DYY..:W/@UXBFUK2[_0[]2MQ8SMVSPG_P"JO>J9:HPY
MXO8W=/2Y]#(P9<C&",\4K,%4DG ')->-#XQ7<WB);2UM4>RC8"1N<@>N*BTW
MXR7WB"]U2.&U3R+9FBW#/IWKC67UF9^S9Z_9:M9Z@S+;7"2E>H7M5NOF[P+\
M0&T?Q ;;)::YD*[7X49->\:UK@T/P])?S]$'.SYNM1B<'.A-1[[!*+B[%Z35
M+6.Z:V:=5G5=YC[A?6HH?$&G7$J117:/(_"@'DFOG&P\6'4_B=K&;V?RGTMB
MN>,$@UF?#7Q%>2>)O"UA?R/'%',?(G7)-QS_ !5Z7]DM0<G+97-/9.USZNDD
M6%2TC;5]ZS+CQ5I-O,(I;^-'/\)-<1\6/$%Q#>6>EP.8?,D1RZGG&X<5YK\5
MKJXT[Q]IOV2,/^\4^43PW'>N3#8#VUN9VNA1IW/HFQUFRU%9'MKA)A%P[*>%
MJ$>*-)9@HOHRQ;:.>_I7E7Q*U"?PK\)[C4=/7R+VZDB+I'U&3@TRXL8H_@_+
MJ"O_ *8D33";ONP.*<<#&2YKZ-V!01[#=:I9V80SSK&'Y7/>F6^M6-S&'BN4
M=,[<CU]*^:;75O%>H^#_  KKMK$M_P#9H6,\4[D;_F/;OQ7:^'/%EIXF\$7=
MU:AK:ZMI&>5-N &7J/I6E3+7!73OT!T[(]OYZ]NM%<G\+O$,OBGP78ZC-]^4
M'(_&NKQS7C5(.G-P9DTT[&GX<D:'7+)E8J1(*^RO#LC2:/:LQR2@KXRT'_D-
M6?\ UT%?9?AK_D"VG_7,5^A\)2?[Q'=ANIJ4445^DG<%%%% !1110 4444 %
M%%% !1110!\]?M#?\?D/U'\J^=O%G@VQ\6PHEW'O9/NG.,5];_&7X?W?BBSC
MGL5,DR-DJ,=*\-D^'>O1,5:R8$<=:_(,[PN)CCI5*<7;NCS*D9*=T>83?#_3
MY]7M]0>(&:&)8E;V'2LWQ5\,X]:URTU:V98[J%MQ+\@UZ_\ \*_US_GS:C_A
M7^N?\^35X<88V+ORLQM):V/%M3^$Z3>(K76[5DBOXX_+=FY4KWP*@\0?!NVU
MV\GFF*[9E (!P?PKW#_A7^N?\^;?G2'X>ZZ?^7)JV3QR::B]"O?/.?!OA5O"
M^EO8M)YD ^5!G.%Z5BZ[\(=*U?5+.]6/8]O,)1SCFO8?^%?Z[_SY-1_PK_7?
M^?)JQC3QD9.<8O45I]$<W'&(U"CH.*6NC_X5]KO_ #Y-2+\/==_Y\V_.L/J>
M);^!D\DCG:*Z/_A7VN_\^34?\*^UW_GR:CZGB/Y&')(YRBNC_P"%?:[_ ,^3
M4?\ "OM=_P"?)J/J>(_D8<DCG**Z/_A7VN_\^34?\*^UW_GR:CZGB/Y&')(Y
MRBNC_P"%?:[_ ,^34?\ "OM=_P"?)J/J>(_D8<DCG**Z/_A7VN_\^34?\*^U
MW_GR:CZGB/Y&')(YRBNC_P"%?:[_ ,^34?\ "OM=_P"?)J/J>(_D8<DCG**Z
M/_A7VN_\^34?\*^UW_GR:CZGB/Y&')(YRBNC_P"%?:[_ ,^34?\ "OM=_P"?
M)J7U/$?R,.21SE%='_PK[7?^?)J/^%?:[_SY-1]3Q'\C#DD<Y171_P#"OM=_
MY\FH_P"%?:[_ ,^34?4\1_(PY)'.45T?_"OM=_Y\FH_X5]KO_/DU'U/$?R,.
M21SE%='_ ,*^UW_GR:C_ (5]KO\ SY-1]3Q'\C#DD<Y171_\*^UW_GR:C_A7
MVN_\^34?4\1_(PY)'.45T?\ PK[7?^?)J/\ A7VN_P#/DU'U/$?R,.21SE%=
M'_PK[7?^?)J/^%?:[_SY-1]3Q'\C#DD<Y171_P#"OM=_Y\FH_P"%?:[_ ,^3
M4?4\1_(PY)'.45T?_"OM=_Y\FH_X5]KO_/DU'U/$?R,.21SE%='_ ,*^UW_G
MR:C_ (5_KO\ SY-1]3Q'\C#DD<Y7,ZMX#T_5]<CU2:+-S&00V?2O23\/]<_Y
M\FI/^%?Z[_SY-5PPV*IN\8,:C);(\XTGP)I^E:Y?ZI'%BXNSEFS7/?\ "J8K
M7Q,^HV;*D4H/F(W)))Y(KVG_ (5]KO>R:C_A7^N?\^35O&.-5WRO4?O]CQC3
M_A7'HWBJ[U2R9%CNMHF1N3P.U9NI? NTU2XN7D8 2S>:"K8([U[S_P *_P!<
M_P"?)J/^%?:[_P ^35JGCD[J+'[_ $1Y]9Z#<6_AE].:;=(4*!\GCTKCO#/P
MA;1]=6_GN/-!R64,>?J*]R_X5_KO_/DU ^'^N$_\>3?G6,88R%[0>OD)1GV/
M';OX1Z9-XDCU9$VR(01SCD<U?^(?A4^(M-22(?Z5;_ZHUZF/A]KA_P"7)OSH
M;X?:YC_CR:CV>-YE)Q;L%I]CP[6OAK)XK_LVYE98YK:-5^8'DBMR/P3+J"W,
M&K2)/:2H$\N/CM7J@^'VNKC_ $-J7_A7^N?\^;?G526-E9<CT%:?8\9C^&<M
MGI\^FVLZQZ?(V?+S\P'IFMVU\#V>E^%)]$L%\J"9&5LGN>M>D_\ "OM<_P"?
M-OSH_P"%?ZY_SYM^=3*&-E]EC]_L>4>"?!7_  @NFW42'S!)T"YJ'P!X1DTN
M\NM2NA_I4DC*.WRDUZ[_ ,*_USO9-2?\*^UQNEDU$H8N7->#O+R"T]=#G O.
M:6NC'P^US_GR;\Z/^%?:[_SY-7-]3Q'\C)Y)'.45T?\ PK[7?^?)J/\ A7VN
M_P#/DU'U/$?R,.21SE%='_PK[7?^?)J/^%?:[_SY-1]3Q'\C#DD<Y171_P#"
MOM=_Y\FH_P"%?:[_ ,^34?4\1_(PY)'.45T?_"OM=_Y\FH_X5]KO_/DU'U/$
M?R,.21SE%='_ ,*^UW_GR:C_ (5]KO\ SY-1]3Q'\C#DD<Y171_\*^UW_GR:
MC_A7VN_\^34?4\1_(PY)'.45T?\ PK[7?^?)J/\ A7VN_P#/DU'U/$?R,.21
MSE%='_PK[7?^?)J/^%?:[_SY-1]3Q'\C#DD<Y171_P#"OM=_Y\FH_P"%?:[_
M ,^34?4\1_(PY)'.45T?_"OM=_Y\FH_X5_KO_/DU'U/$?R,.21SE%='_ ,*_
MUW_GR:C_ (5_KO\ SY-1]3Q'\C#DEV.<H(S71_\ "O\ 7?\ GR:C_A7^N_\
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M]T1Y4/ *Z9;V-OIA6*WME*JDG(_&LB[\"_V-I$]O:Q@S7<I,C(/EPW6O;/\
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M_OD5/11R1[ 0?8;?_GC'_P!\BC[#;_\ /&/_ +Y%3T4<D>P$'V&W_P">,?\
MWR*/L-O_ ,\8_P#OD5/11R1[ 0?8;?\ YXQ_]\BC[#;_ //&/_OD5/11R1[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *2EII9>Y _&@5PI<4W>GJ/SHWI_>'YT!S+N.VBC IN]/[P_.C>G]X?G
M0',NXOO7/>.-'L=6T"\6\M8KE1&V%D4'L:W]R_WA^=9?BAA_85X 0?W3=_8U
M4;W1S8CEE2DGV/D[]D/0=.N_%6LM/9PRM%-*8RR [<-VK[&"XQC@5\C_ +'1
M \4:]G@>;+_Z%7UOYB_W@/QK:M?F/%R)1CA%;35C\48IN]/[P_.C>G]X?G7.
M?1\R[CL48IN]/[P_.C>G]X?G0',NX^BF^8O]X?G2T!=!2T44#"BBB@ HHHH
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M[_OY7$T4<L7NB(XJO!6C-V]3MO\ A=7CC;C_ (26^_[^4O\ PNOQQ_T,M_\
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MI_2N3%? ?:<(?[W+T/:J***\H_80HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,24 '2N&^(K&W*68UB'5DC;(DB!Q^M<2N5.<TI.[D\U:A9G+4QCJ4^5H6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5'_"H?!__0!M?RH^M^0O]3JO_/Q'Y5?V+?\ _/K)^5']BW__ #ZR?E7ZJ_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% ";:*6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 0C-+110 4444
M%%%% !1110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!=3?9[::7^XI;\J
M)Z*\]T?QA/K#-<I?(EO&QWKCH :GD\776H6EW=6X-O!;2; 6Y\P>H]JTY&1S
M'=T5YEJGCK4)%L9[4M'%<S"#'!P?6NYL;B6SMF-],,J 2YXS2<6@4DS3R:*I
MV^K6EY)LAG61NN%KF/&7BM]&U33;2*<1?:'*NW9:E1;*;1V>T4;17-6OB:UT
M_P#<ZGJ$2S2?-%NXW+V-/USQ59VNGW#6]VAN0F8T!Y)I\K#F1T72DR.]8^EZ
MTG]B6ES?2"&22,,V_P!:S-=\<6EO;VWV*X2=[B80AD/W2>]'*PNCK:*XWQCJ
MFI^']#6ZCEWR1 ;\#[V:?H_BF*V6WCU2_C6XGC$JQMP<&CE=KBYE>QU](367
M+XDTR!D#WD:%ONY/6J]]XRT>Q0&2]C!/ &>M*S[#NC<I:Y[_ (3C18YU@GU"
M*&X;&(6///2K8\4Z4S,!>QDKUYZ4<LNP71K4E8<GC31(;I+=]1A6=B,)GDYJ
M;3_$=IJFH7=G#(KR6Y < ^M%GV"Z-;/&:,_C7->//$A\,Z/'<AMNZ58]WIGO
M6:OBR33+<W$]RMXLZ_Z,B<;V]!346U<7,D[';;J=7!W'B^[TO4+2.Y5B+B$R
MB+@%>.AIWA/Q=<^(HTG1CS(5:#NHSU-/D=KBYD=U254N-6M+=]DMPB/Z$TR\
MU!(]+N+J)@Z1H6R/85-BB]1FN \.^+)]8CCO1?H+5<^:F/N\]ZZ>'Q5I-Q,(
M([Z-Y<9V@TW%H2DGJ;-)QUKEK'Q-_:GB2XLK64/';@,V.>*UI?$6G1&16NHP
M\>=RYY%+E8[HTZ :Y+3?$DNO1RWM@^ZWCS\J\[B.U9MCXY::^FDDN%CM[=L3
MQM_RRST!JN1D\R/0**P[7Q=IETPC-U&DI&0A/)'K5/Q%XNM;.QD%K=(]UCY(
MP>2:2BWH5S*USJ*:>M8VA^)+/4K&)OM2--@"1<\ANXK9W!ER.:35@3OL.HI*
M6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img222343278_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_3.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" P %Y,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M :U)3J-HH 6BBB@ HHHH **** "BBB@ HHHH **** "D;I0U-H *<O2C:*6@
M I&I#UH% "4^DVBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I*6B@!E.6C:** %HHHH **** "BFGK0* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4RGTFT4 (M.I*6@ H
MHHH **** "BD:FYH ?124M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %,I])M% "+3J2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HIM*M "TE(U-W<T +12CFEVB@!%IU)BEH **** "BBB@ HHHH 9
M2K2X%(>* '44W-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***;0 ZD:D6EH ;3J-HI: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI
MIZT .HIHZTZ@ HHHH **** "BBB@ HHHH **** "BBFGK0 ZBFK2T +13<FE
M% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 2DW4K=*;0 ^BDI: "BBB@ HHHH **
M2C- "T444 %%%% !1110 44F110 $9I-M.HH **** &D4 4ZB@ HHI,B@!:*
M** "BBB@ HHHH **** "F[J=3* '"@T+0U ";J=3*?0 4444 %%%% !1110
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M %%%% !1110 W=2@YIM.6@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!NVE%+24 #>M,QS3STIM #EI:2EH ****0!1113
M **** "BBB@ I"*6B@!N,4;J5J;0 ^BDI: "BDHR* %HHHH **** "BBDS0
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M "BBB@ HHHH **** "BBB@ HHHH 3=0#FDI5H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
MW4M-H 4'-+2+2T %%%% !129HR* %HI,TM !1110 A.*3=2M3: 'TW;3J* $
M%!I:* &[:6EHH **** $-)MIU% !2$4M% " 8I:** "BBB@ HHI* %HI,BEH
M **** "BBB@ HHHH 0C-)MIU% !1110 4444 %%%% !1110 4444 %)NI:;0
M H-+35IU !1110 4444 (:3;3J* &[J4'--YI5H =244M #=M**6B@!":-U(
MU% #J*** "D)Q2TC4 )NIU,I] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (W2FT^DH *6BB@ HHHH **** &M
M0O6EHH 6F_Q4ZB@ I#TI:* $6EHHH 93EHI: "BBB@ HHHH **** $IM/I*
M!>E+110 4444 %%%% !1110 4444 %%%% !1128]Z %HI-M&,4 +1110 444
M4 %%%% !1110 4444 %%%% !24M1F@!^:6HP:?0 M%%% !1110 4444 %%%%
M "-TIM/I* !>E+110 4E+10 RG+THI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBF4 /I&I%IU #*=12T %%%% !1112 **** "BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2-2TAH ;3J3;3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *:U)2K0 E%.HH *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M :U)3Z2@!:*** "BBB@!*;3Z3;0 +TI:2EH *2AJ;0 4Y:*6@ HHHH ****
M"BBB@ HHHH ***3% "T4FVEH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHI#S0 M%)MI: "BBB@ HHHH 92K2TM !1110 4444 %%%% !111
M0 44VA: '4444 %%%% !1110 4444 %%)BC% "T444 %%%% !1110 4444 %
M%%% !3*?24 (M.HHH **** "BBB@ HHHH **** "BBB@ HHHH ***1J %HIF
M:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%)CWHH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD;I3:
M 'T4B]*6@ HHHH **** "BBB@ HHHH :W6DIU% "+UIU)2T %%%% !12-24
M.HHIE #Z*:M.H **** "BH9+R*'[S8JLVM6J]9* +]%9W]O6G_/2I(]6MI.C
MT"+M%,CF23[K9I] PHHHH **** "D:D;K0.M "4^DI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BDHH 6BBB@ HI&Z4V@!]%,IPZ4 +1110 4444 %%%%
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M'_?7\Q7R$?VB#_SW_6C_ (:(/_/?]: /KWSH_P"^OYBCSD_OK^=?(8_:(/\
MSW_6KUC^T#YS &?]: /J_>I_B'YTM>#^'_B\E\R@S=?>O3M!\3)J"J=^<^]
MSJZ*:C!U!%.H$%-VTZB@!NW\*=110 4FX#J:K7UVMK$23BO/O$OCY-.W?O,8
M]Z /2?,0?Q+^=)YT?]]?S%?-&M?'(6C,!/C\:YJ;]HDK)CS_ -: /KSSD/\
M&OYT[<#W'YU\KZ3\?/M+ &?]:]$\.?%!-0V_O<Y]Z!GLM%8FCZTEZBG=G-;7
M6@0M%%(#F@!:**@NKI;:(LQQ0!-N ZG%)O7U'YUYSXF\?1Z:S#S0/QKG]/\
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MPS\1$U';^]SGWKT73=02[C!#9H OT444 %%%% !1110 4444 %%%% !1110
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M7PS\24U+;F7.?>O2M+U%;R,$-F@#0I",TM% #=M.HHH **** "BBB@ HHHH
M**** "BBB@ HHHH *2EJGJ5Q]GA+4 6]P]1^=&X>HKS?6/&GV.0C?C'O52Q^
M(2S2 &3]: /4Z6N=TG7UO OS9KH$;<H(H =1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 )2;:=10 E+110 4444 %%%% !12
M4QIT7JPH DHJ#[9'_>J19%;HP- #Z*** "BBB@ HHHH 0C-&VEHH *3;2TE
M"=*=14%U=);1EF.* )68+R2!65JWB"WL8FS(,_6N&\:?$&/2HWQ+C'O7SQXX
M^.961T6?]:M1N9N:1[;XI^(T5N7VRC\Z\ZU#XME9#B;]:\ U+XG3ZK(0)"<G
MUK,;4KNZ^;+5KR'.ZA] _P#"WWW#]]^M=!HOQ8$C+NF_6OEMI+L<_-4?_"37
M6FG)9ABGRH7,S[Y\,^/X;K;F4?G7H5CJD-[&"KC-?G3X9^,4MG,JM,1SZU]
M_#WXQ+>>6&F_6LI0:-XU$]#ZAI:Y;P[XFCU*-2'!S74*=P!'2LS86BBB@!-M
M&VEHH **** "FM3J:PH ,FG4W!IU !1110 4444 %%%% !124M "4C2*O5@/
MQK)US5!81DDXXKS77/B4EJ[+YF.?6G8ENQZTU]$O\6:='<K)TKQ"Q^)"W4P
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M&_-/%8&5'5(G YI#$:7/5*:156QOENHP0:N5X]K'T*=]4,HIPXI:0QE/HHH
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M+=J .^HID<@D7(I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,0O"[:C))A<Y->>Z7\+RUZ&,7?TKZ=U#P^MTQ)7-0V/A6.*0'9^E '->!_
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M,<TG@G7&CO$7=WH*/L_P[??;+<'.>*VJX7X<WWVBU3)SQ7=4$A1110 4444
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M)8A:D'Q,^>SD^E?(WC1<7[_6OKGXB?\ 'C)]*^2?&_\ Q_O]:YSZ-;&I\/\
M_7I]:^F_ W^ICKYC^'_^N2OISP-_J8Z9)Z5']P?2G4V/[@^E.H *;WIU,H =
MF@@,,$9%(M.H X3Q_P"'4O+20A<Y%?(/Q.\'M;SR.J8_"ONO5;475NP(SQ7@
MWQ2\*K)!*VSL>U SXQ;4I=+F*YQS6E8:A+JDJKDFH/'>F&TU!P!CYJU?AKI9
MO+Z,$9Y% SUCX;^#FN)879,]*^IO!'AU+.V3*XP*Y#X:^$TCM87V=A7KUE:B
MVB"@4$DZJ%&!P*6BB@#F?%"_N7KYF^*_RK-^-?37B?\ U+_2OF7XL#<LWT-
M'S#XAU)K6\8@]ZU_"_CJ6SP YK#\36#W%XX [U;\-^#KFZ8;48_A0!Z;'\4)
MEA'[P]/6H)/BM,G_ "T/YUE?\*^O/+ \MNGI7/ZSX,O+8-\C?E0!U%Q\6)6R
M/-/YUD7WCB;4@5\PG/O7FNJ6=S9L<AA5OPW(\MPJMZT#.OL]#FU>Z!(+9->X
M_#'X?M')&QC_ $K.^&'AE+YHB5STKZC\&^"X[6W1M@'%(#0\'Z&+.VC&W'%=
MBJA1@566-+.$8XQ6/J7BA++.6 Q3$=%17G=U\3X+<D&0?G5/_A;MOG_6K^=
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M&@DM444E "T4E+0 4444 %%%% !1110 4444 %%%% !29I::W6@!U)2TC=*
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MIZU]N7T GMW4CM7@OQ2\.K-'*=N>* /AK4+B;3;P@$C!KI?#NL2WQ1"2:?\
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M\8VXXKO>E58;5+*'Y>,5DZEXICL<Y8#% '0T5YW<_%""%B/,'YU4;XN6Z_\
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M^]04C[1^$U]OM8N>U>M*<J#7AGPAG_T:+Z5[A"VZ):"22BBB@ HHHH ****
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M'@6WN;1RD8Y'I7IU5K^U6[MV0C-8W.AH_/\ ^)WP_:UFE=(\?A7DUI=3:+?
M9*X-?=?Q0\(126TK;!T]*^*OB58C3=0?:,<UTPU..<>4]?\ AUXR::.-"^>/
M6M?XA77VK37.<\5XC\-=:*W*+N[UZCXHO?,TD\]J'N-2T/ [P?\ $Z/^]7UA
M^S\/W<'X5\G7#;M:_P"!5]9_L_\ ^KA_"B6PJ>Y]:V'_ !ZQ_2K%5['_ (]8
M_I5BN9G:%)FEIE(!]%-4TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<GUKZ\\9:;YUO)Q7RG\5+!K::0X[F@=R+P'J@6\09[U];_#BX\ZQ7_=KX/\
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MQ_\ /.G'P''C_5BC^UGW&N'5V/C_ %/X<R(IQ&?RKBM8\'R6N[Y"/PK[FO\
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M?8/PM_X]8OI7R%X6C\O5%S_>KZW^&%P!:Q#VH ]AA_U8I]16[;HA3V8*I)H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRT.?2]0<JI&#6]\-_%$]C>1JS$<U[!\3/AWYTTK+'^E>567@^;3[X$(1@^E
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M%55K&^\S^*@#ZR\,_%IM0D4>;G/O7J-KK)U73\9SFOD'X?6MVMQ'NW=:^I?
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MM8O.I.37NWPG\,M<21,R=Q7!>"/AK,UQ&S1GKZ5]4?#/P>+!(R4Q@>E(#NM
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M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FB@!:***
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M^)W_ "#6_P!VOAGXI'_3I?K7W-\3O^08W^[7PQ\4E8WTN!WK6".:J8O@-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M",87&*T]0U(6L)!/:M:2V$<1P*X3QC,\4$A'I0,P_$GB*W)9685PMS):W\I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<D"2?>7-244 5O[/@_N5*D*1_=&*DHH **** "BBB@ I,TM-;K0 N:6FKU
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %)2T4 ,V[J:UM&W5<U+10!7^P0?W*<MK$G1<5-10 @4+TI:** "BBB@ HH
MHH :R!NHS4$FG6\OWHP:LT4 9[:#9-R810-"LA_RR%:%% %2/2[:/[L8%6$A
M2/[HQ3Z* "D90W6EHH B:UC;JN::+.$?P5/10 U8U3H,4ZBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "DQ2;J44 &*6BD- "T4W=2B@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *:U.I",T -I])MI: "BBF[J '44@-
M+0 4444 -;K0O6EVT;: %HHHH **** "BBB@ HHINZ@!U%(#2T %%%% !111
M0 4444 %%%% !12&DW4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:
MW6G4FV@!%ZTZF_=HW4 .HHHH :U"]:4C-&V@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *93Z;MH %IU(!BEH **
M** "FM3J0C- #:?2;:6@ HHHH **** $VBEHHH **** "BBB@!*6F[J4&@!:
M2EHH 93EI-M+TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3-
M"TF:6FM0 NZEIE/H ;M-*M+10 4AI:* &[32BEHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IN#3J* &J*=110 4444
M%%%% !1110 4444 %%%% !3<&G44 -44ZBB@ HHI,T +1110 4444 %%%% "
M-2;33J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J3::=10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 W!I5I:* "BBB@ I-U+3* '9I::M.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $IM/I-M  M+24C4 .HIH-.H **9FG+0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%-I5H 6BBB@ HHHH **** "F4^DVT "TM)2T %%%
M% !13,TY: !J;3J-M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%(U-S0 ^DHI: $I:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBDS0 M%%% !1110 444F: %HI-U+0 4TM3J:10 !J=31UIU !1
M110 A-(&IU% !1110 4444 %%%% !12;J* %HHHH **** &EJ U!ZT#K0 ZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"*6B@!H%.HHH ;M
MI12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 -VTH&*6B@ HHHH ***
M* "BBB@ HHHH **** "BBB@!NVE Q2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 AI-M.HH 2EHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "DHJ":]B@4EFZ4 6*8TJKWKF-6\96]HI&
M]1^-<I=?$RWC8CS1^= 'J:R*W0TZO+;/XEV[L/WJ_G73:9XVM[K WJ?QH ZR
MFM5>UU"*Z4%35F@!M/I*6@ HHIK=: '44E1S7"0C+'% $M-9@O4UA:CXKM[-
M6^8#'O7*:A\2+>-C^]7\Z /1Q,I[TZO)X?B=;M(!YJ_G71Z7X\M[C'[Q3^-
M';451L]7@NU!5A5U6##(YH 6BBB@ HHHH 93EHI: "BBB@ HI-P]:;YJCO0
M^BH_.3^]2&XC'\5 $M%0_:H_6C[7'_>H%<FHJ+[5&?XJ/M$?]Z@+DM%1^>G]
MZE\Y/6@8^BF>8I[TX,&H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***90 ^B
MFK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLPR2,&@#[_\  ?Q*%[Y8,F?QKW+0-46^@4YSD5^>/PR\:21W$2LYZCO7V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !112$T +12;J6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I-M+10 F*6BB@ HHHH ***0G%
M "T4FZEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 M%-W4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BF[J44 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J* &4^BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D:EHH 93J6B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EHH 93EI:* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4
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MD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U>;_\
M"1R?WJ3_ (2-_4T >D_;(O[U+]KB_O5YK_PDC^IH_P"$H8?Q4 >E?:HO[U)]
MLB_O5YN/%#'^*G?\)&Y_BH ]&^V1?WJ/MD7]ZO./^$B?^]1_PD<G]Z@#T?[9
M%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R
M?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[
MU'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]Z
MO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ
M/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@
M#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_P
MD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$
MCD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%
M_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7
M]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_
M>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4
M?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\
MX_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^
MV1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /
M1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1
MR?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.
M3^]1_P )')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]
MZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?W
MJ/MD7]ZO./\ A(Y/[U'_  D<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z
M@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_
MPD<G]Z@#T?[9%_>H^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC
M_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9
M%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_ (2.3^]1_P )')_>H ]'
M^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')
M_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\ A(Y/
M[U'_  D<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ
M\X_X2.3^]1_PD<G]Z@#T?[9%_>H^V1?WJ\X_X2.3^]1_PD<G]Z@#T?[9%_>H
M^V1?WJ\X_P"$CD_O4?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ
M/1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"
M1R?WJ /1_MD7]ZC[9%_>KS?_ (2)_6C_ (2.3^]0!Z1]LB_O4?;(O[U>;?\
M"3./XJ3_ (2=O[U 'I7VR+^]2_:H_P"]7FR^)F/\5._X2-_6@#T;[9%_>H^V
M1?WJ\X'B)_[U+_PD3_WJ /1OMD7]ZE^UQ'^*O-CXC?\ O4+XD?U- 'I/VJ/^
M]2?;(O[U><_\)&_K2?\ "1R?WJ /1_MD7]ZC[9%_>KSC_A(Y/[U'_"1R?WJ
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MWJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H
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M?;(O[U><?\)')_>H_P"$CD_O4 >C_;(O[U'VR+^]7G'_  D<G]ZC_A(Y/[U
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M\)')_>H ]'^V1?WJ/MD7]ZO./^$CD_O4?\)')_>H ]'^V1?WJ/MD7]ZO./\
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M4?;(O[U><?\ "1R?WJ/^$CD_O4 >C_;(O[U'VR+^]7G'_"1R?WJ/^$CD_O4
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MD_O4 >C_ &R+^]1]LB_O5YQ_PD<G]ZC_ (2.3^]0!Z/]LB_O4?;(O[U><?\
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MC$QN]2&.?FKZ2^#NE$^2=OI0,^I_AW&5MX_I7HM<9X)M?)@CX[5V= @HHHH
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M^P9/2C^P9/2O2_[,B_NBC^S(O[HH \T_L&3TH_L&3TKTO^S(O[HH_LR+^Z*
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M?]FP_P!VN<\1:<D:G H \L99/,Q6MIVFR3XX-.DMU^TXQWKM/#6G)(JY% &
MN@R;1\M(=!D]#7I:Z?" !MH_LV'^[0!YB= D]*/["D]#7IITV'^[3?[+B]*
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M.H)J?Q%:+&[8%9VD_+,* /3-+DW1BM \UDZ.3Y2UK4 "TM%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!'<'$+5YSXED_>M7HMS_J6KSGQ)$S2M0!1T23]\/K7I>E-FW KS'1
MH66<?6O2M'R(10!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2?>KJ*Y3Q$A;./2@#DXY/W]=GH<GR+7%I"WG5V6AJ55: .E1LJ*=3(ONT^@
MHI#2;J '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>];;":L55OO]2: .+U
M:3]X:IV<GSBK.K1GS&JI8Q-O% '7Z6_RBMM3E16#I:E5%;L?W!0 ^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQ*WR-71USGB1-R-B@#SV63
M_2OQKNO"LGRK7"30-]J_&NX\+(5"YH ZZBBB@ HHHH ***0F@!:*;NIU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4R8XC;Z4^H[C_ %+4 >?>)F_>-6-I3?Z0/K6QXDA+
M.V*R-+A83#ZT >BZ-_JU^E;%8NCY$:ULB@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\M?RK5M/#-M;X^1?RH \X\&^ 4L A\O&,=J]5TVS6TA  Q4T-K'" %7%34
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E7=&17
M+:MIGG,3BNJ)J&2W$F>* .1L='\N0''>NJL8O+0"GK:*O:IU7;0 ZBBB@!":
M3=0U% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CE7=4E(>E &/>V?F9XK'
M?2<OG%=:T8:F?95ZXH RM-LO)QQ6VOW13%A"]*DH 2DW4M)M- "BEI%I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L75+/SL\5M5&T0;K0!R"Z/\^<5MZ?
M:^4!Q6A]E7TYJ18@O2@!T8PM.I!Q2T (:3;3J* $I:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *AN%W1XJ:D8;J .:OM-\QCQ4%OI>UNE=.UN&[4BVRKVH IVE
MOY8Z5HK]T4BQA:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M65JMOYRGBM6HFCW=: .(DT7,V=O>NAT>S\C'%:/V-<YQ4L<(CQB@"6BBB@ H
MHHH *0C-+10 W;3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID@W(13Z2@#F-5TWSF/
M%4;31O+DSBNPDMP_:FK:JO:@""Q@\M0*O"D50M.H **** "BDHW4 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #6I*?24 +1110 4E+10 44F:6@ HIK4+0 ZBBB@ HI,T4 +1110 4444 %%
M%% "4M%% !1110 4444 %%%% "-3&C#CFI** *%QI$5QG<!6;-X.M9NJK^5=
M#13NT9RIQENCF!X%L^NU?RJ3_A";/;C:OY5T=%%V)4H+9'G?B#P7!'&2$'2N
M&;PO$+C&T=?2O8/$DN(2/:O/I)?]*_&D:<J1K>&?!\,BKE!^5=5_PB-GMQM'
MY5#X7F_=@5TE G%/<Y&^\"VTB-M13^%>7^-_A^GEOMC_ $KWZL77-(2\B;Y<
MT]P45'8^$/''@UK>1R$_2O+[NP:UF.1BOM7Q]X%699&$?Z5\X^-/"#6DCD)C
MFB,G%Z$U*<:D;,\[M67< :V;?3Q.HQ6#-"]K<8/'-=1X?N%9E#&O>PN82I[L
M^!S3)HU+N*&/H\D8R!3K>_GT^0<D8KOK/3HKJ$8 -9VK>%"RDJM?7X?'0K*T
MC\]Q&75</*\2UX7\?26TB!I#^=>W^#?B8C! TGZU\MW.DSV+D@$5=TGQ-/IT
MJY8C'O4XG TZRO$Z<%FU;"2M(^]]#\90WD:Y<'\:Z:VO$N0-IKX[\'_$LQ[
MTOZU[AX3\?1W"IF0?G7QN*R^5)NR/U#+\YIXA)29ZY28K,T_7H+Q!\PS6BDB
MR?=.:\=Q<=SZB,XS5XL7&#3J**DL**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 93EHI: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "DI:* &\TM+10 4444 %%)3<T /HI%I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **92K0 ZBBB@ HHIG>@!]%(M+0 4444 %%%% "-TIM/I* "EIE*M #J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"Q&*]8\'_$QXBBM)^M?/8W*^L3ZW*^(&K1J,^U+>\CN%!5A4]>+>$?B(MTJ
MR?K7J.CZU'>(/F'-?(U</*D[,_3<-C:>)BG%FQ124M<QZ 4444 %-R:=3=M
M"K2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;NI10 M%)2;
MJ '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
M: "FTNZC;0 J]*&H%!&: $R:=3=M.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BDW4 YH 6BDI-U #J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BD)Q1NH 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBD-)NH =1110 4444 %%%% !1110 44E)NH =124M !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !124FZ@!=M&,44M !1
M110 4RGTW;0 +3J0#%+0 4444 %%%% !1110 FVC&*6B@ HI"<4FZ@!U%%%
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MM+0 4444 %)2TUJ %I::M.H 3(HIM.6@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &4Y:6B@!&Z
M4VGT4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(U+10 RG4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #*5:=10 C=*;3Z* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &M24^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&IM/HH **
M** "BBB@ HHHH **** $;I3:?10 B]*6BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z4VGT4 (O2EHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &M24^B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#F_$O^K:O/I/^/G\:]!\2_ZMJ\^D_P"/G\: .Y\+_=6NLKD_"_W5KK*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@#F_$O^K:O/I/^/G\:]!\2_ZMJ\^D_P"/G\:
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M %;5Y])_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!E:QI*7D+_+GBO ?B9X92)96V>M?23?=->-?%8+
MY,O'K515V<]>K[*',?&/C*S$-PXQWKBV@#$\5WWCYO\ 2I/J:X=&YK5Q<=3R
MZ->.+?+(IM9#TH6Q]JT1BG;<5/M&;_V71YKM%%;'VI?L7M5X8HXJ>=G6LOH6
MV,YK$>E5I[+"GBMK J.:(%35QJM'GXK*J-2+LCC;NVQ)74^#8L7$?UK-O+;]
MYTKH/"<.VX3ZUZ,*O,C\PQF4NC6ND?3?PK7"Q?A7TYX5?_1U'M7S)\+_ )5B
M_"OI;PJ?W*?2N.MJ?=9->,4CIZHW^FI>*015ZBN5-K5'US2DK,\X\3> 8[I6
M/E@UXCXV^&6T.5C_ $KZS=!(I##(KF->\-1WBM\F:]7#8Z=)[GSN8932Q,;I
M'P-X@\%S6,K$(1BL*UO+C2YQR1@U]?>+OAJLRN1'^E>$^,?AW):NY6,C\*^T
MPN/A67+(_*LPR>KA'SP0SPK\0GM60-(1^->Y>#?B,DRH&E_6OD6\L;G39N 1
M@UO>'_%T^GLH+D8JL3@(5E>)GE^<5<+/EF??FA>*H;N-07!KI([A)0"K9KY
M\&?$X[D#2_K7NGA3QQ'>*F9 ?QKXO%8"=%W/U? 9Q3Q,4FST^DP*K6=_'=1@
MJPS5JO(U1](FFKH****0PHHHH **** "F&GTW;0 F*<O2DVTM Q:***!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*6@ HHHH ***;0 ZBFK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'-.I%!112 T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#>U $QI-M.HH ;NI0:;@TY: %HHHH *;MIU% " 4M%% !1110 4444 %%%%
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M#WPZ8UC.VO<]!M?(C7CM3D989RD]3<HHHK$]8**** "BBB@ HHHH *3K2T4
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M7R6*PTJ,C](P&/AB8+4Z&DQ0#D9%+7G'LA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K/UQMMB]:%9?B'_D'M0!\P?&*\*K/SZU\;
M^.+XO?.,]Z^M?C1(=L_XU\:>,I#_ &B_UH V?!.F_;[Q 1GFOL'X0^ UDCB;
MR_3M7RU\)XU>\BW>M??WP8M8?L<1P,XH [72?#"6-NOR8P*YGQQ?+9V<@SC
M->F3,%B<GH!7@?Q=UL6\4P#8ZT ?./Q;USS))AN]:^7_ !-FXNF[\UZS\2->
M\ZZE&[O7E<D9N[CUYH&=3\,M+,MY%D=Q7W9\%?#J^7 2GI7R3\*-%+7$)V]Q
M7W9\']/$,,.1V% CU2ULXX(0NT5Q7Q!TI);>3Y>U=]7+>-BOV5L^E 'Q!\8-
M!59)CM]:^=;JW^SWQQQS7U?\8FC_ 'W/K7RWK6/MS8]: /4/A5>%;B(9[BOL
MSX:W1>&+FOB?X7*?M,7UK[-^&"GR8OPH*/<;8Y@3Z5+4-K_Q[I]*FH)"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#F_$O^K:O/I/^/G\:]!\2_ZMJ\^D_P"/G\: .Y\+_=6NLKD_"_W5
MKK* "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 )MI:** "BF[J-U #J
M*0'-+0 4A 88/2EHH RM0T=+H'Y<URFI>!8[K/[O]*] HH \AN/A7'*<^5^E
M5?\ A4D?_/(?E7M%% 'S_P"(/A:D,#$1=O2O!/B#X3-D9,)BON[5;-+JU<,N
M3BOG7XI>&1(LI5*3*6Q\5:M;M!=$8Q@UU'@W539S)EL<U:\7^'6@N'.S'-<B
M+AK&7TYKIIR>Q\QF.$O[Z/L#X9^,%VQKO_6OHCPWJ@O8DYSQ7P+\.?%;1W$8
MW]QWKZ^^&.O+<PQ9;MZU=2.ESFRW$/FY&>N44U&#J"*=7(?7!3<FG4W;0 JT
M-0*#2 3)IU-VTZF 4444 (U)DTI&:3;0 ZBBB@ KE/%UT(X9/I755R/BRS::
M)\#M6]&W.KG+B6_9NQ\X?$C4SF05\[>)[@R3/SWKZ)^).CR?O#@U\Y^*+.2*
M9\@]:_2<LY>56/PK/>?G=SFE!+FK2J>*JPJP8Y%75-?0L^-BAU-9<TZBH-"!
ME*U/8WC6\@P<5')]VJR*[2<"JM=:D\SB[H]3\(^+)+:2,!Z^B_A]XODN%C!?
M-?*/A?39IIDP#UKZ/^&>CS)Y9(/:OE<SIT[-GZ!D->LY)+8^EO#]T;B$$^E;
M%8?AF$Q6ZY]*W*_/:GQ.Q^U4K\BN(U-IWWJ3;4&HE/INVG4@"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]7 87ZU-(U/ G@/<T9,?Z5]!^$/"JV<2'9C\*;X*\)I'%&=GI7I-KIZ6\8
M'-?G>-QKJR:/VO*<JC0@I6%L8?)CQBK5(!MZ45XCU/KTK*P+2TF:6D,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6U>?2?\ 'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTG_'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "4FZE;I3: '4M(O2B@!:YOQ1I*W<
M+<9XKHZCGA$R$&@#Y5^)'@_=YA"5\X>*M'-C,YVXP:^]/'7AQ9K=SMKY0^)W
MAWR7E(6F@DE*)XSI6K-:WBC..:^B?A7XF.Z(%_3O7S-=V[V]\>,<UZ3\/]>-
MG-'EL<UV1=U8^/Q%%TZO.???@_55N+-?F[5U2MN&:\&^''BP311KO].]>VZ7
M<BYMPP.>*YI1L?086NJD4B[11169Z 4444 -VTH&*,TM !1110 4444 (31N
MI&I* 'T444 %9NH:6ERI^7-:5%--IW1,HJ2LS@-3\'QS;ODS7G?C+P"HA<B/
MMZ5] -&K=16-XATB.ZM6PO:O0H8N4)(\;%9=3JP>A\)>-/#1LI'(7&#7(Z3?
M/9W@&<8-?2'Q-\*@"4A/TKYSUJR:QO3QCFOO\'66(IV9^,YGA982M='T+\+?
M$)9H@7]*^F/#]X+BS3G/%?#WPWU[[/<1@MCFOJ_P+KHGMHQN[5\KFN&Y971^
MA<.XY3@HMGI%%1PR"2,$5)7S)]^(128IU% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 )CFD9@HR3BEKG/$>O)8Q,=V,"@"]J/B*"P4DD5QVJ_$R&$
MD"11^->2?$7XG"S$@$N/QKY_\0_&%_/8";OZT#/LNU^(T=S)@2#\Z[/0M?%X
M!SG-?"7@SXG-=W2@RYY]:^I?AEKWVZ.([LYQ0(]K!R,TM,A.Z-3[4^@!K?=-
M8>K7BPQDDULW+;(B:\S\<:\+.WD^;'% &=KGBN*UD.6'YU7TGXC01S*/,'7U
MKYW^(WQ&-K/)B3'XUY;%\8GAO /.[^M S]']&\96NH1J"P)]<UT$-PDXRAS7
MQ+\._B\9VC#39_&OI3P5XVCOHTS(#GWH$>ET5#;W*7"!E-34 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %-W4ZFT *#2TBTM !3=M.HH 0<4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?
M\?/XUZ#XE_U;5Y])_P ?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,I<FEH 1:=24M !574I/+M'/M5J
ML[7FVV#_ $H \"^*VN&&*8;O6OC?XC:X9[J0;N]?3GQDO"JS\^M?&WC:\W7[
MC/>@9CVNG_VA=#C/->Y_#'P']H:(F//X5YCX#L1=W4>1GFOLCX1>%U\F%ME
M'<?#SX>QPQQDQC\J]CTW1HK*)0!@XJ#P_IJVD"_+CBMJ@0@&!BEHHH 1E##!
MJE=:5%=+AA5ZB@#@?$7@6&ZB;]V#^%?.WQ0^'"1K*1%^E?8LB"12#7E_Q)T%
M9H93MH&C\V/'WA@V<TGRXYKEO#I-I>+VYKZ%^+7AU8Y)2%KP9K;[->>G-(1]
M+_!_73&T(W>E?7O@G5/M%O'SVKX1^%=\4N(AGN*^R?AO>>9#%SVIC/98SE :
M=45N<PJ?:I:!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4456NKZ.U^\: +-%8,OBRVC."P_.GP>)K><X5A0!MT57M[Q;@ @U8H
M **** "BBB@ HHIK,$&30 ZBJ%QK$%OG<?UK.F\96D).67\Z .@HKF%\=6;-
MC<OYU>M_$UK<8PP_.@#9HJ"&ZCF *FIZ "BBB@ HHHH **** "BBB@ HHHH
M**** .;\2_ZMJ\^D_P"/G\:]!\2_ZMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJQYD+12-169N+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !67XAYT]ZU*S];7=8N*
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M//K7K7PMU&62:++'K0!]U>#]6-]&ASFNTKROX8R%X8L^U>J4 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6U>?2?\ 'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 0W,0FC(->>^-_#BSV\AVUZ16;K5F+FU88H ^)?B5X;\AY2$KPN\5[2^[
MC!K[,^)GA7SEE(2OF#Q?X=-K=.=O>J6AE6I^T1U'PU\0-#-$"V.17UM\/?$0
MFMXP6[5\)>']2_L^Y49Q@U]&?#/QAN\I=]:[H\3^!.Q]7V]P)E!!J8]*YKPI
MJ/VR%#G.1735@>Y3ES1N-6G44E!H&12TW::44 +1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#*!^-8W_  MJ/./.'YT ?0O]H0?WQ2_;(B.&S7SZGQ7C+#]\/SKIM#\?)>D
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MK_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4
M6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V
M@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\
M:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6*
M*K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4
M 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'
MV@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]
MH%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8H
MJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@
M4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%
M'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO
M]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8
MHJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!
M0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H
M%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJ
MO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!
M8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:
M!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@
M4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ
M_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0
M!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?
M:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V
M@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BB
MJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H%
M%BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4
M?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_
MV@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %B
MBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H%
M %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1
M]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_
M &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %
MBBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H
M% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!
M1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K
M_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6
M**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]
MH% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:
M!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**
MK_:!1]H% %BBJ_V@4?:!0!8HJO\ :!1]H% %BBJ_V@4?:!0!8HJO]H%'V@4
M6**K_:!1]H% %BBJ_P!H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO]H%'V
M@4 6**K_ &@4?:!0!8HJO]H%'V@4 6**K_:!1]H% %BBJ_V@4?:!0!8HJO\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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MUH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z
M+/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M(^M5OLCT?9'H L_VD?6C^TCZU6^R
M/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\ :1]:/[2/K5;[(]'V1Z +/]I'UH_M
M(^M5OLCT?9'H L_VD?6C^TCZU6^R/1]D>@"S_:1]:/[2/K5;[(]'V1Z +/\
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M#K$$WW3^M6TF5^E>#^#_ !Y_:&S]YG/O7KNBW_VB-3G-,1OT4B]!2T %%%%
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MC["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*>E6J*
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M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
MJ_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6
MJ* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^
MPK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV
M%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@
M"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U
M:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C
M["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_
M85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J*
M *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK
M5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:
M/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K
M]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:H
MH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["
MM6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85
MH^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *
MOV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5J
MB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L
M*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A
M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
MJ_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6
MJ* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^
MPK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV
M%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@
M"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U
M:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C
M["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_
M85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J*
M *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK
M5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:
M/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K
M]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:H
MH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["
MM6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85
MH^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *
MOV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5J
MB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L
M*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A
M6C["M6J* *OV%:/L*U:HH J_85H^PK5JB@"K]A6C["M6J* *OV%:/L*U:HH
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MA&U,-N@([4".T3[HIU-3[H^E.H *:6IU-/6@ #4ZFCK3J "BBB@!":3=0U%
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M-DG&6A]K:/>"Z@!SGBM*N#\":PMQ;IENU=TKAAD5FT>A!W0ZBBBD6%%%)NH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!1U+3DOHR"N37F_BKX<1WRN?+SQZ5ZM37C61<,,B@
M#XV\=?",*LA6+]*^=_&/P_FL)G*QD8]J_2OQ%X9AOHVP@.?:O%/''PH2Z61A
M#Z]J!GP1#+<Z3<#[PP:]2\"_$J33V0-(1CWK9\=?":2U>1EBQ^%>1ZEHMUI,
MQP&&* 1]4:?\7UFM0IE[>M<5XX\9)J,3_/G/O7@L/B2ZM."["EN/%4LZ$,Y_
M.@;(_$$ZS7I(/>O1OA/C[9%]:\:N+\S7(YSS7L7PDRUU%]:!'W3\+) MG%]!
M7K"G<H->0?"_BSB^@KUR#_5B@"2BBB@04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?
M2?\ 'S^->@^)?]6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 )BC%&Z@&@!:2EHH *JWEJ+B,C':K5% '@OQ0\-
MB6.4A/6OE#QQH+VUTYVXYK[[\7:(MY _RYX-?,?Q.\'^696"?I5DO70\2\)W
MS65TN3CFOJ#X7>)UV1 O^M?*=_"^FW1QQ@UZ'\._%K031J7QSZTT<TH\K/NK
M1]26ZB4@YXK6KRKX?>(A>1Q@MFO4XVWQJ1W%2S>$KH=1114F@FVC%+2$T +1
M3=U.H ;DTJTFVE Q0 M(>E+2&@!N:<.E)MHSB@!U%(#2T ,D02+@UPOCS11-
M9N0O:N]K*\06PN+)@1VK:C-PFF<N)I*K3:9\._$W0S#<2D+CFO-=(O6L;X#.
M,&OI?XI>&_,\U@GKVKYKUS3WL;XG&.:_2L#55:ERL_",WPTL-7YT?1?PL\2;
MO*4O7TYX<O!=62\]J^%OAKK9M[B,%L<U]=> ->6:T0%NU?+YKA^65T?H/#F-
M52"BV>C4F*9#()$!%25\N??B8I:*2@8;12TW=2T +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
M;@C-5+O3(+N,JR#)JY10!Y5XS^'T-XKXC!_"OG/Q]\)SND*P_I7VY-;)<###
M-<IX@\%PWL;$(#GVH&?FMXH^'\UDSXC(_"O.]2TN:U+ J>*_03QQ\+$E60K%
M^E>"^*OA*^Y]L7Z4 ?+D,<ANE!!ZU[U\(K=O/AR*SU^$\RW6?*/7TKU[X<>
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MD(7')KB_#]\]G>*,D<U]'?$[PCGS6V>M?/>J:<=/O"<8YJD8R5SZ1^%'B?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"*XB$T9!KSWQMX;6XM7;;7H]4=6LUN
MK5QCG%!,E<^'?B5X<-K-(0OK7D]O?/8WP'3!KZP^*GACS%E(3U[5\N^*=(:S
MO&(7'-6C'R/:/AAXJ.Z)2_I7U/X,U-;JW7YNU?!'@;6FL[A 3CFOJ[X9^*A)
M#$"_:@I:'NE%5+&\%U&I!SQ5NH-@HI,TM !1110 A&:3;3J* "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;J;R8\T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_ (^?QKT'Q+_JVKSZ
M3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@
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M\X?#'Q1NCB&_M7O>AWGVF%3G-?G6,HNG-G[9E>*5>DC7HHIO\5><>X.HHHH
M**** "DI:* &4Y:*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *YWQE&9-/8#TKHJS=;M_M%J5]J /BCXR:;([38'K7S)J&GNFI$,.]?=_
MQ0\)B:&4[?6ODGQGH8L=0<[<8- '5?"?2XYIXLCN*^SOA[X;B-I&=@Z5\5_#
M'6$L[R,$XYK[5^&/B:WDM8E+CIZT >@PZ/%&H^45*=-B]!5F*9)E#(P84^@"
MC_9<7H*/[+B_NBKU% %'^RXO04HTN(=A5VB@"O'9I'T%3*H6G44 %%%% !28
MI:* $VBC;2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !4%X0(3FIZSM;F\FS8T >7_$.2+[/*#CI7Q]\3T3[1*5]:^B
MOB?XB\E)1N]:^4?'OB 332_-F@9S>DZT=/O@0V,&O=O ?Q6^PI&#-C\:^4M0
MUGRYB0>]+:^-I;7&'(H$?HGH?QOC6-<SC\ZW/^%X1,O^O'YU^==G\4KB)0/-
M;\ZT8_BS<?\ /9OSH&?H%_PNZ+'^O'YTG_"[HO\ GO\ K7P%_P +8N-O^M;\
MZ3_A;%Q_SV;\Z!'WS)\<(ES^_'YT^U^-44S@>>/SK\^;KXM7"Y_>M^=7?#OQ
M6N);E096Z^M 'Z4Z'X_34-N),Y]Z[6QU 7*@YS7QM\*_&DE]Y67)Z=Z^I/"-
M\;BW0DYX% ':4M-7[HIU !1110 4444 %)D4M,H =2TU:=0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!S?B7_5M7GTG_ !\_C7H/
MB7_5M7GTG_'S^- '<^%_NK765R?A?[JUUE !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 1S?ZEOI7B/Q4_U<OXU[?-_
MJF^E>(_%/_5S?C5Q,JCLCY*\<?\ 'U)]:X?^(UW'CC_CZD^M</\ Q&B1%.2E
ML(M25&M25!TL****!"9%#?=--IS=* *C?ZS\:[3P?_KD^M<7)_K*[+P>W[Y*
M").VY]-?#<_+'^%>_P#A[_4K]*^??AN?EB_"OH'P[_JE^E4S.$DWH;M%%%2;
MA29%%-H =2-2K2T -IU%% !2'GBEHH Y/Q1HXNH)/ESQ7S-\4_#/EF0A/TKZ
M^NK<31,,=J\3^*/A\212';7MY=B'"HD?*9W@U5I.21\:3;K"^].:]D^&'B8Q
MM&"_>O-O&FE&UNG(&.:7P7K!M;I!NQS7W5:FJ]&Y^186J\)B;'W3X.U@74,?
MS9XKN%.0#7@OPQU[SEB&[TKW.RF$T"'VK\WQ=/V=2Q^Z9=75:BF6****XCU!
M,BBFTJT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F4^DVT (M.I,4M !
M1110 4444 %8_B;/]GMCTK8JAK$/G6K"@#Y,^+<,K>;@'O7RSXNTZ>2>3@]:
M^[/'/@UM09\)G/M7C.M?"5IY&/D]_2@9\=7GAVXD8_*:K_\ ")3M_ :^KV^#
M3;O]1^E/3X-MC_4?I0%CY-'A&<?PFGKX5N!_"U?6!^#;?\\/TI/^%-M_SP_2
M@#Y37PO<8^ZU'_"+W']UJ^K1\&V_YX?I1_PIMO\ G@?RH"Q\C7GA>XP?E:K_
M (9\,W"W295NM?4<_P &&8']Q^E6-)^#C0S*?([^E 6$^#VD2PF'(/:OKWP3
M"8[>//I7E'@7P(;#R_W>,>U>X^']/^SPH,=*!'1Q_<'TIU(O"BEH **** "B
MBB@ I*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#F_$O^K:O/I/^/G\:]!\2_P"K:O/I/^/G\: .Y\+_ '5KK*Y/PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK4W3FT?O&%K*M231+1117,=H44E&13 6DW4M-;K0 H-+35IU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\C]*5?@P!_RP_2@9\=_\(;<_W&H_X0VY_N-7V-_PID?\\/TH_P"%,C_GA^E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4
M0R6L<G45 VDVS]4S5VB@"DND6R]$J5;*)>BU8HH JMI\+=5J,Z/;-U2KU% &
M?_8=I_SSI?[#M/\ GF*OT4 4/[$M/^>8H_L2T_YYBK]% &?_ &':?\\Z/[#M
M?[E:%% &?_8=H?\ EG2KHEHO2.K]% %:/3X8_NKBIUC5>@IU% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7U#X3UD7D*?-GBOB,RP[A4;/U?(L:JM%1.RHI!2UX)]B%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4F* $&:=110 4444
M %%%% !24M% #**4BC;0,=1110(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\2_P"K:O/I/^/G\:]!
M\2_ZMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %)2U!=2>7&30!#J%\EK;LV><5XG\1?'@LDE DQCWK
MJO''B<6=M(-V*^2/BQXW:2291)Z]Z!F?XY^*S^;(!+^M>1ZQ\1)KASB0G\:Y
MW7+Z?4;EL$G)JM:^&;FZYVL: +LWBN>7DN?SJ[X;\02M?)ECU]:IOX3FACR5
M/Y4W2--:WODSQS0%SZZ^$VJ%[>,D]A78>./$36NGN0V.*\V^$K$6\8KJ/B%:
M2S::^T'I0.QX=XA^)DEKJ!'FD<^M>@_#3XIM-)&#+^M?-7Q!L[BWU"1OF'-6
M?A[KTMG=1AFQS02?IGX#\5"^CCR^<^]>FQ2"1 0>U?)'PA\7>8L(+^E?3GA_
M4A=6Z'.>* -^BD%+0 4444 %)2T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=>"U9V/L(OF5PHHHI%!3=M.HH 2EI":* %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!\*O*:-C%^E CI/A%X2,*0DIZ=J^E=$TX6UNG&.*Y7P9X573XH_DQ7H4:"-
MHH 6EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBDH 6BDW4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444E "T4FZB@!:*** .;\2_ZMJ\^D_X^?QKT'Q+_JVKSZ3_ (^?
MQH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2LV'7K:XQM.?QJ['.L@R*!$M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444FX>M !2TFX>M+0 4444 %%%% !1110 4444
M %%%)0 M%)N'K2T %%%% !1110 4444 %%%% !2-TI:* &4Y>E+10 4444 <
MWXE_U;5Y])_Q\_C7H/B7_5M7GTG_ !\_C0!W/A?[JUUE<GX7^ZM=90 4444
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M'>A:DH=1113 *93Z* &K3J** "F4^B@!JTZBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_"[QXXFB5I.X[U]?_#OQ(+NVBRV>*_./P;JSV-\@SCFOL+X0>)3)#""W84
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&?C"W>SC5G'(]:!'HT>DPQC&/TJ0Z?$>U/AO(;A04D4_C4OF)_>7\Z *O\
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MCZUF?97H^RO0!I_VM[T?VM[UF_97]*/LK^E S2_M;WH_M;WK-^ROZ4?97]*
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MS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH
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MLW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]*
M-+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-
M^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2
M_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?L
MK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[
M6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_
MI1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO
M>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4
M?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH
M_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V
M5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[
M6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?
MTH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO
M>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]*
M -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK
M-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#
M2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?
MLK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO
M[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*
M_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^U
MO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ
M4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;W
MH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'
MV5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/
M[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E
M?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^U
MO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]
M* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;W
MK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@
M#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS
M?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH T
MO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[
M*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^
MUO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^RO
MZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;
MWH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z/[6]ZS?LK^E
M'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]E?TH TO[6]Z
M/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK-^ROZ4?97]* -+^UO>C^UO>LW[*_I1]
ME?TH TO[6]Z/[6]ZS?LK^E'V5_2@#2_M;WH_M;WK,^ROZ4GV5Z U-/\ MCWI
M1K!/>LO[(]*MJ] &S'J>X]:OV]SYE8$%JX(K7LXRN* -5>E+34^[3J!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$9H 6LCQ+G[ V
M/2M>J&L0>?:L* /E+XL1RMYN,U\M^+=-GFG?@]:^Z/''@\WV_P"3.?:O&]9^
M%332L?*[^E ['Q_=>&9I7/R'\J:GA&7^X?RKZE?X0MN_U/Z4]?A$V/\ 4_I0
M%CY;7PO*O\)I_P#PC<W]TU]0'X0M_P \?TI/^%0-_P \?TH ^8/^$=F_NFC_
M (1V;^Z:^GO^%0-_SQ_2C_A4#?\ /']* /E>[\-S;3\IJ]X;\.S+=+\IZU]*
MS_!UF'^I_2K&D_"%H9@?)_2@"7X1:5)$8<@]J^M/!<)2WC^E>4^!O YL?+^3
M&/:O;M L?L\*C% CHX_N#Z4ZD7[HH:@!:*0=*6@ HHHH **** "BBB@ HHHH
M **** ,K6H?-B(KQ'XA^&WO(Y,+GK7OTT/F*16'J/AE+T$%<YH ^!?&GPQFN
MII"(R>?2N$7X13^83Y3?E7Z&WWPMANF),0/X50_X4Y;YSY(_*@#X.M?A+.)%
M_='\J]C^&7P]ELYHB8R,>U?2*?""!3_JA^5;.G> H=+&?+ Q[4 0>$X_[)LU
MW<8%9'CSQVEC:R#S,''K5CQ=K$>C6C@,!@5\I_%?XE8:9!+Z]Z *GQ*^)#7$
MTBK+W]:\EBO)=6O.23DUS&J>*#J-XV7SSZUU?@XQ-,C,10![%\.O"*W'ELZY
M_"OIKP-X=M[*-"5 _"O!?!NO6UA"GS 8KT*U^)T%F@ E _&@#Z'M+J&WC501
MTJ['>1R=#7SY:_%B*>0*)A^=>@^&?%:WRJ0^?QH ]$:=5&:@?4HH^IK"O]8$
M,!;=VKSOQ!\0([-V!DQ^- 'KZZM$W -323+)"^/2O!]+^)D<TX7S1U]:]-\/
MZ^NH0##9R*!GF7Q<T\S0RG%?%WQ%L3#>2''>OO[QYHYO+60[<YKX^^+'A=HY
M93LH \U\!Z@+6^3)QS7V=\(_%4<=O#EQT'>OA*WD;2[[)XP:]E\!_$06,<8,
MN/QH$?<6M>,(O[-;#C[M?)?QH\1I<--AO6K6I?%M9;4KYW;UKQ+QUXL.IR/A
M\Y]Z .19OM6J<<\U]#_!W323"<>E>"^%],>^OU.">:^M_A!X;:.. E>P[4 ?
M0'@:V\J!..U=O6#X=L_L\*<=JWJ "BBB@ HHHH **** "BBB@ HHHH YKQ-_
MJVKSJ9-UU^->B^)O]6U>?2#_ $K\: .Q\,68<+D5UGV%*Y[PJ?E6NJH IMIZ
MY/%)]@7TJ[29H I_V>OI1_9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=
MHH I?V>OI1_9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_
M9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:* *7]
MGKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:* *7]GKZ4?V>OI5V
MB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']
MGKZ5=HH I?V>OI1_9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V
M>OI1_9Z^E7:* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:
M* *7]GKZ4?V>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:* *7]GKZ4?V
M>OI5VB@"E_9Z^E']GKZ5=HH I?V>OI1_9Z^E7:* */\ 9Z^E']GKZ5>I* *?
M]GKZ4?V>OI5REH H?V>/2E&GCTJ]10!56R4#I2M8HW459HH X?QEX72[MG(7
M/'I7RG\5? NPRL(_TK[=O(1/"5(S7D?Q&\'K=V\I"=O2NFE4Y6?-YM@5B*;:
M1^>6I6+Z9?GC&#7J7PO\3?9[B)2V.1WJ/XF>#6M;B1@F.?2O/=&OGTF^49Q@
MUZ>DT?D<>? 8@_0;X>:['=6\8W=J]2MHDFC#5\?_  H\=8\I3)Z=Z^I_".MI
MJ%JHW9XKRZL.5G[%E>.6(II7-\VZTGV5:FI:YSWBM]B2C["GI5FB@"O]C6C[
M*/2K%% $'V<8Z4-:(W45/10!D7V@17*GY0:X#Q9X#CGC?$8_*O5JKW5JMRN"
M* /CCQM\-RK2,L?Z5XYK'AV739V.TC!K[Z\1>#8[N-SL!S[5X5X\^&_^L98_
M7M3 ^?\ 1]=>PD4%B,&O8O OC@*T89_UKR;Q'X5FL9F(0C!JAIFIS:9(,DC%
M(#[F\*>+(KR-!O!KLYM/AU2U/ .17QWX'^(C021AI/3O7T7X*^($5U#&K2 Y
M'K2NXNZ'**FK,Q?'7PY2X1V$?Z5\V>._ ;V4CD1XQ[5]UR20:K;=CFO)OB%X
M&6\CD*QY_"OILOS!P:C)GP.=9+&M%S@CXJA9]+N #D8->I^ O& BD0,_ZUC^
M./ \MG+(RQD?A7#V%S-I5T,DC!K[.4(8NF?F-.I5RVM9GV[X+\2QW,<8W5ZA
MI_EW40(P:^,/ ?CXP21JTGZU](>"_&R74<8+YX]:^'Q^!=)W2/UK*<WCB(J,
MF>D-8(U,_L]?2I;2\2ZC#*:L5X%K'V":DKHI?V>OI1_9Z^E7:*0RE_9Z^@H^
MP+Z5=I,T 4_[/7TH_L]?05=HI@4O[/7T%']GKZ5=HH%8I?V>OI1_9Z^E7:*0
MRB=/'I2?V>/2K]% %'[ OI2_V>OI5S-+0,I?V>OI1_9Z^E7:*!%+^SU]*/[/
M7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]
M?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]
M?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU
M]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10
M!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU
M]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7
MTH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M%+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7
MTJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?
M2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?
M2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]
M*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!
M2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]
M*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7T
MH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %
M+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7T
MJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2
MC^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4
MO[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2
MKM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*
M/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2
M_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*
MNT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH
M_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+
M^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ
M[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C
M^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O
M[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2K
MM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/
M[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_
ML]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*N
MT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_
ML]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^
MSU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[
M10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^
MSU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[
M/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM
M% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[
M/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L
M]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT
M4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L
M]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^S
MU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[1
M0!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^S
MU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/
M7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/
M7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]
M?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]
M?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU
M]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10
M!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU
M]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7
MTH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM%
M%+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7
MTJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?
M2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4
M4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?
M2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]
M*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!
M2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]
M*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7T
MH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %
M+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7T
MJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2
MC^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4
MO[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2
MKM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*
M/[/7TJ[10!2_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2
M_L]?2C^SU]*NT4 4O[/7TH_L]?2KM% %+^SU]*/[/7TJ[10!2_L]?2C^SU]*
MNT4 4O[/7TH_L]?2KM% %$Z>/2D_L\>E7Z* *7]GKZ4?V>OI5VB@"HMDJ]JF
M2$+4M% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
MQP": %HK.NM06#))Q6+=>*8X6QO_ %H ZNFR*&4@UR<'BR.1L;_UK4@UE)%S
MNH +W1X[C.1FLB;PC!(QR@K9EUB-!RPJE+XD@CZN*!F9_P (3;Y^X/RH_P"$
M*@_N#\JMGQ9;_P!]:4>*K?\ OK0!3_X0N#^X/RH_X0N#^X/RJ[_PE5O_ 'U_
M.C_A*K?^^M %+_A"X/[@_*C_ (0N#^X/RJY_PE5O_?6C_A*K?^^M %)O!-N?
MX!^5+#X+@0YV#\JMMXLM_P"^*='XJMV. XH LV>@QVY&% K8@@$8P*SK;6(I
M\885IQ3"0<4")A2GFDQ3J $I:** "BBB@ HHHH **** $I,FEI-M "K2T@I:
M "BBB@ HHI* %K-UR\%I9L>^*TJY_P 40M-"P'I0!\Z_%WQ))Y<RJ3WKXO\
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ME6VI0:Q;@$@YKB/''@F*^A=E0'.>U?3Y?F+@U&1\#G62QJQ<X(^+[:ZGTNZ
M)(P:]>\ ^/F@:-6D_6N?\<>!WLIG94[^E<#!>SZ3= <@ U]A.,,7"Z/S"G4J
MY;6L]C[M\%>-$NH4!?.?>O3+.\6ZC!!R:^)OA]X]>%HU:3'XU])>"?&"W4:9
M?]:^%Q^!=%MH_7,GS:&(@HR9ZA15>TNEN(P0<FK%>"?8)WU0E&T4M% PI":6
MFL*  -3J:!3J "BF[J44 +1124 +12;J6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC^^_6GK\8B?^6WZU\G7'BJ;S#\Y_.GQ^*IL??/YT!<^L/^%P'_GM^M'_  N
M_P#/;]:^4O\ A*YO[Y_.C_A*IO[Y_.@=SZL_X7"?^>WZT?\ "XC_ ,]OUKY3
M_P"$JF_OG\Z1O%4W]X_G0%SZGF^,A7_EM^M6-+^,!FF \[]:^1;KQ9,!]\_G
M5[PWXJF:Z7YSUH%<_0?P7XY^WE/GSGWKV30[[[1&IS7QI\)-:DF,62>U?6/@
MR8R6\?TH$=T.@I::GW1]*=0 4444 %%%% !1110 4444 %)FBFT /HI%I: "
MBBB@ HHHH *K7EN)Q@BK-)0!R>H>%X[ICE :Q9OA]!)_RR'Y5Z+L![4;%]*
M/,_^%;6__/(?E0?AO;_\\A^5>F;%]*-H]* /,O\ A6EM_P \E_*D_P"%9VW_
M #R7\J].VCTHV#TH \WM_AO;Q,"(E_*NDTOPW'9J % KI-H]*7:/2@#*N-*6
M:/:17.:AX(ANF),8/X5W%&T>E 'G=O\ #VWADR(QU]*Z;2="2QQA<5N[1Z4N
M!0 +PH%,FA69<,*DHH P[_PS!> Y4'\*YR]^'EO(Q_=C\J[^DH \UB^&MNKY
M\H?E6[I_@>WM\'RP/PKK=H]*6@"G:Z7#:@;5Z5; "BEII- #J*1:6@ HHHH
M93EI:* "BBB@ I,TM,H ?12+TI: .:\2_P"K:O/Y/^/G\:[_ ,2?ZMJ\_?\
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M3#;QC':N6\,^ AIY7]WC'M7I6EV'V>-1CM0!JI]T?2G4@Z4M !1110 4444
M%%%)NH 6BD!I: "DVBEHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3:*6B@!*6BB@ HHHH **** "BBB
M@ I-HI:* "BBB@#FO$H_=M7G\G_'U^->@^)?]6U>?2?\?/XT =SX7^ZM=97)
M^%_NK764 %)2TE #<TY:3;2B@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *3%+10 F!2T44 %%%% "-3<TXTFV@!,TZDVTZ@!&^Z?I7@?QGFVPS?
MC7O;_=;Z5\^_&K/DS_C6U+XCQLV_W=GQ9\0)\WDG/>N";YJ[3Q]_Q^2?6N,C
MKVX['X%BG>JR/RVIX##O4@HJCE2&;G]31N?UIU+0-C-[^M([/M/-24Q\[:0C
M.9G\X<UZ3\/9'^T1\]Z\Y/\ KA]:]&^'_P#Q\1_6HEL=.#_BH^OOA9(?+BY[
M5]#:"V85^E?.OPM_U<5?0_A\_NE^E>15W/W/*/X:-JBBBN<^D"BBB@ ILB"1
M2"*7'-+0!S6M>&4O8V^3->.>./ANLJR$1_I7T165JVDQWD9^4<T ?!_BSP+)
M92.50C'M7'6[3Z7/W&#7V5XT\ K<*Y$?Z5X%XQ\ O;,Y6/\ 2F!3\*^/7MF1
M6?'XU[#X?\51:E"JLP.17R]=6-QIMQT(P:ZCPQXNDL9%#.1CWI)N+NA2BJBL
MSW;Q)H,.I6[,H!)%>$^-/"+6LCLBXKUK0?&4=_$JL^:DU[28=4@) !R*^HR[
M,'!J,F?GV>9*JJ<X(^;].O)M+NN21@U[3\/_ !XT31JTGZUP7BSPN;61V5<<
MUS&G:C-IET!DC!KZ^I3ABZ=T?FM&K6RVK9GWGX/\7)=PQC?V]:]!MKE;B,,I
MKXW^'_CQHS&&D_6OHGP?XN2ZA3+_ *U\'C<%*E)M'[!E.:QQ$$FST6HVF1.K
M8JE)J\2P[MPZ5PWB+QHEFS8DQ^->73HRJ.R/HJV(A15VST5;F-NCBI P;H<U
MX[IWQ"268 R#KZUZ!HOB".ZC7YLUI4P\Z>YC1QM.L[)G1T4V.02+D4ZN0] *
M*;NH#4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKX7"Y% %O-+35IU ";J,TVE6@!U%)FC- "TRGTR@!5IU-6G4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXE_U;5Y])_P ?/XUZ
M#XE_U;5Y])_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2
MOG[XU?ZF?\:^@9/]6WTKY^^-7^IG^AK:C\1XN;?[NSXC\??\?TGUKBXZ[3Q]
M_P ?LGUKBXZ]Q;'X%B?XK'KUIU-7K3Z9@A**6DH *1_NFEI&'RF@10;_ %P^
MM>C?#_\ U\?UKSEO]</K7HWP_P#]?']:F>QT8/\ BH^N?A=_JXOI7T+X?_U2
M_2OGOX6_ZN+Z5]#:!_J5^E>-5W/W/*/X:-BBBBN<^D"BBDS2 6BBBF 4444
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M+&#)^M>WZ#X@2]C7YLYKX/$T'3EH?L.!Q:JP5SH2*0=:56##(I:X#V HHHH
M**** "BDS2T %%%% !1110 4444 %%%% !1110 4444 %%)2T %%%% !1110
M 4444 %)2TC4 &ZEIE.H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "H+Q?,MV%3TUEW+B@#R#QQX;-\LGRYS7@GBGX6FZDD/E9S[5]BWNE+<9R,
MUA77@^&8G*#\J /AVZ^"[,Q_<_I3(_@LP_Y8_I7VPW@&!O\ EF/RI%\ P#_E
MF/RH ^+!\%V_YX_I2_\ "EV_YX_I7VG_ ,('!_SS'Y4]/ %N?^68_*@H^*A\
M%V_YX_I3E^"Y_P">/Z5]L?\ "O[;_GFOY5%)X'MD_@6@#XP'P7/_ #Q_2E;X
M+G_GC^E?8<WA*UC_ (5JL?#5KG&U: /D%O@N?^>/Z4S_ (4PW_/']*^QXO"-
MM)T05;C\"V[?\LQ^5 'Q/<?!5F!_<?I5C1_@PT-PI\GOZ5]J?\(#;-_RS7\J
M?#X MT8$1K^5 'BWP_\  )T_R_W>,>U>]^'=/^SPH,8XJ2R\-QVN,*!^%;5O
M;"/&!0!97[HI:2EH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\L&7.?>@#Z2!#<BEK T'7DOHU^;.16]0(6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVK
MSZ3_ (^?QKT'Q+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI&6S+5)M%1+=Q-T:GK(K=#2+NAU+112&%%%% !113=M #J*;M- ZT .HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN65&4=SOAB*<]F;5%017D<@X85,&#=#FLCI33V%HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z4M% #*=2T4 %%%% !6+XHE\
MG3V/M6U7/^,?^0:WTH ^4OC!KCQB8;O6OE/7[UKS46!.<M7T;\9F.Z;\:^9K
M@C^U.?[U STSX9^%%U":,E,Y-?4OA/X<1?8T)C'3TKP[X,M&)(<XZBOKSPW-
M%_9RXQTH!'B?Q$\)PV=K)A ,#TKYD\06RPZF0!_%7U[\69A]GEQZ5\B^)#G5
M#_O4#9[1\%8_,:(?2OIEO#:WNE<KGY:^:O@A_K8OJ*^NM-D1=*&?[M CY*^,
M7@9(_.;9^E?+>L::-/OFP,8:ON+XS7$/ES<CO7QCXR96U!\>M '=_"G5&CN(
MAGN*^S/AOJ)FMXAGTKX>^%ZG[5%]17VA\+U/DP_A0(]RMSF%#[5)4-K_ ,>Z
M?2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#F_$O^K:O/I/\ CY_&O0?$O^K:O/I/^/G\: .Y\+_=
M6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH PX%-Q@ 5U7AGPR]U,AV9YK5\/^ YI)%S&:]M\"_#O;Y9:/T[4#'?#OP/\
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M"UZ$<?2GN>)4R;$4GH>A:?XXG7&9#^==5IOQ D7&9#^=>*K>>7T-6(]8:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% #6I*<1FC;0 M%%% !1110 C=*3=3J3;0(!2T44#"BBB@ HHHH **0FDW4
M&ZG4F!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR/6O+J4W%GZWEV90Q$4FST2BH+>Z6X4%34]<Y]"%%%% !29I::U "[J*;3Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M-W4ZF4 .%+2+10 FZDS1104A=U*#3:.:"1Q 88(R*YKQ)X<BU")OD!S72T%0
MW49IIV(G!5%9GRU\2OAF)%E98OTKY@\9>"YM-G<JA&#Z5^DWB+P_%J%NWR \
M5\_?$CX9K-'(RQ>O:N^C6Z,_/\XR933G!'QKI.M7&E70!)4 U[O\._B6T1B5
MI/UKS/QIX&ETZX=EC(Q[5R5CJL^D7 !+#!KLDE41\)1K5<OJ69^B7@;QU'>Q
M(#)G/O7J-E=I=1!E.37P1\.?B8\+1JTA'XU]0^ _'Z7D<8,F<^]>95I.)^I9
M7FT*\5&3/7Z*IV%\MY&"#FKE<Q]6FFKH****!B;J3=124 .W4M-'6G4 %%%%
M "$TF<T-10 ;:6EHH **** "BBB@ I-U+33UH 7=2TT=:=0 W;1MIU% " 8I
M:** "BBB@ HHHH **** &[:4#%+10 4A&:6B@!E. I:* $)HW4C44 .HHHH
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M10 4AI:* &[:6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTT;:6EJ#40#%(U.HH 93EI:* "D:EI",T )DTZF[33J "BBB@ HHI"P7J<4
M+15*YU*.'/S5GMKT:MC?0(W:*RK?6(Y/XJT8YDD'!H&24444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !12&EH ***:S!>2<4 .HJA<:I'%_%5!]?C4_?H WJ*R+?6HY#]ZM*&
MX25>#0!+2$9I:* $VTM%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]\P_\*(4445)T!112-TH -U&:;2KUH&*U-I]% @HHHH **** "BBB@ HHHH
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M7/[H_E7VI-X)@D_@6LJ\^'L+9_=C\J+L7+%[GQ1=?#>2/_ED?RK+N/!$L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O\ JVKSZ3_CY_&O0?$O
M^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+10 RES3J90 [
M=1NIM% #LBEIE/H ;2K2T4 (>E-I]% "4M%% !1110 4444 %%%% !28'I12
MT )M'I2;%/\ "/RIU% ##"AZH/RIC6<+=8UJ:B@"A-HMM,/N 5B:AX3@DSA!
M^5=52,H;K0!YG?>!XI,_NQ^5<QJ7PY23.(OTKV\VZ-U%1MI\+=5H ^;=0^%H
M;/[G]*YV^^%9YQ#^E?5SZ-;2=5_2JDWABVD_A'Y4[BL?'5]\*Y!G]T?RK#NO
MAI-'G$1_*OM"Y\%02 _(/RK'O/ ,+9_=C\J=P/C"Z\"W$6?W9_*L"_T"YM<_
M*PK[+U'X=Q-NQ&/RK@_$WPX5(V/E?I2$?)UXUS"2#NJB;B1CAB:]5\6>$A:L
M_P F*\YOK'R9#Q3!%)>>M/P*9]TD4]>E24+1129I#%HHHIB*EXO%7/#TQCN5
MY[U7N%W"IM-_=R@T ?2/PMU<IY0+>E?3_@^_6:W3+5\2^"=>%FT?S8KZ$\%^
M/$BC0&3]:15CZ"HKC=/\=031C+@FM6#Q1#-T84Q&[15&'5(YNA%7%<.,B@0Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)QUH 6BJ\MXD?4U1F
MUZ*'N* -:BN8N/&4,.?F%9EQ\0X8\_O!0!W)8+U.*R=9U1+>VD^;M7!ZC\3X
M54_O1^=<)XD^*2-&X$OZT 8GQ:U[>LH#5\L>*+UIKM^>]>H>-O%XU!I/FSFO
M(]3;SYF- %>V^;K5E0*AA7:!4U "M2444 %(RYI<T4 0;=O-6],OVAN%P<<U
M7;[IJO V+@?6@#Z6^$FK/)+$"WI7UOX5D\S34/L*^+O@](?M$7X5]F^#_P#D
M$I]!0!O4444 %%%% !1110 4444 %%%% !1110 444S)H ?12+2T %9FNS^1
M:%NG%:=8/BY]FG,?8T ?/_Q3\5-;QRC?CK7R/\0/$3WD\J[\\U[K\8]0*M,-
MWK7RWK4S7.H,,YYH&<U<:3+J$Q(!/-2KX+FVYV'\J]6\"^#?[4D7Y,Y]J]:;
MX3@6.[R>WI0(^2V\/O;G!4T^/16DXQ7L7BSP;]@D;Y,8]JP-)T97N0I7O0!Q
M$?@N:X&0A-13^ [B/)*-^5?4G@KX=QZE&G[L'/M76:M\%Q]E+"#MZ4 ?#5QX
M;D@X9372>#-'Q=ID=Z]4\=?#UM-=_P!UC'M7(:!:_8[]01C!H ^F/@[I("P\
M>E?5GA:S\NV3CM7S1\&YD(A&:^I_#Y7[*N/2@9K#H*6BB@0UJ6EHH ***2@!
M:91FEQ0 +3J3%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!S?B7_5M7GTG_ !\_C7H/B7_5M7GTG_'S^- '<^%_NK765R?A?[JU
MUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !3*?2;: $6G4F*6@ IDGW#3Z;)]PT <'XT_X]Y/H:
M^3?BVXS-^-?67C5<VTGTKY*^+B'=-Q7=1W/@\^^!GS+XBD'VI_K5.UD&*L>(
MHS]J;ZU3M8SMKUNA^-3;YV7?,%&\5%L-+Y9H16I)O%&\5'Y9HV&AAJ2;Q06!
MIGEG%)M-(-212,U=M+F2)@5-4882S@5U_A_PVU\5^7-#V-Z5.4Y6B2:;XFN;
M/;AB!7;Z!\2I[=U#2$?C53_A7,K0[A&>GI7.:IX6N=/<D*PQ6/NR/9B\1AM3
MZ+\(?%C=L#2_K7M/ACXG02*@,H_.O@&SU2[TUA\S#%=9H_Q-N+-E!E(_&L)T
M4]CW\'GTZ6DS]$M/\86EXH^89^M:T.I03?=:OB7PO\8G^0--^M>P^%OB>EQM
MS-^M<4J+B?<87.Z=>UV?02L&&0<TZN,T3QE!<*O[P'\:ZBWU."X4%7%8--'T
M5.M"HKIENBFK(K="#3JDV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHIM #J*1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQZZIRH-.J.W.Z%3[5)0(**** "DI:* &[:6EHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .;\2_P"K:O/I/^/G\:]!\2_Z
MMJ\^D_X^?QH [GPO]U:ZRN3\+_=6NLH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0TM% #=M**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HIK.%&2<55FU!(^XH N45A7'B%(<_,*R;OQI'#GYQ^
M= '9TUI%7JP%>:WGQ*CBS^\'YUS^H?%9%SB4?G0!Z]<:I%#GYA6/>>)(HL_.
M/SKQ'4OBP.<2_K7*ZE\52V<2_K0![Q?^-HX<_O/UKF[_ .)"QY_>_K7@.I?$
MAY<XDKFKWQM-,3AS0![_ *A\4PH/[W]:YK4/BL><2_K7ATVOW$_0FJYENI_[
MU 'JFH_$^1\XD/YUS-_\09ILX<_G7+PZ7=7&.&K2M?!MS<=4;\J *EYXJN+@
MGYC63-?75QW8UW=G\.9Y,9C/Y5T%C\+9&QF(_E0!Y!'I]U<-T:M.S\*W,V/E
M->YZ;\+=N,Q?I76:9\-43;F+]* /G^Q^']Q+C*&NFT_X8RMC,?Z5]#:;X!BC
MQF/]*Z:Q\&PH!\@_*@#YZT_X5N<9B_2NDL/A;MQF+]*]\M_#5O'C*BKT>DV\
M?1* /&],^'"QL,Q?I75VG@J..,#RQ^5=^MG$G1!4GEJ/X10!Y)XB\$(\+8C[
M>E>#>/O!1A+D1_I7V9>6*7$9!'->8^-O!JW<;X3- 'P=XBTR2VF8;>]<^@=6
MY%?1GC;X<MYCD1^O:O*M4\(O:,WR8_"@#CU)J09JY<::\3$;:KF%U;I0!"V:
MAD#-6C'9O*>E;6F^&I+K;\A- '/:58R33*,5[=\._"K3M&2F:J>%?AV\LB$Q
MG\J^@? /@<6JH2F/PH Z7P3X7%O#&=F*],LXO)A"U6TO3UM8%&.:OT +1110
M 4444 %%%% !1110 4444 %%-:D% #Z*** "BBB@ K(\20^=8L/:M>J]]#YT
M)6@#Y(^+WA\R+,=OK7R/XML6L;YSC&#7Z'_$;PO]JMY"$SQ7QU\4O!4D=Q*5
M3N:"CA/!?BDV-R@W8YKZG^&_BXWL,:[\_C7QO;:1/:WPX(YKZ.^#JR[H@<T"
M/:?%5B;[3V;&>*^3/B=IIL[R1MN,&OMY=)-UI?3/RU\U?&?P>^Z5@GK0(\9\
M%^*CIETOSXP:]TT?XL^39JOG8X]:^7K^RFTVZ8X(P:1?%$MNNW>1^- 'O/C?
MXE?;(7'FYX]:\1U+5OMUX3G.365?>()+P$;B:E\/Z?)?72\$Y- 'L?PKMV:X
MB(%?9/PUMV6WBR.PKYO^$7A5]T)*>E?6_@G2?LMO'QCB@L[VV_U*_2I:;&-L
M8%.H("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#F_$O^K:O/I/\ CY_&O0?$O^K:O/I/^/G\: .Y\+_=
M6NLKD_"_W5KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC%5I]#MYE(*C\JTJ*I2DMF9RIQENCB]8\#P3JQ"*?PKS+Q/\.4;?B+]*^@"
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M#3Z "BBB@ IK=:=24 (M.I*6@ HHHH ***:U #J*93Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MINL172CYQ^=:@(/(Y%9'J1DI*Z#FEHHH*"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U)3Z* "BBB@ HHHH
M**** "BBB@ HHILC;5)H BN[A8(&8GM7BWQ*\;#3XY,/C\:[[Q7K7V6UD&[%
M?)OQB\5,WG /Z]Z .'\??%1_.D42_K7DFK>/9+IC^\)_&N;\7ZI+<W;X8]:Q
M+*QGNF'4T =9!XME#9WG\ZZ31?B%+;2KF0CGUKC;;PO<LF=IJ*XT6YM6SAA0
M!]->#?BPRQJ#-^M=)K?Q0\VS;][V]:^4-+U:>Q8 L16I=^+)7A*[S^= &]X]
M\8O?2R 29_&O++Q)[YR>3FM8F34I^YR:[;PSX$DOMI\O.?:@#R4^'KACG#4^
M/39K<C.17TA'\*7-OGRNWI7(^(O +V2L?+QCVH X/0]<DTYU^;&*]Q^'/Q&:
M.6-?-[^M?/6N6<EC(1C&#6MX(U62*[0%L<T%(_27X;>+OM\<67SG'>O9K683
M0JV>U?'OP9UQBL +>E?57AV^\^U3GM0#-^BD%+02,S3EI-M*.* !J;3CS2;:
M '4444 %%%% !1110 4444 %%%% !1110 4E+10 U:5F"]3BFR2"-<FN8\0>
M)([&-CN H Z&34((OO.!5=M>LU.#**\&\6_%5;)G EQ^->:WWQR,<Q G[^M
M'V,NM6C])14\=Y#)]V0&OC[3/C>9&&9OUKT?PM\4EO&0&7/XT ?0 8-T.:.]
M<WX?\01WT:_-G-=(#N&1TH 6BBB@ HHHH *3.*6LC6M62RC/S8Q0!HO=Q1_>
M<"J[ZQ:1]917C_BOXD)8[P),?C7EVL?&SR78";]: /J[^WK,G'FBIH]4MY/N
MR U\:6_QT+3 >?\ K7<^&?BX+IE!FZ^] 'TTDJR?=.:?7 >&?%\=\J_/G/O7
M<VUPMQ&"#0!-1110 44AI-U #J*2EH **** "BBB@ HHHH YOQ+_ *MJ\^D_
MX^?QKT'Q+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 444TM0 ZBD!I: "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-+
M4 .HI :6@ HHHH **** "BBB@ HHI": %HIH:G4 %%-W4HH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI#0 M%-W4M "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N'K0 M%1M-&G5@*J7.K
M00J?F% %XL!U-,,R+U85RU_XHBBSAQ^=<SJ'CM(L_O/UH ]--W".KBHI-4MH
M^L@KQ+4/B8(\XE_6N:U#XK%<XE_6@#Z#NO$UM"#AQ^=8&H>-8(\_O!^=?.^H
M?%9VSB7]:Y?4OB9-)G$A_.@#Z'U+X@Q)G$@_.N3U+XE*N<2_K7@-]X\N)B?G
M/YUC7'B2YN/XFH ]KU+XG'G$OZUR^H?$R1LXE_6O+VN+JX;JU20Z7<W!'#4
M=9>?$&>3.)#^=8UWXLN9\_,U26?@^XN,?*:Z"Q^',TV,H?RH X>;4KJX[M4:
MVMU<'D-7K^G_  I=\9C_ $KI=.^$IXS%^E 'A%OX:N;@CY6K;T_P'--C*'\J
M^A-.^%87&8OTKI;#X;I%C]W^E '@&E_#5Y,9C/Y5U>F_"O=MS%^E>ZV/@N.'
M'[L?E6]:>'8X\?(/RH \5TWX3KQF+]*Z>Q^%<:X_=?I7K5OIL4(^Z*M*BKT
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MV^>'\*^QO!/_ !ZQ_2@#OE^Z*6FK]T4Z@ HHHH ***2@ W44VG+TH 6BDHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>#\Z .THK M_%$4V/F%:EOJ"3 <T 6Z*0'/-+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1124 &ZDZTE.6@!%%.HHH **** "BBB@ HHHH *:PIU% #0*=110 W::
M5:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?\ 'F]7*IZK_P >;T ?.7Q:/[N?\:^,OB$W^G/SWK[-^+7,<_XU\8_$)?\
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MU%-W#UI=P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]:
M%HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]: %HI-P]:-P]:
M%HINX#O1Y@]: '44FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M
M "T4F:6@ HHHH ***2@!:*3</6F^8@_B% #Z*C^T1CJXJ*34((^L@H LTUI
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MB_2NKTWX7Q@#,?Z5ZY;Z'%'CY16C!9QQXX% 'F]C\-8EQ^['Y5NVO@"&,#Y
M/PKM0 O3BEH YVW\(P0XX6K\.APQ= *TZ3- $,=FD?05, %Z49HW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** (+B7RU)KG=6U];4'+8K5UB;RHF/M7BGQ"\2-9QR$-C&:
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M&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT
M:G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H
M>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']
MH>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9
M>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;
M30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J
M?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[
MT?VA[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA
M[UE[31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[
M31M- &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M-
M &I_:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_
M:'O1_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1
M_:'O67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O
M67M-&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-
M&TT :G]H>]']H>]9>TT;30!J?VA[T?VA[UE[31M- &I_:'O1_:'O67M-&TT
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MC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC::
M-3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T
M/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^
MT/>LO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>L
MO::-IH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-
MIH U/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U
M/[0]Z/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]
MZ/[0]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0
M]ZR]IHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]
MIHVF@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]IHVF
M@#4_M#WH_M#WK+VFC:: -3^T/>C^T/>LO::-IH U/[0]Z/[0]ZR]II=K4 :?
M]H>]']H>]9A5J3:: -3^T/>C^T/>LO::558T :?]H5(FH>]9HB:H+B7R5/-
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M533MK4 :?]H>]*NH<]:RMK4JJV: -J.]W=ZMPS;JPX-U:EKF@#1%+35^[3J
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MK['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]J
M,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]J
M ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*]
MJ ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/*
M]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J/
M*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]J
M/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*]
MJ/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?*
M]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU?
M*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]JU
M?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]J
MU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C]
MJU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]C
M]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1]
MC]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M1
M]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?M
M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL?
MM1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH ROL
M?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH RO
ML?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH R
MOL?M1]C]JU?*]J/*]J ,K['[4?8_:M7RO:CRO:@#*^Q^U'V/VK5\KVH\KVH
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M/)% &3]C]J/L?M6MY(H\D4 9/V/VH^Q^U:WDBCR10!D_8_:C['[5K>2*/)%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M([M5_>#GWKNM+UJ*Z4?.#7.XM'TM+$0J_"S6HI%8,,@Y%+4G2%%%% !1110
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M110 4444 %%%)0 M%-W4M "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%(: %HINZG4 %%%% !1110 4444 %%(3BC=0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !113=U #J*04M !1110 4444 %%%% !1110 4444 %%%
M)GVH 6BDS[44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44FX>M)O7^\/SH =13?,7^\/SIOG1C^(4 245
M%]JC'\0IIO(A_$* )Z*I2:I$O\0JM)K4:_QB@#6HK$;7HQ_&/SJ%_$4:_P 8
MH Z&DR*Y>3Q-&O\ '^M0/XJ0?QC\Z .OW#UHW#U%<1)XOC7^,?G563QJB_\
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M+$?Q8;_GK^M68_BTW'[W]: /J'^V;?\ OC\Z3^VK?^\/SKYF'Q:/_/7]:/\
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MT]/$49_C% '0T5CQZY&W\8J7^V(_[U &G167_;$?]\?G1_;$?]\4 :E%9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM-^(D+8_>#\ZW[;QI;3?Q+0!TU%9$?B*WDZ$?G5R+4HI.AH MT4Q9%?H:?0
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M#V0?\LS^5 '%-XBN!CYFIG_"27&?O&NND^'\G_/,_E47_"OY<_ZL_E0!R_\
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M%"/_ )ZC\Z7_ (6A'_ST'YU\H?\ "8S_ -\_G1_PF4_]\_G0!]7_ /"T(_\
MGH/SH'Q0CS_K1^=?*'_"93_WS^=*OC*?/WS^= 'UI'\3HS_RU_6K*?$F(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG$O_ "T'YU5D\;QC_EH/SH ]'^T1_P!ZD^U1_P!ZO,7\<Q_\]/UJM+X]1?\
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MY?B8_/[W]:IS?$V3G]Z?SKRW[+<M_>H_LVY;LU ST2;XFR_\]3^=4Y/B9/\
M\]3^=</_ &+<R=C4B^&KEOX30(ZYOB3.?^6A_.H)/B).W_+0_G7/+X5N3_":
ME7PC<-_": -9_'UPW_+0_G43>.K@_P ;?G5>+P7.W\)_*K2^!9R/N'\J *LG
MC6Y;^-OSJK)XNNF_C:MI/ $[8^0_E5B/X<S,?N'\J .8/BFZ/\;5"WB6Z;^)
MJ[:/X:2G_EF?RJ5?AA*W_+,_E0!P']O7;?Q-3AJUTW=J]&A^%LO'[O\ 2KT/
MPKD_YY_I0!Y5_:%TW=J3[1=,>K5[!'\*7_YY_I5N+X4O_P \_P!* /$_]*;^
M]2>3=-_>KWB/X3MQ^[_2K,?PE/\ SR_2@#Y\-E=,.C4G]EW3=FKZ-C^$9_YY
M?I5R/X0_],OTH ^:%T2Z;^%JL1>';EL?*U?3,?PAQ_RR_2K4?PF"_P#++]*
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MHO11^5 'BL?PEC7_ )9?I4J_"F/_ )Y?I7LVU?[H_*C:OH/RH \@B^%L:_\
M++]*M1_#&,?\LOTKU;:/2B@#R]?AK'_SS'Y58C^',:_\LQ^5>DT4 >?1_#Z,
M8_=C\JG3P#%_SS'Y5W5% '%Q^!HU_P"68_*ENO!<?DM\@_*NSI* /GGQQX)&
MR0A/TKYW\:>&VM9'^7%?=GB+0TNX7^7/%?._Q*\'D>853U[4 ?)FH1F&0Y]:
MCAD%=-XJT"6"9L*>M<HUO)$W(Q0!:WBG;JJQAN]2\T 2^944D@'>FMFH)(I&
MZ"@"S"/,(%=;X7T5KB=/ESS6%X?TF6XF4;3UKWCX=^#6E:,E/TH [+X;^$MR
MQDIZ5[QI7A5%M5^05F>"_#:V<,9*XKOT4(H4=!0!@CPU'_=H/AJ/^[7044 <
M]_PC*?W12?\ ",1_W17144 <R_A.-OX!^50MX-C;^ ?E7644 <E_PAD?]P?E
M1_PAL?\ <'Y5UM% ')_\(;'_ '!^5-;P7&?X!^5==10!Q;>!HS_RS'Y4G_""
M1_\ /,?E7:T4 <3_ ,(''_SS'Y4?\(''_P \Q^5=M10!P[> H]O^K'Y5"_P_
MC/\ RS'Y5WU% 'G3?#R,_P#+,?E3?^%=1_\ //\ 2O1Z* /.5^'<>?\ 5_I2
M_P#"NX_^>?Z5Z+10!YLWPZC_ .>8_*JLOPUC/_++]*]3I* /)F^&<?\ SR'Y
M4J_#./\ YY?I7K&T>E&T>E 'E7_"L8_^>0_*D?X8Q_\ /+]*]6Q[48'I0!Y#
M)\+XSG]U^E0M\*X_^>7Z5[)M'I1M'H/RH \8_P"%51_\\OTI/^%51_\ /+]*
M]GVK_='Y4;5_NC\J /%S\*X_^>0_*FM\*8S_ ,LOTKVKRU_NC\J/+7^Z/RH
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MEINVG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%)2T %%%% !1110 4444 %-:-6X*@_A3J* ,Z]T
M6WNE.4&?I7!^)/ <-RK8C!_"O3:CDA23[PS5*31S5</"LK-'RWXI^$PFWE8O
MTKR/Q'\(I(V8K$?RK[TN-$MKA2"E<UK'@.VN$)$:G\*Z85FCYG%9#3JJZ/SK
MUKP+<V+'",*YUEN]-;^(8K[D\6?"V*7?B(?E7C/BOX3LI?;#^E=L:JEN?#8O
M):E!W@>/Z'XVN;&10788]Z]1\+_%QX=@,N/QKSS6OA_<6;,1&P_"N6GL[O3Y
M.C#%:.,9'EPQ&)PC/L?PW\9 P4&7]:]+T/XDQW@7]Z#^-?GQI_BNYL7 +L*]
M$\+_ !0DMV0-*?SKGGA^Q]-@^()*T9L^_-+U^.\5?G'YUMJP=00<BOD[PG\7
M5^0--^M>LZ#\4(9U4>:/SKAE3:/N<+FE*LE=GK5%<S8^,(;I5^936[:WR7(&
M"*RLSV8U(S^%EFBBBD:!1110 AI-IIU% ""EHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?WGZU3N/B:?^>GZT ?2<GCA%_C_6J[>/4'_+3]:^9)OB4S?\M/UJLWQ%=O\
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MF?RJ6/X<S-C]V?RH Y-?$%RW=J>VKW+=VKM8/AO+_P \S^57H_AO)_SS/Y4
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M'2N[K(T:S^S1J,8K7H **** "DW4M-;K0 NZEIJ]:=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDQ_I7TAX.T$6L*97'%5/#?@]+-5.S'X5V]I;BWCP!B@"5(P@XI]%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $)I U#4#K0 ZF[J=3* '"EI%I: "BBB@ HHHH **** "BBB@ I#2TC4
M )NI:;3J %HHHH **** "BBB@!"<4FZE:FT /HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "D-+10 W;3J** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "F[J=3: %!I::M.H **** "BBB@ HHHH ;NI0:2
ME6@!:*** "BBB@ HHHH *;MIU% ""EHHH **** "BBB@ I*6DH 3=2BFTY:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+CCTJ#PKX)2TC4^6!^%>A6-DMK&!C% $]O"(8P!4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGM7R/\(],FB,.0>U?6/@N$K;QY]*!'=)]T4ZFI]T4Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ
M+_JVKSZ3_CY_&O0?$O\ JVKSZ3_CY_&@#N?"_P!U:ZRN3\+_ '5KK* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2@G%)G- "
MTM-P:=0 5!=6J7$9##)J7FE% MSC=6\'QWF[Y <^U<!KWPK2XW?NOTKW*F/"
MDGWE!_"M%4://K8&E6W1\@>*/@WPY6+]*\>\3_"V:U9RL9_*OT)U7P_!=1G"
M#\J\Y\1_#N*[WXB_2NF%9]3Y/'9#"2O%'Y]W_ANZT^0X5ABG66L7>G,,EABO
MJGQ-\(/,WD0_I7E'B3X4RV^XK$1^%=D:BD?$5LJKX=WB86@_$J>T909"/QKT
M[PW\8&R@,Q_.O"M6\)W6GL<*PQ6-'=7FGR=6&*MTXR,:>/Q&%=F?<WAOXI)<
M;<R_K7J6@>,H+A5S(#^-?G?H/CZYLW4%R/QKU3PS\7GAV!I?UKDG0['U^ S]
M:*;/N>WU&"X4%7'YU9# ]"#7S/X;^+PE" R_K7IFA_$".\V_O <^]<<J;1]I
M0S*C66C/3:*R]-UB*Z0?.*TPP;D'(K(]6,E)70<TM%%!04444 (U)DTII-IH
M 7;2=*=33UH 4&EIJTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJUY9I<H05YJQ2T[V$TGHSB]6\'I=;OD'Y5P6O?"]9PV(OTKW&HY+>.3[R@UV
M4\5.GLSS*^7T:RU1\C^)/A*5#D1?I7EGB#X=S6K,0A_*OO#5O#L-RK80<^U>
M>>(/A['<[L1_I7T&%S:2TD?&8_AV$KN"/B.XTFYL9. PQ5RQURYL6'S,,5]!
M>(?A23N(B_2O-=?^',MN6Q&1^%?24\;2K*S/A,1E>(PKO$KZ+\1IK7;F0C\:
M]&\._%8[D!E_6O!]2\/W-BQPK"J%OJ%U8R<EABJJ8.E65T10S/$85VD?:WAW
MXB)<;<R9_&O2='\30W"+EP<^]?!N@^/)[5E!<C\:]1\._%9HP@,OZU\YBLI>
M\3[G+^(HNRFSZ_BNHIA\KBI=P/>O!]!^*"S;09/UKO\ 1_&4=UM^?]:^<J82
MI3W/MJ&94:ZT9W5%5+._CN(P0PJW7'L>JFI*Z"BBBD,*:33J:10  TZF@4Z@
M HHHH **** "BBB@ HHHH **** "BBB@ HHI&Z4 +5:ZM%N$((YJ:GT </K?
M@]+P-\GZ5P^I?"Y)G)\K]*]OP#U%,:"-NJ"@#YWF^$:EO]5^E.M_A&JD?NOT
MKZ#-E"?X!0MG"O1!0!X[I7PQ2!@?+_2NZT7PJEF%^3]*ZQ847HH%.H BM[=8
M$  J:BB@ II-.II%  M.IJBG4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A
M:DS0 NVBBEH **0FC=0 M%%% !1110 4444 %)BEHH 3%&<=:*P?$&NQV,+'
M=CBJC%R=D1.:IKFD+X@UV.QA;YL$"O!_B!\0A&LBB3]:=\0/B$(Q(HD_6OG3
MQAXN>\D?Y\_C7U>79>Y-2DC\ZSO.E!.,&/\ %'C1[J9_G[^M<Y9^*)(;@'>>
MOK7,W5T\TA)-5MSA@:^ZAAX1C8_)ZF/J2GS7/HWP#X]*M&#)Z=Z^C?!?C!+B
M- 7S^-?!/A_69+.13NQS7MO@/QZT+1J9/UKYG,<O4KN*/O\ )<Z<6HS9]I6=
M\EP@(-6Z\H\'>,DND0%_UKTRQO4N8P0:^%JTI4W9GZQ0KQKQYHENBBBL#I"B
MBB@!K4E.(S2;: '4444 %%%% !1110 4444 %%%% !1110 5SOC.0QZ<Q'I7
M15S_ (PB,NGL/:@#XS^,NI.K3<^M?+NM737-XZDYYKZK^,6BM(9CCUKYCU+3
M3%J1R/XJ )_#?A5M2D3Y<Y]J]B\-?"%KB-3Y7Z54^%.DQW$\08#J*^R?A_X,
MMYK2-BB]* /G*W^#!4#]S^E3_P#"F?\ IA^E?8*^$;)?X?TIW_")V7]W]* /
MCO\ X4S_ -,?TH_X4S_TQ_2OL/\ X1&R_N_I1_PB-E_=_2@#XVF^"V[_ )8?
MI4^E_!KR9@?)_2OL+_A$;+^[^E*OA*R4Y"_I0!XMX,\!_P!GE/W>,>U>QZ%8
M?9HP,8K1AT6W@^Z/TJY'"L?2@!Z]!2T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?\
M?/XUZ#XE_P!6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJSUJBN=L?&%M= ?,N?K6O!J44^-I_6L;,]F-2$]F6Z*16#<BEI&H4RGTTB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._6@#ZQ2^AD^Z^:F616Z&O$O"OCP7^S]YG\:]3T?4/M$:G.>* -RBD7H*6@
MHIN32K0 M%%% !3:=3* %6G4U:=0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!S?B7_5M7GTG_'S^->@^)?\ 5M7GTG_'S^- '<^%
M_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !33UIU,/6@ R:4=:!S2[: %HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFE6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBDS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBDS0 M%%% !1110 F:!2T4 %%5KB\2 <FL>\\516V<L*N
M,)2V,IU(P^)G0=.M4+[5([93\PKAM6^)$4*M^\Q^->?>(OBHFUL2_K7=2P52
MH]CR,1FM"BMST_5O&D=J&^?'XUQ6L?%-(=P$OZUXEXC^)S2%L2G\Z\ZU;QM/
M=2'$A-?18?*+ZR1\1C.).5V@SV_Q!\6MVX"7]:\VU[XC2W&[#G\Z\_:\NKYN
MK'-7[+P[<WF,JQS7NT\'1H;GR-?-,3BW:(R\\1W%XQPQ-0VUG<WTG1CFNST;
MX=S3,"8R?PKTCPW\,L;2T7Z4ZN+I45H.AEN(Q+O(\MTGP'/>8S&3^%=EIOPC
M>903%^E>\>&_A[%&JYC'Y5Z#IOA&VMXQN0?E7SE?.))VB?:8/AJ,E>9\CZI\
M)VMXB?*_2O,O$_A-[%F^3&/:OO[7/"-O<6[%$!X]*\'^(?P_!$A6/]*Z,%FC
MG*TCDS7A]4X7IH^/KJ%H7(Q5(R-NQBO2?$WA%[>9_D[^E<Y;^&9);@#8>M?9
M0KPE&Y^9SP=2,^6Q!H>DO?.HVYS7LO@7X?M.T9,?Z5%X \"-))&3'^E?2W@7
MP7'!&A* ?A7S68YAR)J)]]DN2NHU*:*_@OP.MJD9,>/PKU/3M-CM8P M2VFG
MQVL8 %6J^$K5I57=GZUA\/'#QY4A*6BBN<ZPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J6J0^=;E<5=IDB[UQ0!XWXN\(B^W_ "9S7EFJ?"WS
MI&/E?I7U-<Z2L_45GR>%XV.=@_*@9\I-\']S?ZG]*E'P=./]3^E?4W_"-V\?
M+**AN-/LX5.0HH&?+K?"';_RQ_2H_P#A5('_ "R_2OHG4/L4>?NUB275F'ZK
M0!XFOPE#?\LOTI__  IW=_RQ_2O=K&:S=ARM=%9V]E(H^[0(^8+CX,G'^I_2
MGZ;\(O)F!\G]*^JO[#M9APJFD3PG%G(0?E0!Y9X-\$BQV?)C'M7KVBV/V>-1
MBI;70TM\87%:<4(CH$2#H*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_ (^?QKT'
MQ+_JVKSZ3_CY_&@#N?"_W5KK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\C\=?$9;??MD_6O&-:^+3QR,!+^M;QHN1XF*SN%"5KGUT?B);_\ /0?G2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBFT .HIJTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ J"YNX[6,L[8HO+@6\)8G%>3>/?'2Z?%(/,Q@>M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ+_JVKSZ3_CY_&O0?$O\
MJVKSZ3_CY_&@#N?"_P!U:ZRN3\+_ '5KK* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D-+10!&5IPS3J* "BBB@ IDD22+AE!I])S0!
MSVL>'(;I3\@.?:O._$'PUCO-V(@<^U>RXIK0HW50?PJXS<3BK82G6^)'R9XF
M^#._>1#^E>4>)/A-+:[]L6/PK[_NM'MKI2&C /TKAO$O@."X5\1C\JZ85VMS
MYC&9#3FFXH_/'5?"-U8R-A6&*S8;J[T^0<L,5]A>*?A6LF_;%^E>2^)/A/)&
MSE8OTKMC64MSX3$Y/5H.\#C_  W\1KC3]N9",>]=K_PN&1K?:9CT]:\RUOP7
M=6!;",,5Q]]'=VI(.ZKY(R.)8S$X9<K/1?%'CR34-V)"?QKS35-4FF=CN/YU
M3DO)2<,34+2>9UK2*2/(KXF=9W;*[7<V[[QJ1;V8?Q&C8*7:*U..S[B?;)O[
MQH^V3?WC^=.VBC:*D->XW[9-_>/YTHO)O[QI=HI54>E :]RK<7DW]XU;T6]F
M\Y?F/6JUPHXXJUI"CSA]:?04;\RU/=OAI>2&2+)/6OK7X<S%XH^:^1?AN/WD
M7X5];_#?_4QUYE?<_5,AOH>Q6_\ J5^E25';_P"I3Z5)7G'Z6M@HHHH&(1FD
MVTZB@ INZG4V@!0:#2#BES0 FVEI:* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3=1NH 6BDS2T %1RP),N
M&4&I** .9UCPW%<J?D'Y5P&N?#=+HMB+/X5[)33"C=5%=5/$3I['G5\#2K_$
MCY6\1?"/.\B']*\Q\0?#66UWD1D?A7W5>:+;W2G*#-<)XD\#17 ?$8_*O>PV
M;3B[2/D,?P[3DFX(^%K[P_<V+GY2,5!:ZE=6,G5ABOIKQ)\,@^XK%^E>8:[\
M-98BQ6(_E7TU+'4ZJ]X^!Q&45\,[P,/1?B%/9E<R$?C7I/AWXM,NT&7]:\5U
M;PO<V;'"$8K%6YNK&3^(5K+"4:ZNCFI9EBL)*S/M#0/B<+G:#+^M>A:-XLCN
M0OS_ *U\)Z#XTGM67<YKT_PW\4&CV@R?K7@8K*K:Q1]K@.(D[*;/LFUOH[A
M0PS5BO /#_Q25E4&7]:] T?QU'= ?O,_C7S57!U*;V/NL/F=&NM&>@45FZ?J
MR78'S9S6B6 &2>*X6FM&>M&2DKH"0HR>E<]KFO)9AOFQBG:]KR6<+_-CBO#?
M'7CP1LX$E>AA<+*M(\C'X^&%@]=3T5O'2++CS/UKH=(\31W6/GS^-?(-S\1&
M6X/[SOZUW/@WXB^8R R?K7L5LL<8W2/EL+GT9U.5L^J[>X69<@U-7!^$_$Z7
MB)\^:[B&43*&!S7S=2FZ;LS[JC6C6CS(DHHI*R.@6BBB@ HHHH *;NIU-VF@
M!10:%H:D FZG4RGTP"BDW49H 6BBB@ INVG44 (!2T44 %%%% !1129H 6BD
MW4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **;NI0<T +1110 FVBEI-U "T4F:6@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML.K%71X MW=P=VJQ#X@N8<?,U>L:A\,V&<1?I7/7GPYD3.(_TK:.*HSW.>6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT %%%% !1110 4444 %%%% !3*?2;: !:6DI: "BBB@ HHHH **** "BBB@
MHHHH 2FT^F[: %6EI!Q0U "T4W)IU !13<FE% "T4TTE Q]%(*6@04C4C4=:
M $IU)MIU !1110 44AI,F@!U%%-:@!U%-!IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-R: '
M44BTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4RGTW;0
M+3J0#%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E#
M4F30 E.6DVTHXH 6BBB@ IE/INV@!5I:0<4M !1110 44W)I5H 6BBB@ HHH
MH **:U&30 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD:DR: '4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?
M\?/XUZ#XE_U;5Y])_P ?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !3)(_,7%/HH R+K1TGSE:S)O"L,G\ KJJ2G=F,J,);HY ^#X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <WXE_P!6U>?2?\?/XUZ#XE_U;5Y]
M)_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (>E"TM% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%-H6@!U%%% "8I:;DTJT +1110 4444
M %036B3=14]% MS%NO#-O<9R%_*L+4/AW;7&?W:G\*[>BJ4FC"5"G/='BFO?
M":%E8B$?E7F'B3X1J-VV']*^M9H%F7##-8>H>&8[H'Y!^5:QJ-'D8G*J55:(
M^%/$'PM>-FVQ'\JX;4O!-Q:DX1A^%??&J?#F.XS^Z'Y5P^M_"-)-V(OTKMC7
M[GR&*X?>KBCXEDL[NQ;HPQ4MOXDN[-A\S#\:^C?$7P?V[L1?I7F.O_"V6$MB
M,_E6RJ1D?,ULNQ&'>A@Z7\2I[=E!E8?C7H7ASXM,I3=-^M>/ZEX+N;5VPC"L
MS[/>6+?Q#%4X19ST\9B,.]3[)\-?%B-@N9A^=>E:+\3()0O[T?G7P'I_BB[L
ML9=ACWKK]'^)D\&-TC?G7/*C<^EPN?RAI(^^['QM;7"C+J?QK8M]:@GQAA^=
M?%6@_%M@5!F_6O3?#OQ323;F7]:Y)46CZW#YW3JZ-GTK',DOW34E>9:#X_@F
M5<R#\Z[*R\46MPHRXK!Q:/H*6(IU%=,VZ*K1ZA!*,JXJ99$;HP-2=-Q]%)2T
M#"BBB@ HHHH ***9F@!]%(M+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44VA: '444
M4 %%,R:<M "T444 %%%% !1110 4A:EI-M !FEI,4M "-3:=1M% "TUJ=28H
M 1:6C%+0 RE6EQ2T"L%%%%(8E-I])M%, 7I2T44 )1N%%&T4 +1110 44C4@
M- #J*** "HVA5NHJ2B@"LUC&W:H7TB)^H%7Z*KF9#A%]#&D\-PR9R!563P?;
M2?PK^5='15>TDNIFZ-.6Z.1F\ VTG\*UFW'PW@;/[H?E7H%%:+$5%U,7@Z,M
MXGE5U\,86_Y9#\JR+KX61'/[H?E7M94'J*B>V1^PK>.,JQZG)/*\/+H?/M]\
M*X^<1#\JYK4/A>!G$7Z5].S:4DG\(K.N/#22?P5V4\QFGJSRJV1TI;(^3=0^
M&97.(OTKG[OX<R)G$9_*OL"X\%1R9^0?E67<?#V-\_NQ^5>A'-FMV>/4X<3V
M1\>7'@2:/.(S^59MQX1N(_X#7V#<?#-&_P"60_*LFZ^%B-G]U^E=U/-H]3RJ
MO#DNB/D=]!N8OX6J/['=0]F%?4=Y\)UY_=?I6)=_"@<_NOTKLCF=.6YY<\@K
MQV/G7SKN'^]2KK=W#_$U>W7GPI//[K]*P;[X6NN<1_I71'&T9;GGRRO%4]CS
M:/Q9=1]7:KT/CJXCQF0_G6W>_#>6/.(S6#>^!YX\X0UTJ="9RRIXNCW-:U^)
M$R8S*?SK;L?B<_&9?UKS:X\,7,9X5JKC2;J$]&%#PU"1*QN*@>YZ?\3SQF7]
M:Z;3_B<O&9?UKYJ1;J'^]5B/5+N'NU<L\OIRV.^EG5>GN?6%C\3HSC][^M;=
MK\2(6Q^]'YU\?P^)KJ,CYFK1M_&ES'U=OSKAGE,7L>Q1XCG'<^R+7XB0MC]Z
M/SK6M_'L#?\ +0?G7QG;_$&=/^6A_.M:U^)4J_\ +0_G7GU,G?0]BEQ,NI]C
M1^,[=\?.M6H_%%NW\2_G7R19_$]^,RG\ZW+/XG'C,OZUR2RJ43TZ?$4);L^I
M(]>MW_B'YU.NJ0MT:OG&S^)BG'[W]:W['XCHV,R_K7'++YQZ'IT\YI3ZGNBW
M<;=#4JN&Z&O)['Q]$^,R#\ZZ&S\;0-C]X/SKCEAIQZ'I4\?2GU.YHKGK?Q9;
MOC+C\ZNQ^(+63^,?G6#IR70[56IRV9J45375K9O^6E2+?0-T<5/*^QHI1>S+
M%)M%1BYB;HXIPF0_Q"D.X[;1C%)N'K2TABT444 %-;K3J2@!%I:*6@!E.7I1
MM%+3 ****0!124W- #Z*1:6@ HHHH **9FG+2 6BBBF 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -;K24[%&T4 (O6G4F*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK=:=2
M8H 1:=28I: "BBB@ HHHH **** "BDP?6C\: %HHHH ***3'O0 M%%(2!UH
M*AEO(X?O&JVH:DENAYKAM>\4"/=AJ .X;6X%."WZT^+5H9>A_6O#[KQ@_F\/
M6EH_BXF1=ST >TI()!D&GURNB^(4F5?FKI89UF7(- $M-:G4UJ $I]-'6G4
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M.]CDZ&IE8-7GOAWQ!]L"_-FNZLY"\8- %JBBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &[:4"EHH **** &[:4#%+10 A.*3
M=0U)0 ^BBDW4 +129I: "BBB@ HHHH *0TM(U #=WO2AJ:5IR]J '4444 %%
M%% !1110 4444 %%%)0 4M(!BEH *;NI=U)UH /O4;:%%.H **3=2;J '4A&
M:3=2[J $V^].I,BEH **** "BBB@ HHHH **** "BBB@!-H]!36A1NJBGT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444E "T54N+H1]351M85?XJ -:BL
M.;7D09W5EW'BQ8_X_P!: .PHKA4\:*S8W_K6UI_B!;G'S4 =!13(I!(H(J.Z
MF\F/- $]%<IJ/B86I/S5C2>.U1B-_P"M 'HE%><?\)\O_/2C_A/E_P">GZT
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M70C:JF5KU*W79"HH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_<'TI6Z4+]T4M "+TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .;\2_ZMJ\^D_X^?QKT'Q+_ *MJ\^D_
MX^?QH [GPO\ =6NLKD_"_P!U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1J #-+3*=0 M(U+36H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-W)Y<+-4U9^M2>78L: .
M\5>*A8!_GQBO,=0^*8AN"OG=_6HOBMK+6XFPV.M?+_B+QA+'J##S#U]: /LC
MPK\0O[0D4>9G\:]8TZ\^V6H)YXKXG^$WBAKBZB#/GGUKZZ\+ZG'_ &:I+=J
M*OBB&/#;@*\XOH+9I2#MK<^(GBR.SC?YZ\)U+XF)'>%?,[^M 'L6FZ#;W3#"
MJ>:Z[3_A_%/&"(@?PKRKP#XZBO)HP7[U](^%=0@NK-=K#=B@#D_^%:Q_\\OT
MH_X5I'_SQ_2O2Z* /-/^%:Q_\\?TI?\ A6J?\\OTKTJB@#S-OAG&W_+']*?#
M\-8XVSY/Z5Z310!R>G^$UM,83'X5T-M:>2H&*MT4 )2T44 %%%% !24M)0 F
M32BDVTHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI":-U "T444
M%%)NH!H 6BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U !DTZF4^@ HHH
MH **** "BBB@ HHHH YOQ+_JVKSZ3_CY_&O0?$O^K:O/I/\ CY_&@#N?"_W5
MKK*Y/PO]U:ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *2EHH 3;2T44 %)2T4 )M%+110 4444 %%%%
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M&7!K;CG2495@:RM8].,XR5T24444BPHHHH **** "BBB@ HHHH ;DTJTFVE
MQ0 M%%% !112;J %I&H!H- "9-.INVG4 -:@&E(I * '4444 %%%% !124;J
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!-M%+10 E&T4M% !1110 4444 %%%% !28S2T4 )MHVTM% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4FVEHH 3%+110 4FT4M% "4M%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4;:6B@!-M%+10
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M+#<?O3^=<,\IFCV:/$=-[L^LX]8MY/XQ^=3K>0MTD6OF"S^+1XS+^M;=I\6
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M6I&XA&3VKGO'BE[=S[4 >-1?\A ?6O>OAK_JXOH*\'1=NH_C7O/PU9?+CR:
M/3:Q]:X1OI6Q6%X@F5$;GM0!Y+XT;+/7#V"DW@^M=CXMF$CL :Y?2X"UT#CO
M0![-X"'[M/I7H%<+X'B*QIQ7=4 %<KXU7-NWTKJJYKQA'NMS]* /G[7E/VMO
MK70>#N)%K,\06I%RQQWK0\+2".1<\4 >T:%]Q:Z&N8\.SJR+S73T <KXX_X\
MV^E?.GB,_P"G-]:^B/'<BK:,,\XKYR\0MNOFQZT ;GA[/D\5B>-I#Y;"N@\,
MPEH1Q6+XVM6VGB@#S[2+ W=\HQGFO=?!?@7[5 AV=O2O*O"-N/[07([U]5>
MH(X]-4J!NQ0!R<WPYS&W[OMZ5Q&O>!#;L3L_2OHP\\'D5R/BRUAVOP* / +>
MW.FSCMBO0_">O$;%W5R/B6(1W#;:=X7E<7"CWH ^AM&N/M%N#[5>F;;"Y]JQ
M/";$V8SZ5JZC)Y=G(?:@#RKQUK7DEP&KRN:\-]=8SGFND^)%\?.< ]ZXOPWF
MXOESSS0!Z5X1T/S&1MM>Q:#:BVA QCBN7\%Z:/LZDCM7<PQB-<"@"6BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I&I:0C- "9-.INVG4 %%%% !1110
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M10 4444 %%%% !1110 4FVEHH 3&*6BB@ HHHH **** "BBB@ HHHH ****
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M)_Q\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "FO]T_2G4C?=- 'GWC!/E>O&=>NOL\Q.>]>U^, -CUX+XPSYK8H
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M\%:64ND..] 'NWA&W$=BIQVKH*R_#\?EV"BM2@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6M:V<L2\ UO:3IOV@CBNQTWP?]H4?)0!YS]GFE8 YK=T;PTUPP++7>1>!]K
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M 4444 %%%% !1110 4444 %%%% !132:,F@!U%-R:=0 4444 %%%% !1110
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MT5R-M[GHQBH[!1112+"DI:* &4Y>E)MI: !J;3CS1MH 6FTZF4 .6EIJTZ@
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M6_\ "OXO^>0_*C_A7\7_ #R'Y5ZE]GC_ +M'V>/^[0!Y6WP]A;_ED/RI]OX
MBC8'RA^5>H_9X_[M'V=/[M '):7X92UQA,?A736ML(E  JR(U7H*6@0M%%%
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M@ HI,TM !1110 4444 %%%% '-^)?]6U>?2?\?/XUZ#XE_U;5Y])_P ?/XT
M=SX7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** &L* *=10 4444 %%%% !
M1110 4444 %%%)F@!:*** "BBB@ HHHH 3FCFEHH **** "BBB@!*,#TI:*
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M(]2NH>I:IT\27$/\3"N665P>QZ%//ZT=SZVMOBDK8_>_K6G;_$A),?O?UKY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MONK75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP^9ABE*G&6QU8?-*]!^\?>.@_%"%U7,H_.NXT[Q];7"C+J?QK\^M-^(US:L
M96'XUVVB_%V2-E!F_6N25 ^NPO$2VD?=-OXDMI\88?G5^*^BFZ&OD[P[\6A)
MMS-^M>G>'?B1%/MS*#^-<TJ3B?3X?-J5;J>U YYI:Y;2_&-M<(,N#^-;L.K6
MTPR)!6-CVHU835TRY14:W$;]'!IX.>E(T%HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M".!4E%<[DWN=T81CL@HHHJ2PHHHH **** "D:EHH ;M-.HHH **** "BBB@
MHHHH *2EHH ;M-&TTZB@!!0U&ZC- ";33J** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I-M.HH 2EH
MHH 0T<^E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAD(DA_"O&M9_Y"1_WJ]C^$:GS(?PH ^S_APQ-O%]!7I%>;?#C_CWB^@KTF@
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M?[T ;OG"CSA6%]O]Z/M_O0!N^<*/.%87V_WH^W^] &[YPH\X5A?;_>C[?[T
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MK7F^'LR_\LS^54)O =PO2,_E5^UP\]S%X?&4]KEVU^(<ZXRY_.MFU^)<R_\
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MU?MYBU %^EIJ_=IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%)6=J6L16,9)- %NXNDMQEC6/=>*H+?JRBN!\5_$2*U
M5@)!^=>->)OBV(V;$WZT ?1MS\0((O\ EHHJFOQ'AD; D'YU\?ZI\8&YQ-^M
M4=*^+$DUT!YO?UH ^Z--\4)> 8?/XUK_ -J(JY)%?.WP]\8/>1H2^?QKOM4\
M4?9;4MN[4 >D+K<3-C(J]#.LRY4U\ZGXF+#=;3+W]:]$\)^/(KQ5'F _C0,]
M+HJK9WZ72@@U:H$%%%% !1110 4444 %%%% !1110 4444 %%%% &/KN?);'
MI7S_ /$[SO*EVY[U]%:E#YT9'M7F/C#PK]NC?Y<YH ^$O'GVSSI-NZO/8_M_
MG'[_ %K[$\2_"47<C'ROTKF4^"8\S/D_I0!\[VJWWRGYJ[;PYJ5W9E2Q85[+
M;_!A57_4]O2J>J?#$V49*QXX]*!G%:KXUD2S*L_:O*]6\3>??9+9YKO?%7AF
M>(,H4UYCJ'A>Y\\MM;K0![+\,/%4%OL+,*]JD^(5LNGX$B]/6OD'1X[S3<8#
M#%;LWB*]6':2U ':?$?Q='>^8%<'\:\7DOQ]LW9[U9UG4YYBVXFN8FF.[/>@
M#Z#^%OC!+&2,%\5]8^ _'4=Q#&HD'3UK\[?"NI3QW";2>M?3_P *]2N6,.2:
M!'VEI.H+>0J0<UHUP'A'5#';IO/:NK/B&U5<LV/QH U*CN%W0N/:LY/$EG(<
M"0?G5I;Z*>-MISQ0!\]?&2VW)-QZU\8>/(?+OI..]?=WQ4TPW$,I KXO^)VD
MF&ZD.,<T#L4?AM<;;V,9[U]Q?!V8-!#SV%? 7@W4A8WZ9..:^O\ X2^-X;>W
MARXZ>M CZ>U:0)I\ASVKY#^.ET/W_/K7NNM_$2 Z>P\P=/6OE3XQ>+([N2;#
MYSF@#P'46\S4S]:]R^#]OEHN.XKPZW7[9J7'/-?2OP=T9OW)QZ4 ?4OP]CVP
M1UZ%7'>"[0P0QY':NQH **** "BBB@ HHHH **** "BBB@#F_$W^K:O,[Y2;
M@_6O3/$O^K:O.YHPUS^- &MH4#,!72K VVJ_AFR#*O%=3]@7&* .<-LWI2?9
MF]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .
M;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L
M\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'
MV9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@
M#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/
M[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI
M1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9X
MH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z
M3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-
MZ4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V
M>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2
MND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_L
MS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%'
M]GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;
MTKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO
M[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ
M1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9
MF]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .
M;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L
M\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'
MV9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@
M#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/
M[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI
M1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9X
MH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z
M3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-
MZ4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V
M>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2
MND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_L
MS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%'
M]GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;
MTKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO
M[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ
M1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9
MF]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .
M;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L
M\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'
MV9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@
M#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/
M[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI
M1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9X
MH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z
M3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-
MZ4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V
M>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2
MND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_L
MS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%'
M]GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO[,WI1]F;
MTKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ1_9XH YO
M[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9F]*Z3^SQ
M1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .;^S-Z4?9
MF]*Z3^SQ1_9XH YO[,WI1]F;TKI/[/%']GB@#F_LS>E'V9O2ND_L\4?V>* .
M;^S-Z4?9F]*Z3^SQ1_9XH YO[.WI1Y#5T9T\8IO]GCTH Y[[._O3O)>NA&GC
M%+_9XH Y\1R"EVR>E;_]GBC^SQ0.Y@&-VXQ3&TTR]171BQ44];55[4#T>YR<
MGAE)LY3/X50NO L4HYC'Y5WXA4=J4Q#TH39$J=.6Z/'-2^&L,@/[H?E7$:Y\
M*T8-B+]*^E)+-).HJG<:#%-U K:-1H\O$9?2JK1'QGKWPH9=VV']*\^UCX:S
M0LQ$1'X5]ZWW@>&X!^0&N5U;X7PRJW[L?E71&L?*XKA]2UBCX&O_  M=6;'"
M,,5DRS7EC_>%?9OB'X1QL&Q%^E>5^)OA&5W;8OTKJC64MSY+$9-6HZQ/";;Q
MC=6K<NPKI=)^)<L3 &4_G2ZY\,YH&;$9_*N3N?"-U:N?E85M[LCRU+$X9GN'
MAWXJ$%<R_K7IF@_%!'5<R_K7R#"MU8M_$,5NZ=XIGM" 6(_&N>5%,]O#9Y4I
M:2/MG2_B!'-C]X/SKIK/Q,EP!A_UKXUT/XB-&5W2?K7I7AWXD(Q3=)^M<TJ%
MCZW"Y]&>C9]+V]UY^,'-78[4R5Y7X?\ B!!(JYD'YUW^D^,+:51\Z_G7-*#1
M]50QU*JMS:_LUO0TUM/<5;M=<MYNC#\ZOI-%-T(K/4[^>$MF8#6;CM3?LS5T
MWV-6^E)]@2@#FOL[^E'V=_2ND_L]*3^SQ0(YS[._O2?9FKI/[/6C^SQ0!S?V
M9J7[._O71_V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]G84?9V]ZZ/\ L]?2
MC^SU]*!W.<^S-Z4?9F]*Z3^SQ1_9XH$<U]G;TI?L[>E='_9Z^U']GK[4#.<^
MS-Z4OV=O>NC_ +/%']GB@1S?D-[T?9FKI/[/%']GB@#F_LS>E'V9O2ND_L\4
M?V>* .;^S-Z4GV=O2NE_L\4S^SQZ4 <]]G;TH^S-Z5T:Z>*7^SQ0!S?V9O2C
M[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0
M!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG
M]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;T
MH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\
M4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=
M)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F
M]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[
M/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI
M72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V
M9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC
M^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-
MZ5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W
M]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9X
MH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/L
MS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '
M-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V
M>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C
M[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0
M!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG
M]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;T
MH^S-Z5TG]GBC^SQ0!S?V9O2E^S-[UT?]GBC^SQ0!SODOZ4>2]=%_9XH_L\4#
M.<^SO2?9F]*Z3^SQ1_9XH$<W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V
M>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C
M[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0
M!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TI?L[^]='
M_9XH_L\4 <Y]G?TI?(?TKHO[/%']GB@#G?)>E\IZZ'^SQ1_9XH'<Y_RY*-LE
M=!_9XH_L\4K!=F!MD]*-LGI6_P#V>*/[/6@=SG_+>C[.YKH?L*^@I?L*TK!<
MYS[&Q[4W^SBW:NF^QKZ4?9!Z4]0T.7.D;OX:8=!#?PUUHM5]*7[.M%V+EAU.
M/;PNC?P4P^#8F_@'Y5VODBE\H4^:?<CV=/L<')X'B;/[O]*IR^ HF_Y9C\J]
M(\H4TPBK56HNI$J%&70\ND^'L1_Y9C\JI3?#F(_\L_TKUS[*OI2&S0]JU6(J
M+J<\L%1ET/$[KX;1\_NOTK'NOAHG_/+]*]_?38V["H'T2)^PKJCC)QZGGU,J
MHRV1\WW?PS'/[K]*Q;SX9'G$7Z5]1OX;A?L*KR>$89/X5KJAF4H]3RZF0TY;
M(^2;OX:NN<1?I6/=?#J49Q&?RK[!F\"POGY!5&7X=POG]V/RKOAFS6[/,J<-
MI[(^-[CP!.N<1G\JSIO!=Q'_ ,LV_*OLN?X9PM_RS'Y5E77POBY_=#\J[(YN
MNIYE3AF70^/Y/#=U'_"WY54FTN[B[-7UA=_"V/G]T/RK#O/A6ASB+]*ZH9I!
M[GD5>'JT-CYB:.\B/\5,^V7<?4M7T)>?"H<_NOTK O/A:5SB/]*ZUCZ4CBEE
M&(AL>-_VU=1]VIR^*KF,\LU>B7OPU=<XC/Y5A7?P[E4G]V?RK>->C,XY8;%4
MS"@\:3J?OG\ZTH/'DRX_>'\ZKS> YT_@-4YO"%Q'GY36G)0D9QJXNF=/;?$2
M12,R?K6Q9_$EA_RT_6O,Y/#MS&>%:F#2[J,]&K&6#HS.N&:8FGN>VV7Q+Z?O
M/UK9M_B4#C][^M?/J+=1?WJG2^N8^[5QRRNF]COIY]6CN?2%K\25SS)^M;%K
M\1D8#]X/SKY?CUJXC_B-78?%$T>/F/YURRRF+/2I\2SCN?4T/Q C;_EI^M:,
M'C9&Q\_ZU\M6OC*1<9<_G6U9^.67&7_6N.>4=CUJ?$M]V?34/BY'_CJW'XC5
M_P"/]:^<[3Q]MQF3]:VK/X@+QF3]:XIY7)=#T:?$,)=3WN/5Q)_%5E+K?WKQ
MRP\>1G&9/UKH;+QQ"<9<?G7%/ SCT/5IYQ2GU/258M4JPEN]<;:^-+=OXQ^=
M:UMXPMF_C6N66%J1Z'IPS"C);F^MFS4]=/8]JS[?Q5;-_&*T(?$ELV/G6L71
MJ+H=,<51EU'?V:_I2?V<]6X]<MFQ\PJ9=4@;^(5ER370W]M2?4S?[/?TI#8O
M6NMY"W0BI%>)O2BTA\\'LS!^PMZ4GV-O2N@\M&IRVJM2U'='.&U;TI/LS>E=
M*;%33?[/7UH YS[._O1]G;WKI/[/6C^STIDG-?9FH^S-Z5TO]GI1_9Z4P.:^
MS-Z4OV=O2ND_L]*/[/2D,YK[,WI1]F;TKI/[/6C^SUH YO[,WI1]F;TKI/[/
M%']GB@1SGV=_>E%NU=%_9XH_L\4 <[]G;TIOV9O2ND_L\4?V>* .;^S-Z4W[
M.WO73?V>*3^SU]* .;6W;WI?LS>E='_9Z^E+_9XH YO[,WI2_9W]ZZ/^SQ2?
M81Z4 <Y]F:C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <U]G;TI?L[>
ME=#_ &>/2G+IXH YS[,U+]G?WKH_[/6E^P)0!S7V9O2G"W:NC_L]*/[/2@#G
M#;MZ4QK=O>NE_L]:3^SUH YK[._O3UMV]*Z+^SUI?[/6@9SIMVI/L[>]='_9
MXH_L]:!'-_9F]*/L[>E=)_9Z4O\ 9Z4#.;^RMZ4];)CVKHOL""D:%(NM [HP
MAI['M2-9LE:DVH0PJ<D5AZEXEMX0?F%.-.<GHC"=>G!:LCN)OL^<G%8U]XD6
MWSEZPO$/C:"-6PX_.O*O$OCY?FVR?K7K8? 3J;H^=Q><TJ.S/2M5\>)$&_>#
M\ZX;7/B0%W 2_K7DVL>.'F9@'_6N5O=:GNF.&)KZ.CE*6K/BL7Q))Z19WVO?
M$=FW8D_6N%U+QM/<,<.:S/[/N+UNC&M;2_ \]TPRAKVJ="C16I\G6QF)Q<M#
M*74KJ\;JQK0M-#N;Q@2K'->B^'?ABSLN8_TKU3P[\+4PI,7Z5A6S"E2V.W"Y
M/7Q#O(\/TGX?S7&"8R?PKOM!^&).W=%^E>[:-\-HH@O[L?E75V7@V&W ^4"O
MGL1FSEHC[;!\.*%G)'D.B?#5%VYC_2NST_P!%&H_=C\J]!@T>.'& *N+;JO:
MO JXJ=3J?88?+Z-%;'%P>$TA'"?I5E=(\GHM=;Y(IC6JMVKB<I/<]51A'9',
MK;,G:E\N2NB^PK3?[/6D5<Y[RY*;Y#^E='_9XH_L\4Q7.<^SM[TGV9O2ND_L
M\4?V>*!'-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C
M[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0
M!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG
M]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;T
MH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\
M4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=
M)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F
M]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[
M/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V9O2C[,WI
M72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC^SQ0!S?V
M9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-Z5TG]GBC
M^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W]F;TH^S-
MZ5TG]GBC^SQ0!S?V9O2C[,WI72?V>*/[/% '-_9F]*/LS>E=)_9XH_L\4 <W
M]F;TH^S-Z5TG]GBC^SQ0!SGV=_>FM;OGO72_V>*3^SU]J .;%NV>]+]F;TKH
M_P"SU]J7^SQ0!S?V9O2D6V;WKI?[/6C^SUH PX(&K4M(R*M+9!:E6$+0 ]/N
MTZDZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4457O)O)B+4 1:G>K9VS,3VKPWXD?$ 6*R@28Z]ZZSQYXK%I:R#?C@]Z^0/
MBQXV::295D]>] %+QO\ %1Y)G42]_6O)M9\93W3'#G\ZY_5+RXU"Z;!)R:N:
M?X:N+K!*$_A0!1N-8N)<_,:O>&]1E^V)ECUK1F\(RQ1$E"/PJGINGM:WRY&.
M: /JOX273-;QDGL*[/QOJ[6^GN0V.*\\^$DA^SH*Z_Q];R2Z:^T'I06?/WB+
MQ]+9ZBW[S'/K7?\ PU^*;/)&IE_6OGOXC6MQ#?2$ CFH? >N36ET@+$<T$GZ
M:> /%RZA''E\YKU&&021JP[U\?\ P>\6%E@!?T[U]1>']4%U;1\YXH$=%12*
M<@4M !13=U*#F@!:*** "BBB@ HHHH **** "BBB@!DB;A6?=:8LPP16G10!
MRUQX5CE.2E0#P=%N_P!6/RKL** .57PG&%QL'Y5AZYX*2:-L)^E>C4R2-9!A
MAF@#YN\0_"T7#-B+]*X^X^"ZR2']S^E?6D^D0R_PBJO_  C\!;[@H ^2Y?@>
M-I(A_2N;UOX/FV1CY1'X5]MMX>@*XV"N,\6>&XO)?"#\J!GY]>,?!IT_?\N*
M\VDT\FXV^]?5GQ7\/[?-VI^E> -H4O\ :'W#UH&;?P]\%F^GC.W/-?6'P[^'
MYM88FV=J\R^#OA_]Y$63TKZ\\*Z1''IZ?+CB@1RE](=&M3VP*\J\6?%!M/=A
MYN,>]>K_ !&A,=K)M':OCKXG-="XDV[NIH ]2T/XP/<707SN_K7N_@;Q0=4A
M7+YR*^ O"<EY_:"9W?>K[#^#+RM'#NSVH ]3\5Z/]NL7.,Y%?(_Q?\(LK3$)
M^E?<LUF)K,*1G(KQCXG>"1>1R$1YX]* /SQU"&72[PGD8-=MX3^(<NFHH,A&
M*Z/XA_#N2&:1EB/?M7D=_H=U9.P"L,4"/8[[XN236Y7SCT]:\S\3>)I=6E;Y
MB<FN:CM;R23:0U=9X?\ !]Q?3)N0GGTH G\"Z'+>WJ,5)YK[*^$7A<PPPDIV
M%>8_#'X;LCQ,T7IVKZK\#^'5L+=/EQ@4 =5I%D+>%>.U:5(JA5 %+0 4444
M%%%% !1110 4444 %%%% '-^)?\ 5M7GS_\ 'U^->@^)?]6U>?2?\?/XT =Y
MX5/RK74UR?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 )D44VG+0 M%%% !1110 4444 <UXE_U;5Y_)_Q]?C7?^)/]6U>?O\
M\?1^M '=>%_NK765R?A?[JUUE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %,I],H 5:=35IU !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4UJ=2$9H ;3Z;MIU !1110 4444 %%%% !1110 444W)H =1
M3<FA: '4444 %%%-)H =130:=0 444W)H =12+10 =:IW6FI<9R!5REH$TGH
MSEK[P;%=9^05S>I_"R&X4_N@?PKTVBJYF<D\)2J;H^<_$7P=C8-B']*\J\2?
M",QE]L7Z5]L75E'<H05&:Y35O!\5UN_=C\JZ(5FCP,7DM*HO=1\$ZU\-YK?=
MB,_E7(WGABZLV.%88K[OUCX8I/N_=?I7!ZY\'0P8B+]*ZHU^Y\EB<@E'6*/D
M%+B[L&ZL*U['QQ=69&788KU_Q!\'WCW$1?I7G&M_#6>W+8C(_"NE3C(^=J8/
M$X9Z&UH?Q4FCVYE/YUZ7X;^+.[:&F_6OG"Y\.W5BQP&&*;:ZC=V+=6&*F5.,
MC2CF6(H/WC[B\/\ Q.BD"YE'YUZ'HOCVWF49D4_C7Y]Z7X^N;5@#(>/>NWT7
MXMRP[093^=<DL/V/J\)Q"HZ2/O2V\0VMPHPX'XU=2]ADZ.#7R+X?^,!;;F;]
M:]*T#XF)<;<RY_&N:5)Q/J:&<4JQ[JK!NAS3JXG1_&,,RK^\'YUU%KJ\%PH^
M<9K&S1[E.M"HKIEZBF+*C=&!IU(V%HHHH ***:SA>IQ0 ZBH&O(5ZN*3^T(/
M^>@IV%S+N6**K?VA!_?%']H0?WQ0+F7<LT56_M"#^^*3^T8/[](.9=RU15?[
M?!_?%'VZ#^^* YEW+%%5_M\'_/04Y;N)NCB@=T2G-"TBN&Z&EH&+1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !36ZTZDVT (O6G4FVB@!:*;DTHH 6DI:* $VTM%% !111
M0 4444 %%%% !36IU(1F@!M.6DVTE V/I&H6@\T"&TZDVTZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ IK*&ZBG44 5I+)).U5)-%CDSP*U**I2:V,W3C+=
M&!)X9CD_A%4YO!L4G\ KJZ*M59KJ9/#TY;HX>7X?Q2?\LQ5.;X9PR9_=C\J]
M$HK18BHNIB\#0ENCRVX^%$3#_5#\JR+SX218/[K]*]IIK*&ZC-:+&55U.>65
MX:7V3YXOOA,G/[K]*Y^^^%(YQ%^E?3MQI\<G\(K/FT&.3^$?E7;3S&I'=GF5
M<CH2V1\JWGPL*](OTK$NOAFRYQ'^E?6EQX5CD_@'Y5FW'@F-_P#EG^E>A#-9
M=6>34X>@]D?(MU\.Y5S^[/Y5DW'@69.B'\J^OI_A\DF?W?Z5G3_#-&S^[_2N
MR.;=SS*G#?9'R#-X0N(_X#5630;F'^%J^M+KX5JW_++]*Q[OX3@_\LOTKJAF
ML'N>74X>J1V1\MO:W4/0-49N+N+^]7T==_"/.?W7Z5BW?PA;G]U^E=D<PHO<
M\Z>2XF.QX<FM7<?=JLQ>*;J/'SM7IUU\)W7.(_TK&O/AC+'G]V?RK?ZU0F<L
ML#BZ9RT/CFZC_C;\ZT;;XC7"XS(?SI+KX=S1Y^0_E69-X)N(L_*:/W$S'_;*
M?<ZVS^)DO&93^=;MG\3GXS+^M>5OX=N8>QJ%K.ZA_O4GA:,MC:&.Q-/<]WL_
MB=T_>_K6W9_$Q6QF7]:^:Q<747=JGCUFZC[M7-++J<MCOIYW6AN?5%G\2(SC
M]Z/SK?L?B)$Q'[T?G7R'%XINHL?,WYU>MO'=Q"1ES^=<4\I3V/3I<1RCN?7=
MYX^B\DXD'3UKRKQQ\0_D<+)^M>22_$B5H\&0_G7*:WXJ>]S\]7A\JY)79CCN
M('5A:++7BGQ:]Y(XWYKA;R8W#$DYYI;B1IG))S4:K7U-&FJ:LC\^K5I5I-R(
MEA.*GMLPN#3MM(0:Z#!*VJ.NT3Q.]CC#XQ[UUUM\4)((P/-/YUY"79>AJM-<
MR!L;C7)+"PJ.[1WT\PJT5:+/7;[XE2W ($I/XUSUWKEQJ#'YB<UR>DV\EY(H
MR37J_A'P*]]L)3.?:N:I&EAE<[:,\1CG8Y&UT6XOF'#&NIT;X?RW#*3&?RKV
M;PW\*^%)B_2O1]%^&Z0JN8_TKPL1FD8Z1/K,'P_.=G-'CGAOX6^9MS'^E>GZ
M#\*XU5<Q?I7I&E>%H[7'R?I72V]LD"X517S5?,:DWHS[O!Y)1I+WD<1IOP\B
MM\?NP/PKI+'P_':XPH&*V:*\R5:<]V?0T\+2I_"AD<8C7 %/HHK Z@HHIN30
M ZBFK3J "BBB@ I*6B@!NZG4E+2 *:W6C)HZT "]:=2;:6F 4E+10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !24M% #=II12T4 %%%% !1110 4444 %%%% !1110 4444
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M4%9(****184444 %%%% !3<&G44 -44ZBB@ HHHH **** "BBB@!NTTJTM%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D4 +124M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-D<1KD
MT .JE>:7%>*0PZU#<:U';_>853;Q=:Q]67\Z .:\1?#Z&Z5CY8/X5Y9X@^%$
M<C,1%^E>WW'C&TD7&Y<?6LFZUBTN.ZF@#YPO_A*!G$7Z5EM\)_F_U7Z5]'SR
MV<F?NU7,5F?[M 'SS#\)?F_U7Z5U&B_"--RYB_2O7UCLU_NUH6M[9PX^[0!S
M?AOX7Q0[3Y0_*O2M(\)PV*CY0*I6OB>T@Q\R_G5S_A-+3^\OYT =!%"L*X45
M)7-CQI:L>'7\ZM0>*;27JX_.@#:HJI#JEO-]V058617Z,#0 ^BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F_$O\ JVKSZ3_CY_&O0?$O^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7P=:M*K*[/V##8:&'@E%!1117.=H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N'K0 M)
MMHW#UHW#UH ,8I:3</6DW#UH =12;AZTFX>M #J*3</6C</6@!:*3-(30 ZD
MI:90 ZEIE/H **** "BBB@ HHHH **** "BBB@ HHHH *H:Q-Y%J6J_6-XH)
M&GMCTH \@\;^-#IY?#XQ[UX[K'Q>:WE8>=C\:U/BY<RQF7&>]?+7BO5+A)Y.
M3UH&>['XV'=S/^M68_C6,#,WZU\C76O7,<A^8_G4'_"3W2_Q-^= C[#'QL7_
M )[?K3O^%VI_SV'YU\;?\)1>?WF_.G+XFO/[S4 ?8_\ PNQ/^>WZTUOC6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%%( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\[^ _B!_:4B#S,Y]Z][T*X^TV:MUK*47$]O#8J.(5XFC3:=2+WJ#N#;3J**
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M^,T$?- '>T4@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#F_$O^K:O/I/^/G\:]!\2_P"K:O/I/^/G\: .Y\+_
M '5KK*Y/PO\ =6NLH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NE+1
M0 RE7K2[:0T#N.I*1>M.H$,IR]**6@ HHHH *3-%-H ?12+2T %)FANE-H ?
M124M %34HA);-GTKYU^+]JJPR\=C7T9J#;;=OI7SO\8)/W,OXUO2W/ S>WL6
M?%7Q!7;>2?4UQ-K]ZNV^(1S>2_6N)M?O5[<?A/P;%?QF7J***#$****!A111
M3)L!4&I87:,_+5=I,5KZ-9?;)%&,TBX)R=D6K'6+F#&TM6]9>+;N'&7;\ZW-
M%\ M>1@A,_A6K/\ #&6-<B,_E63E$]NGAL1:\3+LO'UQ'C,C?G706/Q,DCQF
M0_G7-W7@.XBSA#^594_ABZAZ*U3RQ9T*MB:)ZW8_%9EQF7]:Z*Q^+@&,R_K7
MSPVFWD)Z-0&O(?[U3[.)O',\1#<^I['XOIQF;]:Z"Q^+T9Q^^_6OCE=6O(>[
M58A\47<)'S-4.BCNIY]5CN?;MC\6H6Q^]'YUO6?Q3A;'[T?G7PO:^.;F/&7;
M\ZV+7XD3QX_>'\ZS= ]2GQ');GW3;_$FWDZNI_&KT?CRWD_B6OB&S^*<JXS*
M?SK?L/BPW&9?UK-X>QZE/B%2W9]E1^+H)/XEJW'X@BD[BOD^P^+ XS+^M='I
M_P 5TXS+^M9>Q9Z=/.J<MV?2\>IQR=Q5A+A'Z&O!+'XIPMC]Z/SKHK'XG0-C
M]Z/SJ'3:/3IYC2GU/7J*X"S^(]LP&9!^=:D/CRTD_C7\ZSY6=D<32EM(ZNBL
M"/Q?:R?Q+^=6H_$5K)_%^M*S-55@]F:M%45UBW;HWZU*NH0MT:@OF3ZEFBHE
MN(VZ-4@8'H:10M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %)2TUJ %W4M,I5H&.HHHH$%)FBFT .S2TRG+0 M0RVJ3?>&
M:FHH%N4#HUN3G;^E3PV44/W1BK%%/F8E&*V0E%(U)2*'T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_2L"^^#;<_N?TK3VR9YL\EK0V/G :A>0]VJ:/Q-=PG[S5[1??!V3G]T?RK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH ;MI:6F[J
M'44@I: "DVTM% ";:*6B@ HHHH **** $Q1MI:* "BBF[J '44@I: $/2FYI
MQI-M "CI2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[VO/AG;.#B-?RKG[[X66YS^Z'Y5LL0>95X;ML?#%QX)NX\_(WY51D\.WD/\
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MXNMY.ZU9C\1P2=Q2LS15H/J;%%4(]6BD[BK,=TDG0T&BDGL344E+2*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HR*1J2@!]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E&10U-H ?1
M24M !1110 4444 %%%% !29%%-H ?12+TI: "BBB@ I,BEIE #J6FK3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3*?2;:
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M'K0 M%-WKZC\Z7(/>@!:*** "BDW#U%)YB_WA^= #J*;YB_WA^='F+_>'YT
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M* "BBB@ HHHH **** "BBB@ HHHH *2EI* %I*3)I10 4M%% !1110 4444
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M(3Z"O(Q&Y^T\.?PSHZ**0=ZY#[46DI:* "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"WS8Q7'W/Q3$;$>9^M8/Q(NY8?,()KP?5M>N%N&PQH ^D/\ A; _YZ_K2_\
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MI9=Q&1CVKS;2]4FT/4%0L1@U^@?QD\(VK:7)*D8&5)Z5^?GQ&A&GZTX7CYJ
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M1DQXQCM7U!X9M_L^GJN,<5YE:7,S]6R/#RH0M(UZ0=Z6BN<^K"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M><B!F_6NTDU#SH,@YH AU#6A!GYJP;CQ<B,1OK,\22RA6QFO.]1N;GS&QNH
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M:7(F0'-9N-COIU8U-46*5:-M+4FXM%%% @HHHH **** "BBB@ HHHH ****
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ME^&4M<83%=+:6HA4#% %Q?NBEHHH **** "BBB@ I-M+10 @&*6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$O^K:O/I/\
MCY_&O0?$O^K:O/I/^/G\: .Y\+_=6NLKD_"_W5KK* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!)6;KI_T-JTJS=<&;-J /G?XA?\ 'P_UK(\&C_3%^M;/Q !^T/\ 6LGP:/\
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M:: '4444 -:D'6E848- #J3;2T4 )M]Z*6B@ HHHH **** "BBB@ HI*0YH
M=12#-+0 FT'L*8UO&W5!^5244 4KC2X9A]P5D7GAJ*3/R#\JZ2BG=F<J<9;H
M\]O?!$4N?W?Z5AWGPX23/[H?E7KNT>@I#&IZJ/RJE-HXY8*E+H>$W?PM5L_N
MOTK$O/A*&S^Y_2OHXV\;=4%,:Q@;K&*T55HY)951D?*]Y\'-V<0_I6#>_!MA
MG$/Z5]@MH]LW\%4[CPW;29P@_*J59G'/(Z,CXKOO@_(N<1?I6#>?"69<XB/Y
M5]NW7@^!\_NQ^59%UX%@?_EF/RK6-=GE5>'X/8^';SX7SQY_=G\JQ+SP#<PY
M^1ORK[BOOAW$^<1#\JYS4/A>DF<1?I6RQ!Y%7(+;(^*+GPO=PG[K53;2[R$]
M&KZ^O_A()"<0_I7/WOP=)SB']*U]LCR:F1U8['S'')>6_P#>JY#KUW;_ ,35
M[C??!V1<XA_2L"\^$4RYQ$?RI^TBSB>78FGL>?6_C6[A_C;\ZU[7XC7,>/WA
M_.M*Z^%5RF<1'\JR[CX<W46?W;?E1[K(]GBZ9MVGQ2G3'[T_G6Y9_%R5<?O3
M^=>;7'@Z[AS\C5G3:+=PGHU/EBREC,33W/=K/XP/QF;]:W;+XO$X_??K7S+Y
M=W#V:G+J=U#W:ATD=,,XKQW/KBQ^+0;'[[]:Z"Q^*2OC]]^M?%\/BJZA_B:M
M*U\?7$6/G:L?8'?#/IK<^W++XC1R8_>C\ZZ"Q\;PR8S(/SKX>L?B;-'C,A_.
MNCT_XN21XS(?SK)T#V*'$"ZL^V[7Q3!)C]X/SK2AUZ"3^,?G7QI9?&8KC][^
MM;MG\:NG[W]:R=%GL4\^I/=GUS'J4$G1Q^=3+/&W1U_.OEZQ^-"G'[W]:W;/
MXQHV/WOZUFZ4CT(9Q0EU/H?</449KQ*T^+4<F/WOZULVOQ*CFQ^]'YU/LY'9
M',*,MF>JT5P5KXXCFQ^\'YUK6OBB.3'SC\ZCE9U1Q%.6S.GHK*@UJ.3'S#\Z
MOQ74<HX85)NI*6Q-6;KLWDV;-6C63XH(&EODXJH[DU-(,^>?B9XP:P:7Y\8]
MZ\&U7XI.EPP\WOZUV?QONFCDGVGUKY1US4IOMC<GK7KTJ::/QG.<PJ4JK29[
MDOQ2=E_UI_.G+\4'_P">I_.O X]0FV]34HU";'4UM[-'SO\ :E7N>\?\+1?_
M )Z_K1_PM%_^>OZUX/\ VA+ZFD_M&7U-'LT5_:E7N>\_\+1?_GK^M'_"T7_Y
MZ_K7@W]HR^IH_M&7U-+V:#^U*O<]UF^*3A?];^M&G_%1VN%'F]_6O!+C49MI
MY/2FZ3J4WVM?F/6J5-$?VK5YEJ?='P[\<->-'\^<^]?17A?4#<0(<YXKXA^#
M]Y(TD62>U?8W@-RUK'GTKS*\;,_5\BQ,JT%<]"4Y6EID?W!3ZXC[8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH ***2@!:*3=2T %%%% !1110 4444 %)BEHH **** "BDHS0
MM%%)NH 6BDI: "BBB@!NVE Q2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6)XJA\ZP8>U;=4]3B$MN0: /D'XO>'6E$QV^M?+FM:2;74CD8YK[T^
M)FBI);RG;V-?('Q"TP6M](0,<TK%'2?"/RQ<Q XZU]L_#NU@DL8R #\O]*_/
M?P-X@_LV]3+8YKZZ^&?Q*CCMX@THZ>M,1]"K;QKT44OE)_=%<_I_C:RNXP6<
M X[&KG_"46/_ #T_6@1J>2G]T4GDI_=%9O\ PDUC_P ]!^='_"36/_/0?G0!
MI^2G]T4>2G]T5EGQ18C_ ):?K2KXFL6Z2?K0!J>6H[4M4XM6MYONOFK*S*_0
MT 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '-^)?\ 5M7GTG_'S^->@^)?]6U>?2?\?/XT =SX
M7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M _0.:/<MT57%]$W\5/%S&W1J0[HEHI@D5NAIU Q:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**2@ S2TRG+TH 6BBD:@ S2TRG4 +1110 4444 %%%% !1110 4444 %%%%
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M+R.V!+G% $]%8%UXTT^SSOD Q[U2_P"%E:3NQYH_[Z% '645SMOXYTVY("2
M_C6M;:I!=8V-^M %IJ6CK3: 'T4@I: "BH+B\BM_OMBJ?_"06F[&_GZT :=%
M5X+R.X^X<U8H ***CFF2%<L<4 245BW?BRQL\^8X'XUG/\2-)0X,H_[Z% '5
MT5RT/Q$TJ8X64?\ ?0K5M?$-I>8V/G\: -2F4J2"1<J<BEH %I:** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXE_U;5Y])_Q\_C7
MH/B7_5M7GTG_ !\_C0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHVYR:]<\(_!5=4C0^5G/M6-X+T4K=)N7O7U7\,=/BCMTR@SCTH \BC_9P19
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M[H\)T_X.)'M_=?I726/PMCA_Y9#\J]=6%%Z(!^%.P/2L_:,]B&6T(=#S^S\
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MKBO6M/SY(!H =]@@'_+,4Y;6)>B 5-10 @4+T&*6BB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 -:DI6I* 'T444 %(U+10 W::=110 4444
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M2V%G9!6"]*^<OAMXLACL8\,.E=-K7CJ1$.USC'K0!N?$*SL]05Q&%)KPS4?
MS37VZ-.]=1+XX,TQ$C_G71>'=0M+Z9=Q4T 3?#'PC<6L\1VD<BOKWP!:M;V:
MAO2O,/ NG6K^65"U[7H<*PP#;0!J4E+36H 7(I:93Z "BBB@!*,BD:DH ?11
M10 4444 %%%% !1110 4444 %%%% !367<,4ZB@"G+IZ2=<56DT:+J5%:;N(
MU)8X%<WKWBJ"Q5AO Q0,LR6-M'U"U 8[5>RUYIKGQ2AMV8"4#\:Y*\^,$:L<
M3?K0(]XS:?[-&;3T6OGO_A<B?\]OUI!\9$/_ "V_6@#Z%S:>BT9M/1:^>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!4OK47*D$5S\_A9))"=@KJZ* ,"PT-;7&%Q6W%'Y:XJ2B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "DH:DR: $S3ATH
MVT4 +1110 E+110 4444 %%%% #*<M&VC&* %HHHH **** "BBB@ HHHH **
M** "BBB@ I*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *93Z3:
M* $6G4WGM2T +1110 444AS0 M%-R:=0 4444 %%%% !6#XN_P"0>WT-;U8O
MBF(R:<V!V--;F57X&?%_QL/[R;\:^6=:D'VQ_K7UG\:M)FE>;"GO7ROKF@7/
MVMOD;KZ5[5'8_!\\C+VSLC.CE7;3_-6G)H=SM^X:E70[G^XU=&A\VHS[$'FB
MCS!4_P#8-S_<-.&@W7]QJ1IRR[%;S!1Y@JU_8-U_<:F_V#<_W&_*BY/+/L4;
MB5=IYINDR#[6OUJU<:#=;3\AIND:#<B[7*'K5)HCEGS+0^C?@_(-\7X5]D>
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MSKCAZ<=D9T&CQP]A5V.%8^@J2BI-E%1V"BBB@H**2B@!:2EI* $W4J]*-M%
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MSQY*;II#0!Y.IWWV/>O<OA5"/,A..]>(*OEWV3ZU[A\*[@-)$/>@9]5^'O\
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MKX5\!QLVJ(?]K^M?>'P54KIL>?[O]* .KU#PC'>MEE!K&OO!45I"S!!T]*]
MJCK#!;)\^E 'QY\;+5;>.4 >M?.FBM_Q/5_WJ^E/CRPQ-CWKYIT7_D/+_OT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^)?]6U>?2?\ 'S^-
M>@^)?]6U>?2?\?/XT =SX7^ZM=97)^%_NK764 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 C4FTTZB@ HHHH **** "BBB@ HHI* %HI,B
MEH **** "BBB@ HHHH **** "BBB@!-U --I5H =1249% "T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR-6[8_"^XFP?+/Y5]/:3\+HUVYA'Y5V.F?#B!,9B'Y5DZY[M#A]R^(^5=/\
M@_-)C,1_*NITWX+/QF']*^JM/\"VT8!,:C\*VX/#5G#_ ,LP?PKGEB&>]1X=
MIQU9\TZ7\'_+QF']*Z[3/A@D>,Q?I7N*Z3;+TC%2K8PKT05BZK9Z]/**-/8\
MTTWP#%#C,8_*NEL?"4$>/D'Y5U2PHO113PH'08K-R;/0AA*<-D95OX?MX\90
M?E5Z.QACZ(*L45!V*,8[(:(U7HH'X4N!Z4M%!0E+110 4444 %%%% !1110
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MC7S/HMT?[>'^_0!]Y_L^<V\/T%>YW2[K64?[)KP;]G:3=;P_05[[(-T;#U%
M'P'^U79,TUS@>M?)_@FQV^)$WC^,?SK[S_:,\*-J!N"$SUKXUFT5M"UCS"NW
M#4 ?H+^S=#:KIMOG;NVC'Y5] 5\%?![XNC15AC,NW&!UKZ,L?CA%-:AO.!./
M6@#T7QI#;-ICF0*&P:^"_P!H)85FF\O'4U[C\0OC>GV>11-^M?)WQ!\9?\)%
M=. V[)H Y?X?^;_;T>,XWU^CGP!W?V7%N_N_TKX9^%GA5KK4HI-G\0-??_P=
MTTV.FQ@C'R_TH ]+HHHH **** "BBB@ HI*,B@!:*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <WXE_U;5Y])_Q\_C7H/B7_5M7GTG_ !\_
MC0!W/A?[JUUE<GX7^ZM=90 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0>?FH ^C/@WX/$S0NR9_"OKKPSH<%KIZJ8QT]*\:^"NEI]CA..U?0%K&(H5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*:T*-U4'\*?10!5DT^&3^
M55ET6%OX!6I13NR'"+Z'/R^'86S\@_*J$_A.)_\ EF/RKKZ2GS,S=&#Z'GUQ
MX(B?_EF/RK,N/AY')G]T/RKU3:/2DVKZ#\J?.SGE@Z4MT>+W7PP1S_JA^59D
MWPE5\_N1^5>]^6AZJ/RI/)3^XOY57M&<[RVB^A\[7'P>5O\ EC^E9=S\&0?^
M6/Z5].&WC;JB_E3&L8&ZQK5>UD82R>A+H?*5Q\%L_P#+']*S)_@F6S^Y_2OK
MMM*MF_Y9BHVT2U;^ ?E35:2.:614)'QM<?!%O^>/Z5EW/P5=<_N?TK[7D\-V
MK?P#\JHW'A*V<']V/RK3ZPSFEP]1:T/B&Y^#\L?_ "R/Y5D77PIF7/[L_E7V
M]=>"8&SB,?E61=> (6S^Z'Y5HL0SRZG#L>A\177PSN%SB,_E6;-\/[F/^ _E
M7VQ=?#B)L_NA^59%W\,8VZ1#\JT6(/-GP_V/C*3P;=1_PM5=O#EW'V:OKRZ^
M%:MG$/Z5E7'PGSG]S^E:>V1QRR&<=CY5.EW<?9J85NXO[U?3%Q\)3SB']*R;
MKX0O_P \?TJE51RRRBM'8^>_MUY$>K5-%KUW'_$U>SW7P?EY_<_I65<?"69>
MD1_*G[2)R_V?B8GGMOXLNX\?,U7X?'=U'_RT;\ZZ*;X73K_RR/Y51F^&MRHX
MC-+FBP]CBH$$/Q*N8_\ EHWYU>@^*URO_+5OSK)F^'5TN?W;51E\"7<>?D:G
M[I'M,7'N=O;_ !=G7'[T_G6G;_&*88_?'\Z\ID\)WD7\+56DT.\C_A:CDBRO
MKV*AN>XV_P :9%Q^^/YUH6_QL?C,_P"M?.4UG>1]FJ!FO(_[U+V432.;8B.Y
M]4VOQJ9L?OOUK6M?C'NQ^^_6OD./4;R/NU7(?$5W'CYFI>P1O#/*RW/L:U^+
M0;&9OUK9M?B@C#_7?K7Q=#XQN8S]]JTK?X@W$:_?;\ZS= ].GG\NK/K;5OB(
MD\3?O>WK7C7COQ(MTLF'S7F,GQ%F9<%S^=86J>+GN@<MFG&ERG)C,X]O&QD^
M*IA-*^*Y )^\S6S?W1N&))K.V?-76MCXBM+GE<!3EI*5:9*'K05H%+3$-(IA
M6GM24!8%^6MW1]2-I("#BL(G%30AF88I-&E.3B[H]AT'XBR6,8 D(_&MFY^+
MD\D)7S6_.O(-/TVXGQM!KH;/PC=W"CY6K%PC<]ZEB\2X\L34U+X@W5TQQ(WY
MUS]UX@N[DGYFKJ+'X<7,V,QD_A71V'PHFDQF(_E2YHHT5#%5MSR=FN[ANK5+
M#X?N[INC&O>--^$+G&8?TKK])^$>W;F']*EU4CKIY/6J?$?-]CX"N9L90FNH
MTSX63S8S&?RKZ8TOX6I'MS%^E=?I7P]ABQF(?E6$J_8]NAP_?XCYFTOX,O)C
M,/Z5UFF_!0C&8?TKZ;TWP?;Q 90?E6W#H5K#_ #^%<\J[/H:/#]**U1\Y:?\
M&0N,P_I72V'PG2/'[G]*]R6R@3I&OY5((47HB_E6?M9'J4\IH0Z'ENG_  [C
MAQ^Z'Y5TMAX4BAQ^['Y5UVU?[H_*EP/2H<FST:>%IT]D9]II$,*CY15Y(UCX
M50*?14'4HI;!11104%%%% !1249% "TF/>EHH 2EHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!R?Q"YTEOI7P[\6?W=]*3ZU]S^/%W:4WTKX9^-B^5-,?<T <GX'UV*UU!-S
M <U]>?"OQ9;-#$-X[5^<'_"4R:?J/#$8;UKVGX:_%B6W\L&0CIWH _2>WU2V
MGA5Q*HR/6N"^+GB6UM]#DA$BDX->#0_&YX;%?WO;UKS/X@?&:;5%>,2DY]Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C4M% #*=2T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% ";J,TC=:%H =1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MEZ]/Y%FQZ<5J5@>,,C36QZ&@#YU^+'B=H5E&[UKY%\?:XU[<2#=GFOH#XR3N
M&F_&OEG6F>:^8$]Z"CE;C1Y+Z?(!.36II_P_N+@ B-C^%>@^"/"G]I3)\F<D
M5]'^"_@VMU"A,&>/2@1\DV_PQN6_Y9-^56/^%7W&/]4WY5]X6OP-3:/W _*K
M+? ^/'^H_2@1\"_\*QN/^>3?E1_PK"X_YY-^5?>W_"CX_P#G@/RI5^!\>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZR!J '4444 %%%% !1110 4444 %%%% !1110 TBA13J* "BBB@!NTTJTM%
M!1110!4U*7R;<M7D/C?Q9]A#_/C'O7J7B:7RM/8^U?*?Q=UYH3, WK0!A^*/
MBH;>1P)?UK@[KXQ2+(<2G\Z\L\5Z[--<N QZFN?M;6ZO9!C<<T >UM\9)L?Z
MT_G4MO\ &*9C_K3^=>7V_A*\F3.UNE6(?!]XC?=;\J />?#'Q0ENIE!D/)]:
M^A/A]XC:^6/+9S7QWX-\.745PF5;K7U1\+;"2%8MP- SW^U;= A]JFJ"RXMD
M'M4] A*6D'>EH 0G:":Y3Q1XD33HF._&*UM7U,6L#Y..*^>OBMXV^SQR@2>O
M>@"#QM\6EM"X$N/QKQ_6OC.[.V)C^=>5^.O&4UU<R!7)YKB4:[OCD;CF@9[E
M:_&23SO]<?SKT#PK\9-S(#-W]:^3&L;N%MV&J]INN7-A,H+$8- C]&?!GQ&3
M4%0>9G/O7J^E7RWD((.>*^ OA?X]D$T2M)W'>OK_ .'?B87=O%E\Y% 'IM%1
M0S"5<YJ6@ HHHH **** "BBB@ HI,BEH **** .;\2_ZMJ\^D_X^?QKT#Q+_
M *MJ\_D_X^OQH [GPO\ =6NLKD_"_P!U:ZR@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $-)MIU% ""EHHH **** (;J$31X-<]>^'8[AB
M2M=/2;1Z4 <I;>&8X6R$%;=K8B%0 *T-H]** !> *6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(I: "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I,TM% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)2T4 ,IR]*6B@ HHHH ****
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MJFX]:OV]UYF* +]%(IRM+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?#F/;!']*]'KB/ MJ88(\CM7;T %%%% !36ZTZB@!JTZBB@ HHHH ***1J
M,W5(/.4UR=]HY:0D+WKNFC\RH7T]&[4 <-#I[Q]!5C[._H:ZPZ6OI1_9:^E
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M^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E ')M;O2"W?-=;_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
M<I]GD]*/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH
M^SR>E=7_ &6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=
M7_9:^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E
M']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!
MRGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3T
MH^SR>E=7_9:^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U
M?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4
M?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E '
M*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI75_V6OI1_9:^E '*?9Y/2
MC[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*/L\GI75
M_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*/L\GI75_V6OI1
M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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M_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_ &6OI1_9:^E
M'*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4 <I]GD]*
M/L\GI75_V6OI1_9:^E '*?9Y/2C[/)Z5U?\ 9:^E']EKZ4 <I]GD]*/L\GI7
M5_V6OI1_9:^E '*?9Y/2C[/)Z5U?]EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E'
M]EKZ4 <I]GD]*/L\GI75_P!EKZ4?V6OI0!RGV>3TH^SR>E=7_9:^E']EKZ4
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MEQTH$=_X?L_L\*\8K<J&WA$2@"IJ "BD-)NH =124M !1110 4444 %)2T4
M%%%% !1132U #J*9N]Z=NH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHI": %HI-U+0 444FZ@!:*0&EH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHINZ@!U%(*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HI-U - "T444 %%-W4HH 6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI-U% "T444 %%%% !1
M110 4444 %%%)F@!:*3=2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2;
MJ '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2;: '44E+0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !36IU% #1UIU%% !3:7-+0 U:=1
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%)10 M,I]% #0<4N:1NM"T .HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BDHH 6BBB@ HHHH **** "BBB@ HHHH **** &T+3J*
M"BBDS0 WFG+2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %)2TE #:<M-IR]* "C=0U-H ?1110 4444 %%%% !36IU
M-:@!*?3*?0 4444 )FC=2-24 /HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0TVG4M "#I1FE
MIK4 +NI::O6G4 %%)FC- "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **2DR: '44BTM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 RG+1MH
MH 6BBD:@!:*;DTM "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 UJ2G8I",4 .HIN32T %%+10 4444 %%%% !12-29- #
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!E*M+MHQ0 M%%% !1110 444AH 6BFY-**
M %HHHH **** "BBB@!&IM.HVT %+110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110 4444 %
M%%% !1110 4444 %,I],H 5:6D6E- "T4W)I: %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J3&: &T
M^DVTM !24M% "4M%% #**=MHVT (M.I,8I: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "DI:* "BBB@ HHHH **** "BBB@ HHHH 2EHHH **** "BBB@ HH
MHH **** "BBB@ K.UU-]B_TK1JM?Q^9;.* /E3XQ6+,L^!ZU\;^.+!H[UR1W
MK] ?B=X>-Q#*=OK7QO\ $_P^;6XD.WUH X3P;??8[I,G&#7UW\(/%";8E+_K
M7P^+]K"\].:]G^&?CHVKQY?'XT%(_2#PQJ"7EJN&R<5N5\X?#[XH)Y<8,OZU
MZY8>.HKI1^\!_&@3.SHK%A\01R*#N%2?VTG]X4"-:BLAM<C'\0JM<>)HX5)W
M"@#H*\R^*.JQP6\HW#I5W5OB)%:PN/, X]:^?OBE\3$N$E D]>] SQ?XNZ^K
M33 -WKPR*X-U>>O-=#\0O$#7T[D-G)KF/#$;7%XO&>: /=_A3I[/-$<=Z^R?
MAS9F."+CM7S9\'=#,C0G;Z5]>>#=+^SVJ'&.*!':VXQ"OTJ2FQC" 4Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(U ";J
M=3*=0 M%%% !1110 4444 %%%% !1110 4444 )2;:=10 @I:** "BBB@ HH
MHH 0G%)NH:DH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2&EHH ;MI:6B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2T4 -VTM+1
M0 4444 %%%% !1110 A&:3;3J* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 0G%)NH:E H 3;2BEHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBDH 6BBDS0 M%%% !1110 4444 %%%% !3=M.HH 0#%!I:* &[:6
MEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBD:@!:*;DTM "T444 %%%% !1136ZT .HIJ]:=0 4444 %%%% !1110
M4444 %%%% !13*<M "T444 %%%% !136<+R3BLK4/$$-FIRP'XT :K2*O4U'
M]J3UKS[5?B%;P$CS1^=8R_$RWW_ZT?G0!Z\LBMT-.KSC2OB%;S,!YH_.NOT_
MQ##>*,,#F@#8HIJR*X!!S3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHIDD@C4DT .9@O)J,W*#O7.:UXFCLU.7 KD+CXA0K)CS!^= 'J0N$;H:>
MK!J\]TGQA'=$8<'\:['3;X7*@@YH TZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BH)[R.W4EFZ5S^J>,+>U!&\#\: .B>X2/J:8+R,\9KR_4OB-!&Q_
M>C\ZSX?B5 S_ .M'YT >RK(K]#3Z\XTOXA6\A'[U?SKK=/\ $D%XHPP/XT ;
M5%,CE6094YI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K4E*U)0 ^FXZTZDH 6FLX7J:HWVJI:J<G%<CJGCB&W8CS!^=
M'<_:$]:>L@:O-K3QQ%<2 "0'\:Z_2=4%TH(.: -RBFH<K3J "BFLP7J<51OM
M9@LU)+#- %YG"]34?VJ/UKA=8\?6]N3^\7\ZYR3XF0>9CS1^= 'L"3*_0T^O
M+M-^(]O(P'FC\Z['3?%4%XH^8'\: .@HJ.*99ERII] "T4U:=0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !25!=7 A7)KD==\7)IZME\8H Z/5M8AL86)89KP
MGXE_$1+-9-LF/QK*\=?%80I(!+^M?,'Q*^)4EXT@$F?QH [+6/BTWVQ@)>_K
M79^ OB ]Y(@,F>?6OCP:U/>7>=Q/->V?"F>4S19)ZT ?=?@C5#=QH<YKT,=!
M7D/PR8F&+/M7KP^Z/I0!2U2\6TA))Q7E'C;Q\EBD@\S&/>NA^(FO?8;5\-C
MKX\^*WQ E6291)ZT =#XR^,)C=PLWZUY;J'Q>GDE.)3^=>5ZMK]SJ=RP#,<F
MI]+\.7=]AMK'- 'H<?Q8N5?/FG\ZZWP[\89%==TW?UKR&Z\&W<,>[8U8<PN=
M,DYR,&@#[F\#_%;[5Y8,OZU[OX7\1KJ"*=V<U^;_ (!\8307$8+D<BOK_P"$
M_BLW*1 OGB@#Z25MR@TM9^FW7VB!#GM6A0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6L[1+L7-JASGBM&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR3Z%^#]W(RP]>U?6_@MRUJF?2OG+X2^$WACB.WTKZ8\,VAM;=01VH&;M%%%
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M!]D_#50L,5>LC_5_A7DWPV_U$7TKUE?]6/I0!XC\7G<Q3 >]?%WQ$TZ>ZNY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!6O6VQ'Z5XO\ %*1VMY0/0U[/>+N0UYMXTT4WD;C;G- S
MX:^(FGSW5U(,,>37,^&O \EY>+NC)R?2OIS7OAK]KN"?+SSZ5H^$_A:L-PA,
M7?TH Y?P-\*%DA0M#^E=+X@^%<4-FQ\KMZ5[[X5\&1V=JN4 X]*@\:Z;%;V;
M\#I0!^??Q)\'C3WDPF,5YAI4S6>H  XYKZ.^,:Q;I@,=Z^>X[42:E\H_BH$?
M3WP2U=F>$;O2OLKPC(9+!"?2OBWX(V#"2'CTK[4\(PF'34SZ4 ;;,%4DUQWC
MC7EM+-P&QQ6]KVH"QM2Q..*^?/B;XY 61!)^M SR3XN^,V+3*'_6OF'Q%JS7
MUT^3GFO4_'%Z^J32$'.:\ONM&?SRQ6@1DV=F'F4D=Z]V^$MN$GAX[UY);6?E
MR+Q7L7PM&VXB^M S[6^%JXM8OH*]1KR[X6_\>L7T%>HT""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:?"GR8P* .TTFR^SVT?&.*TJ1%VJ!Z4Z@ HHHH **** "BBB@ HHHH ****
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M"/[0D^M3?#0?\3"/ZT"/MOX8S$VL7T%>SV)S *\2^%ZG[+%]!7MNG_\ 'N*
M+-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<
MKNB->4?$F$FUEX[&O6G&Y2*\_P#B#8^98R'':@#X,^*T16\EX[FN,\'S;-13
M/K7I?QAL#'<2G'<UX]H]]]DU)<G'S4 ?<GP9F#Q0\]A7T*D:_8,^U?'WP=\7
MI L0+@=.]?1,?CB+^S_]8/N^M 'G_P 8IE2&;GM7Q7XYFWZ@_P#O5]-?%[Q<
MDT<H#YZ]Z^3_ !!>_:]2;!S\U ';_"^(M>1<=Z^W_A=;G[)%QV%?'/PCT\R7
M4)QWK[@^&]CY=E&<=A0-'H-NNU!4U(HP!2T""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2B@!:*** "BBB@ HHHH
MCN&VPL?:O)?B)K!M[>7!QQ7J]Y_Q[O\ 2O"/BD[>3-]* /ECXK>(Y9+F4;CU
M/>O.?#B-J&H+NYR:WOB9(WVR3/J:QO LRK?QY]: /JWX0^"8KN.(L@/X5[?>
M?#NV33VQ&O3TK@/@K>1>3#R.@KWB^N$.GOR/NTBKGQ=\9/"L=GYI5 .M?,>H
M7DFGZD<$C#5]B?'&9-LWXU\9^*) VIMC^]3)/=/A'XIE:6)2Y[=Z^UOAO>FZ
MM(R3GBO@'X0[OM$7U%?>'PHS]CBSZ4#/2J***!!1110 4444 %%%% !1110
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M4 P/2O28+9+=0J#%8EMKEO H"L*T(=8CFZ8H T**CCF$G2I* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M81G[5%@=Z^XOA$I6VB^@H ]F%+2+]T4M !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS1QDGM0!ZL.@I::OW1]*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MT9/X4 =[\'_"K*\)*5]@^#;'[-8IQCBO,?ASX-%G'$2F/PKVC3[<6]NJ@8H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZE_Q[-7S
M+\;V'DS?0U],ZE_Q[-]*^9OC=:O)#-@=C0!\6^*I@-2?_>KT7X2RAKB/ZUYY
MXJTF=M2?"G[U>C?"/2YHYX\@]: /M'X9G,,7T%>M[@J@FO*/AK;M';Q9]!7I
MMY)Y=J3[4 </\1/$BZ?#)AL8%?'OQ8^)!W3*)?7O7NOQBU*5HY@I/>OB/XE_
M:KBYEQNZF@#FM6\2_P!H739?//K6]X3N(UF5B:\Y@TNZ,Q)5JZ;2X[FUQP:
M/I#POXJAT^-/G Q[UVMO\74M$ $H'XU\M1ZU=1J "U5;O7KSG#-0,^P=/^,2
MW$H'G?K7IOA'QJ+_ &?O,_C7P'X9UR\:Y7+-UKZ;^%.H3R>5N)H$?7&D7GVB
M-3G-;%<CX4D9K=,UUR_=% "T444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+)-%E#U%!1ZQ\,_"K.T;;?2OJ7P/I1M(X^,<5POPM\([88R4[>E>V:?I@M5
M H$:B?=%.I!TI:!!1110 4444 %%%% !1110 4444 %%%% !1110 W;2@8I:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]%R>#8)&R4'Y59M?#$5NP(4"@95\&:.MC ORXP*ZRJ]K;BW7 &*L4""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** $HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%%% !1110 44
MF:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $;I3:=1MH %Z4M)2T %)2T4 ,IR]*-M% "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (31NI&H'6@!U%%% !1110 4444 %%%)F@!:*2EH **** "BDS1F@!:
M*** "BBDH 6BDR*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FMUIU)B@!%IU)BEH **** &MUH7K2XHQ0 M%%% !36I
M*5: $I])@4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 FV@#%+10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->Y^$=7^V1H=V: .XHI%^Z*6@!,BEIE/H *2EIK4 +D4M,I] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$/T%?#7PC7=<P_45]U_"2/R[>(^PH&>VKPH'M6=JFJ)9*<MBFZAK4=E Q)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3(I:90 ZEIJTZ@ HHHH 3F@9[TM
M% !1110 W::5:6B@ HHHH **** "BBB@ HHHH 3(HIM*M #J*** "BBB@ HH
MHH *93Z90 X44BTZ@!.?2EHHH **** "BBB@!NTTJTM% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img222343278_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $S E,# 2(  A$! Q$!_\0
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M*Q\?:_K.AW>MB_\ LO\ 9,-H7LXXD,=VSD&1F)!8!@<+M(P?6N^?X;Z(UFD
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MEP4&GZ]:!1?::[9,9/1T/\4;=0P_G7H-<+33LSWJ=2-:*G!Z!1112-0HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^!0!9HJM]GG_ .?H_P#? H^SS_\ /T?^^!0!9HJM]GG_ .?H_P#? H^SS_\
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M2H]#3 ]UI*6BD 4C?=-+2-]TT 5-)_Y!\?U;_P!"-7*IZ3_R#X_JW_H1JY0
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MZC\#1[%2_ARO^##ZVZ>E>#CY[K\/\C6&J_$+0<"\T?3?$4"C+2Z?.8)3_P
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MT =Q25P7_"R-8U+*Z1X)UBXS]V6]V6L9_%CG]*3S/B3JRY6#0M!7TD=[I_T
M'ZT =]S4=Q=0VJ[IIHX5]9&"C]:X7_A7OB#4F)U;QQJ+QM]Z'3H8[9?H#R:D
MM_@KX64AKVVN=8DZ[]2NY)C^1./TH OZG\5?"6DR-'/KUF95_P"64+^8Y_!<
MUE_\+>AOUSHOAW7-9_VH[,Q)_P!]/BNLTSPOH^BJHL-+L[/;T,,"J?S S6I0
M!P']O?$#5&_T3PUI^DPMTDU&]WLOU5!_6OF[Q=\(/'UY\0KEIM.FO[RYN?-7
M4K?(AY.00Q^Z%]#TQ7VA13$5]/AFM]/MHKB3SIXXE623^\P !/XFBK%%(9YQ
M\<-6TNS\/Z9I^L:5:ZMI^IWR6\R7K;8XHU1I'DSU#!4.,$<FN#_9EU*UM[Z]
ML+;PUI>A6VHVBZI:-I[.\OD&1D59RY)W<;A@XP>E=I\?KZ%/"^G:8_A^T\27
M&J7Z6UO:7TA2(.%9MQ8<@X4@8ZYKG/@/XEN-8\27;7?A_1=#DO=*MKJ%]-D9
MY)85)C13GA0FW&WUIB/<J***0PI&^Z:6D;[IH J:3_R#X_JW_H1JY5/2?^0?
M']6_]"-7* "BBB@ HHHH **** "BBB@#/U_0[/Q-HM[I6H1^=97D1AFC!(W*
M>HR*\KT/]D?X9>']6L]1M-!/VFTD$L?FSNZY'JI."/8U[)15*4HZ)G)6PE#$
M24ZL$VMKGF6L?L[^#KZ[>]TVUN/#&H,<F[T&X:T;_OE?D/XK5 >%?BGX0R='
M\4V'BRS4Y^R:];^3-M'831<$^Y6O6Z*?.^I,L'2O>'NORT/)%^.E_P"&_D\:
M^"M8T +]^^M$^W6@]]\62/Q45VWA7XF>%O&T0?1-=L=0;&3'%,/,7_>7J/Q%
M=*RAA@C(]ZXKQ7\%_!GC.0S:GH-JUYG<+RW4PS@^OF)AOUIWB]R>3$T_ADI+
MST_%':TM>1GX2>+?"K;_  AX^OA"IR-/\0(+Z$^BA^)%'_ C2?\ "R?'_A$[
M?%/@1M3MD&7U#PQ.)Q_WY?:_Y$T<M]F'UIP_C0<?Q7WH]=HKS_PW\>/!/B6Y
M^R1ZU'IVHCAK'5%:TG4^FV0#)^F:[Z.19%#(P93T(.:AQ:W.JG6IU5>$KCJ*
M**1J%%%% !1110 4E+10 4444 )1C-+10!Q_BSX2^%O&4HN+_2XX[]>4O[4F
M"X0^HD3!S]:^=/VB]+^)/PYT>WM](\0ZIJGA621/](8AKN"0'Y49U )4G&#W
M/!]_KNF21I(NUU##KAAFN_#8R6'FI27,ET9XN/RNGC*4H0?))]5H>*>"?BUX
MRT/PQIZ^-_!.L/=>6NZ_TV)9U9<<,\:G<C8ZC'Y5V&B_'3P1K4QA778+*Y!P
M;?4 ;:3/IMD -=[67K'A71O$,)BU/2[/4(_[MS L@_45$JE&I)N4+>G_  36
MGA\50@HPJ\UOYE^J+]M>07D8>":.9",AHV!!J6O,[G]GWPQ'(\VC2:CX9N&.
M3)H][)"/^^,E?TJ'_A"_B-X>8G1_&EOK,*C"6VO62D_C)&5/Z&H]G3E\,_O-
M/;UX?Q*5_-._X;GJ5+7EG_"P/'OA]MNN^!3?PJ,O=:#>+,#](WVM^IJS9?M!
M>$))D@U.>[\.W3G AUFTDMC_ -],-OZT/#U+72NO+4J..H-VD^5]FK'I5%9^
ME^(-,UR'SM.U"UOXO^>EM,LB_F#5^N=IQT9VQE&:O%W%I&4,"",CT-%+2*.*
M^(WPIT?XB:$]C,B6-P'$D5Y!$N]&'KZ@]Q7.?#W]G7P]X/M;D:DL?B&ZG(S)
M=0 *BCLJY./KFO6** .-D^#G@J;EO#=B#_LH5_D:A;X)^"CTT-$_ZYSRK_)Z
M[BB@#A&^"OA8?ZJWO+?_ *Y:A./_ &>FGX,Z,/\ 5:EKL'_7/59A_6N]HH X
M'_A4-LO^K\3>)HOIJ1/\U-+_ ,*MNH_]1XT\11_[\\;_ ,TKO:* ."/P]\0Q
M_P"I\?:LO_72W@?^:TG_  A/C!/N>/YS_P!=-,A;^1%=]10!P7_"+^.X?N>,
M[6;_ *[:4H_D]4=>TGXF1Z)?BUUO2;F;R'"+'9/'*3M/W3NP&]/>O2Z* /B[
MX.Z+XVN/B$D5A-J&ESDL+Z[FB+B-<')=6X8YZ9KZ3_X53+J&&UGQ7KNI-W6.
MX%M&?^ Q@?SKO<#TI:8''Z?\(?!^FR"5-"MKB;O)=YG8_4N374V=C;:?'Y=K
M;Q6T?]R% @_(5/12 **** "BBO-?%7Q*U#0_%EUIT)L#%;M:[;60-]HN?-;:
MPCP<97KT/% 'I-%>1:_XN\8)I6J?:K:33[5"J_:TM/*9$,@!8/YK_P .><>_
M%'_"774/PWU$0ZI)+,MU(MK=E]TK62RA?.#=P 3\U.P'KU%>,6DE[KUGI%K!
MK>I![C59[6TNHKDXEM(SO9R?XSM!4-6SX2UV/4OB9J5K9:_+>V]LLL=S#<S@
M[Y=PPL4?98P""W<GO0!Z=1244@/#_BY\7+?3-9U.PG\&2>(M)\-?9KZ]O/.5
M/LT[?- 44\GG&2/4TGP)2+3?&_B:QU#PA9^&O$4\,5_))97#31RPR$D* Q^0
M@YR!QDU-\1/@'K?C'Q!XDN[#Q6-*T[7DMTN[+[*)-WE* OS9]1FN@^&_PMUS
MPKXLU#7M>\2CQ!=W5G'9J1;"'8B,2.AYZTQ'IE<IXR^)FC>!;B"'5/M7[Q/-
M>2"W:2."/<%WR,.%7) KI+Z"2ZLIX89VM99$95G0 M&2,!@#QD>]>1_$#P+X
MPU+PO'X=A:/Q3'*N[^UKRY%K/;W <%'95&UXP/X0,DBD,[(_%CP[_P )<OAW
M[1,;UI5M_.$1\CSBN\1;^F\KSBNP;[IKQ"/X5>)E\;P+*MM-I']NPZ_)J8FP
MY=(0C1>5C.2PSG.,&O;VZ&F!4TG_ )!\?U;_ -"-7*S-+M UDC>;,.6X#G'W
MC5K[$/\ GM-_W\-("S15;[$/^>TW_?PT?8A_SVF_[^&@"S15;[$/^>TW_?PT
M?8A_SVF_[^&@"S15;[$/^>TW_?PT?8A_SVF_[^&@"S15;[$/^>TW_?PT?8A_
MSVF_[^&@"S15;[$/^>TW_?PT?8A_SVF_[^&@"S15;[$/^>TW_?PT?8A_SVF_
M[^&@"S15;[$/^>TW_?PT?8A_SVF_[^&@"S15;[$/^>TW_?PT?8A_SVF_[^&@
M#,\1^!_#_B^W,&M:-9:G'Z7,*OCW!(XK@&_9_AT%C+X+\4:UX3<$L+6*X-Q:
M%O>&3(Q],5ZE]B'_ #VF_P"_AH^Q#_GM-_W\-4I-'-4PU&H[RCK]S_ \K_M;
MXN>#5Q>Z3I/CBS0<S:?(;*[;WV-E#^!%6;']HSPQ'<+:^(8-2\(7N=GEZW:M
M$A;T6490CWS7I?V(?\]IO^_AJ"^T*TU*W:&[C^UPL,&.?YU/X&JYD]T8^PK4
M_P"%4^3U_$\3U?\ ;9^&NCZE=V4D^HSO;2-$TEO;!XV(.,JP;D>]>W:+J]OK
M^D6>I6NXVUU$LT>\8.UAD9%?"/C3]B;X@ZGXLUN[TFWT>+3+B[EDM8S>;=L9
M8E1C;QQVKZ1\._L^:EI?AW3;:+Q]XHTFZAMT26&VO_,A5P.0H8=,UM4A327*
MSPLOQF:U*LXXJC[JVZ?GN>UT5Y$WPG\>V(SI_P 5M2D;L-0L()1^@%,7PO\
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M^MKY*-GY"HW-D9.2!7L?B;X2^$/&7B+2-=UK0;6_U;26#6=S)N!CPP89 (#
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MY94ZGGN*XCX0:;HW[.>B0:?J?P\U'1[A;*WM+S7K4-?QW B7:I+!F*#JVT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOBY-<V_PM\726;RI
M=II-TT+09WAQ$V"N.<Y]*^6/AS\"_'_Q$\$N)[J]\*Z5?6.DW21ZQ?O>R7%X
MD4OVBX 4@QAQ)%\I/53Q7VGUZT=.E 'QEJ7[+OC?2O%6FV4,-KK]I>#2=^OF
M8(=,^QW\MS( CY<[T<*-IZDYK=^*WPC\=?$?XC0:W%X9CMH=:MM,M9)[B]C:
M31#9Z@UP[C ^;S(\8V=S@U]8T4#/A%_V8_B*^EZC;+H%M;MI=I]@\^&\C$VL
M@ZFUV9XFQB.58V 4R9PP(KZ;_9I\%ZU\/_A-8:/KUJEG>I<W,RP^8LDJQR2L
MZ>:Z_*TN&^8CC->IT4""BBB@!*"-W6EHH P->\ ^&_%$+1:MH>GWZMU\^W5C
M^>,UQ%Q^S7X2AF,^B2ZKX8N /E;1]0DB53Z[,E?TKU:BJ4FMF<T\-1J?'!,\
MC7X=_$OP\H&B?$5=3B!SY/B"P64GV\Q,-0/&WQ4\.ESJW@6RUV!>!+H-^ Y]
M_+D']:];HI\W=&7U7E_AS:^=_P '<\GC_:0T"QF6#Q%I.N>%IOXO[2T]_+7_
M (&@(K?D^.'@?_A'[W6;?Q'8WMG:1F606TRM)M'7"9R3[8KMIHXY8V655>/'
MS!P",>^:\;^)7PQ\%_%KP'KDGAK3-!U/6%BDAM[RT,:^7..S.G0CWIKD;U,J
MJQE*$G3:DTNJU_#3\!OA;]KSX=>,/$%AHVGWUX;V]D\J+SK5D3=@GECTZ5Z)
MK'Q,\)^'T9M1\2:7:!>HDNDS^6<U\&?#C]G#4M.\1Z5KOB6^\.R^#[.\$6I7
M,>LQ-&O!!0LI^]G'&<U]K:-\+_AIX<O+.WLM!T.*[O$9[9'C22295 +,N[)8
M $'(]:UJ1IQ?NNYYF68G,\33D\134'TO?\O^"9][^TQX!AXL]4GUE^FS2[.6
M<Y].%Q^M0'XZ:GJ04Z%\-_%&IQMTEN(4M$_-S_2O4;33;2P39:VL-LG]V&,(
M/R JQ6-X]CV/9XB7Q5+>B_SN>2-XH^+VK2#[%X-T31H6Z-J6I&5U^JQBG?\
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MH\M?[H_*@"/[9;_\]X_^^Q1]LM_^>\?_ 'V*D\M?[H_*CRU_NC\J (_MEO\
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MY'#Y[P%P'6/IO(]/>KM?/G[3$U]X7U_0M=TR-Y+G5+2X\/'RQ]UIL%'/T.:
M/:[?QAH=Y9V=W!JUG+;7DH@MIDF4K-(?X%.>3["MBOD[PYX9O?"GQ)B\#6EH
MUQ8^%1/X@M-P)#NUN%C'_?S=^=3>#/BAXSET?4K^UU=M9OFT.XO;BRFD25[>
MX4_*RQJH,8'(V,3FF(^H=3U2ST6QEO+^YBL[2/&^:9@J+DX&2?<BK*L& (.0
M>17R'J_BK6M>^%?C2"?63KUA_9MG<'S;A)Y8KAIDR-R* H;^X>5Q747'C;Q3
M_P (#KG]H:ZVB^++?6(8+RTE81PPP,,QQPR!6"*ZX_>-GD&@9]*T5YK\!O%=
MQXJ\)79NI;R>>SO9;8RW<L<P.,$!)4 611G&[':O2J0!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'-;Q7&WS8TDVG<
MN]0<'U%%%  +>)9C,(T$Q7:9-HW$>F?2HX;&VM7E>&WBA>4YD:- I<^IQUHH
MH ;'I=G##)%':0)%(=SHL:A6/J1CFGR6-M-YGF6\3^8 K[D!W = ?6BB@!]O
M;Q6L*Q01)#$HPJ1J%4?0"I*** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img222343278_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %P T(# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMXPU1791X+UL@$C(\KGW^_3?A]97]KIVJS:A8S64EYJ<]S'#,P+*C$8S@D4
M:UUX4T6]U8:G<6*O<Y5F.Y@KLOW2RYPQ'8D4Y/#&CQZT=72R47I8ONW':'(P
M6"YP&(XSC-:]% !7->"_^/+5?^PK=?\ H==+7->"_P#CRU7_ +"MU_Z'0!/J
M7_(XZ'_USN/_ $$5O5@ZE_R..A_]<[C_ -!%2>*9[VTT"YO+"[^SS6ZF3)B#
MAO8@U"=KO^MCIE#G]G%=5^K-JBJVGI.EA"+FX-Q-MRTI0+NS[#@59JT<[5G8
M****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI:T.1[A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI"0!DG H 6BD#!NA!^E+0 4444 %%%% !1110 4444
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M*FI&^Z?I0--IW1SO@>TM[;PO:O#&%:4%I#DDL<D9.:Z.L/P=_P BI8?[K?\
MH1K<J8?"C;$MNM-ONPHHHJC **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,3Q?_R*E_\ [J_^A"MH?='TK%\7_P#(J7_^ZO\ Z$*VA]T?2I7Q,VE_!CZO
M\D+1115&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YSX\O-7AU>1+'5)=,6.R%PGV>V5WNL/^\!9@?N+SCWS6WX
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MD;[I^E)I,<9RBTTSD_!6AZ?'HEM?F$27$J%2TGS;0&(POH*ZA[>"3&^&-L#
MW*#@5D>#O^14L/\ =;_T(UN5,$N5&V)G)UI7?5D;V\$F-\,;8&!N4' H>W@D
MQOAC; P-R@X%2459A=D3V\$F-\,;8&!E0<"A[>"3&^&-MHP,J#@5+10%V1/;
MP2 !X8VVC RH.!0]O!( 'AC8*,#*@XJ6B@+LB>W@D #PQL%&!E0<4-;P.%#P
MQL%&!E0<5+10%V1M;P. 'AC8*, %0<4C6\#A0\,;!1@ J#BI:* NR)K>!PH>
M&-@HP 5!Q0UO X4/#&P7@ J#BI:* NR)K>!PH:&-@O !4'%#6\#JJM#&P7@
MJ#BI:* NR)K>!U56AC8+T!4'%#6\#JJM#&P7H"H.*EHH"[,#Q?#%_P (I>_N
MD^55V_*./F'2MHV\#HJM#&P4< J#BLGQ?_R*E_\ [J_^A"MH?='TJ?M,V;?L
M8^K_ "1&UO ZJK0QE5Z J,"AK>!E56AC*KT!48%2T51C=D36\#JJM#&57H"H
MP*&MX&55:&,JO0%1@5+10%V1M;P,JJT,95>@*C IZHJ*%10JCH ,"EHH"["N
M(E\ WL$MU!HWBB^TS2KN1I);*.)'V%CEO+<\H#S],UV]% CS/7="BTW4;>WL
M=%N+D16T4%KO@\^)PIZ;\AHFSU;OUJ:"RGB\:H\>B3F=[LRS230@JBD<NEP#
MDC_8(KT:B@"E?Z/IFJE#J&GVMV8\[//B5]N>N,CBGVFFV-A:M;6=G!;P,23'
M#&$4YZ\"K5% ''O\-?#2Z]IFJ6NF6ELUD[N8XX1B1B."3VVGD5MS:(LWB>UU
MLSL&M[9[<1;>&W$'.?PK5HH X_Q'X/U/Q#8V]M)XA:,0W;7!!M$9)!_ C*3@
MA??K6YH5AJ6G6+0ZIJQU*;>2LOV=8<+V7"\5J44 >=:5X2U+47UJ&^O[BVTN
MXU:69[,Q#,J!@1M?J%;'-9.HZ3J\]W<:'8VNI6UL^J)<BW,*M!M$@9G\[/"'
M&=F,YXKUNB@#FG\(1OIMK:F\??#J(U!Y=@S(^XM@CL.<?A3;OP;'=1>)$-[(
MO]M[-Q"#]SM4+QZ]*Z>B@#B[GP9K4>KWE]H_BJ33DNQ'YD7V))?F1 N<M["N
MQA1T@C263S)%4!GQC<<<G':GT4 %%%% !114<[%+>1UZJI(_*@#CSX$O+*6X
M30O$U]I5A<2-(UI'&DBQLQRQC+#*9/..:Z'0="L_#FD1:=8A_*0EF>1MSR.3
MEF8]R3S7%^'/'5[=CPC#>7%H[:I#=/=R$A2IC^[@9P*]$BFCF3?%(DB],HP(
MH ?13#+&LJQ&11(PR$)Y(^E'FQF4Q"1?, R4SSCUQ0 ^N:\%_P#'EJO_ &%;
MK_T.NEKFO!?_ !Y:K_V%;K_T.@"?4O\ D<=#_P"N=Q_Z"*WJP=2_Y''0_P#K
MG<?^@BMZICNS:K\,/3]6%%%%48A1110 5A>&OOZS_P!A*7^2UNUA>&OOZS_V
M$I?Y+4O=&T/X<_E^9NT4451B%%%% !1110 4444 >83'^U=86YO]2D@F66Y7
M:K[?LX1<KCZ_K7<^&KRXO_#]I<W63*RG+$8W ' /XBLK6]'T^Z\6:1YUI&WG
MB8R]M^U01FNJ1%C1410JJ,  8 %94XM-G=BJL94X)+_@:O\ KY"T445J<(44
M44 %%%% !5;4?^07=_\ 7%__ $$U9JMJ/_(+N_\ KB__ *":3V*A\2*?AG_D
M6-,_Z]D_D*U:RO#/_(L:9_U[)_(5JTH_"BJW\27JPHHHJC,**** "BBB@ K!
MT[_D<-;_ .N=O_Z":WJP=._Y'#6_^N=O_P"@FIENC:E\,_3]4;U%%%48A111
M0 4444 %%%% !1110 4444 %%%% !1110 4C?=/TI:1ONGZ4 8G@[_D5+#_=
M;_T(UN5A^#O^14L/]UO_ $(UN5,/A1MB/XT_5_F%%%%48A1110 4444 %%%%
M !1110 4444 %%%% !1110!B>+_^14O_ /=7_P!"%;0^Z/I6+XO_ .14O_\
M=7_T(5M#[H^E2OB9M+^#'U?Y(6BBBJ,0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "D8;D(P#D8YI:0YVG'7'&: /%;OP[>
M6%U,=4\)>'+:'S&*746GR3QE2>K%6ROOQ7HW@6&V@\.*+1])>%I&8'2U*Q?D
M23N]:Y2[T+XA:E=3-JKV%W;%CY=K#>R6T87L&VKN;\37:>$].FTK1%M9]+T_
M365R1!8,3'CUR0#D]Z .2\7P:6FIMJMI<027MK?0?;096^TH,KMCA[#.>1T(
MS5.W6V%S9:BC@^(9/$#PS'=^\,>Y@R$?W @''0<&O1YM&TR?4H]1FL+:2]B&
M$G:,%U^AIRZ1IR:FVI+8VXOF7:;@1C>1]>M $E]+<P6<DEG:_:IU'R0^8$W?
MB>!7.^ GFETC4)+B#R)FU.Y+Q!PVP[^F1UKJJYKP7_QY:K_V%;K_ -#H KZI
M?R+XZTN,11;80Z_-+AFW@<A<=L5UM8M__P C3H__ %SG_P#015K6=1ETK3I+
MR.T-RL8RZJX4@>O/6K]FM.7=_P##"E7<E[RTCII?U\^YH45!9S2SVD<L\'D2
M,,F/>&V_B*GJ6K.P)W5PHHHI#"L+PU]_6?\ L)2_R6MM]VQMF-^#MW=,^]8G
MA_3M5T^:^-_)9O'<S-./(# JQP".>W%2]T;4[>SE=]C=HHHJC$**** "BBB@
M HHHH PM3_Y&W0OI<?\ H K=K"U/_D;-"^EQ_P"@"MVICNS:K\,/3]6%%%%4
M8A1110 4444 %5M1_P"07=_]<7_]!-6:HZS,T.D7)2WFG9HR@CA3<Q)&.E)[
M%P5Y)$'AG_D6-,_Z]D_D*U:R?#'F#PW81S6\UO+%"L;QS+M8$#!_"M:E'X45
M6_B2]6%%%%49!1110 4444 %8.G?\CAK?_7.W_\ 036]6#IW_(X:W_USM_\
MT$U,MT;4OAGZ?JC>HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH **** "
MD;[I^E+2-]T_2@#$\'?\BI8?[K?^A&MRL/P=_P BI8?[K?\ H1K<J8?"C;$?
MQI^K_,****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GO&D_E^&[B
M%89Y9)\*BPQ%SD$'G'3I6Y;3+<6T<R!@KJ" Z[3^([5+12MK<T<TZ:A;9O\
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M-89=JC/7C'?I6M11222*E.4DDWL%%%%,D**** "BBB@ HHHH **** "BBB@
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MZUV&2>%;A]6GVH6 =AQVZFEK?0TBH\LG+IL:U_\ \C5H_P#USG_]!%2>)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=H(8GMUI.+>J.FE.DJ;4NOK\K=-SUFBN8_X5_P"'/^?2;_P*E_\ BJ/^%?\
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M])O_  *E_P#BJ .GHKF/^%?^'/\ GTF_\"I?_BJ/^%?^'/\ GTF_\"I?_BJ
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M?\^DW_@5+_\ %4 =/17,?\*_\.?\^DW_ (%2_P#Q5'_"O_#G_/I-_P"!4O\
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M.0KJQ5@#Z9!K4K-T'2%T/1;?3UE:8Q@EY6&"[L2S'';))K2H **** "BBB@
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MNU2YP,*.P  'X5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JIJ5A'JFGS64LLT4<R[6:"0H^/8CI
M5NB@"&UM8;*TBM;>,1PPH$1!T  P!4U%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img222343278_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222343278_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $? G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBLS6]=
ML] M([F]\SRY)!$OEKN.3G_"A*Y,I1@N:3LC3HH!R :*"@HHHH **S-5UVST
M::RBNO,W7DHABV+GYN.OIUK3HL2I1;:3U04444%!1110 4444 %%%4DU%7U5
M]/\ LUT&1-_G&$B(]. _0GGI0)R2W+M%%4_[5LSJ_P#9:RAKP1&5HP/NKD#)
M/XT Y);ERBBB@84444 %%%9NE:Y::Q+>1VOF;K.4PR[UQ\P]/4<46)<HII-Z
MLTJ***"@HHHH ***SM;UJTT#3S>WOF>2'"?NUW')HW)E)13E)Z(T:*;&XEB2
M1<[64,,^AIES<PV=M)<7$BQPQJ6=VZ "@=U:Y+166^NVXL+.]AM[RXANR/+,
M$!<@'H6'85J46%&<9;,****"@HHHH **** "BJ::I9R:M)IB2AKN.+S70#[J
MY&,G\:M.^R-GP3M!.%&2?I0)23V8ZBJFG7ZZE:"X6WN8 21LN8C&_'L:MT F
MI*Z"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<1\3_ /D 6?\ U^I_(UV]9'B+
MP]!XDL([2XGEA5)!(&BQG(!'<>]5%V=SGQ5.52C*$=V7;VV-YID]LLCQ-+$5
M#HQ!4D<$$5YJNNZA>^%[#05N9DU9[_[)+()"'"J<DD]>X'X&NJA\)OI\R7C>
M(-:G6W/F&)IMP<#G&,<Y]*R?#NF?VGX]O_$"V,]O9J/W/GQE"\A !8 _C^=5
M&R1QXCVLY15K-Z/7INW\OU([VRN]3^(4VD1ZM?6MI'9H["&8@G  _/)R34.N
MSK+?:C%9WNNWLUG#MQ;R>7%;%5ZLW\1XR?QKM(]!@C\33:X)I3/+"(3&<;0!
MCGIG/%9]SX)LI[^\N([V^MXKTYN;>&0*DA]^,]Z%)!/"U+2Y5JV^O3IY$7AN
M)O$7A;1KO4IY99(7,IY&)&5B%+>N, _6N5OKB_L[^\;7YM=M9#.3!>6CDP(F
M>!M'%>B:'I$>A:3%IT,TDL41;:TF,X)SCCZUD7'@F&?[1$NKZG':7#;I;83!
ME;U&2"<?C0I*['5PU25*%OB2UUZVZ_\ #F_I\\=SIUM-%<?:(WC4K-C&_CKB
MO/M"L;O77U]I]:U&);:ZD6%(IR-IYY/J. ,=.M>B6EI#8V<-K;H$AA0(BCL!
M7GWAWPS+J$NNM+<ZAI[27CH3$=@EC)/&".1SU'K1%K4O$QE*5--7WOKY&;-K
M6K:OX?\ #F+Z:"ZEO7MGGC8J7' #''7K^E;6H6]W9ZSH_A6#5;X6]SOGGN7E
MS,X&?E#=AQ^M;TG@[3C!I,$+2P1:;+YL2J0=YR"=Q([D5;UKP]::WY$DKRP7
M-NVZ&X@;:Z'V-/F1E'"5N5N3N_=Z[I6NOF<O]HO-"\37NAI?7-S9S:>]Q&9Y
M"[PL >C=<<?J*R;&WOY/AZ?$!US4/MD 9XAYY* *V,$=\\]:["/PS;Z9;:G>
M>=<WNH3V[HUQ.VYR-IPH '':N>\+^#DU'PI:I>W.HV\4C%I[,-L1R&."01D<
M =*::M<SE0J\_+;=2LK[;6^XAN9]0\1>)="@&HW5DE[IBS3"WD*\_,3@=,G
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MH **** "J]Q=?9V"_9YY<C.8TR!5BB@3OT*/]I?].5Y_WZ_^O1_:7_3E>?\
M?K_Z]7J*9/++N4?[2_Z<KS_OU_\ 7H_M+_IRO/\ OU_]>KU% <LNY1_M+_IR
MO/\ OU_]>C^TO^G*\_[]?_7J]10'++N4?[2_Z<KS_OU_]>C^TO\ IRO/^_7_
M ->KU% <LNY1_M+_ *<KS_OU_P#7H_M+_IRO/^_7_P!>KU% <LNY1_M+_IRO
M/^_7_P!>C^TO^G*\_P"_7_UZO44!RR[E'^TO^G*\_P"_7_UZ/[2_Z<KS_OU_
M]>KU% <LNY1_M+_IRO/^_7_UZ/[2_P"G*\_[]?\ UZO44!RR[E'^TO\ IRO/
M^_7_ ->C^TO^G*\_[]?_ %ZO44!RR[E'^TO^G*\_[]?_ %Z/[2_Z<KS_ +]?
M_7J]10'++N4?[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZO44!RR[E'^TO^G*\_[]
M?_7H_M+_ *<KS_OU_P#7J]10'++N4?[2_P"G*\_[]?\ UZ/[2_Z<KS_OU_\
M7J]10'++N4?[2_Z<KS_OU_\ 7H_M+_IRO/\ OU_]>KU% <LNY1_M+_IRO/\
MOU_]>C^TO^G*\_[]?_7J]10'++N4?[2_Z<KS_OU_]>C^TO\ IRO/^_7_ ->K
MU% <LNY1_M+_ *<KS_OU_P#7H_M+_IRO/^_7_P!>KU% <LNY1_M+_IRO/^_7
M_P!>C^TO^G*\_P"_7_UZO44!RR[E'^TO^G*\_P"_7_UZ/[2_Z<KS_OU_]>KU
M% <LNY1_M+_IRO/^_7_UZ/[2_P"G*\_[]?\ UZO44!RR[E'^TO\ IRO/^_7_
M ->C^TO^G*\_[]?_ %ZO44!RR[E'^TO^G*\_[]?_ %Z/[2_Z<KS_ +]?_7J]
M10'++N4?[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZO44!RR[E'^TO^G*\_[]?_7H
M_M+_ *<KS_OU_P#7J]10'++N4?[2_P"G*\_[]?\ UZ/[2_Z<KS_OU_\ 7J]1
M0'++N4?[2_Z<KS_OU_\ 7H_M+_IRO/\ OU_]>KU% <LNY1_M+_IRO/\ OU_]
M>C^TO^G*\_[]?_7J]10'++N4?[2_Z<KS_OU_]>C^TO\ IRO/^_7_ ->KU% <
MLNY1_M+_ *<KS_OU_P#7H_M+_IRO/^_7_P!>KU% <LNY1_M+_IRO/^_7_P!>
MC^TO^G*\_P"_7_UZO44!RR[E'^TO^G*\_P"_7_UZ/[2_Z<KS_OU_]>KU% <L
MNY1_M+_IRO/^_7_UZ/[2_P"G*\_[]?\ UZO44!RR[E'^TO\ IRO/^_7_ ->C
M^TO^G*\_[]?_ %ZO44!RR[E'^TO^G*\_[]?_ %Z/[2_Z<KS_ +]?_7J]10'+
M+N4?[2_Z<KS_ +]?_7H_M+_IRO/^_7_UZO44!RR[E'^TO^G*\_[]?_7H_M+_
M *<KS_OU_P#7J]10'++N4?[2_P"G*\_[]?\ UZ/[2_Z<KS_OU_\ 7J]10'++
MN103>?'O\J2/G&V1<&I:**1:"BBL_4;IU>.TAE6%Y 6>5O\ EF@ZGGOD@"IE
M+E5Q-V1>:1$(#NJD],G%.K#A31!=2V["VE=41VEF=7+;BPZGG/R_K4=M<0P6
M46I6#_Z&P5I[;?N" _Q#T([CIBI<I15Y+0GF:W.@HHZUY=J.L7JW>O/_ &GK
M22VUS(MNEM%N@4#H&...??I6T8W,L1B%02;5[GJ-%<#=^)-0L;F>Z-PLP30D
MN BG,1E+@;A[<_E4UW_;'AZVT_59-;GO?.FBCN;>55V,'/\ !@<8I\AG]<CK
M9/3?R.XHKC;>/5?$MSJ=Q#K5QI\=K=/;6\4*KC*8^9\\G)/2I;E]4U/Q$FAC
M5)+5+:S6:XFMT"O,Y..,YVCO2Y2OK-U=1>NVVOXG6T5YOJ6KZS;:1JNFC49'
MN[&]@ACNTPKNDG0''<5#+XFU.\O_  ^D%Y)&L;PPWJJ<;Y&<@@_]\'\Z?LV9
M2S"FG9IW_P"#9_<>G45Y5+K=]OOS;ZWJ3:M'?O';621[XW4/@ _+CIGO6CJ_
MB>[M_$[W*Z@D=EI\L,$]J''[W=GS& ZG;D?E1[-B684[7:_+S_*QZ)17%^(;
M6]BU[3%M]<U&*+4;AD9$==L8"Y^7C^>:S-8U'4M.B\0VZ:G=M]D>S2.0L"X#
M ;B..IH4+FE3&*FWS1V].U_R/1Z*X#1M4NAX@>UCU#4Y+9K.20KJ<>Q]XZ;.
M 3[UT'A6[N+SP99W5Q,\L[PL6D8\DY-)QL72Q4:CLEW_  M_F;]%>;>&+^>_
M&GR76J>(7N))!N"Q9MSANA;;]W YY]:V/'][J5I#IJZ9<R02R3,#L/W@%S@_
ME3Y-;$1QD71=:VFGXG8T5Y[;>([W5/'5@UO=N-,E0IY2GY6<1;SGZ%@/PJOX
M:OY]0%D]UJOB)KB27#!(LVYPW +;>F.O/K1R,E8^$I6BNK7W6_S/2J*\YU#4
M=8LM7N9M0U#4+*,7/^CS1P"6S\K/ ?'.?6M*3Q*]AXJUF"?[;<0"*$P);PF5
M8R5R3QTSQ1R,I8V%[25M;?G_ )':45A>#;NXOO"=A<W4SS3.K%G<Y)^8UNU+
M5G8Z:<U4@IKJKA1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *J:GJ-MI&EW.HW;%;>WC,DA R<#T'K5NN(^*EPP\)1
MV"'Y]0NXK;'JI;)_E4S?+%LJ*O)(VK?Q9IMS;13H)PLJ!U#1X.",\U+_ ,)-
MI_\ TU_[XKC0H10BC"J,#Z"EKG]K(V]G$['_ (2;3_\ IK_WQ1_PDVG_ /37
M_OBN.HH]M(/9Q.Q_X2;3_P#IK_WQ1_PDVG_]-?\ OBN.HH]M(/9Q.Q_X2;3_
M /IK_P!\4?\ "3:?_P!-?^^*XZBCVT@]G$['_A)M/_Z:_P#?%'_"3:?_ --?
M^^*XZBCVT@]G$['_ (2;3_\ IK_WQ1_PDVG_ /37_OBN.HH]M(/9Q.Q_X2;3
M_P#IK_WQ1_PDVG_]-?\ OBN.HH]M(/9Q.Q_X2;3_ /IK_P!\4?\ "3:?_P!-
M?^^*XZBCVT@]G$['_A)M/_Z:_P#?%'_"3:?_ --?^^*XZBCVT@]G$['_ (2;
M3_\ IK_WQ1_PDVG_ /37_OBN.HH]M(/9Q.Q_X2;3_P#IK_WQ1_PDVG_]-?\
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M#."#CJ,T#N:U%4#K6G!I@;N,&$$OG/&#@X]<$@<9Y.*1-<TV5X42Z5FE)"J
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MJ6H)+6.3)7Y&]5H GHJNLC0@+/G':0<C\?2K ((R#D4P"BBB@ HHHH ****
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M^FLK2R*(Q&5"*9),.3C:WR[3M;!X&#S0&AH6>A74^AW]KJ$JQS7MRT[%%'R
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M+15<&2W.')DB_O=U^M6 01D'(-, J$P%#N@;8>ZG[I_PJ:B@")9QN"2#RW[
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MSPN'BD4.C#H0>0:DJ3H3OJ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\)GXM^V(<Z-I+%+;TGF[O]!VK:\?^(9KNX'A/1Y2MU.N;Z=?^7>'N/\ >/\
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MC)&TSR,^%QTQQ6%JOQ#\3ZM"T$NI/!;L,&*V41*1^'/ZUR]%.XP)R<GK76>
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M\D",?RKSK4^%;Z5Z"HQ86 [_ &6/^5:0W./,/@0G:O0-._Y!EK_UR7^5>?\
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M94_U%:3Q)(/F%5)=,CDZ8J#INFM3;M]2LKM 4D1O]TYJ4K;/_$*Y&30@6RH
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M?\@RU_ZY+_*NNCNSQ:NR+-%%%=!@%%%% !1110 4444 %%%% !1110 4444
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M715S'A9_+\5!/^>L$B?IG^E;ZWD6=LF8V'9A6L#RLP7[RY8[5Z!IW_(,M?\
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MK,JO^!%:0W//S&/PR(%BC3E44'U KT/3O^09:_\ 7)?Y5Y_VKT#3O^09:_\
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M!X<QW;F28%CRV ,CT^Z.GI1H/4QX/%;;[U+FPE62VDD+HFTF.% N78YP>6/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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KC'45Z!IO_(,M?^N2_P JD^R6W_/O%_WP*E "@!0 !P *WA3Y6>?.?,?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>lyra-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T19:03:37.2075+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lyra-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lyra-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:href="lyra-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:href="lyra-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:href="lyra-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="lyra-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestments1" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="lyra-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpense" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreement" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="lyra-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:href="lyra-20221231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="lyra-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lyra-20221231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="lyra-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanTables" xlink:href="lyra-20221231.xsd#Role_DisclosureRetirementPlanTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:href="lyra-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="lyra-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:href="lyra-20221231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DocumentDocumentAndEntityInformationAbstract" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntitySmallBusiness" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityExTransitionPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityShellCompany" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:label="lyra_VestingOfRestrictedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:label="lyra_VestingOfRestrictedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:label="lyra_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_ModificationOfLeaseAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GoingConcernPolicyTextBlock" xlink:label="lyra_GoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_RestrictedCashPolicyTextBlock" xlink:label="lyra_RestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OtherAssetsPolicyTextBlock" xlink:label="lyra_OtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:label="lyra_SignificantSuppliersPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:label="lyra_PatentsCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesTextBlock" xlink:label="us-gaap_GuaranteesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_GoingConcernPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_RestrictedCashPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_OtherAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_SignificantSuppliersPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_PatentsCostsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_CashProvidedByFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ShortTermInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesTable" xlink:to="lyra_AccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LeaseRelatedCostsCurrent" xlink:label="lyra_LeaseRelatedCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_LeaseRelatedCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_EstimatedOfferingCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_WarrantsExercised" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommercialRevenueBasedMilestoneAwardsMember" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_MarketBasedConditionAwardsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_InducementAwardPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_CommercialRevenueBasedMilestoneAwardsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PerformanceObligationsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_CombinedPerformanceObligationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentMilestoneAchieved" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lyra_IRC382Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LeaseInitiationDate" xlink:label="lyra_LeaseInitiationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WatertownLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_PercentageOfAnnualRentIncrement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LeaseInitiationDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DefinedContributionPlanMaximumContributionEmployeePercentage" xlink:label="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>lyra-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T19:03:39.5200+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OtherAssetsPolicyTextBlock" xlink:label="lyra_OtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesTextBlock" xlink:label="us-gaap_GuaranteesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LeaseRelatedCostsCurrent" xlink:label="lyra_LeaseRelatedCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:label="lyra_PatentsCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GoingConcernPolicyTextBlock" xlink:label="lyra_GoingConcernPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DefinedContributionPlanMaximumContributionEmployeePercentage" xlink:label="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_RestrictedCashPolicyTextBlock" xlink:label="lyra_RestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LeaseInitiationDate" xlink:label="lyra_LeaseInitiationDate"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommercialRevenueBasedMilestoneAwardsMember" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:label="lyra_VestingOfRestrictedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:label="lyra_SignificantSuppliersPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DocumentDocumentAndEntityInformationAbstract" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:label="lyra_VestingOfRestrictedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:label="lyra_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal jurisdiction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of lease agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Modification of Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ModificationOfLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain Executives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: effects of discounting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertible preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Activities Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Activities Performance Obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development activities performance obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alternative investment, change in valuation technique</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment, Change in Valuation Technique [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds to be occured from future issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds To Be Occured From Future Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds to be occured from future issuance of common stock,.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stock and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of issued and outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_InducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common shares increase automatically in each year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Shares Increase Automatically In Each Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common shares increase automatically in each year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone achievements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Achievements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MilestoneAchievementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Achievements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting for Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WalthamLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Included in Accounts Payable and Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Value Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of exercise warrants common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted to employees, directors and consultants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State jurisdiction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company match percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share -diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture and fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding a December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations Of Credit Risk And Off Balance Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentrations of credit risk and off-balance sheet risk.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on impairment of long-lived research and development assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post-Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post-Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PostMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post-milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease related costs current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease related costs current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of private placement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC 382</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I R C 382 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IRC382Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IRC 382.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense relating to unvested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development activities performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Activities Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development activities performance obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Shares Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares upon exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third-party research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Redeemable Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Bonds and U.S. Government Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds and U.S. Government and Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds And U.S.Government And Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds and U.S. government and agency securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs incurred but not yet paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Performance Obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined performance obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Criteria Related to Scientific Mileston</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance-Based Criteria Related to Scientific Mileston [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance-based criteria related to scientific mileston.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-fundedwarrants, net of issuance costs of $4,244</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Matching contribution expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Costs of Retirement Plans [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 31,827,659 and 13,007,178 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Secured Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured debt obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds for warrant exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits income tax penalties accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities Operating lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software And Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Software And Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants in conjunction with sale of Series C redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of convertible preferred stock to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Executive Officers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds and U.S. Government Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and expected to vest at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the patents cost policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Accretion of convertible preferred stock to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss of Attributes - IRC 382 Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation ownership change.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease terms and discount rate related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Period of recognition (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested stock options expected to be recognized over a weighted-average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DevelopmentMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock and warrants to be issued during period value preferred stock and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrants to be issued during period value preferred stock and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in deferred tax asset valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premium on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Underwriters' Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and other tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern policy text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Bills</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contribution employee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined contribution plan maximum contribution employee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan maximum contribution employee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Supply Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Supply Agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2005 and 2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Five And Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand five and two thousand sixteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights Number Of Votes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock voting rights, number of votes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of restricted stock unit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting Of Restricted Stock Unit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon RSU vesting, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Of Common Stock Reserved For Future Issuances Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares of common stock reserved for future issuances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of shares as percentage lower of fair market value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of shares as percentage lower of fair market value of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease initiation date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Initiation Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease initiation date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance maximum number of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research &amp; experimental expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research and Experimental Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and experimental expenditures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Vested and expected to vest at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Revenue Based Milestone Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Revenue Based Milestone Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial revenue based milestone awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, hold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance initial public offering, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Obligations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of preferred stock allocated to warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Sales Agreement2021 A T M [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_OpenSalesAgreement2021ATMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open sales agreement (2021 ATM) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Change in the Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Milestone Method [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation, date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_EstimatedOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Outstanding at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Outstanding December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share -basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold, public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued and sold, public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash provided by financing activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_CashProvidedByFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund raised for operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of common stock and pre funded warrant net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Common Stock And Pre Funded Warrant Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Suppliers Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant suppliers policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain on short-term investments, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document - Document And Entity Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Watertown lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Watertown Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_WatertownLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Watertown Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Match cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment recognition in future periods to settlement of obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Recognition In Future Periods To Settlement Of Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment recognition in future periods to settlement of obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Available-for-sale Investments by Type of Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market-Based Condition Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market-Based Condition Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_MarketBasedConditionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market-based condition awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual rent increment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Rent Increment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_PercentageOfAnnualRentIncrement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual rent increment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, valuation allowance income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets valuation allowance income tax expense (benefit).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right-of-use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ModificationOfLeaseAgreement" xlink:to="lyra_ModificationOfLeaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OtherAssetsPolicyTextBlock" xlink:to="lyra_OtherAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_InducementAwardPlanMember" xlink:to="lyra_InducementAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesTextBlock" xlink:to="us-gaap_GuaranteesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MilestoneAchievementsMember" xlink:to="lyra_MilestoneAchievementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WalthamLeaseMember" xlink:to="lyra_WalthamLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PostMilestoneMember" xlink:to="lyra_PostMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LeaseRelatedCostsCurrent" xlink:to="lyra_LeaseRelatedCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OfficeAndLaboratoryMember" xlink:to="lyra_OfficeAndLaboratoryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_AccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IRC382Member" xlink:to="lyra_IRC382Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WarrantsExercised" xlink:to="lyra_WarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentActivitiesPerformanceObligation" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CombinedPerformanceObligationMember" xlink:to="lyra_CombinedPerformanceObligationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" xlink:to="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock" xlink:to="us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ComputerSoftwareAndEquipmentMember" xlink:to="lyra_ComputerSoftwareAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PreMilestoneMember" xlink:to="lyra_PreMilestoneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PatentsCostsPolicyTextBlock" xlink:to="lyra_PatentsCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" xlink:to="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_UpfrontPaymentReceived" xlink:to="lyra_UpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DevelopmentMilestoneAchieved" xlink:to="lyra_DevelopmentMilestoneAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GoingConcernPolicyTextBlock" xlink:to="lyra_GoingConcernPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage" xlink:to="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ClinicalSupplyAgreementMember" xlink:to="lyra_ClinicalSupplyAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommonStockVotingRightsNumberOfVotes" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CombinedPerformanceObligation" xlink:to="lyra_CombinedPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RestrictedCashPolicyTextBlock" xlink:to="lyra_RestrictedCashPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LeaseInitiationDate" xlink:to="lyra_LeaseInitiationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDescription" xlink:to="us-gaap_DeferredRevenueDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromInitialPublicOffering" xlink:to="lyra_GrossProceedsFromInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommercialRevenueBasedMilestoneAwardsMember" xlink:to="lyra_CommercialRevenueBasedMilestoneAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_VestingOfRestrictedCommonStockValue" xlink:to="lyra_VestingOfRestrictedCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PerformanceObligationsMember" xlink:to="lyra_PerformanceObligationsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OpenSalesAgreement2021ATMMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccountingPoliciesTable" xlink:to="lyra_AccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_EstimatedOfferingCosts" xlink:to="lyra_EstimatedOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CashProvidedByFinancingActivities" xlink:to="lyra_CashProvidedByFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PreFundedWarrantsMember" xlink:to="lyra_PreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" xlink:to="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SignificantSuppliersPolicyTextBlock" xlink:to="lyra_SignificantSuppliersPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DocumentDocumentAndEntityInformationAbstract" xlink:to="lyra_DocumentDocumentAndEntityInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_WatertownLeaseMember" xlink:to="lyra_WatertownLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MarketBasedConditionAwardsMember" xlink:to="lyra_MarketBasedConditionAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_VestingOfRestrictedCommonStockShares" xlink:to="lyra_VestingOfRestrictedCommonStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfAnnualRentIncrement" xlink:to="lyra_PercentageOfAnnualRentIncrement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TemporaryEquityStockIssuanceCosts" xlink:to="lyra_TemporaryEquityStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>lyra-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T19:03:37.6654+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lyra-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:href="lyra-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" xlink:label="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>lyra-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T19:03:37.2579+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:href="lyra-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityAudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:href="lyra-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20221231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="lyra-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:href="lyra-20221231.xsd#DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lyra-20221231.xsd#Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:href="lyra-20221231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:href="lyra-20221231.xsd#DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lyra-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="lyra-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:label="lyra_VestingOfRestrictedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:label="lyra_VestingOfRestrictedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:label="lyra_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" xlink:label="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ModificationOfLeaseAgreement" xlink:label="lyra_ModificationOfLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_ModificationOfLeaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:label="lyra_OrganizationAndBasisOfPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CashProvidedByFinancingActivities" xlink:label="lyra_CashProvidedByFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_CashProvidedByFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesLineItems" xlink:label="lyra_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AccountingPoliciesTable" xlink:label="lyra_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="lyra_AccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_AccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" xlink:label="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:label="lyra_ComputerSoftwareAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OpenSalesAgreement2021ATMMember" xlink:label="lyra_OpenSalesAgreement2021ATMMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:label="lyra_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" xlink:label="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="lyra_GrossProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_EstimatedOfferingCosts" xlink:label="lyra_EstimatedOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lyra_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WarrantsExercised" xlink:label="lyra_WarrantsExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_OpenSalesAgreement2021ATMMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_EstimatedOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_WarrantsExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreFundedWarrantsMember" xlink:label="lyra_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_StockOptionsAndRestrictedStockUnitsMember" xlink:label="lyra_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lyra_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lyra_StockOptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MarketBasedConditionAwardsMember" xlink:label="lyra_MarketBasedConditionAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_InducementAwardPlanMember" xlink:label="lyra_InducementAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CommercialRevenueBasedMilestoneAwardsMember" xlink:label="lyra_CommercialRevenueBasedMilestoneAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" xlink:label="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_MarketBasedConditionAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_InducementAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_CommercialRevenueBasedMilestoneAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" xlink:label="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PerformanceObligationsMember" xlink:label="lyra_PerformanceObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentReceived" xlink:label="lyra_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDescription" xlink:label="us-gaap_DeferredRevenueDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PerformanceObligationsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligation" xlink:label="lyra_CombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PreMilestoneMember" xlink:label="lyra_PreMilestoneMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligation" xlink:label="lyra_DevelopmentActivitiesPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_MilestoneAchievementsMember" xlink:label="lyra_MilestoneAchievementsMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" xlink:label="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PostMilestoneMember" xlink:label="lyra_PostMilestoneMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_CombinedPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PreMilestoneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentActivitiesPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_MilestoneAchievementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_PostMilestoneMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_CombinedPerformanceObligationMember" xlink:label="lyra_CombinedPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentMilestoneAchieved" xlink:label="lyra_DevelopmentMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DevelopmentActivitiesPerformanceObligationMember" xlink:label="lyra_DevelopmentActivitiesPerformanceObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_CombinedPerformanceObligationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lyra_DevelopmentMilestoneAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_DevelopmentActivitiesPerformanceObligationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_IRC382Member" xlink:label="lyra_IRC382Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" xlink:label="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lyra_IRC382Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WatertownLeaseMember" xlink:label="lyra_WatertownLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_ClinicalSupplyAgreementMember" xlink:label="lyra_ClinicalSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_OfficeAndLaboratoryMember" xlink:label="lyra_OfficeAndLaboratoryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_WalthamLeaseMember" xlink:label="lyra_WalthamLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_PercentageOfAnnualRentIncrement" xlink:label="lyra_PercentageOfAnnualRentIncrement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="lyra-20221231.xsd#lyra_LeaseInitiationDate" xlink:label="lyra_LeaseInitiationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WatertownLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lyra_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lyra_WalthamLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_PercentageOfAnnualRentIncrement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LeaseInitiationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>lyra-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T19:03:37.5453+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://lyratherapeutics.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lyra="http://lyratherapeutics.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited" id="StatementConsolidatedStatementsOfStockholdersEquityAudited">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited" id="StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1" id="DisclosureShorttermInvestments1">
        <link:definition>100100 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100120 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" id="Role_DisclosurePreferredAndCommonStock">
        <link:definition>100130 - Disclosure - Preferred and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense" id="Role_DisclosureStockBasedCompensationExpense">
        <link:definition>100140 - Disclosure - Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement" id="DisclosureCollaborationAgreement">
        <link:definition>100150 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100180 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>100230 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100240 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables" id="Role_DisclosurePreferredAndCommonStockTables">
        <link:definition>100260 - Disclosure - Preferred and Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables" id="Role_DisclosureStockBasedCompensationExpenseTables">
        <link:definition>100270 - Disclosure - Stock-Based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables" id="DisclosureCollaborationAgreementTables">
        <link:definition>100280 - Disclosure - Collaboration Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100290 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100300 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanTables" id="Role_DisclosureRetirementPlanTables">
        <link:definition>100310 - Disclosure - Retirement Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" id="DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails">
        <link:definition>100400 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" id="DisclosureShorttermInvestmentsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Short-term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100420 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100440 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" id="Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Preferred and Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" id="Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
        <link:definition>100460 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100480 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100490 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails" id="DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails">
        <link:definition>100500 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100510 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails">
        <link:definition>100520 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" id="DisclosureCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails" id="DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails">
        <link:definition>100540 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails" id="DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails">
        <link:definition>100550 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100570 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100580 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" id="Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
        <link:definition>100600 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails">
        <link:definition>100610 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100620 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lyra_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_CashProvidedByFinancingActivities" name="CashProvidedByFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_CombinedPerformanceObligation" name="CombinedPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_CommonStockVotingRightsNumberOfVotes" name="CommonStockVotingRightsNumberOfVotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DeferredOfferingCostsIncurredButNotYetPaid" name="DeferredOfferingCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" name="DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" name="DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_DefinedContributionPlanMaximumContributionEmployeePercentage" name="DefinedContributionPlanMaximumContributionEmployeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_DevelopmentActivitiesPerformanceObligation" name="DevelopmentActivitiesPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_DevelopmentMilestoneAchieved" name="DevelopmentMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange" name="EffectiveIncomeTaxRateReconciliationOwnershipChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_EstimatedOfferingCosts" name="EstimatedOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" name="FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_GrossProceedsFromIssuanceOfPrivatePlacement" name="GrossProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" name="IssuanceOfCommonStockSharesUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" name="IssuanceOfCommonStockValueUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_LeaseInitiationDate" name="LeaseInitiationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_LeaseRelatedCostsCurrent" name="LeaseRelatedCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ModificationOfLeaseAgreement" name="ModificationOfLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" name="OtherAssetsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_PercentageOfAnnualRentIncrement" name="PercentageOfAnnualRentIncrement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" name="PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" name="ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" name="ProceedsToBeOccuredFromFutureIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" name="PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" name="StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" name="ThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" name="UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_VestingOfRestrictedCommonStockShares" name="VestingOfRestrictedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_VestingOfRestrictedCommonStockValue" name="VestingOfRestrictedCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lyra_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationLineItems" name="OrganizationAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ClinicalSupplyAgreementMember" name="ClinicalSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CombinedPerformanceObligationMember" name="CombinedPerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CommercialRevenueBasedMilestoneAwardsMember" name="CommercialRevenueBasedMilestoneAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" name="CorporateBondsAndUSGovernmentAndAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_DevelopmentActivitiesPerformanceObligationMember" name="DevelopmentActivitiesPerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_InducementAwardPlanMember" name="InducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_IRC382Member" name="IRC382Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_MarketBasedConditionAwardsMember" name="MarketBasedConditionAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_MilestoneAchievementsMember" name="MilestoneAchievementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_OpenSalesAgreement2021ATMMember" name="OpenSalesAgreement2021ATMMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember" name="PerformanceBasedCriteriaRelatedToScientificMilestonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PerformanceObligationsMember" name="PerformanceObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PostMilestoneMember" name="PostMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_PreMilestoneMember" name="PreMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_StockOptionsAndRestrictedStockUnitsMember" name="StockOptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" name="TwentyThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" name="TwentyThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" name="TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_WalthamLeaseMember" name="WalthamLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_WatertownLeaseMember" name="WatertownLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationTable" name="OrganizationAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_COVID19PandemicAndCARESActPolicyTextBlock" name="COVID19PandemicAndCARESActPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_OtherAssetsPolicyTextBlock" name="OtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_RestrictedCashPolicyTextBlock" name="RestrictedCashPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" name="SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_SignificantSuppliersPolicyTextBlock" name="SignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502422448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyra Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1700838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">393-4600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,992,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,829,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001327273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502670528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,550,000<span></span>
</td>
<td class="nump">$ 45,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">65,344,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,935,000<span></span>
</td>
<td class="nump">2,171,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">100,829,000<span></span>
</td>
<td class="nump">47,918,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,243,000<span></span>
</td>
<td class="nump">4,503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,223,000<span></span>
</td>
<td class="nump">1,355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,392,000<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,281,000<span></span>
</td>
<td class="nump">762,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">109,968,000<span></span>
</td>
<td class="nump">54,867,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,616,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,030,000<span></span>
</td>
<td class="nump">4,258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,549,000<span></span>
</td>
<td class="nump">1,074,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,275,000<span></span>
</td>
<td class="nump">9,789,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,470,000<span></span>
</td>
<td class="nump">18,246,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">667,000<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">14,077,000<span></span>
</td>
<td class="nump">1,926,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,214,000<span></span>
</td>
<td class="nump">20,551,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding a December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 31,827,659 and 13,007,178 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">329,387,000<span></span>
</td>
<td class="nump">227,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income, net of tax</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(248,675,000)<span></span>
</td>
<td class="num">(193,397,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">80,754,000<span></span>
</td>
<td class="nump">34,316,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 109,968,000<span></span>
</td>
<td class="nump">$ 54,867,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501438096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">31,827,659<span></span>
</td>
<td class="nump">13,007,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">31,827,659<span></span>
</td>
<td class="nump">13,007,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501652944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,363,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">38,797,000<span></span>
</td>
<td class="nump">29,694,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,556,000<span></span>
</td>
<td class="nump">14,206,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on impairment of long-lived assets</a></td>
<td class="nump">1,316,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">57,669,000<span></span>
</td>
<td class="nump">43,900,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(56,306,000)<span></span>
</td>
<td class="num">(43,615,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,041,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,041,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(55,265,000)<span></span>
</td>
<td class="num">(43,513,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(13,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,278,000)<span></span>
</td>
<td class="num">(43,513,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain on short-term investments, net of tax</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (55,268,000)<span></span>
</td>
<td class="num">$ (43,513,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share -basic</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share -diluted</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding-basic</a></td>
<td class="nump">30,235,689<span></span>
</td>
<td class="nump">12,986,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding-diluted</a></td>
<td class="nump">30,235,689<span></span>
</td>
<td class="nump">12,986,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501771920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (audited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income, Net of Tax</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 74,492<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 224,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (149,884)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,932,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_VestingOfRestrictedCommonStockShares', window );">Vesting of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,513)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">34,316<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">227,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,397)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,007,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244</a></td>
<td class="nump">$ 96,251<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">96,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Issuance of common stock and pre-funded warrants, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,815,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit', window );">Issuance of common stock upon RSU vesting, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 80,754<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 329,387<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (248,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,827,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_VestingOfRestrictedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_VestingOfRestrictedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121503545152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments Of Stock Issuance Costs</a></td>
<td class="nump">$ 4,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance cost</a></td>
<td class="nump">$ 4,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121498038128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (55,278,000)<span></span>
</td>
<td class="num">$ (43,513,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,447,000<span></span>
</td>
<td class="nump">2,770,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="nump">1,001,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on impairment of long-lived assets</a></td>
<td class="nump">1,316,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium on short-term investments</a></td>
<td class="num">(492,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(764,000)<span></span>
</td>
<td class="num">(847,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="num">(868,000)<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(574,000)<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,411,000)<span></span>
</td>
<td class="nump">2,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,772,000<span></span>
</td>
<td class="nump">1,244,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">763,000<span></span>
</td>
<td class="num">(986,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,637,000<span></span>
</td>
<td class="nump">11,715,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(43,385,000)<span></span>
</td>
<td class="num">(25,820,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(164,000)<span></span>
</td>
<td class="num">(3,385,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(64,842,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(65,006,000)<span></span>
</td>
<td class="num">(3,385,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet', window );">Proceeds from sale of common stock and pre-funded warrants</a></td>
<td class="nump">100,495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering expenses</a></td>
<td class="num">(4,246,000)<span></span>
</td>
<td class="num">(245,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">96,257,000<span></span>
</td>
<td class="nump">359,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(12,134,000)<span></span>
</td>
<td class="num">(28,846,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">46,076,000<span></span>
</td>
<td class="nump">74,922,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">33,942,000<span></span>
</td>
<td class="nump">46,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses', window );">Other Assets Included in Accounts Payable and Accrued Expenses</a></td>
<td class="nump">1,960,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ModificationOfLeaseAgreement', window );">Modification of lease agreement</a></td>
<td class="nump">$ 1,928,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering costs included in accounts payable and accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ModificationOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ModificationOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock and pre funded warrant net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506409440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#8217;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#8217;s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2005</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From inception through December 31, 2022, the Company has raised an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to fund its operations primarily from the equity financings, government grants and its License and Collaboration Agreement with LianBio discussed in Note 9. The Company has incurred recurring net losses since inception and had net losse</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. In addition, the Company has an accumulated deficit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">248.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of short-term investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that its cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund the Company&#8217;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.  The inability to obtain funding as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121585474816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other comprehensive income consisted of unrealized gains and losses, net of taxes from its short-term investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company did not have any element of other comprehensive income or loss during the year ended December 31, 2021, its comprehensive loss is equal to its net loss for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had restricted cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. These balances were held unsecured as of December 31, 2022  at the Company&#8217;s financial institution to secure the Company&#8217;s letters of credit for its facility leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.258%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.696%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.052999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,550</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,747</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,392</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,942</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,076</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#8217; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#8220;other than temporary&#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets.  The Company had other assets of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Other assets are primarily comprised of long-term deposits for our clinical trial agreements as well as prepaid rent related to our new facility lease in Waltham which will be reclassified to a right of use asset upon possession of the space.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.998%;"/>
          <td style="width:1.002%;"/>
          <td style="width:50.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recorded impairment losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the contract manufacturing organizations or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMO&#8217;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right-of-use asse</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9e6d9c4d-d173-4c37-9051-37c0e1abf253;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease liability</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance leases</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 9 for further discussion of the arrangement.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#8217;s policy is to recognize forfeitures as they occur.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:70.807%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.816%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.955%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,235,689</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,986,101</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.68%;"/>
          <td style="width:1.163%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.812%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.173%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.172999999999998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,212</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,339,545</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#8217;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU 2016-13 are effective for interim and annual fiscal periods beginning after December 15, 2022. The Company is continuing to evaluate the impact of ASU 2016-13 but does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501745536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.878%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.834%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.024000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.834%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,669</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,646</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,344</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company&#8217;s cash equivalents were invested in money market funds which were valued based on Level 1 inputs, and highly liquid corporate debt securities which were valued based on level 2 inputs. As of December 31, 2022, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 1 inputs and Corporate Bonds and U.S. Government Agency Securities which were valued based on Level 2 inputs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities have contractual maturities of less than one year. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have financial assets and liabilities measured at fair value at December 31, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506326432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Short-term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.581%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.769%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.607%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.698%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,334</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> debt securities that were in an unrealized loss position as of December 31, 2022. The aggregated fair value of debt securities in an unrealized loss position was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold debt securities in a continuous unrealized loss position for more than 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have the intent to sell the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment, and changes in value subsequent to the end of the period. The unrealized losses at December 31, 2022 are attributable to changes in interest rates, and we do not believe any unrealized losses represent other-than-temporary impairments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> short-term investments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121585560720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.792%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.062%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,293</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">397</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,417</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,382</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,879</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,243</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,503</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of depreciation expense for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionall</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">y, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to loss on impairment of long-lived research and development assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the CMO&#8217;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121585445360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.941%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.735000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.092%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,196</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,961</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">659</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506311936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stock</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Preferred and Common Stock </span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of undesignated preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued or outstanding as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share held.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently has an effective shelf registration statement on Form S-3 (No. 333-256020) filed with the SEC on May 11, 2021 (&#8220;Form S-3&#8221;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has not sold any securities under the Form S-3.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 11, 2021, the Company entered into an Open Market Sales Agreement (&#8220;2021 ATM Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of its common stock, from time to time, with aggregate gross sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, through an at-the-market equity offering program under which Jefferies will act as the Company&#8217;s sales agent. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has received </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> proceeds </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from the sale of shares of common stock pursuant to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATM Agreement. The offering of the Company's shares of common stock pursuant to the 2021 ATM Agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the 2021 ATM Agreement and (ii) the termination of the 2021 ATM Agreement as permitted therein. As of March 27, 2023, the Company terminated the 2021 ATM Agreement with Jefferies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">April 2022 Financing</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (&#8220;April 2022 Financing&#8221;). The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting estimated offering costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,815,159</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds to the Company of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and (ii) certain investors purchased pre-funded warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, with the exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Company.  The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he sale proportionately to the common stock and pre-funded warrants, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants have been exercised as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.468%;"/>
        <td style="width:1.474%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.059%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,259,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">279,696</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,538,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506463584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;). The Company previously granted equity-based awards under its 2005 Equity Inventive Plan ("2005 Plan") and 2016 Equity Incentive Plan ("2016 Plan").</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares plus the number of shares of the Company&#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#8217;s Board of Directors. However, no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,800,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520,287</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,319,569</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the 2020 Plan. On January 1, 2023, the shares available for grant under the 2020 Plan was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,273,106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2022 Employment Inducement Award Plan (&#8220;Inducement Award Plan,&#8221; and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#8220;Plans&#8221;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;), and allows for the granting of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,413,002</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock.  The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. During 2022, the Company granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,813,002</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to certain executives. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remaining available for issuance as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.017%;"/>
        <td style="width:1.677%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.677%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,262</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,429</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock that vest based on the achievement of performance-based criteria related to scientific milestones, for which the Company has not recorded any stock-based compensation associated with the achievement of the milestone as it was not deemed probable as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized stock-based compensation related to a stock option award related to the achievement of a commercial revenue-based milestone.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has also granted options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,648,002</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of  common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s unrecognized stock-based compensation as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.073%;"/>
        <td style="width:0.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.74%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.104%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.714%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Expense<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period of Recognition<br/>(years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,247</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to executive officers, with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.704%;"/>
        <td style="width:1.258%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.432%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.258%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.349%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the stock option activity under the Plans for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.749%;"/>
        <td style="width:0.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.198%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.38%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.344%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.198%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.625%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">918</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,828,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,718</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,284</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,350,357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company initially reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for issuance under the 2020 ESPP.  In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#8217;s Board of Directors, provided that no more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock may be issued under the 2020 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the shares available for grant under the 2020 ESPP was automatically increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,035</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> increase to the shares available for grant under the 2020 ESPP plan as of January 1, 2023. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the 2020 ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506305824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Collaboration Agreement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and as amended on September 26, 2022, we entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the LianBio License Agreement, the Company received an upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#8217;s LYR-220 product candidate.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 808&#8221;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#8220;Combined Performance Obligation&#8221;), and (2) the Company&#8217;s performance of the development activities related to the global Phase 3 clinical trial (&#8220;Development Activities Performance Obligation&#8221;).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Development Activities Performance Obligation. In February 2022, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which was allocated to the two performance obligations as follows: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Combined Performance Obligation and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as all milestone amounts were fully constrained based on the probability of achievement. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022.  There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#8217;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the Company determined that LianBio&#8217;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#8217;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#8217;s consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company achieved a development milestone of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for dosing the first patient in the US, and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with the original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.062%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.040000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.838%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.252%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,489</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,862</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.906%;"/>
        <td style="width:1.245%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.001000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.051%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.224%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,489</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,748</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,604</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company achieved a milestone, which resulted in the receipt of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> milestones achieved during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.  No royalty revenue has been earned as of December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#8217;s directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBio&#8217;s board of directors.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506180496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Income Taxes</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2022 and 2021, the Company recorded net losses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record an income tax benefit for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.729%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.474%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.652%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.299%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,751</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">382</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,076</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,096</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,053</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,512</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,697</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Internal Revenue Code, or IRC, 382 study performed during the current year the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had U.S. federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be able to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss carryforwards that may be carried forward indefinitely.  As a result of the IRC 382 study performed during the current year, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be available to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042. As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company has performed an IRC 382 study during the year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. Based on these ownership changes and the calculated IRC 382 annual limitations, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. For state purposes, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. The remainder of the attributes have an annual limitation that will impact how the attributes may be utilized in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets at December 31, 2022 and 2021 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, has been established at December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance decreased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2022 due to the write-off of net operating losses and research and development credits as a result of the IRC 382 study compared to the increase of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, during the year ended December 31, 2021 due primarily to the generation of net operating losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2022 and 2021. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s statement of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2019. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501714272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Watertown Lease</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#8220;2017 Amendment&#8221;) to extend the lease term through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In November 2022, the Company amended the lease to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend the lease term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The lease includes certain rent escalations. The lease modification was assessed as of December 31, 2022 and changes to the right of use asset and liability was reflected within the consolidated balance sheet.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains a letter of credit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million securing its obligations under the operating lease which is unsecured by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waltham Lease</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2022, the Company executed a new lease for laboratory and office space. This lease will be recorded on the Company's balance sheet when the Company obtains possession of the underlying asset, which is expected to occur in the fourth quarter of 2023, following completion of construction to prepare the premises for the Company&#8217;s intended use. Annual base rent will start at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increasing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year through the original non-cancelable term of the lease, which is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years and two months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the lease commencement date. The Company has the option to extend the lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one additional 5-year term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the lease was not recorded on the consolidated balance sheet as the facility is under construction. When payments are made by the Company relating to landlord-owned leasehold improvements, they will be recorded to prepaid rent as a component of other non-current assets. Upon control of the space, The Company will reclassify the prepayment to the right-of-use asset, thereby increasing its initial value, but the prepayment will not be included in the measurement of the lease liability. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of prepaid rent was recorded in other assets with a corresponding liability recorded in accrued expenses. The lease will be recorded as a component of the Company&#8217;s right-of-use asset and operating lease liabilities when the Company takes possession of the space.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company provided a letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a security for the lease, which expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at which point the letter will automatically renew each calendar year up to but not beyond </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 31, 2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The unsecured letter of credit is classified as restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the leases discussed above, the Company is party to an </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e9f4b3d3-691b-4381-9a0b-ee7b93945cac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2020</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease for office equipment that expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4cef5287-028b-4d16-aa13-f50aae7b67ec;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2024</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The equipment lease is accounted for as an operating lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Embedded Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company entered into a clinical supply agreement with a CMO for clinical production of the Company&#8217;s product candidates at an existing facility and a facility under construction. The Company concluded that this clinical supply agreement contains embedded operating leases as the clean rooms in the existing facility and the new facility are designated for the Company&#8217;s exclusive use during the term of the agreement and the clinical supply agreement contains fixed commitments and variable costs related to production and material costs in excess of the fixed commitment specified in the agreement. The Company determined that it did not control the new facility during construction and, thus, the lease did not fall in the scope of &#8220;build-to-suit&#8221; accounting. The term of the clinical supply agreement is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and will automatically renew for additional successive terms of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless either party gives notice of nonrenewal.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease period for the existing facility is less than 12 months and the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or right-of-use asset but instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate, as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with the clinical supply agreement. In October 2022, the Company terminated the agreement with the contract manufacturing organization.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.964%;"/>
        <td style="width:1.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.982%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,056</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,931</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,542</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building and variable lease costs associated with the Company&#8217;s CMO embedded lease arrangement. During the year ended December 31, 2022, the Company recorded as research and development expense approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of operating lease costs related to the CMO embedded lease.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.947%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.432%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.127%;"/>
        <td style="width:2.019%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.854%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">694</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Effects of discounting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total rent expense under the Company's leases amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506279552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p id="final_fpage" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Retirement Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company made a discretionary match that matches 50%, up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% employee contribution, and therefore a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of employees&#8217; salary. Matching contributions are fully vested at the time of contribution. The Company matched $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of employee 401(k) contributions for the years ended December 31, 2022 and 2021, respectively, which is included in the statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506266032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2023, the Company filed a complaint in the Court of Chancery of the State of Delaware against a former contract manufacturer alleging breach of contract.  The Company alleged in its complaint that its former contract manufacturer breached the Master Clinical Supply Agreement (&#8220;MCSA&#8221;) by misrepresenting their ability to produce LYR-210 in accordance with the specifications and with a robust quality system in place, and failed to return certain customer materials and equipment as required under the MCSA. The Company's complaint seeks monetary damages and the return of equipment and materials that the Company owns. On March 28, 2023, the contract manufacturer filed a motion to remove the case from the Chancery Court to the United States District Court for the District of Delaware.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 27, 2023, the Company notified Jefferies LLC (&#8220;Jefferies&#8221;) of the termination of the Open Market Sales Agreement, dated May 11, 2021, between the Company and Jefferies.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501475216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other comprehensive income consisted of unrealized gains and losses, net of taxes from its short-term investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company did not have any element of other comprehensive income or loss during the year ended December 31, 2021, its comprehensive loss is equal to its net loss for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_RestrictedCashPolicyTextBlock', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had restricted cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. These balances were held unsecured as of December 31, 2022  at the Company&#8217;s financial institution to secure the Company&#8217;s letters of credit for its facility leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ginning-of-period and end-of-period total amounts shown on such statements. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.258%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.696%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.052999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,550</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,747</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,392</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,942</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,076</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Short-term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#8217; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#8220;other than temporary&#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company includes certain items within other assets on the consolidated balance sheets.  The Company had other assets of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Other assets are primarily comprised of long-term deposits for our clinical trial agreements as well as prepaid rent related to our new facility lease in Waltham which will be reclassified to a right of use asset upon possession of the space.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock', window );">Concentrations Of Credit Risk And Off Balance Sheet Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.998%;"/>
          <td style="width:1.002%;"/>
          <td style="width:50.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recorded impairment losses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021. In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the contract manufacturing organizations or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMO&#8217;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right-of-use asse</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9e6d9c4d-d173-4c37-9051-37c0e1abf253;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease liability</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance leases</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized any product revenue to date since its product candidates are in development.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 9 for further discussion of the arrangement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PatentsCostsPolicyTextBlock', window );">Patents Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#8217;s policy is to recognize forfeitures as they occur.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the fair value of its stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Income Taxes</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2022 and 2021, the Company recorded net losses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t record an income tax benefit for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.729%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.474%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.652%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.299%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,751</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">382</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,076</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,096</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,053</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,512</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,697</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Internal Revenue Code, or IRC, 382 study performed during the current year the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had U.S. federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be able to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss carryforwards that may be carried forward indefinitely.  As a result of the IRC 382 study performed during the current year, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, the Company had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which may be available to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset future income tax liabilities and expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042. As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, available to reduce future tax liabilities which expire at various dates through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company has performed an IRC 382 study during the year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. Based on these ownership changes and the calculated IRC 382 annual limitations, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal research and development credits. For state purposes, the Company has written off $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state net operating losses and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of state research and development credits. The remainder of the attributes have an annual limitation that will impact how the attributes may be utilized in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets at December 31, 2022 and 2021 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, has been established at December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance decreased by approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2022 due to the write-off of net operating losses and research and development credits as a result of the IRC 382 study compared to the increase of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, during the year ended December 31, 2021 due primarily to the generation of net operating losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2022 and 2021. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s statement of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2019. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:70.807%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.816%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.955%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,235,689</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,986,101</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.68%;"/>
          <td style="width:1.163%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.812%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.173%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.172999999999998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,212</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,339,545</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#8217;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU 2016-13 are effective for interim and annual fiscal periods beginning after December 15, 2022. The Company is continuing to evaluate the impact of ASU 2016-13 but does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentrations of credit risk and off-balance sheet risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PatentsCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the patents cost policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PatentsCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500745328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.258%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.696%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.496%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.052999999999999%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,550</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,747</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,392</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,942</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,076</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.998%;"/>
          <td style="width:1.002%;"/>
          <td style="width:50.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></p></td>
         </tr>
        </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.792%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.062%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,293</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">397</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,417</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,382</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,879</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,243</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,503</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:70.807%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.816%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.711%;"/>
          <td style="width:1.0%;"/>
          <td style="width:10.955%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,278</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,513</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,235,689</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,986,101</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.83</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.68%;"/>
          <td style="width:1.163%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.812%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.173%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.172999999999998%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,212</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,339,545</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506206352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.878%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.834%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.024000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.202%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.834%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,089</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,669</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;US treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,646</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,344</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506326432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value of Available-for-sale Investments by Type of Security</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of available-for-sale investments by type of security was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.581%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.769%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.607%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.698%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;U.S. treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,966</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,334</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506305824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.998%;"/>
          <td style="width:1.002%;"/>
          <td style="width:50.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of useful life or remaining term of related lease</span></span></p></td>
         </tr>
        </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.792%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.612%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.062%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,293</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer software and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">397</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,417</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,382</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,879</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,243</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,503</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507269472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.941%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.735000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.092%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and employee related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,196</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,961</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">659</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121506266032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved for future issuances the following shares of common stock as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.468%;"/>
        <td style="width:1.474%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.059%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options and restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,259,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">279,696</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,538,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507126256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.017%;"/>
        <td style="width:1.677%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.677%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">508</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,262</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,770</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s unrecognized stock-based compensation as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.073%;"/>
        <td style="width:0.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.74%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.104%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.714%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Expense<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period of Recognition<br/>(years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,247</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Executive Officers</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to executive officers, with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.704%;"/>
        <td style="width:1.258%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.432%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.258%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.349%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plans</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the stock option activity under the Plans for the year ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.749%;"/>
        <td style="width:0.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.198%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.38%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.344%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.198%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.625%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,662,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">918</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,828,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,718</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177,284</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,350,357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,311,333</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501719152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock', window );">Summary of Change in the Transaction Price</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the change in the transaction price (in thousands):</span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.062%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.040000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.838%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.277%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.252%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,489</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,862</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.906%;"/>
        <td style="width:1.245%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.001000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.051%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.224%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development Activities Performance Obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,489</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,748</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,604</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507464688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.729%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.474%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax computed at federal statutory tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development and other tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of Attributes - IRC 382 Ownership Change</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.89%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.652%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.299%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,154</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,751</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">382</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research &amp; experimental expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,076</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,763</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,096</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,053</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,512</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,697</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">584</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500729040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.964%;"/>
        <td style="width:1.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.625%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.982%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,056</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,931</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,542</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock', window );">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.947%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.432%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2022 were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.127%;"/>
        <td style="width:2.019%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.854%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">694</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Effects of discounting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Current portion of operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease terms and discount rate related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501474624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of incorporation</a></td>
<td class="text">Nov. 21,  2005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CashProvidedByFinancingActivities', window );">Fund raised for operations</a></td>
<td class="nump">$ 350,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,278,000)<span></span>
</td>
<td class="num">$ (43,513,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(248,675,000)<span></span>
</td>
<td class="num">(193,397,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">32,550,000<span></span>
</td>
<td class="nump">45,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 65,344,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CashProvidedByFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash provided by financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CashProvidedByFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500781856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 1,392,000<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on impairment of long-lived assets</a></td>
<td class="nump">1,316,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,223,000<span></span>
</td>
<td class="nump">1,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,549,000<span></span>
</td>
<td class="nump">$ 1,074,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating lease right-of-use assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501406592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,550<span></span>
</td>
<td class="nump">$ 45,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 33,942<span></span>
</td>
<td class="nump">$ 46,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121602677072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, gross</a></td>
<td class="text">Shorter of useful life or remaining term of related lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502612016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,278)<span></span>
</td>
<td class="num">$ (43,513)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (55,278)<span></span>
</td>
<td class="num">$ (43,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding-basic</a></td>
<td class="nump">30,235,689<span></span>
</td>
<td class="nump">12,986,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding-diluted</a></td>
<td class="nump">30,235,689<span></span>
</td>
<td class="nump">12,986,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders-basic</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders-diluted</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502529392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">4,339,545<span></span>
</td>
<td class="nump">1,662,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">4,311,333<span></span>
</td>
<td class="nump">1,662,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">28,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121503396080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 65,344,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">29,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">65,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">22,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">2,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">62,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,678,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">7,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">22,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">2,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">4,732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">57,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 57,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500776800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121602692160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 65,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">65,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Bills</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember', window );">Corporate Bonds and U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">62,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 62,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507044608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, held | Security</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt securities, unrealized loss position</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, hold</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 65,344,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500788688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,417<span></span>
</td>
<td class="nump">$ 8,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(4,174)<span></span>
</td>
<td class="num">(3,879)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,022<span></span>
</td>
<td class="nump">5,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember', window );">Computer Software and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 2,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500937760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,067,000<span></span>
</td>
<td class="nump">$ 1,001,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on impairment of long-lived research and development assets</a></td>
<td class="nump">$ 1,316,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501666528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 2,975<span></span>
</td>
<td class="nump">$ 2,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_LeaseRelatedCostsCurrent', window );">Lease-related costs</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,030<span></span>
</td>
<td class="nump">$ 4,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LeaseRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease related costs current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LeaseRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121497307584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 05, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of common stock are entitled to one vote for each share held.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CommonStockVotingRightsNumberOfVotes', window );">Number of common stock voting rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,827,659<span></span>
</td>
<td class="nump">13,007,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock and warrants to be issued during period value preferred stock and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from sale of pre-funded warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_WarrantsExercised', window );">Pre-funded warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_OpenSalesAgreement2021ATMMember', window );">2021 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock', window );">Proceeds to be occured from future issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_GrossProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement | $</a></td>
<td class="nump">$ 100,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement | $</a></td>
<td class="nump">96,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_EstimatedOfferingCosts', window );">Estimated offering costs | $</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds for warrant exercises | $</a></td>
<td class="nump">$ 21,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="nump">18,815,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 79,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock voting rights, number of votes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_EstimatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_EstimatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds to be occured from future issuance of common stock,.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants to be issued during period value preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_OpenSalesAgreement2021ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_OpenSalesAgreement2021ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502653840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">11,538,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">6,259,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">279,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121497558560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,828,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,538,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,447,000<span></span>
</td>
<td class="nump">$ 2,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted to employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,827,659<span></span>
</td>
<td class="nump">13,007,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in Shares available for grant</a></td>
<td class="nump">1,273,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Certain Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear', window );">Percentage of common shares increase automatically in each year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,319,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,035<span></span>
</td>
<td class="nump">987,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear', window );">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock', window );">Purchase price of shares as percentage lower of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember', window );">Market-Based Condition Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember', window );">Inducement Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,413,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_CommercialRevenueBasedMilestoneAwardsMember', window );">Commercial Revenue Based Milestone Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember', window );">Performance-Based Criteria Related to Scientific Mileston</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,429<span></span>
</td>
<td class="nump">31,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance maximum number of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares increase automatically in each year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of shares as percentage lower of fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_MarketBasedConditionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_CommercialRevenueBasedMilestoneAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_CommercialRevenueBasedMilestoneAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502988384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,597<span></span>
</td>
<td class="nump">$ 2,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501666112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 9,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition (years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 9,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition (years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507272960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.30%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121496922928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding December 31, 2021</a></td>
<td class="nump">1,662,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="nump">2,828,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled</a></td>
<td class="num">(177,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at December 31, 2022</a></td>
<td class="nump">4,311,333<span></span>
</td>
<td class="nump">1,662,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable at December 31, 2022</a></td>
<td class="nump">1,350,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest at December 31, 2022</a></td>
<td class="nump">4,311,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2021</a></td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">5.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">7.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2022</a></td>
<td class="nump">7.07<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2022</a></td>
<td class="nump">9.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and expected to vest at December 31, 2022</a></td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding December 31, 2021</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2022</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121503023792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization', window );">Future milestone payments receivable</a></td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,363,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueDescription', window );">Deferred revenue, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, 2022, as all milestone amounts were fully constrained based on the probability of achievement. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember', window );">Milestone Achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember', window );">Pre-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember', window );">Post-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Upfront payment recognition in future periods to settlement of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development activities performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CombinedPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined performance obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CombinedPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DevelopmentActivitiesPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development activities performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DevelopmentActivitiesPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment recognition in future periods to settlement of obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502454672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreement - Summary of Change in the Transaction Price (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember', window );">Pre-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">8,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember', window );">Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember', window );">Post-Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_CombinedPerformanceObligation', window );">Combined performance obligation</a></td>
<td class="nump">11,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentActivitiesPerformanceObligation', window );">Development Activities Performance Obligation</a></td>
<td class="nump">5,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation', window );">Total</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CombinedPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined performance obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CombinedPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DevelopmentActivitiesPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development activities performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DevelopmentActivitiesPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment recognition in future periods to settlement of obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PreMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501558608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2021</a></td>
<td class="nump">$ 11,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentMilestoneAchieved', window );">Milestone</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2022</a></td>
<td class="nump">15,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember', window );">Combined Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2021</a></td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentMilestoneAchieved', window );">Milestone</a></td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2022</a></td>
<td class="nump">11,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember', window );">Development Activities Performance Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2021</a></td>
<td class="nump">3,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DevelopmentMilestoneAchieved', window );">Milestone</a></td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue at December 31, 2022</a></td>
<td class="nump">$ 3,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DevelopmentMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DevelopmentMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121497103712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,278,000)<span></span>
</td>
<td class="num">$ (43,513,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit', window );">Deferred tax assets, valuation allowance income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">40,512,000<span></span>
</td>
<td class="nump">54,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 2037 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">88,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction | IRC 382</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">67,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction | IRC 382</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">125,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lyra_IRC382Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lyra_IRC382Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121507265776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development and other tax credits</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="nump">25.80%<span></span>
</td>
<td class="num">(30.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange', window );">Loss of Attributes - IRC 382 Ownership Change</a></td>
<td class="num">(54.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501661344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 25,154<span></span>
</td>
<td class="nump">$ 46,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">1,751<span></span>
</td>
<td class="nump">7,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures', window );">Capitalized research &amp; experimental expenditures</a></td>
<td class="nump">9,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">41,096<span></span>
</td>
<td class="nump">55,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(40,512)<span></span>
</td>
<td class="num">(54,697)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(584)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (584)<span></span>
</td>
<td class="num">$ (356)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and experimental expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121497939424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one additional 5-year term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember', window );">Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm', window );">Extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreement | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember', window );">Office and Laboratory | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_PercentageOfAnnualRentIncrement', window );">Percentage of annual rent increment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember', window );">Office and Laboratory | Maximum [Member] | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and fixtures | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_LeaseInitiationDate', window );">Lease initiation date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of Deposits | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LeaseInitiationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease initiation date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LeaseInitiationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfAnnualRentIncrement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual rent increment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfAnnualRentIncrement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121501399696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 5,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121585567648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121502655456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total maturities</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: effects of discounting</a></td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(1,549)<span></span>
</td>
<td class="num">$ (1,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140121500927392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Company match percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Match cost</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lyra_DefinedContributionPlanMaximumContributionEmployeePercentage', window );">Maximum contribution employee percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DefinedContributionPlanMaximumContributionEmployeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan maximum contribution employee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DefinedContributionPlanMaximumContributionEmployeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>lyra-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lyra="http://lyratherapeutics.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lyra-20221231.xsd" xlink:type="simple"/>
    <context id="C_50d08448-36cd-45bf-bf96-7b413773153a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76c90dc7-305d-40d5-b5dc-e2b7e2b5fdde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e9a9b4ce-3240-47fa-87b6-f4310526dffe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_19f3c088-c2ce-4eed-bded-16d5bf3a940e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_274faa51-b01e-4850-a412-77a812b2749d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ffdb9268-e81e-4854-abb7-7dc620a278a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd72f40f-15bc-4abd-9ca3-7c1f5c45455d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e3cac587-28df-4995-8b75-2a1e2e20870c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d44362fb-4fc5-4481-be17-c8446450f94c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1150276-615f-4f08-88b8-81bc087d354d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_b11a23eb-8f92-4a47-afbb-ff79b85ab2b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fc16a771-bf4e-44a5-b112-8ea51be13588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:MarketBasedConditionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab6efa41-abc1-41e2-a447-bc1e9acb264e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PreMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_9bef293d-84d2-4550-baa7-b971b193887a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c64f210-b096-4f52-af04-9a9929413c0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_86d35cfd-3d7d-4cd3-aad0-bbb425c6ea04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_65a305a6-5b98-4d3a-a30d-a699dba9390c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_30fc43ea-2218-4e8e-9220-f7894e107d70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_501a2778-23f4-4564-91d7-2770cfe05137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_32a3b395-08bb-4bd8-8e69-bf7a8289138b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_72a3022b-e3e8-4f67-b88c-e60be2a42056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c2e5de28-b6f2-4a80-a975-f131ab84261b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db2e146e-6da1-4245-84c4-73c704b05e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_4b81447d-9f3f-4a61-a5b3-d086c511a31c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e88491c6-140e-4267-b33d-457c84a7b90d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_947e7a14-7124-4460-8622-c6ac515eacd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_24c6e4df-a738-4298-9c1a-6fa22126a4d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_e404146f-8c43-4dcb-b085-fef72fda8da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76580e45-0c6f-4827-9602-bda9e3bdb18d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_56c02857-b6c9-47ae-b10d-01237cf26d18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_162858c9-f666-4eb7-be16-4f285ac5ff81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_b069fcd9-9753-4c58-ba29-e3011d30aa97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e4b292d3-94d2-4fbb-87a6-ac9741243b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0f2c78a8-2fcc-49a1-9802-0c096355e6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_87f11c83-03d7-43d6-be6a-f07729b1a6be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:PerformanceBasedCriteriaRelatedToScientificMilestonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_85081da2-be87-496a-85a8-2491428bc94f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="C_ff6c540e-0dee-49f8-b317-487ce471c7fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:DevelopmentActivitiesPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b5ad16fc-e41d-4d55-b3e3-5c4dc3774b7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_9dcd205a-e6a8-477e-b3ae-d74f48fdecea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2042739f-ff2e-4355-bf6e-f55d146a1334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c7ec31f-db19-4dca-ad79-3648a2ac432f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_ed0926d1-d179-4325-b910-278483ee97af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c6a86586-b423-4033-bd3a-ef5d462ae4d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_97589ddb-9445-4ee0-bf35-ac2868ceabab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aacb10f4-b39c-44f8-9057-452a5c746b5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8ae07729-2d6f-4f3d-99ca-a96fa38b8e31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="C_8e0d2435-49ae-4291-85fd-1d7c3f1ac975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_4825109d-f60c-4752-b276-40c0b1627135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:OpenSalesAgreement2021ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_27b196b3-9d37-40ba-88f6-5c5770d52577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_23a96427-b264-4ccf-a621-6b9aa5d2b550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d87b7e0-a503-4674-86f1-acabd1e0af4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="C_8e5eaed3-f8d9-42a7-a095-56cf4842b09e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2fba1a08-71d7-45ba-a07a-724089146c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_5d2f621d-ce9f-493a-be01-01b725615ebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5bd706c2-ee7f-484b-8abe-a01b92725182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de44d7f7-7bdf-4087-aa60-6edb982677c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6fb4fa36-a2d1-4278-8d67-32d8fe50d72f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bc9a827e-3051-4dad-ab8e-60d812a8a89d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_36e6caae-c368-4a2e-a60b-afef8e9340a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b0e81f8d-8072-4ce7-bb01-1bc6a7641b89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86cdf56f-cd6f-4aa3-8f8d-0db4f6e082d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_df183939-be99-4d3c-9b1f-74b82cfaddf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_b59d6e76-1457-4f77-983e-3ed77e38bb34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ca643c6d-178f-4cdd-919d-765a5892183d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a870f0e-a464-4613-8b30-3072bec4780a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f340881c-2e0f-4b0b-8367-5d095a57a0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bb3a8b23-6728-4d59-a97d-1ecc7e3adfb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c20b9c24-a16c-4bcb-912d-93a745a09007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_98c9dcf4-d3b8-48d5-812c-7b771021577f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_49be5531-186a-4558-b31a-130bbf009546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:OpenSalesAgreement2021ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="C_8f95fb07-e221-4065-a799-bb4bc71b7c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fbac6298-1ee5-459c-a52f-a26dcfb2675c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7887ec17-ea58-4a4a-bcdd-f4316823027d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_fad3289e-7f1e-4eac-8c33-f77ea1386219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b5d83e3e-bc90-46f1-8c80-aac50e8a3314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:PerformanceBasedCriteriaRelatedToScientificMilestonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ce20db0-1512-4e67-bb88-1bf3499c3582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4efe985e-4d85-45ef-b622-70a88c48d6e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_58783042-c5b7-49c6-8ed2-272d1bada5b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cda70942-437f-46cb-bfca-673305f8f4dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_661e6304-38fc-4780-9c4b-9199c12da66d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a1144d35-ca6f-497e-a18a-73cf52e16156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="C_3aa72f08-9dea-4749-a7ce-7cde7d1d2163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6da6f05-7316-4bfb-b017-2251df6ace0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:PostMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1a83be4-a034-4dba-99d0-ff646e8a3287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_64558a68-90ad-4900-b292-8c860e88674b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_317254de-de84-4738-817e-1c29f2dbec3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab8a831d-cce2-4c50-b8fb-f3c8eb1c821a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_de48ac60-b50a-4c29-8f31-b67fc2eace77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_3c41e863-c7f2-463b-9e14-58690fc53cbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3cb6888-3032-461e-8265-3245f2051004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_bfa4b7bb-7c8f-4561-8f51-cc77823b6c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_58907f21-5a15-4e54-ab25-e6d84a3c9652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lyra:IRC382Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4a7c6366-9118-4794-b989-2d8394630634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="C_21d75bf0-5f97-4279-84fa-a52de2aac093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11390654-f6a8-4a62-8bd2-4e84437ccd94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f909c39-112d-4ab7-82d9-d31b6680680d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9fe63fe-accc-4fe2-9acf-9c7f5eb6a624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4a4eab87-52a4-4143-a37b-fabafd2119ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12eb5289-6285-4814-bd77-f25959811158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lyra:CorporateBondsAndUSGovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6447ee5-c057-4921-8817-cccd0a901dc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6e636ef1-70ab-4e6d-bbb9-b62e055ce520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_50d4ea11-cb80-4911-8caa-b2ac6d60f202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2247c2b1-0ab0-4254-9c47-7754e5b3eb9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb418092-ad75-441f-aea1-c853723d2837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_946ce1f5-0df2-4562-bf11-7d539009d00f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:MilestoneAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_a03fff14-a210-4e02-928c-f0e2c6e0d975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_77e94b31-e6d8-437a-8894-b8188333e621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a18f3701-43ff-4fd7-a44f-d3b3dc016a73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_42595f81-0b68-440f-b7f6-c0b65eb4d4fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_435574cf-1a94-488f-97a2-8dce8c5c419d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_7939e4b4-a73f-4851-9eb8-a2e8bee1ad5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_03cb3063-9002-40eb-a812-0f647395fbc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_259fea07-483e-459f-85c3-cc48ff87d140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_86716da2-023d-4ddf-84dd-2aa61048c050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lyra:CombinedPerformanceObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3558ff97-70d1-4ac8-90d8-25851e56f82f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:CommercialRevenueBasedMilestoneAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8445ea3c-4a1b-4d11-bc4a-34295fa25cb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f6258f7a-902f-4145-8c22-422abafbe4f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lyra:WatertownLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e56cf9c7-99bc-4107-a492-f1caeb308084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fc9e381c-707b-4016-a540-87b86a5d1ac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_83e9be91-41f7-4203-b44e-71feb55201e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_42784fde-fb41-49b8-91a2-89eeebce4be2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">lyra:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bce75e89-097d-40fe-96e7-7fef938bd51e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Security">
        <measure>lyra:Security</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Vote">
        <measure>lyra:Vote</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      id="F_4471ca7f-4d79-47e2-9c65-d4f601168d4c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      id="F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_c6a416ad-dce4-436c-b762-84f45186a40a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_2b89e99d-b7ce-4efb-88f7-90ebab7441a0">0001327273</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_d727f80b-943d-4713-9f66-c687759b7604">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      id="F_b556901c-3c67-411f-ae41-cb8f4493d60e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      id="F_1998289b-eb61-4a17-beb7-899c1a25802a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_f6258f7a-902f-4145-8c22-422abafbe4f4"
      id="F_4cef5287-028b-4d16-aa13-f50aae7b67ec">2024-06-30</us-gaap:LeaseExpirationDate1>
    <dei:AmendmentFlag
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_4c389388-d196-4c1e-93e8-ff25ff427d32">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      id="F_9e6d9c4d-d173-4c37-9051-37c0e1abf253">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      id="F_43989a1a-5a9f-4a95-98ff-670e92082ebc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      id="F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf">http://fasb.org/us-gaap/2022#Liabilities</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <lyra:LeaseInitiationDate
      contextRef="C_f6258f7a-902f-4145-8c22-422abafbe4f4"
      id="F_e9f4b3d3-691b-4381-9a0b-ee7b93945cac">2020-04-30</lyra:LeaseInitiationDate>
    <dei:DocumentType
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_42eb2d3f-d752-46f7-9771-2fc3935845e8">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_69772ec5-cd14-43db-b7ff-5dfda3078b0c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_819663a6-f16a-4516-b226-0d7698671862">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_a89c2812-129b-4778-8aff-3ae461fc2b56">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_3a89b6fb-cbd3-4314-97cd-4fdfed40f622">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_4f328c9f-7ed0-4e49-841e-c7d1f6ee560d">001-39273</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_dcfdb3a7-e0a4-414e-a6f8-9a902338be1d">Lyra Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_cf452bda-3609-4013-b2da-e37541d15c1f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_1f54ad1b-612a-4acc-b58c-f3011c2d1e57">84-1700838</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_714514c2-9bc3-4bd0-92cb-67e70d860da2">480 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_99341db8-661d-4888-831a-98528b124ff0">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_38606be7-c1c0-4cfe-9128-2b37b911dab9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_8f792c4d-ab01-4741-8599-2ebcd1dcde30">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_7bbee9ad-a488-46c8-af60-9579f600a4e2">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_3651ce8f-7aff-4112-a004-8c93bba672d0">393-4600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_6e832919-bfd5-4bbb-9394-a61a35c598bd">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_c4d5bc11-7c5e-43e7-8400-00633ecd07a8">LYRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_a1044586-1a2c-4afe-a406-ad6739b4d8e1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_7417bd2d-e6df-42e2-b8dc-2577eff99246">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_c801700d-59ec-4404-8405-e5491793a8b7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_12c591ba-5c1d-4b41-ba0f-8b0843e006b1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_7ca94111-c36f-47fd-975b-68e371344f46">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_5b13891f-d435-447e-b08d-4bc4de4aa432">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f3426001-6fe4-4987-9ea4-549edf6dd019">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_5ac8998e-24ef-492c-8803-81c4da268a4e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_0177a0a5-40e9-4eea-94ea-df58a4c65bfe">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_61be0e36-e015-462a-9771-80600095c64d">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_685f5f0b-dd74-42c8-b87b-94523b4f39a6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_58907f21-5a15-4e54-ab25-e6d84a3c9652"
      decimals="-3"
      id="F_0cb3d9a0-d34a-4eaf-aceb-c47f851a56c8"
      unitRef="U_USD">102992856000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5d87b7e0-a503-4674-86f1-acabd1e0af4d"
      decimals="INF"
      id="F_7196d3a4-a0c3-4979-a03b-ada7e8d99901"
      unitRef="U_shares">31829774</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_52261440-d400-4a41-970e-9e60dd5e449f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_67eabbc7-1ff5-43c2-8e27-61cb811c07dc">243</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_b8dd620c-f11d-4ae6-989d-68e3fc44ab36">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_a0249a7b-0f76-45c8-b113-7d15bfdf6cf8">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_cbf9ddd7-4eb1-42c8-b939-51769252bc3d"
      unitRef="U_USD">32550000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_7f2f5012-038b-42eb-a9ac-7c08e306f08f"
      unitRef="U_USD">45747000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_5454f506-e961-46c8-b129-b5794ff20827"
      unitRef="U_USD">65344000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_a0db2b67-b511-4265-af46-9edac2721a68"
      unitRef="U_USD">2935000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_832afe09-dab5-4275-bfd8-8cfe2a1bd9fc"
      unitRef="U_USD">2171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_e95bd202-b09f-4247-927c-d6caa08ab10a"
      unitRef="U_USD">100829000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_957c004c-653b-4eec-a867-1565c136782c"
      unitRef="U_USD">47918000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_19a16a68-46b7-408b-a9fe-3fdea3e03c40"
      unitRef="U_USD">2243000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_5d7e9662-859c-47f6-961b-121aa93c81e7"
      unitRef="U_USD">4503000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_101c8694-0fed-4a79-9792-d46f70ecd6c8"
      unitRef="U_USD">2223000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_2eef7639-5e70-4aeb-be97-06cb86593036"
      unitRef="U_USD">1355000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_908acbf5-0176-4cf1-a390-2e5e362372df"
      unitRef="U_USD">1392000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_593baab8-bc70-45c9-b82d-dd4e5e9bee08"
      unitRef="U_USD">329000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_8cd11d5b-8f52-4b01-8625-2c7cc84a5975"
      unitRef="U_USD">3281000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_6d08c94e-ce3d-4ecf-93f6-bb1131a42e0b"
      unitRef="U_USD">762000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_2df1f897-2ad9-4631-b476-85e8d1af1fe3"
      unitRef="U_USD">109968000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_f8ec7402-1c80-4abe-a67a-c43c68ebef2c"
      unitRef="U_USD">54867000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_5c0dac01-1201-41d2-9665-9e7373d50587"
      unitRef="U_USD">2616000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_b2d9ac42-6961-4b1d-b2d4-8cf8f7dead3e"
      unitRef="U_USD">3125000</us-gaap:AccountsPayableCurrent>
    <lyra:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_1aabc040-fe2e-4b52-a114-56251109f3c3"
      unitRef="U_USD">9030000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
    <lyra:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_2d06731a-74e0-4562-83d1-b939e9c8b288"
      unitRef="U_USD">4258000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_1f21f01e-658d-46c6-a0cc-d0adde2c0b48"
      unitRef="U_USD">1549000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_3e21e2f9-8b73-49bb-8ce2-373ca92a3b71"
      unitRef="U_USD">1074000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_98ff23fa-97ab-459e-b659-6ec6b0ad6c99"
      unitRef="U_USD">1275000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_d11aec35-8765-4833-a271-a1e7cc0fb5b6"
      unitRef="U_USD">9789000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_78f4567a-d5f7-493b-9d11-67434edcfac2"
      unitRef="U_USD">14470000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_76000ccf-2c69-47b7-8c72-d3222d953e63"
      unitRef="U_USD">18246000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_53ee9229-7e99-4b42-bd4f-ec3f7e334219"
      unitRef="U_USD">667000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_208e673e-ba2e-400d-bafb-4c6aba1080d4"
      unitRef="U_USD">379000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_92ee6b96-2c17-4b50-8508-7961d276e055"
      unitRef="U_USD">14077000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_9f372d27-165e-4bb0-9e79-a9d8b7230aa7"
      unitRef="U_USD">1926000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c0b6afe9-9000-4d0e-9f9f-6226ef0f74ec"
      unitRef="U_USD">29214000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_2d82198b-31f9-4f43-adf8-a6daea0959a5"
      unitRef="U_USD">20551000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_56c11b76-8e55-40de-846b-84e969120be5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_497a63cf-44f8-4747-965b-6c5b772062ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_9503e305-afac-44f9-8fd5-263c499447ab"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_e905d707-7798-4196-a5e9-afe45ed10b2d"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_7d25a8ec-6590-4f04-9671-5b92ad37ddac"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_bb53aa57-4af8-464c-8475-b2d2cc6a6d56"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_4bc50c54-3770-47aa-a79b-1a1c61f9aef5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_f9c948ed-3f1c-4020-96a3-875099fdb3b8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_523c8137-d11e-4037-85c7-5c9cc314c34e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_307ea8e7-65f8-4553-85ed-28fca5b5d077"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_cfe09542-db9a-418e-aa6d-7681e5cf89ce"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_416ceaa0-6ac1-4bac-822d-905dc483bb60"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_aca8c5cc-2734-489f-8082-739542d5dd17"
      unitRef="U_shares">31827659</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_ed9532d1-0d36-4d24-ad9e-ee5885d5083e"
      unitRef="U_shares">31827659</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_07cf091d-c464-4af9-893b-0c4b08afe4e4"
      unitRef="U_shares">13007178</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_b89fcd69-4c91-49e7-a202-c735a1805cb2"
      unitRef="U_shares">13007178</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_8036db4b-0957-4463-8618-13953a4bc625"
      unitRef="U_USD">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_08a13179-3310-43af-b737-a44ec9fc4541"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_55b31397-2382-4a2e-a246-d7b82bc52e5c"
      unitRef="U_USD">329387000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_ba2ef8a1-1c13-4a6d-be2f-b5ef042d624f"
      unitRef="U_USD">227700000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c82e64e5-5c9f-4786-87d7-10a1735b47dd"
      unitRef="U_USD">10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c33dd1c5-e9bd-4291-ac54-73a93b239134"
      unitRef="U_USD">-248675000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_998ffc5e-4d93-4f3a-a9a8-a437fa06bef7"
      unitRef="U_USD">-193397000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_bc7a5e6c-60ce-443f-895b-893645d90d2a"
      unitRef="U_USD">80754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_c7d6e964-8a41-4bff-8dd4-e370ae4fadb2"
      unitRef="U_USD">34316000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_ff8195fd-861d-46a7-9e2c-247d31e77ea0"
      unitRef="U_USD">109968000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_0a4a7e43-bf7a-4ade-b872-e7a2bada3602"
      unitRef="U_USD">54867000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_9b71d78f-f435-4da2-bc83-354811321252"
      unitRef="U_USD">1363000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_e8aef143-4b18-4e82-9b1a-dd2886f2c608"
      unitRef="U_USD">285000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_f8a08acc-5530-45b5-a82f-3798cd98cea8"
      unitRef="U_USD">38797000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_d9016e91-941b-44be-8c1a-6c4723420531"
      unitRef="U_USD">29694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_ea0d2ee5-efec-401a-a2aa-814695bb3925"
      unitRef="U_USD">17556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_05393532-9b7a-4352-b470-eed4ff0a4294"
      unitRef="U_USD">14206000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_231d5903-65a3-4dde-b811-950f9be0c055"
      unitRef="U_USD">1316000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:OperatingExpenses
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_3b825ac3-bc87-4ef7-9df2-4ef6e089032a"
      unitRef="U_USD">57669000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_bbd1c424-4997-43a6-bf2d-64a589447723"
      unitRef="U_USD">43900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_81766c15-5832-4d64-affe-e350533cc868"
      unitRef="U_USD">-56306000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_47a99f22-67df-4419-a481-21b082cdcc93"
      unitRef="U_USD">-43615000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_bf7fdcdb-1e4d-4f47-8ada-474291293fa3"
      unitRef="U_USD">1041000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_57f5e10d-c67e-403a-846b-26cfe68497bf"
      unitRef="U_USD">102000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_18e4f912-5292-4427-b576-9031bde58d31"
      unitRef="U_USD">1041000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_5f654e29-4c42-4c4b-80d7-4e2884f80c16"
      unitRef="U_USD">102000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_28d4b030-daab-43d4-ab28-f4d2ff35b630"
      unitRef="U_USD">-55265000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_dd7e0caf-401f-40c2-874b-58930ef8ca19"
      unitRef="U_USD">-43513000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_64b170e6-94c7-4af9-96ea-bdccf6a246d4"
      unitRef="U_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_87728ba0-0a0b-40ed-992f-348178e995cd"
      unitRef="U_USD">-55278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_003e2956-48c6-499c-8c48-6a57871d9a66"
      unitRef="U_USD">-43513000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_b25a4e98-afc3-419c-951c-9a296c1d622f"
      unitRef="U_USD">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_4bf76f13-21a4-43b6-bcd4-7f413a1076d5"
      unitRef="U_USD">-55268000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_4c8ddd77-176b-4af2-baaf-2136b9f986c1"
      unitRef="U_USD">-43513000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_429929bc-b567-4529-8acf-5d8cadee1595"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_0f3ef7a8-a9f3-47cc-9e4e-17036359ad4a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="2"
      id="F_9e28bf11-a2a7-4755-a874-ab3b8711d0bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="2"
      id="F_fc86e4a6-6afc-4c08-a595-5d3bb0bcfd19"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="0"
      id="F_e2014b6b-bd98-4598-9777-ec5eafed80fb"
      unitRef="U_shares">30235689</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="0"
      id="F_a303d1d5-e1ae-4640-a782-099afb4edbb2"
      unitRef="U_shares">30235689</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="0"
      id="F_a207650a-ca2d-417e-b2fd-2c689dd8b12e"
      unitRef="U_shares">12986101</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="0"
      id="F_6d8ab473-1bf0-491c-8541-e452edbc18f1"
      unitRef="U_shares">12986101</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be"
      decimals="INF"
      id="F_8735df60-8c3f-4677-96f8-188cb4777544"
      unitRef="U_shares">12932377</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_68c1679a-9b58-4cb1-aa58-20f78d27d0be"
      decimals="-3"
      id="F_4e16e9d6-8dfb-4195-a53b-bd075a1be84e"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_274faa51-b01e-4850-a412-77a812b2749d"
      decimals="-3"
      id="F_c6180182-c206-4e3c-ac4f-49db85d43b0f"
      unitRef="U_USD">224363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a03fff14-a210-4e02-928c-f0e2c6e0d975"
      decimals="-3"
      id="F_f9a3562a-0128-4e92-ad86-0d2b0fa2dd1d"
      unitRef="U_USD">-149884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c"
      decimals="-3"
      id="F_97ec9195-39c9-4ace-b8dc-96dd4427a459"
      unitRef="U_USD">74492000</us-gaap:StockholdersEquity>
    <lyra:VestingOfRestrictedCommonStockShares
      contextRef="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58"
      decimals="INF"
      id="F_976fa9ba-b303-4ca2-8f82-d4ae6724f0a5"
      unitRef="U_shares">2600</lyra:VestingOfRestrictedCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_358bbc0f-4764-405e-bcfc-d405b9d0dc58"
      decimals="INF"
      id="F_71e6a9da-5f2e-4ab8-b9fd-fdda10acfd91"
      unitRef="U_shares">72201</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_fc9e381c-707b-4016-a540-87b86a5d1ac7"
      decimals="-3"
      id="F_545df319-8bd9-49f9-b4eb-4e25faea536c"
      unitRef="U_USD">604000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_fe50aaa3-139b-488c-a5ef-6a85186d7af0"
      unitRef="U_USD">604000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fc9e381c-707b-4016-a540-87b86a5d1ac7"
      decimals="-3"
      id="F_49d5b2d4-87f1-4114-8bf4-474c9fad7d29"
      unitRef="U_USD">2733000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_1ece631d-0de7-44ca-a0f7-bf0588be1405"
      unitRef="U_USD">2733000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2ce20db0-1512-4e67-bb88-1bf3499c3582"
      decimals="-3"
      id="F_f307009e-a9fd-4567-bef6-42779a8453ab"
      unitRef="U_USD">-43513000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_4d464c4c-fbb0-4780-b590-66d3f86c341f"
      unitRef="U_USD">-43513000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_03cb3063-9002-40eb-a812-0f647395fbc2"
      decimals="INF"
      id="F_e83419c2-2fb2-407c-9ca1-840db4383e2b"
      unitRef="U_shares">13007178</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_03cb3063-9002-40eb-a812-0f647395fbc2"
      decimals="-3"
      id="F_06960887-79e9-4555-adcc-cddffabf63b8"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2247c2b1-0ab0-4254-9c47-7754e5b3eb9d"
      decimals="-3"
      id="F_8e3c4ada-79fb-4901-b86c-8b7bc4568bda"
      unitRef="U_USD">227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e88491c6-140e-4267-b33d-457c84a7b90d"
      decimals="-3"
      id="F_fea8ebea-dba5-4b92-b093-53c52ad401c0"
      unitRef="U_USD">-193397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_e5f61826-0026-4e04-9808-b3942c5941fd"
      unitRef="U_USD">34316000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba"
      decimals="INF"
      id="F_b915a62d-7d0d-4107-b5c1-0f4d5b62a16e"
      unitRef="U_shares">2718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182"
      decimals="-3"
      id="F_37fad1d7-4d27-481a-b882-4d8d92ea0de7"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_c4b28cdc-354e-459a-8221-1243f1b552a2"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_7966abc8-7276-4a03-b71d-428d8b98fe48"
      unitRef="U_USD">4244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba"
      decimals="INF"
      id="F_1114bd6d-d5c5-4c07-b27d-9910e7f3ca2e"
      unitRef="U_shares">18815159</lyra:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba"
      decimals="-3"
      id="F_b167f8a3-4476-49f5-8659-a75671b349b1"
      unitRef="U_USD">19000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182"
      decimals="-3"
      id="F_33b6924e-752a-4f4e-a66f-07a667984196"
      unitRef="U_USD">96232000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_a7b415f7-9877-4080-b090-e13c88312597"
      unitRef="U_USD">96251000</lyra:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <lyra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit
      contextRef="C_0bf38eb0-07ce-4295-8ad4-ee3b0b6052ba"
      decimals="INF"
      id="F_0e5221e3-ae43-4f8b-bf98-2bfdf11b1eb4"
      unitRef="U_shares">2604</lyra:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8e5eaed3-f8d9-42a7-a095-56cf4842b09e"
      decimals="-3"
      id="F_c33ed15c-35d7-4488-b99f-b5d8b60e181b"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_a0099413-a1f7-41c5-a474-4d5d768625af"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5bd706c2-ee7f-484b-8abe-a01b92725182"
      decimals="-3"
      id="F_5f98f8af-6aac-4194-a3ca-5c8a349d9446"
      unitRef="U_USD">5447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_20617700-02f0-4885-a6bd-41f911f1a741"
      unitRef="U_USD">5447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_3c64f210-b096-4f52-af04-9a9929413c0d"
      decimals="-3"
      id="F_d0d264bb-54a2-447c-bb4c-8b114748e239"
      unitRef="U_USD">-55278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_101ad789-4e9d-4689-b994-2dc5a72e94ac"
      unitRef="U_USD">-55278000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4a4eab87-52a4-4143-a37b-fabafd2119ff"
      decimals="INF"
      id="F_dc800b42-9bea-4116-abb6-df9a87566c63"
      unitRef="U_shares">31827659</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4a4eab87-52a4-4143-a37b-fabafd2119ff"
      decimals="-3"
      id="F_6275c13b-4694-42d3-acb4-ca8d9d25d324"
      unitRef="U_USD">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e404146f-8c43-4dcb-b085-fef72fda8da0"
      decimals="-3"
      id="F_efa330e6-32d1-4e49-a8ac-7adb1d22d36b"
      unitRef="U_USD">329387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_58783042-c5b7-49c6-8ed2-272d1bada5b9"
      decimals="-3"
      id="F_6de6b466-5ba1-4a1d-9179-a7aa0215da51"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77e94b31-e6d8-437a-8894-b8188333e621"
      decimals="-3"
      id="F_34437001-332f-4d94-9b99-a95604cec7de"
      unitRef="U_USD">-248675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_12c1ff27-5713-4d18-a34d-858fa28a88d1"
      unitRef="U_USD">80754000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_4a07d0ce-5ff0-408c-87d6-f39ebb32a6ef"
      unitRef="U_USD">-55278000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_4b0d4dc2-9fc5-4ea6-b561-2f75ff19695c"
      unitRef="U_USD">-43513000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_815c6548-e52b-4cda-b1eb-9258fc317808"
      unitRef="U_USD">5447000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_d526f37c-cefe-4eb4-8856-fe484ba3322c"
      unitRef="U_USD">2770000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_aabd2cac-d74a-47d2-8023-4e557ef45c77"
      unitRef="U_USD">1067000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_0bd55b9b-7907-4a9f-9a0d-01fdd919de8e"
      unitRef="U_USD">1001000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_025a33dc-44b1-4f58-a172-b5995d419e97"
      unitRef="U_USD">1316000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_180785c2-5adc-4b55-9ae6-017c92f14e73"
      unitRef="U_USD">492000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_41ccbd46-430b-4c75-935d-b976ae3c1683"
      unitRef="U_USD">764000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_d4e2003e-381b-4785-8c84-71cfbdf0c970"
      unitRef="U_USD">847000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_0ed746fa-508e-419f-ba04-8bae15e5db9d"
      unitRef="U_USD">868000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_a589a543-52c5-41ce-93df-a23b94594cfe"
      unitRef="U_USD">-946000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_d13f00ff-4c82-4e0a-b680-4d6e2ca8c0f1"
      unitRef="U_USD">574000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_8680fb81-10be-43b8-b936-7e8c79dc868a"
      unitRef="U_USD">500000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_560ba08f-a1c5-4794-a7a2-2cf69d7a97a8"
      unitRef="U_USD">-2411000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_06182f69-dfe4-4206-9605-307929fcb870"
      unitRef="U_USD">2350000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_51ea17dd-35e3-49ea-aa66-e00a920847c7"
      unitRef="U_USD">4772000</lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_4d1b7328-9f96-457f-b4ad-2c512f4564fb"
      unitRef="U_USD">1244000</lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_e21a1c25-2c14-4944-9b63-3f9c1eacb8b9"
      unitRef="U_USD">763000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_3da70b8a-c855-4a25-8fe3-240c8e48875b"
      unitRef="U_USD">-986000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_f22c2d7f-00ef-43b6-b029-a7f081994286"
      unitRef="U_USD">3637000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_f8a9e183-3feb-4fdb-ab1d-211d42f8bd35"
      unitRef="U_USD">11715000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_556b521c-91a8-4bb2-aec9-e9d139f9db1e"
      unitRef="U_USD">-43385000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_1bda3ebb-f869-4619-a6f9-aab5a2fb9851"
      unitRef="U_USD">-25820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_ffe72e54-28b9-4905-9b52-86edf06d1f63"
      unitRef="U_USD">164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_1267322e-4500-4984-ac3e-79e26c5e7f24"
      unitRef="U_USD">3385000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_77263bfa-6f0f-4b35-b04c-3d9adc79ff4e"
      unitRef="U_USD">64842000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_79f3aea8-b6c0-4cbb-af16-63bb6bfbc91f"
      unitRef="U_USD">-65006000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_52e487f5-5bb2-4f81-a355-b173d30329a7"
      unitRef="U_USD">-3385000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <lyra:ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_85cebbfd-f588-4b5b-a02d-f2eb4aec8c85"
      unitRef="U_USD">100495000</lyra:ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_15ad0634-68a6-47a6-bbd2-e94db3a0bfb8"
      unitRef="U_USD">4246000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_a28a90ae-7709-4438-9358-f3741468a0fd"
      unitRef="U_USD">245000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_059ab689-d980-48c5-9db5-636e0411bc7c"
      unitRef="U_USD">8000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_48d217f7-0475-4415-9a1d-991f071e33d0"
      unitRef="U_USD">604000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_a98579bc-6a0e-42fd-9278-8451f5f7b2c0"
      unitRef="U_USD">96257000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_9fb065f3-41a7-4f49-bd29-dc7143f6b1ab"
      unitRef="U_USD">359000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_e531f7e4-140e-4120-90ae-82ef6454e85d"
      unitRef="U_USD">-12134000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_88efb6b2-3f6f-448d-9c36-f41479d53371"
      unitRef="U_USD">-28846000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_26397c30-1172-409f-8e52-c92a1064c7fb"
      unitRef="U_USD">46076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c"
      decimals="-3"
      id="F_d68d94c1-832c-4062-89f0-df0c2fe6491e"
      unitRef="U_USD">74922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_a15a82af-6cda-4891-a473-9224e5faf253"
      unitRef="U_USD">33942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_7b586964-7c65-47bd-befe-55fabf9b6f9d"
      unitRef="U_USD">46076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_6e4f725c-0721-40af-8e06-dd4b72b897db"
      unitRef="U_USD">41000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_74069c22-e164-4a0d-9aca-01f864af36d5"
      unitRef="U_USD">1960000</lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses>
    <lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_d35af7ff-4a58-40a1-a0f2-eed56e966990"
      unitRef="U_USD">15000</lyra:OtherAssetsIncludedInAccountsPayableAndAccruedExpenses>
    <lyra:ModificationOfLeaseAgreement
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_a3cdaac3-b9b5-4f55-840e-c4e9fe941be0"
      unitRef="U_USD">1928000</lyra:ModificationOfLeaseAgreement>
    <lyra:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_fd73154f-1100-4b18-abae-1f1254de0b2d"
      unitRef="U_USD">2000</lyra:DeferredOfferingCostsIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_c2d9d156-63b1-4735-9ca1-d82dce239357">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lyra Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company&#x2019;s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#x2019;s product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 21, 2005&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From inception through December 31, 2022, the Company has raised an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to fund its operations primarily from the equity financings, government grants and its License and Collaboration Agreement with LianBio discussed in Note 9. The Company has incurred recurring net losses since inception and had net losse&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;s of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively. In addition, the Company has an accumulated deficit of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;248.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of cash and cash equivalents and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company believes that its cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund the Company&#x2019;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.  The inability to obtain funding as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_2ea3e886-34a6-4b0b-9bad-c059e1b54ca8">2005-11-21</dei:EntityIncorporationDateOfIncorporation>
    <lyra:CashProvidedByFinancingActivities
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_3196a298-a471-41d7-aaa7-341d3b3f4dae"
      unitRef="U_USD">350400000</lyra:CashProvidedByFinancingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_647d9b4d-85ba-4e94-9f41-3fa09638c9f9"
      unitRef="U_USD">-55300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_5dda34f0-6e35-4e8f-9a31-16c9b66c85b1"
      unitRef="U_USD">-43500000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_51122c2f-18f0-41c5-b485-728f58471fe8"
      unitRef="U_USD">-248700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_79f73130-78ef-45f9-98df-77fbc32e4a6e"
      unitRef="U_USD">32600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_52bb9701-0f74-4b1a-9a07-7d4480e2d33c"
      unitRef="U_USD">65300000</us-gaap:ShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_1405b2d3-e495-4311-988c-ccf78086fe35">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_dbf1e56c-8849-40dd-bf29-f9a61304222a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s chief executive officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the year ended&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, other comprehensive income consisted of unrealized gains and losses, net of taxes from its short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company did not have any element of other comprehensive income or loss during the year ended December 31, 2021, its comprehensive loss is equal to its net loss for the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had restricted cash of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively. These balances were held unsecured as of December 31, 2022  at the Company&#x2019;s financial institution to secure the Company&#x2019;s letters of credit for its facility leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ginning-of-period and end-of-period total amounts shown on such statements. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.258%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.696%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.052999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#x2019; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#x2019;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#x201c;other than temporary&#x201d;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company includes certain items within other assets on the consolidated balance sheets.  The Company had other assets of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. Other assets are primarily comprised of long-term deposits for our clinical trial agreements as well as prepaid rent related to our new facility lease in Waltham which will be reclassified to a right of use asset upon possession of the space.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Significant Suppliers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.998%;"/&gt;
          &lt;td style="width:1.002%;"/&gt;
          &lt;td style="width:50.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recorded impairment losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021. In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the contract manufacturing organizations or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CMO&#x2019;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC 842, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;right-of-use asse&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9e6d9c4d-d173-4c37-9051-37c0e1abf253;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;finance leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized any product revenue to date since its product candidates are in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 9 for further discussion of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#x2019;s common stock, the expected volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#x2019;s stock options, and the Company&#x2019;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#x2019;s policy is to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses the fair value of its stoc&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:70.807%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.816%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.955%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,235,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,986,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.68%;"/&gt;
          &lt;td style="width:1.163%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.812%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.173%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.172999999999998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,339,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#x2019;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU 2016-13 are effective for interim and annual fiscal periods beginning after December 15, 2022. The Company is continuing to evaluate the impact of ASU 2016-13 but does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_6fd987f6-5659-4753-b9f3-c06e6d28d517">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_ce6cfcfb-8039-4223-8b64-b5f718e07a45">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include but are not limited to management&#x2019;s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and realization of its deferred tax assets. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_919e3837-131d-4d7f-93b3-3f07b2e09a71">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#x2019;s chief operating decision-maker, the Company&#x2019;s chief executive officer, views the Company&#x2019;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_34699c96-0366-4d96-b00e-ec5fba8678bc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the year ended&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, other comprehensive income consisted of unrealized gains and losses, net of taxes from its short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company did not have any element of other comprehensive income or loss during the year ended December 31, 2021, its comprehensive loss is equal to its net loss for the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_74021805-11f2-4677-a511-dd99b6854f00">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks, amounts held in money market funds, and highly liquid debt securities. Cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <lyra:RestrictedCashPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f533e5f0-80b5-411e-a22c-2ebc01cc2f64">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had restricted cash of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively. These balances were held unsecured as of December 31, 2022  at the Company&#x2019;s financial institution to secure the Company&#x2019;s letters of credit for its facility leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the be&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ginning-of-period and end-of-period total amounts shown on such statements. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.258%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.696%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.052999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</lyra:RestrictedCashPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_690c74e4-0f42-4782-bb99-76e747d5a31d"
      unitRef="U_USD">1400000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_65a305a6-5b98-4d3a-a30d-a699dba9390c"
      decimals="-5"
      id="F_a85f34af-0ecc-4abd-880f-882e0aca1b8b"
      unitRef="U_USD">300000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_55e2bdd8-bd5c-4abd-9268-c924a23d6665">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.258%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.696%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.496%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.052999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_e890c82a-26b4-4d89-a758-b45b260a0725"
      unitRef="U_USD">32550000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_321d90c3-ef2d-439e-a1c0-837fccd4aa67"
      unitRef="U_USD">45747000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_b8db8048-8fe9-44e5-8c10-d2b20586c1c7"
      unitRef="U_USD">1392000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_7f4ddfdd-796b-4ac1-ba49-cca269f2ca11"
      unitRef="U_USD">329000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_d6b7f0f0-1287-490c-8d6d-002d0a53e26b"
      unitRef="U_USD">33942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_58a9bc1a-6079-40af-afd8-b8f3b523fc96"
      unitRef="U_USD">46076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_ed72b269-357d-4c0a-9c30-c796fca3b60a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses, net of taxes on available-for-sale securities are reported as a separate component of stockholders&#x2019; equity. Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#x2019;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#x201c;other than temporary&#x201d;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <lyra:OtherAssetsPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_24c5d288-4474-440a-afba-6df80801ffcc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company includes certain items within other assets on the consolidated balance sheets.  The Company had other assets of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. Other assets are primarily comprised of long-term deposits for our clinical trial agreements as well as prepaid rent related to our new facility lease in Waltham which will be reclassified to a right of use asset upon possession of the space.&lt;/span&gt;&lt;/p&gt;</lyra:OtherAssetsPolicyTextBlock>
    <us-gaap:OtherAssets
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_ef7bc996-81e2-4238-91c8-fe3cb015451a"
      unitRef="U_USD">3300000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-5"
      id="F_4476dab2-7746-456e-a29b-d2f269d3d5d6"
      unitRef="U_USD">700000</us-gaap:OtherAssets>
    <lyra:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f977a81c-09e6-4fb9-aec2-1d09423cb445">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains all its cash and cash equivalents, and short-term investments at two accredited financial institutions, in amounts that exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lyra:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock>
    <lyra:SignificantSuppliersPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_633b5cc1-d209-47b7-9884-53fea70f14b9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Significant Suppliers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lyra:SignificantSuppliersPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_1b5ea22f-d914-4e2e-b8be-8eade05efdac">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 -Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 -Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_de50a710-10d0-499c-8f4f-d4fee24b7992">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.998%;"/&gt;
          &lt;td style="width:1.002%;"/&gt;
          &lt;td style="width:50.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_cac6b4d7-ce9e-4a34-a2fb-ce5fa17b68cf">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.998%;"/&gt;
          &lt;td style="width:1.002%;"/&gt;
          &lt;td style="width:50.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of useful life or remaining term of related lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.792%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e9a9b4ce-3240-47fa-87b6-f4310526dffe"
      id="F_914cee37-44c6-4df0-9da0-485c022f148b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_86d35cfd-3d7d-4cd3-aad0-bbb425c6ea04"
      id="F_fb809780-9457-4c9b-8ec7-e909b94d0fde">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e56cf9c7-99bc-4107-a492-f1caeb308084"
      id="F_400398aa-01f6-4d14-9c63-9801586ea7b4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_76580e45-0c6f-4827-9602-bda9e3bdb18d"
      id="F_86fa0743-b7fc-40ce-9b89-ac1580345a74">Shorter of useful life or remaining term of related lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_99649401-9240-48e3-82a1-4e7f41121518">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company recorded impairment losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021. In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the contract manufacturing organizations or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;CMO&#x2019;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_8468e7ad-405c-411b-8a03-fa77f03094eb"
      unitRef="U_USD">1300000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="0"
      id="F_b4bdd380-030a-4055-8e09-6dff92855df5"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_b3d4ae6b-5ce7-4009-a3d8-cae7a6de001a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC 842, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_d0216401-aa38-44ea-9ec4-b29f1ce4a9b7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;right-of-use asse&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9e6d9c4d-d173-4c37-9051-37c0e1abf253;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company&#x2019;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_dc30e2f1-1a02-4c83-bdc7-6246c78f36cf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;finance leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      decimals="INF"
      id="F_fc0b125b-32c4-44bb-a04a-556e1a7fd734"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      decimals="INF"
      id="F_3092d553-adb8-49cc-8cdf-9b5ce385bbe7"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_09b6a602-fa07-4e17-a6d3-0d38b6ceab55"
      decimals="INF"
      id="F_6f4463cb-0ae3-4685-be7d-c0d99dd0f6aa"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_1375f98a-0a6d-423f-8def-64de768f4f0b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying good or service relative to the option exercise price. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assessed its revenue generating arrangement in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized any product revenue to date since its product candidates are in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 31, 2021, and amended on September 26, 2022, the Company entered into a License and Collaboration Agreement, or, the LianBio License Agreement, with LianBio Inflammatory Limited, or LianBio, to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 9 for further discussion of the arrangement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_966f3438-6a62-4c2d-b3a4-0e9e2c432e88">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services, potential impairment charges related to research and development assets, and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <lyra:PatentsCostsPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_bcc1b215-1058-43e4-87c2-8ad58f8cbc56">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lyra:PatentsCostsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_7b0311a5-e367-4fd1-b27b-a3bbd92d7acd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, non-employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#x2019;s common stock, the expected volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#x2019;s stock options, and the Company&#x2019;s expected dividend yield. Prior to our IPO in 2020, the Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. The Company&#x2019;s policy is to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses the fair value of its stoc&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;k-based compensation awards to employees, non-employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_d24b4213-7be8-4477-8a63-fa9f60fc5e3a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reported losses since inception and has computed basic net loss per share by dividing its net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive, basic, and diluted loss per share have been the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:70.807%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.816%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.955%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,235,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,986,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.68%;"/&gt;
          &lt;td style="width:1.163%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.812%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.173%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.172999999999998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,339,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_3524f9ba-9ee4-4b01-bbd7-863272cc65fd">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:70.807%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.816%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.711%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:10.955%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,235,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,986,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_3a4cf050-709a-41ae-a0bd-20db13646a98"
      unitRef="U_USD">-55278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_b99001cc-b7b6-4984-800d-a2dd23fe98b4"
      unitRef="U_USD">-43513000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_a408a8f6-76a3-43cd-80e7-0ddae780b11d"
      unitRef="U_USD">-55278000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_03809afc-60e5-4fde-a94e-09a38a466948"
      unitRef="U_USD">-43513000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="0"
      id="F_f867e38f-412d-497a-8968-b1fa094e7b8a"
      unitRef="U_shares">30235689</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="0"
      id="F_a1e84d9e-b54e-4602-a8ff-562fb6248fef"
      unitRef="U_shares">30235689</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="0"
      id="F_c58fe6be-3541-43e1-af52-5d30514cfb80"
      unitRef="U_shares">12986101</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="0"
      id="F_be059c39-685f-4f70-81a6-b1ec6118bae2"
      unitRef="U_shares">12986101</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_86f4b495-62f8-49ab-9c81-9d3508dbefc6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_e1d51fca-7bb2-409d-a703-84c57092c2fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="2"
      id="F_d7db2bef-2e3b-48be-808b-dd0e73334cd8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="2"
      id="F_fab01a58-ba9f-47cc-bca2-14baaa3aaee0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_02544c71-2af1-4353-97d3-bc8b53959047">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.68%;"/&gt;
          &lt;td style="width:1.163%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.812%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.173%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.172999999999998%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,339,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bc9a827e-3051-4dad-ab8e-60d812a8a89d"
      decimals="INF"
      id="F_2d321c9e-f482-4ed3-9640-5b8610926737"
      unitRef="U_shares">4311333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_76c90dc7-305d-40d5-b5dc-e2b7e2b5fdde"
      decimals="INF"
      id="F_a5ab85e1-da55-4f0a-b053-bc850d9e830f"
      unitRef="U_shares">1662861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0f2c78a8-2fcc-49a1-9802-0c096355e6c8"
      decimals="INF"
      id="F_a607f41a-2acb-4034-9275-efc2492f8145"
      unitRef="U_shares">28212</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_8dbaa253-2961-44e7-881c-e343e1226c6b"
      unitRef="U_shares">4339545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="INF"
      id="F_0edccff9-029c-468c-a65b-b48d35d490bf"
      unitRef="U_shares">1662861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <lyra:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_745a770b-a22c-40c6-981f-7709eecbe370">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#x2019;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU 2016-13 are effective for interim and annual fiscal periods beginning after December 15, 2022. The Company is continuing to evaluate the impact of ASU 2016-13 but does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</lyra:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_0008b5bb-bf90-486b-8ba8-5d57cb039e24">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.878%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.834%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.024000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.834%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;US treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company&#x2019;s cash equivalents were invested in money market funds which were valued based on Level 1 inputs, and highly liquid corporate debt securities which were valued based on level 2 inputs. As of December 31, 2022, the Company's short-term investments consisted of U.S. treasury bills which were valued based on Level 1 inputs and Corporate Bonds and U.S. Government Agency Securities which were valued based on Level 2 inputs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities have contractual maturities of less than one year. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have financial assets and liabilities measured at fair value at December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_9a0c4acb-6a7b-4dc3-a32e-fcee713cbeba">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.878%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.834%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.024000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.834%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;US treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_50d4ea11-cb80-4911-8caa-b2ac6d60f202"
      decimals="-3"
      id="F_e1c7e9fb-2469-4da3-afcd-e7e142069dbe"
      unitRef="U_USD">22580000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a6447ee5-c057-4921-8817-cccd0a901dc8"
      decimals="-3"
      id="F_603b61e5-cf5e-4499-b818-56cc4d9936d0"
      unitRef="U_USD">22580000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fbac6298-1ee5-459c-a52f-a26dcfb2675c"
      decimals="-3"
      id="F_422e5b10-b032-44e1-a860-59e6ae7aef6a"
      unitRef="U_USD">7089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b59d6e76-1457-4f77-983e-3ed77e38bb34"
      decimals="-3"
      id="F_1a289cc4-2682-47f1-a2ad-4bdbbb3f6abb"
      unitRef="U_USD">2098000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b0e81f8d-8072-4ce7-bb01-1bc6a7641b89"
      decimals="-3"
      id="F_f7e9f22c-28c6-41c1-9152-630000519e17"
      unitRef="U_USD">4991000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba"
      decimals="-3"
      id="F_94ad8f81-af38-49bb-8607-fa774cfe03df"
      unitRef="U_USD">29669000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156"
      decimals="-3"
      id="F_c3caacd7-b416-4473-816f-90edbbe2384d"
      unitRef="U_USD">24678000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4efe985e-4d85-45ef-b622-70a88c48d6e6"
      decimals="-3"
      id="F_6c1fadbe-80c8-41d2-8658-c76dc81014c8"
      unitRef="U_USD">4991000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_e6da6f05-7316-4bfb-b017-2251df6ace0f"
      decimals="-3"
      id="F_088eaf1d-aeb3-4fcb-971f-fc24b64ebf89"
      unitRef="U_USD">2966000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_8445ea3c-4a1b-4d11-bc4a-34295fa25cb6"
      decimals="-3"
      id="F_b2ffa226-3bae-4c0c-8163-3eb5bb6e0533"
      unitRef="U_USD">2966000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_fad3289e-7f1e-4eac-8c33-f77ea1386219"
      decimals="-3"
      id="F_c4ebbea5-b93c-447c-a0ec-0545764f856d"
      unitRef="U_USD">62378000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_3c41e863-c7f2-463b-9e14-58690fc53cbf"
      decimals="-3"
      id="F_2c3f4c2a-89bf-4923-83d1-091e35398f44"
      unitRef="U_USD">4732000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_fd72f40f-15bc-4abd-9ca3-7c1f5c45455d"
      decimals="-3"
      id="F_a5341e72-7b8e-4024-ada9-e3d71f669a9b"
      unitRef="U_USD">57646000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba"
      decimals="-3"
      id="F_dabaadb1-ce87-4a1f-9dd0-eac5e358e28b"
      unitRef="U_USD">65344000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_5a0f6924-7af0-4d9a-9c4d-c7fc6a276156"
      decimals="-3"
      id="F_fba05cfb-e3ac-4b1c-a135-c9f0a91c0dfd"
      unitRef="U_USD">7698000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_f9fe63fe-accc-4fe2-9acf-9c7f5eb6a624"
      decimals="-3"
      id="F_ec708a41-b5d3-4996-aff2-3a5a13e57135"
      unitRef="U_USD">57646000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_124d8b41-ff59-4182-a81d-1d58c7b53f07"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_8cb1600e-a35e-41d7-8ca7-0009b096e7ac"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_a72f5726-d2f9-4e4f-b70a-f0a58f9a071e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_15394ce2-ec5d-403c-ba80-e82583cc33b0"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_ac07da5f-5c01-4e1f-a163-c8ad08428a37">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Short-term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of available-for-sale investments by type of security was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.581%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.769%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.607%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.698%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; debt securities that were in an unrealized loss position as of December 31, 2022. The aggregated fair value of debt securities in an unrealized loss position was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. As of December 31, 2022, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t hold debt securities in a continuous unrealized loss position for more than 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have the intent to sell the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment, and changes in value subsequent to the end of the period. The unrealized losses at December 31, 2022 are attributable to changes in interest rates, and we do not believe any unrealized losses represent other-than-temporary impairments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; short-term investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_cd768355-98e4-48c3-8b63-ac9a94f9501c">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of available-for-sale investments by type of security was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.581%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.769%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.607%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.22%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.698%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Corporate Bonds and U.S. Government Agency Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cda70942-437f-46cb-bfca-673305f8f4dd"
      decimals="-3"
      id="F_9c893667-cddc-48da-ac4d-e3537aa480ec"
      unitRef="U_USD">2966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cda70942-437f-46cb-bfca-673305f8f4dd"
      decimals="-3"
      id="F_4cd0eaaa-a6b5-4640-98cc-8349eb817548"
      unitRef="U_USD">2966000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_12eb5289-6285-4814-bd77-f25959811158"
      decimals="-3"
      id="F_6fef6e11-0e38-4838-a6fa-8f2361e5ea53"
      unitRef="U_USD">62368000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_12eb5289-6285-4814-bd77-f25959811158"
      decimals="-3"
      id="F_ca862eda-611c-4d8c-8593-24c7653dbcfb"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_12eb5289-6285-4814-bd77-f25959811158"
      decimals="-3"
      id="F_03f5f2c3-66e8-442f-a4e7-d49c6cf91f1e"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_12eb5289-6285-4814-bd77-f25959811158"
      decimals="-3"
      id="F_c0b177c5-50eb-4ad6-9e92-5c0f1fdde7b4"
      unitRef="U_USD">62378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_bdbc8da4-ac80-456b-a1a5-221a1489ae94"
      unitRef="U_USD">65334000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_137267e2-1d84-4159-90fa-54ccf8d45b17"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_725ee1a5-6333-40c3-bea1-924b463b9bfd"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c0a981cf-9180-4a98-b309-f0d0ccf036be"
      unitRef="U_USD">65344000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_a2881671-f9c5-4dc1-8d86-0ffd96d2dbcc"
      unitRef="U_Security">4</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_4612bbbe-da27-43ab-8458-714c3fc0fd00"
      unitRef="U_USD">3900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_a2c68c44-f512-4cb6-b848-8353b5fe38ee"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:ShortTermInvestments
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_0f9c8a70-4247-46e9-bd4f-8aa28ef1c433"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_7c28b43f-5ebb-4f47-aaaf-9570257ad7ca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.792%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.612%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer software and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of depreciation expense for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionall&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;y, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to loss on impairment of long-lived research and development assets. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October of 2022, the Company terminated an agreement with a contract manufacturer. The Company has funded certain leasehold improvements at the CMO&#x2019;s facility that the Company does not anticipate receiving the benefit of in the future and has accordingly impaired the respective assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_64558a68-90ad-4900-b292-8c860e88674b"
      decimals="-3"
      id="F_1f7eeab6-cca9-42d2-acf3-3e205d014f88"
      unitRef="U_USD">5022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f95fb07-e221-4065-a799-bb4bc71b7c44"
      decimals="-3"
      id="F_e3b06aad-c8a7-44e8-ac58-d9c810bf1da9"
      unitRef="U_USD">5293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7939e4b4-a73f-4851-9eb8-a2e8bee1ad5e"
      decimals="-3"
      id="F_971094ff-3cba-4d37-b8af-96ddcad3a54e"
      unitRef="U_USD">675000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e4b292d3-94d2-4fbb-87a6-ac9741243b27"
      decimals="-3"
      id="F_27f218b6-45f6-45bb-8671-5a8540c44a94"
      unitRef="U_USD">675000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9dcd205a-e6a8-477e-b3ae-d74f48fdecea"
      decimals="-3"
      id="F_ea353858-0abe-4768-b739-e84ee43bc262"
      unitRef="U_USD">323000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6f909c39-112d-4ab7-82d9-d31b6680680d"
      decimals="-3"
      id="F_1c6446f8-82c1-4bcd-801b-994fa8fe4f0e"
      unitRef="U_USD">301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bb3a8b23-6728-4d59-a97d-1ecc7e3adfb8"
      decimals="-3"
      id="F_58c397fa-0e57-45b6-bef5-dd8365e69f50"
      unitRef="U_USD">397000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6e636ef1-70ab-4e6d-bbb9-b62e055ce520"
      decimals="-3"
      id="F_2f270764-6007-4d70-b574-d99e6df14d6d"
      unitRef="U_USD">2113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_75657e37-b736-4c10-bb3b-828a7e3b5bfc"
      unitRef="U_USD">6417000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_60c54599-0ea8-4404-bb66-36f5f329fe2c"
      unitRef="U_USD">8382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_d90e6742-91bf-4201-8e3d-87f206857d66"
      unitRef="U_USD">4174000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_9eb3b7da-fe56-4fb6-95e1-87ff7b23d252"
      unitRef="U_USD">3879000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_0b679eed-fe25-4dd7-bf61-88c5073443b0"
      unitRef="U_USD">2243000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_a0fc6013-31bd-4f72-b52b-6e5cda4a4429"
      unitRef="U_USD">4503000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_9f442798-e4a9-4506-97ed-1d027885caa0"
      unitRef="U_USD">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_b9f77330-4a5f-46c8-b25f-396e774f1adf"
      unitRef="U_USD">1000000.0</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_2494ef1d-b648-4c8a-b808-4d284da7bd40"
      unitRef="U_USD">1300000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f2e53c52-5446-41b0-82ba-27a69453ace6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.941%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.735000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Third-party research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_2a44f05a-a6a2-4866-a1c9-740ce7289659">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.941%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.735000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.092%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Third-party research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_9e5e55b6-95f4-4116-aa6e-1818a081fa3a"
      unitRef="U_USD">2975000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_e875c7fd-4489-4db4-b198-c4c577823dfb"
      unitRef="U_USD">2429000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_1b383fc9-f622-4cdb-9c85-6d3e9bbca57f"
      unitRef="U_USD">3435000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
    <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_e4347b46-34c2-4bce-85bc-bb63fb9cae42"
      unitRef="U_USD">1196000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
    <lyra:LeaseRelatedCostsCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_bd263a19-088b-487e-974c-a109f9b4d9da"
      unitRef="U_USD">1961000</lyra:LeaseRelatedCostsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_f6ea7621-3b48-45b8-88bb-797811921d30"
      unitRef="U_USD">659000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_ccfd4855-73ae-4834-9078-a5f95ba32e72"
      unitRef="U_USD">633000</us-gaap:OtherLiabilitiesCurrent>
    <lyra:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_8862ad99-d856-494d-af70-1096e1a9c1f9"
      unitRef="U_USD">9030000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
    <lyra:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_b9d98e14-0a74-4f94-a239-1ddf731b67ca"
      unitRef="U_USD">4258000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_9f2c6838-c4af-4415-9c8e-ebdfffdb1cba">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Preferred and Common Stock &lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of undesignated preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares issued or outstanding as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vote for each share held.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently has an effective shelf registration statement on Form S-3 (No. 333-256020) filed with the SEC on May 11, 2021 (&#x201c;Form S-3&#x201d;), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the Company has not sold any securities under the Form S-3.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 11, 2021, the Company entered into an Open Market Sales Agreement (&#x201c;2021 ATM Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) to sell shares of its common stock, from time to time, with aggregate gross sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, through an at-the-market equity offering program under which Jefferies will act as the Company&#x2019;s sales agent. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has received &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; proceeds &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;from the sale of shares of common stock pursuant to the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ATM Agreement. The offering of the Company's shares of common stock pursuant to the 2021 ATM Agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the 2021 ATM Agreement and (ii) the termination of the 2021 ATM Agreement as permitted therein. As of March 27, 2023, the Company terminated the 2021 ATM Agreement with Jefferies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;April 2022 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (&#x201c;April 2022 Financing&#x201d;). The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting estimated offering costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,815,159&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds to the Company of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and (ii) certain investors purchased pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, with the exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Company.  The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The pre-funded warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he sale proportionately to the common stock and pre-funded warrants, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; pre-funded warrants have been exercised as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.468%;"/&gt;
        &lt;td style="width:1.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.059%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,259,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;279,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,538,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a1144d35-ca6f-497e-a18a-73cf52e16156"
      decimals="INF"
      id="F_34a46877-ffeb-4429-a352-063fb234911a"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a1144d35-ca6f-497e-a18a-73cf52e16156"
      decimals="3"
      id="F_997712ad-b3a4-4e8e-92d4-5f51406b87f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_28599318-bb3d-440c-a8ff-c51682ad9599"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="0"
      id="F_7fc1aa63-156c-4ae4-84f5-11bb4737baa6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="0"
      id="F_313dafb8-de9a-4346-8e51-8bfadaaef7b5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="0"
      id="F_8133c045-fcf3-49e9-be8e-afa86a016470"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      id="F_f8a39eb2-442d-4520-b186-03b085b2b7db">The holders of common stock are entitled to one vote for each share held.</us-gaap:CommonStockVotingRights>
    <lyra:CommonStockVotingRightsNumberOfVotes
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="INF"
      id="F_5c48ce84-8f64-463a-a484-d06c265640f5"
      unitRef="U_Vote">1</lyra:CommonStockVotingRightsNumberOfVotes>
    <lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="C_85081da2-be87-496a-85a8-2491428bc94f"
      decimals="-5"
      id="F_3849bef6-5e26-4de7-bced-e77b2dcca37a"
      unitRef="U_USD">250000000.0</lyra:StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants>
    <lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock
      contextRef="C_49be5531-186a-4558-b31a-130bbf009546"
      decimals="-2"
      id="F_6b16097a-e905-40bd-9068-bc846ebf87e1"
      unitRef="U_USD">50000.0</lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock>
    <lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock
      contextRef="C_4825109d-f60c-4752-b276-40c0b1627135"
      decimals="-3"
      id="F_a1f86b4c-67da-4094-b844-b7679335262f"
      unitRef="U_USD">0</lyra:ProceedsToBeOccuredFromFutureIssuanceOfCommonStock>
    <lyra:GrossProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_4a7c6366-9118-4794-b989-2d8394630634"
      decimals="-5"
      id="F_d09480f0-0dc8-465f-97e0-f9d557e603ce"
      unitRef="U_USD">100500000</lyra:GrossProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_4a7c6366-9118-4794-b989-2d8394630634"
      decimals="-5"
      id="F_f55fce90-2556-4c3c-9919-0c6a9b3330a5"
      unitRef="U_USD">96300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lyra:EstimatedOfferingCosts
      contextRef="C_4a7c6366-9118-4794-b989-2d8394630634"
      decimals="-5"
      id="F_ecd0c70f-16a2-4e94-b41c-0a666e510036"
      unitRef="U_USD">4200000</lyra:EstimatedOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_df183939-be99-4d3c-9b1f-74b82cfaddf9"
      decimals="0"
      id="F_aafe8eb9-815e-4962-b33b-b483519adb6a"
      unitRef="U_shares">18815159</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_8ae07729-2d6f-4f3d-99ca-a96fa38b8e31"
      decimals="2"
      id="F_ad470a76-1791-4cb1-829e-c12ec347593e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.22</us-gaap:SharesIssuedPricePerShare>
    <lyra:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_df183939-be99-4d3c-9b1f-74b82cfaddf9"
      decimals="-5"
      id="F_4ec391c5-e3f8-4f8d-8f81-d5a0677bafc8"
      unitRef="U_USD">79400000</lyra:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d"
      decimals="0"
      id="F_3d37ca1b-aec2-4e39-a07f-c57fbe8f4589"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2042739f-ff2e-4355-bf6e-f55d146a1334"
      decimals="3"
      id="F_46da6ec9-3af6-496d-9b72-afc0d31a804e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_dd5cab61-dafb-4c36-9ad9-afbb168b3e1d"
      decimals="-5"
      id="F_d4de73b2-8ac2-4d6d-a8d8-9cd4dd420a9f"
      unitRef="U_USD">21100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_bce75e89-097d-40fe-96e7-7fef938bd51e"
      decimals="-5"
      id="F_55b2621f-742a-46b9-a4ae-8f726077f02f"
      unitRef="U_USD">19700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lyra:WarrantsExercised
      contextRef="C_bce75e89-097d-40fe-96e7-7fef938bd51e"
      decimals="INF"
      id="F_8df9cdab-b9a5-45a7-8699-cd5b9bb1bf9b"
      unitRef="U_shares">0</lyra:WarrantsExercised>
    <lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_b101314b-be7b-4781-baaf-8d8f56a8acf6">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.468%;"/&gt;
        &lt;td style="width:1.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.059%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,259,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;279,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,538,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f1a83be4-a034-4dba-99d0-ff646e8a3287"
      decimals="0"
      id="F_0cbd9025-c756-45ac-afa1-36795fed1572"
      unitRef="U_shares">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_42784fde-fb41-49b8-91a2-89eeebce4be2"
      decimals="INF"
      id="F_b1da78dc-9043-41fe-8d4d-533adf741f58"
      unitRef="U_shares">6259114</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b11a23eb-8f92-4a47-afbb-ff79b85ab2b6"
      decimals="INF"
      id="F_aada101c-8085-4667-9bd1-65cfacb0bac7"
      unitRef="U_shares">279696</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_b6c86d20-bb0d-4fb3-a584-2eb72e55a064"
      unitRef="U_shares">11538810</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f8af8505-d788-4028-9c77-cd7f0920efa0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently grants equity-based awards under its 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;). The Company previously granted equity-based awards under its 2005 Equity Inventive Plan ("2005 Plan") and 2016 Equity Incentive Plan ("2016 Plan").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiary.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The initial number of shares of the Company&#x2019;s common stock that may be issued under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares plus the number of shares of the Company&#x2019;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#x2019;s Board of Directors. However, no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,800,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. On January 1, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022, the shares available for grant under the 2020 Plan was automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;520,287&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,319,569&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for issuance under the 2020 Plan. On January 1, 2023, the shares available for grant under the 2020 Plan was automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,273,106&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2022 Employment Inducement Award Plan (&#x201c;Inducement Award Plan,&#x201d; and together with the 2020 Plan, 2016 Plan and 2005 Plan, the &#x201c;Plans&#x201d;), which was adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#x201c;Rule 5635(c)(4)&#x201d;), and allows for the granting of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,413,002&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock.  The Inducement Award Plan provides for the grant of non-qualified stock options, stock appreciation rights, performance units, restricted stock awards, restricted stock units and stock grants. In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#x2019;s entering into employment with the Company or its subsidiary. During 2022, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,813,002&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to certain executives. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remaining available for issuance as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All stock option grants are nonqualified stock options except for option grants to employees granted, under the 2020 Plan, 2016 Plan or 2005 Plan intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted under the 2020 Plan at less than the fair market value of the Company&#x2019;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from the date of grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.017%;"/&gt;
        &lt;td style="width:1.677%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.677%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has granted options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,429&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock that vest based on the achievement of performance-based criteria related to scientific milestones, for which the Company has not recorded any stock-based compensation associated with the achievement of the milestone as it was not deemed probable as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of unrecognized stock-based compensation related to a stock option award related to the achievement of a commercial revenue-based milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has also granted options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,648,002&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of  common stock that vest as to one-third of options, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that no more than one-third of the option may vest prior to the first anniversary of the date of grant, no more than two-thirds of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested prior to the third anniversary of the date of grant, subject to continued service on each applicable vesting date and certain exceptions in the context of a change in control transaction. The Company has accounted for these awards as market-based condition awards and therefore, stock-based compensation recorded during the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s unrecognized stock-based compensation as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.073%;"/&gt;
        &lt;td style="width:0.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.74%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.104%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Period of Recognition&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to executive officers, with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.704%;"/&gt;
        &lt;td style="width:1.258%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.432%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.258%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the stock option activity under the Plans for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.749%;"/&gt;
        &lt;td style="width:0.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.198%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.38%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.344%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.198%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,828,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,350,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock for issuance under the 2020 ESPP.  In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#x2019;s Board of Directors, provided that no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock may be issued under the 2020 ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2022, the shares available for grant under the 2020 ESPP was automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,035&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; increase to the shares available for grant under the 2020 ESPP plan as of January 1, 2023. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. The purchase price of the shares, in the absence of a contrary designation, will be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares have been issued under the 2020 ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_162858c9-f666-4eb7-be16-4f285ac5ff81"
      decimals="INF"
      id="F_93d77de7-f8cd-4637-a621-befb11f8cf99"
      unitRef="U_shares">2100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear
      contextRef="C_501a2778-23f4-4564-91d7-2770cfe05137"
      decimals="2"
      id="F_80593f4c-0dcf-4209-b5e8-d8a040608427"
      unitRef="U_pure">0.04</lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_501a2778-23f4-4564-91d7-2770cfe05137"
      decimals="INF"
      id="F_7f63a72e-90a3-4f6a-a359-b02d44050601"
      unitRef="U_shares">8800000</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_bb418092-ad75-441f-aea1-c853723d2837"
      decimals="INF"
      id="F_3393918f-6df1-482b-b346-fad2c31efa4b"
      unitRef="U_shares">520287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_11390654-f6a8-4a62-8bd2-4e84437ccd94"
      decimals="INF"
      id="F_1cfc8a9e-020f-4d6b-9014-93d03b004643"
      unitRef="U_shares">1319569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_19f3c088-c2ce-4eed-bded-16d5bf3a940e"
      decimals="INF"
      id="F_38e92862-c66b-477f-88ec-61a6df6a5bac"
      unitRef="U_shares">1273106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8e0d2435-49ae-4291-85fd-1d7c3f1ac975"
      decimals="INF"
      id="F_deae37d6-c84e-4242-822a-6236193258e0"
      unitRef="U_shares">2413002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_72a3022b-e3e8-4f67-b88c-e60be2a42056"
      decimals="INF"
      id="F_b821c890-ef01-46ac-be0b-0fdc4044a7e2"
      unitRef="U_shares">1813002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9bef293d-84d2-4550-baa7-b971b193887a"
      decimals="INF"
      id="F_bf87339a-30a1-4b16-b404-17d3e0f0b6e2"
      unitRef="U_shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_21d75bf0-5f97-4279-84fa-a52de2aac093"
      id="F_89d53693-d3d9-4511-bf0b-c57a2ac83f62">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_6fb4fa36-a2d1-4278-8d67-32d8fe50d72f"
      id="F_79bef21b-44f4-41ba-82d5-592e944818d8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_fbe437f2-86eb-430a-9aa4-371350cd2f11">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.017%;"/&gt;
        &lt;td style="width:1.677%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.677%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875"
      decimals="-3"
      id="F_8ed4b296-c0b1-4110-ac4c-808652854cbe"
      unitRef="U_USD">850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ed0926d1-d179-4325-b910-278483ee97af"
      decimals="-3"
      id="F_ac3526be-3197-4f9c-9010-d261da3adcea"
      unitRef="U_USD">508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_32a3b395-08bb-4bd8-8e69-bf7a8289138b"
      decimals="-3"
      id="F_8511ef2c-e9bd-4cec-be0f-e97c1d5ba1ba"
      unitRef="U_USD">4597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_317254de-de84-4738-817e-1c29f2dbec3e"
      decimals="-3"
      id="F_49c7e813-f75e-4e76-9211-2bb5728278e1"
      unitRef="U_USD">2262000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_6914e544-14d7-46b1-937d-070ad0eb30b7"
      unitRef="U_USD">5447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_e24084a2-e4e0-4452-83a2-504b4526741c"
      unitRef="U_USD">2770000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b5d83e3e-bc90-46f1-8c80-aac50e8a3314"
      decimals="INF"
      id="F_0beb6d8b-968c-4cdc-b68b-9673063d7012"
      unitRef="U_shares">31429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_87f11c83-03d7-43d6-be6a-f07729b1a6be"
      decimals="INF"
      id="F_842746e5-bd2e-46cc-8f43-a4f32cc04884"
      unitRef="U_shares">31429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3558ff97-70d1-4ac8-90d8-25851e56f82f"
      decimals="0"
      id="F_bdb65154-273a-4810-aab3-ed55637e7014"
      unitRef="U_USD">36000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_fc16a771-bf4e-44a5-b112-8ea51be13588"
      decimals="0"
      id="F_b7807c3e-be34-4250-b051-58db477cd964"
      unitRef="U_shares">1648002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fc16a771-bf4e-44a5-b112-8ea51be13588"
      decimals="-5"
      id="F_efe890b5-7498-48aa-8fda-6c7580e28094"
      unitRef="U_USD">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_9df89c10-6b59-4dd1-bf8c-5301fa17f6cb">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s unrecognized stock-based compensation as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.073%;"/&gt;
        &lt;td style="width:0.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.74%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.104%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Period of Recognition&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3aa72f08-9dea-4749-a7ce-7cde7d1d2163"
      decimals="-3"
      id="F_a3d21c02-fd04-4831-99bf-c6a93076537b"
      unitRef="U_USD">105000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f340881c-2e0f-4b0b-8367-5d095a57a0be"
      id="F_726cafc8-2134-4fd3-a8cc-99e47ddccba9">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_27b196b3-9d37-40ba-88f6-5c5770d52577"
      decimals="-3"
      id="F_7b74cd44-67a1-42bc-a438-e865df1bb68a"
      unitRef="U_USD">9247000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_661e6304-38fc-4780-9c4b-9199c12da66d"
      id="F_b82cbc3a-c102-42a8-9af8-1eb1372ee3e2">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_69536114-b860-4376-95ca-78461195a6d6"
      unitRef="U_USD">9352000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_ab9d51cd-49bf-46c9-adf4-4c979e943bba">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of the options granted to executive officers, with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.704%;"/&gt;
        &lt;td style="width:1.258%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.432%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.258%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_9395252c-d935-48d4-9447-6669e995fc4c"
      unitRef="U_pure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_b40ae8d2-2cd2-413b-8a85-a085e68b6fee"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_14a2a470-32c2-498a-9def-d74ade372222">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      id="F_989176bc-005e-4e05-82b8-ec08357270f7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_60105ab8-d115-43fb-b774-ca89f5f3e922"
      unitRef="U_pure">0.813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_4e70dcac-6c92-49bc-a287-f1600e90d0c1"
      unitRef="U_pure">0.850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_2c4bf5e7-4827-4d5b-85b6-5af85f23269e">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the stock option activity under the Plans for the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.749%;"/&gt;
        &lt;td style="width:0.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.198%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.38%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.344%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.198%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,662,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,828,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;177,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,350,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,311,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="INF"
      id="F_be89f7a1-b0d9-4d8c-97d2-6d71ef6781a8"
      unitRef="U_shares">1662861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="2"
      id="F_abef45d5-850d-4bec-aeb8-e4e5475f0b7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      id="F_1c1013ed-921d-46d4-b15e-a7affbd84a62">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_4be1cc0e-5c1e-4821-998c-f4562d1da8f3"
      unitRef="U_USD">918000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_c7322382-18f5-470f-bde8-2d30c8cadfaa"
      unitRef="U_shares">2828474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_6491068d-1739-40ba-932b-f4d02c14c7f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_ad5767a8-1fcf-48cf-bf9f-ced1ea4d2373"
      unitRef="U_shares">2718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_5e0afd73-2caa-4a51-98c1-17affbe5ef1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_15892346-88c2-4537-b753-f635f441235c"
      unitRef="U_shares">177284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_d8088575-af6f-45fc-9c44-e22b5c81bdd0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_ada0a72c-78af-4aa4-80a3-4a79e3e30a42"
      unitRef="U_shares">4311333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="2"
      id="F_06b964ed-a19c-452f-b55b-600c961fe137"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_2bf10bd1-0c23-47c6-85b2-dd7c14eadaec">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_56788694-8fb8-477d-98f9-87f80c2a4a1c"
      unitRef="U_USD">378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_6e90531d-e6e3-4e42-97eb-94de73cfbacc"
      unitRef="U_shares">1350357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="2"
      id="F_29320b11-050a-4f4a-909d-bf0260e3ecb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f93e0fd3-339c-4f29-88fb-32146343098f">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_b549fcad-63c5-4546-a3e2-9cbcccda566c"
      unitRef="U_USD">328000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_90b2814c-c03b-493d-9b5c-8484fda6b91b"
      unitRef="U_shares">4311333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="2"
      id="F_b6e777d1-a460-4d42-85b7-dd85eae39c71"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_ae518bd8-d16c-430e-a7d8-c4bf8cd2e521">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_24cfb960-4f7b-44b5-a899-e941ad72c51c"
      unitRef="U_USD">378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="2"
      id="F_35b03c91-f5da-430f-8ed1-fe4e6cfae3e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="2"
      id="F_0de3ad60-93d0-4db5-bf34-0b1a8d6cf02b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="0"
      id="F_f14cf241-fe59-459e-b33d-8bf58e10febe"
      unitRef="U_USD">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_da4a8b80-93ab-4576-8360-76869d8a8182"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a18f3701-43ff-4fd7-a44f-d3b3dc016a73"
      decimals="INF"
      id="F_94e7d70f-7000-4b1a-8046-5d1bd8c28e46"
      unitRef="U_shares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear
      contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d"
      decimals="3"
      id="F_6059a37f-382a-426d-967e-bafe268883a6"
      unitRef="U_pure">0.005</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d"
      decimals="INF"
      id="F_b0326e15-c5e7-415c-882a-7ac3f82e91da"
      unitRef="U_shares">987500</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_2fba1a08-71d7-45ba-a07a-724089146c63"
      decimals="INF"
      id="F_fb75451e-f8eb-43a5-abe0-1c24ca3066f4"
      unitRef="U_shares">65035</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_c3cb6888-3032-461e-8265-3245f2051004"
      decimals="INF"
      id="F_951c95dd-e71f-427c-ace6-82fa7869fcf0"
      unitRef="U_shares">0</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock
      contextRef="C_435574cf-1a94-488f-97a2-8dce8c5c419d"
      decimals="2"
      id="F_48b58e88-ead4-47af-a8a3-f0aee582892b"
      unitRef="U_pure">0.85</lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bfa4b7bb-7c8f-4561-8f51-cc77823b6c84"
      decimals="INF"
      id="F_5da2d7d4-f006-4525-b505-68136c143485"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_55489dfb-7ecf-4a1b-a886-06736ed23046">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 31, 2021, and as amended on September 26, 2022, we entered into the LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the LianBio License Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, the Company will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and the Company will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to the Company&#x2019;s LYR-220 product candidate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 808&#x201d;), which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities, or ASC 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, the Company identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial. The Company determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, the Company determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure (&#x201c;Combined Performance Obligation&#x201d;), and (2) the Company&#x2019;s performance of the development activities related to the global Phase 3 clinical trial (&#x201c;Development Activities Performance Obligation&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Combined Performance Obligation and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Development Activities Performance Obligation. In February 2022, the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which was allocated to the two performance obligations as follows: $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Combined Performance Obligation and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as all milestone amounts were fully constrained based on the probability of achievement. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022.  There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement until March 31, 2023. The amendment did not result in any change in the Company&#x2019;s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additionally, the Company determined that LianBio&#x2019;s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at arm&#x2019;s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company&#x2019;s consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, the Company achieved a development milestone of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for dosing the first patient in the US, and the related cash amount was received in April 2022. In accordance with ASC 606, the Company has updated its determination of the transaction price for this previously constrained amount from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, allocated the development milestones to each of the performance obligations previously identified in the agreement in accordance with the original revenue allocation percentages, and is recognizing the revenue under the revenue recognition model previously developed for each performance obligation.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reflects the change in the transaction price (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.062%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.040000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.838%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.252%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Post-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.906%;"/&gt;
        &lt;td style="width:1.245%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.001000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company achieved a milestone, which resulted in the receipt of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of cash. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; milestones achieved during the year ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.  No royalty revenue has been earned as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company&#x2019;s directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBio&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lyra:UpfrontPaymentReceived
      contextRef="C_ab8a831d-cce2-4c50-b8fb-f3c8eb1c821a"
      decimals="-5"
      id="F_cf28718b-ef44-4a34-9db8-eba67e409212"
      unitRef="U_USD">12000000.0</lyra:UpfrontPaymentReceived>
    <lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization
      contextRef="C_de48ac60-b50a-4c29-8f31-b67fc2eace77"
      decimals="-5"
      id="F_9eca4f5f-591c-493d-881a-523da05f440a"
      unitRef="U_USD">135000000.0</lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization>
    <us-gaap:DeferredRevenueDescription
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_a596a35b-8920-476b-a6e0-8ea5a806fefb">Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, 2022, as all milestone amounts were fully constrained based on the probability of achievement. </us-gaap:DeferredRevenueDescription>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_aacb10f4-b39c-44f8-9057-452a5c746b5e"
      decimals="-5"
      id="F_8aaeef4b-bf2b-4ae4-8979-ad6970bc5ea9"
      unitRef="U_USD">12000000.0</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_c1379db8-e17d-42cd-b4aa-023939ec6ee3"
      unitRef="U_USD">8400000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_e5e0368f-28bf-4bcc-b4f2-78fc92157ec4"
      unitRef="U_USD">3600000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_f1150276-615f-4f08-88b8-81bc087d354d"
      decimals="-5"
      id="F_7a5592aa-ec90-44cd-bd40-b219fef49b8c"
      unitRef="U_USD">5000000.0</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_946ce1f5-0df2-4562-bf11-7d539009d00f"
      decimals="-5"
      id="F_32dfcefe-5fa5-4ec2-a2b0-36da5428d67b"
      unitRef="U_USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lyra:CombinedPerformanceObligation
      contextRef="C_f1150276-615f-4f08-88b8-81bc087d354d"
      decimals="-5"
      id="F_b5658cac-b20f-402b-87c0-a2951c5eda4b"
      unitRef="U_USD">3500000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8"
      decimals="-5"
      id="F_d395ff49-aaf7-4d49-91e0-b63ee35101c7"
      unitRef="U_USD">1500000</lyra:DevelopmentActivitiesPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_946ce1f5-0df2-4562-bf11-7d539009d00f"
      decimals="-5"
      id="F_8323657c-404a-4079-9073-b148a437fab0"
      unitRef="U_USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_ab6efa41-abc1-41e2-a447-bc1e9acb264e"
      decimals="-5"
      id="F_5787fd81-0918-4553-8a30-2867578414b5"
      unitRef="U_USD">12000000.0</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_c20b9c24-a16c-4bcb-912d-93a745a09007"
      decimals="-5"
      id="F_f7015d04-fe8c-4db9-ba9c-32d840b60b3f"
      unitRef="U_USD">17000000.0</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_f95d0ffa-de66-4b30-a6e5-cd393abe8d64">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reflects the change in the transaction price (in thousands):&lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.062%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.040000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.838%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.277%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.252%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pre-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Post-Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock>
    <lyra:CombinedPerformanceObligation
      contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c"
      decimals="-3"
      id="F_d93e3685-0702-4217-b8db-4a04bb0e18ae"
      unitRef="U_USD">8373000</lyra:CombinedPerformanceObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8"
      decimals="-3"
      id="F_729cb96e-9119-4311-ad97-f3d1e179cc7b"
      unitRef="U_USD">3489000</lyra:CombinedPerformanceObligation>
    <lyra:CombinedPerformanceObligation
      contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0"
      decimals="-3"
      id="F_325c79a8-1ad3-4d18-8624-9c4b04d8b455"
      unitRef="U_USD">11862000</lyra:CombinedPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c"
      decimals="-3"
      id="F_ab5a9d5a-76e3-466b-b47c-f62e6cb2c7af"
      unitRef="U_USD">3627000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8"
      decimals="-3"
      id="F_0bc6c91c-2605-4b34-81ba-e23e8552669b"
      unitRef="U_USD">1511000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:DevelopmentActivitiesPerformanceObligation
      contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0"
      decimals="-3"
      id="F_4a97e229-63e6-408f-bf9e-22ab4faeff13"
      unitRef="U_USD">5138000</lyra:DevelopmentActivitiesPerformanceObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_d44362fb-4fc5-4481-be17-c8446450f94c"
      decimals="-3"
      id="F_c5b88baa-5f41-465a-b1b8-f0bb1068bf97"
      unitRef="U_USD">12000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_de44d7f7-7bdf-4087-aa60-6edb982677c8"
      decimals="-3"
      id="F_31ca3cbf-77fd-458d-b4f9-e266ba3bd371"
      unitRef="U_USD">5000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation
      contextRef="C_355e0890-9cd5-41a4-bfc3-ab7867b032a0"
      decimals="-3"
      id="F_2659dc58-8d9a-4166-a06a-081ef2f77364"
      unitRef="U_USD">17000000</lyra:UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_12ac0a6a-0c81-4160-82ac-f59f0852c3d5">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.906%;"/&gt;
        &lt;td style="width:1.245%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.001000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development Activities Performance Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="C_97589ddb-9445-4ee0-bf35-ac2868ceabab"
      decimals="-3"
      id="F_675e717c-f505-42fa-930b-749ae7ebeb33"
      unitRef="U_USD">8259000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_50d08448-36cd-45bf-bf96-7b413773153a"
      decimals="-3"
      id="F_cdc9e7a3-55e9-4e8a-9356-9c4c6d773f0b"
      unitRef="U_USD">3456000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_dc68529a-8542-4eb6-a238-fcf035b27a31"
      unitRef="U_USD">11715000</us-gaap:DeferredRevenue>
    <lyra:DevelopmentMilestoneAchieved
      contextRef="C_b069fcd9-9753-4c58-ba29-e3011d30aa97"
      decimals="-3"
      id="F_7e71b43a-e7f2-4b30-b150-7ad1d6489e84"
      unitRef="U_USD">3489000</lyra:DevelopmentMilestoneAchieved>
    <lyra:DevelopmentMilestoneAchieved
      contextRef="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1"
      decimals="-3"
      id="F_fce7f5f9-c3c8-41ed-95d9-d812d835acdb"
      unitRef="U_USD">1511000</lyra:DevelopmentMilestoneAchieved>
    <lyra:DevelopmentMilestoneAchieved
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_3271dea2-b2e8-45db-98c2-6623554a9a9c"
      unitRef="U_USD">5000000</lyra:DevelopmentMilestoneAchieved>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_0d6ebc41-7b82-490a-a4e6-2e9dc7e266d1"
      decimals="-3"
      id="F_d2ada0ba-4bdc-47d1-a551-6b939ddd7ee8"
      unitRef="U_USD">1363000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_8a806abf-db51-47eb-9db3-2d36478d7d62"
      unitRef="U_USD">1363000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue
      contextRef="C_86716da2-023d-4ddf-84dd-2aa61048c050"
      decimals="-3"
      id="F_d8f50307-8840-4a08-b212-84e5645ae633"
      unitRef="U_USD">11748000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_ff6c540e-0dee-49f8-b317-487ce471c7fa"
      decimals="-3"
      id="F_9e5fc6a4-8475-446c-bbe6-1652294ece2f"
      unitRef="U_USD">3604000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_30f50f96-a716-4c0a-845b-aca338b2672e"
      unitRef="U_USD">15352000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_36e6caae-c368-4a2e-a60b-afef8e9340a0"
      decimals="-5"
      id="F_15a5883e-f093-4381-b101-e0322ebab91c"
      unitRef="U_USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6a870f0e-a464-4613-8b30-3072bec4780a"
      decimals="INF"
      id="F_8404e20c-14ae-4936-a122-44edcaa99513"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_517fdb70-f4e9-4ea3-9614-a7cadbed73af">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December 31, 2022 and 2021, the Company recorded net losses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t record an income tax benefit for the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.729%;"/&gt;
        &lt;td style="width:1.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss of Attributes - IRC 382 Ownership Change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.652%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.299%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research &amp;amp; experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the Internal Revenue Code, or IRC, 382 study performed during the current year the Company has written off $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal net operating losses and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal research and development credits. As of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022, the Company had U.S. federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which may be able to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;offset future income tax liabilities and expire at various dates through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal net operating loss carryforwards that may be carried forward indefinitely.  As a result of the IRC 382 study performed during the current year, the Company has written off $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of state net operating losses and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of state research and development credits. As of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022, the Company had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which may be available to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;offset future income tax liabilities and expire at various dates through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, available to reduce future tax liabilities which expire at various dates through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042. As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, available to reduce future tax liabilities which expire at various dates through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. The Company has performed an IRC 382 study during the year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. Based on these ownership changes and the calculated IRC 382 annual limitations, the Company has written off $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal net operating losses and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal research and development credits. For state purposes, the Company has written off $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of state net operating losses and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of state research and development credits. The remainder of the attributes have an annual limitation that will impact how the attributes may be utilized in the future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;assets at December 31, 2022 and 2021 because the Company&#x2019;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, has been established at December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance decreased by approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2022 due to the write-off of net operating losses and research and development credits as a result of the IRC 382 study compared to the increase of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, during the year ended December 31, 2021 due primarily to the generation of net operating losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December 31, 2022 and 2021. The Company&#x2019;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had not accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#x2019;s statement of operations and comprehensive loss. In many cases, the Company&#x2019;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December 31, 2019. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_e9def8d5-a8aa-4574-95b7-9d0b0743e877"
      unitRef="U_USD">-55300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_d65232bc-4f5b-4e8f-8a90-b5ba3f8b52cc"
      unitRef="U_USD">-43500000</us-gaap:NetIncomeLoss>
    <lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="INF"
      id="F_3df4c7b2-497e-4aba-ba9f-0fbce1cf3a7d"
      unitRef="U_USD">0</lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit>
    <lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_b54de03a-d7e8-4375-9513-f7977be1b755"
      unitRef="U_USD">0</lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_d5dac073-8bee-423e-b2c3-7e76e6917ee0">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.729%;"/&gt;
        &lt;td style="width:1.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss of Attributes - IRC 382 Ownership Change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_4012a728-10b2-48ae-9dbc-f022acfd9dc2"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_88ab53bf-c372-4435-9cfb-3fb7fed2d7c4"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_3c4eae92-c36f-45f6-8e9e-06ccfe0a8445"
      unitRef="U_pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_a73b5f4a-26a2-4c7a-ad74-e9c1d347f44e"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_1929f2b9-9e63-4d9d-a4eb-55feb4c799d5"
      unitRef="U_pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_c8a39fbe-9edb-4742-8bdf-b35b8cf04bb9"
      unitRef="U_pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_fc52ed8b-bc5a-4f8f-bfa8-1766a5ad2b1b"
      unitRef="U_pure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_8a9ca961-3ad3-4c8c-8281-684f688b51fc"
      unitRef="U_pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_1f2bff90-1369-4ee1-8c9d-32754eb4a092"
      unitRef="U_pure">-0.258</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_e8912773-4ebc-4bf3-8e2b-b0a4f792c806"
      unitRef="U_pure">0.304</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="3"
      id="F_e753da02-164b-4346-8afb-b21249618379"
      unitRef="U_pure">-0.547</lyra:EffectiveIncomeTaxRateReconciliationOwnershipChange>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="3"
      id="F_8fd9fb87-d9c1-4285-8933-c8a3667d9d19"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_9ac13422-48a3-4380-a7f0-9e6df2c9417f">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.652%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.299%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research &amp;amp; experimental expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_fe259915-acb5-425d-8e07-9b056ddefde1"
      unitRef="U_USD">25154000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_1ec04390-da10-461b-be42-7542e99e1a5c"
      unitRef="U_USD">46462000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c84ce59c-e39b-4d29-abef-1baf84225eb8"
      unitRef="U_USD">1751000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_61d2e678-2d72-4cbc-96ce-362af8d6ca75"
      unitRef="U_USD">7288000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_837d259d-5233-47b8-97d7-89ebe6ed2b13"
      unitRef="U_USD">1295000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_6d4cd829-7ef3-4a19-b6db-762470380fad"
      unitRef="U_USD">848000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <lyra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_08d2f647-6fd4-4580-8001-2c0bbf2f1d17"
      unitRef="U_USD">583000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lyra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_6ebce29e-3fbc-4f00-aaa7-7d9a443a35b6"
      unitRef="U_USD">382000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_80b777e4-9b44-4588-92cd-353eb599433d"
      unitRef="U_USD">9076000</lyra:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_a5e5833e-fbcd-43ec-a9f6-b6d9a2bf3131"
      unitRef="U_USD">2763000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_02997564-c67c-445a-8085-234e7f0ae4a3"
      unitRef="U_USD">474000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_bc680766-1afe-440e-8f8b-4ecaddfeece7"
      unitRef="U_USD">73000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_c1561a08-0464-4991-8d55-ecab7e42e12e"
      unitRef="U_USD">41096000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_bde8846d-e74d-4565-b51c-7f94e1313cf8"
      unitRef="U_USD">55053000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_8cfd3707-88b3-445f-a848-0b1712994346"
      unitRef="U_USD">40512000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_32c3c829-f5b0-411c-85d5-247d8a0d5fb7"
      unitRef="U_USD">54697000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_b7178220-59ed-420d-aee6-985adf4cf42f"
      unitRef="U_USD">584000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_1ca95e21-858d-47db-91ee-88d1f4f98def"
      unitRef="U_USD">356000</us-gaap:DeferredTaxAssetsNet>
    <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_7c5da884-a42f-4f5e-a2d2-53f5002fb7ca"
      unitRef="U_USD">584000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_fcfc616a-b05d-42b0-b645-675d1cbd6ed4"
      unitRef="U_USD">356000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_094b7f3b-f2f2-4ffc-8832-f236afa1a818"
      unitRef="U_USD">584000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-3"
      id="F_b7b50f57-43f6-4196-9bfb-bd439b11da43"
      unitRef="U_USD">356000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8"
      decimals="-5"
      id="F_98c6d185-b53e-4bbb-a592-4fe4d26790d8"
      unitRef="U_USD">67600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8"
      decimals="-5"
      id="F_b61b161c-a820-4dc8-ad85-a3b72c269c31"
      unitRef="U_USD">5700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e3cac587-28df-4995-8b75-2a1e2e20870c"
      decimals="-5"
      id="F_e712a750-bf15-452a-940d-d3ed7009b2d4"
      unitRef="U_USD">23700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_5d2f621d-ce9f-493a-be01-01b725615ebe"
      id="F_46b860fe-da09-4619-8f17-d3713b1f53d9">offset future income tax liabilities and expire at various dates through 2037 </us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_4b81447d-9f3f-4a61-a5b3-d086c511a31c"
      decimals="-5"
      id="F_44370b90-698a-447c-8cb1-41fd5f9c6d7e"
      unitRef="U_USD">88400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189"
      decimals="-5"
      id="F_dffd4521-c1d2-4c24-ba90-17f6f9584ee3"
      unitRef="U_USD">125800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189"
      decimals="-5"
      id="F_4b3283bc-9152-4d10-bda6-e7245df14019"
      unitRef="U_USD">2800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125"
      decimals="-5"
      id="F_c3e04378-2eb5-460a-8eb6-b3857c8fbda2"
      unitRef="U_USD">25500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_23a96427-b264-4ccf-a621-6b9aa5d2b550"
      id="F_52d746ff-b843-4faa-bf83-156ae49aba77">offset future income tax liabilities and expire at various dates through 204</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_e3cac587-28df-4995-8b75-2a1e2e20870c"
      decimals="-5"
      id="F_d4adf1e7-ef45-449a-936f-68c7780b55cc"
      unitRef="U_USD">1400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ca643c6d-178f-4cdd-919d-765a5892183d"
      decimals="-5"
      id="F_9f052d95-250d-4e53-b2e2-8f1c9112db91"
      unitRef="U_USD">5200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c5663cca-489a-4fdc-9fa1-3b4e00ce7125"
      decimals="-5"
      id="F_8e5fa227-eeb1-463b-be96-b363704c6aa1"
      unitRef="U_USD">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_98c9dcf4-d3b8-48d5-812c-7b771021577f"
      decimals="-5"
      id="F_9b47fcc4-1549-40ed-a210-f1aa733c5882"
      unitRef="U_USD">2700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="INF"
      id="F_7f1cff78-cbc9-4f5f-9de5-9990ebcbe541"
      unitRef="U_USD">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8"
      decimals="-5"
      id="F_33275a63-992f-4771-b20f-806e3f26dcff"
      unitRef="U_USD">67600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_dd7d704b-d27b-4f68-83a3-b5bd00f5d0d8"
      decimals="-5"
      id="F_55935067-c679-482a-8db3-34320bc29689"
      unitRef="U_USD">5700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189"
      decimals="-5"
      id="F_f7f1bf3b-694c-4ece-b57f-da2e51016ad5"
      unitRef="U_USD">125800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_5424ce9c-7be8-4c1c-90d8-80aec35a8189"
      decimals="-5"
      id="F_513f3673-af55-4260-ae4c-06936b0b5158"
      unitRef="U_USD">2800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-5"
      id="F_caa5148a-43f4-41e3-a2dc-29858a468f8c"
      unitRef="U_USD">40500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_66e063fc-33e5-4cb1-a079-fd6c176dfc16"
      decimals="-5"
      id="F_de81d4c8-a3b5-4e75-bf6a-e3a0472967f5"
      unitRef="U_USD">54700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_f02466ad-3fa0-43dc-8344-5ad78c963d2a"
      unitRef="U_USD">14200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_38fb7b88-fe7b-4758-b161-5493703f12a1"
      unitRef="U_USD">13200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_0332a0df-1d72-4d57-9c82-4c3672275c84">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Watertown Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#x201c;2017 Amendment&#x201d;) to extend the lease term through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  In November 2022, the Company amended the lease to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extend the lease term&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The lease includes certain rent escalations. The lease modification was assessed as of December 31, 2022 and changes to the right of use asset and liability was reflected within the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains a letter of credit of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million securing its obligations under the operating lease which is unsecured by approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Waltham Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2022, the Company executed a new lease for laboratory and office space. This lease will be recorded on the Company's balance sheet when the Company obtains possession of the underlying asset, which is expected to occur in the fourth quarter of 2023, following completion of construction to prepare the premises for the Company&#x2019;s intended use. Annual base rent will start at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million increasing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per year through the original non-cancelable term of the lease, which is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years and two months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; following the lease commencement date. The Company has the option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one additional 5-year term&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the lease was not recorded on the consolidated balance sheet as the facility is under construction. When payments are made by the Company relating to landlord-owned leasehold improvements, they will be recorded to prepaid rent as a component of other non-current assets. Upon control of the space, The Company will reclassify the prepayment to the right-of-use asset, thereby increasing its initial value, but the prepayment will not be included in the measurement of the lease liability. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of prepaid rent was recorded in other assets with a corresponding liability recorded in accrued expenses. The lease will be recorded as a component of the Company&#x2019;s right-of-use asset and operating lease liabilities when the Company takes possession of the space.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company provided a letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as a security for the lease, which expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, at which point the letter will automatically renew each calendar year up to but not beyond &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 31, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The unsecured letter of credit is classified as restricted cash on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition to the leases discussed above, the Company is party to an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_e9f4b3d3-691b-4381-9a0b-ee7b93945cac;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lease for office equipment that expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_4cef5287-028b-4d16-aa13-f50aae7b67ec;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  The equipment lease is accounted for as an operating lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Embedded Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2021, the Company entered into a clinical supply agreement with a CMO for clinical production of the Company&#x2019;s product candidates at an existing facility and a facility under construction. The Company concluded that this clinical supply agreement contains embedded operating leases as the clean rooms in the existing facility and the new facility are designated for the Company&#x2019;s exclusive use during the term of the agreement and the clinical supply agreement contains fixed commitments and variable costs related to production and material costs in excess of the fixed commitment specified in the agreement. The Company determined that it did not control the new facility during construction and, thus, the lease did not fall in the scope of &#x201c;build-to-suit&#x201d; accounting. The term of the clinical supply agreement is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and will automatically renew for additional successive terms of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless either party gives notice of nonrenewal.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease period for the existing facility is less than 12 months and the Company has elected to apply the practical expedient in ASC Topic 842, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or right-of-use asset but instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate, as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with the clinical supply agreement. In October 2022, the Company terminated the agreement with the contract manufacturing organization.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated financial statements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.964%;"/&gt;
        &lt;td style="width:1.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.982%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building and variable lease costs associated with the Company&#x2019;s CMO embedded lease arrangement. During the year ended December 31, 2022, the Company recorded as research and development expense approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of operating lease costs related to the CMO embedded lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate related to the Company&#x2019;s operating leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.947%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.432%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of the Company&#x2019;s operating lease liabilities in accordance with ASC 842 as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.127%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.854%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Effects of discounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total rent expense under the Company's leases amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <lyra:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_24c6e4df-a738-4298-9c1a-6fa22126a4d0"
      id="F_0cdc65f8-e9bf-4ed2-806d-16269cc522fc">2023-04</lyra:LesseeOperatingLeaseExtendedLeaseTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_ffdb9268-e81e-4854-abb7-7dc620a278a7"
      id="F_d5a66391-124d-4684-9818-bb7758b6bc77">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <lyra:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_db2e146e-6da1-4245-84c4-73c704b05e73"
      id="F_068d9282-f45f-4f59-9cf3-4b0146fc1573">2024-04</lyra:LesseeOperatingLeaseExtendedLeaseTerm>
    <us-gaap:SecuredDebt
      contextRef="C_42595f81-0b68-440f-b7f6-c0b65eb4d4fa"
      decimals="-5"
      id="F_c3e5ea69-757d-47c2-a0f3-993b4fc770fa"
      unitRef="U_USD">300000</us-gaap:SecuredDebt>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_c6a86586-b423-4033-bd3a-ef5d462ae4d3"
      decimals="-5"
      id="F_fbfe2295-d4c8-4cbb-882b-c4c7de10486b"
      unitRef="U_USD">300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_86cdf56f-cd6f-4aa3-8f8d-0db4f6e082d6"
      decimals="-5"
      id="F_c56d9a22-91f4-457d-bcb3-ff6a8ea680a7"
      unitRef="U_USD">2200000</us-gaap:OperatingLeaseExpense>
    <lyra:PercentageOfAnnualRentIncrement
      contextRef="C_947e7a14-7124-4460-8622-c6ac515eacd4"
      decimals="2"
      id="F_2fa09fe1-b15c-4fa4-b523-a4e06521700e"
      unitRef="U_pure">0.03</lyra:PercentageOfAnnualRentIncrement>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_947e7a14-7124-4460-8622-c6ac515eacd4"
      id="F_f0988300-8a6e-4003-bd1c-4909ebddefe0">P10Y2M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_83e9be91-41f7-4203-b44e-71feb55201e8"
      id="F_ad58d419-7e76-4888-aca1-a7948634c222">one additional 5-year term</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:PrepaidRent
      contextRef="C_c2e5de28-b6f2-4a80-a975-f131ab84261b"
      decimals="-5"
      id="F_b5fafbc6-75d0-4536-b7f4-2dd7c6fdd603"
      unitRef="U_USD">2000000.0</us-gaap:PrepaidRent>
    <us-gaap:SecuredDebt
      contextRef="C_7887ec17-ea58-4a4a-bcdd-f4316823027d"
      decimals="-5"
      id="F_0cfd9860-9845-485f-9c82-c260a46d0500"
      unitRef="U_USD">1100000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_3c7ec31f-db19-4dca-ad79-3648a2ac432f"
      id="F_efff79a9-1012-47dd-8314-ae160d97a632">2023-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_b5ad16fc-e41d-4d55-b3e3-5c4dc3774b7c"
      id="F_5228340c-a787-435f-9be4-f6bcd4afea6f">2033-07-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_56c02857-b6c9-47ae-b10d-01237cf26d18"
      id="F_e860c316-2d47-4d89-a140-649df74ded24">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_56c02857-b6c9-47ae-b10d-01237cf26d18"
      id="F_e605793b-82a6-470a-b56b-47d0799d0f7d">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_6bb4be9a-4187-443d-b81b-db6600169f28">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease cost recorded in the Company&#x2019;s consolidated financial statements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.964%;"/&gt;
        &lt;td style="width:1.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.625%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.982%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_56f22476-3d45-4cec-a237-6b86e720998d"
      unitRef="U_USD">1115000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_9141cbe6-6918-4949-a128-017ba334d2b5"
      unitRef="U_USD">1056000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_9f74d2f3-3f1d-4858-bb74-e398df18c42a"
      unitRef="U_USD">3931000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_c897777e-5bab-4762-a64a-3c00f01583bf"
      unitRef="U_USD">4542000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-3"
      id="F_1007527d-ace8-4518-8dcd-4b7c4caac465"
      unitRef="U_USD">5046000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-3"
      id="F_6754eb62-7a2f-4b9f-8b4b-65b2d9c953b7"
      unitRef="U_USD">5598000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_aabae8ed-77a4-4ca7-a18a-55fe017f5875"
      decimals="-5"
      id="F_fa53dcc6-87b5-42f4-8774-c06eaaed272e"
      unitRef="U_USD">3200000</us-gaap:OperatingLeaseCost>
    <lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_55f6a69a-1d20-4f82-9aa0-47c8bf55c63c">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate related to the Company&#x2019;s operating leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.947%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.432%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      id="F_c89e364a-ee95-456a-acb2-9ea4deb94019">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="3"
      id="F_4faf32cd-5e44-4fd8-ab54-0f457879917a"
      unitRef="U_pure">0.082</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_137eafd8-4771-4421-b9a7-35e6c5c171ab">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of the Company&#x2019;s operating lease liabilities in accordance with ASC 842 as of December 31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.127%;"/&gt;
        &lt;td style="width:2.019%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.854%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Effects of discounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_870e6649-5890-4397-a459-baa418ccef29"
      unitRef="U_USD">1673000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_1bf51181-74a5-4e50-a37f-b7f053fcc36e"
      unitRef="U_USD">694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_2637abe8-0ea0-4be2-8209-6ec835888fad"
      unitRef="U_USD">2367000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_2b315e13-63dd-4dfb-ae54-84c6d33ff519"
      unitRef="U_USD">151000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_cac06fbd-d264-4bf2-8f14-1ffda3d0213f"
      unitRef="U_USD">2216000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_d3b5c899-737a-4f50-9ccc-fcf75841e28e"
      unitRef="U_USD">1549000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_30fc43ea-2218-4e8e-9220-f7894e107d70"
      decimals="-3"
      id="F_702f92e4-da81-4af1-b882-8d4a3d558719"
      unitRef="U_USD">667000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_6259786e-c870-4957-a394-6ed0b7136379"
      unitRef="U_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_1354873c-98bc-4dc1-8c3e-5dd5cec5d9fd"
      unitRef="U_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_8a98e217-558c-45ba-9455-27084dcec79e">&lt;p id="final_fpage" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Retirement Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (&#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company made a discretionary match that matches 50%, up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% employee contribution, and therefore a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of employees&#x2019; salary. Matching contributions are fully vested at the time of contribution. The Company matched $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of employee 401(k) contributions for the years ended December 31, 2022 and 2021, respectively, which is included in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <lyra:DefinedContributionPlanMaximumContributionEmployeePercentage
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_1d0f3019-6652-42aa-a079-85e33e088e16"
      unitRef="U_pure">0.06</lyra:DefinedContributionPlanMaximumContributionEmployeePercentage>
    <lyra:DefinedContributionPlanMaximumContributionEmployeePercentage
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="INF"
      id="F_4a244ede-2168-4b70-abc1-35a289e5b961"
      unitRef="U_pure">0.06</lyra:DefinedContributionPlanMaximumContributionEmployeePercentage>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="INF"
      id="F_848e1add-2f4a-4c20-997e-ef44b5b5b293"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="INF"
      id="F_1c0406ff-d1aa-4589-9e3d-38db507619e5"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      decimals="-5"
      id="F_a48ade9a-2ab6-494c-9bdb-4d3ac5f7c712"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_938c4a89-6aac-4276-8bc4-fac64ea9d7a1"
      decimals="-5"
      id="F_ebc46beb-6b8b-427f-ab7d-2464c84ae5e2"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_259fea07-483e-459f-85c3-cc48ff87d140"
      id="F_a874f365-7ee1-4a06-8d7d-b7101d3d8e52">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 17, 2023, the Company filed a complaint in the Court of Chancery of the State of Delaware against a former contract manufacturer alleging breach of contract.  The Company alleged in its complaint that its former contract manufacturer breached the Master Clinical Supply Agreement (&#x201c;MCSA&#x201d;) by misrepresenting their ability to produce LYR-210 in accordance with the specifications and with a robust quality system in place, and failed to return certain customer materials and equipment as required under the MCSA. The Company's complaint seeks monetary damages and the return of equipment and materials that the Company owns. On March 28, 2023, the contract manufacturer filed a motion to remove the case from the Chancery Court to the United States District Court for the District of Delaware.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 27, 2023, the Company notified Jefferies LLC (&#x201c;Jefferies&#x201d;) of the termination of the Open Market Sales Agreement, dated May 11, 2021, between the Company and Jefferies.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M!M(8X/NE$'K7,2=]<[.+_@!02P,$%     @ &X1]5@]?6"+D!   !A0  !@
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MCFV<@5M,TZ'LPARO:7\ET0M825+E559S^(]8D1+(VN1$7ZD9N"'@IDA83J[
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M@)V* $/LT__8)SXT=P%+XCNF;B<4B%LH'!:-/W 5BWIQJ2LF-W;G!L/OBP%
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M%QE(JC[$K6^TW%3GH'=2:YE5EVO.$JZL@?E]*:7>W=@7M$?I\_\!4$L#!!0
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MV$A?J?YE'Z*#QW27TG\BV[)0OW>41%D4O!NE._7RI+KL>L&Q[T]F8R;>D;%
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M]Z] >'HW[ B(EBCY:/<18;O;,]ZUVU[+GHF)C7TH D42;1!@HP#)]*_?/.L
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MV$GAWR&;KQD8%0JJ$?$"U3928W,TUQ$*HYJV25-_OA))/DT*/)MR^EKTP B
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M&O2/H08],I.<:7AR^B3W#Y(*>Z79.;9PK^B:%::?XKP#O!;R#L:'&J+: 2V
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MZ_4[>@).JA3WB"_(Q&B"FH.],X>H\PPAJ1U'6&#%ER B7*2U?)+/%&19NC^
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M85E,D&7!E?Y(<2_A(8:TTVB>>@K%!6&\.YWZ\>J)&$VYPQ#6RDBM5:9_K_I
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M#D10UH(?$E>"'>]V&4XT>#7"EYSCJ(:&=Q3_[2KIB1LFE\<ZU8$QZ*!!5CT
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M-(7HN:>Q%FV!O9RFH&K(#F6T5CIW:/LUS$?[7-7N"%F@+K<<>#W14FH_R5B
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M]Z:3;IC 5Q?>K/FU/RH:;S+^NE(2"J %>+XPQE<7=$#].Y#K_P)02P,$%
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MRC^:W2\XQ'/!>(51+OS"KM>=DL>B<]XT@S'M&ZG[KW@9\G!D<)7^P" ?#/+
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M5[QSI*C9^8_MHW 1'T+]"]&%6"9R.#BW?_4%S _:0 7Z$SZ,;&J3?3&)L<M
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MK$&:@EY>%O!T[A^?F*# 2#I6QTDK:8Q)-NRNP'-!F@<%%LQ8X)-KDJ  W5M
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M4Y!0K"&&L*F._(0-O(_Z@576PK-L;]FQGMGX!]9Y\>#M8/1.-:,MX_NR)XZ
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M=;CXMC/;]E7RK'BN^7V[0+U]UCZW6K3 ^T=X>OBX5^_E"=O6<Q;0:/0JO.O
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MRM<FJ"7H;]G.ZZ5&FM2&/2RPXAOLWDP9;/.S-)*M9J@L!:4HJ>_OA&U33[+
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MP=5%%K)^BE$N$78J_(!WK&Z/ ,30+UXM%[2<:"=[3G# ;IC=0"Y)[2)EHAW
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MS\LE!1R#&B#4=+#J,5@-I8^P=+R3WGAF16QKC"@N&S(*+!66>[R"J/%,N%B
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M91SIAZ[>XI#HP>WJ#?VYAA,W#3X OR]K$//R 2>XKYLOM+S7_P]02P,$%
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M+YTWUX2U>'/9^BS,@R3H"G-2[1^-:/,WS06F>7!Z[B\-,^WH"N*7!=WYT+
M?<\UE:Q]8 >K6^39_U!+ P04    "  ;A'U6\<["],<#  !0"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6R%5FUSXC80_LZOV/%U;MH9-P8#YB7
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MU+.C1ZNRYXM;C"MG=ZK 6AONTO7A.ZV!G7WA4PGF_+IGT1PI];(&^K:&CEZ
M#B/V695V8=B',H?\$*"'?K;.1EMG;Z.3B.\A\UD<>BP*HN@$7MP&'SN\^*7@
M%UQ#$_R$;Y!KEHVUYN4<W/K/\=18C<3YZUCT-7;_.#8UTY59\@QNNM@M!O0*
MNJ.WK\)A\.Z$Y_W6\_XI]-$C-F=>26!JQOZKA,=\/XE^W/?:S-29R?;-0,,4
M46:RPD+C@MD%.%]XN7G[*HW"Y)U!I=(H*7)N4<98_*$D&PH!9XQV8(;QLH;7
ML*#67P&3RABVYKAEV$Q)'".&G3D;JC(H;LZO.G\ US7-.L0-(DC8>4#7N<X6
M#C.'%4Z@I:OK:Y8. OP>!&GG$Y1H6SH9GF.'"2HYC0K6]P:7"8N\:!AUOBB+
M0JCB]?L)_D9>D@3L1"4';24'OUS)IU)#IN:E^ <S]%)9CY7SI(GCY?R"%:JS
M*<HYL]3DS61&Z^9H :M]]\Q+=."NHMBJ4$Q!M^UZ4*.#0+>39@):J)R4'^I-
M@J,B6BTRNS6)7@@DS6L6!@,6^U''Y0D95-/GTHNP/I&_J]BE%P^B4Y4:MI4:
M_G*E/G*AV5<NJUT'LOMEW77&BL)Q'!]P)CN)3SA4+'LRE.M;R3%SB*9PKC9:
M%Q.,D38_JQPD4]J-3BP!UU*Q1U%4LLXN\OX.<TZ8]TW(#AO-686IA*QRW+V?
MS40&VAQCR\DP3["%8EYM8P:.C67V<L_F.S^@6$JU 3 >RP66VBI==W:)H;:;
MKJEA/UW$NKQ)F8-CE4L9O3],6VWS8MFDK:"T>90W?I Y<Y Y@LF:[-%Z2YI]
MS]L,JB:#'I[(=N'D=_VR=J<]Y!=\A=-C#LAZ;)X:[J5I),SSQ4P##4H+F%G+
M-(4:^0E[PP+Z[E K.*KG8B5RP(1M!,B<N1:,WJ%<N]K)(ECA!N(&S9IS-O0#
M^NP$5HI2((7=L#3T8T1)!RCSYE13)&U3)*>;HK[,_=0%8[IMD<4G3(-F$\G+
MHUP\B7Z<B^/M#7);Q@,6\JWARAFF?6<<BU<_49884'%^'E(_'#-7'7=#,.S;
MMMQ[J_%\KF&.%>S<5Q:/LS(G8OP(&;+0&PXC+QV&;F;Y<9\E_I#F4HB'3T,\
MW(]2KY_TV< /+[%RH#-!D_6,#IHP9>=$DV'GCI<97F#=1I@D7I3V<2OQT_C
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M7T=7+?%W!)2=@.-;*<VA83?H?W#F_P!02P,$%     @ &X1]5A2;[\2.!
M;0H  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULC5;;;N,V$'W75PR\
MS2(!%%M7VW$2 [ELT0#9)DC2%D71!UH:V40DTDM2<=*O[Y"R;.W&<?MBD]3,
MF3/#,R3/5E(]ZP6B@=>J%/J\MS!F.1D,=+; BNF^7**@+X54%3,T5?.!7BID
MN7.JRD$4!,-!Q;CH3<_<VKV:GLG:E%S@O0)=5Q53;Y=8RM5Y+^RU"P]\OC!V
M83 ]6[(Y/J+Y;7FO:#;8H.2\0J&Y%*"P..]=A)/+U-H[@]\YKG1G##:3F93/
M=G*3G_<"2PA+S(Q%8/3W@E=8EA:(:'Q;8_8V(:UC=]RB_^QRIUQF3..5+/_@
MN5F<]\8]R+%@=6D>Y.H77.?C"&:RU.X75HUM&O<@J[61U=J9&%1<-/_L=5V'
MCL,X^, A6CM$CG<3R+&\9H9-SY1<@;+6A&8'+E7G3>2XL)OR:!1]Y>1GIC<B
MDQ7"$WM%#8=/;%:B/CH;&(*V!H-L#7/9P$0?P(01?)7"+#1\$3GFWP,,B-.&
M6-02NXSV(EYCUH<X]"$*HF@/7KQ)-'9X\7\F"M=<9Z74M4+XZV*FC2)I_+TK
MYP8QV8UHVV6BERS#\Q[U@T;U@KWIYT_A,#C=PS?9\$WVH4\?J?WRND20!7PI
M"G3JA4X6#\P@/& F1<9+SJS&=^6P/\H%-587P4;C30Q#,?"5FE\CT,*R-I@#
M,V 6"-HP4QNIWJ# '!4KNT[*$C.RLT32HEZSC4@07#@(BJIER7-FUPHN&)$@
M'(N,U/1& ]? -!2RI(-#3[P_D:E&79Z5A-5%Z-ULPW8YMJRV/#?$HK ?P,'Z
MS[M'ZFQ!X2#G5&2%(K-] &$_@:,#&@3]F ;>HW%)V51\$'164IW:(#,46' #
M2?^$@-VO]T!Z8"I; !,Y'1(O=/@M;59N+BE_U7!6F'-*-:%PUG5$KE<+)N9H
MRT2'"RJR<*9,:PK[PLJZV2AFRT)%HXS2_A@LUSAPK+U;J;4E>&&,XC.JB89C
MN'FX@G@<P=U*H-(+OH1UH$-(;6#RNW.\/G\:1V%T2IF'Q*:='6S6#_:(.]V(
M._W?XKYNL[2BOK!9:E>E6\YF)$O#4>_2]=X NWOS5RK@^YHZE3D>&58S*D![
MZ#@65F5.JUR[3;?2;23)Q1P.G9AEK<E4'TV\+D9'I=?O@TX\RX;N5A*E12KM
MGF5,J3>Z:%=,Y1I^HIWUPS2A03+TDV'TL:I:'87^* UAY$?C,4E69L_']L;*
M76]0(S?*"?WH)(5Q,O;NMN&1[*#<EAS2<6SUXEVQ)3>LY/\0C&KC?V;5\M2=
M#LK>T/2].2J(!)VJ&D[\8#1L%;--7Q%E49-B_=$PWGQN9)>,$AC%WI.T8'-E
MR[%KKY+0#TZ&D*9^D,;>+6H]V=D4AY $?DK7TI$3N#\\(8FOT7?AIN,$XG3X
M_59UZC%Y5RQE[_MC61S7-%FC'#H<&Y*P=L?KUOA'\Q\%BE8$;=]M1[L:<-!Y
M E2HYNZA0XJ2M3#-:V"SNGE+731/B*UY\Q#[RM2<"TUI%N0:]$?4:JIYW#03
M(Y?N03&3AIXG;KB@]R J:T#?"RE-.[$!-B_,Z;]02P,$%     @ &X1]5JU
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M67-+O%BW8-I\*6B&;E@EQ3-8:KM)>8$.O<1U:XI[1RR 8S2O>-V]8F^/.:
M_'B+4DC[=ALA4RO(:XHHR0$):;2C5:=6RIA]9@TD4*PA0]0F>E<TX8:@8B +
M)QL5<IJHT5;=:B=-+QI!MC9O=.T=E@7ARIR5&]?H9&2ZF6RD8C/1HG+R[$%H
M(_;<L#3R&J0U,/NY$'HUL0=T@GWZ'U!+ P04    "  ;A'U6Z^:J'58#  #9
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RU5FUOTS 0_BNG@!!(
MK'EKLFRTD=86!!*@B3+X[";7QEIB%]MIX=]C.UG(2EKZ87QI;>>>Q_?XSN>;
M[+FXEP6B@I]5R>34*93:7KNNS JLB!SQ+3+]9<U%192>BHTKMP));D%5Z0:>
M%[L5H<Q))W;M5J037JN2,KP5(.NJ(N+7#$N^GSJ^\[#PA6X*91;<=+(E&URB
MNMO>"CUS.Y:<5L@DY0P$KJ?.C7\]]ST#L!;?*.YE;PQ&RHKS>S/YD$\=SWB$
M)6;*4!#]M\,YEJ5ATG[\:$F=;D\#[(\?V-]9\5K,BDB<\_([S54Q=1('<ER3
MNE1?^/X]MH(BPY?Q4MI?V+>VG@-9+16O6K#VH**L^2<_VX/H ?SX""!H <$A
M8'P$$+: T IM/+.R%D21="+X'H2QUFQF8,_&HK4:RDP8ETKHKU3C5+ILP@=\
M#4NZ871-,\(4W&09KYFB; .WO*0910D7T#.>$4DS("R'!2UKA3E\UCGWD4L)
M6Q2P+(A N%%*T%6MR*I$4!SFO*ITZ):*9_<%+W,4$EXN4!%:RE>:_VZY@)?/
M7\%S<$$:!@F4P1VC2K[6BWK\M>"UU+O*B:NT>J/!S5JELT9I<$2I'\ GSE0A
MX2W+,7],X.ICZ\XN>#B[67"2<8'9"$+_-01>$ PX-#\?[I]P)^Q"&5J^\ C?
MY[I"0107UT.'TV#'PUA3+*[EEF0X=70UD"AVZ*0OGOFQ]V9(V!.1/9(Y[F2.
M3[&G)L]*G6=#(AMD9)&F@.W2BR@*+I.)N^N[/V V#B,_[,P>.19UCD5G.0;D
M(.VS)NUE+^V'G(_.<W[ [(3S<>=\?#)Y%LBX+B]'TR=^RO1Y(K)'0B\[H9<G
MH_3=%G;,+\A.WY8-=M%IZHU^Z:32!497OHN5J7%#A]'L$/="$'I!&,7)U4&L
M_C;T@ZLD]CU_.%I))R)Y*A%Y4YZ'9"3GROC;\+2,JT[&U7DWQCP9UO=S[L[Q
MN#2[)?VKX8^2\$#-@%4X"J-A*;[WYR'U_H>8$_%I-_R7GB&S 4%NKTG0#\7&
M]DX2[#O?O'G=:M>?W=BNY&!]9OHVVWS\H6F:OD]$;"B34.):4WJC2UVE1--'
M-1/%M[8567&E&QL[+'3OB<(8Z.]KSM7#Q&S0=;/I;U!+ P04    "  ;A'U6
M:+&:@4<#  #*#   &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6S-5]]/
MVS 0_E>L3)HV:2._VE!8&PD*:$@P*BJVAVD/QKFT%HZ=V4X+__UL)X0&2C2D
M/O#2Q/;=E_N^NTLOX[60=VH)H-%]P;B:>$NMRT/?5V0)!59[H@1N3G(A"ZS-
M4BY\54K F7,JF!\%0>(7F'(O';N]F4S'HM*,<IA)I*JBP/+A&)A83[S0>]RX
MIHNEMAM^.B[Q N:@;\J9-"N_1<EH 5Q1P9&$?.(=A8?3,+ .SN(GA;7:N$>6
MRJT0=W9QGDV\P$8$#(BV$-A<5C %QBR2B>-O ^JUS[2.F_>/Z&>.O"%SBQ5,
M!?M%,[V<>",/99#CBNEKL?X.#:&AQ2."*?>+UHUMX"%2*2V*QME$4%!>7_%]
M(\2&0YB\XA U#M%SA\$K#G'C$#NB=62.U@G6.!U+L4;26ALT>^.T<=Z&#>4V
MC7,MS2DU?CJ=U^E#(D=SNN TIP1SC8X($177E"_03#!**"CT%6T8SX0&<XX9
M>T GE%4V&6@.I))46^/3>\*J##*42U&@*6:D8M@ESC@[!W/VPY3IA5 *E2#1
M?(DEH$\GH#%EZK-YG+([:NQKP]-&ZY.&TW'-*7J%4QBA2\'UTD3!30A= -\(
MU*H4/:IT'/4BG@#90W'X!45!%&T):/K_[F%/.'&;M-CAQ:_@'1GELS[1SYSH
MHB@K78M^E:-3++G)IT*S5NS?%P88G6LHU)]M,M=1#+9'85\PAZK$!":>>8,H
MD"OPTH\?PB3XMDVB'8%U!!NT@@WZT-/-:FV%4T_"0:=:2;=:LZ9:N:E6]EBM
MKC:W:58'DKA [#MTE0[B^& X&([]U:8<+^W")(E&2=C:=9@.6Z;#7J9S+<@=
MNBIM\%M;I]?]K3G=$5B':=(R3=Y%$R2[%&Q'8!W!]EO!]M]+$^QO:8(PC./X
M61.\M.MM@E'+=-3+]!J4EI38>.M^N.%4;^V&7IRW)G='8!W*!RWE@W?1#0>[
M%&Q'8!W!PN!I\@G>2S\TD6P6>C2*PNA9._0'_%9!_(VIL "Y<,.R0FZPJT>?
M=K<=R(_<&/IL_]@.ZF[:?(*II_Q++!>4*\0@-Y#!WK[Y0Y#UX%POM"C=['DK
MM)EDW>W2?&R M ;F/!<F"<W"/J#]?$G_ 5!+ P04    "  ;A'U676QLG]P%
M  !N-   &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6S-FVUOZC88AO^*
MQ:;I'*FG)'8(T %27]2M4CM593W[<+0/!@Q$36*.;>!4VH^?$U(<C]1-P)GR
MI>4EOOT\=WPW%RX9;"E[X4M"!/@1A3$?MI9"K"[:;3Y=D@CS<[HBL7QG3EF$
MA7S*%FV^8@3/TD%1V(:.X[<C',2MT2!][9&-!G0MPB FCPSP=11A]GI%0KH=
MMMS6VPM/P6(IDA?:H\$*+\B8B.?5(Y//VGN561"1F <T!HS,AZU+]^+:ZR8#
MTB.^!F3+<X]!TLJ$TI?DR=ULV'*2BDA(IB*1P/+7AER3,$R49!W?,]'6?LYD
M8/[QF_IMVKQL9H(YN:;A7\%,+(>M7@O,R!RO0_%$M[^3K*%.HC>E(4]_@FUV
MK-,"TS47-,H&RPJB(-[]QC\R(W(#7.^= 3 ; ,L.0-D E#:ZJRQMZP8+/!HP
MN@4L.5JJ)0]2;]+1LIL@3D[C6##Y;B#'B=$M#ACXBL,U 0\$\S4C\AP)#KZ
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M<6X&90_@^ZF49K.QHUPUB8=_ %!+ P04    "  ;A'U6E><V=I<"  "H!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RM5=%NFS 4_16+35,K-85
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MI2!-@%Y?"H&[B>G6[>6<_ 502P,$%     @ &X1]5G1@0&Z. P  -1$  !D
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MRN>;/?IF(EE>;G/OF52;YG*X!!(!UP'J?,R8?)KHG7/]I23X U!+ P04
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M%&IER7B.I9KRE2U*#C@UH)S:GN.$=HY)8<61>3?C<<0J24D!,XY$E>>8;V^
MLLW8<JW=BSNRRJ1^8<=1B5<P!_E0SKB:V2U+2G(H!&$%XK <6]?NU62HXTW
M-P(;T1DC[63!V*.>?$['EJ,% 85$:@:L'FN8 *6:2,GXU7!:[98:V!WOV#\:
M[\K+ @N8,/J=I#(;6Y<62F&)*RKOV.83-'X"S9<P*LPOVC2QCH622DB6-V"E
M("=%_<1/31XZ '?P L!K -YK 7X#\(W16IFQ-<42QQ%G&\1UM&+3 Y,;@U9N
M2*'_Q;GD:I4HG(RODX17D*(/3ZHN! B$BQ1]E1EP-*DXAT*B6X(7A!))U.HY
MFJLZ2BL*B"W17X)/IR QH>),T3S,I^CTY R=(%*@^XQ50F%%9$OE22NSDT;_
M3:W?>T'_%)(+Y+OOD.=X7@]\\GJX^QQNJTRVZ?3:='J&SW^!;X:W>$&;3)CT
M8"K0C^N%D%Q5[,\^@S7CH)]1G^(K4>($QI8ZI@+X&JSX[1LW=-[WV?U/9,_,
M^ZUY_QB[-L\9I<8[Y"5E6P!UTBF6JD:@J9&^#-2T@:'5;6<=>Z-A$-GKKK.>
MH($W:H.>*1ZTB@='%=]GA*?G)>9RBW0^,$\R(S^%M6IP9:Y+^)CRFC[LB/('
M_K[RPR#7'87]RH-6>7!4^2VHWG6^2V["A.S5%QQN/0K=/7U'=_K'F@E;'^%1
M'Z9;]"D/#Y2'P6A/>$^,[_?G==CJ&1ZO"":QJN"FL4&WL3'3V)*FL=$_C:U/
M_O"@6D>.[^SI/PP:>,'EG@&[T]SUQ?H%\Q4I!**P5##G8JCPO+ZLZHEDI>GW
M"R;5[6&&F;K?@>L M;YD3.XF^@IIOQCBWU!+ P04    "  ;A'U6&>YRLLH'
M  "-00  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R]G&EOVS8<QK\*
MX15#"Z2Q*/G,$@.I)6X!EBYH>KP8]D*1Z%BH)'HD[;3#/ORHPY)HR[0T_+>^
M:'R0/QX/ST>DKU\8_RK6E$KT+8E3<3-82[FY&@Y%L*:)+R[9AJ;JFQ7CB2_5
M6_X\%!M._3"/E,1#V[(FP\2/TL'B.O_L@2^NV5;&44H?.!+;)/'Y]W<T9B\W
M SS8?_ A>E[+[(/AXGKC/]-'*C]M'KAZ-ZPH89305$0L19RN;@:W^(HXXRQ"
M'N)S1%]$XS7*BO+$V-?LS5UX,["R'-&8!C)#^.K/CBYI'&<DE8\_2^B@2C.+
MV'R]IY.\\*HP3[Z@2Q9_B4*YOAG,!BBD*W\;RP_LY1=:%BC/8,!BD?^/7LJP
MU@ %6R%94D96.4BBM/CK?RLKHA%A="J"74:P#R+8^$0$IXS@=$UA5$88'428
MCDY$&)<1Q@<1G%-9FI01)GG=%Y65U[3K2W]QS=D+XEEH1<M>Y'+EL54%1VG6
MLAXE5]]&*IY</"@A*><T1'X:HB5+$B7WHV3!5_06W89AE.GOQ^@N+5IQUAI>
MNU3Z42S>7 ^ERD(&&@9E<FZ1G'TB.6RC>Y;*M4!>&M)0!PQ5WJL"V/L"O+.-
MQ-L-OT38N4"V9=OHTZ.+7K]Z@UZA(1)KGU-1_FG)ZM(,OO>_(XQS+MYSVPIL
MIK@TN$0._A?9\[J#,?K,).U$)><+;8USJ'6.I\GE5.W-R1-P3B2PC'TAT&^K
MLHW]_JOZ'MU)FH@_6G+[KH"-VF'9J'LE-GY ;P9J6!64[^A@\>,/>&+]U*8W
M),R%A'F0, ($T^0=5?*.3/1%.8"(7-RR[?A;N68\^DN-,7^?;ICOC."^4D/"
MW (VR6'93+U;J'F[^'<]W#5U[!R2 &50$VE<B33N+M+&YVCGQUNJQ*D[?)M
M1FA?@2!A;@&;-JK=NK0L?"!.IU $*&.:,)-*F(E1F'HRSD?'"_18]*#;;CW(
M".\K$"3,G1SU"]S>@;H&)!T":A),*PFF'240A03=^X<1W+?Z(6'NM%/_Z!2*
MG NEU?JLJO59YQ'I NV8C-)GQ+--06M-&V%]:QH2YD+"/'.=?5Q3M&9Q2+E
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MN2A5 ?GWAZ*HW]ZH"K:/4;WX'U!+ P04    "  ;A'U6Z5V.RRL#  #E"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6S-5EUOVC 4_2M65DV=M#8?
M?+8#I +=5FG5$*S;P[0'-[D0JTZ<V0;:_?I=.VD*-+!5RD-?B.W<>WS.\<6Y
MO;60=RH&T.0^X:GJ.['6V;GKJC"&A*I3D4&*;^9")E3C5"Y<E4F@D4U*N!MX
M7MM-*$N=0<^N3>2@)Y::LQ0FDJAEDE#Y, 0NUGW'=QX7IFP1:[/@#GH97< ,
M]$TVD3AS2Y2()9 J)E(B8=YW+OSSD>^9!!OQG<%:;8R)D7(KQ)V97$5]QS.,
M@$.H#03%QPI&P+E!0AZ_"U"GW-,D;HX?T3]:\2CFEBH8"?Z#13KN.UV'1#"G
M2ZZG8OT9"D$M@Q<*KNPO61>QGD/"I=(B*9*10<+2_$GO"R,V$OSVGH2@2 AV
M$YI[$AI%0L,*S9E966.JZ: GQ9I($XUH9F"]L=FHAJ7F&&=:XEN&>7HPTR*\
M.QFB$1$9B02K0U'K[^6]&0,Y(3,LG6C)@8@Y^6?X\1@T95R]P\2;V9@<'[TC
M1X2EY%LLEHJFD>JY&GF;W=VPX#C,.09[./H!N1:ICA6Y3".(M@%<%%RJ#AY5
M#X.#B&,(3TG#?T\"+P@J"(W^/]T_0*=1'D+#XC7VX%TF&1</ &0&<L5"?,94
M JFP^8)S$>;#KW,RA5 L4O8'HR8@F3#!2BOR\PMN0*XT).I7E=TYFV8U&W-Q
MG*N,AM!W\&902 F<P=LW?MO[4&5536!;QC5+XYJ'T(OJO;4^A9L^05Z.5>)S
MQ)9%-)?<:M!J-CL]=[4IZGE0T.EX9= 6V59)MG60[!3E4QG&!/\%9 PKO$(S
MO!!U%<F#2"\]H9K MD2W2]'M5U7:[3J-JPELR[A.:5RG]M+.$=L;5=MM>3N5
M_3RFY76K"[M;4NT>I/H)4I"4V[J^B/ CQ926U'R>JT@>Q'KI"=4$MB7[K)1]
M]JI*^ZQ.XVH"VS+.]YZ:#J_VXBX@-^_D9NML]^*NB J"=K!3X.Y&PY2 7-@^
M4B&59:KS+J)<+7O5"]NA[:P/30]K&[$GF+P!OJ9RP5)%.,P1TCOM("69]Y3Y
M1(O,MF6W0F.39X<Q]N$@30"^GPNA'R=F@[*S'_P%4$L#!!0    ( !N$?58.
M+^?^_0(  &T*   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;,56;4_;
M,!#^*Z<,32 -DKAOP-I(%)B&-+2*CNW#M ]N<FTL$KNSW9;NU\]VTE"T---0
M)[XTMN-[[GGN+M?KKX1\4"FBAL<\XVK@I5K/SWU?Q2GF5)V(.7+S9BID3K79
MRIFOYA)IXHSRS"=!T/5SRK@7]=W92$9]L= 9XSB2H!9Y3N5ZB)E8#;S0VQS<
ML5FJ[8$?]>=TAF/4]_.1-#N_0DE8CEPQP4'B=.!=A.?#D%@#=^,KPY7:6H.5
M,A'BP6YNDH$76$:88:PM!#6/)5YBEEDDP^-G">I5/JWA]GJ#_L&)-V(F5.&E
MR+ZQ1*<#[]2#!*=TD>D[L?J(I:".Q8M%IMPOK,J[@0?Q0FF1E\:&0<YX\:2/
M92"V#$AGAP$I#5P@_,*18WE%-8WZ4JQ VML&S2Z<5&=MR#%NLS+6TKQEQDY'
M8RWBA^.AT97 I<A-LA5UX;I^M&N$8QB;2D@6&8*8PCV7&(L99[_,_9VVAU>H
M*<O4$1P X_ E%0M%>:+ZOC:4K6,_+ND-"WID![V0P*W@.E5PS1-,G@/X1FLE
MF&P$#TDCXA7&)] *WP$)"('[\14<'APUX+:J0+8<;FM7(%,JL2X8%U)2/D-3
MR1HF:]B^-Z)K=WRQHC*![Y\,)-QHS-6/ND@5_MOU_NW7>Z[F-,:!9SY/A7*)
M7O3V3=@-WC>H:U?JVDWHT;.\8U$:=1P+E(Y#L0UA&9VU.J3O+VM\=RK?G4;?
M=ZBT9+'>5)PI0J9K:ZD1YX41ZE8LNZ^<_^Y_4->KU/7VDO_>'_D/@TY]^D\K
MUZ>-KD<HF4AL\RDI%"UFC52JHSH.S7 M<)9 ("\:BVDQ"5VKAB"=54S/&J&+
MZOP\MP1KZ[/1_(49#(.G3A^\<H66!/8L<.NO+-Q+D98PS[H4:??JRS0D3^[)
M?@OU+WCD'RK5WYH <I0S-^<HB,6"ZV(8J$ZK6>JBF"">KA>#V"V5,\859#@U
MIL%)S\1)%K--L=%B[N:)B=!F.G'+U,R#*.T%\WXJA-YLK(-JPHQ^ U!+ P04
M    "  ;A'U6:VM86MT"  "4!P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6RM55UOVC 4_2M6)DV=-,@'A7X,(@%MMSU40T7M'J8]F.1"+!P[LPV4
M?[]K)Z2  JJF\4#\<<_Q/<?V=7\CU5)G (:\YESH@9<94]SZODXRR*ENRP($
MSLRERJG!KEKXNE! 4P?*N1\%0<_/*1->W'=C$Q7WY<IP)F"BB%[E.57;$7"Y
M&7BAMQMX8HO,V $_[A=T 5,PS\5$8<^O65*6@]!,"J)@/O"&X>VX9^-=P N#
MC=YK$ZMD)N72=KZG R^P"0&'Q%@&BI\UC(%S2X1I_*DXO7I)"]QO[]@?G';4
M,J,:QI+_9*G)!MZU1U*8TQ4W3W+S#2H]7<N72*[=/]E4L8%'DI4V,J_ F$'.
M1/FEKY4/>X"P=P(058#H&'!Y M"I !TGM,S,R;JCAL9])3=$V6ADLPWGC4.C
M&B;L+DZ-PEF&.!-/C4R6K1$:D9*QS/%P:.K\O7^U;2 M,L63DZXX$#DG#Y0I
M\D+YRO4<F/PH2H V#&U%'NQ@+B[BJZ+"D&?-Q(*,.,6ED$URT!6J-5$LL9./
M,@5.+N[ 4,;UI[YO4)Q-T4\J(:-22'1"2!@AAS"9)O<BA?20P$=7:FNBG36C
MZ"SC'21MT@D_DRB(HH:$QN^'AV?2Z=0[U7%\G5,[E5$%U4Y-Z!9ODB%#A?XN
MP+5_#6?:*+P6OYO,*[DOF[EMJ;C5!4U@X&$MT*#6X,4?/X2]X$N3\/]$=F##
M96W#Y3GV^(GI96NN  @3!I#?$(6'K4ES210&CLF6LW4<M(/HJN^O]]4TAP5O
M80=Y=NL\NV?SM/<GL;<!D\S)!1-D"U0UG^SS3+T2V;01_P \$-.KQ?3>)V8M
M.98'SLRV24>OR<GK,+K9_QVY7V)N#B'=(^_]O0*7@UJXNJ])(E?"E!>Z'JV?
MEJ&KJ$?C(WQRRA?BC:9\KQZI6C"A"8<Y4@;M*_16E6] V3&R<&5T)@T69=?,
M\-D$90-P?BZEV77L O5#'/\%4$L#!!0    ( !N$?5;Q+ M(Y 0  - 7   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;+6877/B-A2&_XK&W>ED9Q)L
MR6!#"LP 2=N=Z7:9I,E>='HAC !/;(N5!"3_OI+MV,8V@GCA)K&-SM%YSM''
M*_5WE+WP%2$"O(9!Q ?&2HCUK6ER;T5"S%MT32+YRX*R$ OYRI8F7S."Y[%1
M&)C(LAPSQ'YD#/OQMRD;]NE&!'Y$I@SP31AB]C8F =T-#&B\?WCPERNA/IC#
M_AHOR2,13^LIDV]FYF7NAR3B/HT (XN!,8*W$V0K@[C%LT]VO/ ,%,J,TA?U
M\F4^,"P5$0F()Y0++/]MR80$@?(DX_B1.C6R/I5A\?G=^^\QO(2984XF-/CN
MS\5J8'0-,"<+O G$ ]W]25*@CO+GT8#'?\$N;6L9P-MP0</46$80^E'R'[^F
MB2@8H,X! Y0:H+)!^X"!G1K$F3.3R&*L.RSPL,_H#C#56GI3#W%N8FM)XT>J
MC(^"R5]]:2>&CX)Z+S=CF8@YF-!0C@Z.X_S>OZIG F[ 8U)A0!<@;@V^K>,6
M(U4!7[R!IVA.&)@&..+@ZHX([ ?\LS1\>KP#5Y\^@T_ !'R%&>' CV1K7_!K
M^5$^_[.B&XZC.>^;0L*HD$PO#7R<!(X.! X1^$HCL>+@7G8_WW=@RBQDJ4#O
MJ1@CK<<[XK6 #:\!LA"J"6ARNCG4A&-GE;%C?_:ARJB,I969XC<Y=008,8:C
M)8F?_QW-N&!R&OQ7E[S$=[O>MUH;;OD:>V1@R,G/"=L28_CK+]"Q?JL#/Y.S
MO32TLS2T==Z3-,CQ\FTCN)!#Q8^60*::A#,YYNK3G60@<>O$;M5BMAU"QT%=
M1S;>%N&TW3>$ZV1P'2W<WYL80\ZL='XL97U%>30G/)T*#^JB;MMMEWBT/3;D
M<3(>YZ1BW;\2YOF\'L2I@-P@%W9+&-J.&F*X&89[$L8$1Y[<8.HQW"H&=%U9
MD1*(MJN&(-T,I/OAR8-%9?[4K7;C;H6O;4-HVW:)K]JN/,_V0N]EH?<^,I3P
M+" GA]ZKAF1W++OCED+71M"P--#*=U[K),)GPN64![(\@,A-UU,O@H*M_'PR
M<=K5\6KI8VK*7% ;4,O\/995$G"T)4S*Q&RE %/F>Z3!,I]VV"T6VVK9Y5FH
MCZLI-\JYT<]Q_W%XX4]=0UA [+1@KTRHC: I8:Y6H%8%'"?4[@FI\SU&U'*=
M,N,EE C,I0C4:Y&CC-H-(W6^Q^BVNI49>@E! G-% O62Y*=F:/W:U*GCMLJ+
M<=KL\$3>!\HE"=1KDE,'YH=VF+3//:9>RZW4\A(J!N8R!NIUS#'TL^P\;J5L
M=<6]A J"N0R">AU4&+/7H)*5!Z+N.]1XGL@3I3I2;7  _O(7!%S)0^H;P8Q_
MKF77]]I-3 $"87)2E6?6.7ZK.^Q.CKAR4U?NNRNGQM-^<G*A!?5*JS#^SYH<
M?:_.1Y)S":&&<J&&]$)-,TW.F; C47QD-.E=-4U8KO*07N6-EDM&EE@0\$5F
MP(^X[X%G'&R:Z+NTJTYA?;'=\F&QIE&O<*+<Q\A%&]*+-@U&DSTC[:VHT6U4
M(;F$BD.YBD-Z%:=!/L=FD?9^I)AG%7EFX6XT)&P97QESX-%-))*[P>QK=BT]
MBB]C2]_'\':27"[G;I*[[J^8+66J0$ 6TJ75<B4?2ZZ/DQ=!U_$-[(P*0</X
M<47PG##50/Z^H%2\OZ@.LDO\X?]02P,$%     @ &X1]5K&L1Q%R!P  J#$
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M@5?=[!4M](H6^4+K^K+5S4%OW>PO4+O[[NU%?'Q06857^,,M(U\C[++?BNC
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M?"<VC);KC=0GP0P8%[/30M\5FCY+7:GOVVO]MOY5A=Y%4_^JZZ5\2(2>-8[
MM1P"8O'&.%O]BM^?&)=YOV%HW(?L8W\K-YTT\.W:X-F-"/P'/I."Y&5NY,%1
MV=Z0Y1(M<H6F,]II"G]ZP"W)I7A8.D6+7*'IO'9BQ+>KD<%;4E]&S.?F6'4J
M)URAZ31U@L*W*PI;0%]=+T$P-_T>=FE'';SP7*)%KM!T1CNUXI\<,* =Z8R&
M5Y=HD2LT_1?:3@-!NP8:&M -W'Y 3V=34T#;.QY*DRLTG:9.XD!KJ>^R>FEZ
MTGX>,!;I]B$-)O 06@9V6@;:M<R-+,+QBR+;#C(T4)VB1:[0= ([E0,/^/D!
M.OW^X!0M<H6F\]KI$FC7)8,38%]3P# TQJ\C4='0= B) CN) NT2Q8'(?J$'
MAWIZ8ERU3O6-*S1].CI] ^T?35SN1]/>@C86Z/81#>:OWRM\L@OJU'02!;[P
MP:2WT]B+;CO<X-SH5,:X0M.I[&0,G!]PSW$J9IRB1:[0=%X[,0/MWUX&[SF&
M#RHPG!NCU*DX<86F'[CHQ$E@%R<.LUS3DY9OC 3:AS3X=(53V3+>.T>48[:N
MSF/)]:.^[-;'<MJG[9FOB^JDTY/GE_[ILCZYU<'4!\D^([8F<AO/<"HAO>.9
M9(S59[/J&T&WU6FE%16"YM7E!J,$,]5 OD\I%8\WJH/VA-SB?U!+ P04
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M6<?\D^>^!+UU79"A$EM+;![*=K7MM.Y<?W&Q?F\[,-=&O,(T[=LGKK="&E9
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M^&QHNX/$7T'*&[*C644/FZ$,MV.T2(P%T<0ZAQ@%3NAZ75B#71A$D_@"[6F
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M!J7QCKM57O5622(K(5 T4Y)>(TFOHUL7JT68[._4V>-[BPM)HU :@](XE!9
M:0)%,S77C->[1QJP=Z$C]E :A=(8E,:AM !*$RB:J<5FX-ZUC]Q3^:1(E!:Z
ML4]DJHA\6T9Y[8+.]!-OJPJA _E0&NTXV])U)([[B93>F]\J/.CP/9060&D"
M13.%UU@"KMT3^$TM9$Y"W1*J@OR7=.=AJ$, I5$HC4%I'$H+H#2!HID2;)P'
M=W*D/ SU': T"J4Q*(U#:0&4)E T4XN-_^#:#8C[7"[#:+;7/+>']Y8<U'J
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M&H/2.)060&FB0QQC4K[F6MB$UO@6GGTD_\,K!+E,Y:M.R_M>4['S>NL-ZEI
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M<<J$HMR3X[^*<51\0;;DX1SNNZJ 7<%#M(+5^<T6'5<&%AC*J\P:8CA\1]>
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M"#T OB><J]>./N/K*UWT&U!+ P04    "  ;A'U6I V>Z)\"   (!P  &0
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ML*<D2;(LC  6=I D& )/(XY@#L #AB2)>P_NO8_B]7LJWOQ_;_0;4$L#!!0
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M(8=\0UL$B/ #RW3)[C;" ,@4@4Q/!KEP.@>0&0*9G1"R][BG".3T)._D#A=
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M%8-BPD(NQ2R44EL(Q82%7(99**.V$(H)"[D,LU!&O@1@N)M[6'IDF(4R\D4
MQS#W"[D,LU!&O@S@&.:#V/;FA3/,0AFQA7J#!CN3:\6K;HD*Q$17 A!;J#^V
MT95%E0A]CGE9BMYZ!<Q"V3O.V?0Q;X)%(29FH>Q=IG$&'O?!BJ0,LU!&;*'_
M,6$@0P+5:F]:)<,LE!%;Z WSK2?\7<C5VHGB[&H+EZE@%IJ^SPA<#_,K=XT)
MZ]%T"3$Q"TV)+;0WJ;?_DD),S$+3UD*CW>J^0I12B>(?_Q?6[\]YE=\;%CZZ
M90=I%J8,RZ:JKOV^._5%\V*W6'"WT/'3?U!+ P04    "  ;A'U6=TMQA08"
M  #Q)   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=E+:N- %(7A
MK1@M(.7[4I(FSJ@GF3;9@'#*#V);0J6FD]VW<0;V$3WH2:@S$B6AJQ\$'Z+T
M]"L?NFG?G\IN/Y3%Q_%P*JMF-TW#CY3*>I>/7;GKAWPZ7]GTX[&;SLMQFX9N
M_=YM<]+ELDWC[8SF^>EVYN+U<\C_,['?;/;K_+-?_S[FT_2/P>E//[Z77<Y3
MLWCMQFV>5DWZ.%Q/EW0YR-UY<K-X>5LUX\N;-*EVD$*0U@\R"++Z00Y!7C\H
M("CJ![40U-8/NH>@^_I!#Q#T4#_H$8(>ZP?)$F5<$B3-L";06I!K(?!:$&PA
M$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;9Q_;
M!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM
M!'H;ZFT$>MMLLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]
MG4!O1[V=0&]'O9U ;T>]G4!OGVUV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VH
MMQ/H':AW$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VSGY4$>@?J'01Z!^H=!'H'
MZAT$>@?J'01ZMZAW2Z!WBWJW!'JWJ'?[G7J7Z?.0R[7G:XW/_TZJI_.]^?KX
MR_+KY.R]7'!.MQ7E^2]02P,$%     @ &X1]5O\GIW7C 0  ;"0  !,   !;
M0V]N=&5N=%]4>7!E<UTN>&ULS=I=3\(P% ;@OT)V:UCIU_R(<*/>JA?^@;H=
M9&%;F[8@_'N[ 28:)1I,?&]8H.UYSWJ2YXKKIZVC,-JT31>FV2)&=\58*!?4
MFI!;1UU:F5O?FIB^^A?F3+DT+\3$9%*PTG:1NCB.?8UL=GU+<[-JXNANDWX.
MM>VFF:<F9*.;W<8^:YH9YYJZ-#&MLW57?4H9[Q/R='+8$Q:U"V=I0\:^3.A7
MO@_8GWM8D_=U1:-'X^.]:=,NMFE8B-N&0GZ\Q!<]VOF\+JFRY:I-1_+@/)DJ
M+(ABV^2[HF?'DV.Z8=I]\I/SAS+' M/.1V]=2!/S]/NXPTCZTV.7"I&/]?%7
M?$],I4]^/^JG75'UP^QTO:_6+X=Y!#8\3K_CCS-^K__+/@1('Q*D#P72AP;I
MHP#IXQRDCPN0/BY!^N 3E$901.4HI'(44SD*JAQ%58["*D=QE:/ RE%D%2BR
M"A19!8JL D56@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56BR"I19)4H
MLDH4626*K!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5H\BJ4635
M*+)J%%DUBJP:15:-(JM&D56CR*I19"U09"U09"W^4]9G:Y=_'#\\\];4W2&?
M#7\RFKT!4$L! A0#%     @ &X1]5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  ;A'U6/F5Y0.T
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ &X1]5FQG%X_G @
MY0D  !@              ("!%Q8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( !N$?58/7U@BY 0   84   8              " @309
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  ;A'U6U=[Q
M,;0%  !Z(P  &               @(%.'@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ &X1]5DM).=LJ @  IP0  !@
M ("!."0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !N$
M?596H3:SX 8  %8?   8              " @9@F  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  ;A'U69)DTV3T)  !T%@  &
M        @(&N+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( !N$?5;I_AH]R (  &8&   9              "
M@<YL  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ &X1]
M5O?^;Z[@!P  ?A0  !D              ("!S6\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  ;A'U69F0*;)T-   8*0  &0
M        @('D=P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( !N$?59H:T(VO0T  (\K   9              " @;B%  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ &X1]5I(93/@K"P  $R(
M !D              ("!K),  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  ;A'U636"%#YX*  "P'   &0              @($.GP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !N$?58KV[45
MIP,  #((   9              " @>.I  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ &X1]5B>*LQO* P  C0@  !D
M ("!P:T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  ;
MA'U6.I1MHH<O   %I0  &0              @('"L0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !N$?5:";S\CJ@4  %$.   9
M          " @8#A  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ &X1]5O'.PO3' P  4 @  !D              ("!8><  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  ;A'U6">X.DN0"  !7
M!@  &0              @(%?ZP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( !N$?58%9-QZ4P,  ( '   9              " @7KN
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ &X1]5NH9
ME_S4 @  208  !D              ("!!/(  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    "  ;A'U6MZ73C+,"  #9!0  &0
M    @($/]0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M !N$?59'XH:P4 4  $8-   9              " @?GW  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ &X1]5DCC).&+ P  [ @  !D
M             ("!@/T  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  ;A'U6%)OOQ(X$  !M"@  &0              @(%" 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !N$?5:M0%AIQ0,
M ,,)   9              " @0<& 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ &X1]5G@: 4TS P  H0D  !D              ("!
M PH! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  ;A'U6
M. /-Z3@$  #J%   &0              @(%M#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( !N$?5:J,E3.R0(  &0(   9
M      " @=P1 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ &X1]5O7U"1\( P  O L  !D              ("!W!0! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  ;A'U6Z^:J'58#  #9"@
M&0              @($;& $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( !N$?59HL9J!1P,  ,H,   9              " @:@; 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ &X1]5EUL;)_<
M!0  ;C0  !D              ("!)A\! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  ;A'U6QD!?&D "  "Z!0  &0
M@($Y)0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !N$
M?58=&+Y3+0,  )4+   9              " @; G 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ &X1]5I7G-G:7 @  J <  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( !N$?59$*@QRX@(  %H*   9
M  " @98_ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M&X1]5L#:HLO/"@  4G4  !D              ("!KT(! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  ;A'U6Z5V.RRL#  #E"P  &0
M            @(&U30$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( !N$?58.+^?^_0(  &T*   9              " @1=1 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ &X1]5FMK6%K= @
ME <  !D              ("!2U0! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  ;A'U6\2P+2.0$  #0%P  &0              @(%?
M5P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !N$?5:Q
MK$<1<@<  *@Q   9              " @7I< 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ &X1]5HI;Z".T P  DQ,  !D
M     ("!(V0! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !N$?5;[!(J8C D  !)P   9              "
M@;9Y 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ &X1]
M5B&=$%F2 @  Z 8  !D              ("!>8,! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  ;A'U6IQ)?3D0"   3!0  &0
M        @(%"A@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( !N$?58UG5O;^ (  -X)   9              " @;V( 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ &X1]5J0-GNB? @  " <
M !D              ("![(L! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    "  ;A'U6CM!C\CT#  #L$P  #0              @ '"C@$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !N$?5:7BKL<P    !,"   +
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4!08     1@!& "$3  !HG $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>312</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Preferred and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</Role>
      <ShortName>Preferred and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Preferred and Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables</Role>
      <ShortName>Preferred and Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables</Role>
      <ShortName>Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Collaboration Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables</Role>
      <ShortName>Collaboration Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails</Role>
      <ShortName>Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Short-term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Preferred and Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails</Role>
      <ShortName>Collaboration Agreement - Summary of Change in the Transaction Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails</Role>
      <ShortName>Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lyra-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. lyra-20221231.htm 6892</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, lyra:LeaseInitiationDate, us-gaap:LeaseExpirationDate1 -  lyra-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="lyra-20221231.htm">lyra-20221231.htm</File>
    <File>lyra-20221231.xsd</File>
    <File>lyra-20221231_cal.xml</File>
    <File>lyra-20221231_def.xml</File>
    <File>lyra-20221231_lab.xml</File>
    <File>lyra-20221231_pre.xml</File>
    <File>lyra-ex10_15.htm</File>
    <File>lyra-ex10_24.htm</File>
    <File>lyra-ex10_46.htm</File>
    <File>lyra-ex23_1.htm</File>
    <File>lyra-ex31_1.htm</File>
    <File>lyra-ex31_2.htm</File>
    <File>lyra-ex32_1.htm</File>
    <File>lyra-ex32_2.htm</File>
    <File>lyra-ex4_5.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img222343278_0.jpg</File>
    <File>img222343278_1.jpg</File>
    <File>img222343278_2.jpg</File>
    <File>img222343278_3.jpg</File>
    <File>img222343278_4.jpg</File>
    <File>img222343278_5.jpg</File>
    <File>img222343278_6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="483">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lyra-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 483,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "lyra-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lyra-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lyra-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lyra-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyra-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lyra-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 526,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://lyratherapeutics.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 13
   },
   "keyCustom": 50,
   "keyStandard": 262,
   "memberCustom": 21,
   "memberStandard": 32,
   "nsprefix": "lyra",
   "nsuri": "http://lyratherapeutics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Short-term Investments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Preferred and Common Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock",
     "shortName": "Preferred and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation Expense",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense",
     "shortName": "Stock-Based Compensation Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Collaboration Agreement",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement",
     "shortName": "Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Retirement Plan",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "lyra:RestrictedCashPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "lyra:RestrictedCashPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Short-term Investments (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Preferred and Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables",
     "shortName": "Preferred and Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stock-Based Compensation Expense (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables",
     "shortName": "Stock-Based Compensation Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Collaboration Agreement (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables",
     "shortName": "Collaboration Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "lyra:RestrictedCashPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "lyra:OtherAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
     "shortName": "Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "lyra:RestrictedCashPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_e9a9b4ce-3240-47fa-87b6-f4310526dffe",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_e9a9b4ce-3240-47fa-87b6-f4310526dffe",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_4cd7d3d4-5ee4-4bb2-ade4-24703e6ccaba",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails",
     "shortName": "Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Short-term Investments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
     "shortName": "Short-term Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Security",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Preferred and Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
     "shortName": "Preferred and Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_a1144d35-ca6f-497e-a18a-73cf52e16156",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
     "shortName": "Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_f1a83be4-a034-4dba-99d0-ff646e8a3287",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation Expense - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_aabae8ed-77a4-4ca7-a18a-55fe017f5875",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
     "shortName": "Stock-Based Compensation Expense - Schedule of Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_3aa72f08-9dea-4749-a7ce-7cde7d1d2163",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_65a305a6-5b98-4d3a-a30d-a699dba9390c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity (audited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
     "shortName": "Consolidated Statements of Stockholders' Equity (audited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_65a305a6-5b98-4d3a-a30d-a699dba9390c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_66e063fc-33e5-4cb1-a079-fd6c176dfc16",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails",
     "shortName": "Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_de48ac60-b50a-4c29-8f31-b67fc2eace77",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Collaboration Agreement - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
     "shortName": "Collaboration Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_de48ac60-b50a-4c29-8f31-b67fc2eace77",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lyra:FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DeferredRevenueDescription",
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lyra:CombinedPerformanceObligation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Collaboration Agreement - Summary of Change in the Transaction Price (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
     "shortName": "Collaboration Agreement - Summary of Change in the Transaction Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_66e063fc-33e5-4cb1-a079-fd6c176dfc16",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
     "shortName": "Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_66e063fc-33e5-4cb1-a079-fd6c176dfc16",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "lang": null,
      "name": "lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails",
     "shortName": "Leases - Schedule of Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical) (audited)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Maturity of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_30fc43ea-2218-4e8e-9220-f7894e107d70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Retirement Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lyra-20221231.htm",
      "contextRef": "C_259fea07-483e-459f-85c3-cc48ff87d140",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation, date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lyra_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyra_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities disclosure.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other liabilities current.",
        "label": "Accrued Expenses And Other Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.",
        "label": "Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year",
        "terseLabel": "Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year"
       }
      }
     },
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance maximum number of common stock issued.",
        "label": "Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued",
        "terseLabel": "Maximum number of common shares issued"
       }
      }
     },
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_COVID19PandemicAndCARESActPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act Policy [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_CashProvidedByFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash provided by financing activities.",
        "label": "Cash Provided By Financing Activities",
        "terseLabel": "Fund raised for operations"
       }
      }
     },
     "localname": "CashProvidedByFinancingActivities",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Supply Agreement member.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreement"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_CombinedPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined performance obligation",
        "label": "Combined Performance Obligation",
        "terseLabel": "Combined performance obligation"
       }
      }
     },
     "localname": "CombinedPerformanceObligation",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_CombinedPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined performance obligation.",
        "label": "Combined Performance Obligation [Member]",
        "terseLabel": "Combined Performance Obligation"
       }
      }
     },
     "localname": "CombinedPerformanceObligationMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_CommercialRevenueBasedMilestoneAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial revenue based milestone awards.",
        "label": "Commercial Revenue Based Milestone Awards [Member]",
        "terseLabel": "Commercial Revenue Based Milestone Awards"
       }
      }
     },
     "localname": "CommercialRevenueBasedMilestoneAwardsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_CommonStockVotingRightsNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock voting rights, number of votes.",
        "label": "Common Stock Voting Rights Number Of Votes",
        "terseLabel": "Number of common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lyra_ComputerSoftwareAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Software And Equipment [Member]",
        "label": "Computer Software And Equipment [Member]",
        "terseLabel": "Computer Software and Equipment"
       }
      }
     },
     "localname": "ComputerSoftwareAndEquipmentMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentrations of credit risk and off-balance sheet risk.",
        "label": "Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]",
        "terseLabel": "Concentrations Of Credit Risk And Off Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds and U.S. government and agency securities.",
        "label": "Corporate Bonds And U.S.Government And Agency Securities [Member]",
        "terseLabel": "Corporate Bonds and U.S. Government and Agency Securities",
        "verboseLabel": "Corporate Bonds and U.S. Government Agency Securities"
       }
      }
     },
     "localname": "CorporateBondsAndUSGovernmentAndAgencySecuritiesMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_DeferredOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs incurred but not yet paid.",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expense"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and experimental expenditures.",
        "label": "Deferred Tax Assets Capitalized Research and Experimental Expenditures",
        "terseLabel": "Capitalized research &amp; experimental expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenditures",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance income tax expense (benefit).",
        "label": "Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax assets, valuation allowance income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DefinedContributionPlanMaximumContributionEmployeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan maximum contribution employee percentage.",
        "label": "Defined contribution plan maximum contribution employee percentage",
        "terseLabel": "Maximum contribution employee percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumContributionEmployeePercentage",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_DevelopmentActivitiesPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development activities performance obligation.",
        "label": "Development Activities Performance Obligation",
        "terseLabel": "Development activities performance obligation"
       }
      }
     },
     "localname": "DevelopmentActivitiesPerformanceObligation",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DevelopmentActivitiesPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development activities performance obligation.",
        "label": "Development Activities Performance Obligation [Member]",
        "terseLabel": "Development Activities Performance Obligation"
       }
      }
     },
     "localname": "DevelopmentActivitiesPerformanceObligationMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_DevelopmentMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone achieved.",
        "label": "Development Milestone Achieved",
        "terseLabel": "Milestone"
       }
      }
     },
     "localname": "DevelopmentMilestoneAchieved",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_DocumentDocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Document And Entity Information [Abstract]",
        "terseLabel": "Document - Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentDocumentAndEntityInformationAbstract",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "lyra_EffectiveIncomeTaxRateReconciliationOwnershipChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation ownership change.",
        "label": "Effective Income Tax Rate Reconciliation Ownership Change",
        "terseLabel": "Loss of Attributes - IRC 382 Ownership Change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOwnershipChange",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_EstimatedOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated offering costs.",
        "label": "Estimated Offering Costs",
        "terseLabel": "Estimated offering costs"
       }
      }
     },
     "localname": "EstimatedOfferingCosts",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.",
        "label": "Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization",
        "terseLabel": "Future milestone payments receivable"
       }
      }
     },
     "localname": "FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern policy text block.",
        "label": "Going Concern Policy [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_GrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from initial public offering.",
        "label": "Gross Proceeds From Initial Public Offering",
        "terseLabel": "Gross proceeds from initial public offering"
       }
      }
     },
     "localname": "GrossProceedsFromInitialPublicOffering",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_GrossProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of private placement.",
        "label": "Gross Proceeds From Issuance Of Private Placement",
        "terseLabel": "Gross proceeds from private placement"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_IRC382Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IRC 382.",
        "label": "I R C 382 Member",
        "terseLabel": "IRC 382"
       }
      }
     },
     "localname": "IRC382Member",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued expenses and other current liabilities.",
        "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right-of-use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_InducementAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement award plan.",
        "label": "Inducement Award Plan [Member]",
        "terseLabel": "Inducement Award Plan"
       }
      }
     },
     "localname": "InducementAwardPlanMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock shares upon exercise of warrants.",
        "label": "Issuance Of Common Stock Shares Upon Exercise Of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants, Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockSharesUponExerciseOfWarrants",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of exercise warrants common stock.",
        "label": "Issuance Of Common Stock Value Upon Exercise Of Warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockValueUponExerciseOfWarrants",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_LeaseInitiationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease initiation date",
        "label": "Lease Initiation Date",
        "terseLabel": "Lease initiation date"
       }
      }
     },
     "localname": "LeaseInitiationDate",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "lyra_LeaseRelatedCostsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease related costs current",
        "label": "Lease related costs current",
        "terseLabel": "Lease-related costs"
       }
      }
     },
     "localname": "LeaseRelatedCostsCurrent",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_LesseeOperatingLeaseExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "lyra_MarketBasedConditionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market-based condition awards.",
        "label": "Market-Based Condition Awards [Member]",
        "terseLabel": "Market-Based Condition Awards"
       }
      }
     },
     "localname": "MarketBasedConditionAwardsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_MilestoneAchievementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone achievements.",
        "label": "Milestone Achievements [Member]",
        "terseLabel": "Milestone Achievements",
        "verboseLabel": "Milestone"
       }
      }
     },
     "localname": "MilestoneAchievementsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_ModificationOfLeaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of Lease Agreement",
        "label": "Modification of Lease Agreement",
        "terseLabel": "Modification of lease agreement"
       }
      }
     },
     "localname": "ModificationOfLeaseAgreement",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_OpenSalesAgreement2021ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open sales agreement (2021 ATM) [Member]",
        "label": "Open Sales Agreement2021 A T M [Member]",
        "terseLabel": "2021 ATM Agreement"
       }
      }
     },
     "localname": "OpenSalesAgreement2021ATMMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyra_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lyra_OtherAssetsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets included in accounts payable and accrued expenses.",
        "label": "Other Assets Included in Accounts Payable and Accrued Expenses",
        "terseLabel": "Other assets included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OtherAssetsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_OtherAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets policy.",
        "label": "Other Assets [Policy Text Block]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_PatentsCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the patents cost policy.",
        "label": "Patents Costs Policy [Text Block]",
        "terseLabel": "Patents Costs"
       }
      }
     },
     "localname": "PatentsCostsPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_PercentageOfAnnualRentIncrement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual rent increment.",
        "label": "Percentage Of Annual Rent Increment",
        "terseLabel": "Percentage of annual rent increment"
       }
      }
     },
     "localname": "PercentageOfAnnualRentIncrement",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common shares increase automatically in each year.",
        "label": "Percentage Of Common Shares Increase Automatically In Each Year",
        "terseLabel": "Percentage of common shares increase automatically in each year"
       }
      }
     },
     "localname": "PercentageOfCommonSharesIncreaseAutomaticallyInEachYear",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_PerformanceBasedCriteriaRelatedToScientificMilestonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-based criteria related to scientific mileston.",
        "label": "Performance-Based Criteria Related to Scientific Mileston [Member]",
        "terseLabel": "Performance-Based Criteria Related to Scientific Mileston"
       }
      }
     },
     "localname": "PerformanceBasedCriteriaRelatedToScientificMilestonMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_PerformanceObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance obligations.",
        "label": "Performance Obligations [Member]",
        "terseLabel": "Performance Obligations"
       }
      }
     },
     "localname": "PerformanceObligationsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_PostMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-milestone.",
        "label": "Post-Milestone [Member]",
        "terseLabel": "Post-Milestone"
       }
      }
     },
     "localname": "PostMilestoneMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_PreMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-milestone.",
        "label": "Pre-Milestone [Member]",
        "terseLabel": "Pre-Milestone"
       }
      }
     },
     "localname": "PreMilestoneMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of common stock and pre funded warrant net.",
        "label": "Proceeds From Sale Of Common Stock And Pre Funded Warrant Net",
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds to be occured from future issuance of common stock,.",
        "label": "Proceeds To Be Occured From Future Issuance Of Common Stock",
        "terseLabel": "Proceeds to be occured from future issuance of common stock"
       }
      }
     },
     "localname": "ProceedsToBeOccuredFromFutureIssuanceOfCommonStock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of shares as percentage lower of fair market value of common stock.",
        "label": "Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock",
        "terseLabel": "Purchase price of shares as percentage lower of fair market value of common stock"
       }
      }
     },
     "localname": "PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements policy.",
        "label": "Recently Issued Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_RestrictedCashPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash Policy [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock reserved for future issuances.",
        "label": "Shares Of Common Stock Reserved For Future Issuances Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuances"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForFutureIssuancesTableTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_SignificantSuppliersPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant suppliers policy.",
        "label": "Significant Suppliers Policy [Text Block]",
        "terseLabel": "Significant Suppliers"
       }
      }
     },
     "localname": "SignificantSuppliersPolicyTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants to be issued during period value preferred stock and warrants.",
        "label": "Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants",
        "terseLabel": "Stock and warrants to be issued during period value preferred stock and warrants"
       }
      }
     },
     "localname": "StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares",
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vesting of restricted stock unit.",
        "label": "Stock Issued During Period Shares Vesting Of Restricted Stock Unit",
        "terseLabel": "Issuance of common stock upon RSU vesting, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock and pre-fundedwarrants, net of issuance costs of $4,244",
        "verboseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of weighted average remaining lease terms and discount rate related to operating leases.",
        "label": "Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases"
       }
      }
     },
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lyra_TemporaryEquityStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance costs.",
        "label": "Temporary Equity Stock Issuance Costs",
        "terseLabel": "Temporary equity, issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuanceCosts",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock, net of issuance costs, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "lyra_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third-party research and development expenses current.",
        "label": "Third Party Research And Development Expenses Current",
        "terseLabel": "Third-party research and development expenses"
       }
      }
     },
     "localname": "ThirdPartyResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty thousand twenty employee stock purchase plan.",
        "label": "Twenty Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "TwentyThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_TwentyThousandTwentyIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty thousand twenty incentive award plan.",
        "label": "Twenty Thousand Twenty Incentive Award Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwentyThousandTwentyIncentiveAwardPlanMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand five and two thousand sixteen equity incentive plan.",
        "label": "Two Thousand Five And Two Thousand Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2005 and 2016 Plan"
       }
      }
     },
     "localname": "TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment recognition in future periods to settlement of obligation.",
        "label": "Upfront Payment Recognition In Future Periods To Settlement Of Obligation",
        "terseLabel": "Upfront payment recognition in future periods to settlement of obligation",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_VestingOfRestrictedCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of restricted common stock shares.",
        "label": "Vesting Of Restricted Common Stock Shares",
        "terseLabel": "Vesting of restricted common stock, shares"
       }
      }
     },
     "localname": "VestingOfRestrictedCommonStockShares",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_VestingOfRestrictedCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of restricted common stock value.",
        "label": "Vesting Of Restricted Common Stock Value",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "VestingOfRestrictedCommonStockValue",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lyra_WalthamLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham lease.",
        "label": "Waltham Lease [Member]",
        "terseLabel": "Waltham Lease"
       }
      }
     },
     "localname": "WalthamLeaseMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lyra_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised.",
        "label": "Warrants Exercised",
        "terseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lyra_WatertownLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watertown lease.",
        "label": "Watertown Lease [Member]",
        "terseLabel": "Watertown Lease"
       }
      }
     },
     "localname": "WatertownLeaseMember",
     "nsuri": "http://lyratherapeutics.com/20221231",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Certain Executives"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r347",
      "r522",
      "r537",
      "r555",
      "r556",
      "r572",
      "r576",
      "r583",
      "r628",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r347",
      "r522",
      "r537",
      "r555",
      "r556",
      "r572",
      "r576",
      "r583",
      "r628",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r339",
      "r347",
      "r374",
      "r375",
      "r376",
      "r498",
      "r522",
      "r537",
      "r555",
      "r556",
      "r572",
      "r576",
      "r583",
      "r624",
      "r628",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r339",
      "r347",
      "r374",
      "r375",
      "r376",
      "r498",
      "r522",
      "r537",
      "r555",
      "r556",
      "r572",
      "r576",
      "r583",
      "r624",
      "r628",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r617",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premium on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "lyra_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69",
      "r175"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r181",
      "r533",
      "r545",
      "r549"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income, net of tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r122",
      "r488",
      "r540",
      "r541",
      "r604",
      "r605",
      "r606",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r612",
      "r613",
      "r614",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r206",
      "r207",
      "r208",
      "r209",
      "r218",
      "r260",
      "r261",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r383",
      "r384",
      "r385",
      "r401",
      "r402",
      "r403",
      "r404",
      "r413",
      "r414",
      "r415",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r525",
      "r526",
      "r527",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r78",
      "r82",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "terseLabel": "Accretion of convertible preferred stock to redemption value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r110",
      "r111",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r82",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r75",
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrants in conjunction with sale of Series C redeemable convertible preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentChangeInValuationTechnique": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether valuation technique or approach changed for measuring alternative investment.",
        "label": "Alternative Investment, Change in Valuation Technique [true false]",
        "terseLabel": "Alternative investment, change in valuation technique"
       }
      }
     },
     "localname": "AlternativeInvestmentChangeInValuationTechnique",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r141",
      "r155",
      "r177",
      "r200",
      "r242",
      "r251",
      "r255",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r420",
      "r424",
      "r447",
      "r582",
      "r626",
      "r627",
      "r674"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r171",
      "r182",
      "r200",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r420",
      "r424",
      "r447",
      "r582",
      "r626",
      "r627",
      "r674"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets, fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r263",
      "r282"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Unrealized gain on available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r59",
      "r262",
      "r282",
      "r528"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r51",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r173",
      "r559"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r45",
      "r50"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r40",
      "r45",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r137"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of Deposits"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r200",
      "r222",
      "r223",
      "r226",
      "r228",
      "r232",
      "r233",
      "r270",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r309",
      "r310",
      "r313",
      "r317",
      "r325",
      "r447",
      "r557",
      "r595",
      "r610",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price, per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued to purchase common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r147",
      "r160"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r291",
      "r292",
      "r551",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuances"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r612",
      "r613",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and 2021; 31,827,659 and 13,007,178 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r97",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Accounting for Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r187",
      "r189",
      "r194",
      "r529",
      "r534"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer software and equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r6",
      "r7",
      "r83",
      "r86",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Preferred stock converted into common stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r573",
      "r575",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r183",
      "r569",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument expiration date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r268",
      "r286",
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, hold"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Available-for-sale Investments by Type of Security"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r266",
      "r283",
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Debt securities, unrealized loss position",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r267",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt securities, held"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r142",
      "r152",
      "r394"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "periodEndLabel": "Deferred revenue at December 31, 2022",
        "periodStartLabel": "Deferred revenue at December 31, 2021",
        "terseLabel": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Description",
        "terseLabel": "Deferred revenue, description"
       }
      }
     },
     "localname": "DeferredRevenueDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "negatedLabel": "Revenue recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r120",
      "r661"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r120",
      "r661"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedTotalLabel": "Net deferred taxes",
        "totalLabel": "Deferred Tax Assets, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r120",
      "r661"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r120",
      "r661"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r118",
      "r120",
      "r661"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r120",
      "r661"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Match cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Company match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r67"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r351",
      "r379",
      "r380",
      "r382",
      "r386",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. federal jurisdiction"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r195",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r219",
      "r222",
      "r226",
      "r227",
      "r228",
      "r230",
      "r437",
      "r438",
      "r530",
      "r535",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share attributable to common stockholders-basic",
        "terseLabel": "Net loss per share -basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders-basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r195",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r222",
      "r226",
      "r227",
      "r228",
      "r230",
      "r437",
      "r438",
      "r530",
      "r535",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share attributable to common stockholders-diluted",
        "terseLabel": "Net loss per share -diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders-diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r201",
      "r390",
      "r407"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r658",
      "r662"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r658",
      "r662"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r658",
      "r662"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r658",
      "r662"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development and other tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "lyra_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee related expenses",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "verboseLabel": "Unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unvested stock options expected to be recognized over a weighted-average period",
        "verboseLabel": "Period of recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense relating to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r167",
      "r191",
      "r192",
      "r193",
      "r203",
      "r204",
      "r205",
      "r207",
      "r215",
      "r217",
      "r231",
      "r274",
      "r327",
      "r383",
      "r384",
      "r385",
      "r403",
      "r404",
      "r436",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r488",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r39",
      "r63",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r440",
      "r441",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r306",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r441",
      "r495",
      "r496",
      "r497",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r306",
      "r340",
      "r345",
      "r441",
      "r495",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r306",
      "r340",
      "r345",
      "r441",
      "r496",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r306",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r441",
      "r497",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r306",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r495",
      "r496",
      "r497",
      "r570",
      "r571",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r444",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r471",
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liability",
        "totalLabel": "Finance Lease, Liability, Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r285",
      "r287",
      "r288",
      "r308",
      "r323",
      "r426",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r567",
      "r619",
      "r620",
      "r621",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities, fair value",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.",
        "label": "Guarantees [Text Block]",
        "terseLabel": "Guarantees"
       }
      }
     },
     "localname": "GuaranteesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r43",
      "r66"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Loss on impairment of long-lived assets",
        "verboseLabel": "Loss on impairment of long-lived research and development assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r29",
      "r138",
      "r148",
      "r162",
      "r242",
      "r250",
      "r254",
      "r256",
      "r531",
      "r566"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax expense",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r201",
      "r391",
      "r392",
      "r399",
      "r405",
      "r408",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r202",
      "r216",
      "r217",
      "r241",
      "r389",
      "r406",
      "r409",
      "r536"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r387",
      "r388",
      "r392",
      "r393",
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r523",
      "r608"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r608",
      "r670"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r33",
      "r240"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r139",
      "r150",
      "r163",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestments1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r480",
      "r581"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: effects of discounting"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating Lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r200",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r421",
      "r424",
      "r425",
      "r447",
      "r565",
      "r626",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r144",
      "r158",
      "r582",
      "r611",
      "r622",
      "r666"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r172",
      "r200",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r421",
      "r424",
      "r425",
      "r447",
      "r582",
      "r626",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r44",
      "r149",
      "r161",
      "r170",
      "r186",
      "r188",
      "r193",
      "r200",
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r224",
      "r242",
      "r250",
      "r254",
      "r256",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r438",
      "r447",
      "r566",
      "r626"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Income (Loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r219",
      "r220",
      "r225",
      "r228",
      "r242",
      "r250",
      "r254",
      "r256",
      "r566"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and fixtures"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r242",
      "r250",
      "r254",
      "r256",
      "r566"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r476",
      "r581"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Initial base rent"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Present value of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r479",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r478",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Operating loss carryforwards limitations on use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r76",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r140",
      "r154",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r123",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "lyra_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Exercise of Underwriters' Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering expenses",
        "terseLabel": "Payments Of Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments",
        "terseLabel": "Purchase of investments",
        "totalLabel": "Payments to Acquire Investments, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding a December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r560",
      "r568",
      "r623"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from issuance initial public offering, net",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discount",
        "verboseLabel": "Net proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Net proceeds from issuance of preferred stock allocated to warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds from sale of pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r108"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross proceeds for warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r170",
      "r186",
      "r188",
      "r196",
      "r200",
      "r206",
      "r216",
      "r217",
      "r242",
      "r250",
      "r254",
      "r256",
      "r270",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r419",
      "r422",
      "r423",
      "r438",
      "r447",
      "r531",
      "r566",
      "r579",
      "r580",
      "r606",
      "r626"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r68",
      "r174"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r70",
      "r159",
      "r532",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r113",
      "r164",
      "r682"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r596",
      "r609",
      "r683",
      "r685"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinBalanceSheetDet",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r550",
      "r597",
      "r609"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r90",
      "r157",
      "r544",
      "r549",
      "r582"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r167",
      "r203",
      "r204",
      "r205",
      "r207",
      "r215",
      "r217",
      "r274",
      "r383",
      "r384",
      "r385",
      "r403",
      "r404",
      "r436",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r238",
      "r239",
      "r249",
      "r252",
      "r253",
      "r257",
      "r258",
      "r259",
      "r336",
      "r337",
      "r524"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Revenue Recognition, Milestone Method [Table Text Block]",
        "terseLabel": "Summary of Change in the Transaction Price"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost.",
        "label": "Schedule of Costs of Retirement Plans [Table Text Block]",
        "terseLabel": "Schedule of Matching contribution expenses"
       }
      }
     },
     "localname": "ScheduleOfCostsOfRetirementPlansTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureRetirementPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r105",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r348",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Options Granted to Executive Officers"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r178",
      "r179",
      "r180",
      "r232",
      "r309",
      "r310",
      "r311",
      "r313",
      "r317",
      "r323",
      "r325",
      "r572",
      "r595",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r1",
      "r143",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "Secured debt obligations",
        "totalLabel": "Secured Debt, Total"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r600",
      "r601",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted to employees, directors and consultants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding at December 31, 2022",
        "periodStartLabel": "Shares, Outstanding December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding December 31, 2022",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfUnrecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued and sold, public offering price",
        "verboseLabel": "Shares issued and sold, public offering price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r145",
      "r146",
      "r153",
      "r602"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-Term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r200",
      "r222",
      "r223",
      "r226",
      "r228",
      "r232",
      "r233",
      "r270",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r309",
      "r310",
      "r313",
      "r317",
      "r325",
      "r447",
      "r557",
      "r595",
      "r610",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r82",
      "r167",
      "r191",
      "r192",
      "r193",
      "r203",
      "r204",
      "r205",
      "r207",
      "r215",
      "r217",
      "r231",
      "r274",
      "r327",
      "r383",
      "r384",
      "r385",
      "r403",
      "r404",
      "r436",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r488",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r231",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalAudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r22",
      "r82",
      "r83",
      "r90",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Vested share of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r90",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised",
        "terseLabel": "Exercise of common stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r23",
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r82",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r58",
      "r582",
      "r611",
      "r622",
      "r666"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r199",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r327",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Preferred and Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r4",
      "r5",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Classification and Accretion of Redeemable Convertible Preferred Shares"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split of issued and outstanding common stock"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r462",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r462",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r462",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Temporary equity, Accretion of convertible preferred stock to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity balance, Value",
        "periodStartLabel": "Temporary equity balance, Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity balance, Shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityAudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r308",
      "r323",
      "r426",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r619",
      "r620",
      "r621",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r206",
      "r207",
      "r208",
      "r209",
      "r218",
      "r260",
      "r261",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r383",
      "r384",
      "r385",
      "r401",
      "r402",
      "r403",
      "r404",
      "r413",
      "r414",
      "r415",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r525",
      "r526",
      "r527",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDeferredRevenueDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureCollaborationAgreementSummaryOfChangeInTheTransactionPriceDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r563",
      "r573",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Corporate Bonds and U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r563",
      "r573",
      "r575",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "terseLabel": "Unrecognized tax benefits income tax penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r234",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r477",
      "r581"
     ],
     "calculation": {
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted-average common shares outstanding-diluted",
        "terseLabel": "Weighted-average common shares outstanding-diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r219",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted-average common shares outstanding-basic",
        "terseLabel": "Weighted-average common shares outstanding-basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://lyratherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r587": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r588": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r589": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r593": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000950170-23-010632-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-010632-xbrl.zip
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M4[G#JAC.U*3GO.KRML;V^DO/I^7#2^RGD8>!WU\B>;]56UK*+@&WL[#</T<
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M_\=^+=)[1PB 5?&?F=PAMHMS5L\*DTFKZ>QCSR 0H>C7?G7^/HUE[K9IP?6
MD@E_E5)[2ND@?^GG&:#+(R:[4AU\^;8]3<FQY0]QD>RU<V-.+>NWC>8#QRTK
M]XH0GE<$'.^1JNJ<F/ ?P-CF)#L-'H?Q6:K%NQ;=4ZRRZ_2V;KK>@  "P<WD
MI)HB^PVU+#_![I$&ZF.IX#S/#,*SAZB5E?E>Z5OLB=/JL?&+0MT\+;T&90ZS
MAHO*L%4P%A[^:N>\:5E7WM%MD3E.=)J?Y1=WHU%OX8XH'_04EL^#R9']V)\U
M^&PINL&W%UFKWER'H KT-B^6KR[/NV+/(MET1B1+7!UY!"H(YV7R=QJ<TB&-
M*HM/&I>E.^+<X[R)11N===XG/)0VSU=X-=9,(@#YPP1JQQ+39DPML*T&@]5*
MJHWO^LP)Y[\N!,RN_3J.\DT6=I(O;:%WHZ:%41DSMAA2B; ^_,Q YMTP]8EW
M5?6G7TJUN5_O5;O>3"5V.A79-7Q*YQHKX[Q/$.<F:>-\[V/V^_QHB'I?LPWF
MFJ#CT53CM;.9GG1FE"H4M:("/']5MF?TL?('5ZUD47WJ%MV(=*+^"5DHD6)U
MS82C"]IABD>G.UH;QFC,R&GYN%SCU\=$"T3_ZF#MXV?G.>  RKR2^.!WEOK@
MP-+]<U>OA;:JLA4^\$EQ509H'V+$A[0U3@VOGLC@37LC2+YR$[>==@^_\S%V
M']D;\Y<LWUMZUO"C$D:*@V.,IBU6=&/JAO$LIH)D2W>QX*.S39AZZ_%4IBU$
M@U(!B$P^'- LNE9!H@W5CD<Y\$DI\*QN,.(77B7IJAF)*! :2YR!Q,4U>HD,
MJV]\S+#?**F]3O%R<"TWED/)C6_#[UOTJ_7&6+YW""\@"*%82ZPDFKH-(=;4
M<7O\]1(-1(OYB,,&5!]Q6-@-Y=9>YK'"?;21RP-(NA>6-+B,=^_M6S&XM9T-
ML4$=\ '%^BBYB_4\='WY>&.3E0U!G_>+:YX<3!%>>#,OJ@HC@N[LO*ROPQ]F
M21#'Y7<1E=;6U'QYD^%Z,L#$:<1&@_4[P4(ZD4'QI [DJ4!#H89Y#ZS6X/BI
M[?[><&:$>^MNRV<@( #8 FK13]QL_3IMLP8]S==\:1JG(#$:2JC*]*[E6(%1
MVD2+PLIN2BAVT&%,A9J@_;L<DE<E6WU:-J' Z;>OV63B"BN*9T.,83Y6MF:1
M@TIT40IR2(-]S.G &8%Q)0[\D)G*!Z#9[JI!IYO)FY/HS\.*="%RCRWN_O!%
MT&-)@?Q(.+<*]X%*"(#9&7B[MIBF&!Z+ -#%@:>;EF^YBL/LQ9+@:&</R/EQ
MA[MV]_7.-B#X7J_B?7BA76;"W S(38G(.5I>?B?1 H^>^5O54Z7U^*4X"/)Z
ME,0(>=1F[!>0GMO+>[8QT\67C>_JDP7/E;!C1B<$-*B'K^I*!_<-OU71*K$P
MC9;WML5"?FSK_(8HLS[9\HH=Z-W?]ZVBCE=%#<)D(NQEK"'60!WR<COEC'+G
M%SLNM6**R<K/ZSSIMXX&/GTU.=G+<E*XG>D_4L\RQT)U(M$JO7PS,G1QD0L!
MO@LX43R!7L5^EL[C@R#O@^+Z.$.5F+S<)[^'2Z=QQ@VPH1O2]/XFLW"]&6?-
MY.[IXZQZ8AV[C(+B1Q0SG*02OBFG9)LD9]Y0OO[Q?.C1M9[$UQM)I%S$,102
M3R,5_@@7B\54VN7SB2PXC"]"=KF9-^#>$KIF*AWNKYJONG+GA"(+L?H9!54\
MC23M$;D?5BH7@ZBQ-:;(-A6U:\28-0?@?VT3.R@(JRGB/GJ=+_0I\W2:113C
M5H^F:^%G'U\N[#.M_#O:-6A\>AI[#;&AV7H###0I!4$ /A</1E(8E.!_HB94
M3UKU"\(=5V*C$:YW#/2@(1X\/'B;#6%]\E]Z-1:[)(P?V=^1P]9&+%X=;3K[
M/4:KAVG<+E_N%E^)5IB ZN>+[?[WP-<_L?S'&,/YTU:BP6+6Q&@S)P(EPJG,
M7U12CW"] D%'-28W42QSSY<Z<)?>]=%N9F=_V SH8TAW\.3"A;WN*5)@5]]0
MC5-(?(SNX1_1O1ZWR^0^L-!IJ(/P4WL1,=D6EWY"N=;1T7PI-'.]$4>Z2!P=
M-<[:20?+O7-:OG]8 "]/(0"401 DI;)ON4E,<4H2<7XP33GD?WOKW0)>-Z>[
M>,1V/W7_]+>63<+M+3';D<!/AIS^_9(KW6]?I!+ZV6+?%S3!^HF5..K, #8L
M=,J/]O0TP7J+*Q@;*A9Q.S^>%P@.=63G+"CWIQ9_9>(9A_UACN4<T$R&L7]_
M+8>4"0[:<2[G!A"9J+#2H/SA>Q)B#/Y#*;:\D*LNQN[E)7EVL+(24YP^#T=5
M_>YP9_QULA,QVF(I":>^\!,V ]ND%XNRHAI@=@@$2:@6OT#@SX9L2Q B (Q)
M*0B *<&IX,CTGU[ Y7%];Z&Z/KXP_SXR9IQQ'.8= _]()OWET3'2*_@G= _(
MW&!ZN( []\J%_7(O?//=/QO]O]Q(ZZ^; :8D%6&":6*6@DMI$KQ-+D^KD 8:
M2#2GZY_IF!^'7,?#/US171]=PS9-^[U]FXK<6NO:LZ'@%9P3E@>D0^F3Y9,<
M^)/6I^!1VC4$@.;QD?X#]=)Z9?<QAS8D)(T( *9YN/0V@2L"$(T 1-']2>#8
M8&/89 F8\>Y[B)PS M!.MJI^B[( 7FM=4[BG#V1" #(E>^#B?[9-T[CUS_W_
M3C;U0%V $?14NOZ;CM[17R2 _RR;[Y#NG]K]3]7.M!A>A0#0"SUB(U?P=DW)
M\I]Z30YIMTL]2W_(C5%*2^@A[^W1@!" -56^F[M-44(936(\QFY2:_ZAWN.;
MIKVW-2[K8/<7A67+U[+WCY#CI5_,O=>]'0+PB:<SXQRC#@'H 7='6R](E1G?
MT"T,LG-X_77T2_]Y8GSW(BC1@RM<\6-#%O\J(>8OTC=-.W8G6V,?!O_QS!+]
M^OY_AGK%-X\(UA\\O0SOTV_]4X>2C.//U\%WQ*\>XJ6_7Z;=>>] *?:4^KRX
MR>WG[F*<!S?^L5T9?(<*_W\<]?\/:V>*$22][C8.WLN"RW__NRY.WNKM<QLQ
M$$=NY^J^U5#A 7%+P-N[B7[E$6U'*=J?9>BK5Z9T[I-VV9!UJ='_[%F"KA/I
M^V N!&#O<AD!>$4R/LV["KY!-T8 I@]:X:$<!06CW=)=7[,?9"&LN8Y_U.W_
M7R*M_^C@P9\(A:P3 3C%A2( %?/@!UQ]=9.>< 1@G<(% 3"O10!NR<O3,UZ1
M(P"D9A$7V,!8DJ"J0LM1HKYBL8.['5^\AWM[BH.#)3F,K&=/.5)A]P0Y]F)<
M-5-E+I<'RILD20Y])M]1?O3-S-Z\' %8DF=.5OWD1 )\P?IM=9%7(3U]4%%M
M<$_OLCE0O-A62"S_Y1-0VO.WL]2OTX 2>1Z27;WE>;WD\C07$GB:[>7$Z7,>
MXL)7EG%(&.PRJQ$XW_:VRP7]C4L4\HQ,38!/ @JT0:I"4Z)]-@N-X5]B0P!N
MKLDU#JNJRLL:7]],G5]S'07V7^D=N?#&L24&GJY_D*'V/)(+ WD0?_S(A(Q%
M(^^KCP5<"W#<,3*K\<N>?Y5GUJ19J1('RW*OEEJLFX\3WR+Q!3^9VZ&,@3AG
MJ+^<8EBHZH#_W/@NI2MU0R]'BF_E,3$-BK1>U/&-A[3!/*2?*!66U59E=[D0
MCU$PID^Y,W0K'"M]>;%P04%-V7,=<TG30@>'085)S>=>#7U^;<TI 5VS0TU?
M9/UAKI)6K$(=AL7 >XXA\/M7'!)J=(XD1W_MM=N5P0_HL4V\8'X%VH26.J=G
MA3-#F+3T]SK<(#Y VV8M8\-4ULD(A'$,=.?W';/&R^_[H!TOQ8T\$G/,AES(
MH%=>PA,L0#JZNI'1&EEG[6US:XC+_)NH],N3'&3MI%H/!=0B&O5^A=$)GE4$
MX(D2?J67;;:1DFV>R1!U!?.87B+C^CZ5NLC%,\UW9XSUV?4.&<2+B^KOK#-G
M%-Q]O.R@I<[6IVNAC)'.SYXJ2;S%GS0"4_=99MO'+P-;]'+R!ZCYC</=:<VI
MZ )%7J6N1[^P^^'.^#,7EQPY]XDOH<EE1(D]]-BDYB$_]7*586S!P/1FK/XP
M[-D3L'+7SQ.Y"4J6D'<P 16GN5PM1ZBA,A.5OJ3K58#W$"E.V@9)MW"D!XXJ
M1R>+QGAFC/98MJ&12#X7<?% O:(CLIA[K-%<?C-72'<PY<MH0?%8G+A.G[=9
MCC%F"0;<47.J'9X+43/#_$.N>G#>24$:LUT\H0[U)"KC)*B?CXM_8\'<>P-Z
M<I2ZON(6_HF"H#7S,/4JJ$KON4=B!4YB_ #W[\)GGFV,"V/OW!E;%U#0F*S.
M*?+*Q;KA5I/^PN@Y!7-4.XZV8"D66U[V3RM*@+1?D7>0&)F3T***A1[!LM#4
M2QXV^7"75EB6AN+"MCS&FS71[([ZN3$YXM#_J>L#0T,MY!3F8#@-TJ:/FIX@
M##9)RRN(!#FPGI<(PHZ<5LVY<0;"36F>O&\<95MX><XH.#,F-V0D2KCBL$W4
M4>RBNIXD7.'A)7'HMA';-B>ZQOE"'-M4O^/K5?)4O1=A6'\S#"W!.#5XT_KV
MY-=-F.#4F%Q[[T8-'?ZR>HZ=$Y"3<#=9(>GDIIZW'JMF8BV5,-V>%63JH#.9
MH3>E-[QD4+I>6U-3&YL+:%WR=$-W__ "@V1:4ZZ]A\)U)4!>/>Q6_G,^0:V1
M8%$\MR?\(*$67_0WM4YRV*=##_$8HK!D$6VM.W&C7BF+F*>1I'1'2-?ZYG)D
M^#KNOE:T;/63F7533-6/TJ,2VFSI7=VV4/R>HH^*MI]-EQE,5Y>D*3^FD/1E
MFP&.%8G&% SG;C-)-0.]#6(33O= IE'G0P\</!=YWOP2FQ5%3W;HD_@S^4Z4
M"XS*$C&S1'?@JJF[1LK J4O+L 7V+*/%D]GSS=KM[!7+T'$)EJ(YX!)ED#;Z
M@QC<./RRGM$2BQ<:K3[((3O><?7#&]SIR;/A,Q?2-?'E75UG,$Y\M.1>479$
M&+M(W;UDV0Y/WJZ1057R)9XH)W=9@:?.%VY,]M_43]SGO]@K2DB61TB:W1R6
MZAM.Y$8E\U/$+5K*?"0<82),K16??O=HN7;(:!-+@$OY4+%2 ;!!MJ:J?6K.
MOW1 7.C%T&DAP/(#AF^&PG%+CD4+(1&Y]*HV;I][3=_&N-U\C\0#1U5V1$0B
M=6#6BDJS_%67<1Z$U</!(.OC65R>1I"!KQ6D' 0FWM6'TWW5C% -HN%;EXA
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MNX[7F'8&G17,#]$EHC7B/A$YF ^A2_-*T'7?L4Q\^[7F,FK9>+]5<O:5ZIC
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M>*]XO=.)2J^*ZZZIT\-EY9KJG[5]R&?T"_ANHC0EPIU2]"TG&!TUS:%+(JM
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M15EO=Y\FB#VK4&3BV_-WA-,VQ!HC2(S8'<E$)3-F\0\X).RRA-XA/L;?E;1
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MD&7MB]L.;P&"-^?F%DH9A@2$'8"4DL$%-LCT9(IPH0>5"_7E73C)_GPM+YS
MHRQ7$ESYYH?^?T,.^_>T6UKJ>A=,*)J<0)> O)D._G>A]R5*7QLRYVA(L-R)
M@+'B4]4<XN.#NP/8W8D*872Y.!96M>=LG4>B":';#1*/BOI2,%1-^JA0GG$0
MWG!:UGW2P>%!H_$0#!@XWZ?4J^H-#NN=;*[%K<$-4KWNY)VVK-V@CKK6U9H8
MT1@Q'3$UK'+W_0VW9.=PU\T.,>X5>6-9SRDH>24/:]%82AX23NT9=9?>K[;D
MB;]'<=%BC;]L#(66J&@J.:UT>O8;_B/&C I$HWU;&](H,0@NE'#MKC"%%7
M:VJ<)\M'<P#!(8?_&+)C9S#WYG8"S^NHU.2 3B@K^^?*R 78BH_*8A%SZS&/
M_A1'1]\/N-.D(=,*=IED''.0."C+H["/)B&%=$3\"T1TRU'4>DK=NL;8I$M6
MUO$TH<.4<!V9/&8NUIOUIDI%HN$E7";9M5]\_"70&Y*GU^9MS=OGP!L<,9Y.
MHO])12+LZA8^"/R[JBBHEXH:,JGOO@U Z\:A3<;;_9@0M;5A[=4Z*Q2"N.:&
MXM9CC:JK%Q*6EP#'2P#K'A>NC5=5D:4[4TIQ;XY<+,3BB>IB9 .1[IV/;9'U
M1:J"#K[WJAUD,G?=Z@N80TH:I J-\!->W]>O][_1+_E!8M/>E 9M3Q6+O0&J
MH2;.[Y ^?:/ETHS_W4-9=<25ZBR4ZY&'87]T$&]*"\6&'Z)GZN2X";^A;OA
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M%J!*VZR,,6[R]L3.>6JIOJXF*==@+'FB3_]9DX[:;1A-1@^K+IPH],?)@TN
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MEVJF")G*#M5NK1F,#DW;BMKQ?2NH_BIR6SZ=?D\24:;BKK (8K1\]D+_8R0
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M)<Q_>6&4P<PA?2/F:R _Z9?-O;SV754>?=2%8-+K6U;0RXG_!E!+ P04
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MI=;HRV]$?ZF<*?J=5VH-THM8=JE$W J5?8QQV!0JXY![\[])Q_[5^F6SXRQ
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MTI%>0QB6/;S/T<"D[ [!_[,Z5##NEM?PT:XA(3M[_U6"M.ON94E,$[(%AYN
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M/9P1[+7==1:)\9C@;<:!& *+RDVJ\=JQ*2E2)R4U?89KUJ#$ ,D80SDWO.Z
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M@B 2>&(R&43=4"P?LWW*5GO"Y\#\VR0_13?=Q!-#.*&J\OI)!PZRG=)8>HU
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M+UNYA72](*EOC)+;A041:S[GN];\(>QS Z2HGBOPSU-BI2-F6T^YA? E[:@
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MD]3IQBOE61&1FZ I^B?*M2##!>2I\T'#/HCR6CO09Z+BAF'9E%(SR[;YZ\!
MQH DUMU7](BF"F&R*T[&UYDJN>1=(LH$VM1O]D/8.LS'?3B8,LV_;*A,+HU,
MKFW<XE*2JA;91$+LFXBONK'*%*ES2B%2.9T+M$T8?FK6F##.).B%^6-?:L_U
M.#K+$V?S1U^&52LL"#F] \_M8 IDI$;^?4F^M'_R->.DC7W?I[E;!&L-!8<'
M#]SC/5PY+,JAJ2E1R)C!XV[P)&@DFZD\=SN^&T% /BY_(4UHJ*SDV]=&LT/9
MG])_QGM4:+(!'Z <[*^^G"H]*[NN[D",XIUV\PE09=0,N><XLWSE9HAKY58G
M:84,W(D&6D\$T^#\ QHW=#QJ?ZR.Z!CV@[GK')[T._?VW.;*23DL$@5*2U "
MS9M25#K=A21$+^M+P/0C/61T,A,U0^Q=F4F]1O6KE0P0P(L64S;$^/L7AU&9
MGQM7VK[BI \39*3M*-5I=NL XHS0RSE%!U!J!O,Z/4^RUWP&X-D=@\)REMP3
MRTB_O0<^*$GJ?2/G;%C@@]<,K6!9H'J\9OV+1X-GIPBRE<UN8Q<"!W=%8B@&
M_KV,[(,4AJK0:KIC>5U;)?<H9^6L/8S7IKKFN^QJ3&!Q,3(PW<_+#0ZFF#>1
M5F5-5#H(VM'0!S4?<13RK<\*B\1F4DZ(.@\/'G5;SY_+_7T:%ON$?V4:6^<?
M@%Z'ETJL9$#L927AS>J:R5H!3$/3QNK"4$Q=K21 S=C8D6L%">?SM]85LYT>
M,)8'3X;/6JY2;5G,ZFRD%AG%QKW*AYI-S[]VR@]=I(9H3A1.<A+16R=AQA&"
M'MY1L6IEF7Y%;UR(1CAZ_UA.87Q#_E0">=-8B;8@'@J'+5*!*L./>I4TD0X[
M]+7T)H^;\0*(,4AE(CKE[-PC@\%QK_6]+185QZ5?$4]R7:70P?DK <;X/8>#
MTH],@N&KP&@4-SD08 G,A"FG1TOR3NZLLN+;L[A>RNR*2@WN(EK\.+.:\'3C
M4J)+?<NU)FLV!COK^P- 6N9J2M>-K-#C'4NP[MP55-*+'JB260F-GG,Y8<K9
M@0R<[7ZJ4/1'1=)ZKT)/LL"+'N381K\,_^Q;NFZE/D>'0 [,8V%5*U8+79L'
ME;HP09;VALJLVN:-,:\&YP<=$0QM*:<$:;Y-X3E4.ZYL)E#)BE/)(RK=I,9-
M^@+YZ3MNOU>!C7AXF%Q['^EE//$/_ACY52?&!6S%&-F"TFR-X0+YT0/0,><E
MFTY<  ;.MC.A;4KVN4/S6IZ:1U3NA2R9=GUFC,<5NK!UM_*F5C[+P[L^FB4T
M>Z8\85B_%$'7KZZPFVFAH^M%<Q&SV.5_A?[FPU"5E -W'S4-F)J<E'@AT>U8
MM.<WQ<VUXZ)"]?+\124%+BJP:3.:M3KFK\&S/M1[C-6J $ Q;[KW5]MU&MTS
MX.=#^+=Z?0T_=W43M?E;:?UBQ0")D[;B;EMJ]IBR7Z=GJCO>9G1M-M<JS\4/
MFD*0IH\@U?#('\9B?\5M%W=U[,\%9[M'K<_@_[8 _W@^PLUD/-GZ(,"S!%U,
MS?##A[XK8=Y(84V8%]Z'FE_)C]<6TN -5B 3D&#S0H3!K1)2H#&EO>>%QB+Z
MPX3MK6IK$*L/1KO[C 7^74D.=R$SZ<;LWM<ZMI.F1C.*-99Z;#D'&*,Z0=Z
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MDJA@:^[H6BHA<P@9DWMVPT1#WAT40I;N_MH&!/#$?(E$[#0KSK#.=8[IK@:
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M2<MY2:BVL+_6(*HWBEYI1WKL_4J.SH8T&\?8MKIJ@_\X(6$K/MZNTF)J1HN
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M?>?9.,VO'>X[<ZTK:@GQ/+OPT;J'.D#V=26M<J&,6U30QI'L.?%ZBRJ$DMI
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MU3#Q&>$^?4(&\8.E^618P5J=LH=*8CX!W\/@7!QU>\W7M%IOV4!Q$2(%\])
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M #<(?4WKJ#??1T3[4V^J-R-9K[8AYB:'HJ?\3R]3+T3)U 2:T+:0 !\FOVM
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M H UOHK-BU%$$_A=J;A963W&;UL.HG=^W,78N;GJ'!B^_;8D@*O=D"E;?RM
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M<I)4=1!3)5HW2L %\Q2(G=\PD-]"D\7/3RW.Y&J=P][C@J\!GRO3I/Y.\97
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M30=$KP1XSFQ_R6M>E'W3J*20C>!R#HLQ-N_LT'$XFE_Y="I7>6+QH^=0)LT
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M0J%V%!*UX']#0?\_S-\2VAT>Y@?<%VEICGU8[[-6, 1J=JS@B62XZP-+R.V
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MZ=HE#<FJ+UDPY]"<^8/N:5K<_#U@AY38+(^+LG^W$'7/$L;3-7:6V5B#$_B
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M6CK:TT:(B F_(2$]3TIZGI;B @7M?_G MP#4YX@PQ)G$1.S &6HB8FHB? <
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MZ(S7Z0W4)*37A,Y>OJM%]MB%AOWVBW.T]V(SREK/<PAKH^@L78?(Z:^+S-]
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MFTLVW]9O*Q/0-M.FO\H<U3F,&I(N,398.NF>Z/:,[-E-9)"LV5)B4P;:JXT
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MIX>AQ/SN;-XWV+Y?3TN=M@O 2+)D+V#\2DWMN]?]OGR.%"0M'Z$SV'^,*!&
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MC2@ ZR'U9;O1?PB4>(6LPG(@U_  F<,E"\,O/>B/UVV"(SI$'$_MAB\)0(J
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M++CLTZTF''K,@QCLV2Z,S?\VD _T67ACZ3!#5J?RABM!1UNA72'-A#A>CJU
M01R=&71K.3/B$U4?',.C")GW/(W<=X'P'EYN:O@G/U5\'H&#VE\R(:-^S\P,
MO;ME]O$;]H"UE%/%2\9KSB/29$4RIF#)_):N]S#S+:-(NKDY_:3(D@:S?'^>
MBGAMFJE)Q>U+ @<<MXY$?;G:-$(D\]HM+AF^D_;(6]'Z;G+XX^?K3U'[TKJS
ME>[)I3GS*3HN"R7@#OI8>AX'&^I[82SQG0HG"QDZ/[(\_:.S89@4(PCB-''
M!07&J7Q-^%OB #0;TJ/_V_ ]!7V!![8?NL./%IN/SN486-5S8A:]*K04W$"&
M_QQ<?7MAZ:6<DAY[ ]6\8[$6;E"6_XPH8-RE2/90W6]QKD* =EOWA3E/)E8
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MGO<Q35C4589O4/W%^E9WEC?Q+[EU_U>R4"796!78%7PE*_8)1?FI+J%#3:J
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M2=<^D7SS"_,I9P G-[-&U]]UE8''O3SVLHD\A(O(D)*Q-\^VWS,]4VP7\-R
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M!(;R5M&DBMMJ?B;[G'WH$'(4^3H*3R1JD&..Q=^I+(/R.#070 P;R +?O).
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M5W*VGG[3R&JL(W_P0VS/LA(/BT*Z*@KA+V9\V?\+9^KED5&)6ZSC=Q8UK4B
M\WG.L*.U1UO&AS"1?APLTA\D=94FQAFPKBH]!('UD[2>$C$SM8L=8M./-3/\
M(]4NUT1D*"5C3S=*&I3;%AGC%&3N\S5-@:0@5> !41"#I;B.+#?T0NTJG-%M
MA[4/W>W5+?[Q/F^R3X: >/C: \_3P-W&7=BL2;I)(800/@=:S-B$=R@VK](M
M@!)\(HFM),"ZR@<RER=UEQ>8'-IB9B/N"-X9RDR!KL,&7OTCW\[(Y:SM))
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MDQBR1ZM+B Q*)7Z!]YQ$]"+P);ADO#8)T*I;20+80227Z@CFM6NN^#1O-6!
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M>NA;_ZQUCS=^'4X!(!HW'*>QK''\OPW*2?*5?[OW^'#V7,9_$QGXJY--!TV
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M(=T6/7RXSE.NW;1$$A2=L14E*:IZ (R&JC>N/SX ^,B^*Z^W04_AV%P2?,^
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M4K,U:6>'^"YLQEFOFR945PB,7E[<C7$B;7X78B0Z^-%=)LRKCRR:P+ECWAT
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M.W.Q*MAD.Y:5YV;RD14-(1N",)XW]EVQV+(]%5Z:?=S]PL4KAS0GM51J<[W
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MLM][A-493A#F<#%-SL_U#?VTR68W1NI9W8:IYL$<+3.CE#O&S$@3#P!D*2*
M8$!6$]FU>)=UX0! ;>_V7RN? FTN0@R)G$@_0?B'M0-@/P@!76RA01;&WQ=*
M 7V!Y$F)(.\B)(:/.KL-9[CYC(6>KJVQ&GX@V=XL2=2UUSK/OH'U*@&SN3$6
M7/YD2]  8=1EUHH7M^.GO<,6K;, @IQ;@&X>(<S^ \'L#;^YN>4!H+^#O1YO
M!S*Y^.Y-=LY*'T#\=%Z*G<+;L,0/'==:G8G>0Z/-]FO2*/3@&?,DGNU2:2[8
M3EGI^Y+TF='[O < J^H5OTM1'(KWH)EK?>$8DT;SLT:&9N56?L&$S$ST]@$0
MT<SXY;0_:JB*1N4 " \YSE7,YM0Y;8^#WJDFA%._(EW*+<,P3-_UMO&E=##7
M1#_:!EOT0#@RU#T0PGCLIA=$@61Z)[#R*"%#P:R0:1<WA*2_%5EB1=U\?0]6
M,WS!.&@;%=XL$S_B^&&&D,U2<CJ:BB]66A\BRJ)I'\"">B9;N$YO; TA&D\?
M %EAZ]G'R08P?F7J.A"_6W7/B[JW&R4QJ,B[19@)EMY:+!_\:ER)W2]/FUP%
M49@0*;>USL#S_9)1:^Y/-FD[2R'$<+QCH7WS\7MN&)9O3O7-L2NKNBQ%9.YW
M$U?!X<&]\7K5D#S89*O:F9R:APD?+2H7"3MWJ:YJ%QVN<J(TU)[.]T,%BW.*
M@L*Q8ZRQ)O2]9(FUXHFK!\#YP!*$V'1^^EV>SLG!IA\SK9+R#U/VSTY@IM]-
MW_1G>?^X5^EM"(V!':9A7[+_5O],O$R#MJO-YS/UH3EH]!.4'#%JNG:L*WY@
ML%F/L/5(0.G>34?T'@CO7,[<G/6AUDD*#IW9=[6%Z'+,HQFT0?17;C5<#<(-
M(YF_^@@$*JR[A);8?U\\+M>#,*;$FYZK0VR"1OI2ZK>0]RQ5@7UMS)=U;]W-
MW<#JWO?VI*_R#CG7WT->.^*C@4HF00MLO]BJ/!B'1GH=-RYP>I4$N;(TR62-
MOS=A'[A1= "LE;5GBCRA1!B#^C5<XTD/B+?^(IGOS5;PQ\XFOP. 33ZYRH7?
MV[;E08B='GT3@,A?*_E>@=J?7+2/_"*A/C(//M8,%3D *,7UN:XW/T)<!*]Z
MJRA0\0<3[OTDIS3S\"O IPN;33YEEZP7B$TGN<BBOW8$#]X6>!2AJNZYR2GB
M,H<M);,3U>B*3F!:%^UIIOA9<9&ZJQ![N'*XXQ".YFGET6$OYHX!CX\J%BEP
MC;7+5Q/90(OV\[9],5*FNK8S53(Z;4(R:Y-;'A]D;'W,B"!S19QN0WF//X;S
MVZC2X_O+]C>F=V*#T+';V;Q;V%8UK14N J636;PQ Z:?E_+B5D_Y-GQ4XG ;
MD_/8!6@:P;E(ZMLL?WF[+_=ZH$R2O0Z!QO834TQ#3>GA5.N*6U[]XR.KEB&T
MX66;M'W*[H7X3^BMG;H^A5&X[*#QV'.1@&R67%6:G/"**Y_'&C[FL)7)6I+9
M:U@7BSLO<M9IL!JZO]KDM%R\AIGF?*8-F-HI*I#9;%'QN=&]([T OH'Y,L'C
MM$@6M#WD+*PPI._LHWU77CR(M6HS.(I5:+-UH5YY!$OU.1/M%2D-,AG.H%=6
M6,0P-%[P=(Y+]WF7K1.XUO=&72>Y0]5W!:*UL.70.\+!Y&UIS[VV:S76YC\3
MO22R_P6BJ2&$))AO:#G,@%LA',0],WI3. :/+0TY;\]5F4PSUGR*&.=]&J+;
M.OH 942T0=*/"7_1L=YUT1R]\ZS*]M4&]@$<A%_TW7G4?45RZ!FQ7%4F5$1-
MS55D[S@+NY4GS3VR7X5CR:?>*PQH(D+]@K% V 5,;P/R*,G!+4]CD%Q)M:56
MW'[Z06WA"X^7=5O8\VM>\8ED^0_SPJ,-BU4*B>V1:MH S+@C[GI;8NC(C_;9
MC@/@NF0F:62#NV/Y^827>M5Z<T*Z0@)FU41NG,Q!E+';N6JFL!$2-LVSLC)\
M9V71'KEFWLXW=D([&%UP V!BH+VWF_8PIS8\XLW08/-=8M-4@J?(S2<DR>5H
M@G&<>4&_P?UE#1#OV.<,03.:6 7$I;6 &[(E5E[Z.Y/7:SX793+!1[X= (SY
M,B7P?KG%P$V-<XPN1.@<* Y]/R6OU:)JW!U#D!96*YZ'1...N#G-A9;/!IW/
M]*JZ38]!-U<3-:>JH+ G>?!/4\$RNZ].@*.;QXAF=\H7"[Q[QVA]98F>\BC/
M-[;&<:H<:5P_!)\V28Y E6S#G5[!XX>9B#9XX_ .S-W9\S)0FM?;<5X%S^>)
MQ:-D>9NSE;6<^ F^]TL?4*LF])\. .8JX2V.KA4[KCHLXW4Q?\D^LF"OF;$6
M9IHC2VFD^UI-CR[;,Z6XRSUQ^_M0Y&7"R?K;_!4095MB GGTRO?-A1":D3$W
MX0\FH;NB;XU5OBCH^4[8,KEG/2#??H#.,/>H/@%R=[@(8H,E6U4P?RRS!PN$
M*:KVC=9A(W<_V'2=YQ? I7Z&I?=,\>_M]LLME=*W@:"?UYT;@O7"VHXI3$VR
M5#EG.!L&36X]J:D8S_36B$,87(]^?\* "9<.R^\\=GQ*9!^*(:RVL;PJ+J#T
ML"=&5=W.YUTZ6Z>L7LFT(6B 9T^/M );IQD29C,B* UP8%[<T_9US]FYJ@R#
MK%&UCZ?O9S5X$:@<'\TE;18EPO6USM.VE,)$F_#*&QNW:E$=M41X@*0]X*2&
MH,2HXUOR>>[N%G4DW\:^NI?*N'6S,=$,?Z0^4;4:N@1F_C!G6;B530_=<E@:
MCG5N9,2+A5?OH"HFFE&ILJ=9H7TAI]W.CIY_$VPB#X_R@_EFX.5B^;; X5GB
M>[\D2,#)"I3ZQ<8QMF3J& _-)6H77YBXPAB0K?-YS';"+]ECQ7P9L_9TH79H
MAG?%C@[@&!I]JE<=RNJ7;^KQK_])R!'GS,H,-XW?M\Z9!8A_%Z<:-E-M(Z^1
M%M;-]EK7L^D'KJXG[<VL'^[%8.F];XO@F)0%-X)5'N!WQ4T2\4^?V"+:W]L4
MGH/VD6[C%U9NW15@Z4AJGY")'U5JO4_$]0FI$T.=+HA3S.Y"]R#%2K0OLWO]
MXJWL02<DJRK<*I?:>+11RY+ _Z6[,R0PE\!5O_U*J0?]-3W]21+DV:V["7GL
M!-L/<EFG/;L7?"?9U!J7 AR:,*^%U,4'PL26(2H>MV]"GZ^1R\\D1P<X5+5-
M.YJ+\H8XFH;_\AVQ/H7ER>O6/7S'IE?1;)!,*P3%]U$1B6\'"BF#>482G/FE
M[I?N=!)TO='_R/7<,9V5.GLWIE].W-ET/YN2E<?<=G.5MSC$ 8,'/87YN^X&
MY[]<DLAR1\)"? .C]J=W^F4WS%1GR42*G4PH](>T".Q*T-#TAQEH"&!0+;-"
M!\!W7#NE:P3/D"&EB)R9R1WZFKTJ K*=BHP1&PT]280> *"!?>@W:>  Z,Q$
MZA/WI@L. "/4,N0FC"7F(CF9:K)S6ULE'33.\>N^=VR ^WDS6N?&'+S+0W.H
MU5&CSJJ@?2=BC+'-9T5:IQD.JIV5F57F+D?X-XYXMPDJ',:@,5;.\4C3!_RC
M^_ ^A;=!6]@LA9AC\C9O-3Z':8"<2&J$X7MC':4G%Y=MR%*$.]#\\N,J0;A.
M,@LQ<C?X;+HL$>=1!-> [IU^?I6PK,&#9%,UP:69GH2OVU(8'%Q^MQU?;OI)
M01_/ZV>GI?K8,#C_+9+^ "AR-AZ\_S2@%4/#J! 5"R-)?OGFT5Y5?Y('7U%I
M)WANVCA-P+P'<( 5EM^$SAE'&:8F-J,)%HIBBY +<'U^:VLJ(85*1 /&>ILE
M/$%[3ONQY.OOTK1*#^>;@E"M?1PZ4)' NRJ4&OBRTC+;AH<H>'8QGD4;*SU
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M;$:S!!'9FVK."+FJVY!S:\7>:J:'PU#@D:<KS5?74QX7]M1DH&/J(%B.:UP
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M*%-V^HQQ5,(,,TMX_ A&23XI7LJ&M>0NJ9)>")_9/3F87M#.*GC>[I.VJBF
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M: _\5MLG"ZCG(OX PRL.*&I^"\N,ST&=*M4+2)1[CC.[H:C-AO@--7VT0BZ
M?BT>M?25/YA^O[K")<7J;.=NO"![DVKQZT[\6\V^VA8%H4V-]:064?0*O7LW
M8; T1JE;,6F9U&1WH/Q=@-)IC[W/BA[CA0-?$B=?62H4S&ONG>L9]9H3//BL
MWH0+H5GJI$_M*7X.M^)JLV.^6,C)FACU6*Y&K-SK_)[!= ?1Y_.H*WK3==#+
M@X[72@!Z#T'"39F'Y:**^6PI]+WZ;TGPEW)AJ'9 T?A?B#8F<-7Y/0/?_00,
MG[UYF"LK,CY7;P5@QD)@]?=DU=UC)[:N+GZR;2YV\\5];0C'S*\6);12:;.A
M.VQI2!*>BU6H3C;)XRDS'S\I)ZZ$M1(?5G_*3SNSVV\DS%V+7O_JHL8S^%!8
M NH2LRGY\)7<#2ZB;?K%TLU*WHG]!?%SSV$U4R6)[E43P+TCK@M/ #U[A4(Q
MLI9/3VBWV%'A5Y":U&$O9O8Y7^YI?N-?-5(W@!XW!Y6[%#S(VB\A9M-S7+VP
M;]#4H:_P^H5II;[+D%CC*\3>L/]8)P0J1L>RKJ%%GTHVLL>WKN,OF@)UN#M1
ME:QO][%,;CWL+_GXV17%2EO1R!'*O)GG ' ?;T%WT8F&W]?=(1KBMEO1A?E0
M[-Q^<-(R)(IH ^T*&"-WLV,]UE* ,4SX::YI[_#^CSY/L^XG4J>SCJ=I9;)8
M8J%_(YH")BC-F8I#F*_(K/*SB-GQ"'>-B-JLOH.__XC_'6Q#<OR5!_#>LQX#
MQ(\QYY,>F =3DKDWF$ZUSET%QR8\B  D!%=FVG]%>ZQ*80^F%[F/53@NC=@&
M>),?$#,16>R0VY1'[UN"LCZ%K#<:77BF';4NC#EF1PA*#ETMV1V0 <UIT9+#
M>>_?68=T+Z:J"W\*%<W,WD+5PSCS+C-VB;/P4]Q[X:5]/4()2(M_@\_0SQD5
M/)/;'&B;NQ2N8U :,D8B\F1<!1"'UK+$;D5NW<@9<%ZL/FYW[\#'-$ <XF/H
MX99*H"RR6=WC 1 8:T''26FD):#8+8CI)06NU6'K$Z]".'VGFTE ),WZQ6LE
M7MG4830)6MWZPTSWB>@EQ!&^."4Y,H#/B7\59$.->\)OLX]0"ROZS;MEC3G0
M7IXPV_OMV6R=6Y@/I2BEK)M>O>^_Q4 ?)MN?#OVB*CB6\N+73T+&K>N/\WX]
M4U,AG'6[%'PEAYF?5M;7>.?'P?N[A(FP?>TBEQW=KO7=:W&N#6E5/)=L%\_X
MV?Q KUY:T8A(U,3"/,#%)8>L8RN)@%T,4#-*FJD'J@LC -\%C^&)+O +"G?M
M0U:N7!I^<P)AL=LSBB^/[KT#+NT7K LIJBARN?&SK<7I) ZVD4Z+C+GM=>H
MO4Y9*&%N:%;AU\B\FTJ$A^?=797U%0H7UI_O)+D7^*-YUGSD@FI9_G!2\<FX
MP4D.H2'2'@+C"#>EJ47:>E24H2CT74/5T8IXW6/@9VS]7"&D*3AIM3/;KSQF
M&U "ET0I,L^YN%Z29;:1BE!&-!>7#IFO\6:"0RFI/8EA:2MB4; $XIMLDX*2
M0:XMPE/PMNE5$T0#6 W99Y"=Y&RVT2\X@SO:.>/='8?Q7AU_?G:*S@6UEXD.
MO\V],J/NOL+PM[C/_0#M"U.LR_N9JD/&-\+![.4?C0\FXUBL.VGPU$]TA8*9
M^JAJ@PB";ZG("E9T;I=\LVRK[NK,MY'><\W/X?+->?(*%KOI:1SMB?7HVX[[
MO(3\5O=QO#]S;343_>S*W,L&%XM\A\Q.QQE,5Y)>*JI5//N==.>H& S A$<9
M)GQ^<Z_VW"!JZ[IX=Z=;3I/88?7?C?GDG5P]F9F4M&=G9:?#LO^,AY>W&)WO
M,KJ^#9!$?L$2?+@&?9WDS%096C%8'57^1<P;L/&"65P 7"\8!4O5=T@BE0D/
ME :OVC&A7[CJ0TIP5:FL,VAK:AG$TW'115NT]_R:;A?;SC$*$2@?>:)"P__$
M"Z';]#!3/CJ?US">V^BW@3#U@$O0>M2#P0]8(Q'0#%ICU@4J VDV[5VM#\/2
MOV*2H"T-&_[./ 6<83-@M6#L;!_,^NGY1=/NW;5\5.M"(P9XLF=7/I#.,O=4
ME=:>9'8^&1=A/8Z;.^M2)PBN8:QSGRL1I39S9F^0)0=.5/9E-X9%#63^57U_
M3^.\Q.&@>EQ*T#7/,;(+DPGTQA+18DSY)O$S#P'?R.[,MT4E8WH'@[+,QQO'
MV3R[7%(Q6&$;T*:+_4V*PQQ56(_'!V_*4Y?D'O)%L:D"^OH@A-[)2_(K8>49
MU^AS[(4ZQN6*-\=;:H]8 /\M9!7W/OZ1M;OL^Z+%F]BQ++%"LCBVM19NYCZ+
MX!$036#Q"YANZ1YHI4MLL3K ^K\+E[>TO@PXEU'J^R%4ZC^A<Y^F-$H$U,8-
MS$K_JM*1MB8K_9!6'"@JZ5>R/!T*MJ* @3K]1Z9X2;'_!9;S\KC='V/?X0EF
MVX!]1[$KW:M98DG)_^*D]H8C'_9@Y9!!/C?I\[F)?\[PZ7_LM3;LA;XGH'31
M.>M\/GSDPC :+E!(X8(66A@2(79_6Z?<L73<KI=4=#'OC0"SB)B3[GPLQMG>
M!YK#IC?:^9])L5IQ*7".B#-7%:C)\]Z#DGMSQ>2^P(#C4QS,_'5PCV!J9>[
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MU=W(9M!=]8(+S=)EO+<$V"JTE_?ZZ<X!W\,HPU$O']]<*'5TOAR0](_7X(_
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MB]FR1!**1W>".H:5!Q]BTB3\Z6H?3O@O7;QY&?VZDGFV4[3<S'T&%K^A]L1
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M#O%OMZ8?P^4M-:JI7*IYA,GE-!7TYNTF4[@E>=>X\@$ADFN,1W29JV@78!>
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M(6CX%:;@#JE]C&&0M"(OQ)@LW36#V93>"':33TJ0??SW?JWU=_!=LL@ SZF
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M K3P&Q=R1ULLD<#*!A^UGF\3K=K/%C:)Q!Y4TBLK:@QGD>D^_);1H<BON,V
ML6W$O89'B:UQRC Z6$IC5101RSC*SDF(ZE"N_;!MJZCE)"5E?.>D3-"&"&%6
M8'T:(B&/KW/?!6Y!)-9E(,B[[2CQE>S\+64+T!Q$O[-KXG+&).@602W='%^'
M^+1M(T"X&0Z9HYR"B137R4.6NE8RVNNX=H'XA%SY@$PF2<,-5[A+PM>NE<SH
M1OJ$=2MBIXY>9\6WEK=MU BW/E013TBJ:]-$EJZ MKCI$>U7UKM#":-<8Q]
M<?!D\;I)V+KU1I<)(:,Z8!&A7Z3:M,1G@0PL1.6?+]<Y.15 B<\+J5FW!ZI;
MX;%8@2>3L^;L%@C6#;IW&XV#R4%3HL=\GLZ:"';6W;V_7!A1%#KG]T>O/?O5
MH'F<5,EB5O]/\,[_-N 5PW3*'D;^&/WP'JX'^!EB,ZW^\+#ZU\,UXC,4=_T'
MNUSOX\\/WK>9<K]BAOW/!5H;(2L3>=K?=[%/MG'KA+RJ7@[BJ.K$U4_*P)(
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M-):'YT=&E <Z\IY+/+9!T.N?M^]GC$O9*J "EELOJ'8B.Z1Z;X:H113ERA[
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MBU,)N\X+"V"P4S/L[IT7/PW:B[CC#6WBD)/'+A[ZF>Y=91U(+@:,#-(X1AF
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M,(H$KJY5KE:=H_4(P O"4J/G[G:7AM0"-R/)ML1*3F4C_-46OH_'@&<$D_Q
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M<8H4"FX/#5ZP/:ERJ.!5/[!:K,LAXID1.LCY\HIM8[VTJB51)5P;CC^0U03
MK]<&)D<0.+#NN)D>MJT9"09QF<^[A31QX>(,%@%1=^\?/ZH-K&"Z+?JJ3!@
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MQE'#7C.#J](W:F,J.9="ECAS"U#N'RK*+=D\*ID*C.?Q!_).^I>024TP^-,
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M7N^^8U7NUGXP]'#)(D7.0]YET-S4F9.U=/15HNFAOG^S./F"U=Q=KE"#X6;
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M'>4:<F?H!_^QAM5S%%':Q> (&8]'ZHVU9VIP>"PEL&6-;>[ZOWX(S!4-P 8
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M/^2\N]XLAG]$=[B0&[26_0.I<2:X%/G;$T'QWW<$>X^@%P47=#?BUPO&[P8
MV]=HG';TMOMV<X)<R[_P(=^I 6[N]0-+@UWXP9@-W?_-?R#"#%@&^8'4WU!8
MRV3@'Z$;SC6Z&CJ<'Q1;*];8MRMZ:&TDG$Q"$6K,'"^^_%F#=7ZH6YP!<Z&+
M\[ I7<<XLZI*J* ;]M302ZA$:*LR]AW<'P^1$3O9/9:T:A)'41I>J?PZ%I+\
M]JUA Y] 8.!C[K<08XH*2?<%S^WZ!0CWW#OY]-[%KL"()BQSDG/K\G#Y=UA-
M<=I24)!]T?%S/!LY":;*"S:@<!]!'WK*%T)569G3-<([IT)CF_8798(+^KM9
M_Q][[QW7Y)8M_ =140$1Z5*BHO0J[= 24.D@B!0%(2HJD B(@ 8(14' T*0C
M76DB)2(@/4@7$.F)TA.$T$FH(03X@6?N/6=F[KWOW/>=.3/W_O+'ER=9V5DD
M^]GY[+76WGLM'VCUC;ILI7F7&5.HM8TNI7<7L-<C[SY&SABLZ^Q_(1U,S-9E
MRH#?!_7]1AJ<6%-0:=V>]%UA)L5T.VKZ0-=>#V7N]<R RP=UX%TO0,F>4H>=
M'E"9]5Y[72=(=_=9[%Z3;!O= >,/Y:^S]WKVPJK74^>R.+R$$73X<?[#P?=0
MZ8*DZR'-K#%A+Z^(F3BFRR"N]);+!TH7PB67U5-GU)51[]6>X!XG*1__@NU,
M4R222BK<ROFPTYZV9_35"JC&(3)74G6N\HZQ("YWMW%+(BENGW;.K)R)E!Q$
MBQ/7-DNJKJ:X0;00JEBFJ!8E2RFGX*HIG=>-B8L6&=]7E=9SIEL5@.M/UPIL
M))/P"DM6D+LN^F1[ 4N[M<\=J3=39H4QR=L9/E!ZA]'8=#L7?4#YWC-'<*EQ
MH>46KY>I0K[]ZPS&2WO=XN>0;I6W;K$J7_>S&[*7=-83:BVV!'OV>Q*\UV>1
M>P/*'/UYU><_[+:LO6[KW>^V2)WO OX2/V\$>&](TC30-- TT#30-- TT#30
M-- TT#30-- TT#30-- TT#30-- T_'TT9#GI_HST"5J!LP'7=WI I4O[+4 M
M.[%+_Q;O['N;;A4P'VFDZ)(62W<7*HQ)W8^(9I0@5G/WU=3W1Q8R[C4I< +R
MBU@KK68P'W$QL$OJ+4]^+'YJ=""^K-!.' GH@51?R<D=R?T_YW+5[2R]VSO@
MC5T>%_+G47S-KFYD'M-DT;-V>Q-+CU]BVPX$=R*7)=WP"=^S;D_ME!YO[1TC
MQMW8!<!]W>OV'OAYKZ&BA,@MYG58WU+I%D7![2=S^CB[N2ZROD1=+:5G%W!4
M*V%C%V"UR;;#Q;H+2!LK!!(KC^P"XL<*N?@C46"<<,G.QIP.]1S&;W0;]L.8
M?'-L=6@MCVM"YF=C\>>1[]9<N*R&OE<+,DU@T'!R.DGX\XW'>A0L_SOJG97"
M[X@E3(UWRZB"RDN_47O0:I-2$Y!+ZN2F?^S:6E$KCM#L>+\B3#X758@8R-?M
M&^'L\IJN$7RG$/;YR9W$R%X@@*H187U]HVT(4WL2R&&EGSG%0\'6I_&07V^G
M'V-1XA8H&Y[>!?"HS7#L_9^7\S[AQXL/CKGOE#D)6<[8LHSO @3\'!YL3[DM
MV5:_&=M^HZ#<*<N[:BJM:?"?GJAB-3H2>PLCD(D+62J).UQU2H3^J[0OQY"-
MK) "]5TB6<DQ9=-@TS*O1T/ MH[!B9W0#FDO6UT*5ER7.-:2R3'<H\'NOJW\
M(!8@:_GVC;\(#$B:V@7H;]I/F"7>V%^,L=H%1&I3+#O IS+L]=Z+T/\ GS0$
ME_+.V482<TSL0V?%OZKIW!:$,M=O#<P CST8L0\5K,BP'_1CO'([E(BR1(F1
M+7FNXZGB PZL4070T+NYPAR-LW4G7I?<8?+W55!J*M0JM'N9U\JQ[-<DS7?3
MJO/T<1U0*=WJ6G#3M'"B=)(*!>N60WZJP.A:5A(%24?SD)^[G5^F%_19LJ+D
MXVSKSE-EG1\0V.FZJ1=[.B=+ YE($#Z$!7'NDGQA.0>%/L_Q[(KQN;!)V)1+
MF,"Q"T>1N3.Z]JU)3AOK]XAM+<P^]$0"7N5&,_<%.Q+J&.E)$*&X^N6[J( ;
M5KYE;KFD>.X<P?D1:WS_HQMQ)]?74.D[@O#/4%,04'FCZ!B$VT:_^DDYX4:O
M3^:U1 _E#&8PRV#R@J8N3QNJ8(<%[E[P,!4=AX,P4?DEL*QR9V95+;^G,U)E
M) MQ[>L9]IEP:-<\Z73++T7(_"'K$+-CQ1I!Z36B_;&E?[G_FNXK.7G;VC+5
M,+DH$E/+V%2X]1$%MMN)]2VE^PZ__^4"BJ-_^[G/H5MP<[1Y48Z_V/9SAZUC
M ^]$#J"^642^+[1Z\R\IRLW^5:8N.F9G&Z<N"7B4)M0=/\O90$!NCN$A 0_/
MJ8+U*6B'RY\U.:;23]2HE&B>81SJ]0>QD@XG/I#B#;N%20_PZ"H9.3T2 <LE
M1^$PS_2.W'P$:Y^?\A;'Q43 =$N0-5*EH*]D6"%C7 @GZG'?;;U"LRW+5L@Q
MJM%DVPEI"G8@[03VY&RO;+7:M6BAP$IW^\L/3&/FCRY8Q 4P(:T^+_W91_[Y
MPG3&L;K;5J"&,B@2D+_.D3DO;O%V7V2L?^D..LX9"<A;/[2:_>M[WG^XJH^!
M-A1<U>!#A=2 RCF7EM=126@Q^$VMJ?>07G1UDJS$@]S>&@-\6C!!1Y;1%F-S
MH^&-3CLA4<LBU!'(/:K]P,78&3:P<VKNJ:W"R$U@A'Q\695;F)LAT>*=DU0W
M9ZO"1MFM_)Y*\N*IK/>)R4!7N(!'=1!H;=3GN7@SB(/LK\=WZ3%L6'**3;N
MQ8HZQ&7\O=]A>TBR*-_$,&!>W&"=(]_,\N@<AV]#6FQ0LX_8"#O=M7G&F9]R
MDT.0]X7 VU9E>DF PM]]T?_@N]-$-!%-1!/11#013403T40TT;^:*&_]X'KV
M[TQYQI^F?/HM"!3R%\Y)U?>W>9PGRLZS V)+_X;T6%<QQR724.9&^N + \\!
MB#&2!477X@';*-J"E!!B'X';N2,^-X8\Q3:\9^#/0<X@=+KO!3D>N396=DC
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M2S:1=T: BQ6+6UO$ZPILN(PYWQV6M3:CFTH_Z;Y>%:'!4(A()K'5NPUW"IW
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MIV=44_8NP(K<W[ZN-)J"+:'*D43USAZJLQI09U'4:[$"PAPVGLT"W-+$]2O
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MHI6D6K]S(^Z9;]S=6G<U@X8GG??<*W^90F>0;? >W_<W'+0_(:*3W5U;F+V
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M1Q)NL#6,3HU;1[^^(W7&5ZX9;MRTQ.09*LI(,<^Q.U_8];*F,6?$ZQ:V&*%
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MR-#8F'&JT2Y 0F?2]!M5$,E#MZPSJ2'@2"RI7[I_IYTU$DJ)J5^_SPBOYRX
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M PO>$;1I_=5">+@+:'*(8O^1_3[4U QF:L8OL3<9'A328MXP4DP9$3F0Z5=
MA942_2@_*%@N84K[?(W &%K_2,Q'0A^$N:L#B+/=!>"6UL174>F^O.GQT@WH
MIWLV03;%7.X7/:77U5KL9LG/A;38!P$>@J:%D@#%U/T]F@+P/?--&<SN@)\]
M"KI)@L@AKA&[XN^> >M3*+/#1FQ,CU%LY$P<Z9PI?]G"Y+?@8R^ HJGC U97
M]("GC*H:MOJ2UHV#!(1D2V_5>:VXG'+4QLQ\YIY*J/>J+ZO2K.;#CECDY/=4
M;G)RYC?<>>#3-[YPZ]>]\A777C+#I1OYO;]>#UK2WU 5#>P^LX[J)+EOIQH
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MY_2<*UK("64 QG#T>/E+PBUJOH71;:Y\\QMJ>DR>'<C#]GX-+$[;S=2WNX!
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M2E_^E5E<]'U0._2D_?<-"Q)4L39"R],XO.9@@L&9ZRMDRWOCM7"H3 NCO<+
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M*&*?'XFQG<.-!58OQ(6IUXKSCF-".;Z\7Q2(6V<)0HB[;"?E0K<'#R+B\%V
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MEM=G9MULROUKQ"6;O]Q]K8:<J9$F#EKG7+PC3$1Y$AD:4**9=EPS&A$Q.*[
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M#.95_'CL_?4$!YL[,S5&PW .*K[WR/4/="+&0_0YQ!#D2;-^AST=)!4OC"F
M[26[9CIS;*>7/MD*F'[SF0XR??KRP[G;JX-F_EF]?8'J#6>7V+,^8S(]T(?7
M*I*3Z[AE"T8N/G,O*-P.0)0<?D@ZU<I;G3T6$"B06;@]KJAIN>NS<=9.+KP=
M[& '_WS(B6Z'29/'UYAX W30U@WX\0:KPR$#G8FF,:2-;GV)0!+RX:M1!<'X
M V&EN 93BNLMMS9P89B2/]I1?NZDPOY%>J?5'=O[*,D9,/N7"M8IYYIWTYK
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M_WSNRG+8]'NYIV?/0,%7GC!9]FCJVB,XSEM:3$1P4:G=(N;.R13Y]R&Y*PM
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MY+4M0$*8<_$1^R[4//$#4-P5V#1%" ==($0SS'HW!GY"N?PGS]/LD)YCIU_
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M*.PH["CL*/P;*%S*U9,#5^(*H?]7_S_.I73PQ<5S_566NZP^_SU!Q2_B %D
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M]/V&DCDMMYQS >'PXR<,EN*\AD+# E_06MRI2ZB>NAQ-'%)"3686\G&Q@!P
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M(S^CHI@JPDEM/%/W1QO[+-X*'Y#CU+5K'=O#L'S7PD._ARF' <O"7A! _NV
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MK:Q';,20U[<0[P6QM@UAX5;=#83@X[1[;XG&+#C;F=:O:> /^Z(B<Q\W-4G
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M&AP> '[6Q-BU"#H'3J$#*H2Z3?I<& IUU0E40-C4$M04W^X/DEXC2"*Z80<
ML?@%E7@Q6ZN 7>?">)/Z]+>;D->MV/MHC0. ::C(Y!#YJ%[_T2=DTR.;O!SJ
M<*.$^_F+C:6S,ZV1B:Y?VF>&/A@PP#@#IN35=B$#H*,$MU2W)YTQ#PS/$MR_
M#3JP7B^4C!M=]9-#3],9BD0DY!8DZP Z1.T+:*GZ:_0FJ=0I,;_@OZ:H]N^
MR?-?/+3N [ _\]T^O H_OC]:\:X._//?/][%_Q]&OD<RP-%X6+AGZ"%[E(X0
MS;MK[X5/2-NX1,/XV;8D-F@3EFRKI+3&S%J9A(L<1)+GS)7>@:Y0*&OG0DJJ
MA-WH)N0921Z4X+-@&,.]?PD'>8)NK@E]SA-%S$/[MV"GO<7^R%GKQG3=^S-
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MX0'\01Q[I;9.]T-^_ON'EX/]ITK'Q%D-::W+CX^EL=[^*5Q,W\69H).=\ID
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MA((YRPNUR6*1B') 4%DHQXD::QBU5QKY,"ZAZ8LN!H=X[!/*8J,/:Y;V112
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M"%8YHLP$=>_V 3]+F+I+%?&N'H9I\RZ"[KDSL,<7%D45069=5-6E%-C-Z&Y
M\0P6?\M:-/$;+LXY3,M:::1R5+L^-?.GSM;O*V[['W,$RU3&J@!DI-9LC,45
M'RH@3D'/+TX1D&R;H6TSQU(WCQA8[38MLLB(Y4->!K2V/,8#Y_L L#-H97K=
MP)F%"C>+:>D8R'"3#,''7X%E=QMQ#M7 N;TV\P&< KAWQ*K@A+L.1BO >R,C
M]^XD7S+-<4G9XQQ(MI S\GX=XU^'27([>B"=8QKF20X7>^*D;:<3ONW4&_J%
MI P0-#\R\Y^3)*>L-G$2@MAE>X,;16;SI(L19_@8O;#[;8$;5(54?/S1+L\/
M\^W!\5[?6%V]%L@I'82PV9P$:Q9RRA;!ZDU5/HS)(>)U9C)S+/XX5\YMN8SN
MA$+*%Y)N QZWM8Q/#A79W'?X*'$7/@7O;O2-?&7D"D.B)"W\2Q:UO>1+2N_9
MZG'>=[?:476_'6(L*IEWN49GOC15&":8IP9*YBWLTU6^9L:_*#L(W=UZLTI$
M8FP<_<^X[3<LO+5CNU.=[Z<Y=LN[6U;>I0!*EDGDH>9D91H0GN.HQ5>(\S6Q
M\QVBU\YH-Z[T9//Y[("BLB]E.:V]GZP\ $3=H18OV8(R<097J-JF<SS^+)M]
M5O$FV3-U91(.A:@ONQ_T"<_?45,61J'3<G%W0C;QB+@RTBW9#\POHI8JFY^N
M'^5*PI=>V&/O;&/1CW]IWB:?H)?')+J@+XJNGJ2JDZY*HX=>,LOC\QD&;CWZ
M[JUKIW8+=TU!<F^0B%)UFON\2.T@JL*+9T..$Q($._LR1L(,M1]$ >JT@@S+
MSCSWUE4Y423^!Y=*\KBOP+#*L<J?=_-%<5; 5&5N:I(,H-+8>.#?Y&-:T-][
M+?N%7_A_AIJN.D#^KM#_R^TI7#:KH=UNEFFHM4=Y7M1OV02$4TP"48'UCH16
M^,L0'YJOPU;J=F5T@>68MF+T3R.#_ IGR7$EF;)O!<6=;XA99(L/1&OE(OO!
MBCA>7?1'#,7*Z%ZV9]/]:66L<Y#EXGC(F_@*CP, ^EHG?)I<]4TQK2TR[4IB
M7>G,&7W)*]XJ? > 8IC),>;U4*O%*N:HSI<4"R-2'S%I,)!1X50/WQNA6<Z(
M;R,"KSPG^_;.D%0S[LQ2YJ\&1=O1CBMN0U78NWV=II[=#T7L EZCO\%?C.FA
M4!#>+RA_%^QBH"3%J+"EBV_Y>H;K*=F49IYE:0?".%AZ ]E2(^VP(+L6Y-DR
M5=MK7^";X=)JJE\7O97##/\1 IS4C7E%G0$=1!TH\_J67.8WSKP.AWW1PK?8
M.T(,G\$B .** <$<PQ6]59'8.NLQZ?S_L?<M\$SO__^3HEQ3[F&5DDO(_5(V
M<=P3$6,N*W*=2T)N8R27YK*$A$*YY[+D+J9<B]P9N6]"")M+AN&_=;Z7\[W]
M?K__[WXYCX>7O=[;9^]M[\_[\GJ^KM+]#6M3S>:D&7'QC4##^N 3H5<\KY'O
MEKVA=7X_@RE>^?U:^ZS-SI>6%\=O9D#1>$ZZKQEGB1I7)*-W R'A_KL?M$]\
MU=F!?$EY*N;%=]C;UG[&DZ%DW/,A]003)$C*&K@\<U^UWF$T_PKIRU DWYNT
M3P!B7-=*3)NDG;O6[(E9;&IZA0RNLVUI))E3KK410W7&AR73(M6[H#)?ZO-S
MW5VP_$^6/#\: KQ'S6(3KV5S+4^Q4<0'*N[DN>9'A C6OSTCD]F!#2.RA[6^
M?BF&;@I5A1TF6ULU\WU!;70JUS_3&'*7-K*RX+1/:_P'Z%:A\ @ ]$=+QMLK
M>NPO[)I'*Q<;-D ^YYWIOZ)C)H&R%]L]2Q!HPAAW&=8[]M;P-V2+)_/>ZTF-
MDU<@[3#.>JYS?B>2K\\]B#_Y(41,44E4R3YM)Q/?&!/W7::4LJ] :JA*4"LA
M3L?#OZV&%TE]"^LZI);?:BZR:^38YH])!%UPR>M>TQZ+Y=\-\$GTS=WHZ80I
M()R(02O)#P)[A=L0/(3L/!OIGEC^+4,@H2?1L6C>'@W=#MSO<%=<B#_Z(0?&
M:>#QSB^!W,M83YXB0,;.>,W-HZ'4:6V^ZXM7Z39T@/D_,'BO37"%L2^LP6RD
M#W_M92RC2%0[UD2'P>Y0%*H=JF.$WV#2]SG\S;8T]&E&DF/](9V>0%["@^X?
M8WOZ>^)0-WNW6Z8%I_\S\,(<Y3?1: V,?XY3<Z:O)39.0)<D$G\^_-?G=_NW
MDP-UZKG^Z@I-]^27<TMF(OVWTU?IMLT614^B@IYUX8.T%[/7J$/QT+QG-WNM
MY+781.JNZ'V91CQ/^?XTI8#Z@FW/;OA:29KH.W8'MC8ERMD?R'%@,I 8\^4
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M+KYU-7Z)?#7+J3VPO1DR/A*];]:M1^RW:=_26<.42UUAYOP<<G7;3)-($#@
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MNG)L8?M-]+L/7IRNEGK/ZR>YGJV]=DV:!-9%O:H,NI^>/SHN^A'Z3BEB.5]
M?+AGL+D[?617G+?#+'D%L=8W,9JX%:$J>&_Q2ZTCH2'3E"APS\F5Z6NE=%3I
M,0G@@O5H2<]5Y8;X>^UM \VQ'Y&J2SZ9T3U"<M)+UKY;#SS.7#@*ES+D7ADN
M-^5"!_?M7Z"KIL*C+PN-G&<O>XM2EKX.U;ZK7&DJN4J(2;\'<J0L1.]J-Q.N
M2:,GT=W5)0C?P^\12S#.$?*._\?/4>NE^=?(3Y=B.Y"JZL'AC(^RTH&R0^1*
MW=RVHYAG\LA'6<M47'9_!]SB/.9Q9\\E;,5 O%'3"'-Y !%PF&;&\>VS)->-
MWI*=[F74TG)J+QG3ZUMLFM+8$WK,+9IW\>,$ZZ\UZ7Z6N3$^)*GZ)X_!O$J
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M9J* [X#)GE#_^\JD-?:.T"L00_+U>D?I_KH@8(17*<T>4V*U4*8!^E:DCVH
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M];L$G\QO/1N8JYC+Y.?(OJ\[QGHDG3;NO:]#T[@#P!H'!3X)NH0LIG9ZM.H
M\#ATIU?NVU0X,@38A&TG@BF![1N8>! K>E*3#!F9/'H 0%M@DXZNIJR@?E-F
MXB? %G-^%<H_F/3]1M5OI'XQ)78H "J688?T#_$)^+2'5V<O\."L<.(\ *B
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M$K47U:=U6WR=COG$B>[=W)X2JQJB(?6+@)-=_#T_;'&,8SY.!(MR;'A^J#X
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M)@X"SW_/G+R(<6N;K7R%C=42(3@M9FY"I[LP8!;BAE),U;2B\>>TW#X+B,5
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M*%B.4I,/!Y\/2Z Y^W-.J]'=+#!_"12UK>FLN&% ?U0 NRNT=-._2];/H*R
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M5ZC.Y/0+HLN\+VAL(M3QO>I%K3?<7@3F&KZ__;'R]A+Y:F3F$B3&!2W=NE+
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MZ^07I%8;'.\\\Q$-)CY+CK5]+;(P6HZF6]#QD(!5S/76AA!=,/)>-XUZGRN
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MY1]1E1+69"IB=81X']*0)'9E+4M>Y%M4<8A>#"W&TL_Z?FG!BV#]PQOX0&O
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M2'&Q#Z9SI,GZ(DAN$+$A5(L#?X+S$-,F!1U\(&O+QTDW-#=FS?>D5]97MOI
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M\6]YBNG$L7MN(P#3K,QS!OT K+$G38-?KS6+G?I>3Y@>J'D^*^W:S?XH+2A
MQT=DQ.</^RL_M5)]V(VAC_DU%7A]_@N;-7JM:0R&-['8_S!R^1]MQN*;XUB
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MT=MK6\"LP!+18-=[B_F[)@Q?RBKW\W<-!*<?@9_:WP-6'$A^[ :QA%EXL2S
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M2ZR6>-9MJT$))Q4H] ;()C[W)I>[#G2#SW4\==DVO>!I;!+T5J\8]"?#?95
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M6>1+1[K>"2%K/;- MQ-[,;LX98RS'O,R[\:!9>/'QA8F1WK<(6#J8AF%0%Y
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M9CW[+,>*^_'1;H:225*ZL)4;1Y<5W,!*N?5X141[?D+DP6)]K%%%B)OVDKI
MW?L"^5^:)2M[7)JYCM3 Z@/Z$L_(8IP)'>OM9S?4^4VQ5\^^'Q(7O-,F>UO5
M2YU5K^S*T#XD#J'>?]3V%N_JULH=R^:&*Q@>8FKN=KE'<C<#>U_I^*Q\*KR_
MAF5JH,+$MG0.*I+49T,?N6&S]=U:5>/(/=\TY@B]7J-!V2?A?0N_!5O^]YBV
M^BE-3>%^CRWGW,OEKBQF!T[KY<72AI8EUW/'%@U'YX0@X#R_D9%Q;@9Z(N8J
M4;0Q+&.R[-HNSO[<I44UE#S;&Z.T<C6YG>8SEO=GCU1*V>%_-0BA1>!RX65>
MM$B54=GSFCDI6+'ALI!([=,0HXD"TACLK-BX9NH,7C_<J;189LG& @]\T7$A
M\",;"??6!EZNE#GU9C:WY;TU#'PA6B_P--,Q"9UE4H&9%^S,"INE$3%NQ^W!
M#XIBXJPU+0H7=RV#Q/PHP<B 8KJ0RDNRN3=:)=-;GAN6<<W1TZC>U@-EW*9P
M"& <F["3T//9 S;X"]E_0V8]PH52.)O?>7$M6,^^)JQRJX/,@<%^IAO>V!=;
M;T!\<04__# A%.XG6"PL*P =2N'7X"VR!<8_3 CB"1]B$N/ N+M\D 9@4C'4
MYT#B]M"MU/C3/:%V4Z?@]CP&8,:!4.VGP*JZ+.OTFG)E7=]'Q(P3DD*R%\WW
M& /93?A^;DS(H;753V 7=:  *FF^E<9 713_*TG#_V?&<7HLU>K2@.+])2-_
MWTN.](^)D/#@QT@T-T:V'R0>YL:X.W[@+!,^TF[YXL/0$DR&%-%\MB7GEPT6
M&!2P+UA?=Z8.*V0X>Y^(,>_#@(:=3\Z%D]!32N&\^,7S7:F!\"7,J46/0X!#
MKM3(8PE2.C=A]#'F2NW3X:SS*X5=8:F7HCN5=I?J?61>O."?@LG7%0(><;Y-
M&QW_I3YWMFH%/$4V;CX1!JROR?\,4@E?=_P2M+6)"O8Y(5V @Y\>2F/6IW 4
M(#?:-S,H')G(C99-C&[Z8]6^GP=;-K,. <'.:.JG&!WJT8Y:GN;)]9;-[ ;"
MX)51D/Z"3:PFP#, ^7RPC_M6$$?W*-1?XKC$^.]YI\>$I80!(GIBF:,Z_QM,
MG$E+Z?E#C)U;&N^_[RCZZ>(_KJ>2J/]7S.M?:CS_7QA-D>=R+RT+(XZFD<N.
M_9-M2!%QQ[2CHS=&_MA$1.P_'6R@7?5SH&FKGWXE'/.@01&5X\@Z]FR=GF0V
MSMY7?#;\58GJM GI$?\@TIMERLJLE. C,O8K..O1C&(&9+_M- S[2G6O,I"W
M.F/Z$'"&S#E:?882/YNT4^\OM>,:AJJOW>['BDG'I3RM"/3Z[&'EUFBW7G@7
MJNLU6^Q_6AG.CF#(\[LX.Q#-6K%=X%!:7>R.Y\9@?2:#)2_C+QQ(=BEV/5O9
ML 7V5F=8J'7%--Z+=UJB_WP)8?C05JMS[!$.DD$VJB@7E"N?@ZK,U5=.C9<)
M[D).YI(N+W9$LP8[5U)!RI4"R<5'MY\1H]9I/N/WI(?X^HYR^:!28O1H.P\X
MS+9LLX[+VD)NYHV99WKBO$%GOI%OS,YJZ#3)P?1;&D5QV(DB5OZ&Z6M="H+G
M'=F8YH)F)>'2YI'<;V>H9,"S+0)4Q]!X)D ;[: 9R-0@@7]_5M+[#I)WM^$Z
MJ>+C"DT@> 3<*+;J.WN+HM@EX0HTUI++@#@$I' \>>\7+AG,\P#NIMQK&'\'
M+FF^.7VEU?HL]:9$_.48X(O5P=("27X+JJ*N",<RG>G2NH_<Z\NM=NH'#*;Q
M&HD#TAA^OZDW%O_3OF4V6M[[D9]Y\7^VU2TBKTL=6"/4\?4?1QJ+T$;ASW*&
M1C_/]+<2A_Z6"?,YT0:QYE\,7"/7K+_NXYD<MPQ%/LL;DPU&/;?,;KV3?LUW
M"#B1IR0 C+Y%?K9>."+1_R-R1D=N_%Q@UW/!6+#H@@4$S#+]FN:1#9#BR&O4
M<^FTN).KZ^TOU=+ _8,6;-M10;J%0H\'Q:_X"<2Y"CPM,V_+SVV_E,\BU?-=
M"<S NK&/[BUVKV5Z@AZCQ&_6-E'FR7GBEZ;B[KX,,JWQDNA9]#3Y^J%W&"@,
M(U\0IWEFP?Z$8MR5B$W,!QE5,%/=9[!$8Q4ATNC^CMUZT9Y_P5Y)<V$#-O4K
M:6]IJJ9X;N?^>L%;])$N&CG%8#"JI_CFJ T++.M"'7</)A=L(KW<YB(@H5<%
M?T2@&,>TR%(F:,U*5 EDX"&,2>,0T"[36[Q:R^%&^R54LLQ0.=/_54(*E?2<
MR^ 0$(#>WL]Y] 'C5T,R&L/+]'Y8 W&TTEHNF(\8C7U/-7Z173S#2DI89-MY
M8SJDZN$%));/6;O.U>]2+Q@XWG8<H4QS'RM^S ]-_$H@M04V6Y)O5J H4*4Y
M:$(=QWT4\!,XQ7/'AJ$2=47#(M;/9E%^!YH_?'=6?U VKCHU]S[1S49>EKQ$
MI9P?5B*IT^\QO_3J\?D!(4_K:P>+;>:\<D.+66_Q=XG VT-DPW&:0N@U>^(%
M&"T4.79JL.C=*OSZ9#,7JX\#,.I!EV3$T)8X\>ATY=8 IO'$*$TEM!0^[8CF
M>1GD0]RJ0V6C@,KD);-1O$GQ]$[H1A'/C,R[12.\Y@#:UM*OZJ=,#=3 +XF!
M\@MU>A[OPV=&H";0G64%E$M*M-_QH$L\22U)54MOM:M@>E#J!Y7<]B_YG_*.
M@<^> D=HT1S6X]E-CX<.UI:LC-J=!0>R4[L3EO<$.S7(=AM9&US[#1N8,UA2
MVD<[FA]\A'Q=6W:_:[!RYFDN6Y5RUDF7+LB8FB9?:*'_05V4'2U!L_ JDKU%
M!.2Q.\C\?+I*93HR6RIQL'=0N/83.[I9\@;_=7%PF!FS%+]A+H]+NXDQIZ9;
MY&F5S&ZH6&:G2C?@&_N]9,;9&CW\B>6INQ5,C _#MDC+=UU LC:GB SX$Z8Q
MOZ(+ \RM+N5K"XC<?:-QBB$7'$&Y&.$$/#M-+ )UX?,5.U57*:4_0)>(]UX;
M@<ZEPE^6XD0LDU?5X*LY]L4_!H"O;$L64W'C < '?DHM$0\_\,B3<!_F]S(?
M)BR%M&*>(]BFM<H<=\!+,"T_EI8(N8N)U,\[9GD>O5]C#^S42Y9HO>&R(W%Y
M,"@V5WCY?$AK(>]N2*5UXH['JU=5;-Q9Z:]BKO?HC=/4'-T6Z0WH<]+?5CWF
MUQ3^G8(HYK1F78QU!:C\^6:RD@&@/U$A</$R31CR#YF*C+>2E(P,Z!,28@)^
MSPL\HBBB)\Z3.?J;%LS+I+^C;N>_[37#5M%9*F]%Q\ Z5&+(H]2VA0^Z^%&)
M32D(/D*^2_:9X7U\_/O<X&,Y5? 41L[GZB,<EJ3;<-<6%EOJ,<%UD]R$L24L
MII7S!> ?RZ^I7A$*#ID8P%- /:#.3O6F0 &/9ZGQTS"V>+!_.&#]-(NW4OL6
M!D&PGY7J$ZGATJ<B-"(*N@T^U=8SDKN=QKRX3;R\#A?1_?K1GZ-K"=I^G46Q
M=<POL0&8]%A-<*4X(!PTSI6#^>40\/S=@1Z0$%>7F\9R>]_%)KW <J*IPE.R
MC24<O3_@I4^4KWF6!-A^Y#\P=45Q#GAF]P4EOL<1&E/Q_-YVT:.6<)OQKE*
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MG9LYOU<4!AC$;H2<>)#IY;L#/[OR*1.25 &MRYE4IODXNXW0PB)#NNF*C2L
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M]<C]PCKN.O64M]"14^65W6;5 Y0\FC27#;-AHO,-( 6\[:Y6_O<RO.:=EB-
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MS5_R>+H#P@4FF 20P\?;$&U/?J46X\V_/)#;*OS(7[0VML[=U[LAL%8&NNV
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M K316.^CNI&-M^)S?=F!-A4I^A J=Z(P9-B7&GR2[U_X;'!&O4]YR<QYY@A
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M^?_X&O^_JAT!2(*+.= "9LOB8,].5K/#R#HYZ7T_!DDD-8L$KP[DI^!KM+Z
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M4+!H.!QVL<UI:8H[I>^I(;R]9D[ASGB+32RW'<?:.P',2;=C=]=$9.L7E]/
M;42D.R@DDMET(*!BR8P-_RI"QSVUR$TE$%[4O-"?$IFJ.C[I@__48QHU],7,
M 'T$"+EXOR"!:L&4&#USSDX7NK*'$D[KW]85&GI?U(-8'=D2'AF<T*LS?3+E
M% &2;(Q6$+O'*Z-.]%:U?BB2%#4T72;B/FVIOZ_M_XR+,O% :E]KQVNK./I
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M E?Y9P!44M:Q_]^F'W2FT?_XG<8-.L2JWGHE0@@2I__YP/3[Z9O?LTS/$'0
MUD)L-9@S4B:^U?.JPTF:'U(5B (QHY]NVI=DN[VE*+V6WRG;-AWA&V_RK(Y&
MQ>^87(9=N(88@,?.ME:&3D-7><2C3%3O@-@?[@-2[5=S$8WOXT'S75,0BWU
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M<2ZS.9JRL=N/"8+-WC<GKBV_G:\Q85[N,&FT9(EUI=]B;%8E#DG-\);;AP2
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M"_ZIOB&T4'>*>@>N(9_6\,!4MCAPY=US+5GN&^#G=_7<3NYP+%<!WSPZ\H!
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MKX]_+((, I;4+0G>.:\_)S<A'BA-<PE-T$**7[>1[)V^\K!9BD+B[VB^)\9
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M9V9H8FN R(ML8>+"2!T(^-'<E59VTT&ZZN2D;$=01,L8H>SVTVA3QJ:.@K%
M:/,64H.PG<X<5\5A&K#ZAK%W?*0F[F1 ^K2+5'J?? KJ1>F[C4,@J*'X2UY.
MA?FJPXWL\:CB-HV'T+%ZL/.%,L<\6:[02R,\9P05%B1"=NK23V="\XG/E9*;
M4C>A+-H>:(>MS]N]+*-:WTM&2\<XRF-/LHYM9(#M7&\S&%\)F6&:^7K"7=>?
M-->0^WW<#\WNG\>F-LN/$P=Q&C\@.BL,N<HA<&*>KNP(C"&WX&ME!1Q)]0W*
M%)J,IZ1Q69YC7O'(8>]XK'7ZQK4@T_^-)O#_9,;N@.^9OW91I/YE%PF)\]7X
MD]&:JR%6D\W8?TW5K.]?7&9AUVY (<=J69Q)4C"AL-C"5$*D)D,XZO@.Z(U5
M<HOBAA\'2D?MD\8?#!F_#9<YR#NEEO% \&,HZGV6O'R20&*57J8=3+8*1ED!
M46%J(\?G7P09]!*"I^J&L7%.YDT>N<4 _H5FUUCX([#XYT:B'H@6E@H1$7H"
MOFTQWV]F@N% 5KJP&!4EUH+$EAV9.!G90]]\=W=D^DXCT^PH=#R?^=6L;5>
M/O(^K9]""52^$_&ZV580RZ^-N5^<_CM<_$LMT4O]+JU!]Z02^,3[1%K:YYX]
M3.CEYOZ[/:NHDP';R@_W!3'!<?3V>@.*Y*+HJ;/U4<I6Y.+5?>33UXJT(_M:
M1Y3@I@7ET.,Y/5FL0[8@+G[Q'8%N@R:/B/WA[9C=+[\#6-! 38/VSZD)K,P
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M4#T^#H[63+N[??2I]QSRWWKF\.,21V#7DH(_C78T/*P"G[P0\V*3<0$BJOC
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MZ @/&E0 %3$XPVN3HG1I;CCC M,C Z<-KPT!:87CNH/7LX_FY4[JN@*7TSY
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M_+93I J.EDH=IJ_^&30"BJZW.3&R4CC#M9W-)DBXMTLR/[%;+,#>M2D2"LU
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MP[[;L7"]*\+LN)_GD)F=9 @N>DCSO*TNZ\4;1+1\(=GXL<]^_]YPH:+W4/M
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M&T'XO?K;&_.UO43KWLN!3"131@Y?;-V'1OONZX.PU:LWZD04T,@6%:5#H/A
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M?Z2XE[+_ CN]AQN"*V.HV&BU0)&=7%#I^F9CHO<%XP>.&'@U44_X=^734[4
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MSWX" ]>E!O4]C"$U<V+@\<P=FI._[@JV)R7!T@XQSM*=*LJCC<ZTH#5M;?8
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MG5DO%X,BQY9+N_X "<Q?+'AHO8&U*G7O9=?@-54R]C=?FAA4<" 7^YN? +H
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MU&,36S5L28GN7%P7T#Q*J&TG*#7DN.$=5KZ!=5:QA^;R'3'G7["D^3=W4_<
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M3?QGCHJ5D8*UL\=_^;I4N^.%$E]>PT#OS-5Q^ .K=B7S^A$\!UJ8'4KW6&:
MSU>58AKZ@\\>(,1;-Z(9*4'VP09[BLF=FH/><V:F6WU7P3Y@B=D"!+#E*$LG
MH\VL^RF:9XR@W;5M47_L9P<X"[8-_?Z;!94L;2#XH\[ 7ZU@\FT$Q8M6>-HJ
MDQV>#SR%&(V+*'VFGPWSVGFW9:'G2"D4"&+IQ/9G!(L*F.W++-C-1-NE0&\*
M'Q4<QM.O$C?M5S"NR$--1T%FA5&H>+&N"OQ<RR/'&QDM/ \M[(/M9R5T)/3>
MF_HR[[V7+U$ZXFS.EYW%V92,L3J*O?_.HI#S%/4&:M:3,8?M1([N<W2_/<5.
MOUUWER&^!_AQ9 \PKK!51ZT?[AK\#%P4!*P8L,U=FYS7N:H/P3717"GQ.\9=
MUZB.HGTU,E,M;PXT9Q^73$VHNP7BI3FHVDB+B8,6 7XA83BVQC*W>K;^/AR<
M&M\PW".='*NX"(K=MBIP]K(>45D0EISQC! Y?-LRZ;;J1AI/$IV'D.N3F'G[
MZ56O(5PZ#4GXE*<I*$<2'<*I#DN-W1V(4OZ.M:%I$LPM[0[,LL]OU8BZYUMY
M/.8\7^'NB9=.E7_](1Z;Y3-D>_7D]I.+U1;<! .4KJ?<D=U9-MXI1E+=2BM8
M(H;!?Y*9[JK%KQ0<9$A?9G8+L3)TJ:P]0,I[KN9J^-E^YBS -#76;;:.RX=V
M_[@@PZRIO*EI''VM; V,"K^"4NHYJ6JC^]V\3-'13IQ0 R8<J!J3?^'ZTU/-
M009SYT@2BMHMHN.1H*DAHI\=N*%._H7COZGV0U]U.%1BZ]D(J'0)R+7$?O?8
M9IKC($*$.0FSAIU"[0%^'P+W95&65:P=TJF.]!>70 -L%&SS#TVH;HLWG?R2
M<O@A[,+V,)*:]]AJ!/&Y LA6X7Y7EJP!M*?+Q+C7F"U6^7=68'EH]J=WU,R6
M!)\T5:1QFX40?,?L+_652_(V'5_Z@LP"P VHFS-Q 50@>SVXG'=WF6P[2:7Z
MMBKXQ;]\Q&YEL+D'P  007!N(9^?R'%&+'GP-W#?F&\RSTY=7RTB2(W8TOOF
MC:VJ14O=R0QNKXN!P<2YES>D R6)V'"3D(IXENX"EWM5NC?=;!-8KXP8_-S,
MPU(Z"89S"BGFA.QBR5 _.+]QE9L_8WDM[2C6D!+Q#!-GZ"JX\]T(<K/CF,\:
M5B-/I>' 5_BV(6=+JI"4^<1U#9'2U<^H2:HZ=#-_S@!]1591G3R3?(JAV<[8
M!01V[H#*M]7 -VRG_7Q'.Y C"OC4XF7Z\X8U_B6E/0"5I+3S)@C$M9M76)98
M&.@Z%5ZK8SI\= @<@)O?S9>;L49CX 99L]J&5(! EVV0^B1>O7-\O$;#0\VB
MJ!T_%IYO'6O?9$5C7H=%\[+%:=*+45Q<"%[CON*63:TX.Q[+.[L)>5X,J/_J
M SQE[5R..OWC^SH6@SL+/\<Q<7NE]KE%&_087&+T2/\7FPIYMK5G]:FA-Z?J
M/QOHKZ]KOUH_%^B4>88*3:CCKM'?V'Y_N8Z6O[S\*N!%;;_]!=(TXSW;W!IK
MB!!Y/PH3<@*P5'\O_SO-QK^+C 0#J4.Y$F^*E&*<($'74WEI'^Z/U76BFW&^
MM$BJW(]K;#+8@'F&N-^',6UQGJC2%9Y&SY-W%1J#KI/)&IW $W3#N+L?#AE
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M (]>71)=MIBU> &1^]0T_:['D7_K!J6\Y97.0(Q,A!(FL)O20KSE:G_B8W5
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M*>F+:&*>6H@3[DC5(-;LXZ%6;![B,!VL"#*1]Z-+IE$\OY<$OXO07,&Z4?8
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M,D2Q3YX*-3]%/V'#Z*X2D7?;4@E8&^IFX_= ;K32=9'2*<&N_ UR_8TN/4
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M@XBH"!'I1:*@2!$0I0A"@G(1 9$."DA45)J 2,>0H$@O4:J"$'J'B!(Z0;J
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M@:W:/5[@0Z)[-;B#Z3@QPJ05VT,QHE&TB)J8%8U8G\+@=[Q&;2/@\NM/ZPU
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M)"[E3E47K]?"4F^;P87,=@J9=!^Q?%AY6QOJ>PM1LYAM\*I.3S!=W*]1%GW
M<:=$NUA?M<S4&C35\SD%5(3(PM*Z\7W>N6SLS==G/QS; +,.PD\^MV &-[W]
M!F'[N$,_[5DG43-@0:'+TH.?*T*NWT\G9%WW#C.5Y?,GW;'WE678*4>?*EMC
MDDJ](]MUHZ&S<-$B^_6[4)% K6=1'RMGHQ>S-ZH:Q+D?D+B7WKMJ>R_*3IBN
M)N)GYATC^7$$(KC:GS\$%0$5(6# ;H(7V,+WT^--+K]]@1][I':[I^U5WK$S
M88R&0ZVB*425EX6OWG/FZ<#6(C\50D12W$_>:3EYWK/?EE][OMLW+#!AYV5S
MMZ:.@XR$KF@BX1MZ-3/"7$[Z"?BT:#N<UO)D*6I..<K/C)NOTXHO_8N6WRCI
MN.04I.=KOT1U<:_41^7%[)']9"AO?JTZ=1QW*NK@]U%ZCQ%/575<^?I.Q#LM
MI6-BP[[FO-Y.'1BG0BC(MF_G/Q=B_PE/NJN 6>3'R;:T]*>I3'YR]E^:K_N)
M)!-R]Y<KVG"H;(GJ!@:]R]5]YJ+R0]>Q:T%Z8@56'=;&PMR/4M]\9_LIUE&J
M^U.&O(WVGLXNX65 1T4Z [!6%TJ@[_@74A H&V(Y#">T%(Q>S<73AB[>-^=S
M7\;<N'?HC/6^MZJS0K0M"M O$?F15Y2@!Y=#9,#\A['\GY.<V.3S^G\A9_\/
MI>';OY=[U+T?]4H)E/3"RO+/N9N'--24]EE9"5D#YS2NIO]Y:<A_!+K28L<3
M]DU&:O)8#BC1"MT[MBS=,F?&H4$8.0;U<>J.$Z)M7(!P7^[\MN@'4^]N)X/Y
MT,<N  U8UVB.AS]47LB];3:WVIY?(T8G\*B.G?-2J*AL+;>I4?L;$<8[14%X
MY;6&*;5MX,"S(TQWP7%[%!;JT$QWRL1_4%[$2/1 F)/5M:C/Z@;_G!DV%GJV
M5ZQN*"78W7BO6WPL(4K:82<-(Q(/\\TW.0L6 E67[K<7$[#+-NEWJ;#A ^XE
M,,[3*H?6L=+M*16/#+B7JR(C\R;WNMW>.$9 Z]^TUG_77=C%+O[5X$77BCM%
M;1C55+(C73V%(=@U*(K#)8+J+5B,W5G7N^K9 CQ"T/?=P7:S.-*T>+H3,'51
M+8>4W>9AK\&$B,;T605)3GOC5;1O)?O)HL6JYZ%QT[3+\2/ZA?%L#B+!*.,O
M.'&WJ-X1Y3!F_G!O,T90_91O'?+Q0&]YVRA]O156Q:TV96K82R%\=-E;NS=%
MR'')Z!X!K!8^K\/+EU1<G)-&9$_@S'P0LV'R!?/$>+"Z7L%I7HDO?2MTT7)6
MDBP]1A$GO.XTE3MH,UMFSX1ZPS\_;SJ9^>5DR7/T3JI-A%[5TC;@U.U7M33V
M+6;C'H('0U[:$D;B35'K4SNK&$]5LWS;3,N[05)WOKT8LZ%$EH51=^CGP^4.
MCLQN ^K XL@^DK7*BT=I%6##]J89L<5M@-%9'NIMV//D<V!_;X&V4Q'-8VWZ
MJ85Z&\.G&[#,-#A;#WN?09"C^23;$-R)4(:M_9@YN(HYU+Z0UBXM-IC'[075
M+J?/,[EI>1@D>5%G;MZP_$:N2?]T%UA:C1\G1X#5EYS^:B@@#N7N)!K5^Y5V
M?MY;@?( )G&2;EFRY9$&FS%+Z .9W5@Z@=<QH^1[HV4A)KH/)(_%K(">RO-&
M]VF_$Y83P *> H2BFGE>!YD1]0T.-1W&,.'S>>?>4XZR%QXN''0P,9Y,WXIE
M!L98:3K6B=L 7-\H^*UQ$TU;LYF!1&CAH.W(2&]I!<B4TN['\ZY8F[ZUDD_*
MJ"3L#H>BS639!9;TV?=OZKEQ7TDA>.B\J#OXOAOF!8+?S463;U)5OQZ4"CQ&
M5HVP*=ORBK32JV^8J!/9<ENR6([1LZW'XD?\WTWW!<;NL$0Y$-;JT]E%7SWV
M:*?OYI,G^N06QHD<H%>&'29;]+ 8E$8(6)SH&>$C6T9Y3I\\!5F9C/*(&!8L
MGQ(K;M^'KMX&0 HQ;R$CHYAR"-?'F&MAL:$0X_4YO,63)O='+[<VC/)L^DL(
ME+#W1XN-@0JBZ.A=^9OE[]7IZ2O@ 6/;0. VT,^AR]_R&FT\19&#7T>WQ4M'
MK CDNC'%CHK&F>LTWGED23M4#KT/5W5+Q=G6XV))1H36?NE U1!/#Z-6Z*%/
M_>O71G$O"&VU0@7-=V^^/ZQH23MCSWB]?\8E, ![3=3^HW*'WQ3L@@G9Y 8G
M7?1*7G,-Y;QL'6*'&GKN^)-I*QNP1N6F>F:KC9F7L/4(\9M-%468>=4=$;G
M741^'$.0"(S%M<DH,@)PU!@]N#^$LN*!>;^ZC^J+N*T%1VG-7QXC9?<BZ/PV
M[\H=G:;]!F6B>J."X%2K7@L_Z#@+J+-@FJ8@6ZTPXM _;[7\#19-G%IAU'?>
MX+W6=E;UX;: F-A)L;]P8&1\DFV%6($"76[-;F!VQPQ3UKAB22/+K4.]T/_U
M.FF"1K4K[\GQCN*L2&G9A6:B,Q(LX&67#:,6-"NJ6<RI8W#]P=P7BR:S\]L
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M#:%$3H\<4!!<E=4)>^8X8X;)<*,1?%D4/=)9I""+9\M_<>7J':\+6TQ0"<T
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M24;T&59K\OI#7 Y*8 L2_>B;V.9]IA3I97J?<OW20$$>Z77L%R2[IJTS=[0
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MB2_QD$2&%4EAW"C:K1F_.7*MX;ZCV5#*0&IJ!I-DG4YW^KLEB&W!(2+R(%E
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M[T=K?WX]H+J<F7$B%+_Z0WUY7P/?,?:'C4MW*D!Z=PIS5-SHZS0:V;DN354
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M;:"#@9Q!)PBQ%/V8K[;N?N:*T>OAI\\-3LQ;6)%)>1$Q6_W6MF#G5Q=S.;P
M*.C6&RI^",P&=:^#&0)]!-?M59@Y[!Y-<0>4B,"$A6C][Q87_E4XA!:'_$\O
MF-X/JLDOL/C%D!1<[+:"$KG: 9?0DN[)2#E=O<3O&CF-,V:CZ( YD XUP1#/
M(A2X1Y1/,"9R#?5Z=US>'#)(Z!NKDQAJF:T-$7,\%/9\=;P)?'1X1)]WZE#]
MI^OD>V]F\W[#/L,NT!0I+=;6>@)?VNK]6S=:8_V4EC$NL_-7!29V0()*5]VM
M[7)9R.X7+-C?,>[U9TTE%L9P62;IE&;B,Q"^%^$+!E;G'_:W0R( ;5_1<UH!
M4!R=]2&N*,=PLX,@^V2,GZ@1*#V;R#8D9//X@$^NT\*N+/@KCO?_AV>]?7>W
M"D+4&WC<+N%&$P*@G6"N.B0.XQ8M/4;SJRF%B:0LZ[>,GB?.3>LPS.N(W"(F
M\IN^,SG)?@W>I?QUID8\37#-7?6+MYW)R[B<ICP*<PB]X[Y5H:<AB)(E@7?_
M,J*!QR!E(JZ4!^HBMEO3/M5AY3O]=T!-/U5-^'8C]4_MHS?.R4-+$M>"(_Q4
MFSW7C@=*XZ#;5E0SYBB:O:^\,?-NRJ!P7<N>6]1A$C$)G"(ML(V79#HK$RYL
M-,NB;>675[KSF2".Y(;0O+I:NY[DY%G890288-C.=K=YN+<VYS!-^EC7TV]+
ML_840O#!_/R/]T"DWE"1(RCDV00-A2MV]=(SL&@1#L& ]B=8Z55F[(7[ENN>
MSYAY*#L@K#SO;'D,:+//(*5D#:28F(XI &1+-)1$??.1S<(,:[*I.,P+0-IA
MF+#[%W,<$-=^=<)%3-WFF"_:YCR9D!]J6RTK]V<Y\)==\NR B-SZ_:&\2ZVT
MEH1\T#F)V4V@6+HHXL=P28CV/$P>,8-=L34XR6X2(-LB+;"8]PQD@N@JFO!;
MS',PRPZ48OJ&%JI9ROJ4G#[CH32]$BI:'R"<?0#^6#QYM4S?M@>',W8(N: =
M84DX_YI4']A)CF?^2:"R ,&$AL4E1RI^!,;<-8\(VHU_^4%6;;W5*$&W\7N5
MR=-M/#^_^C2U#=5Y$GWR[H299_>S;7:3.&(2-F]H(6>\I=U26YS5E7\U\"A+
MI,^99Z]]0;A;&DW)S.LH]F' 2"UZSZ"Q7S<ZX&9B$W_GNVV\VFI)=\0G&YOF
MX_<?H=RJ*#PO'H36^)LQ=V'. RI"XG>VI:/0 %2Y=%#ZN# 5BDM-CX_8$+ P
M_XGPZ5K6N524JY]%4R=_7Y?0+.)918437%['"6)_($79- S?T8HKR\MYW\N=
M8?"/D2KXXRMT_T&NCIYQR3V0E[Q]J]!";"LR1'-W1O3)53[C,-SD(@[4X3F_
M@233MV1;AOQJXK&*]@(D#H:,6:O?W00=L% ;0<!3MN:2WRK*!? E5RV(V/]J
M,%QZE!@ANJ"S:;<M/8(\2-Z6X3F2" JX+C M2A"&.YDF#_?6P8C.(==;[Y[6
M=!S"K/0KN9PJ3P8]T)*>ZHX_PPV7(]7+@[GGGF5IFYWT6H&BD0*X$QZG!%91
M9RE7I"7R!NEK_K F(5Z;J 2-&-"6XJ6!J-X;,P"\)4@!B$^Y)[0-[U?:D/M%
MVA[:G"&)4US%!7(YV <\A<SZ^;DRTU=13R&L@G'/DUYUH_W*DCW7LZXZYZ1C
MW@.RN279%Z5G=3JE@KC?6CE_6YBUUZ:($H ^6I,H5JMX<4&[V:LR$P(CK**.
M NV$1U8%IS3\S40)'TH+YT32E%<E&U''Y-)!-M4H/HI/ILQCWB]+=O@F>,/Y
MY5/9Q!#(#HA\_NW,K;8N1%GG-8*]*7D,0&?:KJ-N5+GWA.MP_D4KF S6:Y4M
M02G$'1!WGD_5"X[+]MV(S\]V,VR?KNKSZN','XH$5%0Z<@-ZG4U^$K][P=3N
MA_C\5E*R%Y.)QPANETWDR&I2+1.?T'E+5 \;VVU+,:6259LBDKAE.&;M9*,@
M/*U',\#25?D!2Q%(@1-9[Z=VHWHNI2R#ISZ#?,&,>6:\)8<Y7FNRR9%G6O!&
MI_,[$+LZZBU&OL2F@.G$_$SUPI7TU&_:,:%@4R3GP,_LO>V/W\AQD48'=C^
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M1[5A<F@PI'3'F17;F+2YK2U(TC7U>^MRB.N0#M7>,',RJN7J^AQGH-L.J%F
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M(WW%E.-K)35LD33]FF$!QHXY$:_KJ*&8X[;. RB"!S?\+A?F.]*$!F123HU
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MU_$"&MQT'GWZ,2/W\;FV*1WP:<!WXI.^0C)'L.'Z#N@ 3=WFQ)/6N !HJ34
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MM\R812D<EL>&OBH.892 FA*_;JE1F"'->H"6)K[Y61!H(TJ4S]A^4_7-Y9#
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MQ-<NAP"7_.'":8#4W)15S:(E>]?MCW6*XL-Z"6<-MT5##QGI2]3R,S^(K5\
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M!:'I4K+;H%(\19T(39]0Q@TFI223^@.CVNEQ*CU6/&-2LV#E.O@D+(W&X:W
M@AV"C!7P[MMM:A)B(E:.J<#C;Q B9V\_J<'Y\ I7AS'!Y-_]&EQJ=UH&?M>
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MJI 1I?!ZL1"3D(3<O5\!A@<K$4VX'8 WH32H7Y9.-]JZ/WR5KXF;,Q2YL1^
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M\^E\5#HSX)%WO6)*;,_$JI5:EGO41PP@-G@#K)V#/E)REQPEVQ&J$;/-3$)
M@0#GI'XY>CF V^2:YD&H.P0.^D,D@7P!:)RENV3DUN<('\8JC.N>0_&W&X@W
M+63:A=L6/M5EIGUT/:0X5E^Q"BU:]_+3:0SIGV)_K/YX,9:'\+!"W^Q)_D:
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M,.AUIXP#):_,8M0&'21HRCX)(B4 NV?E4!8T!*(]O*_P\X!_K&@H8/N6:5W
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MD!*&;-:SWN^O/0!@)+;-][)]#P#JENL%WG9Y93^,Z =J1I<A6?<W*T+]S8(
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MUMEN-,N&L.9?]1GV\ESX%+6$G^2;VP_:+0\6#3]2&<C2#J+>F\FRXETSX!C
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M!"0 ZE)TQZWLGEMB+H'-"#Q<)+<'745ZM%))R@!XA"?-?'PE<6OF#4Z4]/
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MC"]!,KG918BD6N\3H0< C=D#0$NG855(R6[)^LA._GH.PT_/!6_6'8::E /
MI$O!=S2_%[R*>A4ALN/V?'<+M;_#'EH]N1_2?0 (C4O]#J&DPQL/$QW4"OH
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M?%6!RZ_9SJH?4>.NB^Y]O6U:Z^.!:P3/?S/-,J"*$1M(KWQU*YUN:D#_=1S
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MI$/GS36L3!D:$50#U ;53=V>_4\7@=RH;, $4)AKI3&PT6] ('BX#%'^F.@
MGL_%CXU LRW,(\2\$-:*7H8=J5@]ND7I<>WEAFJA-*%K3H-&7+1#87?Q<,41
MV^TM%[WP&+P*%=W=H/ZPKZE)!\1/^C5W1W,">SP:K*/)P_A3=KZ7RW)1%M"3
MUNDCQHJ,/VXDAH"R_3+7$_,E\L GU19"6X>+6E.I-5V+G\ YX^.ZE94IR?A[
M[-2=F,:XJR5WH*JBI-Y7W'M#FY,6^38YNGK<[^H_P%Z;2%$%*MOFQN@Y6X7S
MAFV[E@NB5%=Y.^+/DCBB\E\Q:D) L"OI^6OE-AZ>DR&/X,S[,Y4M*(-$U!1?
M(K+F@T\W]1+Q0K)SM2L$<HI<Z:MCRZY3C+^>Z+/BY4N"/$?C%ICE57VL238O
MPVU98)KQEN7LF#T! 21&>9J=W._RU@4:3MV)R2*+LVU?7F3HASNC5Y \"_AX
MM;472C01L0HYKJ-#3/1#D[JPA>8W^.QM4*EXNF%V78:_B&I-]L6=:D;I="4(
MNS_;U3SES7L_Z%10G96\D3$WPY^O_A.*C>K&:<*D""1K.'9+>D7RA#IAY1E&
M<O7GX@Y<ET"N>&4.216B_<A.TF2WW,'?+E?4G4OE/<F\"F)%&$"P_@!6INP:
M18RVL4F-X+9(*EUI8IG2<M+2B,\]9H=1-ND#+HPB]\ /P*./KK)H/B[9]E.]
MB[<0[A8:(UCH)S.<B49K]72TVBZ0<#EUPL'-C]Z9M[S3B$.?^9&W_;%,(T<$
M6AKJH )'1UF1E"0.6Y>X)]6Z=!+1^S9J(S;,]_U\Q^V@I[4ER+>@SOC"6Y"Q
M7LGUO3K=?US&?OK;#3]TH^6OWW4P>N4(EELW8P(G&.[OMRS_C7?]GJ\[+[6T
M]9*NY62>Z-AI63?-E;_6+W[:#'5_2MQ0T[QWG=T[JE"4RR3%"W+ 7F1DU!L\
MNBS!!Y.[9MFNAD4T5F^K2-D4/-,>5,5ER/L">H&@\SQ<,66\H#2.C[IYWOH6
M5 *_ [)V"/[];DMSQ&^)P/T6I&\$?ZUO46@M<H!1#UC("C\>E$W2]Q]_"O%;
MTAX6V9P0>0O5[=GKOPHGMKSVICW *Y0306>HWJ?Y^4DSYQ_O^UN&FY<<1N%>
M@;\$\_K[@?/1+C+_%>?1M6JC)*X&8?"_NG6C\AD^RLZRK_-]CQ VOWN.QR0R
M8W^--KIL?"9X(RF/?:IW"Q+GKGV.'4QB(A(IHG4>_%]=FYAX- .,MZ!3+8 3
MK^+IVH4F*_"(NJ3>#!1POZ-'>A([T=ER9Q\KFH,HM,X?665 ,N_#OYC]7QU9
MQK5H7_@)5^+?KH([]1T30?MZS?=FM0T47)7O>CA-4K!##"1SNX7,93?:]1AW
MV[UX XRK@EHAS!2R'KI2+UPJ&0F69 4;;=[7#S0]LM9ZSE-P0N#6'IU@@[45
M/QB\16*]8]\V!EX0%K!E?*:G<]0HHFCN] P?4\'CN!NT=)IV3[Y]#PS.KRH$
M.R(E5%4/^%00Z6W3<=2;AG[N\R1#ZWU>K6?L;)Z7&;1()"2Z]]W==Z^S-N@1
MQ30:*ADJ2B.Y+8G")[5HU<2OD_+C(3AN$01&Z;G <\^3G,G8\:GP%8.<>2G>
MF&/@<<Q(WADY.59G\KK E8+ZZ0O%N;!Y+<%YVD0#*I781>S'%B,[\FVD/*W-
M.=*Z_^%2K2G?[_'9IGR$)/ZX1$DO"U%U0)>^6[MK9;C?+8A**1K(PE7X1W&Z
MHZY$+E !^:YMK)X.CHUBW(#-?MUFBXKEF5M0*[K&=$)#152BT5A_;;JDF"57
M^:0TTYXG#EMWM(=M\YO\#=WRS[2N#AD0>DQ&C%8C/YU;T.?WS=TVMJ<O;3_,
M!56[*UR.TH8>;6LI)Y[-=5OL3W\?CJ9D8^@$17D[JIU*C6QO+;N/S_SS+A>3
M6?E&:@9C'7XQ@CY3!/_5^_NO_*BMR9)6;.4??\M /#W56]!;@[EK1[]KI!^)
MF47?!]8):)A74A(Y OF>.^-(":AY$R![4HLM?#K'Y^J_.%%>8M0L>\6^@HTU
M+LW=,'K0CMZQ_[U>^SZ;'_IH-D4PGMY9[+$QL&N(_A^XE^;?)59>/K-;Q OQ
M-/N$'HXIV2>&FNRRKA<_S-Q>X4SYHCC-?[/BAJI27I+1QEF::SU/S^(61''V
M HC:QW]9%/Z308H:)216/&ZMI@?6#8:^=CNQ<>FP$AI+)IB<$A.^[^1;63X?
M*7>H-F07>9..G^Z(//TVZ0/579* "+S.EQ3]W"F+C4K[KZ3M<Z5=,];WDRQB
M6+CY3C^&">H\C/%'X=R,T?/%"=VZP!%GX>H>) M,X7A$RB ,0CH4)7D/#_)?
M/WEP'1K[VQ?" \A (3TGKO"[6!6!?_?W\!;459[G-_90?[0$AD'8\-QZ8&I&
MO]V,1G8YF*- AJBS6'#TIMH5ZS2H> >:A2/!7&MF/*VEE\M79R=_4=M5\%4N
M(_RFZ*48<"3MWX+JX)^)M=QDB)Q*'^0SQNVX,@="Z++8_I/"A$BK,O!HQ%7>
M5FR7]7'\N EWB$$!YUB$^[KNB*HL->3],O4[;\"1"F__57$K-I4>8=IY!89V
M(H^H\4=1Q.G1+B-1=(TI*VB;2#'%/"[=P454^S')G<M-V,U=5PWS&_ !=H/9
MO_R$+/)4>2@^K2%$/ESV$61A>\DQ. Y$X]/AD6;CS/C7F^)O Q5N@TS(GZ8L
MZB*5N\Q!>.3)FMD*&AGON$IH&,K>&PS_?5O\;QRD%.%<WUH67X\L#',)GB''
MR!*H)[/&XX4Q^>>#G+LO-$]?4Q\>$:[@)QJ4R2S'N'0C?FT=N8_*W7TE7ET>
MK5_]3F74I9Y1?DUM=MZ@%N=-K.(6%6*>+^Y*=1/%=:+BO96-T9V^1<'";HOV
MJ%=O#GP7<5 <0-W'O2"5?5Q>=H_8:1WKTT.;A]-2 [IMXR&STP\:NAIY8E*5
MJ=\BJP8>7,F#%RFV27(25W5M""I9+V/NG8BF"SZH(#W>-!!*Q1@VTJW]$0M3
M"=E8_K'"-E-7&+>&=G22#]N+C\&O<M4(N+H%L7U_^-V>WHP*130%\<&L/]=N
M<7MD<@(SYB$2T<%\1/VG-#*;E#W<Q4V9$19\?E,<:W<F'/7)S<,CJM+B@G_T
M2O[\GDS<VQB:T0H5I9!M&IN0R@_=U8^^].UOJVR<N//@:\X2QI[/5P>V%).]
MA6WCV"TC')''30-UJ^M'YBUHC/\6=/1 XPJ<K6/]E+PV?@/9DS*B0GGP_27Q
M47I80_KWZJMC+:'N!=N[!XW-S&3-Q>VL=_7U]3:)XR'VAA>C/Z@\<M[NF$WS
MBWN/&>E,LL289HXS\;"AQ?A;\'>;1F6=0HD72_CZ;-NVT^^*)ZK=-#2)2>)J
M2K7\7_!!]']KR,B 8AU0=77-H&4$3IR5LIU0D&=TV&X#?^%& N]]CW<2S[D_
M34QMX]S9EXEN1/\D[D2HI3S_<,7J^;1/P5?["@-9>D7AT]:[M.^?SXWM%U/)
M-8PH&)*,[>S8LM@>-XI.R>=6)HOSJ88CTXG.Q%28O>NS&:,,Q/ XT6LGE4W>
MCA2/N,%%^/E_P3KYHC=6,1=IA[V?>9+KM$O@JG;UT,#<\0:SMA*R:1 BNZ 7
M^B-W,MC?C=1M VSC@_4X\QLM2Q+QV"WH@-OJ%G3<YP?_')86:*HM58"6\TFA
M?EKM/G/1>M$D??5TX)AU@F (H:6;<V<V.56#? H'3*F<;7KF.Z:O6A^DQZ>%
M^P?>KL3%AJ/L9?DAT#[889^=1E\/7A7(]97^8%Z"T%G$$K+L5T(GS5ERAX,T
M12I>-@V>^%7IG9]/+9\'N?FP:_/)79+0=TS%6Q7,3>(;65V*3%$>'D:S?B<I
M7X>(5##])!=;724W^L!K.8SKU-2Z$NW42X3::&FTJ:OQ_N%U\<7,,^M7;1QW
MYA1<>QUO[NWC!W*'?^-+CQU=7'0[P$R+R"4T5"8[@QJ+.P7%*BM3T2\^(LKC
MJ3P41H$4N9(\<CQQ]K1[TB?4S&;7GT,G$!D[[9,\JQ=6'LW4!>C#2V#<LNDE
M7TYD*!UY&0_;VOY)6TXY\TG!(N2?,ZH]EZA<WH AO7D3S)T3DP?3BLF>%F+U
M3S_T8N5-T/QM)C/NY)[5*=.@1I)JF7QT>>5R72^P(DKR]$-Z)0EUS0'YP8P%
M7"S6IQRK99^@1.%O_.056O3%/%&SC$.2TZ.+HM3WR/5-$1EC/AG&#3[--">]
MD9C5*YI _,8!FHM3SZ]X9R ;^6Q*.=T"4G01^=[Y'-O3KMR27$\&T7)=8H.'
MO7])^*=*6[@&:T\CD]K,Z7))31^I'OJK,%;FH9>P;V#0RVO.9XF1[Y^?XQCJ
M94UTQ@\!HDG+MD@'=W0R"F7S)B1%8FB6ZQ1_2CE7?9)ICGOS+"%^G54Q$OAM
M ;@.3EF0^&Y&,K>7YN,;!8BV9UH<[-U0"D"*>?.L&B!%-)5!]-6(6?3#6;]@
M?AVC2)ODS/!A"*V+19;L&ME P.E]K$QB'!4ASTPD&?[*QJ%T55W]0</$6_X'
M=W 1NTA_7"PUT"^&TV^E#=L%Z1B*H6.SS ?/LK&IGQ;'&DCU$#5\M&>&)5S"
MX6AHY-+UYH1E:G($@H$0#6WPJ"@N??.T)VV>!H-$XG!^_NX%?C>\BJ9$/2@Z
M-S)5^AF@[!&FM*3NQ .TY1M8%\)57H)*6:#]$YLNJO>P)4^ D[3DL[-TK04$
MRI)ICM2D/A:_W^5X(.1/T1-62<+H^>RYH5[GHQO4MXCGQ/Q&+^"YZWQA4"^Y
M&*FH^&,DIB/F?91L.,,.4C+VUV(;@>W4:&-GH7=?+2"/-^^^1;'C(SPM1N!N
MM%>HJQG=<<60XJ#&^6;NS]O1ZM]X@%"<B$O+US/CPN^(MW!7ZIK;5R\U5U)=
M(!OR$F>FY6%=R%WJ #W47)04GDQS>\HHFV\>TQ'! ."88CL=-X%?X0:2K_JM
M-/=R@YV4>(,_1=?@+UKOWVAI][B<FEI^IG_%9&1<0R!_"3/,B0-O"11SEOAD
MY"5TFOHT?I^?"/T )'.E^(<C "%V"[0-U6%=75IO[TC#G@&\Y:]3#V:?4#TR
M%+U+$?D?*3^8H?Y.6?^3TO@M.4 9EAEO ,]]+@TPX$P+C3]6R!O@4%_VE,_J
MM7WG0.Q"D2[Y&]1RAGY/^X=L7=B41'\EU3:7^ ^DI:K"RPV2(>I"_F9>$3])
MU94][1\8Q\%Y,[EJ?P4-3]=6O&<\+_4 +1PSSQ/4=4R45XGQS:7*JB\;*ZN,
MQ30FQ4GXBS XK^J>+$%>L7/KY%>>&+R.["*];TP3E)R/;5LZ0+VVBGD3>EN'
MNY31'M/U2XA4(QIRR9DL:L9J'-'L<&>DF]N7]S4$"L.<=M]BM8ZHPH/Q:X*Q
M29076Q6H+WA_P*Z1 ,+FW:'URM^./ .>:@XA0(A;(XK/0=/"TM _79QN;G>_
MUQ/)N$.] 2#-' VKQ(#3=E'=XPA>0G0X)J_XJS=^BC7N4/F=EH3152KQ8)8-
M1F<(A[ IS?C;]I?/FQ#-&S;4ZR@&Q(#8 #'_<>8/P761[]$C <'6<#&(V/:Z
M-",OTYYY IM3BTA\"$3H[37X>^V$;\S'0M7Q^T5!=+V4"*'54)S?9M9B,3.Y
M_%'(9_\FERZ:>;F.^@]::QZ5CEAY3[LPRAY.&9#Q]A^ :^V)-JIXZNY_V+"W
M9W1&J$Y /B=:'S&I.+JVETE0#-%VI4LDM<5F2F.G&A-:J3CA6'I>/6^YG=FW
MX-/0:\U0 91!]JS86;T,&8Z((1#)FO<@O(:!J>&PG'[-C+XJ*<W]90. HBVV
MV],NION4* O$.W":H2C50Q>K Q16_J>P"G^4"_*C/XP 1*M2EQF* L1D/XGS
M,^/Y,W4>N[K82=!WB41B<><-*XL=Q_@L0A$51TR'=UW#&;V[V:N(GB#4KA]=
MV>B45VQO1C%^?T5&$4*]9YCFNF RE@.^!55AS<YQ^J[T;1WP=8A@JA&MSR^9
MN634"F+C@7G<='WB@G.RA6NJHD0U\9TQI5^SOJM/]DX<#&W'3R NUY:T]>HI
M^X U$,H6!NK6/Z;0-YWUYUDK9NV,AF9.^)GYV9EBK?B99S&O1\Y:KD,&]N2M
M%=/9?_A5W RN\EZ]CF=_PM=YT<0N2@+U?)D09C'<P6* 4:379)*9WYFM%MZ6
M2'W1NO[ NBHZ+W>V2D?,\4R+C2O)0&1QIK+-T%39/;?O4)8Z..Q\#&29$?5%
M VW+Q<?&L+1T ,K,7+'-<#6MG'>']QL?+7N'[Z'9IX_19'F(32/'!B)293:]
M<@<D\N9\' H+4CX,\B27BDI]@O4D'XJ9EXAD35[TM&XPHK8G)&)EX;M/II09
MZ4NRRY,XAH"?4!&J*'%&K6;3!AR%#E4D)7R8HCY-4':E:2Q$Q*NUG]?W,GTW
MO>(OX,7X[<EH9=ZVZ[:5A__.L*M%=9#R>!*Y\(90%8PF2@EM739O,W&Z3G&T
MGKSNQ"FGJ$H^=TNQ(-5*,91*L&N5?U>4/)EE>W(?BM1EAX<42>[[(FN>5/W'
M2F+*\KEWHY9RPR73V.0TL9/2?9Y'"H6F3W-=-1H:]Y&3R1G,]LF&L9!AWC[[
MZ1QV*NUF?.>A?(3M("\7WO@Q@H<MF%T'4V_+,E)58MYB+SP?(UA(ZGK8;D@7
M"\X(RXJ?^-R'JJTU6L\F!@I$$T9+0_[YCLP<,UO;[$$@O57:/>$F_#/N: &&
M%^POA-;9<D>PIGWQ!JPNF$."3$^$>1 Q2<*W67J[-[NI1X-Q$7HW$E>RP8N]
MM(I1W?A?UR?,:MV7/SQZ49"YWLT=APIQ=:\/4HNQ;2XMYL8?'@+E]AI]R'OG
MYN#T;9@,RZ4N/N8Z/7]=*]51^;/<D.U4RN7[8N&Z4:ZGF/'"2L*3,;:/23J:
M(/T])*_;W@5>C^#($*;=2SPXF5*NB-W8,0M!ZS"4YL/0MPQ\60'5M=72NM_J
M!-/X"-T1[>]!:T&I@]JKA<H.63:D\&:9[OAYI 8VS+7<T%95C!9_' 2-L!)^
MEA:I9XX2/YK:'4UT4MIO3FE^KCT4,3\"=:_<]H9NKW@QG+E+Z]V"JEE20'5S
M*Y[UGC.;,D+\F>' %)8 @FOS]T.WP_K12KK"D_(;"V=O!K^>)AB3A[,4P2W(
MCMB%POHW'NDKJD21J9N9ZQ34R>KS5+M9=Z_1;%QOG5L0YV7KQ/,;C5,BO[TH
MH.^VOW0_^9--;&\GROYFVF7MZ8\_-&5.]I]_FB7O^7104K/<(#\_Q:S4L:A'
M(N]Q_'A1XWUTPY=5U$W]IJ3,.9N+\41;8D'\P%M07VTM:WQ/P&7EE5^*5U#Q
MD7DW$6&7$*1OF$N;*]_2PXXEBY.L[TF"!_/TM4U&*HMJ4+C7$?_& A4#1!8\
M8N/A+.T-V,N3@O"["^1NR :7FB^=P0,DT,NKH8:=8Z@ XZ>?P%Q^^8#YBC]3
MUM?^DY+_#,&L.6/?KB[UWDHD\WZCCP!*+6M#CU;*;&6^)/FHW_>;O1/U6U"<
M3X=^*NG@<A/O$'B >]#A!FSH[C5(&\KE61*YE>B"Y:3/_[Y$L-%&#2)<= OZ
M>+VPE7\+8KB,J'W%GZGXRMYL.,TFMN5[-H#M61/I8&X3;]GZ@'#WBQ7QAAVR
MS7\P19,E7#Z>TJB+;F/C;^:<YJH?B=W0.O5FWQVJ%\'PL.@]$B2!/E>*/,:T
M.Z36KR$Z=]Z-T.BUT'[>-BDO"^;*8'^RCC]=8]"*$8L*=7$=,WI(BY;MZB=B
MT%S<28;)I+XTD]+0R'M3_]$9\%M-(V\Y& ZD0[QAR3W##VMMC#?GP%8 M9:)
ML$LK5MIK)*/V%[95R[+<J\(=CE7 3:Y>]K3#:;'SGTVI6*FC0L*C@8<"K9P#
M'X&[+!@H'!R',0-_31X_<Y\.@\Y0+N_"8<^G*4@)2"%PDB$XUYA[R %,*5 ^
M4(*(R)/:!2I'=U)N!+Z>7__%U!_*95/?ZNZ8*T;30OD13E'LUV&(IS?Q4*NL
MHCI^ ]1AE3VO4._87[-MD*WV(U?/AV5Y@OI5NDIIN@5UQ#UD X8?5%S#!X^A
MZ$Y!BI[)EB%7'!>5/YK*B\:GLL#6,2UH@N&PS.I&UP1#TL%=N]Z9OA2D:J1
M,_/5J/<>CM_.?+L(ER-C::1T[A?>0<%&J60HU,I;.:ZL&$CDHB^PD9\S4*@O
M 6RHMMA850K4Z>/8:M@?"@=F3O\V4TE7%*<#S;HYU))+FF7<X61I$,R<G;DN
M@%.<G4]XPK)IYD)=O#=+*@W  _(B%(*L0G!':%A4O;ML&<HYA5Q&U#<#:L:,
MP'7#:?%V*">&'NN2<X!K-C]5S  L/*#9;_UDC&H0/+B:/9?\QL4F&,-IJQ=/
M)G_JKE(@6"Z8Y5L?JAQL2P@AFQ>R,PJV>Q(X(#782F7V(M!!61_3I42RR!N+
MXV)*M[ZII@&BO0,BUVVO*)ZK[_-AU-6&O(V(C:M@+PS-Y9>L,5*3!["<GHI8
MP;&\1&A,2+[WWN#,6;JYYG"G8NU) H([QV' GS9;_K298Q<H27/3=W>.UIZ\
M!]5_]/RR+N^Y,$-^XR@\FH)4%HQ.!(@)K%A+UTB<5"!CL#N%C'5]J]];B?;C
M2]T$W"0>C D8(":Y"AA]_GK,R^6A#"Z=A:&# /I(1K"F#9C-);]^EM&(BN6P
M-9'[ZJL-5."NF<8OH>'] -Q#IFHO%YRN@ON<K)3W BOIX'J4=U'EDAH7*P]^
M@>LIFUD?D'^<)_J]P5\ G06H#D8]94! Y#;2$3F.5 <TLW$9RO5D@[(59_=U
MSXG<?4D'2Y9T6"K6:%Q4(#I>=&MT#7"\CV5=<\48'R.I?1N4%M-]KU+0:TM[
M^@<34$!VEV19C@ FT5],<"-]UTYU77#**"69&G%=\/(ET8M&A_P\!-1G=O%*
M8A+<%WK)KP>+ 456 U+9"1E1@>'P"&R3P,&9BKZ!B_E+['_Z@6.WM4[X4FI,
M]Q7.AP&IX(2=O#7&A/V5N-SHK;!B6_$):8%V1P[6[S&P@-16[ID?WDNQ\O2Q
M="8?>^:EZ<])QG\,EO I"FZO6.J^ID6)U3TGUTD#"SQ)+UE7G9B2=/ED\7:.
ME2FLO\<GL9%\MS51^#3N)$7@[JNL!YVUOAM1_AI^&.O.8&+MJIK*RA!)$:^Y
ML^M^O%K=14><.&771J'O>^-6'9\:XINDS.%IO\NX#: \EZ&*=KK^00;*@",'
M!$+_%/BU8JW8' @R9_I0SJX']%4$?-.=9CQPSA6C"T9RW#&JR_R<L0G@V/A:
M+>""\T9%FM#\LD 02(W$0NZ*#P+JL_M&C@FN@!N/C?4 H,_HESN(?#<NT/5*
M[JV=%J)/KP_(/5*,"3&J:_HS!>T]2FJ^U0'!\7H+!:I"./K+"([K'T>X^D"J
M-\BH 35+,H#GV4\Q/U-PF^W7MF-9!8 L.70")>NQ:-)CS&9''V2"IT#8J0(%
M(P7NXB!/W#>_#/\]8,#VOND!MO<GP"#'5K*.%*2P.UMO.*[; 47 &5T/0<L=
M3HNA-(AA9)TF#X0?K;T^.??B>$^TILVG@>I=%X)F"=1A/@(S.:W7Y($_Z[!#
M"^:%"X[TG:TP'0\QN**?Y1M(P>NX4R)W<N"I8B'P?W1SG4%19TG\3S80E"R2
MA($E"DB0*&$%"4I4ABCK@B", PJ,9(=P"RX@#"!114# T6% 8!)!@F05!A@&
M=,A!8,B"A %D%NOJJFYWJ;JZO=N]W?O0'_I5O5]5O^[7H5Z_/O%Y%I3$,LB=
M/LZ65S"Y?V?ZE+\]]YBIC7'Q1_.5F*^V_L_.NRU[BVB6<.G5V3/>L1'*E$.G
M5C,E/C1Y/<N?64/5":VTQ!9%(.?..LD97M.1P>*SE0V8,MIN#CB6>F\Z%>?V
M9PS(^HK%>2;?O7!5"[6B@&)4Z"J3$5.5:?B&ZJHDH/1]06Y=R4<'TQTO:<RH
MAQ=Q7TUS(X?VHTMP'LOW1K7BGWFM]I>F1XZ&8&9%91@<$&6'N%SLB_C>+GKM
MOIO[1V3>VQ<+FH=_:!DU'GF<FV^<83Y>>E]YMZ$L&$H@%SMP#U%V.)> -I?=
M^2H7UW4K&GC(TVK? TWW'_7&;(D*,AP_=95'[S88"E5<@*92^J7B>04OVT3*
M^<BY3)$?RAK)#BL:E2O5BHUW6MD*W=](N*[W7IQ6=@PT61P!%QHL*'SZX!-7
MK#J'L[49U!<M$>?S0\BI<[!RD8GKDF7Y$UFZ\L_AKRWX:'7X8VU*V3,@X],@
M%SC*G[/?S5_5%?;WCY*N"XJ@.HN!*"&JI(I"87BC%2A"L\3"#]BR[=W0&8S@
M[-7)*ESC-K9+OSFC!WE:$*F\''YR?-B$)7;-%)>CECY]Y;O@H)W.=?4 T^[/
MG8QD="!*!BWN>=I6I='/J;L@4@LJV2@$2RH*08XX.[M>?1LFU6<G2#-HBUJZ
M@+[NMGN.T(?M..V[=-,#'U9$6-OK3$"\,#P^)4)H;UWP;0GJLV;A>4IM[3_I
M[B60PEQP(\WOR%BJ8-A4FIET0O$;/$KJ@8)2^48>^(LO*^OR5;DOO Q$GW.L
M*ZWHX(&@;<623?9\IPMVJ4##,M6YYSS"*.5\OKOQD1?:@/:1B%]_&?UA\NA1
MM$736?L-2!T\G:S_*N81.'/K3M>.72V^ HN'K?HE5@K\C4% $H0?WX0,0A K
MYI9^NM^>(KP3HU1&\3<V>03D8F\_X$^]/[I>[S^ _9@)*L',/KF:G#_08\S'
M_'L\]?Q/R-]ZJ]<,IKE67#&[.J*>"*[[;LB3.?'!0F$T0R<,VV0X'G'-3YSD
MH3'ZOI_R8Q_WK9E.OZR7R;[*RIT#>BP S*D5S9I0W!&BZ7DT$OG*,=G012DZ
MW,ZWNBO_F=518\6/G]/89Z;NM+4;;L-*:UI"U:JGXZ1*V)G?-':K-'ROXX5W
M&@ODBMNTG0/<J-.4]^:K%Q=EE:0M[T0+Y@Y[:^)?:'M;IA;W56_OHDD!_3=*
MW??XZ$"<_DROW^Z13#H0__07?'& B![?._CK^I69W>U+="#*E@Y\NOQ+GH'4
MX]*V*T\'..'$PM$M/B4ZP'?A%[S!'P[DVM9T7W8=HI7O:-NEAK Z7)UYAIN5
MM%D30"./;H'WA.G $[/Z%3FW/;FOU7@6'?@!/DZD?7Y(!QB+Z, $\E<+3,\*
MJI)_OC/Y3P?TE+ 5EJ>'07'4=LB?.C0]YY9>WKC3QT#N<;GS>&7>).82+GY#
MRZO:E'S]@:O%&DY+/Q3]UU#G;P&Z8LX5)V0[MQGPIN)56IM0(QNEZ-U-5<*7
MI=V[EQDH-O\G4AX(=/79RJ0Y(9KOI2-TRG$R1'#88LWDI$)]&&&BE [\)23X
M[QU%^LJD&;YB=9TE8P*N,OA.P/9+;S-R9SB6;1P,'W?;"MB+D*8##<_A6R\
MZNR_](EYG+GQT_H_WZ?_IX*YFSTNH^9VK&@I9YDC&W>C.*HX:.1CE#WM1V'@
MPJ3!URDL_U9(XX4]-E.#\J_9!IY1Q"A*-Y)?:MMKQ*#G5GWHP(></@V46G_T
M!BMV.+)P[*D7 10P@EMWU59T-JLA[>=4 3PF+:&)207EGY6XYOA#L_M@D*W2
M)4F<LZ9N5KQ<*Z>9UC<*IB<66X# !P?UDPQ 4RH7/2F'*:^L7CZS,1 V#R;9
M")F4P<YE(%P'1XH>8RL[4BT6*2Y);",=C-A=?92/@  E-ATE53]8DGC3 \=\
M04*S75S44%"<#"D[A"675AZO_2"U3G%ME"@.SS2H\==9K4]!Y7 F!+G#]O/E
M(!L7'X$BIBQW62$)=CDD*'<J->(&D_]!'595BG#7 4Q8)6P#<KQ8L=D:9#E%
M]'>)-'>/- EFTVHLQ1%V1CDAI"W,/..:9:[@2QQBZ/7,PMM=XUOO3\-K0P/S
M#J6UY.376_3CL7M-:3;:_I'.7<,$9!KI9*P*U17M?WAL'MMG*XDT"7183LK+
MV ,OA[];HCAKOA=,(^FAR@YL^V)_=7?>%DO:I*8,9@>%KP[Q5/ "J5.<SH+[
MA6;YI]ARM",U8]M#0V)[C>AWSJB51_@2/MAF+;PYD:E]NAKM2;2IQB52@^:]
M WBCVK)%MZ9$R&TN8KZ01PF-U>F9Z4A'GSOS)322A6HM6P?\[,D',EH E#E@
MH,P)F W70>&J\@=':R5.N/E;"&H=F6MQ8*(B(+:5@2*G O7X1ZT<G=P%I3Y>
MBUYJKA2^TR&-01[0D^31H[#2P3,#>6X7$Q.MTA^I2=T-[)EW*O3VJK]87IX*
M(Q!5V^_'7J$#'J*J\V UD0!P)OB2CE,LV8. $7BI7KH@-\5J0K0]H[7LV+VK
M^A)7I\BQOOD^Z8D4 I]Z)R(_V2:WB=2/55/B\N$/S>I3W[?$F=@^QT&:"B^C
MLK]CA:7#F!>>EZ&WYX"I*6"!"2*?*U5[B)]_4R/C=L0CHGH+N3852<-%K08N
MF:E3P/IEWD+DW2ZU12?Y,,@]=IXF7='OK.'WM<0T.)7]99@DK3_YHI@'-NT1
MCF^+O4VD:D XVEO H2T) &*(3HOI,<AKW8GQ$\]6I%X7XOBU4XT+APME@WA:
MJHTD@?#[CS@:#;3$S!>O&"%M&I@8(_D/TKX;'Z2I*8>].K;/BS.E%01%564Q
M$+8#7,AEB>O."4J5S6H[#VEE]KV'$=HF9XH2=*%KI=U<8BVM\L\_B=ZK$^\9
M:7\[U2XB'>]:@S--/&'&AFRG.BB.+5J&2)-/J^O %RMO\_:8"3,;%:C+\9;Z
M&S)/S>CN6+,.Q*Y#T):4)?FM"8M!^0S<DS==;9+,9V8>'3-L@=KKQV&\ Q.<
M8V"W\ +X &Q+<WS-Y:J&UTD- -NX\V^=-O6?$_CLA#[_8S;;"M)8KQ)6IP83
MPJWC6G7EHL?CYM!XJGS4I[LHUIC)8:;+M?%4-'?_M$986% F1"2+649S]@93
MWLIR/+368,#ZI//#HSM&+"V/*=!499,KA+'G"\8WI88QY;24H?/4&M^/MTPB
M5.>O.B-=AB!VP0G-W3<&B,4=[AR)*NUE[)F 6=54 ^WUZ;N%GI4E:B%8"^)Q
M)\IYA*'&0XX6%(72P<P:/(2P/@M:8="U9JOHN,ULO@CJR;OHI]  )5[<MB.G
M=VLK7Y<4CT$8!\^_IHS&HG<MPO'\Q.>C7Y#3[X>^Y9:[:9RC[ ^.:9\U51\*
MUPNQBA,!D7J[U @((W?.\G?979_!M'0K72%@;O9W'43WQY)<<=$UT>?/.J\K
M5!H+O\7F'#YR3N\>U7XV[Q 4>JT"$]\_HB*LG'?>L!M09KGTQYL> _W#3U!+
M P04    "  <A'U6)ACFE\)>  "5:   $@   &EM9S(R,C,T,S(W.%\V+FIP
M9^R[951<0;LFV@02/ 0-+@$"P=V=X,'=@SN-NR00(#3N[BZ-!!IIW-W=W=V=
MGGS?G7/FFUFSYLR<^^O>-=7K66N_M6O56T_M7:_LJH;-P]8!'V0E920!<&\
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M#?JOFN&F<]22)I!/Y9'&5UA636N*#5QTO*(3^!/X/TYGG:>/P0 B'FUG>S"
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M[VO/3[20>_DO-3$A7_I:3$<VZ^P93_*!;IV@/"9PF;Y#P2?$ISR:*X[:+Y)
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MO2P)4U7^5<G1YPH5YSCA_ [W&RQ+FR_GCD*;^_.M6E,X[HAN<1'![W$.)VC
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M9-OC4HKN$44)MEB=@33"8XR(-^=,*AB\O[X^1+:^4%28ES?6J2^)4;BAG;6
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ME.E]2M# <AF9:FFC^J5ZQJ<D/@9T=X(/D6(F:<U939+6(Z>]S$0^/DH3JOT
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M&)O,;M:LYN8%[1=+-V=U27TOONL\V#NZ'RA867_50?/=M^JR446=\5P193;
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MKAYLW>G-QD21IZ( >[\D&HNR@)(&(CUZDD$F\WS)HJBW&_.2Y3QZ -LBC*)
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MY%U>[(=4*B)5 N2"_;43#V0O3_BI]B57(NBM<_A!!LI?5:$JEL/&[<IQ5F2
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M(1$@)!(:2([)2YJ$4DL6N''"7;$N<7.W**88=SHIJ^:-8T*"F[^]R6#JM1+
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M5EJGJ4\?7<??QK7_#H?W[WAVC]NC>V!.[L:3\*?RA4/L7N L;C*3B-83OC,
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MH@<;L:DVIV>RVSZ-6SCD7I"DGB:2!B&A-%:$NPF&: DJ%66,!FOJS62B<?=
M,C\KJZL5.97F)B.SB_:F5Y!>^6F5UZ1OB=[]DX)[N).#JO*:5)5HV,A^4]M
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M32<FN'D+]3)S[^$OQWAA(,O^')&!+%\\S+?3RAQ,\6R,6VR%M\M":PT'+],
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M'R!L8A0_FW&,P1_*YN\;-MQ%92WXG2Q_/;=)N*;&SAFR>@"JLA;E!-#0<$8
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M;N\.]8:!27W/V%MNDIRZ4H:WJ[16RLM-0).-O@SYT)P3\_DPIGSLE^F*ZQL
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M_5TEM$=N!E*<!39,^4\T/7 E<4^3VK1:I492%P'XCV22\ZL9 <MI<H:*B@X
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M@E6%.G#:S7.4E,(M)[!7R7^ODP6]#9ADF^;0'./$XR4$?CE1[O-)F([2[6K
MC)0-[]?!HZ_;K\<WOU^]X6[;,-LR;L]"!2S[^P!;/'=(LA\;WHSD03XUM/7+
M/,NXO3*M>_,P9FX,]DBRKTBY:!Y&1S?G2N3H,"FG!C[$YRF\E&5'VX3>>(-:
MYTO.9/#TZ&C*UC/&8<O./_%R@79=D!S^UG_N(#R]^8,0#SYMZ9BO!.,X3U=M
MYQ#^FEJ-6EN[>Q-7#J&UJZZ D%VRS(N1/M/D3>M/G=UCM[$GJ((G=95NKGDD
M;S^_HW8+W1/])O>Y539/D4IBEN##&WQX\%57^_CPAG=T8[1Y?$E3IA4PM>TD
MEF;)@R>/]O>3[OSA-.$'V&]RRP?/7-=74\F"65$[QT"C[M!IY?!5R0=LW#K@
MWI,L.C[]2ZH<G^\X>9V'S#\T+5K9HZW$':-_>V-NX <?'F*F(0[AG$D(9]=,
M[=&YW:&V(5&P;Q)T$0DZ&WZ^DPCB@PQNL5P_@M=$M!#<<KE7^Q8@\J5M0EQ#
M$$9_]0*8"EIR.2S+BZ3UHBEWUS42U10#*"KNZ<<^/?IGXA-,@)#2"1# 2_ !
M*? I]QHFPVP]X2]^Z6N88CR1@]>0.EF"V]/ $0%I*NE>#T)E72$58:Z,VW-B
MAC,.0JMWRZ6^0\K@1K/I?T<654[G>\'*V7/X3M%\EOY_1 ?LYO&XX=L6')"T
M(Q%81^+XMY*]\K,6QO'$]N%=F RPQ@FJ<5LMUI,2V0(R6Z64:SOJ.Y*Y3C+%
MVD(W\74F'I7/HOOP>3-1#T,H(B8Q/X1#N/:)(ABT+]C-M@(3\42QO1^-6?4Q
ML=DE<U$HQ42UK$1;A3C9B(1!<EN.R*(2RKR8D,7[4XQ:!+;P C5J6FVLLZ#'
ML;;R7($,#64[ODPO\W-APC>N]SL="T\;X7_J4>I9OHL8"*NACW/>Y3Y#QKDI
MYP$,U.\3;9UK#GN5-Q=2L%ZRO+!H,R HH&_=>V-^V  E+ X,EVLWC70Q^!QE
MQ]#Q\ZK/CY3Y*@*2_<B+;#S_;A_9'?+R]T\SGV2'K^:X-O[B^@/43HZ"$D5+
MK*74E_W65ID!0@HAQI+*EY5-953'.RIOOXGZ^G(?AI,K@UIZMQ3RZ)7]N#8\
M@[I8E4K &^G[M'D1%54A6TH&4;P2]6N"4,]KD83)ZPK!\)<<ZQ4&YH;<HWR>
MG,P][?+KEZ<GJNA;X35@E1.(=)\BU.#65K,AU '>"(GT!JN7S_,\<;3ZQN6^
M%?O-%\O] 3ZM:?)::624#L:2P#"9LD3D$$)D"1%7M[2<).&'9X(D#ZOW0M2-
MKM[$JVGW&Y1B<G&B^Q.<27N>$&N7,0B<)W*60](&!#SKY'<R"H1\@J:I.^^-
M(#Y_MGT/5F_1-=)71*OE7<3WEY<GVL<OJ],KL2ID*#Q$L</$Y9<\G(L_7Y"4
MFW J(55JB:M43!Z0J5@FZ,*T+?O7NEBC%KZOX,U'(WAS!&_^\&-(KEU:%%X>
MT<?S?PN15ENUD'^U),.Y!K]92<:(74_Y O^K[OFM>?E[Y\3P0E@:5>BR(CWW
M]B:&@EI6_@0YUFWG'.'SJC[WK1;F^67.PYG7.<T&FL24PIQ_MWR9T33]NDIO
M:Z"Y.(8W.2UG0RIY284)2U3%%[/&7KZOF=4>NF) . *^Y[?UL&7YY5"FDUYZ
M<#20Z:0+N"K2]?-%83X-G#VDDO/%VKZ//P92S;I]P2=L+T>>]SEZ6B#S.W@>
M_<B/ID='=A!WZ(!&B^I6-"^Q(GN\L->^MW^GKUGS<"F?[#]]_&S_Z&C_^,F3
MHT>/_\JJ\Q-0HDYY!F<A'M6M7_*__&\AAVV=FG+!2T]CLN8@+CN'^=)7L#KG
M:VF]5QMLS,L-5V[#J_@[6!I^]J]X9SO]!8[;"W\I:0OTO^/E'"_G?;F<Y-XO
MR4?&W5)L']2T.-EO?GFI(:(E:+YG9LY4)+;+G%7F%QV]K4\<K;J=3O%XQ79G
MO\<K]@.NF NGS5!%#7Y()LDQW&C6>5@<";S,Z=&S*JVE$]V;]S]QCI7[1T=D
M6O;N2;=TY523FCOI76NR\=[MSB$8[]T/N'?*(Y@Z8F'R1Q'GE^K6HN"/UN1&
MDJ\YK,,&"*:8^LM]SK)^\6W]^^F[21R71P[&=A:03 13(PMF0/F271NNNEI5
M("*2;AH:_5EP?P2F2;"LLN.]WIU#-M[K'3-9?WEY,MZ/W=FL\7[\B/M!:J*1
MI@#K) Z^T+QP5]+L,F_TK\N\;8U1VW.2Y(L@U3Q>I=W9U_$J[>15\B35UI"+
M&?T<+W;EV+>9FJ_5R$J/95GYLJ6&"^#(9I.$]N]OWVV2F\KGI8[/HG+=ZR:^
MFL&6:9#=J^T)K%G,E0*F05\3X6HA.]0'4Z7N ?TZFK8VY3E*G94%5>LZ.Q#)
MC!)C=X[O*#%NM\2(9 1[A:& $/+Y0BH^8Z+UZX2',EAS;B3N*_$N]&4A9"9Q
MHH3<6_JO;Z$24$?%W>S3-GTQ2H%=.9*C%/@1H:=T;3G.NH:1KD;OSG@Q=F67
MQHOQ RX&%*"F.9B@-:@58K: ER?3;5=DQ&9]&R9R7W6VK8E#UP@/KRO;OC2]
MOD(!(1-SZ#.#/L.O:5P7X"-?+!A^30\Q1=K0LJ)[*5HZU/DG)>>US#I[_&RQ
ME3[9=\ %<F7995K7U95CI4 ;G>$:"%=OQ\S[.JB@BX$P5'#;-5GL8BT5=U(!
MP5"U+%\L#!M)@FUN;)4C1TYH 5'SSET]Z<&SO$QMGT=^\S3YL%X)A?!D$Y+R
M*X+^G(TX#;[[SO78X-)QM#4=>+2 [AWSS@F*]=;)J5!M**J^,&FF]\O44BZ!
M4;OV0(U:E/HMKCCD[Z3V+2$H7[*1*991:O^]K^H_9IO"+JM,TBQS*;]_:2R$
M7[_9KE=&MZ,_M0F7C'A,_YS&5,-H95M4& +@VB+%V36=W38I_PA.BA9[V.@P
M'TCM5Q$U][;<)L+;[/KPRO$8ZH[I2S/M04FU6L;W7>$TS<9M<H= GK'"/K1^
M6$'=2C!P1X6M*S)-_E%=T;6M_=/0%:9E*<#/M66'C5FE8+$>GJ^46B*5=)EG
MX$0%DP 2T%P90JHJ*/W</'\*!4E=:Y4DS83"20M;)DAJN:+8D&H@>75I4$)*
M_[E^1^#B.-PH-P<;/B^VE$1"_D.?C MQM:D\+I][!O="W;BB>C7P1!0\T<C3
MHO-5\N_#-O77?IG?)L&9]VF6.RZ,?YBT:&4=A=5,SIYB7^7639.3L-R&MYB)
M.$HCL2$R#.9=TWCDFXJ#"Q*34D5#5V1N:N;((&6CS4\VPD;<N]?OQ);V.3T2
M##X-N,D;O>)11-V8Q( + XTMT8_:=AR"2\DH=FVX.;"O=PLW?H>*'KYSQ>B[
M "-Z)HC/L?CUMIR5&[YZX=GP:&!ITQO@B8T7V[XV)IE?F"4*8V";59_ P[/>
MP!@SA0#P(:)?0CQR$%ASK&]#F X6WT!/-F0V-: U!WZ2%7QKF2R8/,]A/_R<
M% C=5N>&BV19PL<1PH@?/27MNVY=Y,TWOD@OT[S@@M$H-"<650OJ-NEX.42V
MX=/JM ;04AX1.DW.@ +M#YG;R:=K2P$E.D#K2?$LK ;X*'D-R(!R2Y1V=%K3
M5KMN",:T\2!3ZROT&H@ZM(RJ33S)(4Z3HWV:ZKH)7B]^Y]SDMGR$OC!)NK+
M7@J6;M0]][7R\_%8^3E6?O[P8RAY6Y3P.X&5YJ#'H8^0)2^LH/_J(&N%<<"U
MNJA*+KEGYFDG&/M81K;VT3.RB=,U(D_AW<2E\QQB$3>+^5HG3LY:I19X0*+@
MP&10@'H.;9>Z%J0'UF60"2AH>>#]Y.:([":]@/B'*,A)WYLOG: '1[1\R*H
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M)_SV8)$R,Q>P]LS,4]KW:%.:_!.M&M<<\ICLC%A#?H03NVV$^E0N.LWXX,Q
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MJ&NB//LFHSR JR7#>\$TV-5SZR1QE@=WJ$6RM3%</)BL35I;YC^.4DV3ETR
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MCR=MV$0"LSK'.\B87E5Y@'NC23552<]<!W>9S@/9K:U_NZ[(Q!:9^+_$#U2
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MEJO@"(NSE[S!7>5C_@ZT4AHF8*KZ.')@XS'_>//NA)E?NT9ORUQ.3W!UI(J
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M0")<I:Q;FP\3O6D#W> OJ>\1RIC[9Y]#817M7MD^:"U29N3,0.9KPSHAWA6
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M2KT,\J8;*37HBY,=0MT!79ZZE;Y_.2JA,3XHS,Y*7TJ>T14V-4,C7<$'"2<
M+QQ>2%IN;G2%@NY737D)HL5<EY "QKH?I930\-%POUL=Y[6Z\C";6E]\H,_5
M!WJY#3EG-E-EHGA:B74F2QE9CEX60SD\]"&:]!K'=MYPJ5L_PO:[6T5U&U\B
M2@=]69/-QO/MV=KL9MTZ7)]^ORB,118^+5EP3D-[.Y0#\WUP\308G1,(4!T-
M_X%'2)H^;T<$%Z[P/QH7! YXOHW#?+@6^%C>].@F/J09+:PM:'^RYM8+# J5
MQ4$2!E/8BM^^YA_$<*7&[(U1MH[H8.5 'DR*;ZJ!5VA/M,^1WBA:G5"T=N$
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MAT5&+XJS+^X\8]8X'JFFZ+D:CETQGMK!U!7I'::M/#)9HZ9:0[8HWBQ-$I7
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M^:#?MO6>B94J<I%S&4 (F8)4PL]=+-4)O<I%>$Y)>+:"3=29:0*)43JS0WU
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M02&1SJ!GR/.W XZ^VQJ4>L 8,D7G)1#'X(J*3IZ\H.&4&>2\R>6S;FUUP%E
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M5%.H7Y-,\KJPBN=UNT>F![=E/?;#]\^?G4]<Y@"WNVL'E(3*VGLEP[<[,,E
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M;>(RYN(-1^XZV2^:TVGBQ.NZV=I=]_9FRC]R3;<!CJ%[I$#FRQ)%%U<F?-%
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M>%C'/F%I Y8$VBSS)&]V)>*YA\TTL_Y"[8#6D5%F6'DPI+BU"S$-[3IT?!C
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MLVE+Z3=E;IS.CC,PL$.,D[[V'Y:$S*WO:UMP/XD(?O(=COPG7.!7H3[?<3C
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M!F"_ Q3+_38F)D&AKN'#2V-@"_U-AV.NK/NA43+IZ7>$ 7G%!D?$C0<!]N\
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MQS/@0U726@Z!1R@3-VW!VR(+OG^LN95%(-QP['-V+M"2/=.H.^H\= UN(VD
MCD+X!MHCB%WF0Y!1Z!%9.-8TQ)SV#\^,OX_:V6C72].9>;HJJ[#'P!9L"),N
M'0I+R.^K14#/T'RUR(;-01.[HC>,H9J=@!B.)"J!(8QO[P\SLYQP8%-WNZP9
M]F3,6\FIJ\=HR(GZ81<8-(HE\Q9]#5 C6/F ;SK2Q-4;U%U4BE058K6I,+"K
M";O &)R=PA8SG?;@2K>%]@#NRV,0E/(MF"E 0O&1EG.^7OVP+ZO".C]E!$Q1
MPPY6(989D9GIZ>KLK!\D("^1;@YYIRP,/R8IT@*A%%SVT[9;-%_B2$C[;9GL
M8"0N&1Y92-;@WV"PT:8)&K40+''A.3[U.8'(MF#ZL-%8(+Q*'#(Y?(0_A^;/
M'QN1 HE6"9"SN/>D\]0=HK@)PV/HWA_46;$TC#VB8>PW2\/8(HKPY,LPQ=1*
M.[Y+6';GI;3%.Q=&6IS99T@_8,:#(;8SBX_ [I?5";T$"[AXRX])F00Q9"UY
MSZ8_1.):E.RM(,V\?BR2O9VXRHPE W2]2*D3G#\77(?Y=F_TQT7NZ>C(^;0[
MY_*;Z&@E!!B2]V2!SU[5H^ 71,(.2;7$!KA #:V"4^+/&?,&G$8GY1@DULSC
MC-)H2+"P.\PNV2:'O*E_<?HX;5)&$&CO>Q_$MDUME9XT.,OKH7K-]*84I'0H
M*4">HCI=\9:/74$VGGBG$'&H,P1B@;+=7C&I!\_:J6D[SX7EAL0DS<DA2[7^
MSNB6SR1@,_/R)9T^"6)N5#L[6KV$@@L)DK J0Z9%(8QN]0V 1:S+K:Z'AFRA
M>:9;"EE:6O0%F4Z6\YJG-)?LOG(CJ)IM<#^57,#\S[*=J?2<ZXM0C_][5MTS
MJQTB$!K&\B#BK0^PV\>A#X;:U )'VV(QWQ^O^0Y$3):Z.S:5R#IF*Z8+:0[E
M)ALG,!R%D21$7+(M)8%52J '48N!HM28^I)=;P:?PDWO=\!62;XAT)WQQ\@>
M:^+&C*H/2Y.'URCORW^ GA]=0YY;:)2J]"I]2=K2=67Q9F2:E$U5=-;N/1(A
M5OM7AYA7^*4UM9,0$MEQRC.44CVF5>[<B[S'2P07,/"'GZ5\XB^!]I?M=29E
MN0./:/$3W;;3I"I+0%HEO<[E_<DFY[$#G9_4"F^\EC:GZ]7?]9->B $?2)_2
MI9_A,#"=7=%*$J3T]AV+A.4Z0X7AS.@]Z*T].9?2>]6\U;$$T9'"[[AO[@JD
M!4>\8&N4:D3E-K@,?"D,'BTLOZKTQ7S::^Q0/'R2^%QN"UJG>>BZGXXDI]*&
M(Z<& 1SB5[ARH$!Z/KZ)3:7?Y'13LJ==5).]4S%2'(^2GXQ>CDOO]?'4>CQ%
M6F(/'L6.)E9JWA(]WOPL1^+'>R3*(KU?WR>8%K9WZ1Z-ALU7!Y5 L%O=LJU(
M)>K7)_7:3Q8XU"?GQ\-FE 8R#!Y[43*G.#8H>\I\N=0S%>6$<HG//^K5'$.G
M>\@PI:+ 85)$-Z"O&^I*1SG,O=U-N;5Q,;75S$$1"C6B'I6R6++O<%8CZ@<.
M>FL69D*1C=%2JM<T5[]PJ P+NP)G':@P"W5,0-\<,>\NJY"M;@8Z $R\>TSO
M:)=5MCN]K+J-!BK:21TN,/_76BP;GW7=?8<=GS[UR<3,1U%O+/F'HIS2_27E
M,C-5R<M.E$KX#JD!4C'4-AS8<Z2A.8T&N#^[4/T48F$4T'CVZQNM6.'E3/5@
M%59/O*H7 K(L@A.B6>S51VJOXO:GNS,9L #YRM>TDO8-\\R0JVHJ[NBNP_:;
M5RL,T5?>LE )<F0*0?$IQVF-T@!']S(7)\ 73UX,H;N[PCZ U)GPX;*9$OA+
M4=]P"@],L=S>PR3=M>FZY-O\.$86!([9<;")JB57.C7PF]"$-!+3;TK56RSM
MX6"STJ?CY^'!MR>9D\J*H@C9N;039&4X9.#WGY.G"3,33YN@OJ>(60@C\:-L
M]F5QJP_<6:X5>06X]Q^6K?B BE[OFC8_:B0QSL6)028K[YX#^&Y6F]>T@]S%
MFC4-I*.$-B1$XE$)\",+0)D'Y)%$VJ[(_!9('R:(7>B;SFFAG!- $6T.&M6"
MH:AD;>BA-^51:P!>Y^=M"Y\OC/[O]R']8HY\_L'<\ZZ-;2IHJ"XJ;\<TWDAD
M!,^HV:;BM"I/L1*'UBGA!M%;4<L-8KFB7).JVCHUW#>%-)X.?QYN]D89YFAK
M_+[=>2#96&SYRZ]?9(D7/:=+8Z#=Y+I&?AV5''$O)Y8HEQQY[EZL,?)VT=NE
M"6DNTXD_I9]#O:N:<6(R9S^=X!(6R.;/7W^;/K6 Z"0+.9(O-49_+67&7^1<
M+0AB<2/%7;@X!<C*12N5UX38]6VS&?011\]PD[<A$>]7G0P@EZ\%3AW(RJR$
MXA8<?O/GEZ/WVZG7.%9''4O:);MC%"P"%4[OUS6MK)ZH?_3W+UYP:C\Y4A@G
M#FU-(5NR4TUFGU6/:"F7M*1B1MJ8VMQ!Z,L3_GQ$>(BON^^F>]/?SJ\NP[8"
MO$<''2H^3@\3UV8E4WE?R8#E 3[.OZ77O<8[ZW H?2:6? ]7.5&_&DMCX;G$
MDDTTH:WP/U(,F6H&CL-A..&S5N]Z]2+>?;6G4S(2?C)V0A][;)-TFSK+=# ]
M0WTH/'P<?5ZG:FDF*K;?Z\>]4*$+0Z2M2N/Z9K?XWA\K\O&W"_)Q03X^^3+,
M*UIG6Z?OI[!]5P1)-&'#,9 <HS.*L"]\D]"=:T'2$.ENWQP0,#;M:['0'@Z/
M0&Z[ZNF5,C[^"JWK2$<KFIXXC\H97?$Y9I,K\4 =.3I1!%$N.W)\/JR,R.^O
M/_WM9\MV>)1.]!F)OYF@C7Q![0Z?489.0Q7?7*@5CM@9$H2B)0+LHU*P72GT
M 36MN24!\6><Y*9.E@!=G'L,UC,#A]+[?/?EUZ]2<+,%-5.?6C6MX5IQQ8<V
M6'#/@0\8:OLS,QE*KM0G9YQ :@')(H1*_.:Q#<N*8,4V#0NDA8R#V@ V17@4
M8 L:O94=61.ZXXWUYC1HXMI9T\J9?*LFO+K9>!O3N@'33'V"?BO[;R/I[V!
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M(W2*U^!48%N"\";-YH5<9:2D@#O7%LS<,*-70=94GE(*X+-B%0DZ>>CAB0S
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MIZ*GX$WS[O;J\R4,9%#G-Z\$V6:'I+A@FS!ATCR'K.=G0Z@:C38HDQZ<V@Z
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M+!9*6BTD%M)8("/_0=GP!73U"-#5YPOHZJV!KA9GXC%-S2:+[H]L51R8=!4
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M7VW;X<;#]%. )GH4Y.'"]\KI4)Z#ZM>P#?D("J^]@-P7A[;]LT(SLP8&8%(
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M6[Y9X:_KG["/07''+;&N/PGL6W)%%%/U93^(P_^V;JXJ5YS'A$M;HJM@W$;
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MOC1SMK#\+8L:V/JN;U%C-LM8O?:48Q*K+V6OVI8..5) %+M0H/:>*]65MYS
MY!4H[ /;<K/ZYT"=A9K_)!(UM#X*LGR^ D'Q%64^MR 5:D+!6(;,N4UV-S7,
M5'YOB1-,(7/H]P,=!%OB#V+4?]\TJTI8Y00\QE<VFYA!I/)GR:D:Z.\5J@<X
M9W24,=L, :\B3# +^55YN>NTPG+ICG6(ZNM(X:@@.Y"@@AZ$0/[0$VO1*OF#
MTM'53!_>HL#"V?<JPH^U>H7N@\I1,"@E6 )&3[HZ9?A8"C/S0)PGX#O9TC:P
M-'E^C?B=4[#JDOR40 ]BS<+?8,]HLNBNHOD 5B-J6)C<\6SUY26QJ\256XPP
MTIAWCH3EFTP_)5^_;MJS$?N$B(HKLQ\R)33X!O6B+):.LA6>M:2X3Q(9$G*R
MCJ(R2]F1V J.J9S;L:X=34*=MVUSQ1SR<5*91)Z_<4%[<JC#G2L7(ETBS,K"
M3* (Q!Y7>*XBN]6+5F?J+LY8%O@[W*^;RD>)ETIB?TUC].QQAXX61MHT*MS,
MFVE4L+)KOU-+<UY>@@(_[T<O& 8&I0\N[R:H(<H*N?ZB*4;@!R5'5"H1Y7<L
MZRUE%&B4@:A49I60\(?8 ^._3<5:DU_(RW:<'M%YL!RL MPWCV!7$8-MZU ,
M9.UK!=D&JI7E[/] S_ZOY028V=V4;_+ARBPE:B#(;F:/JG ^D]W-Q,J4+5)7
M!3D9;>IPA,,5A_ %-EZMFAABHO2::CYV+J?=3[TUM[4D 8)>T,#(13>,V;2-
M3-'>[UB%LAD(X;$$I([Y^GSFI&K]QE^6^G'GIC\0,AQQ!R(;Z;:L7"'<H]1A
MXX,4_STR88T/:042$0V@?\!!VF6XM; FHQQ<$M)2X=<&YT_?F &9A<.*^G:$
MU94^G'@W7,7>2IT$IQ3])CF5<!'Y9GSSS/]@;!I;2]-/1:C""/1A&ZIW;G@\
M[!6%/U[)=0>UL87S/LXEF*X(G,"EC51XA;L>PDWG!>PB+LV^'_4&N0Z!Y;.8
MV0_5S(8:0RF%1-7\E9[W^2X59;3VEV8J;_3V"L@HD UJ?8;9+&<HLAD/,@ED
M(O!2R(6]/2HI/)BS1K/!!YBH&U,\D[A#:)=CFD.HW4</@KH]6:^ K@8O5NLH
MTT?$-_YRI5BC MD[,6L$C9$&Y! 6@KN*]&[*MNL9X%5QH6OZ.!8'-C-A(T<9
M!Y#U$&%YV>@:>YC.EX25KO;>EN6D_\;E%X<G;W9TM+QD1^Q;A*?//LE6SY\^
M>T$3P3 M;[J!)0;0VQ4B5CE]"^+0@D^?D<&'5"*/#S"MA%Y=-*LK(.+,9'$,
MHR0/EL1]1["FED\CM<MAB4CL*J&VG8"1"ZY&6'J_%#96E5M'.SNTX,_0S+M?
M]V7L4 DA8FDHS_W$K0X^RN]D27$PCS=TMOJ_4J+S-H60^1JW6(;:S[VC<^4N
M!9Z%4=E[)13_P5'IJ3+6M,1+:[D$QJ'H3<<X;15.-<#?J85X6)X20Z%X&K/@
M9T8/)7T!>O6PC$.6>TW(>U?'#+<)%S!SY6:&'O]Q'5$+UNH.6*M/%ZS5@K4Z
M@85(Z57$9R+/84V^0%(YW',J$XM<]9$D'/)L-A='<HFC=)P"A=5FB_F,Z3 ]
M>*G5C>,+35X21?FQW"Q*+NNVR8NIG,3\$Q:-XV<\E[ADA-4B/&UR0&!HEPP[
MIFSO.%/)06+5;-[&U&G(-9/WIQFE02+@R'XQ>UYQP"@,$9*:PZ#T%Y3[#D.+
M90,?OG5H%:?T6#H!,Z]H[OV8]B(2THF"C3QS"ALFF0[_3RK1A5+"HSK2%DMR
MITY5W70&L*X>'+MO[-/&_+LATYXOXMZAALN*6*ZG; *U"C[Q;B9O/F_*7(F@
MB7:[J5YI^TZ0=U#@HGBBD:YIB^Q+:4H#M/B+DBP2%0ZH_4GPDUK[Y3#-53+2
M8^18+)WJ'<O#I&AFV*+P&$)+,O>@F:4'ST9JWSH);,]#:!%2X_\=_''S$D*H
MDSRD3#;27@IPLU4(.[9Q'5.?!@A6LIL9C2+% 5[SJD/SD]OMJ^;@Z$(0%ZJH
MTS:2K5.Y,R\NRPZ=/+)^T-G1"*4L4_>%T3N_KB^UNM2[\U;96\>#D5<8>-G3
MZ5H? F@&YO_BT#$+.W77FI^CST([6L*W4"ZC-=@VM7^ \8\L^;N9U^[0]6X'
MU3<*P!6TJ /?.#DKJ1;AU]ME60Q(=#3M>5Y+5DTF22Z5V2F'^JP,9.?R#BHG
M<EXK,#+IHPW,OUJDHOR"*U35BK8%_^YL]1V-CM8^$6!SPB%OG:'6 3'V$;.P
MG#(?ZBGSLJ):W[D(?P@I%!?7$]N@&UC-@TAZ4\6>JR/!D^L45R^'%E(7/1O-
M>#EN30Q7&[ICH/V0^9;R:>@>!-T?ZXMGM/"Y@RXV=^:ASTO<JS*FSD)O-UF6
M<+@Q=Z<^AL%6YS.39&$(UUG142=D:DEI X\*N!?2JI9S%WHL6=WMC#+='L?/
M )N6U,K4J-Z"QZ01I,8YRF@DF5([3&MB0UEZ;6Q4<!=L>T#X9N1+/(=J4S(=
MZ6  ([#B-.H"S']7RV$IJ02]5N^;(U0S(\>Y1--:$N1G5/:VP4KL0NW&+8IW
ML.94I\2)JV;]V[*+XJ32CCC4TOS]+U?H= Y11FSRP'=X49/ZO47-)V#Y6)^_
MB0PK2J)\"9>.,W[(OLHNDDQO60%U)2\PK)&=G0+B[4I/L;*++E4F_:WEI7 &
MIY*),1<J@ 7Z\5![NUN4FYYA)FF+?BGYY-[M_>++WW)*,O0N_=[IAM-+*X4,
MCZZ*M$FYK(V4&#'6@Z]&&W]2X[$=SY8A!8@3=J<A+I[!A^H9S*'9->$2=GQJ
M?6BIU4W]Q*1W9A'MJ=I2(M:*(SN! \F6#4C \R'W9U/O1JA*P0I)E=_6Z(_B
MF><1]5$-PW8IYD=:SA*L_=&FL]F&I-B -J_A!,[S0/00U'(?UXY<NDU^:WO$
M#T8N+98RYW><(/FXQPZ=H8I)5*72]T0WO;24/.Q#XKLAX0)6[BQVQCM-3 5:
MU,NF%"A 7(_<$077+RC6CSZW,#\;>UB?13O+1W@'@R+/$P)BX7CQWX^=T=G*
MOZX+9,;*6@HK1U7D.7UH0=U&6O":]O/;-B:(9/J(%$^K279#5_E5-Y0]OA>A
M%Y26"C S'#+NUWPG#3^JRMX[9NUS1()R63):6  ; 0<R+0Y]'Y_X!SI=Z?A;
M?8=R$E[GCV^^_^$[31:V!+]L&/^N*/^T G6V^L?@EQ !'7X\>W/&)Y]\<X3+
MPT0=!=,']#" "5=S6+Q,Y>YK 9&XBA=J@"31;]$Y7T+6(]I$TVY$"E8' \ L
MZ_F7_B2$I4?>YYV7 C-K<;+A.(%#9 B@=4]H4[A6'$K7QG]1SJ,R$2Q Q>N.
M0U/1.L95M2[)["L,"E\ .A=#42;'R[(K!7?*L27@8/Z"[%KB(?:#]\HVJNF0
M26:G>QOXC4RR8@:J(FE6JRYF#DVSFQ)K<]RLO*'P$9?(M>HJPL]S5)4)>50M
M8M$:1AOGL_.3F8=Z;<=WUIZD&U\V$&%ZR\)1$D+W$D1J:+,#Q=8%&)L.9R/,
M#U/<$W#43!BJJQWSO&TV?K\2-QU7G/S9AFHJZ?" ,J"4K&'G^EZK-BA0:!(@
MG6*:"6_)SQW5<Q<G]X-%\GRV('D6),\)+,0I'H68,-L^I!WH7..#6 [R\FB]
M5CNJ-&^;AU[,-N =K?RUZ068;6ZQK9>,D-34++17"/2:K8IV@"P9D?SY\U);
MOQ)U%G;7]"/@,^GXV'&R,:1IZ#BB$DUC!9C<T1I\9]LX1OF:<<8G"^C-S#Y(
M3/R45.%Q@8-(.RY N2SG=H(7CIV9-SOC9ZN_N4T^=/.P<2K84\Z7GOD@&-W8
M%]3;ER=,D-1#>-PY-9UME7H%\[VU-SDR^N 3:-9XR29]P"'VD%8>N.<Q#3]$
M'O0D):<WZ[@+,.E6.5M]?\WSXK*QU0<>7$?D/_YQLL05$T \@,CJR?MIY6F"
M: [CV'*AQ;8HL&O[C@5Q;)YM;K6^9.1U '4AYZ\]KBE<G '^73)Z/]R^59&P
M+L+5&<U>SQ#  JF=7_&=KMJ2V#=M,I7)@,< ;OSW__E_?GW^]-E?/^\"_1E=
M\\+'-$U[. -%S?S]I#EZXW12PA/:=N;8JVQ[#F29$Q>O7^B;A*W5T&=I@V;:
M1R;N_+')%W;9.?N'Q@@T Z,M  A&]8@=1OS+X&, JMZ(_[L))*ZS5E%;GHZN
MA4RXOF94YF[Q6YE8MJ?T15IW6MN[X9[D9HLHX+A9;1PE !-Y?;<>_WRFFP;D
M;U<1MH^&!J;ABM2KAFUUIKE;$^;:@1 X42=_OU$<$-5,ZI-)'I?[!1Y7#+"X
M7K>?T._#"0;DKUA>K7D.R=%6UK\,-:LBA".?:OF]J+A6I=NF=1E+E32[DZ+L
M&@,%QKEPQS*/+:<YCJMT^G_]A_]6H)5KW7[H(ZP@UG:D_G.V^H(H+#NMI762
M8$#RCCC>*Q>$)TORVORYD6G)?D9CS60&5$XSD2Q($Z(@@^Z"M53V9T;2";C%
MY#$ N$[+^XD2*8X5VWT*1V.<;(GO-*UZ S1Z2,>7[_R0TN19Z^@ERR><7/(;
MHZW=H=-C<K5UBC?U;B.-)$TNTVU"OB)+Q48- 4)T4C4[D_-[DL5I".+]NR*V
M>D*%]IH<Q95K[\A<=W3(BK:+2VE1;R!*"%*J9KZ"E.K.7Q !"1:!]Q7A]@.7
MPA< 1'_M$N))\0$IQP=&L:TWW>64AV.^A"H/0L>8C*P(A\Q-9X+5+]%V-&V1
M'%\_LC^&YO@U5Z"UJ5[]=.\^G)>7BO.W@*,(+()+1*\H\7Y3MMC/K?QC=6 R
MMP@8B>/@1:K/Q(AA?U,F,O5+K/=K;DXJCKC<4O8730:&(HLA(GU<1^12"_Z=
MVF[PT'$.(%C2NE "*@\-1$G3T/71<GI^KIU%6:4(*YB5H8XK>"D5/Y@U>\\F
MX-6(!#HD;\PZS)(3TX>G!V6_O'Z!@G!-=D#27T&A^"8FBEH&V 8Z:Y*_((AI
MB!?KF'X!\JD+[7-E9',^6WWK#[\&+1[ES'V;A,,YGE?N4IH(QEY0@B]JVACA
M4_XOB//,?2%H+__0K)25(:UFC>"B0^=LDW4XGI5S(/FQ5LAX>,2/<'BR/CR1
M?ZH*661(LY9A!GXYUAP)'LHUXB-CXCW_NKV[4+M*LZ=RWRE%7 (,,QA*HYT3
M=91#=2Y0+Q0)>_K,M.B#]X>]>$E5WO7P-#E5&*OG!^64@$]0,(I8)I<2R9Q7
M5E_8/^+&E6S#P[(58FOJM"&D=O/6A42<*&LV>AU9!].H"2 +SE7S_)C\*=:W
M;L(R;3T;71!W"9=)J-:0N9JGRF%V-S_?C\MG64Z W]31R&NL3O=5A)YD(=G'
M!$0;QN#DAF61+46G?7A8=!GCN2WX4V)P^9;>CKM_6?D1N5LWFV"5%<]\A95P
M]&\'EJ7J_+ME++DP-5'B$F':T 7<M<%.]$+D*((2_.ZZZ2:2PRDF,LU%_*0I
M\RAKT0O@WLBFUPDB ,$&YQ0LL$?:IX=^-I.AN[D/>G#,RIAP-88<L[=3.D&8
MU2EW8V;O-\R7M,S-\**8/C,S"8M9R850DFL,@U8$QS?&0!K8NXG^Z/(#%1\J
MH6KDL&UT&X23A5N-X/;<<_Y6C[;..R;T;^53;$;M$Y$YC;\@#0;Q! C.S_QY
MD^X)I<01%D@6J.A"SR)?DO*[-QGE< %>PCI[WE':3:]V9(C$\M(- )>T(Y4M
M'E:R<I$H*COD4++( D7]6#MFX@3SFA]DP=4ARK5("4?UN8*7>%N=#[RB.TM]
M/*[3:@&BW &(\M<%B+( 44Y@(9HL:.Q-29/8@=[%^DM"OG!.Z OVM;A28G2C
MM-)A$MVBZ'P0@'#7N]R?(5=Y2U)8)$NMV>20CX]IZ%$=L!XU.AY&R>.U8"\B
M:=L,.CO2.818M:04LH\!-]);VA]3C[+([C["P.%HX-0#99^X/4DWW+0G<LT9
M G_DEQT7]DVY/DBG$@/L@8OJ\>8A5(TQW-HIGI5 ,L3V$E@MN%0?&H(N?"Q)
M/EOF9UZ $4DNI"UWB6O7)'T<7%X7T@$&9.;5H=.FV4N2JO5ND(:<$E/J[7L,
M5,],DV6_N?&3Z4K*C9G>G5\ZY#5OWBZ'ZHE:LG><8WT-UM^  Z9\R8Z4%\JN
MXJU';J7"NQD#$XB1 KR88=)^&V(N-/*RV)B4;"D-.P1:(SZQILR*6(=%'3!!
M9V4!N%V0.#!98[I$('8R8"LA>5R2X ]F!]PWW4;').%2/V8.'MCRM-,B8.VS
M8#Q'+5;^,OYHN"RI6S[TF#1'VE RCEDW Z+."-[[;JWT.E&QTG*MS?8J2<O'
M815$4] U%:NFRK^#;G[M7@@N1<=',7*CM'<I"D8F>-2F7];T-6 JC;"*F P_
MM^X)B3+;/H*I_9ACMAMWWR2DMH2IV.0^0+W$\[_<] '4-2*_C< +4=?F;,,1
M^_2X3KQEQ]^-$'+,FRS@ /)%ZV&W9E@B!$&V?O51QN<B!^#6.V!HB%-"W?PJ
MZ04DRI8N(FTEHP%(:3Y''<T9^J":6X2###ZI_#R0]T;W]4<  V>>))OI#81V
M.M(IQ/C+\C><4MU\#LIFOSZ>,,T._[GXG!N7)E^B2DSX"O-IH;R"^":RB'/:
MJKM0-QT!#X"-\BA7%T3;<=6$1.>QF6%:;+CV6W11]B'7AQR<F@R@1%+J2F&N
M42#.H,[SICDG8C!_I?-&&B YEMK&$A@+!NGEI 8%K(J!YEHT+KTV5!RAVXJ\
MK_QBMB5R/?@55;:;84?QU2;(M(SI,RFXV9.]/7XQ[>2U-$ES*QP+RM45]7,5
M*=@XADVR;'V$6)$,5MY%V28Y GII*AQ? P%/$2^1,H;3BI8D?10[RNU.2G81
M<<!SD"PML->VQN*NL6\ KZAJK@AU>"GAHS\:::(+>L_^U: 9=I1^]Z=[&ULK
MCOZ21KQU!60VA+XU2CPP\_E$D@HK-1M-B;QP(Y45A(PN([-=/AEK4CB5@Y"_
MX^\.@15E\M$4LV-E(M!EA;T2;G*EFS2AM4F?!-X17W,K).\@%11&$7]'OX1Z
M?T[WDO/(C;399"%B&754D.<>Q(3G*)[=IQ)9,*&8S6G?C63IPV -61R0WUAU
M99T=V3?M4,$<43X-_=.HK7@S/+=63OC);Q_/ONRZ9B-$:F3.OFU\I$1!$3$:
M7'!X<WFV^O;@=UJQ^KN/WGW0Y+?EU_7F+%O][?6KE\^>/+#).;K/_D^^VW_^
MP![F#ID+>EG/G_P-B:/_)C!VB:SU*W* O"_K_*DB+!;?Q"SQ YN.HP]/A\ #
M>Y;;O]KOO9OJSO/5JZ;=G]%V_89T1GZPH&U\], FX.C+A ,0-#/G6A,MOW=H
MOB*K+FV5J?//C)3$92B7BQP7BJV! H&]@@_HAAEM'/;<X$1!)3*X4 <5WJ.V
M%25Z,X"*Z_I2,P$'I/+4CC,RE!%F;<MB[G9!YV\V(PN!&FU\HVX;;76DXT!Z
M8C<B@<120?# 7S7U>0NBMO G=L:SZ _'+LV@0>NC]2>"#EDWA;#$C,2F,NT$
MY=<B,EH8P3E5O6J;C9-V5^0&Z%H)<R6%_*K;AN_Q*SXR\= %C=AO0[<.+EMB
MR+%WCAJJ1AH.;2.A"\N\P,?E:R[EG=_?E3!EW0FPMV.\R2FIK^6<9X-XU3;0
MSZP.C-*FV"JPQAZMY8YY? +^*26[OOD.P-*Z,6=]Z,VC.[IPQ79AS'LXF^2>
M;8YL"EX9*Z,BP-IV#@E:=TFJ;]4A$GT1/T/-'9HIFC&MS1"&,27H,I6DF/,:
M-\$=Z3,@9@1#?=YSTLG5P#S<N(,YC3:_A07D.DCNY1@_LA]78&>GC$E_#07\
MU4W6YHH[A'^'S2&.9NI>X*J4O@*0E$\MQ)%"G.U>G26./C(7V8A^0)\AHI7'
M-B=><D1=%@,>G;$DJ8@456%0M+$1&6@2/X^0,_:O@;_*]4.A+%"PZJB'8)^#
M)6<&/<2O#>H4Y+")[WH-@6+3QBZ03%^I<7$N* %OOJ%BP0R.UKY=N"N-=[@:
M5!P%FQ-X>@V3A>$OCTBLO$VT==.YD)E+YL. LOE>$;-M@4^<<Y0$OV0Z\\!N
M,>J+D6YW7<V+W_6A8E4_?;I@5>\-J[H$ +_5>4SA)5;-R51-3/)":8.9(V!?
ME>CF0VA_*4*X6H/+O6$OFLT 6^@-Z*[L.IR26T?UW0/C8J.1E,(LHRS1G<F5
M7HZR41B*2O;GKMX$[OGYH8[EI]%832TJ-5(3Y)00#\'X,11?&0>S1 8/9O>\
M Z2(Y)*^',CGR6N[@D>+,T -QDO,8DKF=DM.9(!'=HEV+AED28 VS\$FE!J+
M:."(5[;<\"YW-<:S=4RI4KLKDE%WO*7J@1PU_:\B;&T>0K(AP=W2U#8/1=U\
M(S+$J@(:8G""N=CG92BM<[':WN:Z'1_XOL5!3)$MY*J1L!^A\'HPSH0>/9*Z
M!I9CRE4^'C"X$;DIF27BZ+KH-:(QDY@=42AT2H'#%B/.UI623A*^7H>[+=N=
M)!"9C!=JIO(A)1N]3SN]H$X9&2H+,]+9X(KZ= ;#]Z^=RM-:GS^%::OR*\S7
MB$A^ZW" 4"!.,82K]O02,/B#QK),!(E:J2C=AWC07W;?A6[TS1 T(0]**IV#
MS1!/1IW0*FC)W-RL<-6T17)46!ZV=JA<HBV)E@*$(2$W'VG,1V</#<OTB*[]
MXS2U0A)XY"GM]2SQJ J5<"\HQY/<1L\83_]T/HRSA824\CYDQBUI'^H)7'BN
M.<F?3=(3@:$H:+0 G1-;];+?@9A8HJ83/6[?L3_S=4K!BJ:CHU+2770 M_34
M1SML*5V02G&C=+1X?0]F&;X3F2T?%?6L;L>@>8L6U'12BNBS"LD!^A?6;'T-
M+R'7'#E=E=>113>2?-B6\-&%9R67RRZL?W%XDCUPMOJ[D!V "C5HI1MT9N0D
MK$-IA9*,2#0W_I!TO28_C0O6#\1YFX13-L'J?2HA%+AT%>5>FS7RZBRZ)1&:
M _<<_78TS-H^A&A3,/6)#?]TO"+ H$V%] *D1]$_"<[S$6[0S"Y]#-:$<$#:
M'+@P_X78 $V6!0ZXLJM<SC!-\E#96RH"::W>#@#E,9<Y 73;G%+7ZE1)KEQH
M:_("O4U]B]X_4\&>^L4T6^NVR8N,T9]6- <+_=>1SL[C.G(7:W?["7U#CM[.
M$8:A[!#Z,+&&'TJB3C0!9;,+;D1:K84LZR 79%W+;O5G=W9^9G60[,_^<K9Z
M(RS)(V*4Z"K[FS>;4(L"$?E.$,N6*J54%Q:-%VH]J1-:=5>N(RE?ML.'NAU^
M,%*TVZ:JFBN<6W !PF$C$D7AU&2*Q='1-!6R_6D>$<774"Z6#&<=;;U]Y:P<
M- 6Q@OW2Y1P4. -6G\^9T+(1@.M7;L19O^+-[7< "MQ#380";O:H(C9XXYS@
M^Z(\"I(>T+ZF$S2=GY$+@BG"TS$T"L5&_U#^].RXQ2<38;'VP@?#=**/5.=L
MZK>I;\?_+.8E'P?%DRSRL7A5:Y!C&>67$^<-IWGTII#] 8;OHMQ; !PKMBN9
MK57I&+_OU-GD:0,M57*3A.FG2])><TT13'PW]G -)RE7-F5NX%HQ5\)UK(*/
MRWHN\?MOA@7S>F/"Y<"&&QA(+ ?N,5USV6E*U*5Q0+A&9"6A);C$\ ]F*;Z#
M8YS6G4)T(JI+K:"I;)J<+J6B [\W<ZI>X9PU!X\_<J6A-1#LC]K9I9,/F,1)
M^0498EJM:/LGBL20+1!R"G"E42NR/L'SIT)@RGVI9,Y-1EUZ0Q'WD^'.VZJD
M9@I$C\0%2/K?FIZG$D[\_MGJRU][LN/DTZBD2<"KL_K(+&2=6UBUSI*VQ=9%
MEFJ,5J(-:8[9$KW135N -@%$@C2=?R^Y5W&\L2/3D+8\&D8=?W$'<'1F$=N<
MAD"7*"4<N%ETDG?1XU&'AOY*YLX-ZDY(=;, BH;B?A#=1=/V(*VCQ/?X1\PN
M:P0J_,-]U<3P)/ 9.[_K0$K,7I^\#..;T!J HT0G+ON-G7-OXW>[T9>/I 3P
M6LIM?+W9#/C]V(*F/WU!XF7?@T!(B:.U\UD,_0^T7%^#P(A7)K5[^L$]^^MG
M'Y$GM\/*M6--GWC8<Z>U/P"4K_?0B-?*]H)?0S[-V&BY(2XF=;#]3O%K'XG>
M0G?,GT7_)PH%F$^[^!-;R4(U%6T/.N2_P%OCY2$.6VATK\V315*MD6]OTFFT
MGP]!YMAH_; XZ,QWV<O7=N5D6D+2:LPE3[A(I*O,U3K_LXYZO3F7A[E6Z5];
M[+( "<.V/:J)":]U/Z.I^]47+T,,PA7,>2X05JP]V,R"V=)Z@\-LZX9RG>40
M6F4N%X(B^KBDZ[3LYPTZERYISYIM1-O1[ YE8HC\LIS],+](<PZ!P9:_)VHA
MO!CMCT3?E6;4[Q7$5VBO:3:;H>UF:FVIU)1*;6"1YE44W[*B*"9V-6@9LTS6
M>##H4@?XL3\6 E,,'=KA#]ZFY<P?DP_UYD*POFI/^<!I^<&D!R6@<-<N<.O$
M)]40$D]\)Q*S$;"4#TRPV?F#8UCZ7#Y<O.6S!6^YX"U/+K#[:5:-R8:]UP+K
M^XN66CT:\;6OFK8JEB#WP2RV>[9Y7R&0RV*V5D.@V/AP?(65*)-&YVEVK<6J
MJO_=1;DNA:G;J TI(/?:=4S5F&;GS-UL13(-5 2P!64]<9M @YK70N@VYS8*
MH>O62J!M+AKZNI#NBG8(7#1&/=MXE/QR#72/SI=^(:EH301_I7F8ZN)<1. R
M6'QTZ;12(W"] 3 B:)B,GMA E( (%/?T_'S+^8EYY0=)KF8-7K]Y>3CEG9IA
MT]^CV643%Y/23$U7T-%WRC$'74T)^460ITV=5E316:MAYE[, =7,E[LY%!B]
MF;' $:*PJ9CRJ$3)"1_EV8?"M2JS3NL%Z,YB44KVBINK.CX0J'^88)F#$[]Q
MFM;ZQS."AGCIKFUIW#3 =#R3(7 JQJ;K15J#! !ZZIBE?['>W;&=TSG[$@Y!
M]RY$4,D3W5ZF3)>Q67)!ZQ-)E(1Q2E<A)U/,N\/2"4'.XW+REP/O]A/Z+<"^
MVC[+^\$'L(R3\BO:$C;Z)4@H(L9RQ^Q>>CS>=&C-8A@8A,TU,P6,4Q"N>=*8
MCD@H7O5S,1>0T8U?E4-AFU]*@C-A*=O&'$/2HVJ1V///8NU$,AP^2UM7<=&8
M</I)WW*45TWE/-XZBM>CM!HW^R;R.ZG<V79L+Q@@+&R*,ZD+/T>795.%=);8
MG]""*Z\G),O/5M\;O,B(.&,">YZ'I=RN 524TM#L2]GK/BC<\CDE$KQX'3G*
M_)T^@-:*YY5WKI?VX2[HJ;C/N!GJCO(]4;7,'OI&M6PL5\;Y3C'E6OY7A2-6
MMEQ%(3.&3X:4GTH"&XFWG0."#5(&3K+3]2&SIT4B3$O _!($$&>KE\#F2W'!
MOI#1^[]VA^<P?\;=G2U2!FW;A \V\C_G!25;_<-%8.#\775NU&$@I#]KV8Z<
M2&YJ"'X5[!QME*'J* ?*/V(\Y54G91K>I5&,B\ &^CS89%7%27'.3@898SA4
M=@'\.<E1VPX$7)(J4Y0^YHLI0RSU_4?NV O#Q;I2_(+4TP)[LT4ST$7Y+I2H
MWR']CE3S7WB2=F5OC:)F "V.0E9I;( Q+42VA\ER"&BYHW/6%$\>.6A@:S97
ME^Y1J:-Y&OIXX<?EPBSIH=_<X<"'0Q3/8G.)(YZTR;DHP<JH;)"J<*23Q>R)
M1WD^I%L/)0&$<A1/P7FLNW%T1T"UR'_J^G"@!.Y2K3T$%@:FI'9+%NKAK.G[
MIL^Y('G6*\=E:9/=A)&/Z^R*!>..%:=GZWF10<8J6..KH9&])76!OHTDO_^1
MT, 8WY\M?1R2%*3RB&F\\"Z4J^U])295XO28G,#V]+&W/TT+\</-PPXU\E=4
MMA<%8"[<PHU%P:HYY.B D(,XXZ8]\+R!EQDE3&F@B'I.NLD#1F,D\!3_7J>^
M$Q$"-C4;!P()G*V^"YVRE")@F$%D4AGJT-D7%*XFQF0-+L]F;%(R:\&P?"X)
M-2"?P9%N=N"\XR]<8\4T$1&R!N3N)3V/M^\J7'U'^$BL%D2+0*2:_[8VL4V,
ML+I1H6LL6QG=TJ*LAEX$3 OGO6:Z&**3<B-_%&7(0MJA3=*GT54O*_(G%SJ&
MH>%A5[?X[E!M(J#2*'^9OH3$63]2>QB#1:\YAYK@3$852 1\05JU"R\\0(YK
M)X\\?Q;ENP9L[TIS1;Y@+31)F\%??2?<4BQ 35%C<ESY** '/ A159KJRXMF
MWU_W0-ICPS7\3MIWU^ 9<B%W;FK-_!#8[RMFLA/DM^B*$XR66W] "T2C!>O=
MT&E/;9(E;DV+59R":_5&_<TI0]^C59D)096":W7].N;_DAR@#YSV#:KFU#ZN
M*@+LB=QJ>]RS[;B3-;B+R[+Z0O \89*3W66Z3L()0.S<E*MLW2].LS^6@"VP
MYY\#N48$ 'O*\ ZUK!I!P?$>XXR+7BD]W@*\PP\;W0?(@MK[CL6:4S*%LA81
M \;A:.RC+?*S:8]L%/K1RSOV(.C8(4!27:1S..78;X(KL"&P8#6_./TJBDU
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M.6E],P>SOVR1'[P9?U(0&UA,6TIBM*'+)#3/(\7!OK$')[&;33;Q,8JUNR]
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M7?PHL@F*.BENVTRJY:.]&/JBN6(L3AB?0EWQX-.>)#Q,DGT52RGX"^1B^2\
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M[?>$ZGMQ]!$,\Y73S"(L/Y&>L#N-BH,M*E BL4)W:!_V#2<G7M'6HJ^\NJ"
MIST</1$#,0NNWE3,#S2W&7=-1Y60<P07VA!RV527:/"L\G+7K=;^71&<*3_W
M>Z@#)\OZ,$IFAC95?NJYO1_.?1X=&-^4B*L;Z-C6&U',4G/&A'HAJC(D5_P>
M'?H),.I-I)&![@S][<M?!4\<_M(.E=-&V',@)>EIT3V"]C:D?$ LPYTW]/"8
MHWA.;UT!ST2,'%J0XV/^X@?1%:QR]KG(>LNL;/WWN4TB9W5?= ]1]HK)H.[R
M;KV5VI5$5([!0NM%? H:;)63R/(V2(1Q8)J,+4M^I'UY,O=H8U;)-VE,21Y[
MU96]19=.!GBVNOUNT7E)R.G^T$VC8R]*5J#3=R?3^V.-)G$\!/[XTKM/?K!4
M!2359[G9=JC\B'JFP.N-:H5?@?ZILUOM-0'F-=40A\WB<'ZI4=^/?ZFMA//2
MC+35MY3[UP>:(C1B3A?]V>HE*0"Q'TFRRU2]/)!\GM\&G?BP)J2'IXE;U0?N
M1J?'*R>2AOF>CAKQB3$G]*@%:>D506]>,B_-5@%*^*N\.O[>[REX%L%1S=?>
M?WU<?NHC/X7O93X?N#/Q$W5!5Z6[=--V.6Z/UC,VTM#['=$2)U?!-83.7VH3
M&B6%!4:M2M*FO3Z@L6;CJHH2>Y'@U9\]1"/6ELS;!MJ-3@]^C>BC2\P28'.W
MFQHCNJG:7>]FGQ,<,;=D-1DQ8GCO&]V.A9^G*$U*\IK@'B.CQPV+-$SF\N@V
M%ZX8H(PJG0Y!/PQF5JA!_+3UBHH0GP6E'.'"I?Z&H>K+)VR:8QQBY.82>X4S
MDCEW YD'YTLE74MS1@@/>#%Z2S)PIF@D=2;_+^<-?G-P3D:;GS.53X<.S?P@
M80T.]^ACQ92M"6O6K9P6\%40X(S"&DZ!0Z?5E+")S:(SL=!<\*/T=C<] CE-
M> *T JOC9ON\_./X]>:782.GQ,@?Y,9K=KJ4KR@$<>9DZ*9'@S_;_):ALCT=
M3<[[>UBE[-"B$N *;DS%^NTI#;)O.F[B%6<,N>Q:UDM0JC#,2@H2F+C!&4T]
M?"*.1T$2PC7&HX]*9B!7N<3;GX%<5RAK,RP(YX;IKM D;AP[YDF4\8%C&0T&
M-XWPG@<(J@AV0E4SMR891R.SL6DZ;(>NV7 > .\D&B?KO(:%8_W;499 &"")
MFUQV;D+(&CEG@B"SP+=F6&H>E^^QY,AN-YF:D'Y==F]77^6PAJ>5&EJ6P?MB
M]F,J5M8Z(C*(00CT-N"-C4X;V[1 #V7,"BNSYJD"ZB$+!".&S$'3.E9BJ7!
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M3J+DG,=ND/@XB8GHL"223R-P3 #!MG&:O"!Z' 'J$7JB_;WD!DB)M7-7K+/
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M]<99TQ&B9LOO*U!-H@!SR&*<%6XN+*ICM_!LY_D<CKS,,VJ]FNNF:[^]=T
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MQXP.L4(I<E86.I4,_PX6$.@$K[=&*K?H($ZN]'3EWN+]?'TX/!J?_NG-BK!
ML/PT7+Z>INK&)8MCFN,_8..3Z5)_CIY"%WY1O:&[OX>IQ.5K##:BQMA)*7;B
M,(>#DS_M'.DT]M1L:)+ACNS1OM[ZW3:WN67/W:T\.1J/3DZ/#U^-#TX.3\9'
M?R+9>(/UT48Z.G>A.:VMW_.?_C/$J 9%CJH$HQHPQ"PH(^ @('4<7[W+F^;A
M33)',P&4^"DF)H 11-T F+LA.@IU"YIAN>4<DR'A?VB-. V!=-Q&$E??6/J#
MW9;_[^G0T^&SH4-LQ0V735&P$.0HMWW0T<6; 19C-R..-RQG10S+'TMM^=,0
M\&@T"Q$'"5[#?YI$( J.Q5>8"0/JP&Q9DN5MNTI*$@MGLV$7[#0T45]=\5S.
MP@5RC'E>+'6=,R?"Q,L,=D0TF#A<D+N"'0-A%L+*EF](L_%$WY,+Z(G^:80O
M]DT"R6O3"?9(A#)@Q(TFU@A6B=FAU N&<C(ZX_4Z;*ZS,B1J7?)3E+1 ]/ON
M]S\<$R0/PF@F32 5R?E"PNA!G)=LP="_5"JYB03IM(9TO?WX_3[E:\[KC?)B
M@6T9$6<+7;"F Y/^ ^7N9,'O8-X1L,^8D /VCP3/#@S1F0IC00$J"=PW-_4*
MZ]J/<EZ,4W"$Z0QA)?A<!+60@O:GL0"+RS!+_L48@UA4 XJC]H.?<SZ2B[B'
M2 R$]5&$W/%, +P&;1^ZM3?Q]22-]1_0SDPQ$;1V6ID&F/,,"FN2:WL9'>[X
M"B(<$K :W6(W$PKS3CCU0A< K>8"N3U4N>=9MM2/E3;EA)*/$.^D$0B\5)F2
MTZ/6JU<*??ED:NLOX4L^L?J' O!H^ ZWGH-,$<XQ*L'JV0B8)WAAD^HUO@T/
M4R\D\:X3>\< ]%"51II*2E%2;(3*TS63E_=$ZND" ,0;;.#Z CAOAL=DG!0<
MX_AP:-*0B"H,"DD+ O#H9'A@\I42;.U;V9$8[#-6FCK-#NDJ2084UEF*"54)
MEKHG+:\+L[TS%&H$#4C)[>RBDAV:P!I@%XN06<8M,.9MN)6_+:A>T>TN*[=E
M0%BNZV&1.0GO"C5GR@PD&$64HGQ5Y&_$=^%X3P<'!T>#\>'IK;A/[4/R;.(Q
M^G<"$2NA.U":ZLO9&I@\XNHHM(A/.+2"Q'%PM&^I PD8@7KXKCB5:*:')A#D
M>#@RSY.T;Y$<28E28R]R>1M"SY(.=\M5&P0_OSIV") !^5P2-*!'C%R$"]1%
M[G"?7Q ,TI1\Q!.0E=<OW[1(^I81UP)[(0<ZO7N]E^BFSD@Z:_1>IOV?1R?#
M_;O?QSG AY$[" M)I;$UU6'I7I#;$RCV%/_@JC71,1!]S33C)./BG19R!4)(
MJ9FYE!*!E;0$+1+C(Y%R6(:@<TMYN9NN05]H#&_$%F=V1V"1D0*\\DEMV76A
M<Z-FCO.41[$::9K6J M7ROV:KKS5 * P(_TC?IX6 [^C_S*E2/UA64]0MB$9
MKWR-Z.[GHR.'&1!Q'AX,C\QO].QQZ'(=\"B]!S^,!KH\'S2)%'-!2F[=V<V!
MF?-&43VO.<P44^< ,GU_!G$Z/&EH* XDNJF/-J= I5ER#.VM"W&MNQ:X0CYQ
M= _?F3"-AW6>'0P/7IUZY]E#.,\.AB<'QR>@>1SL'XV.#_;')\_->296OFLD
M-3/(C.XTS[%=M7%VKTG'PY1;IU#Z.M>992O)NAV?D1'N&\;R5.FI<D>I\NZT
M3D\L_3DX3RQ/1"S&9"#WUY5HZ.*I=F7;JG?:TT]_SM+3SU/0CRGKQ5*(&E%R
MZL*$HNK%(B6H$,+)ACE2)XL:JW\3*:# ^$T2*Z<D'NUDH$EN=3%UXST.X9&5
M:Z(':(7G$P(9XS;&- .*#<'2/8WVYKYX&GT*&BV5^HK-&=!G@Z7T2)NK=,(T
MU4%JY+HIZRA298GQLJ6)Y;7-,-U';RW)^3*;[RVS.?9E-@]19N-YO^?]SX+W
M6_TLY&CFP+)^3E**L<XDF7!B69)-BQ"[84:$7DDQ%8M5U,J^6:>#N:)&A N&
M<2X5ULTO9@E'=<R;F)*T^B4G':C$?P#I7'F#JT^7RQ/T4Q"T+N88<%?B6)>W
M51@#W2 ]SU-0?T[34]!34- ,41S<O#[,F'4#3]JJ@8'(3X%QZ0'GP_*OK8 ;
MV/PB_(.!NAZX#@WM"T%48'BZS+-,I03!JFY45%>JV5,<Y2'59GA"[<NE\83Z
M)+49<;R&%KN)3AP;!A3*Q0 OER7>8Y:6F@8)"T4(TTT_;^-U+G*<$7Y!4-U7
M 3S5%/&$I8\]4G9&:4,U)>\;M/K29@D+5*BOXGC$5#.I&[ )8KH@X)9:@*#.
M4N3"W$JD2E(T4>[P?K7ORRUV$*5YKWK9AL&9$4CI<J -*I5=(KQ0!2(+V\^C
M(J?S,AU_.U:6,!:1_@5F2%OK26-<2PJ;W9BETD45.M.5:TD$=>##E%HMW+$8
MVZJZ"\D5!K#;OYJ3UT%(.C],(QEPD, >4,. ;00=5NW98?"^+A Z=9YCUOVU
MXJRSU3Q!-X,E1TBWL"SSB'ND<T,?DR382<1G)?6_Q7I-^YE,88*CS>=SOX+Y
MR93DTN1 ,C,G+5%GWU,W4]84@!"OJYEIGS,,_D;WE/#3"4R"TN>H9,U<>'?3
MUU]^<N!BNF7KX#JRJ4VVMLXUQO-/KO!;TK*<FF),*LV?LTN"AI?6J#!8I$I7
MZY+ET*XZ6<.EM K!I&+:_J) Y'G;T@7H9!#,\FN>]@2+/HCU(F17F#1+.+A]
M:X[]V#$3DVH!:-MX5N[8P?4,6]K"$3*.\S2\@AG1P'"=:! L^D@E2Q,Q"L5C
MPE^5LJH-/Q;R,MUO7E-&J)!GAJGNA-(+%X[[U-[6MXH:T1#^[9*Q<#F633>,
M4;LZB57(^=:0-UT1&5#%OB3B@:766Q6%M84YSFI@CUA0NJ:_U0J?<G"BRRY]
MA@@;*Q@ME6 ^;\&U0]+=ANM:I8$3W(DY%@7AE'2Z;FS9-/D X=9BUX>I87T(
MO6V&Y]+6O#! % SV7,D-'0;OI(F03$V_N8&T-I*2V_-$V )-#XY@TBS"D#@9
M$+SU *VNL1D"T-.<(?7Y<'DS6$.(L5[APF4"#<9C!$R+9P+'T*VP4SP3/M$)
MI9I'+.L*+,VBB2&? ?JNVJ/XZHGGRASN2LZG7N143=!N2EYA]BS>W)\/QL/C
M1O7 FB[E5'+H5!J0K)VH5,K4338_8EI0%7$Y&ZQ\=W#;%XA1-.RDMIKAUAKR
MLEBFTB]!1J' %5A.W7<+]> DWH-M.:09<\DTL2R@5F"L\'FJE*3F,\ ]Z_E"
MZS/2789*BJ5_ (C;0E&Q*'6UB?("FR#PLH3PB5NCO+T"+L/583)-[%1 :@ZH
M.WE&#>=#XA<6.9-5K&%PH93!].#_'K[Y5;='HZ^=RZ"?]:!#@_?Q #*CW7BM
M6YVWG;2DN5GW$V[E./,WGA]^!VA2,G\:D2-'16II?S)#;0#I:O'6?&^U0K#L
MOLZ^9E1IOR+^](5@V+8YU[\V9)U1Y>HJ#9=2#-MQ0UO;JNM8J>>76E\'OW;>
MGM$_5T;/:LL:\T4;7@V;U:69@6-+@8%"K<I8N^\VHSIHS.A5Q#])+0'Q ?P(
M^#N61!/Q%+@5I>[K:JB>7A<.H36W$O%/YN7 4H&@J/.\.F@V1SL7K56I)R5^
MS::7X=32D]$QS7*J1?\P727S.S9SO<WJV&0#1]DSK=:X-0P:H03*,1 -;K"J
MPG6Y%_4V:-OK+@>CW1>[^R95V>1UK4WC0OV<[$JR0:]Q2[A^><TX)O"^6[S(
MIYS=(^7LQ*></1JR\P^XB#N!Z_S>.+H^6FMZ!UOR^?OPK<TN/[.FT:^[L/GT
MO0K]P.3V!V.F6>B8^P""L8VV-GJX\C*U]$/X,40!;8?=.E D5B97J"B_S A7
M\.>1XZ A6",70Z7Q650J?P7U_FV2PW\9=N7,@ZP\]ZO_@1T*KIFAK8?U0'MD
M+MDX-U$ !S2#-=%?3FLR+]R2$Y$7:XU5"PID;<X5OW\C@-T9!5B$2S9E&4=_
MW<=R!Y[(?-=81BU'5)=5+%8:K'6"=AVC5JE"Y5/R-L)V(LO0891D.B#SD6U!
M='F%E?: Z4A)=Y #E[NZH=PND]G,+7")9!HKZE" Q\-@DQS&9T#&;XCD>V[R
M7+G)WVTB@/;ZFZLJ4$,9+!I&@1L'5XEQAW04,(:QKPCR(X'M2C0L$N<Z=/(!
MICLMUBB5 8:B /ERO<]K'1&OYKX8&N7"4PP!%.@APT](\PX=^IQJE@-[J,H*
M.PK"BHM\&::84JUYCFY-KTE:@!DU07'<P3PM60/^FCZV2GW>N%]&+_(;_^!8
MKQ=J40G^\;$3DB0RU)";"!PV9S2RM2IKD_1;'LEF>9#I-)H%?T9H;?CV^0Q$
M<O "DPQ2BICAOP?!?^5 RG_-,3WLCS"Y#C,.2OT61F']<A!<Y#5\\Z^@I,.S
M%T#VX2*7[M]_S#"BE\688!4K0?OFY!^.M*U=""W?XK-F0;T MH?N7N8"# H[
M=B 5*;(&WU5P-1+MLA8^PAW'?QX='#DO$'@M1^$T9^$PIP&_E<0+_3U$>4NF
MB8J;Z2"MNN!5I</POM+BL[:[UV>4_78)/^]-EGO\DTZ2<%)",(FV2G6> R\N
MS:_!TJIAR7LQ++T2]HIQ/EY/S@BV!HK3.7E<I>AS&'4LB@36D>!$]<GH+R/(
M'79K)2-,I-;:],V.!6[T61,6%BE B20(6VM=]<XHA&=+F6!.81QE$J*VN<$5
M:ZR1^DARL ;%75*4$B&@\ RG<*Y?IY[A+8O381[=NW(UA=4SUH=O;8JPCYR[
M@+U";<R.+E 4Y45,J@OQS;.+\^!X_UCCKV->);T95F).2.(P03RK@M*)S2VB
MCIZA]#=0!=S#RAHA\ G-18BQV'D0>2<Q)^9+I^0IR-W\&A4H#*L3XA1<EGD"
M2WD=O!B]-";8)@Q^$+P8OVQCBUC@>"=)N$'2 CWB]G)^<? 2$RF!1:D;V)N2
MF(^=B9L]K:F4<[GA3H4:%QQV,"NGU(75G9';FXU)* HY(2/44Y$$4>81+PY?
MTE."SZ^AR4LL3:":A2PRZ1QK(/-;*[]D7.UN?#S.^58<C73OQ/U. M]XB).@
M'!$T&Y[X+&#."_3-X<;JSGN- ["?FS13;$B6TN[$019RQKWP:YEN<TZ$DEQ2
M++E0DV5C[\4>0>A7!31)FVA\ )MN]\HNFTTV0J!K4Q.,JB/>JLE=2J;LT&!V
MT-RO8?!>1.>B+K#K$<EC83O$"1IW#$<AQ%H$<HPI3RRJUFRP<(;[W\E=NH_"
M&\8_EC=XQ\XSU2^L47.+DHF>PR+F_!!%F3^2*4>W/:3.@=+H@N"#-F$,(GPV
MLHDX<RZ93^JB%.C]TB@BZXD:M1U@.%4MLT4%!13RI7D3C8%8(LDZUU.K3$*F
MJRL,C>6''2C4&H6(\QK1897J9C_:KP2,< W_XP8:MM#0>IR,>:=]3.O,1.*U
MQ+]B5X2L+&,0\-R<;^BT1QI"5[EEF$7&?0BT(4:\OP!NHO/BIZZ5Z5G)<V4E
M*\6+;7H7#F.%&:LEZ&%E4U5-:VQ-^(#&JC9449')=&L?[4:V'B>-NY^IR[SB
M[%WTT!9S.]=499<5Y^V&MLXOB'/X4,.5; T>HW49/S:_C/5?9&KA>YH)X2?7
M\(6-C&J?S7:/;+93G\WV:-ELGF7>K\F@!(LX\T-4'8ZL=95H/%_#2.+M*EYG
MGF/H[G9]D/IG4[]-%>ON:;+OM^WY QA8=\QYS1=0R9,7T:?/.?OH]5_453!7
MU2R/!^(!E#)R5FM+$HS27,=&-!]B'?HV\$<X)LSO3IR&/LU<#:RHA.664_9Y
MK!%RI/N:6\*MW*HB3X,<2U-!Z;XB0P7.D,K;890D)^ KLD\LXH<5V?^HXTLQ
M8'B;)Z#IPKZ%I?AJ*.\>73)5?AT6<:FGJ:MU;INIUI9-@(=4')-DAJ@*U*33
M2>H*2WO-"CP.:1E&^H3QS*:)4W J< !EGI)[';7PE*93SI1BG<A&-]P/W8,2
MF%BOQ PLU%Q21&B;$U!@PJ^L3.F> G?>DE8_H9ZH+SN:\_K1%*&]DR(TG_ZZ
M+5?EL:/RW56T[?YIQ+3(#BF1Q0"S4<PMUE8K"CP*_)8SUU@NA#%,)*&RL^1*
M1,3VNP/:\&HG'?!J_C9^8[J^<[]^<>[7@W.R'[XTS\L>F#X_K^-%AJT)!W.R
M#$F);"C#.O79<C:C!S>ZCJT6PQOX)6YTV)4_>^\V9SH)!>MB*_VA\\\7VG\L
MSFC? ]&#5'J0RO[N^4__J>:+-%\JM:=M:<V4&MAF8+IQAM@$E"880".C8,?H
M/0ZO(%P$O-A P>.8FH&K9#C F LRUO#$:9U1K,=#I??HFGC2?!+2U.J!ZYR*
MD)0X&FJ\?(CQH[T8Y%+MR@R]!>32$GI-,76GMHB^<?[Y(SV%V$>) /F52:4S
M1E%[J5,$B?1$VZ,+Y(GV:1HREHR_U P6K"E:1/F(>7F)^$M7^E$9RIPJA9G5
M"3FLSW_[6+JE19R'W4+41:>NTYYND6=*H*$VF\PJ:G1S=I[6^W/O/*T_4?-5
M%'RZ7R1B;JJR%'@FU8Q/K55XK1GO":H_A^L)ZNF$IT,UA$&8V!H1(X(<)Y:+
MH$E]1SP9]>9(/1D]!1F!$LAA>!OL$LQVD]%KO3P-?ZUU2:,R6.CD10*^5IE.
MW2?H=OG&(*@K_(&\0[$BN%GR 0V<[U(4GR2<)\\^715/GD^";S,'.ZYPHM&.
MP$OS['(OY;+KLE1.%-KWUWD47!#T4M^5+& ]<*W4._X[LDK!IUZCV0^X<08,
MM&+AF]H$V$PI4)&*;2E6T&E>!H^9_RKE\%%0A8B2S1EV8,>'JY]"5QU/1N/K
M+N '"D!F19ZFG&A& .&VX91X#F+&I TF2^+Z5RJ+\Z(T33K,-SJ<@\/@DT$U
MXFAAJ=HI@HW*C 8V =QH>##&)I -B"625@B2$B=3S+8S=2*P)A@@6XV<#D2$
M">SM-.6\OZ0C1<WV(P&N5=G>)G _R?6"*$-15-0J7G]GM 3=_O01SUF^/7?I
MSNMQ6\Q?4[".S35B:X/ <3N@EV'0Y1M$_)#/'P,GA+ 2.6 OX :1 TNSQ/ZJ
MY0(?26WK #-/'*+5@MDV$0BC(B_+%6@W@R MX!,"6ZA552=\V-9F42<M;,LK
MS-753+$;D+OSLR:*HFYT5IDILI-AFYW)/+R8)W:[H9\ZVC5D04J(/B!$+KF6
MM).N) $Q%93Z&4Q7%1WZ![7=J&8YN^:!K8 I==?@ X>OQ-PICJ6J;@I1<CMT
M8$YU850.FO8>C=S65(CT5X'4[N)R7?WJ: 8F@V@57U3ZO\'GJ:#- 4W;*2KS
M96_W*'M[Y<O>/(C[DU_#6^*S6!O?^C.QN$996=9FJ_:1\3ZV""9PU+I=:2;P
M*TZ^A6&G<5)&5 #C<.#;&R!Z5>6YWMX_9@V$Y%9RD$GM-=?1:MHKJ0#=3:I0
M@T&S0'?K&@9GNL(/Z^H)-T.*X ;2X155?=0'<FQTL[3-K( LL.$5EV\20M%
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M&D4,C\Y]YU -AW<,1-E&:&$:H8P07:B+)F&'%;K&%LNAK5%A[1=T*<%8"XS
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MYG-SA8(POB+YH9WI+/N:H'JR''VY'$1TDS<Q"5,:IIPIV$1*_-H8^<[(S34
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M\JR739/4Z&? M$L5U<3"%V%%!?.+19I$[.D82/Q,U#OVAIB7589YLJ1%@IB
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M0Y"2A-')5MNJ-(3>94JD-3%_%$I%I0R. LZ2YL1N<_8HX)8AFCR"%,_R%'1
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ML["?WISR]O5FF[GVRM]Y6W;HLGA-_EZ:/)EG00E?056TH(8:HDB2"@]Z8:S
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M59U8L39P=NX"H^(5W'S"$YTZ"WHG,2^[);R$E<N[1[\2=?I]$<[5=5Y\#5[
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MT\ '4$;^116E O*)$^RI]R'+\JN06/9[(.'&38 UJ 3O LJKM\.S(=^<KHN
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M-UL<A5[(;3;-0J[:8O:6XX8OZ%QM^S*UKWHHD8SSM/8\:W)N*J=A9%N.9SZ
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MO$C*7JO;:W4:K4;'Z;8:35 B&+G=HI3EL5M!&!:'57N:O_@97!O)LYWRIA[
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M?5]QFS!UG)BJ&,G)F%2!"P=!<#(F9$P(4Y2\)H-#X""#<Z &I^G8O>=:*B!
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M<""4HE#M(-R!J@!% #J(_ ^1P#M3"5I"_H=C6PS8=25 77AIE/4R OR?H)9
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MCMLG>>_AZB/X)9Z(XI"R)(?OD5!,5W&"DT="69(C1A1E28[;(_ENL[<1]T;
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M3J:#AZ9IY(Y!M)G.9[%XS",19V?)@2*;A(%6=&?KSK E.!(<CP*.'T8+8&2
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M"H>F3 E;_JG5R%.4!,.JR 3!L)(PU#G)>//",WM5EK-\78K#.0SQV*.&?9_
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MG><'%*$^YK@O,&#B5D2NC/$'Z0H#<2.W(W2J3%[^FONIV&;/GQJ0PHNXG<(
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MT[ZO=$B;V0@'?.0C9 -)52'I?M0?>"QD\_A<Z]Z4)"@("FZ2@ONQ&VZ9@N[
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M8UZN<$_3!O9+TP8=#V?U/8D^8=ESH8$+4&LM3GTN:&CMY^4KP"EP2DE.P;^
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M[,A@><KBTDFU+9/;,SB7+=5]%DU>*D^F7)PLV%HF_I2I./%P<:#I307AX?Q
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M-W C(<.T"W81\6?-)E:WOR!'?7DA/XM7&)BPG)VWTS0Y(6O&994UU^(;YY6
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M@:+N,46=UW]%G5C1(PM)W6E3QG^2DRGO-5JSE0,V(:2#7>N_7</Z)(1TD J
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M"8BD(6A8X50*#H3JVD$&!BD%!QBD'61@D%)P@$':008&0:<&G=I+%[P4KLR
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M^34(JA1,@*IAYB %4=[,05 %%NTM:%B*4PH.=0-N0 8&Z0 '&*0=9&"04G"
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M+.H+C5@.113XB_4S!0%1=]X T, B70 !BS0$#2Q2#!"P2$/0P*(=Y[&@B()
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M5?6E^7O[U'"'@1O>=*LT&N[0<YQ?'^Q5&RD\V=._D,]%PHG?\*_R+]%S)C(
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M M<-X<K?67SRES?V&Q"WAW'.E__]?DA^_/7X^^')\1\_/A^=#LCGKT?#S:K
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M:L<NB-&0^5,TU-<PLA29O^/D)ZT2\F-(#GD/"M4%LG_(_NDSAA\>O\I&S\@
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M)XQ,\\# BQO[\U %C-#3WM)J517$%-PAQ](,,2,I4IJG*,T8)R2EQ*^)Z\<
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MW"X:&<PNCD,0D>EW/(P,3BI$+O#1,[(1^CHX_?.B;2HRD0.8Q*"%20@<P 3
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M&: 9H%ED!@)H!F@&:#828XU,Y(!F@&9Q&0B@&: 9H-E(C#5^(P2  X"+RV8
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M2(PU,I$#F@&:Q64@@&: 9H!F(S'6^(T0  X +BZ; 8 #@ . &XFQ1B9R0#-
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MGXFKJ[.D.K>U7(9:FE".][E<EK9Y%4<-:V2JCJE._.YP"_T4)E/.#ZH9JVK
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M?+C&OE/VHB/D'X^6WH;8V1C<UM%FG-H\^(VDA254.;3RO\"1_PFP5C@7%;G
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MRE!D!3,JE5@YQ8?L5'#DVEC%8=.LY$+;@ZH9J%,!\Y8X6%G[E!WI"(O'@((
M!8E "Y,0.% 0H"!Q41!)N1186E046"#&4HY$FG'DTH(1YGD)=F;(CJ /HB!_
MIFRP-,B4?>4(60:4OTPU]'6E_,5^M;4NNZ:?7>U+=1ZL&&I=QLT\!\T#0,>K
M:'-PT^EX!0RP9X X$U+EGLT9P3%B7&=(&)6A/,TM9H0H7>A!@E#;Y3/!]1]U
MGO]-#PGF[C201UD+ TW XO=?D8D< !X /BX# 8"?', S;B@I7($P*S+$&/$
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M  F(VUB !$R.!!2.&>.,087(%6)2$Z0D$TAK27/AJ)9D9W;!?<(_CT "4BJ
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M-LV^^NER14Z"TWK[6[<@J;F9F\R/Z4T7IFO.=PII5[RX,GW&"]<[;-5]L[
M:];76;6'&(V-SW6QSVP:\+*JRB]F=:J-5]G>6O*.Q=C2(/*.);DGB:9UV75D
M<U%9MKU[UYMA;96OF%2NIZ-K9C^8I6MT;\=I%]CZRF;FI*:%@4O2N BS[K%E
MV^T3AFRCH\WXW6'>8%ELH%MAW','J4E]C[D]KNS1])B+0M]DSC>9.\X%_NB;
MS#U]D[G]6Y%C1>:@5.MR!O#KI@_WV8AEL1UYNIY;[N>R/0"TWI,=Q?H-MENK
MTP\@L-@.5 \2S?A]X?>VIAMP65<4OX/.!DW/2E-WO]T.S,N91> 6 @]W BYZ
M?PVG-TM,WZ4XLJDP&95M+SJS7VF?M'6K=A+\)VS\[,9D8S^X/2O19EZP)?)W
M&P$@4-OJZBYPO[K':E,TW?ZM':%]D\&6M]!N-Q!L$>2BV1#=;J3#E+?G"FV+
MDBS5.64H9$0B'"<:4:DT(EBJC)BV5^%>,A-^-QE,"_6N*J\,!#!.Y/\JFLO7
MBQJ4@*I\M-N3QHNUU+ 97V#2C-CXK,%'B2"[*.<@:R0D1QQ'UG&3=2)VTMV&
M374"OOUD<,2OO^ME?W);&?'*4!?HZC[*5S]/K-?0-:_LH:(Q7FYQ6N]6'8AV
M18*2N_@S&V5>3MN$TBO;_/5S64H;7V9ZT!;"-2.V<6PNL<\BU14SVJ5!MN[>
M#NBV$W+9E!8ZN%!M"QU@IV&S25N'<PEV=./!)\#"RW"Z_G6JI>:P=P_BZ[K&
MNOUJ#(+Q#+X8=)6M13FWSLUV,2?#.<]595RI[O5</ROKJC:3KQLUKU\&/Q4_
M@QTSU^N;E8C]G^J?^\2 =KU?P=7KE[>/L$=32V=Y/:@<84>SM\*]RV4PO\)/
ML[H]WS7]H=6P8?1U![!6Z#)QT8@W9L#KGP,&[]2G[&X,UV72WGN2!N7]!,,N
MXYI6F.\G0R98E\$2US!4K:WS?L=C5H_XRQE@,#:?3\TMEBQ #&2(X;HK.[]Q
MKP!ZAZYA;&Z78YTQ+8HS?9]LG]--/BY;".R&L3=-76F/->;=PKKF)KNJVNB?
M=C4[=O"-N/>I%<\,UPR2<(!6O;!T>=EWRGW'96;38O.*MU.U5Y+M@+;Q7?]D
M(P0#A>.T6M_I>X<LG02G&_JKVV+9<Q7+/ET-%C;=,JO^$>V6I#OV62J@Y0F5
MR8(WQ73:FC<NO=V<5 URV=MCDU7YZU>FL/G;]?)TI3_<"LRA565J"/3'C$.V
MM^L#=]>E7?.;]13ZG0MDIM'J3E-FH-UIKCZL7K8^[QJ:UWVMGG8B&XW3NX;M
M?96"P7&H6>;!*KNQC/YO!VOWCOTNT.I--]?^.W/6M;XHA4M!<H4(K/FJ5U+(
M2KE\2_NSN]A,:;ZH3,9B[?7'8WE+>B8'^V&#SZR KT"C(4\45IZ -F)Y<-X2
MR?I"6GO?GZO>SYH:)C)<8N?BL@9FU^74E'2J%_R_VQRU%6:NV])4K03 (UB;
M<- =OB^%@O%RT;3GQ;#)+^0">',W^K,C=\OA"F"8!K36K63T3']\[Z+U6.W0
M7BM0W3N99S@)@LE>%O.3X-/J$\U3EH]<50S]&K>:1EJ-YR#8BH(1P(A= F _
MKW6BJ<).M(U<++_,K-^H_.S>T"(W]RJPDN6B6E&PE6*R,#BD/UU?UW$_.07>
M)F9L81C!YO9&6""N#&=T;_>S U%%,81)2\7=4L@^L 466Q^Q/B%X9.<#-!F/
MK1I=DLZ]:SOZ!B^NO<]])S$4C('M;7TYZ\SQL\W =?SN/(^.%NQ>DK=JP#NV
ML5FD35G57=&6+L=3L4I<3M;2:ML2;%=&;YM:9D[]6E)U(2;]G*=3UR#,@F56
M-;/6LMFB)HXO7/;JLM!):<K,*6FW0E53U+WSM#6_,)OJ3]7,ITRL53ZQ413+
M=W)2V[A\[$&JZPK)BH>OY7=P2.N>O6UT$P&SI-9R<U;T1ENV41_<;7" X]:'
M&<CE+;K*&,JI!>SM6]CM!0=SY"1N!W8:<-/SV-9C/HG8W%P6EI%G0YAN!*C;
MDO9XK2?B3FQHF-%4PBJK;LOF"@F9PE223<N9L533J05/E:5W[T,Y/__4^T_<
MH5J/\. G=Z9V8O]<W5#8GNN]I+4Y>P[:.DY?S&7W$JV7I"^<Q57S1<&+[QC
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M/<W[T,)<,\KKE9BFT^[TW&!)-\:'@LU^+<K^IL$E%AQTO[^?Z2F[NG([LP\
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M=(I9)7B=U<?W(X/>@:D4,WN+/ E,^=V!^OF\ &DR<VJ'-((\:R45R!-P!MK
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M\ZP)SFRBRQF'.Z[M*??[V7RQICUCKSV]]O3:TVM/KSW7M.<?L_)6S9EXS7F
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M$DV".(QC6Q\#_H"/S:4*7I=7\)HW3L#R5W4@6'T9J/]9%-> ; 'S!E]4I=H
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M=X]>C6.XLNUH^SLW:I?9+&<W^ @H>8!J[*)LV#0HEF6,QQ,<.S(Q/2P<N==
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M>J]G.:MJ.#Z)C1Z6Y8)/U;A1];CU[XA.L.]/X?$#<P]H6T ;<I+E2DD M#&
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M)$HW#DA[R;72>G[)*L"2B^:RK.!-Y0IVK.V/0]#X_N.[VU.G8(E#^_^=T/'
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M$:GJ6V8L+3TZITHJ*['G6/\Z%JN8TR# 00*4.$]_/2(3FP!P$4$R <;8M(H
M<@T/=_]\9SK$WN(EH!\C*>QDBQTC6F&^@9@HYE2R*J 0*-@23 AD0@DB20A'
M>*D)VW0EO1[J!D!05WSS<9)J8-]VQ$H0:O%CT_W:D/VTM+F)8UY(MYMM<"JS
MQFV1B%B[Q@Q%2D?%X( UM'(*519^<9QB76VDWWZ/8EA%3QT+S!EC/\XE2DZ.
M=X_/@=.Z=7!2I"C#LHISLE -L7-L+$<%CFC]K^O!Q83 _-?+>I*.ZGZDZ4>9
MZ[[V78>\#<JFGEPV*HPZU-'1!_2+^OYR/.HBN#%[1*</J_7Q\QJ1><5)! 6
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M>8VXY!72TGHDK?/2$;A@R9ZQ>O [NKL0+'K;VZ5G0O!H-$]& ?VA16: _C'
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M&?PE*\\\PYIO#,UA.%C.O$:4$H6X5QY5E&(4I*JX)U@ZN?<PX;[GRO(!(V3
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ML .5QD5)P8 C!$DG6(5QY3 .WSH@.L?#N\GX8CZA]/_4T_/77<#A;>J]$&>
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M[&)L8'F3XS)Z)UM\DZ[4/=$"RB_]BXNO&CBO";5W)T7Q8;SQ$HOC@$E&K0T
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M[P\GO_?A;FG>UHZ:?T#OMGT.8YMSU9WJB]03Y2C?PM;JH,ME]U2ZO']:?(>
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M&2"K]JS:CTVU$V\Q9Q5&3A.,>$D,,IY3) 6GOJH\T6)C.GQ9>ERR8!%C'N"
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M4N8D=_;3G53VM^OXO4?G9<F6 Z>'9M%F"/!R&"5#@*.# ,:6"LNR1$0'#Q
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MN?/E7&:]MP!5*3'4,L(-XT0K8#I:^-R70G+GMG+N!&<<X(DAA782S@%C&7U
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M/'# SCK.=Z[Y6 '3XGF=D1]883:]J)N ]DZ3UU_Y8%U0.,0-5YX/^6\\!I@
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MI.6T)$#V.>%22J*,HD05)5CS&3>,;0WID)DKM2LIX=07A#/D*\X=L(QW6@C
M>VZK?^(N'MD(O!T\1=1C;+9L0_8D"$71M1K^!H)LH4H\N!<FV"((50"2,?8/
M"D5]72HK)N$&][0;J] L*-A*0/G-BJNN]S2TZ)<;568^BF3!'W9A:1QFVF>T
MSA]FTN?)B@C]U \LV32SK_=S);U<]LIT,:UJ[DA>M7E/DW^A03Y15UVY ]J^
ME\JZ>>+S7,J'Q/&@%^H$;F)A$2W!CMBV>T!L2XX=YAI,S< KA8>_VG8/S&WL
MRG8V<BB*0YL<)$V?!A_8)\"OSD7:UUR<)K_#04%N-_6BX5?8M9,UC13N"3<<
MP7F5OYK;\OT[KL4 2>W)(@88'KEQ\.8K9DY7.@'R3W4S(; AV&RZ><W5%F,+
M[V3ODKB$*\V:19;_<D\7X<9KRS".1)B>Q(C$5]B.6GCEM<E)(6Q*N,AR#+=Q
MPJPM3.ZMS=.M7 O#G+".2:)SSPA7,B6J+ 3Q-*-*2\YRJC?ARV\=&[[=5Q "
MI/FQVHJK+3O7I->GU;(QX/=.=BWZ#DXO@G!K.A1A0]QND6.P>MZ\$FD.%58S
M'K9$Z+;(W#U^9DO =>AD(X2X/O]LPSD[57^X7:[9S@\<0< #93PLYPMM)SST
M6J4K-\//HS2]29JFQMM2YBDI)8[JECC?"PN##,M3Q7.;BG3+85)(63A#"^*4
MD"!-N2(:!QU[GM%<LBQEQ=:,XWTG/-!3>O32- BR+NL!Y.$\RK+F7>MF,;8(
M=Q_1@^"\]T6I2D)3"NJT@+V7&>5$.9JGMBQ4GFUY$#(#-)-13ZRF)>'6**)L
M49(LYU(Q97C&=HSYU-.7 8PC.GREIF$EG@-*NB;-T:JK8\ETQ'AD!W.//&?]
M!(-_'35/ZJH?*]F+]:#;U0ST&JAD$PI187/A^J&?#TJ-L56]EWHV0=,%C8_.
MT+@"1/&83"$8DQE/#5&%+ C/4))JQXG/03ARY9W*MX;P:*$LS;TACE.+99F"
MZ,QE1!A@D*PHN"[,MENM"\Q573$T<@,]?G;XQPSVOK/[LB-GB [<+C/6MB$.
MUH0'X[W:G>1SJ_,C0M,]9X_,?<!KCLLVL55K9EWVM:XW&Z)770.*JWY(W@.)
MJM7+81B*5)_)165ADY^!(B\]UYG-2%Y2#3)+4E*J5!/G"EUF)1=&F2/8H$75
M0+J@^[4?!_YZ*V&D/@\)9Q),^AG-:KI B=734!DWS@L&2C%E$J@,-!Y1BF;$
MBU0IH+0<D.$14-D_9F.W7IIR3$1VF@2UM*2LOCBE1><,VMI]BY)N>O"&%V5-
MWPRAJ74<C#"T%UEAFS@8(0Y&.*(%?AT'(\3!"$,ESA>7VEETI:]W$HH-%/?4
M065N>=";&JB .5^-T;^5M+/)9'25J ^-<WWD/ 3)SE^]">AJ<6 _46$EYK3=
M+K$?NF#4V 8G0)A^H7#^>=4&;+;(?<# EUK^N2L/8C7^ M_T,?Q^LD7P2%SW
M"K@@H83!S6EM QVV\UP,@XT7DJ:N+Q=CWW<_*WZ#;L#EAPTV[<9I\&H.1'>N
M21 :H6$@1OU6^J:NYJ\N'WTQP?SVE_/59Q>:$EY6?6M,//FC:JJ0T&3J=KK6
M,W%E _% #/TWF$31';@VI3ZDJ6Q</L'^KYT#:![QFC_3^E[M&%,"U!!\I/-4
MD:W5[-=EK?@C#.F87LS:U;2;^94\]O'KGZ,UL+WXV/-./'I6C2Q(!M+.JD4C
MGKG5 /?IGG=U ZY?[L?-)G8R3TT&YBJSO ##599$49Z2G)?6%QQ(F6UUS1.Y
M 3-7%$3GIB2\4(!;:6I)2EE6&!S&3K\H4_);RB;VR) AG?BX/;N!TZ^-:03K
M>9E+VLX,"@!<FD5-Y6/2?IZ*HLPTD4SE0,>I(EKDV"[<ID59VM1CD/=A:/\M
MKH<:;?4S.3K"Q_1AI/LC)_O9>(2JS%4A_:=S>G\ P@XYFU4WV0E>N^FV_6F"
M$\<*0I>)4MW0DP4VVD96H6BU;;NY993U)1T+$+1:T>!&B_I2%51TE_")B1BH
MMS%/RU9!80,&?G>>O*\G(%DD9R<[9=B U[4['Q_S634%RC#7.U*N[<4ZX->[
MEF<7C11Q^V#C%AT43W#3UV?7J<V,7>P4OB._#H/S..#7*7NR<GI/GHL<Z[8S
M4KK^ [=W'%CIX;@&N3<N&]"O[1[=N@F6X 18FZ!0^1R>&##XR<;M>U#;\\ZB
M0?4T# Y:NU$'W/O^"]UHO<4T9S@]J+$PQ:X!VT-]<'U>(ZBR\'$P]&X$OZ$9
MYALSK7>W]NM@?F=>K!DQRROW8!)[I,^ ZZ<=S*^;#VK<S_9;D[T/WY8ZUYIK
M5RK"*>9,\,P2+:DF5N=YFM*\]$SNIRTU[,0Y;-![W+"O[$<=M<W7:9M%ZFV
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M7S1N(F=W'4NQ?13CISR+4RXVS,9OKVOA<(/;L3/WTSDM8WO8573QD.UAS\)
MKRW;<3CL&CO&'E*&6>P8.R2[X5]?9#/@O+TPJ/N'X618#VSO#RM>O)_DW0&R
MX-&L^$UB[_B#LM<XOXPL788Y]\Z5@G"1*Z*,9J1TBENG2Y[2<M/YE:7>\,PI
MPACV<G#2D9*QE/A"EMS1M+#%+;V6;G6"T9WCZE%@'KZ"H*?9+6/JH_AY:O$3
MZP"^-92VYL =CB4VL)T^+$P6F^P<P*(??%YK#,KW6))[Y3-F+!&.<\*]E41I
MP4GJN2AD49:TV.KPL'<LN1HZ_<TU2#-K(?O)K'&+F#UAJT'[[+N?Y0V!^2B
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M,D:GX$U-V&SJLY26),\%(YPI14![EZ"T79:Y5$I'\_OH^-%5HYX][YCT?(7
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MKNW5S__SUQ\OII>CG_\_4$L#!!0    ( !R$?5:2S!PK]10  -;H   1
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MWC#+55F @G4IR=9VRK7+.'(,M^_'!MVI32WT]*JN&QN@:A<.+2T&[B9*UI/
M-AZU"Z.M#84K3;6.>G<<-PUA-6 T[-(&!2Y&KGJZ6*"R <@R)M4,BT1C:TOH
MRPV[:?6<VS$-DHNIQ6_<F&VIF:<,U>\TS14%;"\65N+Z%3'"CQF78=FX=[8
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M()R%/M>;@"-[X+9*JD@7*-OCF20"7V!O9Z(=TRJ=L_^SS>>+%[$%N'0T#GX
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M1[/GHIP "X&:?#[KU^1OC@9M"&]R9!H;WJJ[LR<7>DY1(P^QD33?C^XO*_$
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M.CTM,/0KB6$YC8"J2;" -3G-F#/RA>BPI-?7P1-V ZVVXN-V1M<IG*FS'?(
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M8]-9]JBJS*R9Z>[JZ5VCKASM*),R'55;6_:L#2*#$KJ# !L );$__7/W.!
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M+R[>YG#I=(7_*EF&XVCUH/2%%P4@8 SF)]E*TH78%PO:=U<_+E42^6C!H?\
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M57?T$3FA-'BU=YF]IK4CX6=/),_>BO;"\I.@X*I>;+T0]FYPWP28%; EX"9
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M/@NL]FG53VV'G&8$"RW.O>UL>;5:\84/2HGM3<3G'&\YPTZ4A1=A/U91C&M
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M,(V(;OD&9-AF+CXH#G08Y?:*@HMJ+2MLJ,KK>RW,R@,K(XSWG##1Q0:]A,.
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M.JD,<DD'#Z(JJ/>%O])?XB8/1B<E\%RV=SZV!/^&^7(&'5O3$#JX1D+M3E@
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MM$.'DB-#< RJ5$3Y1ZE(_A11%"<LE[MPJE467^+&BV81%8Q(XTA_6JWB=AC
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MKC;L#(\$'^VT/JL5V=6Z[]01.C<Z]W[H>SH7#SZ8.FO\K+ /"H>F_O<:#_'
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M?_FG/WS\\/L_J2E,#L/Q[:DB=K7XG9J>9*"TR4))0CADR7'J9&!9C70_C39
MG+-PC@"99IQ*LZ>)YV4B1Y\$/,%2E26'5<'9Z3R U]OEJ+,.E5;/O7ZE@UP9
MPL-$UKDI,<XJ'FA'.X/?^,#T;K->B^WT*>)D+K4P35019I(R,Z3'H(C8HX/K
MP%6KRN0.DG*E5D3>X3%!+@3.16AJP!(A1Q,66A%6Y.5T[BC<;1YC.!SA.5Z\
MM/(!IP094739CM&&[*)8["Y*!UV!]31#@WH(+" CY\CZ@UF$@E!'0W"BZ0K=
M_]_ TMEIC=;7K[/J0-/P]RD*XT9U7#*U\X1D"EH?'6Z([:B2>M/YUL,)(X*.
MK)?[U_#^.=S$8-%>@OT+)K7UFSO_+>$\D'X06+KP+L$UY$4W/K+@M_]&=O3'
M]Q_^G7H(OP8-=<SK-62:!4.NE)/*_%9QUDZFX4U+X=IF[71-<C8MKD*B5V&)
M&N,/B?W;6*V-#"#@9".U-AA#<37-Q"H.^2G$ /(MALGC+QO4>;:$WS7SJ24A
M.8C:*GUY(5XL(F8C4DV[7581#)/$F:3.E,*S)2,&(](M[X65/J\)"\Q3?4%.
MKEY.TF\7?D06'?TD:T%GRP(<IU8@2 KQ1E3-EBY$)2!3 _DDUVH# HQ^1>S0
M8#%$C>3)%%-\X0O!K\:^$/9FAOQHN&]^.]NL<23,W8-^+R;J/7%G?UVMUIX?
M44=;=.['ZS#VQ&QY'09/USA^21I1+58HI/Q0>>1S0HR4N39N1<6NCA'3S KU
M[:<GOJ74/8^O OFYD/MPA4F9(/;GU _2*.CU]!11>R\8+XJF FB"-<P#&DM1
M'*9TA[A:!:Y_2U4.6$@<J+T9N_CT^CMJ\J%-N AR[P*,V&#!%V:43[.F84G,
M&KHS)E74TY:T=U 1C7+IY*8Q*9>SF71!6&[JT02^])UGZ,PZDB ,2\LZQK[<
M"/;MRS"ZW"2;B.LSO,U99PJK1X*U69Z!9DZHX9(],_S'OP;V9D83>XJ5ORQ0
MOL.98]VM1]Z+4$@D.5LQLE^*I5P77PO@,+5U$X5SSA<Q3K;1"L^6-Y'_ @?V
MC?!D%5HC7Y\G;*VXR$;%M:2.$8RYH]2J6_74*WZ3T<IV Q0#=N->PR]A8#97
MF8!7===M5++(RG$Y3=ME*VG;.J@'9-/5U0GO%.EO.RE:T0 0.+@P1<HX=A2U
M%>+/@'#82.N*MO.L1;N:U8 7&8DJHM[SZ0GQ6KD+\?D1+MU.@FDET:S[P^]N
MH$W&"*\&[98XPS>>[] K+5(3S6^T4(+FVWANA('K*4#M:[/O<=&P8(F*3/0=
MF8TW\(=G3_4R*!#.>!JGQ;+7X2M&VA%(X[,7_8TG:FJW96<V@H!6_-&$DI:&
MBCQ[L54PRP1*076*".BQ(D'2D(MM=WY%ZR1R2T2\:6*H7*)IS%+^C 3 OQ+F
MB91!X:OG7):O:(ERKDCK;Y,#/P7GX%X$"6S$9QP_;7$5+/C;?_&#I]UG DA$
MD"F*C$@RH#E@\477DNN]?!=].E_DH8&K9;E,HW1",(_H@/*#;O&Y72NIGEXA
M</9NF0L&:M5"O#OG\J=OW95SZ=3Q(_9IP/ZS#*,5^<F/PG\B<1MB6Q!AW%$T
M918:TF-01^0TL8BRV:@TV4WF=_MLTB1,&"5HLS7 2\W$6CM&A&U#?F&+3O9K
M)S"NK2Q]IMZR2'[GX8?=2<P-8T6%PY<[B!"ED/[ER'C7#:>*UP#%<SPQG+:R
MM.Z"@./:*T.P2DR0\AC$%X62=XB=UJHVN7/%T@KG?;OLS)D#XXU [/!SOH[X
M7/:FP<]"(G8'"QM%^R;">'"RQ0+.!/Z&=9WK8S( ^=D!EAS,%@3-.R4*10)M
M829,BS.A0E>P^_ 2(U-WXP;Z745[-(&;=>QPFD%?2VD?R6X6T?V!WNW"%4X>
ML)=N88GQ%>F]8_:T_JYT82R5K@,EZUNIVY@MC9Y236I<,(S4A*-.3,-VM=61
MTNQ#S#[##K0[MA#/(-U/XWBSTE5Y:X[VQD\AO,J4M\&.]69%9I(B>S$D?U-K
M8=S3QC6)*:HXLZ2<,+/"J:"$,]#!C(33[6<"R23Q+R/JNYUO&S1,6^28H>>^
M=_K8UT9WA*BL@^5X?L)!D>VT]NAD@J9NES8](9NO?V':^XC29=7IK,RR?G*[
MGCAX2(3XAE/^R2APR\ERP [:>&=!XW;**#&Q5+1VS@LI.E:ZX%TIZ%]V'!I(
M2V(6G*_P]3K#=FDP_>#'[&SGYFVO*1-F<<G/MQZADN(0_3H >FC:\_"3;. /
M%OK(O@_Q5];\.=/CX:)M)->V,&%2'C)8N38BDI#:K$8&F]G9RK9W$ID6$^LI
M7%A/ 7^=FR99^BC=/9A//$"$+O2>%RL_\#&.CVW3+91>*M+2+<X0[ZSXLFWM
M[ DDEG9>AOAHU!%UGY/#Z8+1DQ>H<$EFWKV<%1GK6/EL>>D'7C#W/4%H:A+R
MM5DFR^:-Z"86=STWTO!'@])(P%(1NDE]-=P\K3VF3<SA?&Q_+VJS)<>8SAZG
MRV<']1LMX(??W (Z.*HSIW%OF->5=?9MN!/%)?>C4DA4ZZ)/K@Z<!EV#IBO0
MK@+J!E*C&V3#>[-DB^PN<HU)U:H>.6B W3(]+%V4>BD&SJ$0J (>@Q'-&SID
M=\ <: U07+7FJN#_S(F0JB^:WA(_49FXAHF$:U71JNFQA9,8=UNBV\O,4E+L
M?-!2[[2==[?FTR#8$.ZRVEW*0\BZ0U3!KNL+K8+^YJ/D-.A^L(.PY7:LW$"6
M0KV]4I"TC/HJL!"X=@+HV(INNG?U J;79_K778VT&\CZY2<LR77TK;K\H#J_
MHWO6#;K_[HMHP6BYK Q+!ZS<AQJYG'_AB>P#O@YC^'W1 %O36];NM%Y+'HR2
M15HB@I07B-0)O\6?L6*.;>1T6PLWHY.9OD-8-%&X7D88AG@"NI<;!?H6_UPQ
M'SCM%>QH/G#J'20>5M=?>!'6GK4PF3);K+/TYRY'#[0COO%G)#&FJ77@P!0.
M[_GBK?AYN )A' PBFC D/QJ-1 UEV*^2ML/G]#D,^%:V.%YN@D4+WPE1U$V=
M1'/HTHLRP;N @2^<,2*G*6\0,%%NH&'0')-ZC$JH1U-_+(JSP2<'X:YCA^%<
MY1A24'.)!$>E"]?'-I5DJN3TN"8EBS2N65'4TL@C04$-PK\"#B69''>A#&0!
M"P*\A4CU*M8G4ZQGWMJ'+\A&IN]HM4K -U1\R^2,K%3631C[-$P,0=YB+'JX
M]H\.^%1!<R@9)FGF*IO0TH*P7U-1V 6X)&HS<#AR+XN#;ST]*VB,#SCRR=\2
M]+#A#-Y$S:"U+4X$*D91Y'_Q5NL_4:V$9B<':RA^7\<JJ/>E8&R _?&P3&C=
MYLTNOKHEV9W%EY\% >YFP?NB*VL*WQ:W:'3%=>Y'S9'()W(K"][5:(GNFJY<
MZ&IG7>MIVV%K5+L*V[9E/54=6Z MJV>C_N@N%/HL4[V>W,Q"<:.0J/^HW,^G
MN>4O/-CP<Q[/(W_=%.+";*N1)#MABY3P&)3)GYRW6H]SEWJDV#A7 2PG!3CY
MN9=XRJIK >''(HP)+$\;C,-71O2NQ\WF4?CS2Q%Z;3P)28T1N8%*+3H4N+OZ
M89D::@:N@GF>WU;5]7&K5N#8=U=D+45VY+?0N9P!4Z;<NI!?R6P)!P<(T:CN
MF*;598&B90)?L+7\%D/%9E0Z"EL]@QA]28C12CVUU<S&J%[.PSS@*3IT(].(
M%4ACYS3B:W_E2UGC6?#0K%+>0E5%I><V'R921@R^_(W38G-GZNZ&X%#3# N,
MQV54?7"AJAEOAI6JGE &*FV=GWT!FV$8<#E@M(4)X(:--H15/-MPDKNTRREN
MCM04!VKH?%ZX.U4+YM8IE967QAY)Y951V2-N#K>ENEC67_A;<O_*Q0O_' ;)
M<Z/8@5M#K"N-U'M[&%KWA/W"O8C- E?[4<% .7L"8],&2#U#+SM-L /T9@=Z
MB:Q*V;& V;F9#B=3.5 LM\WL?V82.=GI+@.?Q',H%E<KL,->9#]7\U/1D&4V
MW5&H(:HTZ*# (E-5-UTL*"4)AC?L45>!2@!9-9NZMI.2S*T,IG1;T=^E>NI1
MYHH#4Z:T\6/AI.([R93M3M(R7^+NL%*+K]9AY$5;.3E:C9M*W?6FJ2Q#7\^%
M?I39FXFJ;AZ/9B*OD*2K%;%C'"Y#Z8])BH^:!V)5543A)GX((BYSI>@(Z>J"
M#Q^E53.+<")HLVV6H%IC"ZH5-ZRO57%AZ5P-3TM]S$H6E@HC_5$MSH1]^,BD
M1#BJ5<K4[6RQ-D-&V?%BIK"^))PRP>+Q$2K[PJ/'L&)87&<Q0.>:YE*Z^W6D
M1XJFY"98\.@5OPXP+1=^/'<S"*!Z:-[/'D:OFUDDNX\W]N2$S'4$'_N&)H*^
M*D9C4;#P<[6G ?[L3"',>UV'<W@SG\. -T_U$"U&Q)SE$]J0670G;G6!<;;V
M=YI<\@5BCF YXB8)HVWFXH:C4;#H& NWX(?UAI)""5M*?N!:*H9T1>041;&'
ME="IV=HUV+ T2@!F),C?Y+!26TYX*IK8T4XT\Z9P7H>+V&7KFNC=LG"&BO.
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MIQ)!!=7O-68%A#)@XLE+%@G#G^8Y84.4':]D"!R\A)V_,6L<#+^<L+(2D2%
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M3+65#H @-7#\%7R;?K^GA-SG$5W<3R]AQAR635^)FE/?S*@#89_T(3/,X3"
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MW;UUYZ;N.;8%$.1>RO%8Q2NVFZA0I012/3 8!!YF3">2ZA^9_:)#TL>^;/I
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MM[3'OM=XTF8M5=,!I=:I([KKT@-<#$LD1;4%\G35I",JO<I2YD6LWQ.A1UN
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ME%A(^&+SDG(4C,;6Z]@?>2/^\)( 9!)K[=M&(W0VSY*PE_8<[26^-&[SVO%
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MIJ-Z?066<5(>UNB\!>GM&]JNZ.:!+C')_AZIHB34&*MN<1@2UA*(K_Z^: Q
M1&:YBE=(MBV923E8K4U(/) )Q46SC5U:M[JV;6("52Q/95>[\E+H,TBGM[6
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M0KM*$=7S94W3.@;]\73>SF/: T(AGS2C(#NH/3!(G;?6'K"=#C'%SMH.X%]
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MQ@;(KMZ=WX#J_?D!U_+B)%@_A0&LF!XZ;;?H7GA3GKFW;QA^@#8<22\R2U/
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M,AJ;2,!'LCO.D@1GR10D9Z.W-7$%.I*0%GFZO>-O:MS C\A2'<5$:'G^FL(
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MS@YO6BK@>DX;/0K\SGTB4V'IJNE!S]%)>6-3 >?J];J[-[ *4J\0<O7:*'>
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M;?<*U^EW1@C6+X6[)0H.2GJ,?S44RTE_?H30UB;12B56B6^2A*'_S<S]NHW
M,OU5,GG:M("KD8(Q GR28LT$QFI$C!%FBGYB FA5,FR$V@59_.O'<?DP3O4@
M ]C*?GV$P(J5(P-XGTG4F%R<PMV[ #AZ#*<EBR-BV\J]$!NY/^GV?9Y!R0@!
M9V]IUC2U.YO/H&2$@"OOZ:'702.!(SP':M-L9SGN6UUI?6^$O%W;PLW)#" S
MVA\<(>^)=]YLM4K RLO (+S9G9[)+RQA5^XC>&5;.#$R+\DF#[V"RVP*6E%=
MA0Y^.*W!*#\5($=$_ 3.PMR'_T]K^,FT#EW=?;V4LBL.@-MH6@EYCZ7CA=GL
M6P-Y1ZCC=<?L6QII@V<?%<DF[56O/];QPF86KHZB,]?QFF86+I"R&]CUVF:C
M/8*P![>?4FF3#JW+"^UZL33[EN9</W8OU=3<7[&A7=ZN%U.S;YDZ.<I=+YIF
MWS+I=*\/4GG-O=7KQ_M>+8:K)=#MVTH\;WZU&I-IP1[%CAD<4"U6KV8&@[4$
MKN,P]%[CI$ 4@4#PG 4!+*9V'RWC9$/^.K(GQ3B#WGQ98Q).3F]Z6Q,)R&O6
M&,2O7] 2''_SC/Z5HBV"69J;I5EU% ,3K?'=#IS2ZS/^7"?^09#.7.LGU"'"
M^_%]M?_(W$EAV[L<&] ^PQ )H#@"E?A; !_ '3XO7K;X/?\:@ATA9[Y\0C(+
M+B&H%_!9@%4>XF_NT6204-S@X\8+X>]D'[8 &>Z[1NM8:%AON8(6VCZDC:FN
M41/H>^%3OMV&^X,8IPH)B0X&EG&>K+RH9"-TFTCC$ ;%F10%C[4C9K[$A;<C
MS'2'ND&B/!!ZQC924V,'HAS<(?6JNF%]A=GZ.D=;&.V\VS<_S(GVDJ8 _5_P
M[+TQ(.@RDC;N? 0)42(B'\Q?0[CRV">8N+TVJEZV2&V-LE(0%G+P).,!KZ4V
M2@Y"N29^.?#PFO>'3I6R]CXJ3I+"_Y,^QT\@0XI@<60<ETL*1]4Q]7%D[23D
M\.%I*WT2.]Z\(N4BH/(Z56)S.^A#!MW.9*"A---&0TW?*!,;09!* Z70VT0-
M\_*>6 KD&Y#Z"=Q2YB+1P?1%GWO#:B1]5[W5N)L6OH][#X9ZP+N%XXDC^[M0
MU+<$8^^XR_@=+1L'WA9<<1QG2JW7(WII)7W<[BX3]R6]S[KP.?[^9AAYK'=E
M>RXI,6(QSK<%.,[*O2I_+'N&XVF,SV5(KO'%<>R&Y4=E"](0J9Y'S+DT(Y;C
MD/7*L *37!\O#BV"]FQNI!D.'<>L5W94L8(Z_@JS[VL7SR@[Q"M*Z^)_#C4&
MKM<8S/OH>0UJ:))X]RD<: H'FL*!1N\'G )P1N90GD)MG/ D3[$@ML2":(IX
MF!SPHS!@6V!"<-5).7G.[;3,L.V$KG+BY"ZW8AELLX\YZ(^=O.,VK<80SDBM
ML.U \AK;(K7'X8[4Z@RV"O\^74"]NM"MLY^7CH22RW['G@7R]ODYOO7\]7SY
MO ;T0!@$._K;(:_"B6-B,KE/)O?)Y&[HL8;<"XW)!F_J$2S/^,)Y"BO1;;+2
M#V2E;RO U/>8W/8&? =LWE(>P[R0.U%=6/5GQ/W,3T:.]%]_-*YZ3Y9\>ZZ+
M3%ZZB*(SDQ'?RKNUE'(S6?4GJ_YXY:Z$+NCX^Z#)F&\3GY\KLM4O$.YB.;"N
M1KO$.%]!;6",T:VIE^=&M H"@QOX%^A_:HE,[Q%Z&_#LO8&4DQIS+';Y.8(8
M416M'N(TO49";8\F@M.E<DU_HEX&;OMH0:X16\&L3@[/R<!L;X#X T_-\FQ-
M]LY-C-T^#-J9S;49O.X7US_^Y1/;F-7XNPF+*),!17X(F9X&)O0%9,6J/I Z
MJE32FVUT$9DF68U ]-.1./3#KPM\-E#V4?-O0Q)#Y<KV7P<BZ#.,X";?,$EJ
M_MVD9#D>8 *' *^'+7+]B[<!7 DIZF7"'(U039&N<1WG49;LN2YC>ELK#B;.
MD<IHK-$+4ZB.^ MI"K(4YV4OM.HPC+_A>]2!!)S=/4K!%8C $K99_=S1AA(N
MWAM?N#3^;L+5C"UJZ$;Q@$8/_V^>P#2 /M,+)MO+))MSV4;4VBH]2%G]L8O\
M![B!Q74IG4<OJ?I%Y&0 @Q[(@XBA'DOI MT-T=5^+?!0RHYB0A# 5027T/>B
MK'HE_A(E!XL+(KC<(^D]HM-+T97Y-=P_HC6#Z+HXV^!C;KXLNB3H(LS??WU]
MS08..3V$9+F"TM/ A$ZI:!-:+5FQ#HS9*0]C8*HLGJM.AT<0>2&V\\Y\/\E/
MPE<Z#V/:MBAI,FJX>-G&&<?]E"++SL%#T+2X.(Z*@OFFSD8M(XFC(%&M+AB&
M$PN(ZP"<.M,H-A='05 PX-2WB% X.PZ7T T@/);JMJ5+!.O4MM9P_-&M6(X#
MQ3>#U?%AG_?N!@%U4 A9@+H;]:"H\IQM\'0T/$JD&S1-IHZ"<(;\%IIL'8=,
M05:U]'#'\S]WO)*)Y,_EP<4\\Z00=CQI<T<NX[DY)L14F:WM67$\,W-'!)6=
M-XXG7NX(8V^NH2&2,8\/;BF'4@G=GR?HZM"INZY*'/\RX5C'4=TO5N+XDU-Y
M8=AAX\>G/;?+)<#/08Y_7:#K&7ZJ$/DPA+5X\M$D>AE]P*',FLRR.X!8MGA3
MF./RF(W&C(GJ&-E20.[B!*"#OM'B!J*.6,9 +SP#$>'0ED+2L+34=O\94#"'
MM!2"@\8L"G'J.)BETZ[4A.[!/;J_HBT$5X:P^;<(G;UKN"THI,7>=AG&TL6>
M8WW@\*MH1=2B1Y#X@!G<=/:PUD"!"Y/"*$?TE;IB'*G)-^H IO5>19>[%H7A
M4ARH^B 5JQQ:71DVOO+M 56VUN*X0;\'+&GJC^/6ZAY05-*FM)JR1[SENRMK
MCENQ>V!0O@;HN)E:"YYT-;(7*W6<>:'M5L$328?/8^B](N["9M/)(&CXC8[R
MHSN5$6R8X'WTF,0^2 ]Z"V+ 6@8CV5F*AK%AJIC+RM^5$2S7\0;_MQ"B4>5O
M3)_62!9>>2D(Z@VNXU0:#AV?ZN\M]9$E ?IR3=S0[#<*O?NC^-K;0B3-BY3Z
M!P;#T"80\Y<7$IB1_HT$B-PT%(>T@8&K7Q1"4Y876[ULF A1HZ0%*&EL ]D_
M)^R$+8S&-I ]]G>F)V1] =*"&#?M0RS5Q%Y3'B[@:HV#6%)0$""01?+C& 3^
MH*2QCPJI+C;P3HT>!39J]1K934Q)JYVLTUSHA/JRXT'UY^*G10F?[-/L=T,<
MY7XR2+-A4[UA.!Y(?>XV;U]5)E,S_T N+D23 9F+4GG_&L)8/&*4.+XR/='+
M(_:5\:^4O<0FCXZQSKCJ5KJOGLN#0WQ&OT%7</41M?(\.KZ3OK)7L/61TK\-
MFVFG(=EHO.3SH_$-(JTZ2Z"/,+[V4JQ;X__<_B.'.R_$U0KHO^5F%SUK2!.E
M5T&2D?=Q&1*ERQNPC5.8<6?(ZV$B0?-4V5=V% ,3);("QU=@R9I[X3-(-MS,
MV9P.VFSF7Q'K)EG\+2(?8U<9H+:;\MY3R3&8!7H=)QEA$_":X1W.$0#TMC80
MS=T4K-93(O!*:""EK-!+;D#J)W!;JAK<4ARB7D834F.J2F,T@WQZ6P-$7WDA
MOM$_K0'(<-PV401Y[,SI8 )SK 876CWWM#UM9RQ3_*&49(6>L"H"O8<]$Y"H
M-\3J8TJK$54V;S6R1BSR"FOQ>FA3OZY1$W1]")_R[3;<SU8)(,O*UL/X'2S1
M:CE;D-G< .ET%W%Y>HANML*>!B;TF,3H(,SVC^A,R;![#-VJ"657>X$R*-/3
MI@D)U429GD9V2X;N4?-E\1B)RV/4II:H-!Q.8C;7)C/GRR7TR<.XHFYFS*C@
M)&AL1N!T,(AQP#YC0(T6A#!;>QNA_>"DE8FK)O!SM)WPU9%UO:RU,*& $W8]
M""N^$DYM:YRM<4W;/$G8CQ.8S;6Q9/GBRUMA"V<4(35C@7Y$JG,"*(\FI+H8
M,8P";[Y< "^\3;&^7QUI3 LHH[F1L,Y7A!U:YIQPII?E)/TV.Q\/IX,VKB@4
M^K:IH'"XD!^P+DKC#;F.QBXU3<+FQ34E+@CDWFVX'2V9SBTZJQ ]/MJ6G6?&
M'D,C;Z'OW$<P*Q.%G7(ZLYD1M1IL/1@LV#*ZWL+4I1)=IV!RP.DC[T+9;FH)
M\V*Y@!3X\K:KP+&MCI9,!W$#^%9<V17F4N]EW(S,>21(:6@Z,D.'3[X>NL%U
M<#O^L(#K&Z^#I.R/=APXL=OZ$)5&=R8[BH_9VF"A%;S!]3<W4D^S?+RN,X=*
M;10'&432&TU/E]_P^SK**/*.XP9&IWY:Q_&1</:>UD)ANE8=!XONDZWCPW6'
M.HY.QX##@Y8C\-DZCIZ$(YU[\%]$J6&14[RY%=GZM;N*@53L2QTF*6>]XVRE
MX-^O0R?E17<<.D&0:7-#TGSTCN,C\O+7 >+IJNY*+(58E(.JP E5<)R?S@]U
M: G_,PRACD.M9* [C=5P/"%*!PM$(TKD(N%AJO/G;&O'D50\'P01/XZ#U6%7
MLJ.,'$\WI+A%I2X)%PD9E;WD L8<3\TDR6+T,MQ:0;%#U^\@GMC1>HZGHE(4
M3PP__$6"Q&4H7@REX^FZ%%F*ZQNZ2*C8)YUD$*SCF<X4&8QM'.L#I]$>@3+A
MR'TDA[,9,"9/L5U$EP:1,D]Q8L+[* -N,W8<]A) [7C!=/5SD1+ /T0Q]'%@
M1'TYH#>=H!/XT!\NZ$TDZ A0XN<2>A,).@M;XUE&A=EE6:JXF-%>@%0P]6IO
ML",YY;&8'4[4'T?8(3-?'K 869K*T:2;*>&5H;31;LQ/I(8A]Q<O@5CM%5%[
MVLXD(X@8P +)*@X:/F'JRPBM.-W&DN?+1>-"V:?.>[4E8#F%0Z]^:V6&[*=\
ML_&2_7SY%>"L]""8[=!H*Z2[XKB(^@4 Q_>BSG$>945]Y[#(^]W<96.KO#L2
MM:4)LG"M6&_RE8>Q;:IU#CR4#U>?*FT8*V04]YA79X)+..VZ0T9EIB%.0LM$
M?^7"QE9[1@VT2:H/E<NC GW_Z.W)2[B;''Q!4#Y_ ^$.?(ZC;,W/%=UA.(NG
M_G?@)<_?XC-G7(UB^T31-_E9;U7&L7BR9\[1NJF]1$%YEN#JG+C*Z6R#?^HR
M3^98QG6Q XE2*M>QM3V$7W/S'PHZV3,-829'<3_[5;?NA^/%:[W*A^LEF'_T
M(5:<TLY'ZNO"K*<@?7OJ])T)%5MYT!I[;6-52-4+?$T#Z25\>$P\)5)QM$;
M.L4\E"=J>FLB6V;N68 ,%N^E\-,S%VIBXH )$*4%MT7!<8+L2JDM#5EE!"-Y
MNI<P @$)N8*O.:82KUV9GJYX"5?_8_H(DMO--HSW0& 7US&R/8!@=]T"^/$J
M@K\#5NIIN;[:4D[S$:[_NH6KMZ+FICYK/--"NL-.;=4T/G\?.'X?[ ?B]LYR
M_(K8$40-&WZ(>R13 RG_@/_G%:E(__[_ 5!+ P04    "  <A'U62%&6==!4
M  "&3P, $    &QY<F$M97@Q,%\Q-2YH=&WMO7MSW$:6)_JW]U/@SF[/%B-
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M)6A8_U:KTEC08&P/YD)\',B!![[O]VCC!X@^LS'=OH0M4W/TY.I]Q[L==H.
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M<C1@A2+8@TA@W=+0HI-1 CL3^EP2PJ($NP*,.K3AD@[[Q_G1IY3AMU^2N$5
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M*EDPA>-'J[+')+]4QI*B]&K6%%T.>[DAC'21.;])B_R\LP?P(H?Y9!3$$I:
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MLQ+#Q=#B.U&&Y(>L*:"%6*^*W%'<8-U62\%(A%'T,6/>W+,!XQ=^GLH,VL%
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M)^*!#/D*IOE&V%3DZR8J): <:.=@"0(%!O6J278907>E*X>$)&)&I"9^.I!
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M7$?1JP728GOOTENNY;QMPJ]!93Q^>O#\Z,FP9>XX1<-5P^]5%T*E[NSO9Z]
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MX3KJ-+K JLRQNR,O&PDV_$]=N:H]Q11.B.59NVQ7>VDZ&N+0S9"J4K(W 6/
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M+SHOBM8>Q=UUB=N82G 6->N"](D#^';**)NH8LUC^@=EZ%&>2:M4J</SVOB
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M<I87K F5\9.+E\BJF6JSI1_=^:ZOX-]%II@P[.TR5]-:1R_K="XQ:HAI LJ
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ME8 &A3?AE@C/GDVKWME.+GO0T7LD[<$GG\&9''&UAAIS)4+J5[1(;O<OO^G
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M%M5M?=/;V&*VJU\?+HV1*6"8:=;*&B:^,C'#73H![\_4Q8VU"0-2,ZT1A%2
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MA;AP+C!V3$)FY_Z9>9%L69;_BCH5#T&T",9L47C6BQ;]!14+\)I-<D;MY%L
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MKK9P8:T3_:[2::,SO'&GWL*[G$Z>8,MJLVX;@S? []&+D_5U4M7EI<'3 G_
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M:*PV$)7_\K?W[Z82RS"J6$%4RJW"ESR4Y29$1=FK0R2 Q*8Z-)BL[8;:%;W
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MCJC^ QT=Z[)H0=!R8Q976W;GK[D(3A&Q8;[4-6X/JB_SM(9IJ(WJ\$\OR3=
M:#>B7^ZI]K>%+;[&V/5[QYFKS>>V[!:;)U;K."W//;MK%?"H\*,8*(B56E2.
M7%IRMR_I%+&0YD:W>#O55"FL<@%H/OM4OT1&"*N[8#X2O]YR!?4#XNZ<[P:E
M5\/U.3M%05YWU8%N[9:;D)X#!7D'3VE?XO;FKJV&M,R[N,F3NP$S'TT:PX.[
M,9YS&L/=.97O;AK#GS,98]:18C7D.B3["7]<%:D1%R4H*5W*<:]XT,$TH'*
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M-!Q0)'$1)UA? H>J4_\.1XPI6?=KLFS*/"^O2!43% ;(ID)?"ICW(%EK5'>
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MX69AZ(/Z6I4P%M=Q'N$ZA\U";$9TWMGEJJOCXP#<.-@(,I*RC"L.8]4Z5*R
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MK+DH8S)H9Q@8V^&7["5T0&LN2Y,Y-FE:6GX#EK7?FD.-&H)*!V1OIUTA^6,
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MM7%ZOKGD0GSH96:8%1IWF@VTA?/0.Z<;IO*?!V7"?J0JP8=J9%B[$JE4L)0
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MLA!]9AWSD,7/+NDWCGM338*Z<9KA0*/V@MH4\V8EDUURJ)8Y>(%3DF*_7'#
M#3O05OTWE%?%#1=_K$AT(O8*R]Z 0LYL=.)]]B*ZU]]%KVE.D?<%9D<>U'N-
MXV0M]/PY"?B1Q?26AYRZJV!31$JW+(X;O:K]$8MX_J(]N+_1]KVL>QL)[OW
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MNFGK(J$;V+G =T-+^ PZ@Q9E%Y*MY7_SDWECQ[FJ0O<','_*5#EB-%<P#2X
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M69?9]??_[;MOMLTN__[_!U!+ P04    "  <A'U62,)AL.0"   U%   #P
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MP'>?H.,O)@=S7@_B\JBB2,"E0\P5H9H[; +61$]RQ!#A8,.>%&: XB@60VJ
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MTXF7@2A5!J0K'CEK^J&J%1=E>0,@1$E3PP/CCQRFBY[[JLWW[0(6%)A&-AZ
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M&5EDYJC=:^H'TD_?])KF0?9_ %!+ P04    "  <A'U6U2@#KFP%  #$+@
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M3V5KE%.<XMY!<G 0N] N(,M3Y! Q"V%[#I_;V]EY)$Z![P"O.2LQ>A;AD[?
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M(HF+$GV\AUC;"&2B2>L*9-BV>,^W%5<,(&%!,K]?VLF'3&-<K@9M4AR)#_3
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M_TE!_*BGK0W@OYF"H/?TJO]Z_A'/?QR8;/;37Y[_.*Z+_*?_ %!+ 0(4 Q0
M   ( !R$?59!1_.OR78  -.@   2              "  0    !I;6<R,C(S
M-#,R-SA?,"YJ<&=02P$"% ,4    "  <A'U6R=Y03"7S  #S P$ $@
M        @ 'Y=@  :6UG,C(R,S0S,C<X7S$N:G!G4$L! A0#%     @ '(1]
M5GH8#!4%>P  K:4  !(              ( !3FH! &EM9S(R,C,T,S(W.%\R
M+FIP9U!+ 0(4 Q0    ( !R$?5;(;@J*K(0$ /D)"0 2              "
M 8/E 0!I;6<R,C(S-#,R-SA?,RYJ<&=02P$"% ,4    "  <A'U6VQ?GTM)1
M  #S8@  $@              @ %?:@8 :6UG,C(R,S0S,C<X7S0N:G!G4$L!
M A0#%     @ '(1]5F:&MW(]3@  D60  !(              ( !8;P& &EM
M9S(R,C,T,S(W.%\U+FIP9U!+ 0(4 Q0    ( !R$?58F&.:7PEX  )5H   2
M              "  <X*!P!I;6<R,C(S-#,R-SA?-BYJ<&=02P$"% ,4
M"  <A'U6![EXL9:Y!  2DT  $0              @ ' :0< ;'ER82TR,#(R
M,3(S,2YH=&U02P$"% ,4    "  <A'U6DLP<*_44  #6Z   $0
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M82UE>#$P7S(T+FAT;5!+ 0(4 Q0    ( !R$?59\X^!WHE8  '89 P 0
M          "  5GK#0!L>7)A+65X,3!?-#8N:'1M4$L! A0#%     @ '(1]
M5DC"8;#D @  -10   \              ( !*4(. &QY<F$M97@R,U\Q+FAT
M;5!+ 0(4 Q0    ( !R$?5;"@3UJ'@D   =5   /              "  3I%
M#@!L>7)A+65X,S%?,2YH=&U02P$"% ,4    "  <A'U6PFNPN1P)  #U5
M#P              @ &%3@X ;'ER82UE>#,Q7S(N:'1M4$L! A0#%     @
M'(1]5D+S]F-P!0  SRX   \              ( !SE<. &QY<F$M97@S,E\Q
M+FAT;5!+ 0(4 Q0    ( !R$?5;5* .N; 4  ,0N   /              "
M 6M=#@!L>7)A+65X,S)?,BYH=&U02P$"% ,4    "  <A'U6N$XV1A4C  "[
M\0  #@              @ $$8PX ;'ER82UE>#1?-2YH=&U02P4&     !8
,%@!Q!0  188.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
